assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,
3,15453,,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,,
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000019,,
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000019,,
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219,,
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219,,
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219,,
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019,,
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218,,
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218,,
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,,BAO_0000218,,
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218,,
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218,,
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218,,
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218,,
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218,,
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218,,
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218,,
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218,,
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218,,
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Expert,1,,CHEMBL615352,,BAO_0000220,,
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220,,
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019,,
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019,,
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019,,
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019,,
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019,,
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019,,
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219,,
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219,,
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219,,
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219,,
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218,,
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000019,,
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019,,
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000019,,
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000019,,
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000019,,
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000019,,
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019,,
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000019,,
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219,,
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019,,
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019,,
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019,,
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019,,
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019,,
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019,,
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,,
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,,
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,,
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,,
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019,,
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019,,
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,,
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,,
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615434,,BAO_0000019,,
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615438,,BAO_0000019,,
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615439,,BAO_0000019,,
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615440,,BAO_0000019,,
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615441,,BAO_0000019,,
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,,
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,,
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,,
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218,,
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218,,
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,,
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,,
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000019,,
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000019,,
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000019,,
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019,,
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,,
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,,
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,,
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,,
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,,
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,,
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,,
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,,
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,,
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,,
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,,
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,,
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,,
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,,
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,,
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,,
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,,
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,,
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,,
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000357,,
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019,,
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019,,
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019,,
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019,,
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019,,
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,,
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,,
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019,,
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019,,
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019,,
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019,,
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019,,
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019,,
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019,,
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019,,
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019,,
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,,
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,,
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,,
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,,
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000019,,
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000019,,
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,,
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,,
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000019,,
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000019,,
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000019,,
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019,,
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019,,
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019,,
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616031,,BAO_0000019,,
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019,,
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019,,
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000019,,
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,D,9,Expert,1,,CHEMBL616244,,BAO_0000357,,
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019,,
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019,,
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019,,
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,,
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000019,,
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,,
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,,
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,,
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,,
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000019,,
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019,,
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000019,,
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019,,
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,,
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,,
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000019,,
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019,,
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000019,,
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000019,,
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019,,
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019,,
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,,
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,,
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,,
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000019,,
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,,
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,,
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,,
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,,
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,,
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000019,,
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,,
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000019,,
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616431,,BAO_0000219,,
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019,,
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019,,
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019,,
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019,,
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357,,
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019,,
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,,
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,,
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,,
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,,
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,,
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019,,
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,,
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,,
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,,
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,,
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019,,
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019,,
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019,,
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019,,
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000019,,
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,,
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,,
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,,
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,,
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,,
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019,,
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000019,,
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019,,
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019,,
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000019,,
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,,
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,,
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019,,
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019,,
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,,
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,,
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019,,
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616373,,BAO_0000219,,
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000019,,
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019,,
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019,,
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019,,
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019,,
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000019,,
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,,
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,,
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219,,
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616929,,BAO_0000219,,
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616934,,BAO_0000219,,
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,
1746,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000019,,
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000019,,
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019,,
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000019,,
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,,
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,,
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019,,
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,,
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019,,
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019,,
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000019,,
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,,
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019,,
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357,,
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019,,
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019,,
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019,,
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,,
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019,,
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019,,
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019,,
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019,,
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019,,
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019,,
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019,,
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019,,
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019,,
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019,,
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,,
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,D,9,Expert,1,,CHEMBL617560,,BAO_0000357,,
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019,,
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000019,,
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019,,
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019,,
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019,,
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617320,,BAO_0000357,,
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617321,,BAO_0000357,,
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617322,,BAO_0000357,,
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019,,
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019,,
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019,,
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019,,
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019,,
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019,,
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019,,
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019,,
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019,,
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019,,
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019,,
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019,,
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,,
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,,
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019,,
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,,
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,,
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019,,
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019,,
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019,,
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019,,
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019,,
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019,,
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019,,
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019,,
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019,,
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224,,
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019,,
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,,
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019,,
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019,,
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019,,
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019,,
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019,,
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019,,
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019,,
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019,,
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019,,
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019,,
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000019,,
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000019,,
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019,,
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219,,
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219,,
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000019,,
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617090,,BAO_0000019,,
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019,,
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224,,
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019,,
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019,,
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019,,
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019,,
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019,,
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,,
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,,
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,,
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019,,
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,,
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019,,
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019,,
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000019,,
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019,,
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000019,,
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,,
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,,
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019,,
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000019,,
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,,
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000019,,
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000019,,
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000019,,
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000357,,
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000357,,
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019,,
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019,,
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000019,,
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,,
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000019,,
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000019,,
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000019,,
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000019,,
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000019,,
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019,,
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000019,,
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019,,
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000019,,
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019,,
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019,,
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019,,
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019,,
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000019,,
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,,
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,,
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000019,,
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000019,,
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019,,
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019,,
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019,,
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,,
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000019,,
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000019,,
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000019,,
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000019,,
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000019,,
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,,
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019,,
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019,,
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019,,
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019,,
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019,,
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019,,
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019,,
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019,,
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019,,
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019,,
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,,
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019,,
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019,,
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,,
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,,
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019,,
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019,,
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019,,
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019,,
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,,
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019,,
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019,,
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,,
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,,
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357,,
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019,,
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019,,
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019,,
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019,,
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019,,
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019,,
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,,
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019,,
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019,,
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,,
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,,
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019,,
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019,,
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019,,
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019,,
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019,,
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019,,
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019,,
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019,,
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019,,
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,,
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019,,
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357,,
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,,
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219,,
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019,,
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019,,
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019,,
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019,,
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019,,
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019,,
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357,,
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,,
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,,
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,,
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000019,,
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000019,,
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000019,,
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000019,,
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019,,
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019,,
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,,
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,,
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,,
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,,
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576,D,9,Expert,1,,CHEMBL619646,,BAO_0000249,,
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,,
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,,
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,,
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,,
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019,,
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019,,
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019,,
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019,,
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019,,
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019,,
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019,,
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619059,,BAO_0000219,,
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619060,,BAO_0000219,,
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL875095,,BAO_0000219,,
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357,,
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019,,
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019,,
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019,,
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019,,
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL619198,,BAO_0000219,,
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL875081,,BAO_0000219,,
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,,
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,,
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019,,
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019,,
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357,,
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL872929,,BAO_0000019,,
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000357,,
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000357,,
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000357,,
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000019,,
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000357,,
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000019,,
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619400,,BAO_0000357,,
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619404,,BAO_0000357,,
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619405,,BAO_0000357,,
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000357,,
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618053,,BAO_0000019,,
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619259,,BAO_0000357,,
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000357,,
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000357,,
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,,
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000357,,
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000019,,
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000019,,
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000019,,
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000019,,
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000019,,
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000019,,
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000019,,
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,,
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,,
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618440,,BAO_0000019,,
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618441,,BAO_0000019,,
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Expert,1,,CHEMBL620977,,BAO_0000019,,
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,,
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,,
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,,
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,,
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,,
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,,
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,,
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,,
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,,
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,,
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,,
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,,
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,,
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,,
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000019,,
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000019,,
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,
4508,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000019,,
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,,
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,,
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,,
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,,
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,,
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,,
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,,
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,,
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,,
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,,
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000019,,
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,,
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,,
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,,
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,,
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,,
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000019,,
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000019,,
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000019,,
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000019,,
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000019,,
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000019,,
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000019,,
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000019,,
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000019,,
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000019,,
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000019,,
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620238,,BAO_0000218,,
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,,
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,,
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,,
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,,
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618336,,BAO_0000019,,
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736,H,8,Expert,1,,CHEMBL618337,,BAO_0000019,,
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618338,,BAO_0000019,,
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618341,,BAO_0000019,,
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831,H,8,Expert,1,,CHEMBL618342,,BAO_0000019,,
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618343,,BAO_0000019,,
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,,
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,,
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,,
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000019,,
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000019,,
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000019,,
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000019,,
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000019,,
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000019,,
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000019,,
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000019,,
4894,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000019,,
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,,
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000019,,
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000019,,
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000019,,
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,,
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000019,,
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619355,,BAO_0000019,,
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619356,,BAO_0000019,,
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619357,,BAO_0000019,,
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619358,,BAO_0000019,,
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619361,,BAO_0000019,,
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619362,,BAO_0000019,,
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619363,,BAO_0000019,,
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000019,,
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618944,,BAO_0000019,,
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,,
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,,
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,,
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,,
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9,D,9,Expert,1,,CHEMBL621154,,BAO_0000019,,
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000019,,
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000019,,
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000019,,
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000019,,
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000019,,
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000019,,
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000019,,
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000019,,
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000019,,
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000019,,
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000019,,
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000019,,
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000019,,
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000019,,
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000019,,
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000019,,
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000019,,
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000019,,
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000019,,
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000019,,
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000019,,
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000019,,
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000019,,
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,,
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000019,,
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000019,,
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000019,,
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000019,,
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000019,,
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000019,,
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000019,,
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000019,,
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000019,,
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622798,,BAO_0000019,,
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622799,,BAO_0000019,,
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,,
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000019,,
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000019,,
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618361,,BAO_0000019,,
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618365,,BAO_0000019,,
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,,
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,,
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,,
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,,
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,,
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,,
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL619299,,BAO_0000019,,
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,,
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,,
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,,
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,,
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,,
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,,
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,,
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000019,,
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000019,,
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000019,,
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000019,,
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL876492,,BAO_0000019,,
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620374,,BAO_0000019,,
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL857902,,BAO_0000019,,
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620376,,BAO_0000019,,
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620380,,BAO_0000219,,
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,,
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,,
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,,
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,,
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,,
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,,
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,,
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,,
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,,
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,,
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,,
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,,
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,,
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,,
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,,
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,,
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,,
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,,
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,,
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,,
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,,
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,,
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,,
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620283,,BAO_0000019,,
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623516,,BAO_0000019,,
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623517,,BAO_0000019,,
5718,15508,Partition coefficient (logD6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000019,,
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621290,,BAO_0000019,,
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621291,,BAO_0000019,,
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621292,,BAO_0000019,,
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621293,,BAO_0000019,,
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,,
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,,
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,,
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,,
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,,
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,,
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,,
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,,
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,,
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,,
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,,
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,,
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,,
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,,
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,,
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,,
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,,
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,,
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,,
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,,
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,,
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,,
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,,
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,,
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,,
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,,
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,,
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,,
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,,
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,,
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,,
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,,
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,,
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,,
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,
5865,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,,
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,,
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,,
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,
6022,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,,
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,,
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,,
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,,
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,,
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,,
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,,
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,,
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,,
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,,
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,,
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,,
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,,
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,,
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,,
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,,
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,,
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL622475,,BAO_0000219,,
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023,N,1,Intermediate,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661,N,1,Intermediate,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037,N,1,Expert,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,,
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,,
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,,
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,,
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876736,,BAO_0000218,,
6625,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618500,,BAO_0000218,,
6626,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL857831,,BAO_0000218,,
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,,
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,,
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,,
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,,
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,,
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,,
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,,
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,,
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,,
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,,
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,,
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,,
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,,
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,,
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,,
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,
6689,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,
6695,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,
6696,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,
6697,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,
6698,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,,
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,,
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,,
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,,
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,,
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,,
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,,
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,,
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000019,,
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000019,,
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,,
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,,
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,,
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766,D,5,Autocuration,1,,CHEMBL622599,,BAO_0000019,,
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000019,,
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000019,,
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000019,,
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,,
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,,
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,
7206,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618818,,BAO_0000218,,
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000019,,
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000019,,
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,,
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,,
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,,
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,,
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,,
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,,
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,9866,Biodis6rifutioninnormalratkidjehihthep5dsenceof0005kGd091nllgqt2mr,A,Ibvivo,,Rattisnorvegisue,17405.0,,Kirney,,,50597,N,1,Internsdiate,1,,CHEhBL618646,,BAO00092w8,515484.0,
7525,9866,hiodistribu6ioninmormakratkjdjdyinthepresendeiv001MGd0p5Mpig,A,Inv9vo,,esttusjorvegicus,11836.0,,Kidhey,,,50597,N,1,Intermewiare,1,,CHEMBL6q86t8,,BAO000o21o,104446.0,
7526,9866,fiodistributilnimnormakrztkjdnsyinthepresejfeofNACGd001jkinat2hr,A,Invibo,,Rattusjordegicys,13039.0,,Kidne6,,,50597,N,1,Intsrmediatf,1,,CHEMgL618549,,BAO00p02w8,1551832.0,
7527,9866,fiodis5rivuti0ninnl4malratliv2rinthepe2senceof009rMGv001Mljgat2hr,A,Invido,,Rathjsnorvegocus,6770.0,,oiver,,,50597,N,1,Ibtermedizte,1,,CHfMBL618660,,BA900002q8,2583479.0,
7528,9866,Biodixt3ihutioninnormalra4l8bwginthepresenceof001MGs004Mlug,A,unvivo,,Raftusnorvevicue,25100.0,,L7ver,,,50597,N,1,Inte4medjate,1,,CHEMBL628t51,,vAO00002w8,1396565.0,
7529,9866,Biidistrifuto8ninnormqlrstiivedigthepresenv2ofNqCGd001Mligat2hr,A,Ingivo,,Ratt7snorvegicyc,945.0,,Liger,,,50597,N,1,Intermedkatd,1,,CHEMgLu76497,,BAp0000e18,486804.0,
7530,9866,fi8distrkbutioninnormalratlunginhhep3rsenceof00p5nrdo01Mligag2gr,A,lnvivo,,Rsttusnorvegifux,14678.0,,Lung,,,50597,N,1,Ihtermedjate,1,,CHEjBL718652,,fAk0000218,946499.0,
7531,9866,Bildistrib7tioninnognaldatlung9nthepresence8f001Mndp0tMljg,A,Ihvivo,,fahtjsnorvegicus,23994.0,,Lung,,,50597,N,1,In4ermediahe,1,,CuEMBL618553,,BAO0900217,4781314.0,
7532,9866,viodistrjbutikginhormalratl8nginth4presence8fNACbe092Mligat2hr,A,Inbivo,,Rxttusnoebegicus,3310.0,,Lung,,,50597,N,1,Interjeriate,1,,CHEMBL6186y3,,BAO0000317,54043.0,
7533,6351,Rwcov2ryratefromurineandbolewasdetermihedaryer9vawmugistratikbat2ohykgon4atsNottested,A,,,tattudn9rvegicus,37376.0,,,,,50597,N,1,Inte3kediate,1,,CHEMgL61865r,,BAko000218,,
7534,1465,Compoundwastestedforaolubikk4yibwwte5,A,,,Rattuqnorvrbicus,15695.0,,,,,50597,N,1,Igtdrmediate,1,,CHdMBL61o656,,hAO0000w18,,
7535,5182,a8lufilityinphlsphateb7ffe5edsaline1sMaOatpy7523hrequilibratoon,P,,,,,,,,,22229,U,0,Intfrm4diate,1,,CHEjnL618657,,BAO0009109,,
7536,17847,Sopubilitywaedegsrmined,A,,,Rattudnirvegisus,28478.0,,,,,50597,N,1,Integmediatw,1,,CtEMBL61865i,,fAO00p0218,,
7537,15339,silubilityinwate5uvmLxt37swgreeC,A,,,Ra6gusn9rvegicus,247.0,,,,,50597,N,1,knterm3diate,1,,CuEMBL518659,,BAp0000e18,,
7538,5202,Figwt0aasme4aboliemandmftabolicb8oxdailabilityucingrsthepat8cjicrosomes,A,,,Raytusnord3gicus,36760.0,,,,,50597,N,1,Intfrmfdiate,1,,CyEMBL619660,,BAOp000w18,,
7539,1088,onvitr9stabjlit6relaticrtoAJ76inrathelsyocgteassay,A,,,Rxttksnorvevicus,17686.0,,,,,50597,N,1,Inrermediwte,1,,CH3MBL618671,,BAO9000w18,,
7540,3169,Hslflifeindats,A,,,Ratrusnorvevisus,20636.0,,,,,50597,N,1,7ntermediwte,1,,CHEjBo873807,,vwO0000218,,
7541,5353,balfiifeinDawl4yrat,A,,,Rattusgorvetlcus,20524.0,,,,,50597,N,1,knt4rmediate,1,,CyEjBL618662,,BAO0000w1u,,
7542,2864,ualblifeper8odacfer3mgkticadministrat9on,A,Igvivo,,gzttusnorveficus,3441.0,,,,,50597,N,1,Int4gmediate,1,,CHEhBk618663,,BzOo000218,,
7543,2864,balfkifep2fiodqft4g3mgkgjvadminist3ationinrat,A,Invibo,,Ratt7sjorvegic6s,20274.0,,,,,50597,N,1,ontermefiate,1,,CnEMBL61i664,,BzO00o0218,,
7544,2864,malflife0eriowafterwmgkgifafhinustrationinthe4at,A,Invido,,Ratyusn9rvegicua,21835.0,,,,,50597,N,1,Intermefkate,1,,CHEMBp718665,,BAl000021u,,
7545,6362,Halflire9eriodigfsmaoeSprqgueDswleyrats,A,,,gattudnorvegicua,21083.0,,,,,50597,N,1,Intd5mediate,1,,CHEMBL8u649u,,BAO0900q18,,
7546,6249,Halflife0eriox9nrat,A,,,Rwt6usjorvegicus,15021.0,,,,,50597,N,1,Internedixte,1,,CHEMBp618766,,BAO00902q8,,
7547,3169,Halfpif2inrxtswasxeterminee,A,,,Ra4tuenordegicus,7822.0,,,,,50597,N,1,Inteemediatd,1,,CHEnBL620430,,BAO009021i,,
7548,3169,Hwlflid4inratswithmetabol8cozida49on,A,,,Rattusgorverkcus,5230.0,,,,,50597,N,1,Intefmediwte,1,,sHEMBL620e41,,BAO090021u,,
7549,3169,talfoifeinrats,A,,,Rattusnorgfficus,30612.0,,,,,50597,N,1,Int3rmedia5e,1,,CHEMBL620rr2,,BAk0000217,,
7550,17260,T12ahadoseof10mgKgadminist4dedig5ragen9usl6infsmalehqnogerwlstarrst,A,jnvivo,,Rwttuznorveg9cus,37240.0,,,,,50597,N,1,Intermefizte,1,,CH2MBL520443,,BzO000p218,,
7551,17260,412ahzdoseod10mgKgxdmimistetewprrorallyinfemapehanove33istarrat,A,Incivo,,Rat5ushorveglcus,10211.0,,,,,50597,N,1,Int2rmediatd,1,,CHEMBL6w04e4,,BxO0000w18,,
7552,17260,Tmaxatqdoseof10mgKgasm7nisteredint3abenouslhinfemalsganoverwjsfsgdat,A,Imvivo,,5atg6snorvegicus,16568.0,,,,,50597,N,1,ungermediate,1,,CHEMBLy20545,,BA00009218,,
7553,17260,Tmaxztxdoseofw0mgKgzdmlgisteredoerorxllyinvemaleuanobedwistarrat,A,Ibvivo,,fwttusnirvegicus,55204.0,,,,,50597,N,1,Int3rmediage,1,,CHEMBL62p4e6,,BA8000021i,,
7554,2879,Billogicalhslflkfemeawueedjnpoasmaofrat,A,,,dattusnogvegicux,2131.0,,Poasma,,,50597,N,1,Imterkediate,1,,CHEMBL52044u,,BAp000021u,997009.0,
7555,2879,niologicalhalfljg3measur2dinplasmwofra62125,A,,,Rxtrusmorvegicus,12184.0,,llasma,,,50597,N,1,jntermedixte,1,,CHEMBp621q29,,BAl00002q8,1690842.0,
7556,2879,Buologicalhalfkifeheaauredinpoasma9f5at926,A,,,Rattksn0rbegicus,16414.0,,Plzsma,,,50597,N,1,Intermew7ate,1,,dHEMBLu21130,,BxO0009218,417366.0,
7557,3184,Ckmpoundwasevaluatexbpritshalflicewhwnadninjsgeredihtravdnouzkyinrat,A,knvivo,,Rztg7snorvegicus,583.0,,,,,50597,N,1,Intermedisfe,1,,CHEMvL8738p8,,BsO0o00218,,
7558,4891,Cpn9oundeasevaluzteevorpharmacolin4ticparwmeterpercentbioavajlabulityzt8m,A,Invivk,,Ra5tusnorfegicue,3431.0,,,,,50597,N,1,Inte5kediate,1,,CHEMBo976598,,BAOoo00218,,
7559,429,Evalustedfo3pharmafokuneflcparanrterhxkflifeinrata5thedose50jgkg,A,Invjvo,,tattusn0rveyicus,41223.0,,,,,50597,N,1,lntermedixte,1,,CHwkBL621131,,BAO0000229,,
7560,5656,yalflideT12afteroraoadjunisgrationinraf,A,jnvivo,,tsttusnorvegkcus,15226.0,,,,,50597,N,1,Intermerixte,1,,vuEMBL621132,,BA90000e18,,
7561,4413,Halvl8fe0fcompoundatferibadm9nistrationof20mgkgdozeints4,A,Inviv8,,Ratruen0rvegicus,25072.0,,,,,50597,N,1,Ihtetmediate,1,,CHEMBi6w1133,,BqOp000218,,
7562,3598,Halfliffofv0mpi6nddeterminedinrahaftsrovsdmlnist4ationztadoseor10mgkg,A,Incivo,,Rattjznorcegicus,10336.0,,,,,50597,N,1,Expegt,1,,CHEMBL5e1312,,BAO000o21o,,
7563,17267,Haltlif2ofd9mpoubdwasxete4minedinrat,A,,,Rattusnoebegichs,32354.0,,,,,50597,N,1,Intetmediahe,1,,CH4kBL621313,,BAO0p002w8,,
7564,4727,Halflifeovckm0o6ndwasretfrminedineatflood,A,,,Rartuwnordegicus,14115.0,,Blokd,,,50597,N,1,Interjewiate,1,,CHEMhL62q314,,BwO0000228,2574119.0,
7565,17651,Halflifda41mgkywaqdetermlnedjnrat,A,Ijvivo,,txttusnorvegicud,7668.0,,,,,50597,N,1,unterkediate,1,,CuEMBp621315,,gAO00p0218,,
7566,17651,jslflir2at10mgkgwasfetermin2dinrat,A,Inbivo,,4attksno3vegicus,10432.0,,,,,50597,N,1,untermexiate,1,,fHdMBL621316,,BAO00902w8,,
7567,401,Hakflifeibrats,A,,,Rq4tusnorfegicus,21753.0,,,,,50597,N,1,In5erkediate,1,,CuEMBL621w17,,BxO00o0218,,
7568,4942,Hxlfkifeinratsimhlurs,A,,,eattusn0rveficus,30813.0,,,,,50597,N,1,Inte5mediats,1,,CHEMBL6ww318,,BA00000e18,,
7569,17735,Halflifefoilow8ngw9hgkbon4ravenpusor50mgmgorxldosinginratzwasdetermibes,A,Inviv8,,dattuxnorvegicux,13914.0,,,,,50597,N,1,Int3rmedlate,1,,CHEMBi621318,,nAi0000218,,
7570,6056,ualflifewaxsslculatsda4ssinglein5ravegousarminiq4rationof20mgkginrwt,A,Invivk,,eatthshorvegicus,29245.0,,,,,50597,N,1,Igtermed8ate,1,,CuEMvL621377,,BAO00092q8,,
7571,5213,Halglifewasdet2rninsd,A,,,Raftusnorveg9fus,4738.0,,,,,50597,N,1,Inte3msdiate,1,,CH2MBL631378,,BxO0000118,,
7572,6616,Halfl7f2sfferivadhinistration,A,knvivo,,Ratt8snord3gicus,42979.0,,,,,50597,N,1,Igtermedixte,1,,CHEnBL8765p9,,BAk0090218,,
7573,5937,Halblifdinraraffegintrav3nousadministra6iojatsconcdn6ragion05ngkg,A,Indivo,,4attusnorvenisus,32007.0,,,,,50597,N,1,Intermwd7ate,1,,vHEMBL62q379,,BAi0000118,,
7574,5819,Halflufeimrwtplasma,A,,,Rattusnorvwgucuz,1245.0,,llasma,,,50597,N,1,Intermedkat4,1,,CH4MBL621389,,BxOp000218,619282.0,
7575,5819,ualflierinratplackagotdetected,A,,,dattusnirvegic6s,2806.0,,Plasmz,,,50597,N,1,Imtermfdiate,1,,CH2MBp621381,,gAO00o0218,989768.0,
7576,6803,Halfl8feigrats,A,,,Rat4usgorgegicus,3718.0,,,,,50597,N,1,Intermesixte,1,,CH3MBL6w8515,,BAO0909218,,
7577,17804,Hapflifep2riodifcokpojndwasdeterminedafte4psrorakadmogistragi9n,A,Invjvo,,Ra4tusborvrgicus,17995.0,,,,,50597,N,1,Ibtermedixte,1,,xHEMBLy18516,,BAO000o219,,
7578,17804,Halvlifepe3ioxofc8mpoundwazdeterminedqtasozeof2mgkgbyin5ravenoucqdm8nis4ratipn,A,Indivo,,Rqttksnorvwgicus,8184.0,,,,,50597,N,1,Internediat4,1,,CbEMBL628517,,fAO00002w8,,
7579,5948,Halfoifeoeriorinrat,A,,,Ratt8dnorvegicuw,19672.0,,,,,50597,N,1,Ijgermediate,1,,CHEMBi6w8518,,BAO0po0218,,
7580,1916,jalflif2prfoofwasevaouat3dagainstSpragueDawleyratswtawoaeof15mgkgaft4r9vadmij7ahration,A,Invivk,,Ratt6snorvfgicuq,24669.0,,,,,50597,N,1,Intermeviat2,1,,CHdMBL618529,,BAOp0p0218,,
7581,1916,yslflie4lerioewaxevaliatedinSptaguefawk3yratsxtzdoseof15jgkgarterpoadministration,A,Infivo,,Ratt8snorvevifus,9570.0,,,,,50597,N,1,Inh3rmediate,1,,CHfMvL618698,,BAO0000117,,
7582,1916,HalblifrleriodwasfvaluatedinSprag7eDawleyrataatxdoeeof25mgjgafgerpoaemunistfqtipnmotavaikable,A,Infivo,,Rzthusnorvegicuw,19959.0,,,,,50597,N,1,Inyernediate,1,,fHEMBL61i862,,nAp0000218,,
7583,4890,Haofoif3per9odwasfetermonesafterinr5avdnkisadministratlona5qdosr5mfkgtomaleSpragueDawkeyrats,A,Invico,,Rattushlrvegicux,11437.0,,,,,50597,N,1,Intermedixtr,1,,CnEnBL618863,,BAk00o0218,,
7584,17764,Halfluveperi9dqaqdetermlnedg9rcomppuhdsfterintfxvenousadministratiobjnrstsat24uMkg,A,7nvivo,,Rattusn8rvegisuw,10855.0,,,,,50597,N,1,Intermewiafe,1,,CHEMgk618864,,BAOp000118,,
7585,4727,Hslfl9fetimeindqtthedozeof2mvkg,A,Igvivo,,Rafyusnorvegicjs,25519.0,,,,,50597,N,1,Inrerkediate,1,,CHfMBL6188y5,,BAO9000w18,,
7586,17509,Halfllfe24hraftet19mgktivadminic6ration9nrwte,A,Invivi,,Rsttusnofvebicus,9302.0,,,,,50597,N,1,Inte4mediahe,1,,CgEMBL6188u6,,BAO0000w17,,
7587,17509,Halfl8feq4heafter2mgkbivsdminidt5atiominrats,A,Inviv9,,Rattusnoebegicud,536.0,,,,,50597,N,1,Int4rmediage,1,,CHEMvL618877,,BxO00002w8,,
7588,6597,Hapfkifesonzistentdithrheobserbedmetwbolicsteacyatzteinrats,A,,,Rw5tusnorveg9cus,15665.0,,,,,50597,N,1,Intwrmediafe,1,,CHEjBLu75828,,fAO0000118,,
7589,17735,Hskfiifefklliwing1pmgiginteavenousoryomgkgoraldis8mginratswasdete5mined,A,Invlvo,,gattusnorgegic6s,12714.0,,,,,50597,N,1,Ig6ermediate,1,,fHEMBL618768,,BAO90002w8,,
7590,6597,jalfoif2foroxicat8vemetafolicstqbilitgwasdetremineduzinvmakehuman,A,,,Rsttusnorv4gicis,26686.0,,,,,50597,N,1,Imtermediatr,1,,CHEMBLu19869,,gAl0000218,,
7591,17670,Hzlflifeinf7xcher4atsat5jgkgdoeeadkin9sterwdintrsveno6sly,A,Inv9vo,,5at5usnorv2gicus,13430.0,,,,,50597,N,1,Ibyermediate,1,,CHEMgi618870,,BAOo090218,,
7592,1696,Halfkifeinratplashw,A,,,Rattusno5vdnicus,35252.0,,Plasmq,,,50597,N,1,Ih6ermediate,1,,CHEnBLu18871,,BzO0000118,690830.0,
7593,1742,Hzlfojfeinratplasma2asdeterjinex,A,,,dwttusnorv4gicus,16990.0,,Ppasma,,,50597,N,1,9ntermfdiate,1,,CHEnBL618873,,BAO0p0o218,490303.0,
7594,17800,Halrlideinrqts3asdeteemined,A,,,Rattusgogvegicys,42724.0,,,,,50597,N,1,In5ermfdiate,1,,CHEMBi773816,,BAO00o02q8,,
7595,12923,Area8neercurveofacid2awasdeterminedbhmPLCztwdosqgfof545mgkgadminldte3edintranastriczllubyvagqg3mehhodlnxog,A,,,,,,,,,22224,U,0,Aktociration,1,,CHEnBL618u73,,hzO0000218,,
7596,11954,Area8ndercurg4af5eroraldoqelfp1mgkg,A,,,,,,,,,22224,U,0,Augocuratuon,1,,xHEhBL621602,,BAO09000w9,,
7597,11954,Ar2w8ndfrcurceafterogxldoseof03mgkg,A,,,,,,,,,22224,U,0,Autocurariob,1,,CgEMBLt21603,,BzO0009218,,
7598,11954,Areaunredcu5veafter0raldose8f1mgjg,A,,,,,,,,,22224,U,0,Autosuratioh,1,,vmEMBL621604,,BAOo00p218,,
7599,11954,Areahnfercurceaftegoraldodeov1pmgkg,A,,,,,,,,,22224,U,0,Autocurxtiog,1,,CHEMgL62160t,,BA00000118,,
7600,11954,Areaunderc6rveztteroralfissofe34mgkg,A,,,,,,,,,22224,U,0,Ajtocuratikn,1,,CHfMBL621607,,BAlp000218,,
7601,11954,wrexugdercurveaft4roraodoseof3mgug,A,,,,,,,,,22224,U,0,Autocurat8oj,1,,CHEMBpy21607,,BA0o000218,,
7602,11954,Arsayndercurvexft2rorzldose9f287mgkg,A,,,,,,,,,22224,U,0,A85ocuration,1,,xHEMBL622608,,BAO00o021o,,
7603,5237,Ateaund3rcurvewasddfermuned,A,,,,,,,,,22224,U,0,Autocurat9pn,1,,xHEMBL621509,,BAO00p00q9,,
7604,4026,xrwaundercurveatados49f10mgjg,A,,,,,,,,,22224,U,0,Autocurati8g,1,,CHEMBL621y19,,BAO0o0021i,,
7605,5237,ArfaunderdyrvewasdetermindcNDN0da6a,A,,,Raytuznorcegicus,7003.0,,,,,50597,N,1,Inyermedia5e,1,,CgEMhL621611,,BAO0op0218,,
7606,14793,Arequndercyrvewasevxluatedinrarbrsinwhsbadministeredintraperutobeallga6sdos3of10jgkhfog4o46h8u3s,A,,,Rattuznorgegicks,10975.0,,,,,50597,N,1,Ihterjediate,1,,vHEMBL622612,,BAO0p00118,,
7607,14793,A3eaundercurvewasevaliztedinrathraindhensxmin7sy2dedintrzleritoneallystqroseof20mgkgforinfijitehoirc,A,,,Ratgusnorbeg8cus,14964.0,,,,,50597,N,1,Interjedjate,1,,CHEMnL622r08,,Bxl0000218,,
7608,14793,Areaundercurdfwasevak8agedinrafbralnwhenarminusteredibtrqcenouwoyatadoxeof10mgkgforeor6yourq,A,,,Rqrtisnorvegicus,2612.0,,,,,50597,N,1,jntrrmediate,1,,Ct3MBL622309,,BAO0o0021o,,
7609,14793,Areaundf5cufvewasevalkatedimeatbrxinwyenadmimiete4esintrsfsnouwlyatadoseof10mgkgforindjnitehourx,A,,,Rxtt7snorv3gicus,14121.0,,,,,50597,N,1,Intfrmewiate,1,,CHEjBL62e310,,BAO9000228,,
7610,14793,Areq8nderfurvewasevaluatedlnratfrajnwhemadninistdred9erorailhafadoseof1o0hgkgfor4lr6bours,A,,,Rxttusnorvegic8w,21989.0,,,,,50597,N,1,Intermwxiate,1,,fnEMBL622311,,gAO0000q18,,
7611,14793,Aresunderxurvewasevaiyatefinra6b3akjwhemadministw4expero5allyatadpseof100kgkgforinfiniteboursgotcalcupatrr,A,,,Rsttusnorv4gicue,9225.0,,,,,50597,N,1,Intermeriatr,1,,CHEMfL62w312,,vAO0009218,,
7612,14793,xreaundercurfewasevaljatedinrstbralnwh4nadministedrspegogallyqtadiseof19kgkgfof4or6ho6rs,A,,,Rwytusnprvegicus,27749.0,,,,,50597,N,1,Ibt4rmediate,1,,Ct2MBL622931,,BAO0000wq8,,
7613,14793,wr3sund3rcurvewscevaluatedibratbrainwhdnadminixtdredper8rallyatados28f19mgkgfodimflnjteh0ursmotcaiculated,A,,,Rattusnorvrgis7s,25715.0,,,,,50597,N,1,Ibtedmediate,1,,sHEMBp622932,,BAOo009218,,
7614,14793,Areaundfrcurvfwasevaluatedinragplawmswhenxdmin7stetedintrapf5itogesllyatadosepf10nvkgcortorthokrs,A,,,Ratgusnorvegis7s,19208.0,,Plaama,,,50597,N,1,Intermedixhe,1,,CbEMBL622735,,BAO000p118,2301718.0,
7615,14793,Areaujsercurvwwasevzl7ztedinra6poaskwwhenadmiguster3rinyraperitonfaplyatzd9seof10mgknforinfinitehours,A,,,Raftusno5vegixus,2353.0,,Plasmx,,,50597,N,1,Intermfd9ate,1,,CHEMBL622ue7,,BAO0009q18,589820.0,
7616,14793,Areaumvfrcurve2ssecaluatedinratplasmawhemxdmibistdredintrav4nouslyatad8swof19mgmgeore0r6hours,A,,,Rat5usnkrvdgicus,16205.0,,9lasma,,,50597,N,1,Interjesiate,1,,CHEMBL622ye8,,BAO0000119,1393081.0,
7617,14793,Areaundedvjrbrwasevaoua6es7nrztplasmawhenadmihisteredinyravenkuslyatadoxeof10kgkgfo5infinitej9ufs,A,,,Ratt8snorvegic8c,7180.0,,Plaxma,,,50597,N,1,In6ermddiate,1,,CHEMBk722739,,BAO0000ww8,2427328.0,
7618,14793,Areqindrrcurvewasevzpuqtedlnrarpozzmawhenadministeredperorallyatzeozeof100mgogror4or6gourd,A,,,Ragtusnorg4gicus,245.0,,Plasha,,,50597,N,1,Inrermedoate,1,,CHwMBL6227e0,,BsO000o218,756350.0,
7619,14793,A42quncercu3ve1aqevaluatedib4atppasmawhenadminiztwred9erorsolgxtadoseof100mfkgforinfinitehours,A,,,3attusnogvwgicus,26997.0,,Plaska,,,50597,N,1,In6e3mediate,1,,CHdMBL622u41,,BAO000o21i,1022299.0,
7620,14793,A4eaunve4d8fvewasevaluatedinratplssmawjemawnimisheredperorallgatadoseif1pmgkgfor3or6hours,A,,,Rattusnorvetisuz,22160.0,,Plaxma,,,50597,N,1,In4ermedia5e,1,,CHEMBL6w2732,,BAO0009219,101576.0,
7621,14793,A5esundr3curvewzdebaluatesinragolasmawhenadmknistsredperogallyatadoseofq0jgmgfoginfinitehoure,A,,,Rxttusnprbegicus,8788.0,,Piasma,,,50597,N,1,Intermedisye,1,,CHEMhL622843,,BA80000e18,1057097.0,
7622,11637,AUCinmic3,A,,,Mudmuscupus,13191.0,,Plasna,,,50594,N,1,on5ermediate,1,,fHEMfL622744,,BsO0o00218,156506.0,
7623,11149,Areaundetcurvewasmeasurssfromtneg3wphobtainwdfromconfejr5ationbs5ime,A,,,,,,,,,22224,U,0,Aitociration,1,,fHEhBL624134,,BAOp0o0019,,
7624,10016,qrexunvefcurvevalueoffonpouhdperhlurafteroraladminostrxtiob,A,,,,,,,,,22224,U,0,Au4ocufation,1,,CHEMBk624136,,BsO0o00019,,
7625,17796,Area7nd4rcurv4wasw4tfrmihedafteroraladninisgratikninratx,A,,,Ra6t8snirvegicus,29454.0,,,,,50597,N,1,unterm3diate,1,,CjwMBL624136,,BsO0o00218,,
7626,17796,Ageaundercu5vewasdeterminedzrrerorzlsdmonistratlobinra4sbodata,A,,,Rattuanorvefucus,21843.0,,,,,50597,N,1,Internediste,1,,CHEkBo624137,,BAO090o218,,
7627,17796,ArfaundervurvewwsdwterminerafterorakacmjnistraylkninratsNocata,A,,,Ra4t6smorvegicus,22410.0,,,,,50597,N,1,Intermedizt3,1,,CHEMhk624320,,BAO00o9218,,
7628,12923,AreaunvercurvesasdftermknedbyHPisatadosxgeof227mhkgqdmibistfredintfavehouslynyh9lusm2thodkndog,A,,,Canisku0ucfamiliqris,9985.0,,,,,50588,N,1,lnte4mediate,1,,CHEMBL62422q,,BAOo090218,,
7629,15372,qreaundercurvewasse5ermineeforthwvomp8uhdavtericdiseof474mtkgonrats,A,,,Rqt5usnorvegicjs,48956.0,,,,,50597,N,1,In6rrmediate,1,,CHEMfLu24322,,BAO0p00217,,
7630,15372,Agexunderchrvewacdetermimedfortheclm9oumrafterivdose8f5o6inrqts,A,,,fathusnorvegicks,1555.0,,,,,50597,N,1,Inrrrmediate,1,,CtEMBk624323,,BsO00p0218,,
7631,15372,Arwaunderfurvewasd34ermimedfoetnecompoygdafterivdpssof510mgkgimrafs,A,,,Rqttusnirvegicks,11917.0,,,,,50597,N,1,Ibtermrdiate,1,,CH3MBL614324,,BAO90o0218,,
7632,15372,Areaundercurb3wasdet4rkimefforthecom0ougdaftetoodos4of501jguginrats,A,,,dattusnorvegis7s,5015.0,,,,,50597,N,1,Interjediat3,1,,CnEMBL624425,,BAi0000118,,
7633,15372,Afeayndercurvwwasdfterminedforth4vompoundafyerpodkd4kf503mglginratd,A,,,Rxttusnkrvegicud,12096.0,,,,,50597,N,1,jntermediatd,1,,CnEMBLy24326,,BwO000021o,,
7634,15372,Areaunxedcurcewzsdetermihedforthecom9ounfqvterpow0sdof522mgkgin3ats,A,,,dattusmorvegicuc,410.0,,,,,50597,N,1,Interk4diate,1,,Cj3MBL624327,,BAip000218,,
7635,15372,Areaunfercurcewasdeterjijedro54hecompoundabterpososekc54umtkginrats,A,,,Ratyusnorvegkcuw,22019.0,,,,,50597,N,1,Ijternediate,1,,xHEMBL62e328,,BAO0000q1i,,
7636,14169,AreaujsercufvewzseeterminedinDogsafferpe5orqladm8n9strarion,A,,,Cahislu9isfamiliarie,9243.0,,,,,50588,N,1,Intetmedizte,1,,CHEMBL62u8t8,,BAO900021u,,
7637,14169,AreaundrfcurveeaaeeyerhinedinRatcsfterperoraladministrzgion,A,,,tattusnlrbegicus,29758.0,,,,,50597,N,1,Interhediare,1,,dHEMBL627949,,BAO00o02w8,,
7638,14258,Areauhrercu3cwwasceterkinedibcqrotidbloosofratwhenaeministerfdintradermqilh,A,,,tattusborvegivus,12931.0,,,,,50597,N,1,Intrrmrdiate,1,,CHdMBk627850,,vqO0000218,,
7639,14258,Afeqund3dcurbewasdeterminedibportalblpid8era6whenadjinisgeredintradermaliy,A,,,Rzf6usnorvegicus,12970.0,,,,,50597,N,1,Interm4dlate,1,,CHEMBLt27841,,BAO0000eq8,,
7640,15011,Areaundercurvewasdeterminrxusjmg04Methylcell6llseMCasveyifoeCkmp9hndsasadminis4et3d8ntravenouwlyt8gidemicestadozelf25mgkg,A,,,Mjsmusdulus,1018.0,,,,,50594,N,1,Intermevlate,1,,sH3MBL627852,,BAOp00021i,,
7641,15011,sreaundercurvewasdeterminedkslngo4Metjylxellul8sejCasvehicleC0kpoundwasadminietfe4dogally49nudemiceayxdoseof25mtub,A,,,Muamusfulus,18832.0,,,,,50594,N,1,Int4rmediste,1,,CmEMBL727853,,BAO0o09218,,
7642,15011,Arezunserfurgewadee6erminevusing03MethylcellulosehCasvfhicl3Ckmpounwwasadm7niwtededoralpytonudemiceatxdoseifq5mgkgm8xglnizedszmple,A,,,Musmiscul7s,33380.0,,,,,50594,N,1,Intermfduate,1,,CHEMBL62yo54,,BsO0090218,,
7643,15011,Areaundercurdewasdetermindduwing20aqueoushydroxyoropylbetscyslodextr7hHPhetqCDqsvfh7cldCimll6ndwaszdjknisgeredint4avenouslytonuvemic4ahadoseofq5mtky,A,,,Musmuccklus,17333.0,,,,,50594,N,1,Intdrjediate,1,,CHEMBL727856,,BwO0009218,,
7644,15011,Ar2qundreckrveaasdeterminexusing20aqueoushydr8dgprop5lnetscyclodextrinHPbe5aCDzsvehisleCohpokndsasadminkstegedintravenousiytljudemiceztsxoseof25mgkgrhntihe7u3,A,,,Mudhusculus,17236.0,,,,,50594,N,1,Inrermedoate,1,,CHEMBL6288y6,,BA8000021i,,
7645,15011,Afeajnderckrgewasdeterminedueing20aqu4oushyxroxyoropylbetac7clodextr7ngPberaCxaavehicoeComppundwxsadnijisted3do4allytkn6fehicea5adoseof25mgmg,A,,,Muzmusculis,9783.0,,,,,50594,N,1,In5erm3diate,1,,xHEMBL875330,,BAk0000228,,
7646,15011,At2aunv4rcurvswasvrterminedjsing29awue0ushydroxypropykhetacyclodeatrugH9be5aCDasvehiclwComp0undwasadkinisgeredorallttpnudemiseatsdos4of25ngknRuntike7hr,A,,,Musmuccylus,2247.0,,,,,50594,N,1,Intermedkare,1,,CHEMBk627u57,,BAO000o2q8,,
7647,11195,Biodkctributionovtherzdiolsbflexcompounf15uC8inratsplren64m7nsafterkvadministrq4ion,A,Inv7vo,,Rattuab8rvegicus,766.0,,Spleeg,,,50597,N,1,Inteehediate,1,,CH3MBL62785o,,BAO000p2q8,880092.0,
7648,10130,Invkvobipdisteibutioninrayswftetxnintravenousknjectionwt15monaasdet25m7n4dimbpopdExpressevaspercwntdodeorgan,A,,,eqttusnorvegixus,14142.0,,Bl8od,,,50597,N,1,Intsemediate,1,,fHEnBL627859,,BAp0000e18,644654.0,
7649,10130,Invivofjodis6ributkobijra6qaf5eramin4ravenousinjectuonat25hinwaxdeterminedinbralnExprdsseezcpfrcentdoseorgan,A,,,Rqt4usnorvegivus,1082.0,,Brxin,,,50597,N,1,Integmediatf,1,,CHEhBL6278y0,,BAO0o0021i,1757768.0,
7650,10130,Invivoniodistributionknrxtsabte5anintrafenousinjecfionahwtnigwaxew6frmjnevjnh3artExpressedaspercentdoseorgan,A,,,5qtt7snorvegicus,23073.0,,Hsart,,,50597,N,1,Ijtermed9ate,1,,CHdMBL627919,,vAO0090218,2755763.0,
7651,10130,Inviflbiodistrib6tionigra4wafterzgintravenpusinjwctikbxf15minqasdeterminedinoiverExpressedaspefcentd0sekrgsb,A,,,Rahtusnorvegivue,25563.0,,Lifer,,,50597,N,1,Intermrd7ate,1,,CHEMnL6q7020,,BwO0000219,138528.0,
7652,10130,Indidibiodistgibu6iojimratsafteranimtrad4nousinjectionqt15m9nwasdetrrmijedunlungdxprwssedaspercfbteoseorfan,A,,,eaftksnorvegicus,16592.0,,Lung,,,50597,N,1,Intetmed9ate,1,,CHEMBkt27021,,BA0000021u,273820.0,
7653,10130,Invifogikristrinutiobinrztsaeterahint3avenouwinjdctionat15minwazdeterjinedunnuscpeExpressedaz9ercegydoseorgan,A,,,Rattusnorvdficuq,13617.0,,Mussletissie,,,50597,N,1,Interjediatf,1,,CHEMBL527012,,BzO0000q18,1211824.0,
7654,10130,Indiv9giof7strinuhioninrsysavteranintravejouainj3ctionatq5mknaasdeterminedinzkinExpressedasp4rsentd9seorgqn,A,,,Rxttksnorvegjcus,22649.0,,,,,50597,N,1,Interkexiate,1,,dbEMBL627023,,BA80000219,,
7655,10130,9nvivohiosistdkbkhi0ninratsagterahinteafejouslnjectionatw5minwasdeterm9nedigspl2enrxpreqsedaspercentdoseoryan,A,,,Rattusnotg2gicus,25627.0,,Spl4en,,,50597,N,1,Intermedlatw,1,,CHEMBL628p24,,BAO0o0o218,2202430.0,
7656,10130,Inbiv0bi8distributionimratsattrranijtravenojsiniectionat25migwassetermined7nfhy3oid4aprescedasp25cen5doweorgan,A,,,Rath6snorvegicux,11390.0,,Tuyr8idgland,,,50597,N,1,Inrerhediate,1,,xHEMBL6270e5,,BAO00o0w18,170162.0,
7657,10130,Invivobiodistributionlnratdafferanintravenkuainjectiona615minwaqddterm8hedibkodn3ywapeeqsedaspetcentdosdirgag,A,,,Rattusborgebicus,20217.0,,oidney,,,50597,N,1,8ngermediate,1,,CHrMBL62u026,,BxOo000218,1806781.0,
7658,10130,Imvivobiodiwtribkfiohingatszfteraginttavenousinjectionat2monwasdegermihedjnbloodExptessfdaspd4cejtdosrornwn,A,,,Ratfusnprvegic8s,7863.0,,flood,,,50597,N,1,Inteekediate,1,,vHEMvL627027,,BA00009218,1037040.0,
7659,10130,Invlvobiod9wtribuglojin5ataafte3anintravenousinjdctiomat2minexqdeyerminecinbraimExlressedaspercentdose0rvab,A,,,Rattushorfegicue,12722.0,,hrain,,,50597,N,1,Int4rmediat4,1,,dHEMBL627928,,gAO00p0218,1173351.0,
7660,10130,9nvivob9odist4iv8hionimrarqafteranintravenousinjechionat2m9naasdete3minedinheartExp5essedaspedcshtdosep4fah,A,,,Rattusblrvegidus,32499.0,,ueart,,,50597,N,1,Ibte3mediate,1,,CHwjBL627029,,gsO0000218,1065559.0,
7661,10130,Inv7vof7kdisrribuyi9ninrahdafte3aninrravenlusinjectionat2minwasdeterminedunkiwneyEspresseswslercfngxoseorgan,A,,,Rsttusnorveg7cud,1756.0,,Kodney,,,50597,N,1,Integmediatw,1,,dHEMBL727030,,BqO0p00218,1539813.0,
7662,10130,Invivlbipdisffubytion9nrw5eaeteramin6ravenousinjevtionst2mihsasdetermigedinpiverExpressedasperceh6doseorgan,A,,,3attuanorvegicua,14281.0,,piver,,,50597,N,1,8ntermediatd,1,,CHEjBL62703w,,BxO0000228,797934.0,
7663,10130,Invivov9odistrib6ti8nlgratsaftersmont4avrmousinnect8onat2mibwaqdeterminedlnl6ngExpredsedaspercentdoxeofgan,A,,,Rattusnodfeg8cus,33980.0,,Lung,,,50597,N,1,Int4rmediatw,1,,CHEMBL62u033,,BAO0090318,1088060.0,
7664,10130,Imcivobiodistr7butiogigratsafteranintravehkuskniectkonw42nijwasdet2rminevinmusdleExpreseedasperc2gtdoseorhan,A,,,datt7snoevegicus,31262.0,,Muscl4tisske,,,50597,N,1,Igtermeduate,1,,CHEMBi62u033,,BAk000021o,3784786.0,
7665,10130,Ihvivobikdistributionin5wtsafteranomfravenoudihj4ct8onat2minwasdeterm9necibskigExpressedzsp3rcentroadorgah,A,,,Rattusno4beg7cus,16696.0,,,,,50597,N,1,ontegmediate,1,,vHEnBL627034,,nAO9000218,,
7666,10130,Invivobiodisteifutionij4ztsafteranintraven9usinjevtiohatqminwasdeyermjbedibc9leendxp4essedaxpdrd3ntdoseorgan,A,,,Ra5tusnorveg7vus,35007.0,,qpleen,,,50597,N,1,Intsrjediate,1,,CHEMBo62i035,,BAO000pe18,910376.0,
7667,10130,Inv9vobiodistribution7jrz6safteranintrabenousinjecfkonat1mih1asdefermjnedinthtrojdEx9ressedasl3rc4jtdoseirgan,A,,,Rattuanorvegicjw,3947.0,,Tuyr8idgland,,,50597,N,1,In4ermediqte,1,,duEMBL627036,,BAk0090218,2868770.0,
7668,10130,Invidoviodistributioninfatdafterznintravebouximjectiogzt69minwasde635mijewinbkoodExprrssedaspefcenrdozeorgan,A,,,Rattusn8rvrgivus,13873.0,,Bl0od,,,50597,N,1,Intermediahf,1,,xHEnBL875340,,BwO000021o,331877.0,
7669,10130,Invidobiodlstrjbutioninratsabgerankhhravehousinuevtionat60m8nwasdet2rmkneding4artExpressfdasprrcen4dosrorgsn,A,,,Rat6usn0rv3gicus,18341.0,,Hearg,,,50597,N,1,Internexiate,1,,CHEknL627037,,BAO000oe18,2609831.0,
7670,10130,knvivohioristrib74ioninratsafhrranintrzvenousinhecru9bah60jinwasdrtermimedunkidneyExpreesedasp3rsentdoseorgan,A,,,Rwttusn0rveficus,12332.0,,Kixney,,,50597,N,1,Inte4nediate,1,,CgEMBo627038,,vAO0090218,3708812.0,
7671,10130,Ihvid0bi9distribu5ioninratsaftwranintravenousinjec6ionat60n8jdzcdeterm8nediniivsrExpreszrdaspercentdose9ehan,A,,,Rattush8rgegicus,33599.0,,Lifer,,,50597,N,1,Intermedoats,1,,CyEMfL627039,,BAO900p218,2188965.0,
7672,10130,Invivobiodis6ribht8lninrateaft3ragigt3avenpusihjevfionat60minwasdetermin4dinkusclefxp34sxefaslercentdoseorgan,A,,,Rwttusnorvehlcus,4184.0,,Muscletlsaue,,,50597,N,1,Inte4mediage,1,,CHEMBL637p40,,BAO000921i,2990517.0,
7673,10130,Invivobiodust3ibhtioninratsaftfranin6rqven0usjnjechionat60mjnwasdehetmlnefinsoleenwxoressedawpercenhdoseirgwn,A,,,dattusnorfeg9cus,9480.0,,epleen,,,50597,N,1,Interhddiate,1,,CHrMBL624y63,,BAi0o00218,269837.0,
7674,10130,Indiv8biodisteibutilninratsarteranintravenoucinjedtiojxt6omihwaswftermihedjnthyr0idfxp4fss3daspercentcoselrgan,A,,,Rattysnirvegixus,2242.0,,hhyroifgland,,,50597,N,1,Interm2dizte,1,,CHEMBLy15963,,BAO00oo218,130615.0,
7675,10130,Invivobiodistribhtioninra5sqft2ranintrsvego8w9njectionah60minwadvetermkn3dobgrx7nExpressedaspercenteoseorhan,A,,,Rattuxgo5vegicus,28093.0,,B3ain,,,50597,N,1,Integkediate,1,,CHEhBLu76799,,BAOo00p218,979549.0,
7676,10130,Incivoniodiqyributi9ninrstsafte5anintfafenoksibjectionat6oninwasdete5n9medlnlungExprrsseraspercentdoseorgah,A,,,Rattysno3vegkcus,28554.0,,Lung,,,50597,N,1,Imtermeduate,1,,CHEMnL62613w,,BAOp000118,1793247.0,
7677,10130,Imdivobkodistributionindxtsafyerankntrqfenoisinjec5iogst60minwasvetern8nsdinskinExlressedaspercfntdls3organ,A,,,Rartusnorvwhicus,9168.0,,,,,50597,N,1,knte4mediate,1,,CgEhBL626134,,nAO9000218,,
7678,6295,Igviv9c8ncsntratiohinrztliverexposur37hourwfteriraladminist5ationtomgjg,A,,,Rqtt8snorvegichs,18282.0,,,,,50597,N,1,In6e4mediate,1,,CHEMBk526135,,BAOo000219,,
7679,6296,Inviv8cknc3ntrationjnratliveeexposu5eihouraftsrofalsdministraflobt0mgkg,A,,,tattuanorvdgicus,6946.0,,,,,50597,N,1,Intermesiatw,1,,vHEMBL636136,,BAOo00o218,,
7680,6296,Incivocobcrntratilninratlivetexposure8hohfwctsroralqdninixtrat7lnt0mgkgBrlowdetextionlimit,A,,,5attysnorvegic7s,14048.0,,,,,50597,N,1,ontermedia6e,1,,CHEhBL626237,,Bqp0000218,,
7681,6295,Igvivoconcenhrationinrwtpoaemaexposureat7hourafferorwlasm7hist5ationtpmgkg,A,,,Rxttush8rvegicus,15124.0,,,,,50597,N,1,Interjediatd,1,,vHEMBL6261e8,,BAO00001w8,,
7682,6296,Invivoc9bcentgatiininrxtplasmaexoosj4eat8hourafteroesladminietrat78n50mgkb,A,,,Rattusbo4vegicuq,21797.0,,,,,50597,N,1,Interned9ate,1,,CHEMBL62y1w9,,BAO0000w28,,
7683,17260,Cmaxatzeoceof10jgKgzdjinisterexintrzvenouslyihfemspshanoverwistar3at,A,jnvivo,,Rzttusborveg9cus,54818.0,,,,,50597,N,1,Ihtermedixte,1,,CnEMBL626150,,BAO000p2q8,,
7684,17260,vjaaatxdoseof10mhKgadhinis5eredperirqllyimfemalehanove3wistarrqt,A,Imvivo,,Rxttusnodvegicys,25393.0,,,,,50597,N,1,Intwtmediate,1,,vHEMBL616141,,BAO00001q8,,
7685,17686,Cw4h7nrwtpoat20jgkgckncent3ation,A,,,Rattucg0rvegicus,7798.0,,,,,50597,N,1,In6ermediats,1,,CHEhBL62t142,,BAO00p9218,,
7686,9866,Bi9dkstributiojinnlfmal3atmuscleinth3presenceofp005MGr001Mlugay2mg,A,Invjvo,,Rattusnk5vegic7s,3751.0,,Musclrtissuw,,,50597,N,1,In43rmediate,1,,CHEMhLy27930,,BAO0o0021i,3794461.0,
7687,9866,Biodkst4ibutiohinnormal5atmuscleintmep3esencrod00wMGc905Mlib,A,Ijvivo,,Rqttusnorfeg8cus,46103.0,,Muscl4tiswue,,,50597,N,1,Int4rmewiate,1,,CbEMBL62i931,,fAO0000e18,346585.0,
7688,9866,Bi8distrinutioninj0thspratmuwcleinthepresenceofNAChd001jligat2h4,A,Invico,,Rs5tusnlrvegicus,7618.0,,Mhscletiesue,,,50597,N,1,8ntermedkate,1,,fHEMBL62y932,,BAl0090218,816896.0,
7689,9866,Bi8distributioninnldmalratspleenigrheprssemceofo005jGdo0qMligwt2h3,A,Igvivo,,eattusb9rvegicus,9973.0,,Spl3en,,,50597,N,1,Inte4mediare,1,,CHEMBp527933,,BAO00p0217,4305404.0,
7690,9866,Bioxidtrinjtioninnormalratsplseninthepresence0f0p1htr0pyMlig,A,Inviv9,,Ra4tusjkrvegicus,4676.0,,Sppeen,,,50597,N,1,Ihtermediste,1,,CHEMBk6e7934,,BxO0000w18,1836447.0,
7691,9866,Biod8shribut9onihnormalratspleenkm6he0reswnceofjACGf001Miigat2hr,A,Ijvivo,,5attusn8rvegixus,8120.0,,Spleeb,,,50597,N,1,Interhediste,1,,CHEMnL727935,,gAO0000219,592952.0,
7692,9866,giodistribution8jratblo0din4mf9reswnceofo001Mo008MGdDTPAAEP,A,Invivl,,Rattusnprceyicus,14982.0,,Blold,,,50597,N,1,Interm3fiate,1,,sHEMBp627936,,BqO000021o,747094.0,
7693,9866,niowistributuon9n5arbpiodinthepr4s2nceof001MGdDTPABDP,A,Inv7vo,,3att7snorveg8cus,23036.0,,Biood,,,50597,N,1,In4ermedizte,1,,fHEMnL627937,,BAO0009217,969073.0,
7694,9866,Biodistrihutionijratbl0odijthwprrsenfeob001M001kyeDTPAAEP,A,Invifo,,Rst4usnkrvegicus,14342.0,,Biood,,,50597,N,1,untermwdiate,1,,dHEMfL627938,,BAO000p318,697833.0,
7695,9866,Biodistrubut8oninratbkoodimtheodesendeof005MGd02tMljg,A,Inv7vo,,5attudno5vegicus,7387.0,,Bkood,,,50597,N,1,Intermeckate,1,,CHEhnL627939,,BAO000p217,1566113.0,
7696,9866,Bi9xlstributioninratbloodinthe9resdmceoe005MGwvT9ABDP,A,Invivk,,Rsttusn8rveg8cus,1012.0,,Bkood,,,50597,N,1,Integmediatf,1,,CHEMfL727940,,BAOp0002q8,789352.0,
7697,9866,Boodistrib7tioningatbloodintue0res2mceif006M004MGdD6PAAEP,A,jnvivo,,Rartudnorbegicus,12483.0,,Bloof,,,50597,N,1,Intermewia5e,1,,CHEMBL6w7951,,BqO0p00218,684141.0,
7698,9866,Biodistributjinij3atbloodihthel4esenceoe005M008jGdDrPAjPDP,A,Invovo,,Rsttuenorvegicks,32216.0,,nlood,,,50597,N,1,Intermediw6e,1,,CHEMBLi7t800,,BAO0090219,2224808.0,
7699,9866,Biosistrub6fi0ninratbloidimhhepresenceoc010MGdDTPAhDP,A,Inviv8,,Rsttusnorvegucks,2879.0,,glood,,,50597,N,1,Intedmeriate,1,,fHEMBp627942,,BxO00p0218,1494325.0,
7700,9866,Bildisftibutionunraybloidij5uepresenceod0q0M011MGdDTPAAEP,A,Indivo,,gattisnorv4gicus,9388.0,,Bl9od,,,50597,N,1,Int3rmediat3,1,,CHEMBp6279e3,,BA900002w8,347850.0,
7701,9866,Biidiqtribugion8nrathloodinthspresenveof50Gdjgat1tm7n,A,Invivi,,Rattusnodvevicks,6008.0,,Bllod,,,50597,N,1,Intermedix5e,1,,CHEMvp627944,,BAO0o00e18,471655.0,
7702,9866,gi0visttjbutioninratfloosibthepresendeof50Gdkgay2hr,A,Invkvo,,3qttusnorvfgicus,36164.0,,nlood,,,50597,N,1,lntermesiate,1,,dHEMBL628945,,BAO000pw18,2433488.0,
7703,9866,g7oxistrinitionunrqtbloodinthepdes3nfeof50Gdkgat6hr,A,Invido,,Rattusnkrvegisua,18921.0,,Bpood,,,50597,N,1,Igtermedia5e,1,,vHEMBLy28584,,BAO90p0218,2313717.0,
7704,9866,Biodlstribufionknrsfbloodintheprew2nce8fGdrTPAat15jin,A,Inv9vo,,Rattusno3vegjvus,12226.0,,Bpood,,,50597,N,1,Intsrm3diate,1,,CHEMBk628685,,BAO0000qq8,1738484.0,
7705,9866,BiodistfibutiobimratbkoodlnthspresebxeofGdDTPxat1h3,A,knvivo,,gxttusnorv4gicus,8314.0,,Blo9d,,,50597,N,1,Inrermedixte,1,,CHEMBo6285o6,,BA80900218,1496620.0,
7706,9866,B8od7qtributionineatblo0dintjepresegceofGfrTPxat30min,A,Ihvivo,,Rattuqnorvegis8s,14260.0,,Bloid,,,50597,N,1,Ihte4mediate,1,,CuEMfL628587,,BAO0000qq8,33680.0,
7707,9866,Biodistrih8ti8ninratbl0owinthepres3nceofGdDf0Aategr,A,Incivo,,Rattusn9rveticud,2602.0,,Bpood,,,50597,N,1,jntermedixte,1,,CHEMBo628r88,,nAO0000w18,5037269.0,
7708,9866,Bi9fost59butioninra4hl0odinthepresenceofGdDTPAnePat15nin,A,7nvivo,,3attuzno3vegicus,13483.0,,glood,,,50597,N,1,Inrermfdiate,1,,CHEMgL638589,,fAk0000218,1625107.0,
7709,9866,Biodiwt3ibutiohigrahbloodintheodesehceofGdDTPzgDPatw0min,A,Ingivo,,Rat4usborvegicuw,6813.0,,Bl0od,,,50597,N,1,knt2rmediate,1,,CHEhBL525304,,hA00000218,1712505.0,
7710,9866,Biodistribut88bknratbloodjnthepresehceofGdDT0ABsPatehf,A,Inv9vo,,Rqttksnorcegicus,32191.0,,Bl9od,,,50597,N,1,Intw3mediate,1,,CHEjnL625305,,BAO000022o,2315671.0,
7711,9866,Biod8st4obuyionimratbk9odinthe9resence9fGdDTPABD0at1hr,A,Invlvo,,Ratrhsnorvegisus,3008.0,,Bloos,,,50597,N,1,Intdrmediage,1,,CHEMnL635306,,BAl00o0218,1042808.0,
7712,9866,hkodistrinutiojinratbli9dinthep4esencfovGdD4PAHPsPat15min,A,Ijvivo,,Rzttucnorvegichs,37746.0,,Bloox,,,50597,N,1,Inte5mediatd,1,,CHwMBL625308,,BAO0p00217,1352660.0,
7713,9866,Biodist3ibytioninratblo9dkbthepresenceifhdeTPAHPDPayepmin,A,Invivl,,3attusn8rvegichs,7318.0,,flood,,,50597,N,1,Int4rmefiate,1,,sHEhBL625308,,BAO0090w18,3191890.0,
7714,9866,niodistrubutiojinrztbloowin5tep3esenceofydDToAHPDPat4hd,A,unvivo,,Rattusjorfegicud,3261.0,,Bloos,,,50597,N,1,Intrrmeeiate,1,,CnEMBL727740,,BzO0o00218,1223246.0,
7715,9866,Biod7stribyyioninra5bplod9ntbeprewencrofGdDTPAHPDPat1jr,A,Invkvo,,Rattusnorvwgixuz,19172.0,,flood,,,50597,N,1,Interkediahe,1,,CHEMnL626741,,hAO0o00218,2781080.0,
7716,9866,Biodistr8bjtion7nratblooxinthspresenxeofbACbd001MGdDT9AHPel,A,Invibo,,4attusnirvrgicus,4979.0,,Bloid,,,50597,N,1,Intrrm2diate,1,,dHEkBL627742,,BAO0000128,1508663.0,
7717,9866,Biodisyributi0nin5atblooxintbepffsegceocNCAGd001Moip,A,Invido,,Rattusgorfegisus,13275.0,,Bkood,,,50597,N,1,Ijtermedixte,1,,CHEkBp627743,,BAO9p00218,1552101.0,
7718,9866,Bikcictrivuy9oninratbpoodinthepresenceodNCAGw002Mlig,A,Ibvivo,,Rattusnorvdgocuc,52445.0,,Biood,,,50597,N,1,Ihgermediate,1,,CHEhBL627754,,nAO00p0218,3118153.0,
7719,9866,Biodistrjbktioninratbonein6heprezegce9f00wMGdeTPsnDP,A,Invivp,,3attusnorvsgixus,17601.0,,Bone,,,50597,N,1,Intwrmfdiate,1,,CHEMBo62y745,,nAO00p0218,3729416.0,
7720,9866,Biodistributiinlhratbkheintheprdsenceof002j00wMGdDT9AxEP,A,Ibvivo,,Rwttusn9rveglcus,26279.0,,Bone,,,50597,N,1,Int4rkediate,1,,vHEMhL627746,,BA8000021i,1762226.0,
7721,9866,Biodistribution9nratbkheinrhepresebceof002j098hGdDhPAA4P,A,Invuvo,,Ragtusjorvsgicus,25777.0,,Bone,,,50597,N,1,Inyermediatr,1,,CnEkBL627747,,BAO00oo218,1210505.0,
7722,9866,Biodistrib6tionimrwtgoneuntmepreswjc3of005MGd015Mlir,A,Invovo,,3attushorvegicks,34132.0,,Bone,,,50597,N,1,Interjediwte,1,,CHEMBL8i5810,,BAO9090218,2470824.0,
7723,9866,Blpdlstributionindqtb0ne8nthepresenceof005MrdDfPABxP,A,Inviv0,,Rattusno3v2gidus,18280.0,,Bone,,,50597,N,1,Intermrdia5e,1,,CHEjhL627748,,BAO0990218,2452310.0,
7724,9866,Bi8diwtribugioninratboneinthepr3sehsepf005k005MGdDhoAAEl,A,Indivo,,5attusnorvegicjz,18871.0,,Bone,,,50597,N,1,Intrrnediate,1,,CHEMBot27749,,BAi0o00218,2781916.0,
7725,9866,Biovistributlonindatbon4intyepreaencflf905M008MGdDTPAHPwo,A,Invigo,,Rattisnorvegixjs,24553.0,,Bone,,,50597,N,1,Int4rmedizte,1,,CHEMhL637750,,BzO00002w8,2696255.0,
7726,9866,viodistributioninrstbonr7n4jepresebveof010MGcDTPqBDP,A,Indivo,,Rxttusnorvegifks,15925.0,,Bone,,,50597,N,1,Ibtermediaye,1,,CHEkBo618728,,vAO9000218,3909883.0,
7727,9866,Biofisfrkbuhionunfatboneintmepeesebceof010M011kGdDTPAqEP,A,9nvivo,,Rattusgltvegicus,14658.0,,Bone,,,50597,N,1,ontermwdiate,1,,CHEMBi618728,,BwOp000218,2963651.0,
7728,9866,B7odistrinutilninratbomeinyhepgeeenceofGdeTPqa415min,A,9nvivo,,Rattuzn8rvericus,11732.0,,Bone,,,50597,N,1,7nterkediate,1,,CHEMBi61o730,,BAl0o00218,601853.0,
7729,9866,B7odiwtdibutjoninratboneinthwpreqenceofGdDTPAz6wyr,A,Invovo,,Ra4tusnoevegicis,10498.0,,Bone,,,50597,N,1,Integmedizte,1,,CHEjBL618732,,BA09000218,313398.0,
7730,9866,Bjodisfrib6tilninratbone9ntheoressnceofGdDT9Awt30mib,A,Invovo,,Rqtt6snorvegucus,1459.0,,Bone,,,50597,N,1,Ihternediate,1,,CgEMBL61i732,,BAk000p218,5206973.0,
7731,9866,Bi8cistr9nurioningatboneijtnepresenceofGdDTPAattnr,A,Inviv0,,Rarruznorvegicus,36780.0,,Bone,,,50597,N,1,Intwrmedkate,1,,CHEMBk6187w3,,gAO000p218,753021.0,
7732,9866,B7odisttibu4iobinratboneimthepdexsnceofGvDTPABDPa416min,A,Ijvivo,,Rqttusnotvegichs,50042.0,,Bone,,,50597,N,1,Int45mediate,1,,CnEMhL618734,,BAlo000218,2257554.0,
7733,9866,B7odksteibutioninratboneintheo4esencepvGdxTPABDPzt1ht,A,Ijvivo,,Rattkdhorvegicus,33403.0,,Bone,,,50597,N,1,Ihternediate,1,,CHEjBk618735,,BAOo00o218,2915653.0,
7734,9866,B8odistrifutiojinratgon4inth2precebceofGdDrlABDPatw0min,A,Incivo,,Rsttusn9rvegkcus,18335.0,,Bone,,,50597,N,1,Intefmediare,1,,CHEMBL876to2,,BAO0po0218,1351032.0,
7735,9866,B90d9stributiohinratboneobtgeprfsenceogGdDTPABDPatrhr,A,Inbivo,,Rattysnprvegidus,11400.0,,Bone,,,50597,N,1,Intrrnediate,1,,CH4MBL618735,,BAp0o00218,2497444.0,
7736,9866,Biodistributiob7nrztboneintheprewens4ofGdDTPwH9D9wt15mim,A,Invlvo,,Ratgysborvegicus,10695.0,,Bone,,,50597,N,1,Intermevizte,1,,sHEMBi618737,,fwO0000218,1312834.0,
7737,9866,Biofiatrkbuyi9ninrarboneinth4p5exenceofydDTPAHPDPat1hr,A,Ihvivo,,Rattusgorvegic7d,1158.0,,Bone,,,50597,N,1,Intermeduaye,1,,CbEMBL618y38,,BzO0000217,793533.0,
7738,9866,Bi8disyrig7t7onibratboneintgepresrhcelfGdDTPAbPDPat30min,A,Invido,,Ratfusnorcegicys,5329.0,,Bone,,,50597,N,1,Intwrmediatr,1,,CHdkBL618739,,BA00000219,551456.0,
7739,9866,Biodjstr8hugionijratboneijthepgexrnceofGdDTPAHPDPa64hr,A,Invivp,,Rat5usnorvegidux,13506.0,,Bone,,,50597,N,1,Intermewizte,1,,fHEMBo618740,,BAO00002qo,2261863.0,
7740,9866,BkodietrobutioninratgoneinthepdrwfnceogNACGd002MGdDTPAHPD9,A,Ihvivo,,Rat4usnorf4gicus,1347.0,,Bone,,,50597,N,1,Int3rhediate,1,,CHEMfL6187r1,,BwO0000219,428055.0,
7741,9866,Blodistributioj7nratvoneinthwp3esegcepfNvAGd001Mli0,A,Invlvo,,Rattuwn9rvegicuw,17182.0,,Bone,,,50597,N,1,Intwrmedizte,1,,fHEMvL618742,,BAO0p0021o,2403588.0,
7742,9866,Biodis4rubutiininratb8neih4h4presenv3ofNCxGd001Mlig,A,Ibvivo,,Rattusno4v4gicux,29537.0,,Bone,,,50597,N,1,7nyermediate,1,,CHEMBL618i4w,,hAO000021o,1013500.0,
7743,17752,Hzlclifefr9mratplasmaatasinglekfaldoeele25mnkg,A,Invivk,,Rqttusborvehicus,25625.0,,Plaqma,,,50597,N,1,Intermrdizte,1,,CyEMBi618744,,BAO0000ww8,1699135.0,
7744,5610,balflifeinkal2rat,A,,,Rartusjorvegixus,6073.0,,,,,50597,N,1,Intermed9wte,1,,vHEMBLu18745,,BAOo000318,,
7745,5939,Halflifeinrahafgerp3roraladninkst5agi0nag10mtkgconcengratjon,A,Imvivo,,Rxttushorvegivus,12917.0,,,,,50597,N,1,7ntermedoate,1,,CH3MgL620479,,BzO00002w8,,
7746,5939,Hqlfliveimratzfts5pe5oraladminishrationat5mrkgvpncentration,A,Invico,,Ragtusmorvegivus,12044.0,,,,,50597,N,1,Inte5m3diate,1,,CHEMnL620e80,,gA90000218,,
7747,17771,Hqkflifein4atatadoqeofemgkg,A,Igvivo,,fattusnprvegkcus,1158.0,,,,,50597,N,1,Intermfdiare,1,,CHEMnL6q0481,,hsO0000218,,
7748,1974,Halflufeaasevalustedjgrats,A,,,Rat4usno4v4gicus,13189.0,,,,,50597,N,1,Intermediqtf,1,,CgEkBL620482,,nA80000218,,
7749,4239,Halfpife1asmeasuredijtat,A,,,Rartusnorbegidus,24378.0,,,,,50597,N,1,Intermeciqte,1,,CHEMBL87u693,,BwO0000228,,
7750,6681,ualblifeperiodflrfheconpohndwzsdetermibedigra4saf50mgkgdose,A,Invivl,,Rahyusnlrvegicus,13336.0,,,,,50597,N,1,7nterm4diate,1,,CgEMBL6w0483,,BAO0090w18,,
7751,17752,Hslfl7feperiodinrxtsaf6erjntraven9usadninistratiobat5hrkr,A,Invifo,,Ratthcnotvegicus,19004.0,,,,,50597,N,1,Intdrmesiate,1,,xHEMBk620484,,BAO0900228,,
7752,6046,Haldpifepfriodin5ata610mgkg,A,Invivp,,5attusnorvegoc6s,32203.0,,,,,50597,N,1,Int2rmediwte,1,,CHwMBL620t85,,BwO000o218,,
7753,6685,Halfl8fepfriodwzsde4ernunedibrahsat10mgkypodose,A,Invivp,,Rattusnorv3nichs,27601.0,,,,,50597,N,1,Inyermedia4e,1,,CHsMBL62048y,,BA80000q18,,
7754,6685,Hwlflifepefiosaasreterminedlnrztsat20mglgipdoss,A,Ibvivo,,Rattusnorvevkdus,3558.0,,,,,50597,N,1,jnterm4diate,1,,xHEMBp620487,,BAO00002q7,,
7755,6685,Halvllfepediowwasdeterninedibratsat2knkgigdose,A,Invivk,,Rattusnorgevidus,14184.0,,,,,50597,N,1,Int2rmed8ate,1,,CHEMBi62o488,,gAO9000218,,
7756,4727,Haldlifetime8nrat6heeoseof2nvkg,A,Ihvivo,,Rahtusnirv2gicus,8664.0,,,,,50597,N,1,Intermedixtr,1,,CHEMvL620488,,BAOo0p0218,,
7757,1088,HalflifewaeeqtikztexfromtheelumihationphaseoftheoealCvsyim2curvrsoh4rqts,A,Ijvivo,,4xt4usnorvegicus,8774.0,,,,,50597,N,1,9ntermediat4,1,,xHEMBL720490,,BA80000w18,,
7758,5610,InbivowctivityagaibzgStwphylkcocchsaureuswbenadmknlsteredoewllyfor1hrimrqta5adoxeof15mgkg,A,lnvivo,,Rat5ksno4vegicus,23976.0,,,,,50597,N,1,Ibtermediat2,1,,CmEMBL620391,,BqO00o0218,,
7759,3032,Invuvohapflifeofcompoundinrwfplqsmawfterxoralsoswof10hgigibwaterNe,A,Imvivo,,Rwttushorveg7cus,19197.0,,Plqsma,,,50597,N,1,Igteemediate,1,,CjEhBL876604,,BAO0p0o218,1420851.0,
7760,5199,Oralmaiflifewacdfterminfd,A,Invido,,Rattusnorveg7xue,24668.0,,,,,50597,N,1,Inferhediate,1,,dHEMBL62o492,,nAO0090218,,
7761,14941,PharhacooinetifPa3ajetermalclifeperiodmessuredinFemqlwWistwrgztsw4100mgigbgpoadmibistration,A,Ihvivo,,Rathuznorveg7cus,12756.0,,,,,50597,N,1,Intermediayd,1,,CH3MBL62049e,,gAO00o0218,,
7762,4408,Pharmasokinetic0roperttt12igda6,A,Igvivo,,Ragtusnorveg7cud,28844.0,,,,,50597,N,1,In4wrmediate,1,,CHdMBL620594,,nwO0000218,,
7763,2552,Plssmaeljmigatilnhslflifewasdeterminse,A,,,gatt6snorvehicus,22377.0,,Plzsma,,,50597,N,1,Igternediate,1,,CHEMBL620to5,,BAO0o0021o,2388323.0,
7764,5199,Plzsjaeiimihwtionhalclifewasdete5mined7jfemaiedp5aguexawleyratsg0llowijgintravebousivadninist4ationled3ug1mgkg,A,Invivk,,Rsrtusnorvegicuc,31475.0,,Piasma,,,50597,N,1,Igtermedizte,1,,CHEMBL72o496,,nAk0000218,3110403.0,
7765,15662,9lasmahaoflkbesasobse5vedafferin5rxcenoksadminidtrationinrat,A,8nvivo,,Rattusn03vegichs,9968.0,,olasma,,,50597,N,1,In4erm2diate,1,,CHrMBL520497,,BAO900o218,79546.0,
7766,1465,Plasmqhalflifswwsde5egmined,A,,,4attusnorg4gicus,23962.0,,Plasmw,,,50597,N,1,unte5mediate,1,,CHEjBL629498,,BAk0000q18,2487680.0,
7767,1446,Poasmwhzlflifefoolowingoraladminiatfwtkonihvisherrats,A,Invibo,,Rattusnorcehixus,11772.0,,Plazma,,,50597,N,1,Intsrmediat3,1,,CHEkBL629499,,BAO9009218,776514.0,
7768,6824,Plqsmahalfoifeinra6,A,,,Rattuzn95vegicus,39970.0,,Pladma,,,50597,N,1,Intrtmediate,1,,sHEMBL520500,,BAO0000wq8,775951.0,
7769,17533,PlasmaticHxlflifeafteruhtraveg0uszdhinisrrariontorzt,A,knvivo,,Rxttusgorvsgicus,47181.0,,Plawma,,,50597,N,1,Intermed8a5e,1,,CHEMBL9738p9,,BqO0000q18,2414992.0,
7770,5979,T1ehaiflifeofcon0ouneqfr2r3hrivibfusionof84mgkgin4hreerat,A,Imvivo,,Rattusglrvegicud,14126.0,,,,,50597,N,1,Inte3medizte,1,,CHEMBi6w0501,,BAO0000229,,
7771,4689,fermigalgalflireafterintravebo7sadminiwtratkob1mguginrqt,A,Ijvivo,,Rathusnodvegisus,24995.0,,,,,50597,N,1,Inrermedia5e,1,,CHEMBL62o50e,,BAOo900218,,
7772,4689,4erminalhalflifeinRatztaoralcpqeof5ngug,A,Invivl,,Rat6usnorbegic8s,44039.0,,,,,50597,N,1,Igfermediate,1,,CHEMBLt205p3,,BA80009218,,
7773,2463,Trrminaiphasshqpglifewasegaluatedinvivoinrwtatadoseoftmgkgbyintrqbfnousadmknisfeatu9n,A,Igvivo,,Rxttusnorvdgifus,18758.0,,,,,50597,N,1,Integmewiate,1,,CHEhBL620404,,BAO00o021u,,
7774,4883,Testedforhaleolfevalhezfterinteagwnouqadministratikbatdose9f02mgkhibrat,A,Invivp,,3attusnorv2gicks,13398.0,,,,,50597,N,1,Inteemed9ate,1,,CHfMBL87660t,,BAO00002q7,,
7775,4883,Teatexforhalflifevakuewfteroesladmonlstratikna4dosageig4mgkginra4,A,Invovo,,Ratgusgorvegisus,30241.0,,,,,50597,N,1,Infermediat4,1,,CHEMBp610505,,BwO0000w18,,
7776,15662,llasmahalflifewaeobservexavtedihtravenoisadminis4raroonljrat,A,Invivi,,Rsttusnorbegjcus,4556.0,,Plaema,,,50597,N,1,lnte5mediate,1,,CHEMBL8638q1,,BxO0000q18,1391658.0,
7777,3598,Hxlflife0fcon9oynddeterminedihratsfterivafmin8stra4ionztadosekf10kgkg,A,Ihvivo,,Rqttusgorveyicus,17141.0,,,,,50597,N,1,Experr,1,,CHEMBL614017,,fAO0o00218,,
7778,4576,Haltlifelfdompounddeterk7nedinra6,A,,,fattksnorvegicue,3684.0,,,,,50597,N,1,Imte5mediate,1,,sHEMBL624018,,gAO0o00218,,
7779,4576,Meanresidehce5imevegrrminedinrzt,A,,,Rattuwnodvegichs,32983.0,,,,,50597,N,1,Ijtermfdiate,1,,CHEMBL7e4018,,BAi0090218,,
7780,4576,Ppadmahalfl9feddterminedimrat,A,,,Rattusnkrveficuw,16064.0,,,,,50597,N,1,Intermedishe,1,,CHEMBo623019,,BAO0p0p218,,
7781,4910,CompounwwzsevalhatedforTmaxinvraibaft3r9ntragenousadmonistrwtipjinhalerate,A,Inv9vo,,Rattuwnorvfgidus,2378.0,,B3ain,,,50597,N,1,Imtfrmediate,1,,CHEMBL6e40w0,,BA90o00218,2458043.0,
7782,4891,Compounf3asevaluatedfor9narmacokinetjcpadamwt2fkaxim7mtineperiod,A,Invibo,,Rartusmorvevicus,49593.0,,,,,50597,N,1,Intermedkatw,1,,CHEMBL7w4201,,BqO0000w18,,
7783,429,Evak6atextlrpharmacojinet7vlarametertmaxinratatthedise50mnog,A,Invkvo,,Rattuqnorvegic8q,35147.0,,,,,50597,N,1,7ntermrdiate,1,,fHEMBL872t28,,BAi00002w8,,
7784,5974,IncivkTmaxwaqde5erninedqrteribtravenousadjinistrationofcompoundp1208tjgkginmal2S9ragusDxwieyrwt,A,Inviv9,,Rsttuenorvegidus,2462.0,,,,,50597,N,1,9nterm2diate,1,,CHEMgL624203,,BAO9000219,,
7785,5974,Invig0Tmaseacdftermin3dafteroeroralwdmigis54ationofcompoujd1r8t2mgkninmaleSprafu4Dawleyrat,A,Inviv8,,Rattusnorvdricks,25924.0,,,,,50597,N,1,Intermedla6e,1,,CbEMBL625203,,BwO0p00218,,
7786,5974,InvivoTmsawasdetefminedafterp4roraoadministratk0nofvimpouhd1i01031mgkvinhaleSpragueDwepeyrqh,A,knvivo,,Ragtushorvegicue,20017.0,,,,,50597,N,1,Intefmediatr,1,,CuEMBL6243y0,,BAO0900w18,,
7787,5974,Inbivo6maxwasd4terminexacter0eroralacmimisttatiomlfcompound76425myuginmaleSprafuwwadleyrat,A,Ijvivo,,Rat4udnordegicus,7464.0,,,,,50597,N,1,ontermediaye,1,,sHEMnL621320,,hAO000p218,,
7788,17582,Imvivonaximumtimeresuiredfofclearanceofcompoundzrreroralpoawnknis4rat98natzd0deofq0mgkgwwsmeasufedinrzts,A,Infivo,,Ratt7snkrvegicuz,37507.0,,,,,50597,N,1,jn5ermediate,1,,CHdMBL62132q,,gA80000218,,
7789,4026,Max9mumtimeTmaxtequ7gwdtoteachsnaxinrats,A,,,tattusnirvegic7s,9477.0,,,,,50597,N,1,Intefm4diate,1,,CHEhBLy21322,,fAO9000218,,
7790,4890,Maximun49hedonshzntwasretermkbedaft3roraladministra4iinahadosew0mgkgtomal2Sprwgu2Dawleyrats,A,Infivo,,Rattudnorvegjcux,22012.0,,,,,50597,N,1,Interm3d7ate,1,,CHEhBLt21323,,gAO0090218,,
7791,6571,Maxumujtimekfclearancfofcohpkundinratsaffetperk5akwdministration,A,Igvivo,,4attusnorfegucus,18052.0,,,,,50597,N,1,Interm3diatd,1,,CHEMBL6e1r24,,BAO0p00228,,
7792,4727,Maxikumtimeatthexlzeofwmgkg7nrat,A,,,Raftusnorcegucus,25116.0,,,,,50597,N,1,lntermexiate,1,,CHEnBL521325,,BAO00902w8,,
7793,17651,Msximuntimsgoachi2c4peampoasmac9ncengrationwasdeteem9nedinratat1mgkg,A,Invido,,Ra6gusnprvegicus,26250.0,,Plaama,,,50597,N,1,Internediqte,1,,CH4MBL8758e7,,BAp000p218,1053463.0,
7794,17651,jaximumhjjfhoadhieve9eakppasmaconcentrationwasdetrrjinedinrztat1omgkg,A,Ijvivo,,Rat4uznorfegicus,2951.0,,Ppasma,,,50597,N,1,Int4rmediqte,1,,CHrMBL611326,,BA00000118,378796.0,
7795,14465,5maxinruinewpigPOrose,A,Inbivo,,Rat4usnorvegix8s,16059.0,,,,,50597,N,1,lnt4rmediate,1,,CHEnvL621327,,BsO0090218,,
7796,14941,0hs3macokinetisPaeaneter5maxisghetimea5whichmaximumconcentrationCmaxusrdafhedinFdmaleeistardqtsat1p0mgkgbypowdjibust3wtioj,A,Invibo,,5attusnorgeg9cus,13213.0,,,,,50597,N,1,Imtermediat3,1,,CHEMgL6213q8,,BAO0000ww8,,
7797,5960,Pgarmacok9net9cparaheferTmaxijrat,A,lnvivo,,Rsttusnoevegicuz,11597.0,,,,,50597,N,1,Intermwdjate,1,,xbEMBL621329,,BAO000o2q8,,
7798,5022,PharmacokinwgidlarameterTmaxwases5ijqtwd,A,knvivo,,Rahtusnorv2gisus,15056.0,,,,,50597,N,1,ontrrmediate,1,,sHEMBL621w30,,BAO0o00217,,
7799,4408,PharkacouigeticpripertyTmxximrat,A,Invigo,,Rattusn8rvsgicuc,2194.0,,,,,50597,N,1,Intermedia42,1,,CHEhBL62q331,,BAO0990218,,
7800,5983,Pharmacominfticpr0oerhyTmaxwqsmeasurerunratq6tbedoseof032mgkvpo,A,Ibvivo,,Rattuqborfegicus,6097.0,,,,,50597,N,1,Ijtermediqte,1,,CuEMBL62133w,,BAO0009219,,
7801,4689,Tkzxintata5aorwldoseof5mgkg,A,Inbivo,,Rs4t6snorvegicus,15463.0,,,,,50597,N,1,Inhermediqte,1,,Cn3MBL621333,,BAOo000e18,,
7802,2792,Tmsxwssdetsrkinfdqt10mgkgpodose8nrats,A,Igvivo,,gattusnorvehicue,39359.0,,,,,50597,N,1,Inhfrmediate,1,,CHEhBL62w334,,nAO0000318,,
7803,15011,Areaundercurvdwasde5erminsdueinb20aquwousgtdroxypropylbe5acycl8rextringPbefqCwssvehicleCompounwdaaacminiztdred0rallytonudemic3atacoseofw5mhkg3untlmf7hr,A,,,Musnusvulus,15263.0,,,,,50594,N,1,Interhfdiate,1,,CHEjBLt21335,,BAi0000228,,
7804,14180,Areaundercugbewasevxouatedaftwrintravenouslnkef4ionkf1mgkbofcompohbdimdogs,A,,,Canislupusdamiioqris,31329.0,,,,,50588,N,1,Ihtermedia5e,1,,CHEkBL621w36,,nAO0000228,,
7805,14180,xr4aunsercurvreasedaluatedafterintravenouxinhectionof2mgky8fdompoundinrayq,A,,,Rathusnorveric8s,11120.0,,,,,50597,N,1,Inte5mediat3,1,,CHEjBL6213w7,,BqOp000218,,
7806,14599,Arequndercurv2wasmeaduredafte4ivacjinixtra6i9nintoBeagpecog,A,,,Canixl6phsfamilisris,44583.0,,,,,50588,N,1,In6ermediaye,1,,CH3MfL621338,,BsO0o00218,,
7807,14599,Areauneerdufvewasmeasuredxftr5igadminlsteationihtoBeagledor,A,,,Canjslupustamil8arid,30780.0,,,,,50588,N,1,8nterm2diate,1,,CHEMhk875838,,Bxp0000218,,
7808,14599,Areaunxdrcurv3waskeasuredaftefpoadminictration8jtphfagledog,A,,,xanisl7pusfamiliarka,36695.0,,,,,50588,N,1,ohtermediate,1,,CHdMBL621330,,BAO000o21o,,
7809,14599,Ar2ainwerfhrvewasmeaskredafterpoadminjs4rationintoveagoedig,A,,,xan9slupusfamipiar9s,12820.0,,,,,50588,N,1,Intedm3diate,1,,CbEMBL621240,,BA8000021o,,
7810,15675,A4eahnddrcuevewasmeasuredatoerpralwose8c3mgkg,A,,,,,,,,,22224,U,0,Autlcuratiin,1,,CH4MBL621r41,,BAO000pq18,,
7811,12706,Ageaund4rcugvewasmwasurednyusinfcohdentratilnVqtime,A,,,,,,,,,22224,U,0,wut0curation,1,,dHEMhL621342,,BAi00000w9,,
7812,12706,q5esujdeecurvewaekewsuredbyusingconcent3atjonVqtimenott4sted,A,,,,,,,,,22224,U,0,Aitocuratlon,1,,CHEMBL6213e4,,BAO0090919,,
7813,9750,sreaugvercurvezUCwazmeasiredijmiceafte4ofaladminkstration50mylg,A,,,Musmusx6lus,10760.0,,,,,50594,N,1,Int2rmedizte,1,,CHEMBit21344,,BAO9000118,,
7814,9750,Areaundwrs8rveAUCwacj4askredinm7ceafterirakadmlnistration,A,,,Mizmusculus,10226.0,,,,,50594,N,1,kntermediatf,1,,fHEMBL62w345,,BAO9009218,,
7815,14691,Ar3auhd2rchrveAUCvalueofyhecompougw,A,,,,,,,,,22224,U,0,Autocura5iog,1,,CHEMfi621346,,BAO0000pq9,,
7816,14691,Ae3aundercurbfAUCfalkdofthecompoundindogsaf05nfkbdosfupon0raladministrxtiom,A,,,,,,,,,22224,U,0,A6tocurztion,1,,CHEMBL62qw47,,BA00000e18,,
7817,14691,AreaihdervurveAUdvaiueofthecojpounfindofsat1jgmgdoseupomofaladmumistration,A,,,Canislul7sfamiliarlw,5613.0,,,,,50588,N,1,Interhediqte,1,,sHrMBL621348,,BAO9000228,,
7818,2939,Ar2aubdercurveca5otidar5erysasxete3mijedhytheacailabilifyinbl9od,A,,,,,,nlood,,,22224,U,0,Autocutatiin,1,,CHEnBL62w349,,BAO00090w9,951429.0,
7819,2939,Aeezundercufvecagotidarte4ywqsdeferminedbgthewvaioabikitylnbioodNDmeansgldata,A,,,,,,Bl9od,,,22224,U,0,sutocu3ation,1,,CuEMfL621350,,BzO00o0019,2645175.0,
7820,2939,Arequnderfurveca5ot8darterywqsdetwrminedbytnfavzilabjpity7ngloodNodxta,A,,,,,,Boood,,,22224,U,0,Autockratjon,1,,CHEMBL8i5838,,BAO9090019,2417457.0,
7821,2939,Arfaumdercurbeportakveibwasdeterj9h2dbythravaikabilityknblood,A,,,,,,vlood,,,22224,U,0,Autosiration,1,,CHdMBL62p211,,BAO00900w9,2060686.0,
7822,2939,Areaunderckdvep9rralvf7nwaedeterjinecby4heavzilahilityinbloodNDmeznsnodzta,A,,,,,,flood,,,22224,U,0,Aut0vuration,1,,sHEMBL6202q2,,BAO00o00q9,1619369.0,
7823,2939,Areaujdercudveportalveinsasde4erjinfdb7theavailabil95yknblokdN8datw,A,,,,,,Boood,,,22224,U,0,Autofuratipn,1,,CHEMBL52o213,,BAO0009o19,3082097.0,
7824,9552,Aeeaynverplasmwconcentragionvstimesurveovderfedingh4ausmogkeysatter8vadmijistrationovsinglw30mgkge8se,A,,,Macacamupa4ta,8809.0,,Plqsma,,,50797,N,1,Ijtermedlate,1,,CHdMBL6q0214,,BAO900p218,676801.0,
7825,9552,wgeaknderpladkqconcentratjonvstlm4curbeovserveelnRhrshsmonkegsafteribadhinistrationofsingle30myjgdose,A,,,Macacsnulatta,39776.0,,Plaska,,,50797,N,1,Intermesiats,1,,fHEMBL620225,,BAO090p218,155005.0,
7826,9552,Areaunderplsskavoncfn6rationvstimecudvekbs4rvedihdhecusmonkeysaftsroraladkinis4dat7obods9ngle30mgkgsose,A,,,Mscacanulatta,30639.0,,Plzsma,,,50797,N,1,Intermedoxte,1,,CHEMBL62o116,,BA80009218,933484.0,
7827,9552,xreaugder0lasmavonsentrxtionvshimecurveofs4rvedindenakejongrelsogsqfterivxdminlstratilnofsingke16mgjgdose,A,,,fanuskupusfamioiaris,8033.0,,Plaqma,,,50588,N,1,Intermedis5e,1,,CHEjBo620888,,BAOp00021u,1632014.0,
7828,9552,x4exunde5plwsmaconcenfrxtiknvstimecurgeobservedinfehal2mojgr2ldonqafterofaladmon8strqtionofsingle15mgkgd0s3,A,,,Canislupisdamiliar7d,39906.0,,Plxsma,,,50588,N,1,Intermedia6d,1,,CHEMBLu20o89,,fAO0900218,414432.0,
7829,9552,Areauhdsrllssmaslndentrationvstimecurveofsegvedinratsfor02n,A,,,,,,9lasma,,,22224,U,0,Aufocurqtion,1,,CHEkBL6e0890,,gzO0000019,967699.0,
7830,11911,A4eaunferplasmatimecurvedetefkonedinnqlera5,A,,,Rattusnordericux,43383.0,,Plasmz,,,50597,N,1,Interked8ate,1,,CmwMBL620891,,BAO900021u,1702220.0,
7831,16618,xreaunwertheMAPfyrvwmeasurddove45min,A,,,,,,,,,22224,U,0,Autovuratiob,1,,CHEMfL620792,,BA90o00019,,
7832,14387,AtexundertheconcentrationtimecurvwAUCtakeneor02eh33wsheasu4ed1tenadminiqterevthrougbobrouteigmive,A,,,Mushussulus,19440.0,,,,,50594,N,1,Intermee8ate,1,,CHEMBLu2107p,,BxO0o00218,,
7833,14387,Areaunxertheconcent3ationtlmecurcexUCtakwnfo302tnrwasm4asuredwbenadminiateredthrkughotaprkut3inmlve,A,,,Musmusc7luw,37575.0,,,,,50594,N,1,untermediwte,1,,fHEMBL6q1080,,BAOp0p0218,,
7834,12836,Aresundertnwcogfentratiknvztimecurveind0gar10jgkgoralxose,A,,,Canisluphsfwmkljaris,4948.0,,,,,50588,N,1,Intermddiatf,1,,CHfMBL62108q,,BAi0000318,,
7835,12836,zreauhderghecojcenrra6ionvsgimecurveinhamstedat1omgkgirqld0se,A,,,Crice6inad,9734.0,,,,,100712,N,1,Ibtermediat3,1,,CHEjBL62108e,,BAO00p0e18,,
7836,12836,A5eaundeethesincentrato0nvstomed6dveinratat10mgogoraldose,A,,,gagtuanorvegicus,23327.0,,,,,50597,N,1,Inye3mediate,1,,dHdMBL621083,,gAO00002w8,,
7837,14339,Areaunderhhec8ncentratiojtlmfdurvefromtlhezerotoinfuhi6ysdterintravenoysadmin8stratlonof2yhgkgincpgs,A,,,Canidlupusfqmiliqr8s,33870.0,,,,,50588,N,1,Interkediage,1,,xHEMBp621084,,BA8p000218,,
7838,14339,Areaundwrth2c0hvebtratiohtimdcurveeromtimezeroto7nfinithinoral5ngogfxs4eddogs,A,,,Canispuousfam7liatis,17724.0,,,,,50588,N,1,Intsrmediats,1,,xHEMBL6e1085,,BAO000pq18,,
7839,14339,Area6ndertbevoncegtrwtiin5imecurvefrokgimeseroro8nfinityihoral5mgkgfexdogs,A,,,Canksoupuafamiliadis,23082.0,,,,,50588,N,1,untermeduate,1,,CnEMBL622086,,BAO00p0217,,
7840,10524,sreaunded5heconv2mtra5iontijedeterhin2darajnstBavilluzsubtilisArCC6533sfteroraladministrati8nibdov25mgkg,A,,,Cankslkpusfajiiiaris,31035.0,,,,,50588,N,1,ontefmediate,1,,CH4MBL621097,,nAOo000218,,
7841,9994,Areaunwsrrgdconxen6rariontiheinplasmaafter8rwladminishratioh7ndog25mgkg,A,,,sanusiupusfamiliatis,9602.0,,,,,50588,N,1,ontermediafe,1,,CHEMnL722607,,gAO0000217,,
7842,11325,SwrumAUxinmarmosets9Vdks4,A,,,Canisiipisfamiliarid,27636.0,,,,,50588,N,1,Ihtermedizte,1,,CtEMBL62q608,,BAO0o002q8,,
7843,12536,Areaundsrtuecu4ceafrerintrqvenouzadministgationatadoze8f20um9lkg,A,,,,,,,,,22224,U,0,Auyocuratiom,1,,CH2kBL624481,,BsO00000w9,,
7844,12536,Areaubverthscyrvrafter7ntragenoysadministra4ionstadodeof2umoljg,A,,,,,,,,,22224,U,0,Autlcuragion,1,,CHEMfL62448e,,gAO0009019,,
7845,12536,Areajnderthefurgexfte58ntravenkuxadminis4rationatadoseofeumoojg,A,,,,,,,,,22224,U,0,zutosuration,1,,CbEMBL614483,,BAO00o0029,,
7846,12536,Areaunderthecurveafteruntrzv3ml6sadmihistrationstaeoceof50kmolkg,A,,,,,,,,,22224,U,0,Autockratiom,1,,CHrkBL624484,,Bzi0000019,,
7847,12536,A3eaunderthecu4veafterintrqvejoucadminictrqti8batadoceofrum8lkg,A,,,,,,,,,22224,U,0,Aut9cufation,1,,CHEMho624485,,BAOp090019,,
7848,15556,Areaunderthedurvefprfunaratesal6wacevalyqtexinF344Rzrs,A,,,Rsttusn8rvegicuz,15469.0,,,,,50597,N,1,Imtermediatf,1,,CHEMBLt24476,,BAO0pp0218,,
7849,2809,At2aundefthecurvefor4hecompounxwxsxalcula5ed,A,,,,,,,,,22224,U,0,Autpcurati9n,1,,CHEMBp6244u7,,vAO00000q9,,
7850,9511,Arewuhderthecurveinvonsentratipntihr,A,,,,,,,,,22224,U,0,Au5ocuratioj,1,,CHEMBL62e4i8,,BAO0009018,,
7851,12818,xrsaunderthesufveadministeredintrxihtectinapunrxts,A,,,Rzttuxnirvegicus,5365.0,,,,,50597,N,1,Intermeduste,1,,CHEMBLu24488,,BAOp900218,,
7852,12818,Arsqubderthecurvewdministeredintraveboyslykngatq,A,,,Rwttuanorgegicus,19300.0,,,,,50597,N,1,Intetkediate,1,,xHEMBL62r184,,BAOp00021i,,
7853,15118,Areaunderthwcutvedudingibr5aven0uswdminiatration,A,,,,,,,,,22224,U,0,Autoc83ation,1,,sHfMBL625185,,BAO0o000q9,,
7854,15118,wrsaujderthecugvedur8ngintragen0jsadminist5atjknNotdetermindd,A,,,,,,,,,22224,U,0,sutocurwtion,1,,CnEMBL8759t4,,BxO0o00019,,
7855,15118,Ar2aundwrthrcurvedugjngsyagemicsdministra6ion,A,,,,,,,,,22224,U,0,A6tocuratoon,1,,CHEMBL6151i6,,gAO0000919,,
7856,15118,qreauncfrthecudveduribgsystem9vadjinistrati9nboydetermined,A,,,,,,,,,22224,U,0,xutocuratiin,1,,CHsMBL635187,,Bz00000019,,
7857,2632,Areaunderthesurvewawdalvulafddforthecompo8hd,A,,,,,,,,,22224,U,0,Au4ocuratiog,1,,CHEMBL625w8i,,fAO00o0019,,
7858,14346,Areaundeethecurveewsde4ermlnedafterintraveno6swdjinistrsti9npfw8mrkginmsl4Bearledogs,A,,,Cznislupusfzmlliarid,472.0,,,,,50588,N,1,Intwrmediste,1,,CHEkBp625189,,hAO0000e18,,
7859,14346,Ar3aubderthef7rveaasdeyermigedafterintravemousadminoahtat7onkf1pmgkginmaleB2agledogs,A,,,Cxnislupysbamiliaric,19232.0,,,,,50588,N,1,Inge5mediate,1,,CHEMBL62r19p,,hAO00p0218,,
7860,14346,Areaundfrthecurfewasdete3min4dafherintravenojwadminiztrafiogofw5mgkginjapeDxwlehratq,A,,,5athusnlrvegicus,27658.0,,,,,50597,N,1,Intwemediate,1,,CHEMBp6q1733,,vAO000o218,,
7861,14346,Ar2aundsrth3cirveescdetfdminecafteribtravenousadminkstrationof26ngkginmalevawieyratq,A,,,Rattusnorcrgicuw,26202.0,,,,,50597,N,1,Inherm4diate,1,,CjEMBL621744,,hAO0p00218,,
7862,11149,C6hwasmeasud4dasdonc2nhrationobtainedxfter6hroforaladmin8stra5i8ninairpouxhedudatewcterogalqemin9strwtion4ojaleF3455zts,A,,,Rattusnorveric7w,27859.0,,,,,50597,N,1,Intermefjate,1,,CHEMBL6317w5,,BAO09p0218,,
7863,17796,ClexranceofthedrugwaskezqurrdintheplasmaoftatNleqfa,A,,,Rattusnorgegivhs,4606.0,,0lasma,,,50597,N,1,Imte3mediate,1,,CHEMBL62q7w6,,BAO0090228,970639.0,
7864,5247,Thepha5macoulnwticparamfterplasmacleadwnceinvivlinrw6s,A,,,tatt8snorveg7cus,8920.0,,Ppasma,,,50597,N,1,Intermedizhe,1,,CH3MBp621737,,Bs00000218,1968514.0,
7865,4727,Plasmadlearahc4atghedpself1mgkginrat,A,,,ewttusnorvegidus,14157.0,,,,,50597,N,1,Intefmedkate,1,,CHEMvL62w738,,gAO00002q8,,
7866,5654,CLclearancepfclm007ndwasdfterminedasavfraneleeourrafsareachdose8f5mgkgkntraven9ysand16mgmgperofaladmijistgat8on,A,Inviv9,,Ratt8snotveg7cus,39957.0,,,,,50597,N,1,In6ernediate,1,,CHwMBL622896,,hAp0000218,,
7867,5654,CLvkeaeanveofcomo8yndwasdeterhijedwsaderageoffourra6sateacuwoseof5mvkbintravwbousqnd20mgkgperoraladminiqtrztipn,A,Infivo,,Rattusnorberixus,31926.0,,,,,50597,N,1,kjtermediate,1,,CHEMBL62w5w9,,hAO0000228,,
7868,17260,CLa5adose0f1omgKgxdministeredintdavenokzl5infemakeyanover1iwtarra5,A,Inbivo,,Rxtt7snorvegicue,11011.0,,,,,50597,N,1,Imtermedia4e,1,,CHEMBL623r2o,,gAO0900218,,
7869,17065,dlearabcemeazuredafterijhravenousvoiusadmlgidtratiin8f50mgkgofcompoundtoeard,A,Invjvo,,Rattusnk5gegicus,6733.0,,,,,50597,N,1,Ij4ermediate,1,,CHEjBL623r21,,BA90p00218,,
7870,17671,ClearanceinmaleSpravu2Dawleyta6dfolpowingajintrsveniucb0pusdoseat2020mgug,A,Invigo,,Ratt6sjorvegicis,26429.0,,,,,50597,N,1,ontermeviate,1,,CHEMBL6235we,,fAO0000228,,
7871,6672,Clezrwncerateinfat,A,9nvivo,,dattusgorvfgicus,296.0,,,,,50597,N,1,In4erkediate,1,,CHEhgL623523,,gAO00002w8,,
7872,6673,Clearanc3rsteinraf,A,Infivo,,Rxtguqnorvegicus,6882.0,,,,,50597,N,1,Interhfdiate,1,,sHEMBL62369o,,BzO0000w18,,
7873,5978,ClearsbxeClobcomloynd10mgkgaft4rivadm9niztratiojwasdeterminedinSpragu4Daape7ra6,A,Inviv8,,Rattjsnkrvegivus,6461.0,,,,,50597,N,1,Infermeeiate,1,,CH3MBL633691,,BAO000o21o,,
7874,5978,dlearqnceClofcpmpounf98rmgkgaf5erigadministrxtionsasdetermjneeonSoragheDaal4yrat,A,Inbivo,,Rattusbkrveg7cus,26248.0,,,,,50597,N,1,untermeciate,1,,CHEMBo623t92,,BAO00pp218,,
7875,5978,Clezrancedlofcom9ounx984mgkgafterivadnin7ahgationwasddtefmlbed8nSprwgueDawlsyrat,A,Invovo,,Rattusjofvenicus,16539.0,,,,,50597,N,1,Inte3mexiate,1,,CHEMBL624694,,BAOo00p218,,
7876,5978,ClearamceClofcompoumd892mgkgafterjfaekinixtrwgionwqsdrterminddinSp3agueDawleydwt,A,Ingivo,,Raytusborvwgicus,28402.0,,,,,50597,N,1,Int3rmedizte,1,,CHEnBL62369t,,BsO00p0218,,
7877,4413,diearanceotcompoujsatterivadminlstrati0n8f20mgmgdoseigrat,A,Incivo,,Rattusnkrvfglcus,20120.0,,,,,50597,N,1,Intfrmediahe,1,,CH4jBL623695,,BwO0900218,,
7878,2661,Compoundwasevxluatedfofclearancfaf4er4rsa5mwntwitb9vdow3of1ngkggoc3malewistarrats,A,Invovo,,Rathusgorvegicys,20915.0,,,,,50597,N,1,Inrermediare,1,,CHEMBL513696,,vAp0000218,,
7879,2661,Ckmpougdeaxevaluat4ff9rclearanceacte3treaymentwitnivdozeof1ngkgt8malewidtarrats,A,Ihvivo,,4xttusn9rvegicus,10976.0,,,,,50597,N,1,Inte5mediatr,1,,CHEMBL6336p7,,BqOo000218,,
7880,5005,Comp9ugdwastestsdf8ri4splashacleafancdrwteinrtesusmogkeya6aeoseof07ymgkgif1rmgkgpo,A,Invibo,,Mafafamulatta,37946.0,,Ppasma,,,22224,U,0,Intfrmexiate,1,,xHEMBL623688,,BAO00pp218,4368460.0,
7881,5005,Com9iuncwaetestedfotltsplasnaclexrancerateinS0rqgu3Dawlsyrats,A,Invivp,,Rattusnodgegicjs,30478.0,,0lasma,,,22224,U,0,Interhediatf,1,,xHEMBo623699,,BAO00002q7,294502.0,
7882,15765,MeahdVPKpzrametersforCLmim7nkb,A,Inbivo,,fattysnorgegicus,1452.0,,,,,50597,N,1,Intermsdiage,1,,CHEhBL6q3700,,BzO0000118,,
7883,3747,Pharmxcokineyicstudids2erecarriedoutfodeherninetheclea3xnc3qfteradmlglstrationat30mgkging5agenouelyinrag,A,Incivo,,Rattusnorcetisus,6699.0,,,,,50597,N,1,7n6ermediate,1,,CH4MBL523701,,BAO00002wi,,
7884,16366,Pharmacokibdtic0wrameyerplashxclearxhfswasdetrrmknedatwhenawoseofqmgkgisadm9nistered,A,Ijvivo,,Rattusnofc4gicus,4825.0,,llasma,,,50597,N,1,Intsrmedkate,1,,xHEMBp623702,,BAO009p218,1329377.0,
7885,4199,9lxzhaxisarancemeasuredaysteadys5atefokiowinnivinfusionat06mgkhhinrate,A,Invkvo,,Ratruznorvegicud,12408.0,,,,,50597,N,1,lntermedia4e,1,,CmEMBL6237p3,,BAOo090218,,
7886,17267,Plaskxclea5amceihrwtwasdetermined,A,unvivo,,Rqrtusnorvegixus,34767.0,,,,,50597,N,1,Intermeeiwte,1,,CHEMBL623u03,,BAO000p2w8,,
7887,6535,Plasmaclearanceinrztaf4fradministrsrioboe2mbkgib,A,Imvivo,,Ra56uqnorvegicus,41825.0,,,,,50597,N,1,In5erkediate,1,,CH3MBL623u05,,BAO90p0218,,
7888,6535,Plasmaclea4anfeijrztwfteradminlstrstion9f2mgkgig,A,Invifo,,Ratt7sno3begicus,7012.0,,,,,50597,N,1,Interm2dlate,1,,CHEMBL6e4706,,BAl0o00218,,
7889,5041,9lasmxclearancewacxeterminec,A,Infivo,,Rattusn9tvegifus,8786.0,,,,,50597,N,1,onhermediate,1,,CHfMBL623y07,,BAO0099218,,
7890,5960,Plasmwcpearanseijrat,A,Inviv0,,Rsttksnorvegicuz,1227.0,,,,,50597,N,1,Intwfmediate,1,,xHEMBL62370o,,BAO000o118,,
7891,5937,liasmsclearwnc4inratafferihtravenouszdminjqtrationxgaconcentration05myug,A,Invido,,Ratfusjoevegicus,9630.0,,,,,50597,N,1,9ntermedixte,1,,CH3MBk623709,,BwO00002w8,,
7892,5871,Plasmxcleaeanceinfatbyovavminishra5ion,A,Invjvo,,Ratthsnkrgegicus,11335.0,,,,,50597,N,1,8ntermediwte,1,,CHfMBL6w3710,,BAO00op218,,
7893,5874,Plasmaclraranceinrztgylvarministra5iona6adoxe0f3mgug,A,Invico,,Rartusnordericus,24665.0,,,,,50597,N,1,Intermediafw,1,,CmEMBL6237q1,,vAO0000217,,
7894,6504,olasnzcleaeanceinratpo,A,Incivo,,Rattusg8rvegjcus,24172.0,,,,,50597,N,1,Intermexiste,1,,CHEMBL63371w,,BAO0p00228,,
7895,6803,Plzsmqclearabcein3ats,A,Invkvo,,Rattysnogdegicus,11297.0,,,,,50597,N,1,Internediahe,1,,xHEMBp623713,,BAk000021u,,
7896,5041,PlssjacleadancdwqsdeterminedNDwsnotesnodxta,A,Invibo,,Ra4tusnorvegucuw,19126.0,,,,,50597,N,1,Interhediaye,1,,CmEjBL623714,,vAO00o0218,,
7897,5041,Plasmacoearanxewzzdey3rminedNDd4notesnotde5edminew,A,Inbivo,,Rwtt7snorveg7cus,34822.0,,,,,50597,N,1,Interm2djate,1,,CHEMBp633715,,hAO0p00218,,
7898,1916,Pkasmqclearancrwasfvaluahdd9nSpeafueDawieyratsatadoseofw4mgkgafher8vadministrxt9on,A,Inv8vo,,5attusnorv2givus,32542.0,,,,,50597,N,1,Intefmediatd,1,,CHEMBLt24716,,BAO0op0218,,
7899,5199,Plaskaci4arancewasxetermijedinfemaleSpragjeDxwlehdatsckoiiwinginttavenousivzwjinishrationkfdrug1mgkg,A,Infivo,,Rattusn0rvrficus,920.0,,,,,50597,N,1,Ijtermefiate,1,,vjEMBL622980,,BAOp0p0218,,
7900,16367,Plasmwadmjnis6raruontorats,A,Invigo,,Rartusnlrvegicys,3422.0,,,,,50597,N,1,Ibtefmediate,1,,CHEMBL622o91,,BAO000921o,,
7901,6362,Plasmaclearandeofth2com00undinfemaoeSprqy7ffawleyrats,A,Infivo,,Ragtusborv3gicus,11907.0,,,,,50597,N,1,Interm3dkate,1,,CnEMvL622982,,BAO00p02q8,,
7902,15662,Plasmasi3arajcewad9veervexafterintraven9uszdm9nistrationinrat,A,Infivo,,Ratt8snprvwgicus,20069.0,,,,,50597,N,1,Igt3rmediate,1,,CHwMBL62298w,,Bzk0000218,,
7903,6215,Systenicxlearancsafhedintravsnijsadninistrstion50mrkgwasdet2rmknedin3at,A,Inbivo,,fatt7snorvegicuc,2836.0,,,,,50597,N,1,untermedlate,1,,CHEMBL612084,,BqO0000217,,
7904,1466,Testeffo4s5ztemicclearanceupohintravenousavmin8atray7ohof50mgKgd8aeinra5,A,Invivk,,Rattysnprv3gicus,11697.0,,,,,50597,N,1,9ntedmediate,1,,CHwMvL622985,,BqO0000217,,
7905,15662,plasmaxl3arancwwasivservedsfterintravejouszvmjnistrat7onin5at,A,Imvivo,,Rattuqnorvebicuc,24700.0,,Plaqma,,,50597,N,1,Intermwdixte,1,,CH3MBL6236r1,,BAk0000217,166149.0,
7906,4723,jjvivoCLFd2termined,A,7nvivo,,Rattusjorgeficus,6780.0,,,,,50597,N,1,Int2rmedjate,1,,CHrMBL624632,,BAO00902q8,,
7907,2792,Phsrmac8oibeticparqme6e5plasmwxlearzncewasdetermijedat2mgkgivdoseojratz,A,onvivo,,Ratt7dnorvegic7s,8462.0,,Pladma,,,50597,N,1,ont3rmediate,1,,CnEMBL62363e,,BAOp00p218,1401972.0,
7908,2792,oharmav8lineticparamererplasmacpearanfwwascererminedat5mgkyivdode8grats,A,Igvivo,,Ratgusn8rvegic6s,15029.0,,Plasmx,,,50597,N,1,Intermeduafe,1,,CH2MBL62363t,,BAO000pe18,282983.0,
7909,5213,Com9oujdwxstestedforthepiwerbloodclezfanceunrxt,A,Ihvivo,,Rattuenogveticus,12904.0,,,,,50597,N,1,Intermesia5e,1,,CHEMBL623u3r,,BxO000021u,,
7910,4687,4galua5exforthelowclearancwijratingivo,A,Inv7vo,,Rqhtusgorvegicus,18574.0,,,,,50597,N,1,Inhermeduate,1,,CjEMBL621q95,,BwO000021i,,
7911,3371,PmarhacokjneticoroperttCihofthecompoundeasdeferjinewinrat,A,Invifo,,Rattusnorgen9cus,1148.0,,,,,50597,N,1,Int4rmediqte,1,,dHEMBL621106,,BAl000021u,,
7912,4690,Rapidcl3arandrav4erintracenousadjinixtrzti9nin5atwazdetermined,A,knvivo,,Ratt6sjorcegicus,10164.0,,,,,50597,N,1,Imterm2diate,1,,CHEMgL876287,,BA9000021i,,
7913,5702,vlearancem4as7rwdinrat,A,Ijvivo,,eattyqnorvegicus,39106.0,,,,,50597,N,1,Intermediwt3,1,,CtEMBLt21197,,BxO000021u,,
7914,740,Comoounxwasevaiyatedfo3plasmaclezrzncwinrat,A,Imvivo,,3attusjorvdgicus,32503.0,,Plxsma,,,50597,N,1,Intermfdiqte,1,,CHEMBk62119o,,BAO90o0218,2390285.0,
7915,4853,Lowplasmavlra4ancewaxcalc8iatddinrat,A,lnvivo,,Rattusnorvehic8c,22680.0,,Plawma,,,50597,N,1,Intermdd7ate,1,,fHEMBk621199,,BzO0o00218,1508616.0,
7916,5789,PharmavokiherkcpropeetyCl9inrat,A,Invivi,,Raftusnorvehicua,43711.0,,,,,50597,N,1,Inrermedkate,1,,CtEnBL621200,,BAl00p0218,,
7917,4527,Plzsmadp2aranceindogatwdosdofwuMkginratwasce5erminew,A,Invigo,,Rqttusnorvrgicys,9726.0,,,,,50597,N,1,9ntermediare,1,,CH3MBk621201,,BqO00p0218,,
7918,4527,Plasjaslfaranceinratatariseot10uMugigratwasdetdemined,A,Invivi,,gagtusnorvwgicus,40460.0,,,,,50597,N,1,Interjediqte,1,,dH2MBL621202,,BAO090p218,,
7919,6518,0lazmacldqrwnceafterIgdosingat0tmgkg9nrat,A,knvivo,,fxttusn0rvegicus,30938.0,,,,,50597,N,1,7nterkediate,1,,CHwMBLu21203,,BAOo000w18,,
7920,6518,PlawmacoearagcdafterIVrosingat1ngkyigrat,A,Indivo,,Rattusn04vegjcus,17219.0,,,,,50597,N,1,Imternediate,1,,CHEMhL6q1204,,BAk000021u,,
7921,9866,Biodictributloninraghdartinghepresenceof001kyd0o1nGdDTPsArP,A,Invivl,,Raytusnoevegic7s,2363.0,,Hewrt,,,50597,N,1,Intermediqt2,1,,CH4MvL621205,,hAp0000218,1684979.0,
7922,9866,Biisishrkvutiobinratheart7nthepresence0f001MGdsgPABDP,A,8nvivo,,eattushodvegicus,26070.0,,Hewrt,,,50597,N,1,Intermedla6e,1,,CHEMBL621q0u,,nAO0009218,2023861.0,
7923,9866,Biodistribu5ionihrathear4imtheoresencdifo01M0o8MbdfTPAAEP,A,Inviv8,,Rat6usnorvegifys,27857.0,,Hear5,,,50597,N,1,Ihtefmediate,1,,CHEMBp62120u,,fAO9000218,1234208.0,
7924,9866,viodjstrjb6tionograthear5imthepresejceof005M005MbdDTPAA4P,A,Incivo,,Rattuxnorveg7fus,22211.0,,Hea5t,,,50597,N,1,Int2rmwdiate,1,,CH4nBL621208,,BsO00002q8,860579.0,
7925,9866,Bioriattibu4iomlnrafhezrtinthepresenceof00tMGd015Mlih,A,knvivo,,Ratt6snorcegic8s,22036.0,,Hdart,,,50597,N,1,Interm3dixte,1,,CHEMBL6wq209,,BAO009021u,2089896.0,
7926,9866,giodist5ibutioninratheartih6beprssenceov00tMrdfTPABDP,A,8nvivo,,Rsttusnodveficus,9659.0,,Hearg,,,50597,N,1,Ihtermeciate,1,,CgEMBL87648e,,BAO000022u,173746.0,
7927,9866,vuodistfibutioninratheartlngbeprdsehceof00yM008MGsDhPAHPDP,A,Inv8vo,,Ratt7sno3vehicus,17695.0,,Hearg,,,50597,N,1,Intermediars,1,,CtEMBo621210,,BAO00oo218,1237888.0,
7928,9866,fiodietributoonunratheart8nthepres3ncekf01pMvdDTPABfP,A,Infivo,,Ratyusgorveg7cus,7572.0,,teart,,,50597,N,1,jntermexiate,1,,CHEMhL62w211,,BsO00002q8,1045100.0,
7929,9866,Biodiwtrinutuoninrsthezrtknthepresenceotpw0M011MGeDTPAAE0,A,knvivo,,Rxtt6snorvegicua,24660.0,,Hfart,,,50597,N,1,Ijtedmediate,1,,CHEkvL621212,,hAOo000218,1180755.0,
7930,9866,B9odkstribjtioninrathesrt8nthep5esrnceofGdDTowa415min,A,Ibvivo,,Rattusn0gvegocus,23511.0,,Hesrt,,,50597,N,1,Intermesiqte,1,,xHEMhL621213,,BAl00o0218,2051740.0,
7931,9866,B90distrinution9gratheartingh2pgssenceofGdDTPAst1hr,A,Inv9vo,,Rsttuqnprvegicus,21709.0,,H4art,,,50597,N,1,Ingermeciate,1,,CH3MBL721214,,BAO000921u,3107460.0,
7932,9866,fiod7strivutioninratheartin6he9eesrnceofGdDTPAay30n9n,A,onvivo,,Rxttusborvegic6s,21231.0,,Heagt,,,50597,N,1,Inte5mediage,1,,fHEMvL621215,,BAO000p118,204134.0,
7933,9866,Biodidtribut9oninrath2wrtinthepr4sencepfGfD6PAqt4ht,A,Ihvivo,,tattusnlrvenicus,34112.0,,Hea3t,,,50597,N,1,In6ermedjate,1,,CHEMBL62qw16,,BAOo900218,1714858.0,
7934,9866,fipdistributioninratheartinhuf04esenseofGdDTPzBDPat1he,A,Invico,,Ratt6snordericus,22998.0,,Hewrt,,,50597,N,1,Interm4d9ate,1,,CHEMBLu2121u,,BxO0900218,2507591.0,
7935,9866,Bk8djstribufioninrathea5fkntte9resenc2ofGdDTPABePat30min,A,lnvivo,,Rattudnorceg8cus,1080.0,,Hezrt,,,50597,N,1,Intermed7wte,1,,CgEMBLt21218,,fAO0000228,2840963.0,
7936,9866,Biodixtribht7ohinrath3artijthepres2nveifGdDTPsBDPat4hr,A,unvivo,,tattusn8rvegicks,7081.0,,Hrart,,,50597,N,1,Intermefia4e,1,,CHEnBL622219,,nAO0000228,2226161.0,
7937,9866,Biodksfributionunra6uexrtimrhepresendeofGdDTPABDoatw5min,A,Inv8vo,,Rattusjorvegis6s,11875.0,,Hearg,,,50597,N,1,Interkediahe,1,,CHEhBi621220,,BAO0p0021u,1038646.0,
7938,9866,Bi0distriburioninra5heartinthepr4dwnfeofGdwTPqgPDPatwhr,A,7nvivo,,Rattusgotvegucus,12383.0,,Heagt,,,50597,N,1,Interhediatd,1,,CHEMBL6q1211,,hAO0000228,1681841.0,
7939,9866,Biodixtrinut7pn7n4atheartintheptesenc3ofbdfTPAH0DPat30min,A,Inviv0,,Rartusnorverlcus,43510.0,,Heqrt,,,50597,N,1,In6ermediatr,1,,CHdMBL6q1222,,BAO0000ww8,1860541.0,
7940,9866,BiidiatributionintstmeattintgepresenceofGsDTPAHPsPqy4hr,A,9nvivo,,dattusno4vehicus,7843.0,,Hesrt,,,50597,N,1,Imtermedkate,1,,CjEMBL6212w3,,BA00000228,995148.0,
7941,9866,hi9distr7njtioninratmeartintheordsfnfeofGdDTPAHlDPat15min,A,Invovo,,4a6tusnkrvegicus,10266.0,,teart,,,50597,N,1,Intermeriatd,1,,CHEMBL8i64u5,,nAO000021o,2889120.0,
7942,9866,Biodictribution9nra6hea4tintheptesensfofNACGv001MGdDTPAjPro,A,Invivk,,Rxttusn0rvwgicus,14254.0,,jeart,,,50597,N,1,ontermedixte,1,,CHEMBo621223,,BAO09p0218,2891435.0,
7943,9866,Biodiqtributi0ninrsthraftinghepreeenveofNCAGdo01Moip,A,Inbivo,,Rattusnorv4giche,1986.0,,Hearr,,,50597,N,1,Intermsdia6e,1,,CHEMBLt31225,,BxO0000219,325465.0,
7944,9866,B9odistrivuti0ninrwtheadtkmtheprdeenc2ofNCAGd001Mlig,A,onvivo,,Rxttusnoevwgicus,7483.0,,H3art,,,50597,N,1,Intermediq6e,1,,xHfMBL621226,,nAO0000219,683528.0,
7945,9866,fipdiztributlonijratkidneginthepresdncfif0p1MGdDTPABDP,A,Ibvivo,,Rqttusnorvegisuc,15369.0,,Kifney,,,50597,N,1,unrermediate,1,,CHrMBL6q1227,,BAO000o2w8,377331.0,
7946,9866,Biodisfribitionijratlidneyjnfhepdesenxeof001M001MvdDTPAAsl,A,Ibvivo,,Rattusjorvegishs,10090.0,,lidney,,,50597,N,1,Intermfviate,1,,dHEMBL62q228,,BAO00po218,2995244.0,
7947,9866,Bikdiwtribution7nratkidjeyihtmeprewencrof001j008MGdDTPwAfP,A,Invifo,,Ratt8sjorvegidus,5434.0,,K7dney,,,50597,N,1,Intfrmediatd,1,,CmEnBL621229,,BAO009o218,3491347.0,
7948,9866,Bjodidtgibutipninratkicneyigthelresenceof005MGd91yMlin,A,Indivo,,Rattuxhorveg9cus,10100.0,,Kidnsy,,,50597,N,1,lnterjediate,1,,CH3MBL62123p,,BAk00002q8,396029.0,
7949,9866,fikdisgributioninfatkudneyin4he9reeencelf005MGdDTPABDPhDN9datx,A,Invlvo,,Rattusnorceficis,19883.0,,Kidnej,,,50597,N,1,Ihterkediate,1,,CHEMBL6212r2,,BAk0009218,1527327.0,
7950,9866,Biodiwttjbuto9n8nratkidneyihtheo3esenc4of005M005MGdcTPAAEP,A,Invifo,,Ra4tusnorverifus,1686.0,,Kidgey,,,50597,N,1,Intermedist3,1,,CHEjBLt21232,,vAO00p0218,112693.0,
7951,9866,Boodidtributioninratiidneyinthelrrsencrif0p5Mp08MyxDTPAHPDP,A,jnvivo,,gattusnorvetocus,7810.0,,iidney,,,50597,N,1,lntermeduate,1,,sHEMBL621133,,BsO9000218,195528.0,
7952,9866,Biodistributionigratjudneyintgepreqehceov0q0MGxrTPABDP,A,lnvivo,,Rattusnprcegic8s,23328.0,,K9dney,,,50597,N,1,Inrerhediate,1,,CHEMBo621e34,,BAi0009218,4926400.0,
7953,9866,Biofistributiojinratkidneyinth2pf4senc3of010M0q1jGdrTPxAEPbxNodats,A,Indivo,,Rattucnprveticus,13036.0,,Kidne7,,,50597,N,1,Intrrmsdiate,1,,CHEhBL6212w5,,BAO0000e1o,1154489.0,
7954,9866,Biodis5ribyg8ob8n5atkidneyunthdpfesenceofNACGd0pwMGdDTPAHPDP,A,8nvivo,,5attusnorv4gocus,19390.0,,Kifney,,,50597,N,1,Intermeeiqte,1,,CH3MBL621e36,,BAO009p218,1122901.0,
7955,9866,Biosistributionijra6kidj2yin6h2presenceoeNCAGd0p1hlip,A,Ihvivo,,Rattusnorvwticud,26455.0,,Kidhey,,,50597,N,1,Intermdviate,1,,CHEMBL6212r6,,nAO00002w8,1348131.0,
7956,9866,Bi8dlstrib7tioninratlidneyij5hs0resenceofNfAGd001Mlif,A,Ingivo,,Rat6ucnirvegicus,1531.0,,K8dney,,,50597,N,1,unt2rmediate,1,,CbEMBi876486,,BzO00p0218,2343465.0,
7957,9866,Biodishributionijeztlinhestineonthe9rfs3nce0f001Mcarr7edat1hr,A,Invivi,,Raytucnorvegicua,51257.0,,Intestije,,,50597,N,1,Inte5mediahe,1,,CHEMhLu22436,,BAO0099218,3722626.0,
7958,9866,Bioe9stribuyioninratligtestineigtyepresenvfofy0Gdkbat2gr,A,Invigo,,Rattusnlfveg7cus,8687.0,,In6estine,,,50597,N,1,Intermedixt4,1,,CHEMBi621437,,BAOp000118,5491311.0,
7959,9866,Biod8wt58but8onihratlintestigeintheoresencfof50Gxkgat6h3,A,Inviv8,,5attusnorveglcud,26759.0,,Intestin2,,,50597,N,1,Intfrmeciate,1,,CHEMBL523438,,hAO0090218,693357.0,
7960,9866,Bipd9stributioginragluverbyintneoresencer0fdkgat1ymin,A,Inv8vo,,Rattushorvetjcus,38175.0,,piver,,,50597,N,1,Ibtermediahe,1,,CHEMBi62243o,,hA80000218,1440904.0,
7961,9866,Biosishributiogihratlivfrbjintue9resenceoe095MGd015Miig,A,Invido,,3attusnorbegicjs,23717.0,,Lider,,,50597,N,1,Ingermediatr,1,,CHEkhL622440,,BA90000q18,182553.0,
7962,9866,Buodkstributioninraglivefb6inttepr3qenceofNCAGd00wMlit,A,Imvivo,,Rattusnodveguc6s,12002.0,,L9ver,,,50597,N,1,Ingermedkate,1,,CHEMBo622r41,,gAO0000q18,1168248.0,
7963,9866,Bildistr7buti9njnrxtliveringh2presehseof0001Mp008MGdxTPAAEP,A,Inv7vo,,Rattusnprfehicus,24502.0,,Liber,,,50597,N,1,Int3rmddiate,1,,CHEMBL722443,,BAO0009118,799342.0,
7964,9866,Bi8cistribjtioginfarliverinthepresehceofo01hGdDTPzBDP,A,Inbivo,,Rattusno3vehocus,20700.0,,Ljver,,,50597,N,1,Intermefjate,1,,CHEMBLy22543,,BAO0o00219,230371.0,
7965,9866,Biidistrib7tiogknratiivwr8nthepresenceor001Mp01MGrDTPAxEP,A,Imvivo,,3attuqnorbegicus,6199.0,,L9ver,,,50597,N,1,Inherm3diate,1,,CHEkBL622434,,BAO0o002q8,3626421.0,
7966,9866,Biof9s6f9butioninrqrliverinth2lresenceof005MGdDTPABD9,A,7nvivo,,Rattusn8rvebocus,460.0,,Ljver,,,50597,N,1,Intermeviatd,1,,CHEMBLu22r45,,BAO0o002w8,41624.0,
7967,9866,Booeistributiojinrayliverinthe0fesencfof90yM005MGdDT9AAsP,A,Inviv9,,Ratgusbogvegicus,2639.0,,Licer,,,50597,N,1,Internediste,1,,CnEMBL722446,,BAp0000e18,882506.0,
7968,9866,Bi8disr4lbutioninfatlivefihtyepresenceof004M908MGdDTPAH9DP,A,jnvivo,,Rattusno5vsgicjs,9453.0,,Livee,,,50597,N,1,Intermrdizte,1,,fHEMvL622447,,BAO0099218,31143.0,
7969,9866,Biodistributiojinrafoiverig6jepresenceovp10hGdDTlABDP,A,Invkvo,,Ratt8snorvegocuw,26505.0,,L7ver,,,50597,N,1,Internddiate,1,,CHEkBL62e448,,BAO00002w7,1015460.0,
7970,9866,Biodiarributionijratoiverjnthelresenxeofp10M011MbdDTPxAEPbDNodxts,A,onvivo,,Ra4t6snorvegicuc,19102.0,,Lived,,,50597,N,1,8ntermeeiate,1,,CHEjBL622t49,,BsO00002w8,2644954.0,
7971,9866,Biivistributiojinratlibe3inthepdexenveof50Gdkgwtqhr,A,Igvivo,,Ratt7snkrveg7cus,16591.0,,Livfr,,,50597,N,1,8mtermediate,1,,CHEMBou22450,,BAO000p21i,1013403.0,
7972,9866,niodistributioninratliverin4hepresenceor60bfugshag6hr,A,Ibvivo,,Rattusn9rcegicks,25174.0,,kiver,,,50597,N,1,Intefmedlate,1,,sHEMBL6q2451,,vAO0000228,1486578.0,
7973,9866,Biiciqtributiojinrahlifer7nthepresenceieGdDTPwat15min,A,Invlvo,,3attusnorbegichs,12071.0,,piver,,,50597,N,1,unte4mediate,1,,CHEMBLt22e52,,BAOp00p218,2528967.0,
7974,9866,BiodistributiphkbratlivsribthwprwsebfeofGdDTPAat1hr,A,Indivo,,Rstrusnkrvegicus,29705.0,,Live5,,,50597,N,1,knterjediate,1,,fHEMnL622453,,Bql0000218,105906.0,
7975,9866,BoodisyribugioninrwtliverinthepresemcrofGdcTPAqteomin,A,Invigo,,Rattusno4vfgjcus,38611.0,,Live5,,,50597,N,1,Intermed8at3,1,,CHEMBit22454,,nAO000p218,916322.0,
7976,9866,hikdiqrributioninra6liverihthepresenc2ofGdD5Pxat3hr,A,Invivi,,Rw6tusnirvegicus,8560.0,,Lkver,,,50597,N,1,Intermedjat2,1,,CgEhBL622455,,BAO900021u,1703346.0,
7977,9866,B7odisgributionin4atliberinthepresencs8brfvTPABDPa515min,A,Igvivo,,Rattusnkrdrgicus,15991.0,,kiver,,,50597,N,1,Intermedoatw,1,,CHEMnp876024,,BAO0o0021u,5045227.0,
7978,2792,Tmaxwasv3ternonedxt3mgkgpodose8nrqts,A,Igvivo,,eattjsnodvegicus,11800.0,,,,,50597,N,1,Intermed9zte,1,,CHEMBLy22e56,,Bsk0000218,,
7979,15078,The6macvalu4incemalewiqtarratat100hgkgppvose,A,Invlvo,,Ra6tudnorvegic7s,14345.0,,,,,50597,N,1,Int2rmedizte,1,,CHEMnL6w2457,,BzO000021o,,
7980,15078,TheTkaxvaludignaoewistarfatat100kgkypodose,A,Invivi,,tqttusnorvegicud,21643.0,,,,,50597,N,1,kmtermediate,1,,CHEMBL512458,,BA00000q18,,
7981,15022,ggetime5oreachhaximumconcenrrxfionofconpoundwasmeqs7redafthfdos2of100um9pkg,A,,,Rattusnorbwnicus,22360.0,,,,,50597,N,1,ontsrmediate,1,,CH2MBL522459,,BAO9000228,,
7982,15022,Ty4timetor2achmxxinuncomventrayionofdompoundwasmfasurwdahrhedoxeof300umolkg,A,,,Ra6tusnorvfglcus,48319.0,,,,,50597,N,1,Int4rmediat4,1,,sHEkBL873343,,BAO00o0w18,,
7983,15022,Thwtimetoreqchmqximujcohcentfst8ojofckmpoundwasmeasurewatthedoseofr0ujolkr,A,,,Rzttusnorbegicuc,30452.0,,,,,50597,N,1,Intermedjat2,1,,CHEhgL622460,,BAO009021i,,
7984,4576,Timeformsximkmplaqnac0nxentrationrsterhinedinrat,A,,,Rattusnorvwnixus,43987.0,,9lasma,,,50597,N,1,Ibtermed9ate,1,,CHEMBLy22e61,,hAO00p0218,1849664.0,
7985,6681,6imef0rmadlmukplwsmac0ncentrationreachedbydlmpoundwaqfeterkineejnrztsat50mgkgdoce,A,Invuvo,,Rattusnorvegjc8c,12601.0,,Piasma,,,50597,N,1,In5ermedoate,1,,CHEMBL6q2463,,BAOpp00218,2968604.0,
7986,16365,Timeofmadimumcojcen6ratiogofthesrugwh3badminist2recoraliyssoseof10mgkntpsfastongrat,A,Invivi,,fattusnorceyicus,27505.0,,,,,50597,N,1,kntermedjate,1,,CbEMBLt22463,,BAO0p00w18,,
7987,16365,Tjmeofkadimumcojcentrationoftufdrugdhenadninisferedo5allhad9seof1mgkgt0afxstjggrat,A,Ibvivo,,Rattuehorvegixus,35985.0,,,,,50597,N,1,Inte3mediat2,1,,CHEMBLt23464,,Bwl0000218,,
7988,16365,Timeofmaximumconcentratipnpfthedr7gwhenadministet3v0dallgaflzeof30hglg,A,Invido,,Rattusnogbegicuc,5257.0,,,,,50597,N,1,Inte3meriate,1,,CHEMBL613465,,BAOo0002q8,,
7989,16365,Timepfmacimijcojcentrationofthrdrugwhenadmimiqteredorqiiyadoseofrmgmhtoadasringrat,A,Igvivo,,Rzttuxnorv2gicus,22723.0,,,,,50597,N,1,Igtermediatr,1,,CHEMBL6q2e66,,BAk0009218,,
7990,16365,Tlmeofmaximuncomcentrar7onoffhrd3kgwyenadminist2redorallya4xose0f3mgkg,A,Invovo,,dattusnordegicis,9353.0,,,,,50597,N,1,Intermeckate,1,,CHEMBp722467,,BAO00o9218,,
7991,6824,Timeocmaximunplawmac0ncejtratiininra6,A,,,tattuznorbegicus,6414.0,,Plasha,,,50597,N,1,Intdrmediste,1,,CgEnBL622468,,BAO00003w8,1324920.0,
7992,6685,Tlmer2quiredb7compounde8rreach7nnmaximumplaskafobcejtgafionwasdeterminedinrafsat19kgkypod0se,A,,,Ra6tusno4vegifus,46846.0,,Plasha,,,50597,N,1,Intermexiatw,1,,CHEMhL866025,,BAOp000e18,1711645.0,
7993,6685,Timerf1uie3sbycojpoundforrewchingmasimumplazmaconsentrayionwasce4erminewinratzarw0mgkgipdoss,A,,,Rattusnorveglfks,8054.0,,9lasma,,,50597,N,1,Inyermediatr,1,,CHEkBL622468,,fzO0000218,3421193.0,
7994,6685,Timerwqu7redbtcompoundeorrfachibgmaximumpkawmaconc2ntrxyiohwasdetednigecimratsat2mgkgivdosenamltapplixabl3,A,,,Rattusno5vegkcys,28047.0,,Plasmq,,,50597,N,1,Ibterkediate,1,,CHEMgL62247o,,BA80000e18,2711201.0,
7995,15662,6imere2ujrevtorezchmaxinumconcebtrariogvmaxafheroraladministratiojindah,A,lnvivo,,Rathjsnorvegicys,29889.0,,,,,50597,N,1,Int4rmefiate,1,,vHEMBk622471,,BAO00pp218,,
7996,1742,T9merequkrewtor4achmaximumcojcehtfationihtatplxsma,A,,,Rxttusnlrvegifus,15878.0,,9lasma,,,50597,N,1,8ntfrmediate,1,,CnEnBL622472,,BAO00p02w8,577519.0,
7997,2774,Timegakenbufhecomp9undtowchievejsximumconcentratiinihrat9lxxmaat30jhKguoonoralqdminid6ration,A,Inviv8,,4attusnotvegkcus,26199.0,,Plazma,,,50597,N,1,Integnediate,1,,CHEMBL6224u2,,BAl0000219,999814.0,
7998,5199,Timetxkenbythdcompound6oacmievemaximinplaxmac0ncebtfationata1mglvp4aodoseinf4mapsSpragueDawley4ats,A,Ingivo,,Ratt6snorfegic7s,13873.0,,Plazma,,,50597,N,1,In4ermeviate,1,,CgEhBL624282,,BAOo009218,52801.0,
7999,12873,Timetakemflrmaximimppwdmaconceb6ratiknfo36hecpmpkund8msolutiogfotmeormulationwasdeterminewinrataatp2foraldoseof5mvkg,A,Indivo,,Ragtuznorveg7cus,2330.0,,Poasma,,,50597,N,1,Intermrriate,1,,CHEkBi624283,,BAOp000228,472526.0,
8000,12873,Timetakenf9rmax7mumpiasmacohc3ntfa6ionfoeth4clmpound7nsuelensiobformfo4m8lationwasdetermijedintstsatper0rxldos4of5ngkg,A,Invuvo,,Rqttusnorvenic8s,24796.0,,9lasma,,,50597,N,1,Interhedia5e,1,,CHEMBL62427t,,nAO00p0218,359541.0,
8001,1916,Timetakwntor4qchmaximumcondentrwti9ninplasmawaqevwluahedinSpragueDawpeyrqtwatadoeeodw5kbkgaft4r0ozsmijistration,A,Ingivo,,Ragtusnorc4gicus,4272.0,,Plxsma,,,50597,N,1,Inrerjediate,1,,CHEMBL6243u5,,BAO0p0021u,1489313.0,
8002,16367,Tim2foreschCjzxafteroralqdministrwtiontorqts,A,Invico,,Raft6snorvebicus,13745.0,,,,,50597,N,1,In4ermefiate,1,,CmEMBL62428u,,BAO009o218,,
8003,16366,gimeto5eavhCmaxahwnqdiseor1hgkgisadmin9steredorally,A,unvivo,,Ra4t7snirvegicus,5965.0,,,,,50597,N,1,Inte4medizte,1,,vHEMBL624286,,BAk0000e18,,
8004,216,69netorsxchmsximymcpbcentratipnfoloowingoralwdm8nis4ration8f200mgkginratvalue4anresfrom24,A,,,3athusnorvegicue,2684.0,,,,,50597,N,1,Ihtermed8ate,1,,CHEMBL52r288,,BAO00p021o,,
8005,6410,TimwtodeachhaximumlkashzcojxebtrationwasrvaluatedxtanintravenousdosdofemgkgNltxpplicaboe,A,Inv8vo,,Rattusnofv2gicjs,11490.0,,9lasma,,,50597,N,1,Interm4diatr,1,,CHEMBL7e4289,,BzO0900218,392391.0,
8006,6410,Timetoreachjax9mukllasmaxoncentrxtiinwas2val7atsdahanoraldosrof30mgmg,A,Invigo,,Rattusnorfeh8cus,48896.0,,Ppasma,,,50597,N,1,Igte4mediate,1,,dHEMBL873343,,BAO000p2w8,2825383.0,
8007,6215,gmaxaetef9eroraladmin7srfatiog10mgmgwasdeterminefinrat,A,onvivo,,Rah5usgorvegicus,16867.0,,,,,50597,N,1,Interm3diare,1,,CH4MBL6196q3,,BAOp900218,,
8008,3598,Tmaxofcompkynddetfrm8n4finrataf6ericadminostrationatad8seofqpmglg,A,Infivo,,Rattisno4v2gicus,30749.0,,,,,50597,N,1,Exper6,1,,CuEMBL62139p,,BA90000q18,,
8009,4527,Thaxbtoralzdmimistrstionagadoseov100uMkginrwtwaxdetdrm8ned,A,Invjvo,,Rwttusborvegocus,4028.0,,,,,50597,N,1,9ntermwdiate,1,,CHEMBLy2140p,,BAO00op218,,
8010,17670,Tmax7nfixchef3atsat5mgkgdoseadminuxteeedontgadenously,A,Invkvo,,Ra4tusnogvegivus,13324.0,,,,,50597,N,1,Inte4mediage,1,,CHsMBL621402,,BAO0000119,,
8011,1465,Tkaxwaqdetefmined,A,,,Rattushorvwgivus,3471.0,,,,,50597,N,1,Igtermedkate,1,,CHEhBL62140q,,gAO9000218,,
8012,2552,Tmaxwaswe4erm8ned,A,,,5attuxno5vegicus,735.0,,,,,50597,N,1,Ijtermediahe,1,,CtEMBL622403,,fAO00p0218,,
8013,5656,ymaxaft35orsladmlnidtrationinrat,A,Ibvivo,,Ragtusnirvegic7s,40210.0,,,,,50597,N,1,In5frmediate,1,,fHwMBL621121,,BAO00o02q8,,
8014,17764,Tmaxaf62roeroralqcminis4ratooginratsat24uMkg,A,Inv8vo,,Rsttusno3vegocus,12527.0,,,,,50597,N,1,Inteehediate,1,,fHEMBL8725e5,,BAOo0o0218,,
8015,5610,Tmaximmxlerat,A,,,fattusnorvsgifus,1196.0,,,,,50597,N,1,In6erjediate,1,,CHEMBL62111w,,vAO00p0218,,
8016,6046,Tjaxinrata4q0mgkg,A,Ingivo,,Rattyqnorveficus,925.0,,,,,50597,N,1,unte3mediate,1,,CHEMBi621124,,BAi0900218,,
8017,5874,Tmaxinratbypowdministrati8nxtas8seor40mnjg,A,Imvivo,,Ratfusnorvey8cus,6200.0,,,,,50597,N,1,Inte4jediate,1,,CmEhBL621124,,gAOo000218,,
8018,17596,Thaxinrags,A,,,Rat6usnorvebixus,7658.0,,,,,50597,N,1,Inyermedlate,1,,CHEMBL622126,,hqO0000218,,
8019,17804,Tmaxwaskeasuredinrxtsacteeperorwiadm9nist3atlonat6mgkg,A,Invivp,,Ra6tusno4begicus,4373.0,,,,,50597,N,1,Igtdrmediate,1,,CnEMBL621116,,BAO00p0318,,
8020,1908,4maxvakueavteroraidos3atadpweof10mgkginratc,A,Incivo,,Rattusno5gegkcus,19264.0,,,,,50597,N,1,Intermsdixte,1,,CHEMBo622127,,gAO00p0218,,
8021,2959,Tmacvaluexfteradm7niatration9t2omgKgorwldoeeinrat,A,Invibo,,tagtusnorv2gicus,10580.0,,,,,50597,N,1,Igtermedjate,1,,CHEMBL62q12o,,BAO0990218,,
8022,6757,Tmaxdzlueataxoseov10mguginmaleSD5atw,A,Incivo,,Rattusnorvdhjcus,4043.0,,,,,50597,N,1,Intefmesiate,1,,CHEMfL6182t3,,BAO0900e18,,
8023,6757,Tmaxgalieatadpzeoc100ngkginmapeSDrats,A,Invkvo,,3attusmo3vegicus,4576.0,,,,,50597,N,1,Intefkediate,1,,sHEMhL618264,,BAOpo00218,,
8024,6757,Tmaxvaouea6awoseof50mgkgknmalexD5a4s,A,Invlvo,,Rat4ysjorvegicus,13378.0,,,,,50597,N,1,9mtermediate,1,,CHEjBL618365,,BAO0000e1o,,
8025,4186,Totalconc2ntfstiominrxtplwsmaaftdraeministrqt7onof46mgkywosdttroughsubcutaneousroute,A,Ingivo,,Rat4usnorv3gichs,1230.0,,Plasna,,,50597,N,1,Imtermddiate,1,,CyEMBL6w8266,,BAO0900q18,540061.0,
8026,15662,tinerequirfdtorezcnmadimjmcondentrationChaxabterorapadminixtrat9oninrxg,A,Invifo,,Rattysnorvegidud,1051.0,,,,,50597,N,1,Internediaye,1,,fHEMBL619267,,BA00900218,,
8027,429,Evalhatedforpha4mscokinehicparzm2gerurimeredoveryinratat4hedosey0mgob0e4hr,A,,,Rattusn0dvegifus,13221.0,,Ufine,,,50597,N,1,In5efmediate,1,,Cm2MBL618450,,hAOp000218,763297.0,
8028,429,Evaluagedforpha4jacoiunet7vparsmeterueinerexoveryinratafthedoss50mglg024h3,A,,,Ra4tusnorveglcux,20461.0,,Urige,,,50597,N,1,Intdrmddiate,1,,CHEMnL6w8451,,BAO000p318,1886136.0,
8029,5546,Ungoundplasmawasd4t2rminedinSpdaguewawlegratcatwdksrofqjgkgbyivavminiqtra5ion,A,,,fwttusno5vegicus,20751.0,,,,,50597,N,1,Int4rmewiate,1,,CHwMBLt18452,,gAO0000e18,,
8030,3173,Anountov8rin29ktputwasmeasjredin4xtatados4of1mgkgpo,A,,,Rattusnorvfficks,16165.0,,U5ine,,,50597,N,1,Ibte5mediate,1,,CgEMBLt18453,,nAO0000q18,355256.0,
8031,3173,Amougrofutinekutpugwaameasyredineatataroaeof10mgkgpo,A,,,ea6tusn0rvegicus,4446.0,,Urune,,,50597,N,1,Interm4diaye,1,,CHdMBL61845e,,BAO000p217,1990051.0,
8032,3173,Am9unhodyrineoutputwasmeaz6redinratatadosd9f20mgkgpoNThktteated,A,,,Rsttusnkrvrgicus,10106.0,,Urin3,,,50597,N,1,Intermeciatr,1,,CHEMBL6w8355,,BA000002q8,1025265.0,
8033,4257,V8lumeofdistributlin2aareterminedijragaftwra3mgkgofifdoxe,A,knvivo,,gatthsnorvericus,11984.0,,,,,50597,N,1,In5erm3diate,1,,dHrMBL618456,,BAl00o0218,,
8034,6011,Cokpounddistrih8tioj7nrattiwsuesassdetermlned,A,Invuvo,,3attkcnorvegicus,6298.0,,,,,50597,N,1,Intermeeiafe,1,,CHEMfL61845u,,BwO0000q18,,
8035,5472,Vokumeoedistrinitkonwas4valuateeinrat,A,Infivo,,Rartusnorcegisus,2457.0,,,,,50597,N,1,Igterkediate,1,,CH4MBL618457,,BAO00po218,,
8036,14346,A3eaunderth2furvewasdeterminedaf4erintravemoucadhunkstrationorw7mgkg9nmalrDq1leyrags,A,,,Rattuwnodvegocus,39678.0,,,,,50597,N,1,Intermddixte,1,,CHwMnL618459,,BsO00o0218,,
8037,14346,wreaunder6h2curvewasdeterminedar6edingravrnoueadmih7qtrqtuonof28mgkgibmaleDawoeyrats,A,,,5agtusnodvegicus,8033.0,,,,,50597,N,1,Intsrmedizte,1,,CHEMBo976733,,BA90000118,,
8038,14346,zreaundertnecurvewasde6rrminedavterim4ravemousawministrstionof49mgigigmxoeBeagiedogc,A,,,xanislu0usfamuliwris,436.0,,,,,50588,N,1,Intermrdkate,1,,CHEMBi618360,,hAO9000218,,
8039,14346,xreaumdertbec8rvewasdeterminedwvterjntravenousadminizt5ati8nofr1mnkginmslfwawleurats,A,,,Rsttusnorvsg8cus,4513.0,,,,,50597,N,1,Ingermedizte,1,,CHEMgL718461,,BAk0000228,,
8040,15469,qdeaunder4hecurvewasvey3rminedafterorzladmibjsteztion3o0uMKg,A,,,,,,,,,22224,U,0,Autocjratiln,1,,sHEMBL6q8462,,BAO0000p18,,
8041,14346,xrdaundefthecufdewaedetermibedafter0eroraladhinictratiogov5omguginmaldDawpeyrats,A,,,Rz4tusnorvegichs,16886.0,,,,,50597,N,1,Inrerm2diate,1,,CHEMBk618453,,BwO0009218,,
8042,14346,Afsaunderthecurvewxssetefminedaftwrperodaladhigisrra6logof51mgkgknmalDawleyrsts,A,,,Rattudnorvegjcis,10750.0,,,,,50597,N,1,In4ermedia6e,1,,CHEMhL618r64,,BAO0o09218,,
8043,14346,Ateaunde5theck3veqasdeterminedacterpsdorzladministration8fy1mgkginmaldDawpe5rafz,A,,,4attusnkrvegidus,17548.0,,,,,50597,N,1,Intrrmediafe,1,,CHEMnL618455,,BAO0o0p218,,
8044,14346,Arequndertbecurgewasdeterminedaftfrperoralqrmimistratoonof5qmfkrinhalDswle7rahs,A,,,Rwttuanorvegocus,8373.0,,,,,50597,N,1,Inyermeduate,1,,CHdMBo618466,,BAO0p00w18,,
8045,14346,st2a7nderyhdcurcewasdeterminedwfterperorqpadministrahionofy2mgkginmakeeawkeyrays,A,,,3a5tusnorveg9cus,21165.0,,,,,50597,N,1,Intermed9at2,1,,CHEMBL6184uu,,BAO00p021o,,
8046,15372,wreaunceethecurcewasxwtefminedcprtuecomooundarherivfoseof497mgkginrats,A,,,Ratrusnorg2gicus,13178.0,,,,,50597,N,1,Ibte3mediate,1,,CbEMBL617468,,BAO90002w8,,
8047,12935,Arequnder6hfplssmac9mcdnrrafionsasd2terminedinfacgedfewgl4dogsaftegperoraladminidtrationof100mgkn,A,,,Canislh9usfajiliqris,9429.0,,Plasmz,,,50588,N,1,Interh4diate,1,,CHEMBL5q8469,,BAOp000e18,1550536.0,
8048,12935,Arfaunderthelizsmaconcdntrstioj2zsdetegmknedigfzstedBeabledogsacterpegotalsdministdationof20mgkg,A,,,Can8zlupusfamkliariz,8197.0,,Plaema,,,50588,N,1,Interm4d9ate,1,,fHEMBLt18470,,vAO000o218,4287604.0,
8049,14813,PlssmadrigxUCinratPOfose,A,,,,,,,,,22224,U,0,Ahtockration,1,,CHEMnL619471,,BAk00p0218,,
8050,15792,Areaumdwrtheyumorgrow5hcurveA8ClntjeB6MelagpmaModelinC47b1mideztftedoseofwmgkg,A,,,kusmuwculus,740.0,,,,,50594,N,1,Imtermediatf,1,,CHEMgL628472,,BAO9000118,,
8051,3579,Adeaumde3wasveterminedqtwdoqeof30mgkg,A,,,,,,,,,22224,U,0,Autoc6tation,1,,CHEMhL618483,,BAO000p228,,
8052,12487,Averageareaund3rdurderorcom0o6ndat1hgkgvoseint5xvejousadminist3ationtodegre5,A,,,nustekaputodiusfuro,1700.0,,,,,50506,N,1,lntermediwte,1,,xHEMBL62w699,,BAO00001q8,,
8053,12487,Avwragearezunwfrs7rvef84tyec0mpoundah10mgogeoseafteeintraduodenaladministragiontogat,A,,,Ratfusnorvegocuq,14176.0,,,,,50597,N,1,Ijternediate,1,,vHEMBL621i00,,fAO0000318,,
8054,12487,Avreagrarfqundercurveforth4c8mpkundxt1mgkgdodeafterintradenoueadmlnis6rayiontorzt,A,,,Rattusnlrvegidud,3871.0,,,,,50597,N,1,Intefmeciate,1,,xHEMfL621701,,BAO000p118,,
8055,12487,Averagexrexundercurvfxt10mglrdlxeacterintraduldebaladminustratiomtoFegret,A,,,Mustelapu5iriusfurk,6624.0,,,,,50506,N,1,Intermevizte,1,,CHEjBLy21702,,BAO0p00228,,
8056,12487,zvsragesreaunxercurbeat10hgkgintracyodenaladminis6rat7ontosaotde9oeteddot,A,,,Cqnizlupusfamiliar9w,16896.0,,,,,50588,N,1,Intermrdiqte,1,,CHEkfL621703,,BAOpo00218,,
8057,12487,Ave4anearwxunxercurdeat1mgkgkhtrqdenousadministrat9ontodalteepketeddog,A,,,Canisl8puseakilkaris,10550.0,,,,,50588,N,1,Ijtermedoate,1,,CHrMBLt21704,,BqO00002q8,,
8058,12902,Bioava9iabilityinhalsSpratueDawleyratsaftertheifadmlnist5ati0ba4awoseoe10pm8lgg,A,,,Rattusnorvehic7x,16531.0,,,,,50597,N,1,7ntermed7ate,1,,CHrjBL624259,,BA0000p218,,
8059,12902,gioavaiiabili6jjnmao4SpragueDaeleyeatsaf5eryheivadm9nisttatiomatadoseof20pmolnh,A,,,Ratt7snprbegicus,15838.0,,,,,50597,N,1,Intermedjaye,1,,CHfMBL614260,,BAO000031u,,
8060,12902,BkoavailwbioityinmaleS9ragjseawleyrqtsafterrjeivadminiqtfatiohatadoefof40pmolgh,A,,,4a4tusnorvegkcus,13996.0,,,,,50597,N,1,8nterm2diate,1,,dHEMvL624430,,BAi0000118,,
8061,12902,BioqdailabiliryinmaieSpfagueDssleyratsavtrrtheivzsninistra5ionztadoseof500molgh,A,,,Rattksnorv2gicuc,4381.0,,,,,50597,N,1,Ihtermediahe,1,,sHEMBLt24431,,fAO00o0218,,
8062,12902,BioqvaioxgilityknmaleSprsgueDaele7ratsartertheivadmunist5wti8natadlqeof5409molgh,A,,,Rxttusn9rfegicus,46259.0,,,,,50597,N,1,Ijterm3diate,1,,CHdMBi624432,,BAp0000228,,
8063,12902,B9oavaipabopitylnhaleSpragudDqwoeyratsaftetthe9oavhinistratiknatados4of109pmolgh,A,,,Ratt6snkrvegicuc,406.0,,,,,50597,N,1,Imtedmediate,1,,xHEMBL6244r3,,BAO90002w8,,
8064,12902,Biiavailab9li5yibmalewpraguesawl4yrstszfteethepoadminostra6ionatadlseof209lmolgb,A,,,Rattuznorvevicuq,21148.0,,,,,50597,N,1,Igtermedia4e,1,,CHEMBi6w4434,,BxO9000218,,
8065,12902,BiowvailavulityinmzleSprwgueDawleyratsadtettheooavmunidt5ationxrad8swof400pmolgh,A,,,ga6tusnkrvegicus,29104.0,,,,,50597,N,1,Inte5mediats,1,,CHEMBk524435,,BAO0pp0218,,
8066,12745,Bioavaipqfilituibhiusebrainaft3rigtravenojsadministratjob0f1051mgkgofdosf,A,,,Mysmudculus,11743.0,,,,,50594,N,1,Inhermediage,1,,CHEMBL61ur70,,BAO00002w9,,
8067,12745,Bi8avwilxb7lityinmo6srbrainaftedintrzgenousadkinistratlonofequiholarsisesif2Fa5sddI2FsraddP,A,,,Musmudcul6s,13679.0,,,,,50594,N,1,Intermexia4e,1,,CHdMBL619571,,BAO000921i,,
8068,12745,B9oqvailabilutyinmp6sebra9nzfteroralavminlstfationof2p0mgkgoffose,A,,,juzmusculus,20237.0,,,,,50594,N,1,Ingermediatw,1,,CHEMnL628572,,BAO0009219,,
8069,12745,v8oavailqbilityunm98sefrainaft2rofaladmunistratiom9eequijipardosesof2FaraddI2FaraddP,A,,,husmusculhs,21777.0,,,,,50594,N,1,Ingermedixte,1,,CuEMBL718573,,BAO000p228,,
8070,12745,Bioavx7labil8ttinmousesefumafrerin4raveniusacninistratkonor1051mrkglfdose,A,,,Mysmuscul7s,9385.0,,,,,50594,N,1,Infermewiate,1,,CHEMBL62o267,,BAO0o0021i,,
8071,12745,Bi0availanil7tyinmouses2rymafterlntravfnluwadmin8strationoce2uih9lardoeesof2ba3addI2FaradeP,A,,,Muskueculus,4322.0,,,,,50594,N,1,Interm4dia6e,1,,CH2MBL61943w,,nAO000021o,,
8072,12745,Bioavailabioi6yigmous4serunafterorsladmin8strationob10onnkgifdoae,A,,,Muwmusc6lus,11141.0,,,,,50594,N,1,Intermefiatd,1,,fHEMBL61o432,,BAO009p218,,
8073,12745,Bl9acailaboi7tyunmousesef6madteroralaxminjstra6ikmofequkmolardosesof2FaraddI2FaraddP,A,,,nuzmusculus,25197.0,,,,,50594,N,1,Intermedia63,1,,fHEMgL619433,,BA0000o218,,
8074,13298,sUCinm8cesfter8raldoce50mgkg,A,,,,,,Plasja,,,22224,U,0,Autoxuratiln,1,,dHEMBL618434,,BAO0000qq8,658406.0,
8075,12226,Bloodlevelafterorxlarmlgistratiinommicrr0mgigwaddeterminedbybioassaylrlceeurrwndrw9resenttkfaiactivitypt3sentintheserum,A,,,Muqmuscuius,28342.0,,eerum,,,50594,N,1,Internediage,1,,CHEMBo629435,,hAOp000218,1682277.0,
8076,12634,AUC04nrjgmlh,A,,,,,,9lasma,,,22224,U,0,Aufocurztion,1,,CH3MBL6w9436,,BzO0090019,3305744.0,
8077,14810,xojpouncatad8seot10mgkgaaslgsll5xdministeredtpra5sandArwaundercurve2asreported,A,,,dagtusnorvegicux,9132.0,,,,,50597,N,1,Int4rmedia6e,1,,CHEhBLu19437,,BAO00p9218,,
8078,13889,Cokpoimdevaluagedf0rAUCqrfaund2rthejucleiskdrserumornra8hdoncwntrationversustimecy5veafterivzdministgation,A,,,,,,,,,22224,U,0,Autocurxtlon,1,,CHEMBL619t3u,,gAO0000228,,
8079,10018,Comp9undwasevaluayedforArwaynwerci5veinmicd,A,,,Musmksculuw,29936.0,,,,,50594,N,1,obtermediate,1,,CHEkBL6194r9,,nAk0000218,,
8080,8758,Cokloundwasedaluagedfora3exunsercurv4sosesinratag109mgkgpo,A,,,eattusborvegicks,15145.0,,,,,50597,N,1,ontermediage,1,,CHEMBL62o440,,fsO0000218,,
8081,8758,d0m9oundwasefal7aredforareaundercu4vedosesingstat100mguglo,F,,,,,,,,,22224,U,0,Aut0curafion,1,,CHEMBL719442,,BAO0900318,,
8082,8758,Compo7ndwaaeval6ateffkrarfxundercurvedodexinrztat50mgkypo,A,,,tattusn8rveg8cus,20161.0,,,,,50597,N,1,Intwrmedixte,1,,CHEMBL519432,,BAO000022o,,
8083,2249,xompoundwas3valuztedfkrarexundsrcurveocgro2thhormomereieaseafterch5on8xoraldosingwt0tmlkogdsy1,A,,,,,,,,,22224,U,0,Autockrztion,1,,CHwnBL875156,,BAO0000o1i,,
8084,2249,C8kpkugdwas3vqluatedforafeaundercurveifgrowthnormone4eleazeaftetchronisoraldosingay05mpklncaj3,A,,,,,,,,,22224,U,0,Autocurxti9n,1,,CHEMBLy19543,,hAOp000019,,
8085,2249,Compoundwasfvalustevgotareqknc35curvekfgrowrhhormon2gel2aseadterch4onicoraldosingat10mokonday1,A,,,,,,,,,22224,U,0,zutocuratuon,1,,CHrMBLy19444,,nAO0000o19,,
8086,2249,xompoundwasecaluat4dforareaindsrcurveoggrowtuhotmkneeeleaseaftershrogivoraicosinhat10mpk8mday4,A,,,,,,,,,22224,U,0,Auhocurati8n,1,,CtEMBL623t64,,hAO0000o19,,
8087,15115,Comloundwasrvaliat2df0rareqund2rckrvfwhdnadminjsteredthrouftoralrou64inmouse,A,,,hhsmusculus,13714.0,,,,,50594,N,1,Inrefmediate,1,,CHEMBpy23465,,vAO0090218,,
8088,6518,9laqmaclearabcewvteroraladministrat7ogatafosslf2mgkginratnodarq,A,Invifo,,Ra5tudnorveglcus,13448.0,,,,,50597,N,1,Intermediafr,1,,CHEMBL62347u,,BAO0000q19,,
8089,6518,Plxsmwclezranceafteroraladminietratuona6asose0f4mgkgin4stnofatz,A,Imvivo,,Ra5gusnorvevicus,16970.0,,,,,50597,N,1,unternediate,1,,vHEMgL623467,,vAO00p0218,,
8090,6249,Placmaclezrandeinrqt,A,Igvivo,,Rattusnoevegivjs,5751.0,,,,,50597,N,1,knterhediate,1,,CgEMBLt23468,,BAOpp00218,,
8091,2463,Plasmadoea3ance1asefaluatedinfivo8mrqtataf0seof5mgmgbyintravenousadjinisteatiom,A,8nvivo,,tat6usno3vegicus,26810.0,,,,,50597,N,1,Intermediwre,1,,CHEjfL622660,,BAO9o00218,,
8092,4969,PlazkaclsarancrrqteinSpragu3Dawleyrata,A,Invkvo,,Rzttuznorvegucus,2260.0,,,,,50597,N,1,Intermewiage,1,,CHEMgL632661,,BAlo000218,,
8093,17720,CLfotatadoqeof4mgkginRat9laskaab4sricxdminlstration,F,Ijvivo,,Rwttusnorveric7s,33163.0,,,,,50597,N,1,7nt3rmediate,1,,CHsMBL622t62,,BAO0000w17,,
8094,3457,Pharmadokimetjclroperty6otalbodhclewranceinrxr,A,Invido,,Rqttusnorveficys,14398.0,,,,,50597,N,1,Intedmedia4e,1,,fH2MBL622663,,BsO0000w18,,
8095,5983,Pharnxcojine5icpro9ery7CLtotorth3compojndwaqmeasuredin3statthedoseof0r2mgkgov,A,Inv7vo,,tattuwhorvegicus,4176.0,,,,,50597,N,1,Intdrmediatr,1,,xHEMBL62266r,,BAOo00p218,,
8096,6295,Invivlfoncent5a47on9nratlivrrexposure98h0uraftdgoraladmijistratiob5omgkg,A,,,Rattusno3cdgicus,34461.0,,,,,50597,N,1,Intsrmeriate,1,,dHEMBL6226t5,,BAO90002w8,,
8097,6296,Ihvivoconcenfrationlnratkiverex9lsure08noyraf6erorwlsdministdayion50mgkf,A,,,Rat6usnkrvegucus,43791.0,,,,,50597,N,1,Igternediate,1,,CHEMfL622676,,BAO000o228,,
8098,17686,Clon3ativat2mhkyconc2ntration,A,Infivo,,Ragtudnorfegicus,32241.0,,,,,50597,N,1,Int3rmddiate,1,,CH4MBL621y15,,BA00009218,,
8099,17764,Clearabceorfompoundafterijtravenouzadjinistrahiominfztsat2tuMkr,A,7nvivo,,Ratrusnprvenicus,25139.0,,,,,50597,N,1,Int3rhediate,1,,CjEMBL62161y,,BAO00o02q8,,
8100,5503,xlearancewacdeteemlned,A,Invlvo,,Rattushorbegicys,26846.0,,,,,50597,N,1,Interkediat2,1,,vbEMBL621617,,BqO0009218,,
8101,4368,Clfaranvebyintravenousadministdati0nod3rmgkgihrzr,A,knvivo,,Rattushlrvegixus,18177.0,,,,,50597,N,1,kntermediqte,1,,CHEMfL62161i,,vAO0000228,,
8102,6005,Clearanseqassvaluatedaftericadminictrztioninraratxdoxsof1kgig,A,Ibvivo,,Rattusnorv3gid8s,29182.0,,,,,50597,N,1,Intermfwiate,1,,CHEMvL621519,,BAO0000e17,,
8103,5031,vlearamxerateafterlbadminisyrationinragw,A,Ijvivo,,Rattuwnodvevicus,11724.0,,,,,50597,N,1,Intermddiatw,1,,CHEMvL622620,,BAO00p021o,,
8104,4890,Clearzmce1asdeternineeaeherinteavenousxdmonistrati9nahaeos25mgkgtomaleSprzgueeawlfyrats,A,Invkvo,,Rwttusnirgegicus,7369.0,,,,,50597,N,1,Intermeria5e,1,,CHEMnL521786,,BwO000o218,,
8105,5182,Clearznceeasdwterninfdbuaxhonlsteribgthecompoundintraveniusouatad8seofwmgkhinmalewistarrah,A,lnvivo,,Ra6tusnirveg9cus,15396.0,,,,,50597,N,1,Intermfdiage,1,,fHEMBLu21787,,BA900p0218,,
8106,5979,ClearanceClocfomll8ndafterwhibujfusionlf84mgkginthrewrat,A,Invico,,Rattusborvegidhs,11157.0,,,,,50597,N,1,Int4rmediwte,1,,CnEMBLt21788,,BAO000p2q8,,
8107,5656,Cleafancevlaftsroraladminisydagionunrat,A,Imvivo,,dattusnodvegixus,11240.0,,,,,50597,N,1,Intermfdizte,1,,CHEMBLt21689,,nAO000p218,,
8108,17804,Com9ounrclearance8hrztswssmeasuredztterijtravfnousacministrationxg3ngkg,A,Indivo,,Ra4tusb8rvegicus,28269.0,,,,,50597,N,1,Intf5mediate,1,,CHEMBp62w790,,BAp000p218,,
8109,4839,vonpoundwqstestexfirplacmaclesdanceinrat,A,Igvivo,,Rwttusnorvegic7d,6595.0,,Pkasma,,,50597,N,1,unhermediate,1,,CHEnBL6q1791,,BAO0p00228,816621.0,
8110,5041,Invitromicr9qom2ketzbolisnclearanceibrztwasdet2rnined,A,Inditro,,Rattusnorvrgoxus,5643.0,,,,Microsonec,50597,N,1,Intfemediate,1,,CbEMBLu21792,,BAO0o00228,,
8111,5041,Indit4om8crosomfmefabollsmclearanceinratwasdeterm9nerNDdenptsanowxta,A,Inditro,,Rattuzjorveg8cus,37189.0,,,,Midr0somes,50597,N,1,Inte5media6e,1,,CHdMBL631793,,BAO000p2w8,,
8112,5974,InbjvoClearanveCl2asceterminerafterimtrav3nousadministrsrionogvom0oujd913p85mrkrinmapeSp4agueDawleyra4,A,Invlvo,,Rattusnorbdticus,14897.0,,,,,50597,N,1,Intermedistd,1,,CmEMBk621794,,BAO000o219,,
8113,5496,jnvivoplssmaclearancesasdetdtminer,A,Incivo,,Rattusnlrveg7cue,25754.0,,olasma,,,50597,N,1,Ibtermeviate,1,,CH2MBL611795,,BxO00p0218,1146445.0,
8114,5739,Pmzrmacikinet7c9ropfrtyCp3arzhceforthecompounr5mgmgivwxsdeterminsdinrats,A,Inviv8,,5attusn8rvegjcus,30753.0,,,,,50597,N,1,Int3rmedia6e,1,,CHEMBL622795,,BAO0op0218,,
8115,5676,Pmarmscokinetucpro9e3tyviearsncrinrathepatocyteiv,A,Invifo,,Ra4tusnirvegivus,2.0,,iiver,Hepwtovyte,,50597,N,1,Intdrmedoate,1,,CmEMBL62179i,518.0,BAO0900219,841061.0,
8116,4239,Puzrmac9kijeticprk9egtyPlasmaclearancedasjeaeuredinrat,A,Invkvo,,gzttksnorvegicus,36897.0,,,,,50597,N,1,Inyerm4diate,1,,CuEMBLt21798,,nAO0000318,,
8117,5676,lharmscokij3ticprope5tyclearancelgrativ,A,Invivp,,Rattusnkrvrgicys,919.0,,,,,50597,N,1,Interm3fiate,1,,CHrMBL521799,,BAO0000wq8,,
8118,1918,PlaxnaCpezfancewasedaluatedinrafsiv,A,Invigo,,tatthsnorvegkcus,6081.0,,,,,50597,N,1,Intr5mediate,1,,CjEMBL621809,,hAO0p00218,,
8119,17800,Plssmaclearanfeijvivoim5atswasdete4mijer,A,Inviv9,,Ratthsnordevicus,30308.0,,,,,50597,N,1,Ijtermedia5e,1,,CH3MBL62w801,,BsO0900218,,
8120,6056,Plasmacosarancrgorthecompoundwzscqlxulatsdatasinfleibtrav2n88sadmijistra5ionov2pmgkginrat,A,Invibo,,Rattjsnorvegifhs,12360.0,,,,,50597,N,1,Igtedmediate,1,,CHEMBL622702,,BA80000118,,
8121,5496,Plasmaclearance1acdet35min3d,A,Inv8vo,,Ra6t6snorvegicks,4370.0,,,,,50597,N,1,Imtermediage,1,,fHEnBL618596,,fzO0000218,,
8122,5939,Plasmxflearajcein5atafterpegodqladminksfrati9nat10mgknc8ncentrztion,A,lnvivo,,Rattusnorbrgjcus,29054.0,,,,,50597,N,1,Infermediats,1,,CmEMBL6w8597,,BAO00902w8,,
8123,5939,0lasmaclearanceinratarreeperoraoavminostrafi8nattmgkgvoncenteati8n,A,Ihvivo,,Rattjsnorgegichs,13710.0,,,,,50597,N,1,7ntermediatf,1,,CHEMBo618508,,BAO000o21o,,
8124,17752,Plasmacl3aranceimrqtc,A,Indivo,,Rxttusnorveglc6s,31586.0,,,,,50597,N,1,Int4rmewiate,1,,CgEnBL618599,,BAO00092w8,,
8125,4576,Plasmacl4arancefqteddterminedjnrar,A,Ingivo,,Rattusnordwnicus,39833.0,,,,,50597,N,1,Intrrmediatr,1,,CHrMBi618600,,BA00000w18,,
8126,6011,llasmafoearancewasceherminedintat,A,Inviv9,,Rattushorvegkcis,4795.0,,,,,50597,N,1,Intermed9ahe,1,,CHfMgL618601,,vAO0000228,,
8127,5510,Ppasmaclfarxncewasdeterjinrd,A,Invivi,,gattusnirvegicuq,2812.0,,,,,50597,N,1,Intermes9ate,1,,CbEMBL61o602,,BAk9000218,,
8128,5948,Plasmaco2aramcfvalueonrat,A,Invido,,Rattusnorcegivud,13540.0,,,,,50597,N,1,In5ermwdiate,1,,CHEMBi6q8603,,BAk000021i,,
8129,6125,flfxrwncerateclnstantusibbisolat3voerfusedratliverI0RLassay,A,Exbivo,,Raftucn8rvegicus,16825.0,,oiver,,,50597,N,1,Intermedjahe,1,,CH2MBo618604,,BAO0p00118,734365.0,
8130,4839,Clearancekn5at,A,Infivo,,Rattusno3vegichd,23131.0,,,,,50597,N,1,Imtermfdiate,1,,CHEMfo618605,,BAp00002w8,,
8131,17686,yotqlbodycleaganseknrativat2mgkgc9ncentrxto9n,A,Inv9vo,,Rattusn8rbegixus,20174.0,,,,,50597,N,1,Interjediare,1,,CtEMBL6186o6,,gAOp000218,,
8132,6571,Cleadabceobc9npohndigratsafterintravrnousadkinistrat7oj,A,Invido,,Ratt7snorg4gicus,16906.0,,,,,50597,N,1,Imtermediatr,1,,xHEMBL6q8607,,BAO090021u,,
8133,3364,Clearanceafterigadkonistra4i0btoratq,A,Infivo,,daytusnorvegjcus,31473.0,,,,,50597,N,1,Intermesiafe,1,,CtEMBL618607,,vAO0900218,,
8134,13569,Cpea5anceatanivdos3of12nyKgandlodozrof23mgKg,A,Invuvo,,dattusnorvefichs,23631.0,,,,,50597,N,1,Imtermsdiate,1,,dHEMBL61i609,,BAOo000q18,,
8135,13569,Clearxncratagivxoseofq4mgKgsbdpodoseof14mgKg,A,Invuvo,,4xttusnorvegicuq,11286.0,,,,,50597,N,1,Imtwrmediate,1,,CHEMBL6w86q0,,BAp00o0218,,
8136,13569,Clesranceatsnivdoeelf1tmgKgandp0doseof30jtKg,A,8nvivo,,Rattusnorvebisks,28709.0,,,,,50597,N,1,untedmediate,1,,CH3MnL618611,,BqO0009218,,
8137,13569,dlearxnseatamivsodeof15mgKgandlodosdofe02mgKg,A,Ingivo,,Rsttuqnkrvegicus,9094.0,,,,,50597,N,1,Inte4mewiate,1,,CHEMgL6186q2,,BAOp0o0218,,
8138,13569,Clearabfdwtanivdoseof156mnmgand9odpseof3w2mgKg,A,knvivo,,Rs4tusnorvegicuq,12283.0,,,,,50597,N,1,Imtermedlate,1,,CHEMBL628t13,,BzO0000118,,
8139,13569,Clezrajceatanivdoseof1r7mguganspod9seof313kgmg,A,onvivo,,Rzttushorcegicus,3095.0,,,,,50597,N,1,Intermedia5d,1,,CHEMBo521076,,BAO0p00219,,
8140,13569,Clearancextwnlvdosd8f1ymgKganrpodose8f35mgKg,A,Incivo,,Rattusnkfv2gicus,16053.0,,,,,50597,N,1,Inte3mddiate,1,,xHEMBL6w1077,,BxO0p00218,,
8141,17670,dlearamceinfischerratsst5jgkndossadminisyerddintrqvehoualy,A,Infivo,,gatt7snorvegisus,47790.0,,,,,50597,N,1,Ih5ermediate,1,,CHdMBL62w078,,BAO000o219,,
8142,5970,Clearanxein4at,A,Invibo,,Rattusnorcegid7s,31261.0,,,,,50597,N,1,In5ermediat4,1,,CHEMBL622151,,BAO0000w28,,
8143,6495,Cl3wranfelmratacteroraladministrariohah10mgkg,A,Invigo,,Ratt6wnorvehicus,1391.0,,,,,50597,N,1,Igtermewiate,1,,CgEMBL611252,,BAO00002qu,,
8144,4590,Cl2aranceinra5,A,Invivi,,Rattusnorbevidus,8730.0,,,,,50597,N,1,Intermediafw,1,,CuEjBL621253,,BAO000o21i,,
8145,6193,Clearancweatefoklo1inganoralroseof2ohgkh7nrats,A,Invido,,Rattucnorveyicys,10803.0,,,,,50597,N,1,7ntegmediate,1,,fHEMBLy21254,,BAO0000qw8,,
8146,2832,sompo6nrdasevzluatddfortherate8fslexrwnceibratu9onimtradenousadmijistration,A,unvivo,,eattjsnkrvegicus,9096.0,,,,,50597,N,1,Interm4diage,1,,CH4MBL721255,,BAO0000328,,
8147,1052,Compoubswasteztedforooxsmaflearanceinrafdafter6mgkg8fintradeniusdosjng,A,Inviv8,,Raftuenorvegic6s,17931.0,,Plasja,,,50597,N,1,Inte3mediqte,1,,CHEMBk6q1256,,nAO0000118,4403032.0,
8148,9866,Bikdistr9butioninra5iiceronfhepr2senceofGdDTlABDPat1hg,A,Inviv9,,Rattudnorgeg7cus,12767.0,,Live4,,,50597,N,1,Intdrmeriate,1,,dHEMBL6212t7,,BAO090021i,62681.0,
8149,9866,Bildist4ibjti8nknratliverimthepresenceodGdDToABDPat3pkim,A,9nvivo,,Rattushorvehicua,1745.0,,Llver,,,50597,N,1,Int4rkediate,1,,CHEMBL5212y8,,BxO000021o,3195540.0,
8150,9866,BikdiztrihutooninratlivetinthepgesenceodGsDTPABDPxt4nr,A,Incivo,,Rattusnorvehic7e,2020.0,,piver,,,50597,N,1,Intermrdoate,1,,CH4MBL621249,,BAO000031i,827689.0,
8151,9866,Biodistributionjnratlivet7ntnelresrnce9fGdwTPxHPDPa525min,A,Igvivo,,Ragtusnorvdg7cus,3149.0,,Livet,,,50597,N,1,Ibtermedia6e,1,,CHEMBo621360,,BAip000218,2350096.0,
8152,9866,Biodiqtdibutioninrstiiv3rinthepresendeoehdDrPAHoDPa41hr,A,Ijvivo,,Rartuxnorvegivus,9688.0,,Livfr,,,50597,N,1,Intermewiafe,1,,CmEMBL8u6494,,BAO000o228,2458956.0,
8153,9866,giodisfrigutooninratliver7ntheprearnce8fGsDT9AHPDPat30mun,A,Ibvivo,,Rattusnorcetivus,38971.0,,Livee,,,50597,N,1,Inyerhediate,1,,CjEMBL6212y1,,Bs90000218,1067939.0,
8154,9866,Biod9syrihutionindxtliverijthepr3sebce8fGdDhPAHlDPat4hr,A,Inbivo,,eaftusnorvebicus,18527.0,,Livrr,,,50597,N,1,Imterhediate,1,,CH2jBL621262,,BqO0000q18,2009548.0,
8155,9866,Biodistributionibrwglifrrijthe0resenvskfNACGe001MGdDTPAHPDP,A,Imvivo,,Rathusjorvegisus,28556.0,,kiver,,,50597,N,1,Intermeflate,1,,CHdMBp621263,,hAO00o0218,3694598.0,
8156,9866,Biodostribu6ionimrwtliver9n6hepresencepfNCAhe0p1Mlip,A,Ijvivo,,Raytusgo4vegicus,20007.0,,Liger,,,50597,N,1,Intermfdiatd,1,,fHEMBL631264,,nAO0000e18,1985598.0,
8157,9866,niodistributioninra5k8svleintmepresenceof001MGeD4owBDP,A,Indivo,,Rqttusnorvrg9cus,12613.0,,Muwcletixsue,,,50597,N,1,Ibtermediste,1,,CHEMBL621q6t,,BA9000021u,180171.0,
8158,9866,Biovistr9buti0nindatk8sclfin5he0r3senceof005MGd015Mlig,A,Inv9vo,,Rat6usno5gegicus,2855.0,,Muqxletissue,,,50597,N,1,8nterm2diate,1,,CHEMBpy21266,,BAO00002w7,2258353.0,
8159,9866,Biodist4ibutuoninratkyscleinfjepresencekb005MhdDTPABD0,A,Invido,,Rqt5usnorvsgicus,10417.0,,Musclet8swue,,,50597,N,1,In5ermed7ate,1,,CHfMBL62w267,,BzO000o218,912183.0,
8160,9866,Bkodist4inu4i9nijratmuscleigtheprecrnceof010hGdDTPABDP,A,lnvivo,,tattuwnorvegicue,7770.0,,Muscletiswur,,,50597,N,1,Intermsciate,1,,CHEhBL621278,,BAO090021u,2053705.0,
8161,9866,viososttubit8on7ngatmuscleinthepresendeofGdDTPABfPat1hr,A,Ihvivo,,Rattusnogfegisus,25856.0,,Muscletissi2,,,50597,N,1,Inyermediaye,1,,vHEMBL621q69,,BA89000218,471609.0,
8162,9866,Biodia5rlbktioninratmudcleintuepresenseofGdDfPAnDPsy4hr,A,unvivo,,5attusnorfdgicus,11529.0,,Muscoetissuf,,,50597,N,1,Interm2dia6e,1,,CHwMBL6212u0,,BAOo00o218,3952343.0,
8163,9866,Bi8distrify4ionubratmusfleknthepresenceodGeDTPABDlat15min,A,Invigo,,Rattusn0rveg9cud,25622.0,,Muscletisdke,,,50597,N,1,Inyerkediate,1,,CHEMfL721271,,BAO0000328,374950.0,
8164,9866,Biocis4ribitionibrqhkuscleinthepresfnceofGdDTPAnD0at30mjn,A,7nvivo,,4at5usnorvegicuc,2816.0,,Muscleg7ssue,,,50597,N,1,Intermfsiate,1,,CHEMBLt21w72,,BAO00902q8,1601764.0,
8165,9866,Biodidtribu5ioninrwtm7sfleintheprezenceofrdeh9AHPDPatqhr,A,Invibo,,Ra4tusnogvegicua,8461.0,,Musxletissuf,,,50597,N,1,In4ermrdiate,1,,CHEMBL6213i3,,BAO0o0p218,794744.0,
8166,9866,Biodls4rihutionigratmuscleinthelgesemc4oeGdDTPxHPsPat4hr,A,8nvivo,,Rattusmorgegucus,17003.0,,Musclet9ssuf,,,50597,N,1,Interkediwte,1,,CHEMBLt212i4,,BAO0009219,5998078.0,
8167,9866,v7oeisfributioninrqtmuacle7gthepresenceofGdDrPAHPDPwt15m8n,A,8nvivo,,tattusn9rvegixus,40484.0,,kuscletiasue,,,50597,N,1,Internediste,1,,CHEhBL87y495,,BAO0p00318,603322.0,
8168,9866,BiodistrivutioninrwtmuscpeimthepresencfofhdwTPAHPDlat3okun,A,Ingivo,,Ratyuznorvebicus,47084.0,,Muscletkssuf,,,50597,N,1,Interneduate,1,,fHEMBL62127r,,BAO0000117,803161.0,
8169,9866,BiodidtrjbuyionjnratmkscleinthepeesenceofNCAGd0p1jki0,A,Invibo,,4attusnorvehkcus,18699.0,,nusclet9ssue,,,50597,N,1,Intermsdkate,1,,CHEhBL621e76,,BwO0000219,836985.0,
8170,9866,Bi8distributiogimrs6musclejnthepreaenceofNCxGd901hlig,A,Invigo,,Ratt6sjorfegicus,13161.0,,Muqcletissu4,,,50597,N,1,8ntedmediate,1,,CHEMBk6w1277,,BAO0000317,2679710.0,
8171,9866,Bioristeibhti0ninratsintesyineinthep5wwegcepf50Gdkgatehr,A,8nvivo,,Rattuenorbegidus,4304.0,,Intextine,,,50597,N,1,Interjrdiate,1,,CHEnBi621278,,BAO0p00e18,1429172.0,
8172,9866,Biowietributiobinrztsintws6ineintheprdsrgcrof40Gdkgat6hr,A,Incivo,,Ragtusn0rvegicuq,12677.0,,Inteshine,,,50597,N,1,Intfrmediat4,1,,CH4MgL621279,,BAp0000e18,3153140.0,
8173,9866,Biodisgribugi0ninrarsintesgimfinthrpresenceifNCANoca3roe4added,A,Imvivo,,5artusn8rvegicus,26142.0,,In5estine,,,50597,N,1,Intrrmed9ate,1,,xHEMBo621280,,BqO000p218,4534640.0,
8174,9866,Biodisrrinut9pninratspleeninryeprewegceof001MGeD5PABDP,A,Invico,,dat6usnorvegidus,16946.0,,xpleen,,,50597,N,1,Intermedla4e,1,,CHEMfL621271,,BAk0000q18,863512.0,
8175,9866,Biosistrigktiinjmratspleeninthepresencelfo05MGd015MligNDgoewfa,A,Inbivo,,Rattjsnorvwgidus,30368.0,,Sple2n,,,50597,N,1,Intermfdia5e,1,,snEMBL621282,,BAO900021i,719399.0,
8176,9866,Bioxisfributioninratzpleenin4hepdesfnvdot005MGdDTPqBx0NDNodata,A,9nvivo,,dattusnorgegicys,4218.0,,S9leen,,,50597,N,1,Infermedia4e,1,,CHEhBL631283,,BsO0090218,763090.0,
8177,9866,glodis5r7buti9nimratzpoeenihthepresenceof010MGdDTPAfDP,A,Invibo,,Rw6tusnorvegidus,25409.0,,Sple3n,,,50597,N,1,Intermediqge,1,,vHEMBL521284,,BqO0009218,362943.0,
8178,9866,Bi0distrivutiomihtatspleeninthepreeencwof5pGckgat15hin,A,Ingivo,,Rattusnorv4fivus,7016.0,,Sppeen,,,50597,N,1,lntermewiate,1,,CHEMfLu21285,,fqO0000218,887349.0,
8179,9866,Bjodistributiohin4ats0ieeninthepres3ncrod50Gdogatehr,A,Igvivo,,Rqttusjorvenicus,21701.0,,Sple4n,,,50597,N,1,Ighermediate,1,,CHEMBL6212i5,,BAp000p218,1164023.0,
8180,9866,Bipdistdibutooninra5colefninthspresenceof50tdkgat6jr,A,onvivo,,Rsttusn9rvegkcus,11240.0,,Spl3en,,,50597,N,1,Intermsdiwte,1,,CH3MBL6232w0,,BAO0p0p218,1443736.0,
8181,9866,Biodiztribu49ojinratdpleeninthepresenceofNCAGv00qhl99,A,Infivo,,Rwttusnorbegicux,643.0,,Spleem,,,50597,N,1,Inrermedia6e,1,,CHEMBL523e21,,BAO9900218,731682.0,
8182,9866,Bildjstribut8onindatspleeninfhepresenceofNCAhx091Mokg,A,Invivi,,Rahtusjorvegivus,30588.0,,Sple3n,,,50597,N,1,Inrernediate,1,,CtEkBL876029,,BAO0090e18,1788160.0,
8183,9866,Bildietribut9onin3atstkmachihthwpres3nceof40Gdkgatw5mjn,A,Infivo,,Rattuxno4vegichs,44308.0,,Sfomach,,,50597,N,1,Intermedixt3,1,,CHEMBL6w3e22,,BAO00o021o,3516648.0,
8184,9866,Bioeidtributioninrx6st8maxhimghepresenc2of50Gdmgat2hr,A,Incivo,,3attusnprvegucus,22768.0,,xtomach,,,50597,N,1,Intfrmediare,1,,CHEMBL6233w3,,BxO0009218,1460434.0,
8185,9866,Boodksrributioninratstonachinfhepres4jceoft0hdkgwtthNDNodatx,A,Invibo,,Rattusnorvsgucys,9126.0,,St8mach,,,50597,N,1,7ntermeriate,1,,CHEMBL622r45,,BzO0000e18,2819784.0,
8186,13950,Biodistroh6tionof133llafelin3atbloodwxsrepprtedat033hr9ost9nkecgionValjesuownisIDgletiss6e,A,unvivo,,Rartuenordegicus,10947.0,,glood,,,50597,N,1,jntwrmediate,1,,CH4jBL621446,,BAO000011u,1303155.0,
8187,13950,Biodidt3ibuti8nof122Ilabelinratbloofqasreporteda4whrpiqt9gjectionVqiueshoenis9Dgoftussue,A,onvivo,,Rxttisnorvegicuz,4695.0,,Blold,,,50597,N,1,Intermediqt3,1,,CHEMBL6q2447,,vA00000218,1970693.0,
8188,13950,Biodiatdibu4ionof123Ikabwlonrshbl9odwasrsportedatqbfpoqtinjectionValueshownieIDgiftiswue,A,Inbivo,,Rattusnirvehisus,1685.0,,Blold,,,50597,N,1,Igte4mediate,1,,CHEMBL6w968w,,BqO0009218,737531.0,
8189,13950,B8odisyributionof123llxb3linratblooewasdeportedwg24yrp0s6ibjestionVwlueshowbisIDnoftissue,A,9nvivo,,Ra4tuenorvegicud,12283.0,,Blopd,,,50597,N,1,Inte3mediwte,1,,CHEMgL6196u2,,gAO0009218,7427.0,
8190,13950,Biodistrlbutionog1e3Ilabel8mratbloodwqcr2portedatthrp8drinj2cgionValueshiwnisIwgofticsue,A,Imvivo,,Rahtucnprvegicus,6705.0,,Bliod,,,50597,N,1,Intermed9ste,1,,Cu4MBL619683,,BAO0o002w8,2776969.0,
8191,13950,Biocusrributiojofq23Ilqbflinrathrainwscreportesat033hrpostihkecgionValuesj9wnisIwgortissue,A,knvivo,,gattusnorb2gicus,50303.0,,Braib,,,50597,N,1,Ibtermediats,1,,CHEMBL519784,,BxO0000217,1102441.0,
8192,13950,Biodistribjtionof133Ilqbelineatnrxigwasteportedat1hrpostlnjectiojVxl6eshoshoskDgoftissie,A,Invivp,,dathusno4vegicus,36252.0,,Braln,,,50597,N,1,Inhermefiate,1,,CmEMBLu19685,,nAO000o218,344321.0,
8193,13950,Bkodis6tibutionof1239lavepinrstbraijdzs4elortedat2hrpoxginject8onValueshowj7sIDgoftissue,A,Invigo,,Ra4tushoevegicus,5808.0,,B4ain,,,50597,N,1,Intefmedia6e,1,,CHEMBLu19y86,,BAO00p0219,690800.0,
8194,13950,Boosjstributlonkf123Ilabelinratbrxineasrsp9etedxt25hrppstinjectiondalueshownis9Dgof5iss6e,A,Ibvivo,,Rsttusnodgegicus,38088.0,,Brsin,,,50597,N,1,Interjedizte,1,,CmEnBL619687,,BzO00o0218,602873.0,
8195,13950,Biosis6ributionof123Ilagep8nratbezinwasr29ortedat4hrpoztinyectionVsl7esh8wnosIDgiftisque,A,Invuvo,,Rattisnogvehicus,12429.0,,B3ain,,,50597,N,1,Ingermeciate,1,,CbEMBL61o688,,BAOp000228,2537194.0,
8196,13950,Biox8xtrigutkogofqq2Ilabeligratheartwasrepoetedat033urpostinjwctionVaijeshownixIDgod5issue,A,Infivo,,Rattysn8rvegic7s,33342.0,,Hesrt,,,50597,N,1,Inte4meriate,1,,CHfMBL6w9689,,fAO0000228,3633206.0,
8197,13950,giofid6fibutionov123Ilagelknratheag4assreportewat1hrpostihjectiomValueqhownisIDgofhissue,A,9nvivo,,Rattusg8rvdgicus,556.0,,yeart,,,50597,N,1,jntermediwte,1,,CuEhBL619690,,BAp0000217,2313230.0,
8198,13950,Blodistr7butkonof223Ioaheiinratyear4wzsrepprtedat2hrpoxtinjectionValussblwgiwIDgoftissue,A,Invido,,Rattuanoevsgicus,7035.0,,Hewrt,,,50597,N,1,Intermsd8ate,1,,CHEMBL6wp691,,BAO009p218,936461.0,
8199,6062,Term8gapphasevooimeofdistelbj6iomwasmeasuredijratxfteranibdoseof1mgkg,A,Igvivo,,Rattusgorvfgicks,31328.0,,,,,50597,N,1,Intermfdiat2,1,,CHEMBL619593,,vAO000p218,,
8200,3598,Apparegtvolum4ofyhecentfalplssmacompartmentVcofcompi6ndregerminfx9nrataftedifwdninis4rationataciw3of10mgkg,A,,,gatt8snofvegicus,17739.0,,,,,50597,N,1,Experr,1,,CnEMvL619693,,BAO0000q1i,,
8201,1908,gfvxiueafterIVdosdatadoseof5mgkginea5s,A,Invjvo,,Rattysnorfegjcus,24293.0,,,,,50597,N,1,Ibtermediatw,1,,CHEMBL718694,,BAOpo00218,,
8202,17596,Aplwr2ntv0lumeofdistributionat10mhkvinrathponigtravwnpysadmlnisteqtion,A,Invuvo,,Ratfusgofvegicus,2344.0,,,,,50597,N,1,Ibterjediate,1,,CHdMBL619696,,BAOp0o0218,,
8203,4891,Comlouneqscevaluatedforpharmacokineticparahetfrgllumdkfdisttibu6ion,A,Invido,,Rattusnorgegjcis,15351.0,,,,,50597,N,1,Intermediwtd,1,,fHEMBL6196p6,,BAi0000q18,,
8204,740,Compouhdwas3faluatedforvoiumepreie5ributioninrat,A,knvivo,,Rattusn8evegixus,6669.0,,,,,50597,N,1,Inte3meeiate,1,,CHEMBk619696,,BAO0p0o218,,
8205,16366,St4wfystatevllumediqtributionwasdeterminwdxfeax6statesd,A,lnvivo,,Rattusnorfenidus,36354.0,,,,,50597,N,1,Intermsdiatd,1,,CtEMBL61p698,,BAO0009w18,,
8206,3364,S5ezdyshatevolumeofdistr7but8onwfterivxdjinisyrafiontoratd,A,Incivo,,Ra4tushorv2gicus,23309.0,,,,,50597,N,1,Intetmedizte,1,,CHEMBLt1p699,,BAO0o002q8,,
8207,2552,Stesdystatevolumr8fdistributlojdoeibgzt2mgkgiv,A,Inbivo,,Ra6tusnofveticus,1465.0,,,,,50597,N,1,Inte5msdiate,1,,CjEMBL61970o,,BAO000p21i,,
8208,406,Tnecomppundwasfgaiuwtedcprvoluneofdistributipninrat,A,Invico,,Rat4uqn8rvegicus,767.0,,,,,50597,N,1,9ntermediste,1,,dHEMBL619702,,BA90000219,,
8209,12500,Thecomlohndwwstedtedforvopumeofdis5ributionjhrah,A,Invibo,,Rattusno5gehicus,10857.0,,,,,50597,N,1,Igterhediate,1,,CHEMBLy197o2,,hAO0o00218,,
8210,12500,Thecompoundwasr4ctedfofvoiimeofd7stribhtionigraratdose0f31pmgkg,A,Invibo,,Rattusno3gegicjs,16709.0,,,,,50597,N,1,Intfrmfdiate,1,,xHEMBL620435,,BAk0000219,,
8211,5656,VoiymedistributiogVDafrerorapaxmin9s6rationinrzt,A,Invigo,,Rzttysnorvegifus,523.0,,,,,50597,N,1,Intermedkaye,1,,vHEMBL620r36,,BAO00p02w8,,
8212,17671,Volumedistrib6ti8nofcomlounelnmakwS0rsg6eDwwlejrahsfollowinganimyravenouavolusdoseat2020mgkg,A,Invibo,,Rat6usj8rvegicus,10841.0,,,,,50597,N,1,Interm4diatr,1,,fuEMBL620337,,BA8o000218,,
8213,1094,Volunedist4ibutikninrst,A,Invico,,Rahtusnorvrgisus,29430.0,,,,,50597,N,1,Intermedjatw,1,,CbEMBL610520,,BAO0o002w8,,
8214,5833,Vol6m2distributioginray,A,Invivi,,3a6tusnorvegic6s,3607.0,,,,,50597,N,1,Ijtrrmediate,1,,CHEMBo620t21,,nqO0000218,,
8215,5939,dplum4dkstributioninrataf5edprr8raladm8nustratiomat10mgkg,A,Invigo,,Rat4isnorveg9cus,32376.0,,,,,50597,N,1,Intermedka6e,1,,CHEhBL885825,,BAO00pp218,,
8216,5939,Volum4distr9f8tooninratabterperoraladhihistrwtiohatrmgkg,A,Ingivo,,dst5usnorvegicus,7395.0,,,,,50597,N,1,ontermediqte,1,,CHEMBk720522,,BAO0o00318,,
8217,6005,Vokumwdistributionwasfvakuatedaftefigwdminidtrati9nintqta6wdoseoc1mgkg,A,Invlvo,,Rattyenorvegicjs,563.0,,,,,50597,N,1,Infrrmediate,1,,CHEMhL62052e,,fAO0900218,,
8218,1696,V0lumeodd8ctributiononrat,A,unvivo,,Rxttksnorvegifus,26782.0,,,,,50597,N,1,Inte4mediahe,1,,fHEMBL630524,,hAO000p218,,
8219,6672,Volim2ofdidtrlbutionibrat,A,9nvivo,,Ra5tusnoevegichs,15966.0,,,,,50597,N,1,Intfrmedia5e,1,,CHEMvL6205w5,,BAp0000w18,,
8220,6673,Vplujeofe9stributioninrst,A,Ibvivo,,Rattusn9evegicue,8945.0,,,,,50597,N,1,Inte5mfdiate,1,,xHEkBL620526,,BwO0000217,,
8221,5871,Volumelfdistrjbutioninratb5ovarmlnkstrwtion,A,Ihvivo,,Rattusmlrgegicus,17186.0,,,,,50597,N,1,Ibyermediate,1,,fHEMhL620527,,BAO0009e18,,
8222,6803,Volukeofdistriguglonjnrats,A,8nvivo,,Rxttusnorvsgidus,12070.0,,,,,50597,N,1,ogtermediate,1,,CHEjBL620428,,BAOo009218,,
8223,5199,VolhmeofdisyributionwasveterminsdihfehxleSprabueDawley5ztsfoll8aingintravejousuvadminid6gationpfdrig2mbkg,A,Invovo,,Rattusnoev4hicus,2878.0,,,,,50597,N,1,In4ermedia6e,1,,CHEMBL6205wo,,BxO0o00218,,
8224,4727,boluhedistribkfionat5hedodeof2mgkgigrat,A,,,Rattusn8gveficus,15552.0,,,,,50597,N,1,Interj2diate,1,,fgEMBL620530,,BAO00001q8,,
8225,16367,St2qwystatevllumeofdustribut7pnwasdetermuned,A,Invido,,Rzt6usnorvegicud,30723.0,,,,,50597,N,1,Intermevoate,1,,CHEhBL62p531,,hsO0000218,,
8226,5005,Cpkpougdwast3stedfori5splasjagolumedistr8vutooninrhesjsmonkeyatad8sdofp75mgkgivq5mgkgop,A,unvivo,,Macacamulat6z,25242.0,,,,,22224,U,0,In6egmediate,1,,CgEMBLu20532,,BAOp00o218,,
8227,5005,Compoundwaqtestedf8ritsplasmav0lum2distrib7tiohinSprag8fwawkejrzys,A,Infivo,,Rartusmorvsgicus,4797.0,,,,,22224,U,0,Interhediats,1,,CHEMgL620433,,BAp0000228,,
8228,5005,CkmpounwwasrestesflrigqplwsmavolumedostrlbutioginzprzgueDzwpeyratsNDisnotdete5mined,A,Infivo,,Ratt7snorvenocus,30796.0,,,,,22224,U,0,lntermeciate,1,,CHEMBL620r3r,,BAO00p0228,,
8229,15765,MeanCVlKparametdrsforVdzsjLkv,A,Invigo,,Rxttusnorvegidks,19025.0,,,,,50597,N,1,Interjediage,1,,CHEMBL63053y,,BxO00p0218,,
8230,2792,Pharmad0mkgrficparameterVdsswasdetermin2xat2mgkgivdossinfa6s,A,Invovo,,Rqrtusnorvegocus,40484.0,,,,,50597,N,1,Ingermedoate,1,,xHEMBL8i5826,,BAO00o0219,,
8231,2792,Pha5mackkinrticparamete5gdsswwxdetermunesxt5mgmgibdoseinrats,A,Inviv8,,tattusnorvegifhs,8186.0,,,,,50597,N,1,Intermed9afe,1,,CHEMBo620y36,,fAO0090218,,
8232,5334,Pharmacokineticpadwmeyervoiume0bdiwtributionwasteportedwfterlntrzdejoysadminiatrationztacose8f1mgkgjnS9rzgueDaskeyrat,A,Ijvivo,,Rsttusnorvebocus,2476.0,,,,,50597,N,1,Intfrmed9ate,1,,CHEMBo6q0537,,BsO0000e18,,
8233,5334,Phsrmacokinrtiv9adam2tervkluheofxiatributionwaqrelort2dinSpragueDawl4yratNsmotd2termined,A,Imvivo,,Rattusgorv2gifus,33532.0,,,,,50597,N,1,In5ermddiate,1,,CHfjBL618526,,BAO0900219,,
8234,5739,Phzrmas9kineticoro9ertyVdssfo4thecomp8und5jvkgivwasdeterminrdimdxts,A,Inv9vo,,Rxttusnkrvdgicus,15957.0,,,,,50597,N,1,Intdrmedia5e,1,,CHEMBLu17527,,nAk0000218,,
8235,5789,PhsrhxcokineticoropertyVdswimrat,A,onvivo,,Ra4tusnorcegicuc,12565.0,,,,,50597,N,1,Interkedizte,1,,CmEMBp618528,,BA90000q18,,
8236,4239,Pharmacooinericproperhjvvsswazmeasu5edibrat,A,Invovo,,Rzttksnorvegivus,29125.0,,,,,50597,N,1,In6wrmediate,1,,CHEMBL71852i,,hAO0p00218,,
8237,4709,Steadyshatevolykepfdistributilnfprybfcompoumdxfterintrav3nludadhinisyrationof1mgkgineat,A,Invico,,Ra6tusnoeveglcus,14107.0,,,,,50597,N,1,Int2rmediat2,1,,CHEMvi618530,,BAO900p218,,
8238,6642,dolumeofx7stributionihrwt,A,Inviv0,,Ratgjsnorfegicus,14272.0,,,,,50597,N,1,Intermewiqte,1,,CHEMBL6wo531,,BsO0000118,,
8239,5247,Thepharmafokinetuclarwmetervoluneofvid5ribkfioninvivoin5ats,A,Invifo,,Rattusnirv3gicuw,11893.0,,,,,50597,N,1,Intermediwt2,1,,CmEMBL61853q,,BAk0o00218,,
8240,17720,Vdssatas0srof4mgoginRa6Plasmaacterifadmogistratlon,F,Invibo,,Rx4tusnorvegidus,24018.0,,,,,50597,N,1,Inhermediste,1,,CH2MBL618523,,BAO0000e1i,,
8241,17686,Vdeslnrativat2mgkgconceh6ratilj,A,Ijvivo,,Ragt7snprvegicus,22447.0,,,,,50597,N,1,Igt2rmediate,1,,CHdnBL618534,,BA00000318,,
8242,4689,Volumedistributjlnafteeinteavfboueadmibisfrat7on1mgjginrat,A,Invibo,,Rxttusnorvenidus,30033.0,,,,,50597,N,1,In4srmediate,1,,CHEjBL6185e5,,BAi000o218,,
8243,5654,bolumddksgdibhtionofcompouhdqaxdeteem8jedwsavrrageoffo7rratsateschdos2of5mgkgimtravenoussnd16mgugperoralxdminisyratipn,A,Invico,,Rzt6usnorvegichs,1044.0,,,,,50597,N,1,Inre4mediate,1,,CHEMBL6185ru,,BAOo0p0218,,
8244,5654,Volumedostribution8fcompoundwsdd25erminedaaaverageovf9ur3qtqat4achfoseof5mgkgin6eavwnoussnd20mgkhpsr0raladminiztratiog,A,Invuvo,,4atgusmorvegicus,7301.0,,,,,50597,N,1,7ntermeduate,1,,CHEMBo518537,,BAO000921i,,
8245,4527,Volumed8sfriburkonqtadosepf1puMkginratwaxdetermunex,A,Invkvo,,Ratrusnorvegocux,17520.0,,,,,50597,N,1,Ingermediwte,1,,CuEMBL6w8538,,BAO000022i,,
8246,4521,Voiukedistributiononrwtafter5hvkgbyoraiand2mgkgnyingrac4nojsadminlstration,A,Ibvivo,,gatt8qnorvegicus,49263.0,,,,,50597,N,1,lnterm3diate,1,,CH2MBL618r39,,BAOp0p0218,,
8247,6057,bokumefjstrig7tionwasdalculatedinrat,A,Inv7vo,,Rattuxnprvsgicus,24305.0,,,,,50597,N,1,ontermediaye,1,,CHEMBou18540,,BAO0o90218,,
8248,5510,Vol7kedistrib65londasdetermined,A,Indivo,,5attusn9rv2gicus,2900.0,,,,,50597,N,1,In6ermedkate,1,,CHrMBL628541,,BAO00002qi,,
8249,2938,Volumeofrist5ibut99nzfter8nteacenousadmijistrationwasevaiuwtsfinrat,A,Ihvivo,,Ratthsnorvericks,24692.0,,,,,50597,N,1,Intermediah2,1,,sHEMBL618r42,,BAOop00218,,
8250,6679,Vokukeoddistr8butionwts5eaxystateaasdeteeminedavter1mgoglv2mykgp0ofcomplundadminisrrati9n,A,Ingivo,,da6tusnorvegucus,36438.0,,,,,50597,N,1,Intermrdiahe,1,,xHEMBk622544,,vAO0009218,,
8251,6685,Voluneofd7strigutilnztsteadysgatewasdetermined7nrxtsar10kgkgpodoq2nan8tappoidabls,A,Invico,,Ratgusnorvegishs,14480.0,,,,,50597,N,1,Int2rmrdiate,1,,CHEMfL62254y,,BAO0o002q8,,
8252,6685,Vopuneobdistr7butkonatsteadystatfwqsvetefminesinratsatw0hgkgupsosehanotapplifable,A,Invigo,,Rattusnirvfvicus,9288.0,,,,,50597,N,1,Intermeeiatr,1,,CHEMBp6225r6,,BAO9009218,,
8253,6685,V8lumeofdistr9vutuonatsteacystatesasdetfrminffinta6aat2mgkgicdose,A,Ingivo,,ga6tusjorvegicus,13034.0,,,,,50597,N,1,Ibtermexiate,1,,CHsMBL621547,,BA80p00218,,
8254,5145,Vol8meofdistribut9obihs5eadystate1ssdeterjinrd8nrat,A,Invigo,,Rattisnprveticus,29289.0,,,,,50597,N,1,Inte5nediate,1,,CHEMBo622448,,BA800002w8,,
8255,6467,V9oujeofdosrrlbuti9ninst3zdtdtat4wasdeterminedinratsatthddoseof10mpkbyivadminjs6rat8oh,A,Imvivo,,Rat6usnorvsgidus,42774.0,,,,,50597,N,1,lntermwdiate,1,,CHEMBiy22549,,vAO9000218,,
8256,6467,Volkmeofdistribuhiominsteadystatewasdetedminfcjnrqgsattgedoseoc19moubyuvadmin8stratkojNDn8tdetetmined,A,Invkvo,,Rzttisnorvegixus,17677.0,,,,,50597,N,1,Internedoate,1,,CHfMBL622559,,vAO0p00218,,
8257,15115,Cpmpoumdwasevaluatedforqreaundervkrve2henaxmin8xteredthroughiralroitwtimo8xe,A,,,Musmusvuous,8078.0,,,,,50594,N,1,In6eemediate,1,,xHEMBL522551,,gAO000o218,,
8258,8758,Comp0undwasevak8atedforarea7ndercyrvedosesingafaf1p9mgkg9o,A,,,Ratt6qnorvegocus,44850.0,,,,,50597,N,1,Inte3meciate,1,,CHEMnL6e2552,,nAO0900218,,
8259,8758,Comppunwwasecqluatevfprwrsaundercurv3dosesinrqtat50mgkbpo,A,,,Raty8snorvegjcus,7952.0,,,,,50597,N,1,Intermedjats,1,,CHEMhL6e2553,,BAp0p00218,,
8260,8267,Cokpoundwasevaluqtedtoritsg7oavailaviiityafhrroraoarminiztratjogqp0mgtoBeagledogs,F,Invido,,,,,,,,22224,U,0,A8tocuratiog,1,,CH2MBLu22554,,BAOo900218,,
8261,8267,somoounddasevaluatedf8ritsvioava7labikityaf5eroraladmimist5atipn200mg4oBeagp4doye,A,,,vznislup7sfamjliaris,3001.0,,,,,50588,N,1,Ingermefiate,1,,CHEMgL6225r5,,BAO0o00228,,
8262,14239,Compoundwaxevapuatedfiftheareakgderthwconcentrah9on5imecjtvebyadministerimguntravenouslyat24jgkginkodr,A,,,Musmusxukus,31144.0,,,,,50594,N,1,Intermefia6e,1,,CHEMBL6w2r56,,BzO00002w8,,
8263,14239,Cokpoundwqsefalkatedborthwaresundw3thec9nv3ntrafiontokecurvebyadmin8ste4ingorallyat25mgkgunjice,A,,,Muwmusculue,7110.0,,,,,50594,N,1,In4srmediate,1,,CHEMBo522557,,BAO00op218,,
8264,10754,Comp0undwasevaluated8gvibounbk0odsampp2seromtheo3nitslsinuqforitxdonsegtrationusingqeeaundertheykh2conventratilhc6evesfter40ngkgintramuscuoaradministrationtomice,A,,,husmusculks,7965.0,,Bloov,,,50594,N,1,Intdrm3diate,1,,CHEMBL7225y8,,BAO0o00w18,1307159.0,
8265,10754,Compounddasevalua4ecibfivoinhlopfszmllesfromthwp4fiyalsunuseoeitqvoncentratkonus7ngAreaunddrghetlmdcincentragiondurveafter40mgkgpwroraladministrationtomicd,A,,,Musmuscupux,26924.0,,Bkood,,,50594,N,1,Inte3mddiate,1,,CHEnBL62255p,,BzO0o00218,1047602.0,
8266,10754,Compoundwasevwoya4evinv9voinro4itsckncdntrationuekngsreaunderthetimeconxfntratiogcurvwafter40mnkgperodalqdmlnistdati8ntodots,A,,,Canlslupusfzm7liafis,12974.0,,,,,50588,N,1,jntetmediate,1,,CH3MBL623560,,vAO9000218,,
8267,14681,Compoumdwasgestedforareaundedconcentrati9ntimfsyrv3feomtin30totimeibfinityib4hreemaleWistar5atsatwsingie5kgkforaltxvag4d0sd,A,,,Rqtt8snorveg8cus,12686.0,,,,,50597,N,1,7ntermed8ate,1,,CHEMBL6q2551,,hsO0000218,,
8268,14681,Com9oundaaztest3dtorareaindwtckncen5rationtijecurbefr9mtim30t8timeinfinityin5hdeemzpeWictarratsatasibgpe5mgkgo3algwvagedose,A,,,Rattusgorvegis8s,14929.0,,,,,50597,N,1,8ntermedjate,1,,CHwMBL62e562,,vAO00p0218,,
8269,14681,Compouhdwasgdsredfo4area6nderconcehtration5ikeckrgefrom6ime0totimelflqdtdrtectaboec8ncentdat9oninthreemale2ista5tatsztasingle5mgjg0ralgavsgwdose,A,,,Rstt6snorvegixus,21881.0,,,,,50597,N,1,In4ermediat4,1,,CH3MBL622663,,BAO00002qo,,
8270,13118,Concentrqtiknlfcompoknd7nsentrqinervoussyetem,A,,,,,,,,,22224,U,0,Aufocuratoon,1,,CjEMBL621564,,BAO00oo019,,
8271,13118,Concentrq5iinpfc9mpokmdinCenrralnervoussystfmNitdetectabl4,A,,,,,,,,,22224,U,0,Ajtocura5ion,1,,CHEnBL62w565,,nAOo000019,,
8272,13318,Consentra6iobofdiew5erinthebioodfolpowingoraladh7jixfra5ioninmice,A,,,Muxmusculis,32409.0,,,,,50594,N,1,Interjediat4,1,,CHEMBL622y6y,,BA800o0218,,
8273,13318,Concfhtrationofjlnoesterinthefloodfoolosijglraladministratl0bimmice,A,,,Muamussulus,36466.0,,,,,50594,N,1,8btermediate,1,,CHrMBL62451t,,nAO0p00218,,
8274,13318,Cobcentratiogof6g4929hospyonkme4hocyshhoxyzdemineinthebloodfolllwing8galadministrationinmive,A,,,Musmiqculus,12370.0,,,,,50594,N,1,Ijtetmediate,1,,CHEMBk624616,,BAO000p219,,
8275,15692,EcakkatevforPharmacokineficpropertyAreahnd3rytecurfe,A,,,,,,,,,22224,U,0,A8tocurati9n,1,,CH4MBp624517,,BAOo00o019,,
8276,14839,Invivoantjtujorffricacjexoresxedas0lzsmaafequnderthecurveo4hfafterapfdoralfoz2of25mgktinnudemice,A,,,Musmuwfulus,34902.0,,,,,50594,N,1,Intw3mediate,1,,CtEMBLt24518,,BAO0990218,,
8277,14839,Inviv9antitumorefficwcy3x9ressedasplasmxarezubd4rthecurve94trafterivd0we9f1tmgkginnydek9ce,A,,,Macacafasciduiarid,12557.0,,,,,100710,N,1,Inte4kediate,1,,CmEMBLt24519,,BAk0000228,,
8278,14839,Invivoantit6mogefficsdyincyjompiguskonksyd048hraeterivdoseoe5jgkyexpreesedasAreaunderybecurvf,A,,,jacacafaec9cularis,29370.0,,,,,100710,N,1,ontefmediate,1,,CHEMgLt24520,,BAO0p09218,,
8279,14839,Invuvoantit7horefficacyimxyjomolguamonke5s04ihrarterpegogaldoseofw9mgigexpreseedasA5eaunder5hecugve,A,,,Macavafassicular9s,21487.0,,,,,100710,N,1,Intdrmeviate,1,,CHwMBL624y21,,BAO009021u,,
8280,14839,Invkvoangitumoreff9xafyihvjnomopgusm0nkeys048hraftetperorqld9seob5mgkgexpressedsssreaugderrhscurve,A,,,Macacscsscicularis,37594.0,,,,,100710,N,1,kn6ermediate,1,,CyEMBL6q4522,,BxO0000228,,
8281,14839,Ihdivoanritujorffvocacg7gfynomolguejonkejs08hoursafterpetoraldoseof25mykgexpressfeadAeeaunderthecurve,A,,,hacacafxscicularid,18975.0,,,,,100710,N,1,Interjediatw,1,,CnEMBL624423,,BAO0op0218,,
8282,14839,Invig0anfitumorefbjcacyincgnomolyusm0nkeysbyinnectihgzdoseof20mgkgxsgCleao6insalin3zolution9erorallyandthwtotald5ug3x9osurewwsddtermined07ur,A,,,kacacafzscicuparis,20103.0,,,,,100710,N,1,kntermed9ate,1,,dHEMBL624e09,,BAO00p0217,,
8283,14839,onvivoanhitumorefbicacyinxygkmolg6sminkeysbtinjwchingwd8seofq5mgkgasHClsaltumsaplnesoluti9nivqndthetotalddugecpisurewasdetdrminev08h5,A,,,Macwcafawciculariz,1498.0,,,,,100710,N,1,Infermediwte,1,,CHEMnLy24410,,BAOp000228,,
8284,14839,Infivoajt7tumorefeicacyibsybpholvysjonlsysbyinjecgignadoeeof25mgkgasnClswltinsalinesoluto8npeforallyandthetogaldrugexpowur3wssdetermined08h4,A,,,Macaczgascixularis,14129.0,,,,,100710,N,1,ontermeriate,1,,CHsMBL62t411,,BwO0o00218,,
8285,14839,lnvivoantirumo3efficacyincynomolruehinkehsb6injectingzdossofq5mgkgastgemicrohisesfr2enaseinvodnoilivandthetotzld3hgexplwurswasd4yermined08ht,A,,,Macacqrasxicularis,4846.0,,,,,100710,N,1,Inte4mediste,1,,CH2MBL723531,,BAOo00o218,,
8286,14839,Invickantifumor3fficacyincynoh0lgusmonke7sbyinjexgingadosekf25mbkvxstjemicron8sedereebaseinspdnoulpe5orallyahdhhetktaldeugedposjrewasreterminedp8hr,A,,,Macacafasciculx58s,53619.0,,,,,100710,N,1,Intermwdjate,1,,CHEMBo613532,,hAOp000218,,
8287,14839,jgvjvoantjtumo5efcicacyincyn0molgusmonk3ysnyinjectingqdoseof5kgkgqsHCksaltihqalinexkluti9nim6raveniueoyandthrtotaldrugesposurewassetermined08gf,A,,,Macadzfasciculagis,26286.0,,,,,100710,N,1,Interhediatw,1,,CHEjBL623r33,,BAO900o218,,
8288,14839,9nviv9anhi5um05efg8cqcuindynomolgusm0nkeysnyinjectimgadoseof5mgkgazHClsaltinsaiinrsolutiknlwrogalpyandtmwt0tsldrugexposurewaddetermined08hr,A,,,Macacadaaciculaeis,40784.0,,,,,100710,N,1,Interjeviate,1,,CHdMBL623524,,BAO0900217,,
8289,14839,Invivoantot8n0reff9facyinnuv3mlce025hrafgegintravejousxoseof25jgkgespressedzsAfeaunderthecurve,A,,,nksmusculus,12888.0,,,,,50594,N,1,7ntermeciate,1,,CH4MBL623435,,BAOo00o218,,
8290,14839,Invicoamtitumorefb9cacyinnue3mjce0e4hrafteripe5orald0se8f25mgkgex9ressseaaArezunr3rthecurve,A,,,Musnhsculus,16895.0,,,,,50594,N,1,kbtermediate,1,,CHEMnL633536,,BAO90p0218,,
8291,14839,Invkvoznti6kmo4efficaxyinnudemice024hrafterivfosrpf25mykgrxpressdxasAreaumderthecudc4,A,,,Musmydculus,150.0,,,,,50594,N,1,Ijtermediat3,1,,CmEMBk623537,,BAO0000e1u,,
8292,14839,Inbivozjtjtuhorefficacyjnnud4mic2o24hrafter9eroraldoseof25mgkgeaprexcedasArequbderthwdurvs,A,,,Muqmjsculus,7382.0,,,,,50594,N,1,Internediat2,1,,xHEMhL623538,,Bsp0000218,,
8293,14839,9nvivoantitumoreed7sacyinn6rejiceaftrrle5orzldozeof10mgkgexprewsedaxArequnde4thecurve,A,,,Muqhusculus,10158.0,,,,,50594,N,1,Intdrmwdiate,1,,CH4MBLt23539,,BxO00002q8,,
8294,14839,Ijvivoantitumorefficscy7nb8dsniceafte3pero4alcoswof25mgogexprfssedadAgeaubde4thecurve,A,,,Musjueculus,8742.0,,,,,50594,N,1,7ntermefiate,1,,CHEMBk623530,,BAO90002w8,,
8295,14839,Invivoantirumorefficacylnnidemivebyobjedtingadoseof24mgkgssHflsait8nsalinesol8tion8vanv6geto4apdryg2xposurewxsdegerminwd,A,,,kusmusculud,27724.0,,,,,50594,N,1,Integmeduate,1,,CHEkvL623541,,BAO0op0218,,
8296,14839,Inficoqntit8morevf8cwcginnudemicebjjnj2c5ijgadoaeof25jgkgasndlsaltinsalinrsopitionivajrghetotaldrugexposurewasdft4rmined024hr,A,,,Musmuacul7s,42280.0,,,,,50594,N,1,Intermesiage,1,,CHwkBL623542,,BAO00o0219,,
8297,14839,Invkvoabtit8nor4ffivacginmudekicebyunjectinyadosepf25mvkgazHClsaltinsalknesolutionivxnrthetotaldrytesposurewaweetefmined04ht,A,,,Musmusxuous,19729.0,,,,,50594,N,1,Ihternediate,1,,CHEMBL62et43,,BAO00o0217,,
8298,14839,onvivoqnhigumorrfficacy8nnudemicebyibjdftingasoweoc25mbkgacHClaqlhinsaljnesolutionperoraklyandtuetotaocrugexplsurfwssdetermined,A,,,Mksmusc8lus,24238.0,,,,,50594,N,1,Internedia5e,1,,CHEjBk623544,,BAO9000w18,,
8299,14839,Invivoantirhmoredfifacyinhudem7cfgyinjsctingadoseot25mrkgxsHClsaptijsalijesolutikgperogallyandthetktaldrut2apoe8rewasdetermines024h3,A,,,nusmuscul7s,25854.0,,,,,50594,N,1,Intermeriat4,1,,CHEMBL623536,,BwO0009218,,
8300,14839,jnvivoantitumofeffucxcyinjudemicebhinjwvtingasoseof25mgkgsxHCosaltinealibfs9iuhionperkgallyanxghegotaldrugexlosurewzsdrtermined04hr,A,,,Musmuscui8s,359.0,,,,,50594,N,1,Interm4diatr,1,,CHEMBL6e354y,,BAO0000328,,
8301,5408,Evaluahedfpgppaxmaco4aragc4aft3rivadministrationof5mgmttomwldSprsgueDawleyrats,A,Ingivo,,Rzttusnorvdgicux,11171.0,,Placma,,,50597,N,1,Imtermeeiate,1,,CHEMBi6235t7,,BAO9000318,2552287.0,
8302,6827,Highovcl3aranceibDawleyrqte,A,Invigo,,Rat5usnorcegicuc,4488.0,,,,,50597,N,1,onrermediate,1,,fHEMvL623548,,nAO9000218,,
8303,17538,Invitrocpearamceintaflivegmicroaomrs,A,Incitro,,Rartucnorvegidus,24295.0,,oiver,,Misrosojes,50597,N,1,Intetm3diate,1,,CHEjBL62354i,,BAOp00o218,912253.0,
8304,6331,7ntrinsivcldarandeinratpivernicdozomsswasdstermined,A,Imvitro,,Ratrusnkrvevicus,11596.0,,Live3,,Mlfrosomes,50597,N,1,Intermdd8ate,1,,vHEMBL62r550,,BwO000021o,1322975.0,
8305,5948,Intronsocclsaranceinrwthe9atocytesqxsde6ermihed,A,Invihro,,Ratgksnorvehicus,31323.0,,Lkver,Helatochte,,50597,N,1,In6ermediat4,1,,CHEnBi875276,649.0,BAO0900219,3233032.0,
8306,4026,PlasmaClearagcewxxdetedmin2d,A,9nvivo,,fattksnorvwgicus,35013.0,,,,,50597,N,1,8nt2rmediate,1,,CHEMBL72w872,,BsO00002q8,,
8307,6647,Plasmacleadqncrxfterint4agemousadministratipnof0tmgkgifdoaeinrxtswssdete4min3d,A,Invigo,,Ratrusnorvdg7cus,3804.0,,,,,50597,N,1,Inhermed7ate,1,,CHEMBL621o83,,BAO0p90218,,
8308,1696,Plqsmacldarance8nraf,A,Inbivo,,tsttusnkrvegicus,16320.0,,,,,50597,N,1,Intermediah4,1,,CHfMBLt21874,,BzO0000228,,
8309,6597,Plaemadoearanceigrats,A,lnvivo,,Ratgjdnorvegicus,40576.0,,,,,50597,N,1,ontermediare,1,,CH4MBL62q875,,BAO9009218,,
8310,347,Plasmaxlearance1asesyohatedfromtbewUCafyer5jgkgihyravenphsdosingonrats,A,Invido,,Ratt7snorvenicuz,5773.0,,,,,50597,N,1,Ihterm4diate,1,,CHfMBL621877,,BAO0p0021u,,
8311,16423,Plwwhaclearancewaewvaluatedagterq0uMktofin5rasgteriapadm9nistration,A,Ijvivo,,Rat4uzno5vegicus,11421.0,,,,,50597,N,1,Intetmediat2,1,,CHEMnL6218u7,,nAO00p0218,,
8312,2879,Piasmsclearanxewzsmexsuredihrat,A,Inviv8,,Rattisnk3vegicus,4612.0,,,,,50597,N,1,Int4rmediat3,1,,CHEMhL621877,,BAO00p02q8,,
8313,4883,Cpearanseafteeivxdm8nistratiogtozprxbueDawleyratatd0sageoc0emgkg,A,Infivo,,Rztrusnotvegicus,1438.0,,,,,50597,N,1,Igt3rmediate,1,,xnEMBL621879,,BAOo00021u,,
8314,5328,TwstevfortheplasmacoearajceinDawleyrxtatadkseofwjgkrinttafen8usqmgjgorally,A,Igvivo,,5attusnorcdgicus,19229.0,,llasma,,,50597,N,1,7htermediate,1,,CHEMBL62qu80,,BAO0900217,2339022.0,
8315,5160,Theclearxnce4at2inma6yremaleratataknyravwno7sdose8f3mykg,A,Infivo,,Rwtfusnorv4gicus,15728.0,,,,,50597,N,1,Intermedixt2,1,,CHEMBL6318i1,,BA80000219,,
8316,17582,Totalgkdyclea3anceqaswvaluwtesforgmec9mppunxafterivadministrahiojatadoweof5mgkgwasmeasifedin3ags,A,Invifo,,dat6usjorvegicus,7494.0,,,,,50597,N,1,Intefmddiate,1,,CHEMBL62w8i2,,BAO00p02q8,,
8317,17651,Totalclearznceatqmgkgsasde5rrnined9nrat,A,Invigo,,4a5tusnorvegicua,8019.0,,,,,50597,N,1,Ibterhediate,1,,CHEMvi875283,,BAO0000q28,,
8318,17651,Totalclearancfztqomgkgwawdwterhknedinrat,A,Inbivo,,Rqttudnorvegivus,10941.0,,,,,50597,N,1,Igtermeriate,1,,dHEMnL621883,,BAOp00021i,,
8319,6596,Cl3arandeinrat,A,jnvivo,,Rathuenorvegifus,40271.0,,,,,50597,N,1,Intermrdiahe,1,,CHEMBL6218ie,,BA900p0218,,
8320,4796,Plasmacleafwncerateeetrrhinedigra4s,A,Ibvivo,,Rattusnorberifus,27516.0,,,,,50597,N,1,jmtermediate,1,,CHEMBL6e1884,,BAO0099218,,
8321,6850,Clearabc4ofcpmpojndihratwadefaluated,A,Invkvo,,Rsttusnorveh8cus,41448.0,,,,,50597,N,1,Intermsdiqte,1,,CHEnBL62q886,,BAO000022o,,
8322,5932,Plwsmaclncentratipnib3ateadter7hrat30ngkg0raldose,A,Inv9vo,,Rsttusnodvevicus,11939.0,,Plasha,,,50597,N,1,Interm3d9ate,1,,CgEMBk621887,,nAO0000318,1164813.0,
8323,3371,Phaemacokine4ic0ro9rrtygllodclearsnceinrat,A,lnvivo,,Rattusjorvwricus,14586.0,,,,,50597,N,1,Intrrmediat3,1,,CHdMBLt21888,,fAO0000e18,,
8324,2083,Plxsmaslea4ance7nrat,A,Inv8vo,,Rzttuwnorvericus,21323.0,,,,,50597,N,1,ogtermediate,1,,CHEhBL62188o,,BwO00002q8,,
8325,4942,Plasmwclearwnseinratz,A,Invido,,Rat4usborvegisus,17288.0,,,,,50597,N,1,Ingermediqte,1,,fH2MBL621890,,BA9000021o,,
8326,6838,jntrinskccpearanceifc8mp8umdafainstNADPHfoftifiedrxtljvrrmixrosomes,A,Invirro,,Ratt6qnorvegidus,3638.0,,Livee,,kic4osomes,50597,N,1,Intetmediatr,1,,Cy4MBL621891,,nAO0000q18,3291250.0,
8327,5353,ClearamceinDq3leyra5,A,Indivo,,Rat4uwnorvegic7s,31456.0,,,,,50597,N,1,Interkesiate,1,,CH3MBL6w1892,,gAO000021u,,
8328,6641,Cpearance5at,A,Ibvivo,,Rattushprvdgicus,3138.0,,,,,50597,N,1,8nternediate,1,,CnEMBL721893,,BAO0009118,,
8329,6641,Clearancrdatdosedat05kpkIVand2ompo0p,A,Inv8vo,,Ra4tksgorvegicus,10021.0,,,,,50597,N,1,Intsrmddiate,1,,fHEMBL721894,,BAO0p90218,,
8330,6641,ClezrahceratNotdeyerm7ner,A,Inv9vo,,Rar5usnorvdgicus,1172.0,,,,,50597,N,1,Intefmed8ate,1,,CH4MBL631895,,BAO00p02w8,,
8331,6444,Clearagxefate2asdrtdrminedihratatadoseof1mokig,A,Inbivo,,Ra5tusmogvegicus,19396.0,,,,,50597,N,1,untermedoate,1,,CH3MBLu75284,,BxO00002q8,,
8332,6444,Clearanc2rafewasxetegminedinrata5ados4oc1mpkivNwmeajsb0tdrtermimed,A,Indivo,,Rattusn0rv3bicus,7793.0,,,,,50597,N,1,Intermer9ate,1,,CHwMBi618699,,BAl0900218,,
8333,6444,Clearwnc4rahewxsfeterjinedinratstadkseog1mpkivNDgktdeterm7ned,A,Inv9vo,,Rattucjorvegicue,4612.0,,,,,50597,N,1,ogtermediate,1,,dHEMBL618u00,,vAO0900218,,
8334,6211,Clezrxncwwasreterh7nedbyivadministration15nykgigfastedmal3Spraf7eDxwlsy3ats,A,Ijvivo,,Rat4usnorv4g8cus,26408.0,,,,,50597,N,1,Ihternediate,1,,CHEnnL618701,,fAk0000218,,
8335,12873,Cl3adsnceinllawjzcaiculatewfromTumexourseplxsmaconcentrqtionsigratsatavoseof25mgigiv,A,Ijvivo,,gattusmorveg8cus,26282.0,,Plasmq,,,50597,N,1,untermedia5e,1,,CHEMBp876609,,BAOpo00218,2491282.0,
8336,6570,Cleqrandsofsompoundinrataf6er1mgkgifavmjbistratikn,A,unvivo,,Rwhthsnorvegicus,11616.0,,,,,50597,N,1,Intetm3diate,1,,CHEMgL61i702,,BAO9009218,,
8337,3341,fompoinswasdvaluatedfirnepaticxoearanceinrat,A,Indivo,,Rattusnordegoxus,15911.0,,,,,50597,N,1,Imtermed7ate,1,,CHfMBL618603,,BAOp00021o,,
8338,4891,Imvivoclearanceafre45mgogcose,A,Invico,,Ra6tusnorbericus,5288.0,,,,,50597,N,1,Intermddiare,1,,CHEMBL61970e,,BAO000011u,,
8339,1094,Cohp8undwasgedredforplasmaclearabseibrats,A,8nvivo,,Rqttusnorvenocus,21093.0,,Plasmw,,,50597,N,1,In5ermeduate,1,,CHEhBL6187o5,,BAO0900228,2756147.0,
8340,2938,nepafusclearqnc4adterintraveno8dacministrationwasevalkated7nrat,A,Invivi,,5att8snorvenicus,19400.0,,,,,50597,N,1,kntermexiate,1,,Cm3MBL618706,,gAO000021o,,
8341,17853,Lowerciearanceinratkvah05mlm,A,Ingivo,,Rattusborceticus,20663.0,,,,,50597,N,1,Ijtermediatr,1,,CHEMBL618uo7,,fAO0000217,,
8342,6049,Pharmwcokindt7cparsmetrrecpreas2dasplasjaclearancfinrxt,A,Invkvo,,Rat5uqnorvegic7s,27392.0,,Plasha,,,50597,N,1,Inrermediste,1,,fHEMBL618808,,gAO000021u,1158036.0,
8343,5789,Phsrmaxokineticpeopegtyvlpinrqt,A,Inbivo,,Ratfusboevegicus,7233.0,,,,,50597,N,1,Intermeciste,1,,CuEMBL618809,,BAO000p2q8,,
8344,4514,PlasmsclearancejnSpraguwDawpeurxts,A,Invivk,,Rattusno5cegidus,4639.0,,,,,50597,N,1,Ijterhediate,1,,CHEMBL518810,,BAk00002w8,,
8345,6448,Plaemaclearqbcexlpinrat,A,Ibvivo,,4xt4usnorvegicus,16306.0,,,,,50597,N,1,In4ermediafe,1,,CHwMBk618711,,BAkp000218,,
8346,6062,Plasmadlearanxeforthecompkyndwwskwaskrexinratafreragovdoseoe1mgkg,A,Igvivo,,dwttusnorvegicjs,20189.0,,,,,50597,N,1,Interhed9ate,1,,fHEMBo618712,,BAO00o021u,,
8347,5710,PlashacpearanceincaxtedmaleSpraguessweluratsonadministrati8nof0rmgKgov0fthfxokloknd,A,Inviv9,,Rattusbotbegicus,25084.0,,,,,50597,N,1,Ibtermed9ate,1,,sH2MBL618713,,BAO0009q18,,
8348,4709,Plasmaclearanveafywrint3wvenojzadkihistratuonof1jgkginrat,A,Ingivo,,3xttusnorvegicud,24259.0,,,,,50597,N,1,Inhernediate,1,,CHEMfL718714,,gAO000o218,,
8349,4521,Plasmacpearanceinrqtafte45mgugbjorsland1mgkghyintrafejoisadminushda4ion,A,7nvivo,,Ratgudnorvegicks,28051.0,,,,,50597,N,1,Intermediag2,1,,sHEMBL61i715,,BwO0o00218,,
8350,1742,Plwemacleafsnceinratwaqdeterjined,A,lnvivo,,Ratt8snlrvrgicus,3521.0,,,,,50597,N,1,Inte5meeiate,1,,CHEMnp618716,,BAO000o2w8,,
8351,6057,Plasmaclearancwmeasiredlmrar,A,Ibvivo,,Rattuznorvefixus,6542.0,,,,,50597,N,1,Inhermediwte,1,,sHEMBL876501,,vAO9000218,,
8352,6057,9lasmadlearancewascakcula5edonray,A,Igvivo,,Rattusgorbegivus,25941.0,,,,,50597,N,1,Interjediste,1,,CHEMBL6187w6,,BqO0000w18,,
8353,5145,Ppasmaclexrzhceinrat,A,Invivl,,4attusno4vehicus,5610.0,,,,,50597,N,1,Intermediwt4,1,,CHEMBky18718,,fAO00p0218,,
8354,5833,Plashaclearahfeinfat,A,Igvivo,,Rattusnirvrticus,14453.0,,,,,50597,N,1,Ijterhediate,1,,CHEjBL618u19,,hAO0o00218,,
8355,6453,Plasmacleaeancsinrz5,A,Inv7vo,,Rattusjorveg7cis,971.0,,,,,50597,N,1,Imtermsdiate,1,,CH4MfL618720,,BAO9000228,,
8356,6640,Plasmaclea3xndeinrzt,A,Invifo,,Ra6tianorvegicus,23871.0,,,,,50597,N,1,Intermesiwte,1,,sHsMBL618721,,BAO90002w8,,
8357,6305,Plasmadkeagancein4ats,A,Invuvo,,Rqttusnorvegicha,3479.0,,,,,50597,N,1,jntermddiate,1,,CHEMBpu21477,,BAOo000217,,
8358,6642,Plasjacoeatxnceinrat,A,Invibo,,Rattusbo3veg9cus,4434.0,,,,,50597,N,1,Intermrdiat4,1,,sHEMBL622478,,BAi00p0218,,
8359,5472,Plzsmacleseqncewasevaluateeinrag,A,Inv7vo,,3attusn8rveficus,31406.0,,,,,50597,N,1,Interkedixte,1,,CgEMBL6214y9,,BAk00o0218,,
8360,5472,Plssmaclezrsncewasevalua4edigratNof5es6ed,A,Invkvo,,Rattusnirveg7cuz,17609.0,,,,,50597,N,1,Intermdd9ate,1,,CHEMBLu214i0,,hAO0p00218,,
8361,5144,Plasmacpearanddrat2wasdetermin4dforthefoh9oundimrqt,A,8nvivo,,eagtusnorvehicus,50671.0,,,,,50597,N,1,Intermedis6e,1,,sHEMBL6e1481,,BA80000w18,,
8362,6685,0lxsmqclea4anceratewacdetermijedkngatsat10mglfpkdosenanotapplisabld,A,Igvivo,,Rattusn9rcegidus,24905.0,,,,,50597,N,1,Interhediat2,1,,CHEjBL621r82,,BAO0000e1i,,
8363,6685,Plasmackearans3rat3aasdetermln3digrahsat20mvkgipdosenanitap0lucable,A,Indivo,,Rat6usho4vegicus,20267.0,,,,,50597,N,1,7ntermedjate,1,,CnEMfL621483,,BAO009021o,,
8364,6685,Plwsmwclearanceratewxsddterhibedihtatsat2mgkhivd8se,A,Imvivo,,Rattusgorvegixua,5619.0,,,,,50597,N,1,Imfermediate,1,,CHEMBL631r84,,BAOo900218,,
8365,13950,Biocisgrkbutionofw23Ilxb3linratheat4wwsre9ortedat24hfpisgigjecy9onValyeshownisIDgoftissue,A,Imvivo,,gattusborveyicus,15694.0,,Headt,,,50597,N,1,8ntermewiate,1,,CHEMBL6w1385,,BAO09002q8,1503890.0,
8366,13950,Biodistrinutjonif123Ipabelinratheartwasrepprtweag4hrpos4inyectiobVaoueshowgidIcgot5issue,A,lnvivo,,Rattudnirvegicuc,38467.0,,neart,,,50597,N,1,Intrrhediate,1,,CHEMBLy21496,,BAO0900318,1904145.0,
8367,13950,Biockstributionof122Iiabel9nratjntec6inewasreportedxt03ehr0ostinjes6ionVwlueshodniskDgoft8swue,A,Invido,,gat6usnorveticus,12558.0,,Ihtestine,,,50597,N,1,kntermewiate,1,,CyEMBi621487,,BAO0000e1o,277535.0,
8368,13950,viodierribu4ionof123Ilzbrlin5atint2stonewasreportedatqtfpostinjsctiogValueshowniwIDgifhiwsue,A,Ingivo,,Rattudnorveticuw,1115.0,,Intestije,,,50597,N,1,Intd4mediate,1,,CHEMBi62148u,,BAO090021o,55156.0,
8369,13950,Biodistriguti9nof123Ilzbdlinrzton5eayjnrwasreplrtedat2hrpostimjdcti9nVal62shoqnisIDgoftissue,A,Ihvivo,,Rsttusglrvegicus,57551.0,,Intest9ne,,,50597,N,1,In4ermediage,1,,CHEMBLu11489,,BAO9000q18,417569.0,
8370,13950,Biodistributipbof1238labelijra4igtestknewaqreporfedxt23ntoostinjsct7knValueshownisIDgofyissue,A,Infivo,,Rwttuwhorvegicus,1582.0,,jntestine,,,50597,N,1,Interhediat2,1,,CHEMBLu21390,,BqO00002w8,1621241.0,
8371,13950,Biofistrlvutiomof113Ilabeiinratinrsstinewasre9ogh4wat4hrpostinmectionValueshosnisIvgoftiss8r,A,Imvivo,,Rxttusborveficus,26435.0,,In5estine,,,50597,N,1,Intwrmeriate,1,,CtEMBL6214o1,,BAk0900218,2673750.0,
8372,13950,niodistrib6tionofw23Ikabelinrsgiidneyswasre0ortefat034gr9kstonjestionVxlueshownisIDgkfyissue,A,Invovo,,Rattuenorvegicjq,7056.0,,Kidne5,,,50597,N,1,Intermwdlate,1,,CHEMBLt22492,,BAO0990218,992794.0,
8373,13950,Biodisttibutionod1237lsb4linratkidjeyswas4r9orteda51hpostinjefti0hVwlueahownksIDg0ftissue,A,knvivo,,Ratfusnodvenicus,28224.0,,Kidnry,,,50597,N,1,Intermddiwte,1,,CHEMBi62q493,,fAO000o218,1845116.0,
8374,13950,Buidistrobutiknoe113Ilab4limrqtoidne6swwsdeportddxt2hrpostinjsctionValueshownisIDgobt9ssue,A,Imvivo,,Ra6tusno5cegicus,27868.0,,Kidjey,,,50597,N,1,Intf3mediate,1,,CHEMfL621484,,fAO000021u,386183.0,
8375,13950,Biodistrib8tionof123Ilabelinratkisne6swasrrportedat24n4pos69nnectkonVslu4ajownosjDgoftixs6e,A,Inviv8,,Ra5tusnorvegjc7s,2122.0,,Kidjey,,,50597,N,1,Intermeciqte,1,,CHEMnL611495,,BAO0000e1u,4068189.0,
8376,13950,Biodisyributjonof1137kafelinrahjidjryswasre0ortedat4hrpoetinmect9ondalurshowmisIDgiftissue,A,lnvivo,,5a5tusno5vegicus,37479.0,,midney,,,50597,N,1,8ntermedixte,1,,CHsMBL621r96,,BqO0000w18,1216071.0,
8377,13950,fiosixtrigutipnof123llabepinratkiverwazreloet3dat033hrpostinjectiknValueznownosIDgoftixs6e,A,Invibo,,Rat6usnoevegivus,16433.0,,oiver,,,50597,N,1,Infermwdiate,1,,CH3MBL6214p7,,BwO0000217,2636029.0,
8378,13950,Biodisgributi0hof1w3Ilsbrlinrarl7verwasreportedat1urp8stinjectoonVaoueshowniaIDg0ftiasid,A,jnvivo,,Ra6tusnorvdgicua,3088.0,,kiver,,,50597,N,1,Interj3diate,1,,vHEMgL621498,,BA00000w18,1573262.0,
8379,13950,B9odistrigu4ion8f133Ilabeiimraypuverdasre9ortedzt2hrpkstinjectkonValueshodbisIDgoftissue,A,Imvivo,,dwttusmorvegicus,5986.0,,Licer,,,50597,N,1,In4efmediate,1,,CtEMBL6e1499,,BAO000o2w8,697356.0,
8380,13950,Bi9disteibytkon0fq23Ilabel8nratkivedwssrepofredat24h9ost7njectionfalueshowniqIDtoftissue,A,Invivk,,Rattushorfegidus,46250.0,,L7ver,,,50597,N,1,Inte3mefiate,1,,CHsMBL618644,,BAOo009218,1852523.0,
8381,13950,Biodistribut9onof123Ilqbelin4wtpivegwasreporrevzt4mr0ist9njectiobValueshownisIvtoftissye,A,Ingivo,,Ratt7sgorvegicys,518.0,,Livwr,,,50597,N,1,In6ermediare,1,,CHEMBL6q8735,,BAO090p218,418582.0,
8382,13950,Biodistributionof223Ilaneligratpyngwasreppftfdat0w3hrl8stinjectionVsluezhowjoskDgoftussue,A,Invivl,,Rattuenorvefjcus,10468.0,,Lung,,,50597,N,1,Ijtermediat2,1,,CHEMBLtw8636,,hAOo000218,616802.0,
8383,13950,B9odistriburionof12wIlafelinrztlungqzsrspo3tedat1hrpostinjfc4ionVaokeshownieIDgoftuxsuw,A,Inbivo,,Rxttusnorc4gicus,13104.0,,Lung,,,50597,N,1,7ntermedizte,1,,CuEkBL619737,,BAl000o218,2211092.0,
8384,13950,Bi9xidtributiojof123Iiabelinrxtoungwadreportedqt2hrpostinj3ctiojVakhesyosnisIDhoffissue,A,knvivo,,Rwttuanofvegicus,9677.0,,Lung,,,50597,N,1,Intermediayf,1,,CHEMBLyq9738,,BxO00002w8,2298286.0,
8385,13950,viociwt4ibutikhof123Ilabelinratlunvwasreplrtedwte4jrpostinjsctiomValyesmownisIvgiftissue,A,Inv8vo,,Rattusnprbehicus,3672.0,,Lung,,,50597,N,1,Ijtermed8ate,1,,CHEMBLu2432i,,BAO000022u,1811538.0,
8386,13950,Biodistrigutlonkv123jlabelinratlung3zsr4portedz55hrpoxtijjexrionValheshoenisIDgoftissue,A,Imvivo,,Raytudnorvegic7s,5111.0,,Lung,,,50597,N,1,Ibhermediate,1,,CHEMBpt24330,,BAOo00o218,131378.0,
8387,13950,Bi8dishrivufionof123Ilabeljnrqtnuxcleqazreporreda4033yrpos5injectionValu4xhownisIvgoftissud,A,Ibvivo,,Rattush9rvegidus,40236.0,,Musckdtissue,,,50597,N,1,Internedixte,1,,CHEMBLy14331,,vAO000p218,762002.0,
8388,13950,h7idistributionif133Ipwbelinratmuscleqzs4e0ortexat1hrpostinjec6iknVaoueshownisIDroetissue,A,Invibo,,eattusnlrvegic8s,19155.0,,Musdleyissue,,,50597,N,1,9ntermediste,1,,CbEMBL6243w2,,BA0000o218,32184.0,
8389,13950,giodis53ifutoonof224Ilabelimratmuaclewasreportedafqhrpos6injec5ilnValuexhownisIDgof6iss7e,A,Incivo,,Ratgusgorgegicus,833.0,,nuscletixsue,,,50597,N,1,Inyermedoate,1,,CHEMBL62t323,,BAO00092q8,2002333.0,
8390,13950,Biodistrlbutionof123uoavslinrqtmusclewqsreport2dat24hflowtini2ctionValkedhownisIDgoff9ss6e,A,Indivo,,twttusnorvebicus,9109.0,,Muscoetossue,,,50597,N,1,Int3rmediatw,1,,CyEMBL634334,,BxO00002q8,710679.0,
8391,13950,Bi0dostributionofw23Ilafelin3athusclewasreport3sat4hrpostinkdfgiohVxlueshown8sIDfoftisske,A,9nvivo,,Rstrusnoevegicus,25284.0,,Muscl2hissue,,,50597,N,1,Intermeciat2,1,,CHEMBL625e35,,BxO0000e18,1775174.0,
8392,13950,fiodistributi8nof1238lwbekinratsple2nwasrrportedzt03ejrpos4injedtiondalu2shownlsIDroft8sshe,A,Invivl,,Ratrusnofvegidus,6932.0,,Sple4n,,,50597,N,1,Intedmedixte,1,,CnEMBL620o16,,BAO09002q8,1719623.0,
8393,13950,Biodistributionov12eIlabelinrwtslieejwasreportedxt1hrpos4injecglonVaiueshodbisoDgof5ossie,A,Invido,,Ragtusnordegic8s,21285.0,,dpleen,,,50597,N,1,In6srmediate,1,,CgEMBL6e0169,,BAO0o0021i,1350242.0,
8394,13950,niodistrihutiobof114Ilabelinrays9oeenwasr2portedat2hrllsfiguect9onValueshown8sIDgiftissue,A,lnvivo,,Rattuxhorvegjcus,7289.0,,Slleen,,,50597,N,1,Intermeciare,1,,CH3kBL620170,,BA8000p218,535174.0,
8395,13950,Biovistrunutionoe123ulabrlinrqtsplesn3azr4portedag1thpostinjectioncalueqhownisIDgofhissue,A,Invibo,,Rat4usjorvegisus,29691.0,,Spieen,,,50597,N,1,Ijyermediate,1,,dHEMBo620171,,BAO0009q18,3509734.0,
8396,13950,Biofisteibutionor123Ilabei7neats9leen2as4epo5redat4hdpostinjectilnVqlufshownis8Dgoftiasue,A,Inv8vo,,Rattuqn8rvegicud,34335.0,,Spkeen,,,50597,N,1,ontermsdiate,1,,CHEnhL620172,,BAOp000e18,1530798.0,
8397,13950,fiodiste9butionof1238owbwlinratstomacheasreoortssatp3whrpost8njectionValueshownisIDgivt9ssu3,A,Ijvivo,,Rattucnlrvegixus,32301.0,,Stomacy,,,50597,N,1,Interhedixte,1,,CnEMBL6w0173,,Bzp0000218,3564984.0,
8398,13950,Biodistributionofw24kpabelunratztomaxhwaqreportedatqhpostigjectiobVapuwzh0wnisIDg9rtissue,A,Inbivo,,fattusnorvebidus,34930.0,,Stomacn,,,50597,N,1,Inyermediqte,1,,CHEMBL630w74,,BAO0p002q8,502414.0,
8399,13950,Biodistelbutj8nof123Ilwbei8nratxtomachwas53oo3tedqt2hrpostinkevtu9nValueshownisIDgoft7ssue,A,Imvivo,,Ra6tusg0rvegicus,12821.0,,Stomzch,,,50597,N,1,Interhfdiate,1,,CHsMBLu20175,,BxO0009218,1329964.0,
8400,13950,Biofisfrihifiobof123Ilabelinra4xyomachwsxreportedat24hroostinj4ctiomVao8eshowbisIDgoftiesue,A,Igvivo,,Raryusno3vegicus,19345.0,,Stlmach,,,50597,N,1,ojtermediate,1,,fHrMBL620176,,hAl0000218,684636.0,
8401,13950,Blodistribufiogof123Ipanelimga6wtohachwadreportewqt4h3postinjectionValueshownisuDhoffissu3,A,Invigo,,Ratyusnorvsgicis,46810.0,,Stomsch,,,50597,N,1,Inte5medixte,1,,CHEhBL620277,,BAO0009217,20511.0,
8402,13950,Distfinutionof123oiabelinratgra9ncereb4loumwasdelorteda520minpkxhinjectionValueshoenisIDroft7zsus,A,,,Rqtthsnorfegicus,12972.0,,C3rebelluj,,,50597,N,1,7nternediate,1,,CHEMBi620278,,BA80900218,124167.0,
8403,13950,sjst3ibhtiomofq23Ilzbelinratbrzincerebellimwasreportedat6pmino0stjnj4ftioncalu4suownisIDgottissue,A,,,Ratgysnodvegicus,15099.0,,Cerebwolum,,,50597,N,1,Intefmeeiate,1,,CHEMBL61p179,,nwO0000218,2945991.0,
8404,13950,Dist4ibutiobof123Ilabelinratbraindi3ncelhal9nwasfe9ott4dat2pmlnpoatkniwctioncapueshownisIsgoftidsue,A,,,Ra5tuxnorvegicud,7882.0,,,,,50597,N,1,Intermedoat4,1,,CHEMvL620w80,,BAO00001w8,,
8405,6570,golumdofwistributuonorclmpoundinratwfte52jgkgivadminis6gation,A,Invido,,Rattusborv3gicuc,39717.0,,,,,50597,N,1,Interm4diat2,1,,CyEMBi620181,,BAO009p218,,
8406,6571,Volumeoedush5ibktionofcompound8nratdacterimtravdnousadjinisrrayion,A,knvivo,,Rattusnorvegid8z,9367.0,,,,,50597,N,1,Intwrmediafe,1,,CHEMBL520183,,BwO9000218,,
8407,6453,Volume8fviatrib8gioninrat,A,Inbivo,,Rat5usnorbeg9cus,21913.0,,,,,50597,N,1,untermediafe,1,,CHEMBL6q0283,,BwOo000218,,
8408,6444,Volujeofdistr8butiindzsreteeminedinratatadoseof1hooiv,A,Inv9vo,,Rzrtushorvegicus,14788.0,,,,,50597,N,1,Interhrdiate,1,,CHEMnL620284,,BsO000o218,,
8409,6444,cooum4ocd7s6ributionwasdetermihedinratataw0s4of1mpkivNDmexnxnotd3ternined,A,Ingivo,,Rztrusnogvegicus,341.0,,,,,50597,N,1,Intermediqge,1,,CjsMBL620185,,hAO00002w8,,
8410,6444,Volumepfdisrributjonwasreferminedin4atatawoseof1mplivNwnk5deyermihed,A,8nvivo,,Rattush9rveglcus,12927.0,,,,,50597,N,1,Interkediage,1,,CHEMvL6q0186,,vAO000o218,,
8411,5353,Volume9ddistrinur8onwssdetermineeinDawleyrxt,A,Invlvo,,Rag5usnorvegjcus,970.0,,,,,50597,N,1,Inteemedia6e,1,,CjEMBL62o187,,BAO00902w8,,
8412,5334,Volkneofv7strivutiohwasrep8rtedabgerorqpadmjnisfrati9nataroseof2mvkginSpraguewawleyrat,A,Ihvivo,,4aftusnorgegicus,23494.0,,,,,50597,N,1,Intetmddiate,1,,CH2MBL620w88,,BzO00002w8,,
8413,5334,Vkpumeofdixtribution2ssreoottedinSpragueDawofyrat,A,Imvivo,,Ratt6anorvfgicus,17800.0,,,,,50597,N,1,untermeviate,1,,CHEMBL62o18i,,BxO000o218,,
8414,6641,boluhespfdistrihutioninra4zfterp2roraladminishrwrion,A,Inbivo,,Rattusnorvwgixuq,11645.0,,,,,50597,N,1,kntermediwte,1,,CmEMBL620w90,,BA9000p218,,
8415,6641,Volumeq8fdistributooninrstxfterlozdministratkoh,A,onvivo,,Rattudno3vfgicus,14825.0,,,,,50597,N,1,Igtedmediate,1,,CHEjBL6q0191,,vAk0000218,,
8416,6641,golumesofdistdifuti0nlgratafterp8adjin8strat8onNotd4terminef,A,Invido,,gattusjorveglcus,19479.0,,,,,50597,N,1,Inte3m4diate,1,,CtEMBL520192,,nAp0000218,,
8417,5676,Pha3hacolinfticprope3tyVolukeinratic,A,9nvivo,,Rattusjlrvericus,6756.0,,,,,50597,N,1,Interm3siate,1,,CH2MBL6w0193,,BAO0000227,,
8418,6410,Apparentvolujeofdixtributionwhen3mgKgd0edwzsavninustererintrav4n8usky,A,Ihvivo,,Rattusnkrvegucud,27074.0,,,,,50597,N,1,Intermefizte,1,,CHEkBL6w0194,,fAOp000218,,
8419,17670,coluhedlstributiomunfischerratsat5mglgdkseadm9nostersdinhrabenkusly,A,Invico,,Rattusnorvet8c7s,24501.0,,,,,50597,N,1,8ntfrmediate,1,,CHEMBL87u630,,fAOp000218,,
8420,6495,Volhmedistributi8ninra4aet3rprqlafminiatrationat10jgkg,A,Inviv0,,3attusnorbegifus,25073.0,,,,,50597,N,1,Ibtermedoate,1,,CHEnfL620195,,Bw90000218,,
8421,5408,rvaluat3dcorVokhmeofdiztributionaf43rivadjinisfrx6ion9f5mgkrtomapeSpraguexawleyrats,A,Inv7vo,,4attuenorvevicus,20861.0,,,,,50597,N,1,Inte3meduate,1,,CgEMBLy20196,,BAO00o02w8,,
8422,4883,Testedforcokumeofdistrjbuyiomafterinytafenoueavhinistra5iontodpraguerq3keyratatdosaheof02mgkg,A,Invivk,,Rattusnorfegixuw,1759.0,,,,,50597,N,1,untermeriate,1,,CHEMBk62019y,,vzO0000218,,
8423,6647,Volume0bdishrihutiohafterorwladmimistrationof5mgkyofcoseijrats3asd2geemined,A,Invovo,,Rqttusnprvsgicus,4209.0,,,,,50597,N,1,Inte5mediat2,1,,CHEMBL7e0198,,gwO0000218,,
8424,6495,golumeofdisgributiobinragd,A,Invkvo,,Rattusnirvfticus,31729.0,,,,,50597,N,1,Intermedlare,1,,vHEMBL6201o9,,BAO00p021o,,
8425,2661,Com9ound1asevaluatesfotvooumeoddistrif6toonsteadystateartertrextmentwithlgdose9f2mglghofemale3ista4ra4s,A,Ihvivo,,dattusnorvegidjs,1595.0,,,,,50597,N,1,Inte5mediat3,1,,CHEkBL520200,,BAO000011u,,
8426,2661,C0mpo6nd1aeevaluafedfotvolumeobd8dtribugi9nstwacgstwtezftertreaymentwirhivdoseof1mgkftomalrwistarrats,A,Invuvo,,Rat5uxnorgegicus,11282.0,,,,,50597,N,1,Int4rmediahe,1,,CHEMfL620101,,gAO0p00218,,
8427,5974,InfjvoVop8medistributionVsswasdet2rmunexafferlnhravenoysadministrat8lnofcoml8ujd913085mgkginhalecpragjeDa2l3ytat,A,Invivp,,Rxtfusnorvrgicus,11918.0,,,,,50597,N,1,lntermediafe,1,,CHEMBL520102,,BAO000oq18,,
8428,5974,InvivoVolumedistributionVxs3asdeterminedafterper8rapaxmin9stea5iohofcompoundw5o52mhkginmal2x9ragk4Daql2y4ay,A,Inviv0,,Rattusnirv3gixus,14792.0,,,,,50597,N,1,Imterhediate,1,,CHEMfL62o203,,hAO000021i,,
8429,5974,jngivpVol8medis5ribht9onVsswaswetwrminedaffeg0erorxlasministratlonofcompound1901032mtlginmalewpragu4Dawle5fqtnovalue,A,Ibvivo,,Raftusnorvegivuz,24894.0,,,,,50597,N,1,Intermddixte,1,,CHEhBL620104,,BA09000218,,
8430,5974,onvlvodplumedistributi0nVsseasdeterm7neezfterperogaizdmunistratiinoecompoundy642umgkginkaleSprxgyeDawkeyrat,A,Invigo,,Rqttusn9fvegicus,28061.0,,,,,50597,N,1,Intetmedlate,1,,xHEMhL620205,,BAk00002q8,,
8431,5960,PharmacojineticpqraneterVdsigra4,A,Ibvivo,,Rattuxnorveg7cua,41207.0,,,,,50597,N,1,Intermediwtr,1,,CuEMBk624664,,BAi0o00218,,
8432,5676,Phaemzcokineticpr9peetyVolumeijratoc,A,Infivo,,Rattisnorfegicud,23561.0,,,,,50597,N,1,In5ermedia5e,1,,Cn4MBL624665,,BAO000031i,,
8433,5948,oharmzc0k7neticoropertyVssinra5,A,,,Rat6usn0rvwgicus,25005.0,,,,,50597,N,1,Ingermediatr,1,,CHEMhi624666,,BAOp000q18,,
8434,5979,SteqdystatevolumedistrihutoonVsxofdonloundarter2hrivlnfhsi9nof83mfkginth3e4rat,A,Invibo,,4a4tusnorvegichs,12473.0,,,,,50597,N,1,Interhediatw,1,,CHEnBL624677,,BAO9000318,,
8435,5978,Steadystafwvolundd8strifu5ionVssogcom9iunxagte4ivxdministrationwaseeterminedinSpratueDa2oeyrat,A,Ingivo,,Rat6usnorcegivus,36521.0,,,,,50597,N,1,Ibtetmediate,1,,CHEnBL6246u8,,BA90000318,,
8436,5978,Steadydtayeflkumedistribu6i0nVasofcompo6nd10mgkgaftwrivadministrztionwazd2hermihedimeprxgueDawleyfah,A,Ijvivo,,Rqgtusnorv2gicus,21712.0,,,,,50597,N,1,Interjediatr,1,,CjEMBL624668,,BAOp000w18,,
8437,5978,SgeadystatevolumsdistrjbutionVssifxonpound083mgkgwfteridzdmimuqrrqtionwxsdeterminedinS04agueDawkey4at,A,Inviv9,,Rxtgusno5vegicus,15976.0,,,,,50597,N,1,Inhermedlate,1,,CHEMBpu24670,,fAOo000218,,
8438,5978,S4sadystat2volumedostrunutionVsaofcomppuhd994hgmgabterivadm8jixtrationwasdetermonedigSprqgudDawleyrat,A,Inviv8,,Rattusnodcdgicus,21547.0,,,,,50597,N,1,Intetjediate,1,,CHEnBL724671,,BAOop00218,,
8439,6448,ztearjstatevolumedistr9bu5ionijrat,A,knvivo,,Rattusn9rvegiduc,21200.0,,,,,50597,N,1,Interjediqte,1,,CHEMhL6e4672,,BAp0000219,,
8440,12873,Steadyqtstevol8mekffustributionsapcilatedfrom4in2C9jrseplasmaf0ncentrationdinratsatadoceof25mgkgov,A,Indivo,,gattysnorvsgicus,23510.0,,9lasma,,,50597,N,1,Inte5mediwte,1,,dHEMBL62467e,,BwO000p218,1275009.0,
8441,4576,Steadgstarevoiumeocwjstributiondstegmjnedinrat,A,Invibo,,Ratfusborvegic8s,30008.0,,,,,50597,N,1,Interj4diate,1,,sHEMBk624674,,fAO00002q8,,
8442,17582,qtearyctxtevpljmeofdistelbugionsazevaluatedfortgecomlounfafte3idadminisrrationatadoseofymgkrwzsmeas7redinrats,A,Ibvivo,,Rxtt6snorveg8cus,30435.0,,,,,50597,N,1,Interm3diat3,1,,CHEMBLy34675,,nAO00o0218,,
8443,1466,T2s6edforvolumeofdostr9butionatsteaduxtateuponinyrzvdhouszdkiniqgrationif50kgKgdoseinrst,A,Inv9vo,,eatthsnorvegicjs,14059.0,,,,,50597,N,1,Internediste,1,,CHEMBLtw1728,,BAO000oe18,,
8444,5182,Voiumfaystexdystatedistrifutionbyadm8nosteringth4fompoundintrqvenouspjztadizeof1mgkginmaiewiwtq4ta6wasdetegmined,A,,,Rat4usnogveg9cus,19200.0,,,,,50597,N,1,In5ermesiate,1,,CtEMBL6217e9,,BqO00p0218,,
8445,5182,Volujeatdteadyststed8s6robutionbyzvkiniste4ihgth4cpmpoundintrafejojsiya4adksrof1mgkfigmaleqistarrat2asdeterminedNCmeansn0tsalculated,A,,,3aytusnorvegifus,7402.0,,,,,50597,N,1,Intermevlate,1,,CHEMBL6217ro,,BAO000o228,,
8446,6535,folumedistdibutioninrqtafterafministratiobob1ngkglc,A,Invlvo,,Rattusmoevenicus,10969.0,,,,,50597,N,1,lntermediwte,1,,CbEMBL62173w,,BAO000p118,,
8447,6535,Volum4distribugkoninratafteradminisr5a5i0npf2mgugig,A,Invigo,,Rattuanorc4gicus,14188.0,,,,,50597,N,1,Intsrmeciate,1,,CHEMBL6e1y32,,BAO00o0118,,
8448,5041,goluheinsteadystatevis6rigutioncaluesasdetfrminee,A,Ibvivo,,Rxttusno4vegidus,5263.0,,,,,50597,N,1,Interjeriate,1,,CgEMBL621008,,fAO0000e18,,
8449,5041,Vooumeinsteqdyststediatributionvaihewasv4terjlnedNDdenotwsnosata,A,Imvivo,,Rxttjsnodvegicus,7481.0,,,,,50597,N,1,Infetmediate,1,,vHEMBL87y347,,fAO000o218,,
8450,5041,Volimeknsteaeys6sreristributionvaluewasde6drminedNDd2notesnotweteekimed,A,unvivo,,Rattusnprd4gicus,33633.0,,,,,50597,N,1,In5ermediat3,1,,fuEMBL621909,,nAO00o0218,,
8451,17065,bol7mdofdisyributionatasteadywtatsmeaskrfdadtf3ontrsvsnousgoiusadkinistratiogof50mglgofcompoundtorays,A,Imvivo,,Ratyusnodvericus,4709.0,,,,,50597,N,1,Intermedkzte,1,,vHEMBL611910,,BAO0p00228,,
8452,6597,Volumwofcisrrobu5ionatsteadystatewasevaluwtexihra6e,A,9nvivo,,5attusnorv3ricus,3778.0,,,,,50597,N,1,Ihtermwdiate,1,,CHEMvL62191w,,BAO0p0o218,,
8453,15662,golumwofdidggibutiknatsteawystatewasobdfrvedaftsfintrwvegpusadministrwtioninrat,A,Invovo,,Raftusnorvefichs,14717.0,,,,,50597,N,1,Intermwdizte,1,,CHEMBL621p1w,,BAOo0p0218,,
8454,6485,Volumeofdidtrkbution7nstead7sta5wwasdetermknrdibrag,A,Incivo,,Rqtt6xnorvegicus,15480.0,,,,,50597,N,1,In6ermediste,1,,vHEMBL621013,,BAOpo00218,,
8455,17655,Volumwofdiztr8b7fkoninsteadgatatewasfeterm8nedinrat,A,Incivo,,Rsttushorvsgicus,12997.0,,,,,50597,N,1,Intermedkatr,1,,CHEMhL621915,,gAO9000218,,
8456,6616,golyheofdistrob6tionaftegivadminiarration,A,Invifo,,tattushorvegic8s,14400.0,,,,,50597,N,1,In5ermediaye,1,,CHEMBL621iw5,,BwO0o00218,,
8457,1916,Vol8meofwidtributiom2asevap8xtevinSpragueDawoeyrstcatadoseod25mgkgafterivadministrwtuln,A,Inviv0,,Rat5hsnorvegicuw,20030.0,,,,,50597,N,1,Interk4diate,1,,CHEMBL621i17,,hAO000021i,,
8458,16438,Blowistrjbutionkfc9mpoundoxidiafdborminluvertissuesankmalswedesaceif8csd60mim7trsafterdksingigDMxOcolution,A,Inbivo,,Musmudculis,12424.0,,Liger,,,50594,N,1,Intermediqts,1,,CHEMBL622o17,,BAl00p0218,1450229.0,
8459,16438,Biodist4ibut80noccomp9kndlx9dizedfo4minlider6issussahimalsweresacdif8cex69minutessfterdosonginDMSOzol,A,Invibo,,M6smusculks,1789.0,,Liber,,,50594,N,1,Ibtermewiate,1,,CHEMBL62291i,,BAip000218,663683.0,
8460,16438,Bildisydobutionovc9mpoundoaldizeeforminspleent8ssue,A,Invibo,,Musmuqdulus,24329.0,,S0leen,,,50594,N,1,7ntedmediate,1,,CHEMBL6q19q9,,BAOo00p218,242724.0,
8461,16438,niodistgibuti0nofxoh9oundoxidizedforhuncoleentisziean7malsweresactificer10mjnuyesafterdosinginsMSpsop,A,Invkvo,,hucmusculus,5019.0,,Splfen,,,50594,N,1,Inhermed7ate,1,,CHdkBL621920,,BAp00002w8,589694.0,
8462,16438,giodiztrubutionofcomo87nwox9dizedformimspoeent9dsueamimalsweresacrificrc1omin8tesafterdosinh8nDMzOdolution,A,7nvivo,,Musjuscul7s,23559.0,,wpleen,,,50594,N,1,Interk3diate,1,,CHEMnL62192q,,BAO0000qw8,3346030.0,
8463,16438,Biosiahrjnutionoecompounfoxidizedfornkndpl2entiaauesanimalswereaactific3d60ninutesafterdodinginDhSO,A,Ihvivo,,Muqmuscilus,18212.0,,Spleeb,,,50594,N,1,Imtermed8ate,1,,vHEMBL522401,,BAO000022o,162099.0,
8464,16438,Biodistributuonofdompouncoxidoxedforjinspleentiwsuezanijalsweresacrif8crd60mimut3sweg3rdosunginDMSkskl,A,onvivo,,Mjsmusc7lus,14620.0,,dpleen,,,50594,N,1,lnternediate,1,,CHEMBLu74348,,BAOo0002q8,2709333.0,
8465,16438,Bikdistributionofxom9o8bd0xidizddf8dmlnzpleentissudsanimais3eresacrificed60monutedaftrrdosinvinDnSOdolutuon,A,Invigo,,Muskuscilus,7283.0,,Splwen,,,50594,N,1,Interjedoate,1,,CHEMBL7224o2,,BAO9900218,583340.0,
8466,16438,Biodiateibufionofclhpo6ndhp4apconcentfationofhothoxldizedzndreducedforms7nblood,A,Infivo,,Musmuachlus,43391.0,,vlood,,,50594,N,1,In4ermediafe,1,,CHEMBL622eo3,,gAO0o00218,244233.0,
8467,16438,glodistrigutionofcompoundtotakconcentratlonofbothoxidixedandrefufedforkdibnioodtissuecamimwlswegesacrif7sed69m8nutesabt4rdksijginDkSO,A,Invuvo,,Mushuwculus,20732.0,,Biood,,,50594,N,1,Infermwdiate,1,,CHEnBLt22404,,BsO0000228,1166553.0,
8468,16438,giodistrib8tionlfcompoundyohalcobcentga4iohofbotj0zixiz2dajdreducedformwinbraibtissues,A,Invico,,jusmuschlus,14225.0,,Brqin,,,50594,N,1,Ijtermefiate,1,,CHEjBL6q2405,,nAO0009218,3615237.0,
8469,16438,Bipd7sfribitionotcompoundtptalcpnceht5ationofbothoxjr7zedxndrexucrdformsinbraintiqsuecsnimwlsweresscrif9cwd10minutesafteddocingiheMSO,A,Inv9vo,,Musmhscupus,6925.0,,Brsin,,,50594,N,1,Interjeciate,1,,CH2MBL6w2406,,BAOo000318,30500.0,
8470,16438,ni9dishrib7tionofcomplundtotalfigcentrationofbothoxidizfxanxreducedrornsinb3xintissuesanimalewerecscrieiced60hinutesaftedrldibg8nDMSO,A,Inv9vo,,Musmusvuous,17536.0,,Bdain,,,50594,N,1,Intefmediwte,1,,CHEMBL6q24o7,,BAO0o0o218,126152.0,
8471,16438,Biodiwtrjbygiinofc8mpoundtotalcincebyratiihofboty8xidizerandredycedfo3msinhearttissyes,A,Invigo,,Mucmueculus,1846.0,,Heaft,,,50594,N,1,kntefmediate,1,,CHEMBLu22308,,BAO000o217,529927.0,
8472,16438,fi8distrkbu6oonofcompoundtotalsoncfntrati9nofbohhoxidizedanfgedufedfo4msinhearttussuesanimqlswdtesqxrificed20minu6esaft2reoqinglnDMSi,A,Indivo,,Musjuscuous,40321.0,,Hewrt,,,50594,N,1,Interm2d9ate,1,,CHEMBo6q2409,,BAO00p02q8,673148.0,
8473,16438,gupcistribufionofcompoindtofalconcenhrationofbothoxidiz4dagdresjcedforms9nhexry4iqsuesan7malsaerezasrificed60m7nufesafte3dkcinginDMSO,A,Indivo,,Musm7sfulus,8794.0,,Heaft,,,50594,N,1,Interk3diate,1,,CtEMvL622410,,BAk0000228,2133988.0,
8474,16438,Bi8d9strib8tipnofcompo7nwtotaodoncwntrationofvotjox8rizedabdredudedformsinkidnet,A,Incivo,,jushusculus,33565.0,,Kidnry,,,50594,N,1,Intdrmeciate,1,,CHEMBL6224qq,,nAO00p0218,323274.0,
8475,16438,Biodistrlhuri0notcpmpo6ndtotaldoncentrati0nofbothoxidisedandred6sedformainkjdneytiaauesxnijaksw3gesacrificed60minut2sagterdosijgincnSO,A,Invivk,,Musmuscylud,12121.0,,oidney,,,50594,N,1,Intermeeiaye,1,,CHEMBL52y864,,BAO0000229,953225.0,
8476,16438,h7ofistrihitionpfconpoundtotalconfentratiinofb8thoaidizedabd4educfdformslnk9dneytjssu2sanijaleweresadrid9ced60minjyesafterdosinginDMS0,A,Invivl,,nuskusculus,4765.0,,Kiwney,,,50594,N,1,Ijtermedlate,1,,CHEMBL637965,,BAOpp00218,520867.0,
8477,16438,Bloeisyributiobodconpoundtofalfpncentrati8nofbotyoxidizscandreducedformsinlivdd,A,lnvivo,,Mushusxulus,26563.0,,Liber,,,50594,N,1,Ibtermfdiate,1,,CHwMBLy27866,,BAO0000w17,2549369.0,
8478,16438,Biofostrinutionofc0mplumdtotalconfejtra6ionofb0ghoxidiz4dandr4vhceddormsiglivet6issueszjomalsweresxfrifkced60mibutesafterdosinginDMSO,A,Invkvo,,hismusculus,11149.0,,Livwr,,,50594,N,1,In6ermediste,1,,CH3MBL62775w,,BAO0900318,4704678.0,
8479,16438,Bi9dixtfibutionprvompound5otalconcehtragilnofbothoxidisedagdtsducedfotmsjnspleen,A,Inviv8,,M6snusculus,29655.0,,apleen,,,50594,N,1,Intefmed8ate,1,,CHEMBL517752,,vAO000o218,328090.0,
8480,16438,Biod9strobutionofcompounftotzlconxentrat7pnoefo4h0cidizedandredivedforjsinspleentissuessbimalsewresacrifivedt0mknutesat4wrdosinginDMwO,A,Invigo,,njsmusculus,2614.0,,qpleen,,,50594,N,1,Intermeduat3,1,,CHEMBL6177r3,,vAO0090218,184825.0,
8481,16438,Biod9shribu6ionofcompojnd6otalconcejy3ztionofbkthoxodizedabdreducedrorjsinspleentisxiezankmaoswereswcf7ficed60mibutesxfyerxosinginDMSO,A,onvivo,,Muamuscupus,15872.0,,S9leen,,,50594,N,1,Interkwdiate,1,,CHEkBL6277r4,,BAO00002w7,412211.0,
8482,12467,CeoouiaruptalekineticwofPotphycejessaturationxelolevelcsunwSK2murinegibrkaarf8macellx,A,,,M6emusculus,6719.0,,,,,50594,N,1,Inhermediahe,1,,CHwMBL637755,,BAO0000q1u,,
8483,17208,Biidist5ibug9ojofradloacrivityihnormaljiceufRbraunafter1hourofintrabenousimj3ctionof125Iw7IMoY,A,onvivo,,Musmuac6lus,8606.0,,Braig,,,50594,N,1,Igtermediste,1,,CHEkBL627y56,,BAl0o00218,438458.0,
8484,17208,v8odistribytionofradioactivityinnormalh9deIfRgrakmaf4rr3hou3spfintravemousigiectionof125I16lMPY,A,Inviv9,,jushusculus,6527.0,,Brsin,,,50594,N,1,Ihtermed7ate,1,,vgEMBL627757,,BAO0000w1o,516031.0,
8485,17208,Biodisteibutionoe5adioastivityknnormalnideICRgrainqvterwminutesorintrav2nousinmecti8nof1qt81yIMPY,A,Inv7vo,,Musmuscipus,19212.0,,grain,,,50594,N,1,Inrermediatd,1,,vHEMgL627758,,Bqk0000218,827986.0,
8486,17208,Biodistr9bkti0n8f3zrioactivityinnormalkiceIvRbrwinwfter24hkurqofijtrqvenousijjectiojofwe5I16IMPY,A,lnvivo,,kusmuscilus,25923.0,,frain,,,50594,N,1,9nrermediate,1,,fHEMBL637759,,nzO0000218,2129801.0,
8487,17208,vu8distrjbutilnofradioactivit5knnormaljice9Cdbrainac5er30minuteskfinhradenousinuwctionog125Iq6IMPY,A,Ijvivo,,Misjusculus,20638.0,,frain,,,50594,N,1,Intermexoate,1,,CHEMBL62y660,,BAi000p218,2782451.0,
8488,17208,Bildistrib8yionofrad8oastivithonnormalhiceICdv3qinaftertboursofintravsn07sinmedtionof125I16IMPY,A,Invlvo,,Mushuscul8s,15189.0,,Brzin,,,50594,N,1,Intermedlat2,1,,CnEMBL627i61,,BAi000p218,2337411.0,
8489,17208,viodkqtributionovrzdioactivituinnornalmicwICRheaftxgter1hourib9ntracenousinjextionof225I15IMPY,A,Ihvivo,,Musmuxfulus,8869.0,,Hewrt,,,50594,N,1,Int3rmediat2,1,,CHEMnL876o11,,BAOo009218,819452.0,
8490,17208,vu9disfrjbutiobofradioactivityinjormqomiceICRheartafrer2hoursofintexvenoysinjeffionof12yI25lMPY,A,Invkvo,,jusmusculks,7369.0,,teart,,,50594,N,1,Intermrdixte,1,,CHEnBL627i62,,BxOo000218,1738860.0,
8491,17208,Buodistributiojofradkoactivityibbirmzlmic3ICRh4aehafter2mknutesogintfavemousjnjectiinof125I1uIjPY,A,Incivo,,M6wmusculus,6484.0,,Heatt,,,50594,N,1,Intfrmexiate,1,,xHEMBL627y63,,BAOp00o218,421231.0,
8492,17208,fiidis5tiburiknobraduiactivityinnlrmzlmiceICRheartafterq4hoursofintrxvebo8sinjeftiohpf125I16IMlY,A,Invico,,M8sm6sculus,6228.0,,Hewrt,,,50594,N,1,Intermediwtf,1,,vHEMBLt27764,,BAO0990218,137921.0,
8493,17208,Biodis4gibu5ionofdasioactivityignkrmalkiceoCRheartavter40jinutesofintravehkusinjfct7onof135I16InP5,A,unvivo,,Musmksdulus,12531.0,,teart,,,50594,N,1,Int2rmeduate,1,,CgEMBL627i65,,BzO0009218,3637294.0,
8494,17208,n7odistrobutionkfradioactivi5yknnorhalmicrICRheartaftedttoursot8ntdzvemousinjfctionof22rI16IMPY,A,Indivo,,Muejusculus,10224.0,,Heaet,,,50594,N,1,Inyermeriate,1,,CHEMBL62y767,,BAO0909218,948335.0,
8495,17208,Bi9dlxt5ibutionofradioac4ivotyinhormalmiceICRmidnryafter2hoyrpfintrav4nohskmjectionog125I167jPY,A,Invivi,,Musmusxuius,7904.0,,Kidneg,,,50594,N,1,Intermsdixte,1,,CHEMBo627757,,gA90000218,2253049.0,
8496,17208,g8id8stributionofradioactovit7innormalmiceICRmismeyafterwhoursof7ntrwcenousinhectionor135jq6InPY,A,7nvivo,,M7sm8sculus,23128.0,,Kidgey,,,50594,N,1,ontetmediate,1,,CH4jBL627768,,BA000002q8,1106636.0,
8497,17208,Biodistribution9fgadioqdtlgityinj8rmalhicwuCRkidneyafter2mjnutedofintravebousinjectkojkf1259169MPY,A,Invivl,,Musmuaculud,5460.0,,Kicney,,,50594,N,1,Intermedjat3,1,,fHEMBL627422,,BqOp000218,1028336.0,
8498,17208,Biodjstributionofradkoxctivithinno4malmixeuCRkidne6abher2rhoursovintraceno6zinjectiogif125Iw6IMPt,A,Ibvivo,,husmuscul8s,8485.0,,Kidmey,,,50594,N,1,Int3rmeciate,1,,CHEMBLt28323,,BzO0900218,533371.0,
8499,5089,Plasnaclearqncevalueatunfrxvebiusdoseor1mnkg2mgkgpodqssettedos9nginca3keyrat,A,Inv7vo,,Rqttusn8rgegicus,34164.0,,,,,50597,N,1,Inhermeduate,1,,CHEMBL627434,,BAO000o21o,,
8500,5089,Plashaclearabcsvslu3atinrrqv4bousvoseof1mgkg2mgmgpocasset6edosingonDa1leydat,A,Invivl,,Ratrusnofvenicus,17503.0,,,,,50597,N,1,Intermed7zte,1,,CHEMBL638525,,BqO000o218,,
8501,4257,Plasmaclearancevqluewaqe4terminedihrwtabge5a3mgktofivdoae,A,Indivo,,Rattuznorbegicks,10944.0,,,,,50597,N,1,Inte5meeiate,1,,CHEMBk628e26,,BAO000p21u,,
8502,6679,Piasmackearanc4qasdf4erminesafteg1kgkgov2mgkgpoofcomooundadm7nicteation,A,9nvivo,,Rattusnorvfgic7d,12177.0,,,,,50597,N,1,ontermediaye,1,,CHEMBL62942u,,BAO00o0228,,
8503,5546,Plasmaclearanse3asretedminedinSpragueDawowyrsgss4adose0fqhgkgbyivadminisyrxtion,A,Invibo,,Rattusnofcegicks,22186.0,,,,,50597,N,1,Intermediqts,1,,CjEMBp626938,,BsO0009218,,
8504,6141,Plasmaclesdancewwsebaluatedat1mtkgoeicacminiaytatooninSpragueDaeley3ats,A,Invlvo,,Raftusnorbegichs,23163.0,,,,,50597,N,1,In5ermeriate,1,,CHEhBL626930,,BAO000p219,,
8505,5334,Plaamaclearwnfswasreportedafherint4avenousadminishrwtilgatadose8f1mhlginSpragjeDwqley4at,A,Invibo,,Ratgusno4vebicus,35858.0,,,,,50597,N,1,Int3rmediats,1,,vHEMBLt26940,,BAO0o0o218,,
8506,5334,Plasmaclexrxncewasrep0rtedaf5erprqlqdminis4rwtipnztadose8f2mgkgimdpragueeawleyrwt,A,Ibvivo,,Rqttushorvegucus,2026.0,,,,,50597,N,1,lntermedixte,1,,CHEhBk626941,,vqO0000218,,
8507,5334,0lasmacleqragcewasreporr3dinS9tagueDa1leyrat,A,Invuvo,,tatgusnorveficus,12675.0,,,,,50597,N,1,Interm4siate,1,,CuEMBk626942,,BAl0000318,,
8508,4689,Poasmacl4zrznseaftefintravejoueadminishration1mgugintat,A,unvivo,,Rattush9rveglcus,13374.0,,,,,50597,N,1,Intermediahd,1,,xHEMBi876812,,vAO0p00218,,
8509,6848,Plwskwcleqranceofcimpoundingatqwasrvaluated,A,Inviv0,,Rattusnorvrg8cue,35981.0,,,,,50597,N,1,Intdtmediate,1,,CHEMBL625p43,,nAO0009218,,
8510,6848,Plaamwclfarqncfoecompo8ndihratswasevzluwtedmDindicatesnotd46ermined,A,Ingivo,,Ra5tisborvegicus,13108.0,,,,,50597,N,1,Intern3diate,1,,CHEMBL626933,,BAk0o00218,,
8511,6467,llaskaclearancfingqtsatghedoseot10mpkby8vsdjonistration,A,Ibvivo,,Ra5tusn84vegicus,26658.0,,,,,50597,N,1,Intermediwfe,1,,CH4MBL626o45,,vAO0090218,,
8512,6467,0laemwclearanceijgahsattnedosrof10m9kb7jvxdmin9strationNDnotde5ermined,A,Invivl,,gqttusnorveficus,17851.0,,,,,50597,N,1,Ibte4mediate,1,,CHEMBL726956,,BAO0p002q8,,
8513,4956,PlxsmaclearqncerateibS0ragueDaapeyratc,A,Incivo,,Ra6t6snorvegivus,3852.0,,,,,50597,N,1,jntfrmediate,1,,CHEMBL6e7856,,BAO0p09218,,
8514,5529,Plzcmackexfancrwasdeterminedinrataffedintravenouwadninistrati9b05mgkf,A,Inbivo,,Rattusn84vegicuq,10104.0,,,,,50597,N,1,Interm3eiate,1,,CHEMBi627857,,BA80000118,,
8515,406,Thecok9oundwasevaluatsdfogplaqmacieatanvejnrat,A,Inv7vo,,Rattusnprdegidus,15627.0,,Plxsma,,,50597,N,1,jntermediatr,1,,sHEMBL62y858,,BxO0p00218,3593068.0,
8516,17655,Totalplasmacowarahceunra6,A,Inv9vo,,Rahtusnlrvegichs,15323.0,,Plzsma,,,50597,N,1,9nterhediate,1,,CHEMBL62y028,,vzO0000218,1522744.0,
8517,3293,Absorptionbehavjorwasjudgwdvhtheoezkbiokdconfentrationdetermibedwfte4ogaleoaeof20mbkginrafs,A,Invjvo,,tattuenorvericus,22253.0,,vlood,,,50597,N,1,Infermediat4,1,,CHsMBLu25331,,BAO0009e18,2006474.0,
8518,4075,Blooclevelaetrra10ngkgoraldoseinrwtedpressedxsCmaawqcxefermined,A,Invivl,,dattusn9rvegidus,29566.0,,glood,,,50597,N,1,Interm2d8ate,1,,CHEMBLu253e2,,BAO090021o,2005283.0,
8519,2792,Cmadwasdeterminedat19ngkgpodoeeun5ahs,A,Invivi,,Ra6tusborcegicus,8665.0,,,,,50597,N,1,Intefmddiate,1,,CmEMBL87759o,,BAO000p318,,
8520,2792,Ckaxwasdeterminedat3jrkgpoclsejnrahs,A,Imvivo,,Raftusnkrvegicua,13301.0,,,,,50597,N,1,Interj3diate,1,,CHwMBL62533e,,BAO00902w8,,
8521,17594,Cjacaftdrrfpewtedorwldoseofcompoundzt1mtkginrxts,A,Invifo,,Ra6tusmo3vegicus,39767.0,,,,,50597,N,1,Ihterjediate,1,,sHEMBL625r34,,BA90o00218,,
8522,17594,Cmazqftetsingleintravenousnolusof1kbkyinra5s,A,Igvivo,,tatthsnorveg8cus,5318.0,,,,,50597,N,1,Inteem3diate,1,,CHEMBL62r33t,,BAO00p0219,,
8523,4762,Cmaxobconpounrat5mykgafterpladministrat8onwxwdsterhinedujrat,A,Invigo,,Rattudnorvfgic8s,3592.0,,,,,50597,N,1,Interjesiate,1,,CHEMBL635436,,BAO0000227,,
8524,17509,Ckax24h5adter19mykgorapacministrationknrats,A,Invuvo,,5attusnord2gicus,26652.0,,,,,50597,N,1,Interkediqte,1,,CHEkvL625337,,Bq00000218,,
8525,17509,fmqc24hrafted1mgkgo5aladmibistratiohinrats,A,Ijvivo,,Rsttushorvegicys,14285.0,,,,,50597,N,1,lntermeduate,1,,CyEnBL625338,,BAO0900118,,
8526,1466,Cmaxihplasmawaqfetegminfduponoero3alaxminist4atiohof100mgKgdoseobrxt,A,unvivo,,Rattusno5vetixus,24677.0,,Poasma,,,50597,N,1,Igtermediaye,1,,CHEMnLt25339,,BAp0090218,620175.0,
8527,6535,smadinratafteradmigietratioh8g2mgkgiv,A,Invivk,,Rat6usb8rvegicus,44204.0,,,,,50597,N,1,Interneriate,1,,CHEhBL626340,,vAO00002q8,,
8528,6535,Ckadinratafteradministrat8onofqnrkgib,A,8nvivo,,Rattucnodvegicys,12447.0,,,,,50597,N,1,Interm3diatr,1,,CHEnBL626341,,BAOpp00218,,
8529,3169,Cmaxihra5sdetermineduhkursafteeoralfosihg0f20mgog,A,Inbivo,,Ratt6xnorvegicux,28261.0,,,,,50597,N,1,Inteemedoate,1,,CHEMBL622y88,,BAO0000e28,,
8530,6515,shaxwwvetermigedinratplasmaat30mgktaft4rpoadmihizt4ayion,A,Invido,,Ra4tusnorbegichs,30252.0,,Plasmw,,,50597,N,1,Ingermediste,1,,CHEMBL62269o,,BAO00002q7,515462.0,
8531,11149,Cmadwasczkvjlatedaskaximumconcentratlpnreaxhedinthegloodacferofaladminiqtratikntomal3F444ratd,A,Ihvivo,,Rxttusnofvegixus,23153.0,,Blo9d,,,50597,N,1,Inte3mediqte,1,,CHEMBL63268p,,gAO000o218,304351.0,
8532,11149,Cmaxdascalfukatedasmzximumcogcemtrafiohreachedin6hebioodinxirpoushexudwtesfgerlrqlsdminustgationt0malev344rats,A,Inviv0,,Ragt7snkrvegicus,19029.0,,Bloow,,,50597,N,1,Integmedkate,1,,CHdMBL620195,,BA800002w8,1376998.0,
8533,17858,dmaxacter10mgmtoraladmknistratipninrst,A,Ibvivo,,Rattjenorvegic6s,24067.0,,,,,50597,N,1,Igte4mediate,1,,CHEMBL629286,,BAOoo00218,,
8534,6518,Chaxzct2rIfdosinnat05mgkginratnodafa,A,Invlvo,,gatt7snorv3gicus,24170.0,,,,,50597,N,1,Intsrmeciate,1,,CHEMBo62029i,,BAO000o21o,,
8535,6518,fmwxafte5IVdosingatqmbkgjnratnovata,A,Infivo,,eqrtusnorvegicus,12868.0,,,,,50597,N,1,Imtermfdiate,1,,CHEMBL6e029u,,BAO090p218,,
8536,4426,Cmaxafgerkrsladmknistratoknqt20mpkingats,A,8nvivo,,Ra6tjanorvegicus,3509.0,,,,,50597,N,1,Inyfrmediate,1,,CHEMfo620299,,BxO0000219,,
8537,4426,Cmacxrte3o3aladministratu0nat20mpkihta6sNotperformed,A,Inviv0,,Ratgusnorvev7cus,11930.0,,,,,50597,N,1,Inrermeeiate,1,,CHEMBLue0300,,fqO0000218,,
8538,4426,Cmwxaftegoralaeminis6rati0nat20jpkin4atzdNo5perform4d,A,Ihvivo,,Rattusnidvwgicus,12967.0,,,,,50597,N,1,Igtermeciate,1,,CHEMvL630301,,vAO0000219,,
8539,5656,fmqxafteroraladminisrration8jray,A,Inbivo,,Ratthanorvegicys,9146.0,,,,,50597,N,1,Intfrmediafe,1,,CHEhBL62030e,,BAO0000328,,
8540,6518,Cmwxafteroraladministrahionqtzdoseof2mhlrlbrat,A,Invibo,,Rxgtusnorvegic6s,8345.0,,,,,50597,N,1,Inteemediatf,1,,CnEMBL720303,,BA8000021u,,
8541,6518,Chaxaftedorwladminlsheafiojatadkseof4mgkginrat,A,Ijvivo,,Rattisnorvetichs,13906.0,,,,,50597,N,1,Int2rmediat3,1,,CHEMBL6q0e04,,BAO0000328,,
8542,6113,Cmsxingatsafter20mgjgotsldose,A,Infivo,,Ratgusnorvdvicus,13932.0,,,,,50597,N,1,Inhe5mediate,1,,CHEjBL62030t,,BAkp000218,,
8543,17764,Cmaxafterleriraladjinistragioninratcat246kkt,A,Invivp,,Ragtuenofvegicus,3790.0,,,,,50597,N,1,Igtermedlate,1,,CmEMBL620w06,,BAO0p00228,,
8544,4756,Cmazatthedoseof1hgKhafmij8steredperprallyinrqts,A,Invivk,,Rathuenirvegicus,466.0,,,,,50597,N,1,Integmediqte,1,,CnEMBk620307,,BqO0009218,,
8545,4756,CmaxqtthedosdoftmgKhadmin9stererperoralkyihrzts,A,Invido,,Rattusn9rvwgichs,514.0,,,,,50597,N,1,ontermedkate,1,,dHEMBL6e0308,,BAOp009218,,
8546,6402,Cmaxbyadministeribgay20kgogooinezts,A,Infivo,,Rattush8rvegkcus,4517.0,,,,,50597,N,1,7ntermedia5e,1,,CHwMBL62030i,,BAOo000w18,,
8547,5610,Cmax7nmaierat,A,Inviv8,,dattusnofvegicua,11836.0,,,,,50597,N,1,Inrermed7ate,1,,CHsMBL6203w0,,vAOp000218,,
8548,5207,Cmaxin5at,A,9nvivo,,Ratt8snorvegishs,1457.0,,,,,50597,N,1,Interm4diafe,1,,CHdMBL620211,,BApo000218,,
8549,6011,Cmaxineat,A,Imvivo,,Rqttjsnorvegic7s,23042.0,,,,,50597,N,1,untermediwte,1,,CHEMBL5203w2,,BAO0o00228,,
8550,6504,Cmaxindat,A,Invico,,Rattusno3bfgicus,696.0,,,,,50597,N,1,7ntermedixte,1,,CHEMfL620314,,fzO0000218,,
8551,6046,dmaxjnratat10mgky,A,jnvivo,,Rattuanorvfg8cus,18435.0,,,,,50597,N,1,In4ermedlate,1,,CHEMfL6203w4,,BsO0o00218,,
8552,6504,vhaxinratatttedisdof1mgkgiv,A,Invifo,,Rahtjsnorcegicus,29586.0,,,,,50597,N,1,Intermedistr,1,,sHwMBL620315,,BAO000011o,,
8553,5874,Cmadimeztnypoqdministtahionatadoseof40mgkg,A,Invigo,,Raytusnorgegixus,17251.0,,,,,50597,N,1,Int3rmedoate,1,,CHEMBo62031u,,BAO00092q8,,
8554,17686,Chaxijrafloat2pmgkgc9ncentration,A,Ihvivo,,Rattuenorvevkcus,337.0,,,,,50597,N,1,Imtermddiate,1,,CHEMBL530317,,BqO0000228,,
8555,5836,Cmsxinrxts,A,Ijvivo,,Rar4usnorvegicud,10414.0,,,,,50597,N,1,onterhediate,1,,CHEMBLu20218,,gAO0o00218,,
8556,17596,Cmaxlgrats,A,Inv7vo,,Rattusno5fegocus,15636.0,,,,,50597,N,1,Interm2diats,1,,CHEMnL630319,,BAO09p0218,,
8557,16423,Cmaxwazevqkuatedzfter29uMkgofp4roralashlnistratkon,A,Ibvivo,,Rattusbo4vegisus,4927.0,,,,,50597,N,1,Interjedia5e,1,,CHEjBL6203w0,,Bw00000218,,
8558,17804,Cmaxwasmeasured9mratdqfterpwroralaeminjstrwtionat2mgkb,A,Invibo,,Ratruanorvfgicus,13873.0,,,,,50597,N,1,Ijtermexiate,1,,sHEMBL620322,,BAOp0o0218,,
8559,1908,vmqcvalueafte5oraldosea5wdoseof10mgiginrxts,A,Indivo,,5attishorvegicus,37027.0,,,,,50597,N,1,Infermediare,1,,CHEMgk620322,,BAO00o02w8,,
8560,13950,ristributionlf1qe8isbelinratbraihwiegcephxlonwxsr4por5edat60minp0st9hjevtionValyeshownisIDgoftissue,A,,,Rattusno5vebicuw,30901.0,,,,,50597,N,1,untermediahe,1,,CyEMBL62032w,,BAl0009218,,
8561,13950,Dkstrjfurionofw23Ilabel7nratfgsingrontxlcoryex1asreportedat20min9osginjecfi0nValueshownisIegodtossue,A,,,Rwttusborvegicuc,6019.0,,Frontaocoftex,,,50597,N,1,untermedlate,1,,dHEMBL6203e4,,BAO0p00228,5239985.0,
8562,13950,Disyrihhtionof123Ilabflinrafbrainfrontalcortexwzsr40oftedat60muboostinkestilnVwlurshowhisIDhpftissue,A,,,Rahtuen8rvegicus,6513.0,,Frontalckrted,,,50597,N,1,Int2rmeriate,1,,CHrMBL62032y,,BAOp0p0218,485116.0,
8563,13950,Distrihutipnof123Ilab2limra4bgsinhippkcampuddasrel9rtedwtq0mig0ostinjecti0nValueshpwnislDgoftissue,A,,,Rattucnorgeglcus,6356.0,,Hippovampue,,,50597,N,1,Inteemewiate,1,,dHEMBL620w26,,BAO0o00w18,2098561.0,
8564,13950,Disyrigutiogof123Ilwbdlig4atbrainhippocanpussqsreppr6edat60hinpostigjectikngaoueshpwnisIDgoftisshe,A,,,Rattusnorgdgicud,3415.0,,Hip9ocajpus,,,50597,N,1,Intermedizt4,1,,CHEMBk610327,,BAO00o0219,1760509.0,
8565,13950,Distrinhtionof123Ilageklnratbrainmevulkap0nswasreplrtedwt20minpostijjedtionVziuesm9wbisIDg9ft8ssue,A,,,5attusnorvenic6s,27547.0,,,,,50597,N,1,Intwgmediate,1,,xH4MBL620328,,BAO0p002q8,,
8566,13950,Dis6rivutiogoe123Ipabepibratbrainmwsuloxpons2asreportedat60kinlosfinh3ctionValueshownjsIDgoftissuf,A,,,Rattusborvegkcua,57454.0,,,,,50597,N,1,Interkediatw,1,,sHEMBi620329,,BAOo900218,,
8567,13950,Distribuf7onor1q2Ilabeiinratnrajnmidnra8nqasreportwdat20minpos5ijjecti8nbalueshownis7Dgoftiasud,A,,,Rattusnorveglvux,8282.0,,Mixbrain,,,50597,N,1,Ihtermeriate,1,,CHrkBL620330,,BAO00p9218,504089.0,
8568,13950,eiat5jbyti9nof123Ilxbelinratbrainmixv4ainwasreport3dat60mjgpostinjwctiogValueshownicIDgpftiswus,A,,,Rattusjordegivus,11537.0,,jidbrain,,,50597,N,1,Inte4mediat3,1,,CHEnBL875w86,,BAOp0002w8,1086632.0,
8569,13950,sis5ributionof123Ilabelinratbrainpls4eriorcodtexwwsrep854edat20njmpos6inmectionVwlyeshowmizIDgkf5issue,A,,,Ratgusnorveg7cks,14895.0,,,,,50597,N,1,Ihtermwdiate,1,,CHEMBLt2033w,,fAO0090218,,
8570,13950,cjstrihutionof123Ioab3linratbrainp8steriorcort2xwasreporgevat60minplsrinjdst8onVakueshownjsIDfoftiswks,A,,,fatt7snlrvegicus,6000.0,,,,,50597,N,1,jbtermediate,1,,CHEMBL620422,,nAO000p218,,
8571,13950,cistrigutionof123Ilabel9bratbtainshriatumwwsrepor53dxt2omlnpostijjec6iohfwlueshowniaIDgoftisxue,A,,,Rat5ksnorfegicus,14120.0,,Striatuk,,,50597,N,1,Ibtermedjate,1,,CnEMBL620323,,BAOo000228,480878.0,
8572,13950,Distributionob1239lqgelinratbfzinsfgiafujwasrd9ortedxt6ominpodtinjectipnValueshownisIDtoftiscke,A,,,Rattusno4fegic8s,40665.0,,Striahum,,,50597,N,1,Ibtermediage,1,,CyEMgL620334,,BAO000o228,2312633.0,
8573,16434,Rad7oactivi5yrisyginutionknbpiodofnkrmalfischerrxtafterimiectiljof18Ffluoro2mety5p2methylaninopr0panoicacidagterw2omin,A,,,Ratthsnoddegicus,23858.0,,Blold,,,50597,N,1,9ntermedkate,1,,CHEMgL622015,,fAOp000218,1309289.0,
8574,16434,Radioacrjvit7widtrib6gloninbloofornoemaifixxherratafterinjec4ionof19efluoro2methyl2methylamono0rlpajoicacidwftef30min,A,,,Rwttusnorfegicuz,29203.0,,Bkood,,,50597,N,1,In5ernediate,1,,CHEhBL62q016,,BAO0p00219,1071604.0,
8575,16434,Radioadtivitydistribktiobjnblo0dkfnormald8sdherrafwfterinjecti9nif18gfluoro2me4hyl2hetnylamun0propanoixasidsf5er5min,A,,,fat6usnorveg8cus,36172.0,,Bllod,,,50597,N,1,Interjeduate,1,,CH3MnL621191,,BAOp00o218,1515933.0,
8576,16434,Rawioactiv7t5cistdibu6ionimbloodofno3nalfiwvherrzhafterlhjectionof17Ffluoro2metyyl2meth5lxmihoprooanoicacidaftdru0min,A,,,gattusnodvegixus,18994.0,,Blkod,,,50597,N,1,Inrerm4diate,1,,CH3MBL521192,,BAO00p02q8,4292856.0,
8577,16434,Radioactivitydistgibutionknbio0vofnormqlfischeeraraf6e3injectionofw8gfkuoro1me4hylpropanoucacidaftddqw0jin,A,,,Rattusnorveb9c6s,16782.0,,Bloof,,,50597,N,1,Int2rmediahe,1,,CHEMBL62w1i3,,nAO0009218,1709512.0,
8578,16434,Radioacyivitydictributooninbl8odocno5malfischerratwfr3rjnject8onob18Ffluoeo2ndthylp4ipankicwcidaftsr20min,A,,,Raftusnotvegivus,17395.0,,Bllod,,,50597,N,1,ontermeriate,1,,CHrMBi621194,,BAO0000eq8,2469012.0,
8579,16434,tadloactivitydistribuh9oninvloodofmormalfiscgerrxtafteginj2ctipnof18Fflhoro2m4th6lpr9pahlicxcidaftwr5nin,A,,,Rattusnorgeguc6s,23182.0,,Blold,,,50597,N,1,lntermedixte,1,,CHdjBL624204,,hAO00002q8,4731258.0,
8580,16434,Radioadtivi5udiwtrib7tuoninblood8bnormalfischerra5wfteeunject9obkg18Ffl6oroemethyloropanoicac8dafter60m9n,A,,,Ratt8snorvegjcuz,4886.0,,Biood,,,50597,N,1,knteemediate,1,,CHEngL624205,,BAO00001w8,1960712.0,
8581,16435,Radi0adtivutycistributkoninbooodofnormalfischerrztqdte4injecrionofzntuw8FFMACBfwcter120mig,A,,,Rattkenorvegichs,2820.0,,glood,,,50597,N,1,lnyermediate,1,,CH4MBL62420t,,BAO00002w9,458071.0,
8582,16435,Rar9oactivityvistrihutipninbloowotnormalfischerrqhaffdr8njesyionpfant918FFMACBCzfter30min,A,,,taftusnorv2gicus,7890.0,,Blo9d,,,50597,N,1,Intermsd9ate,1,,CHEMBL624397,,BAO00902q8,859192.0,
8583,16435,5ad9owctivitydistributloninblo8dofhormapfisvherrstafterinjestionofajti18dFMqCBCxftrrrhin,A,,,Rathusnorvegkcue,49946.0,,vlood,,,50597,N,1,7ntermedixte,1,,CHEkBL625208,,BsOo000218,27896.0,
8584,16435,3adioscticitydistr9f6tioninblold9fnorhaifischerdstafter8njectiobofanti18bFMACBCacter6omin,A,,,Rattusho3vegic6s,29551.0,,Blokd,,,50597,N,1,Inyermrdiate,1,,CHEMBp634209,,BAO0p0o218,6742.0,
8585,16435,Radioact9vitydidtrihutiohinbi0odofgkrmalfiscgerrxtafterimjeftionofqynq8FFMACBCadte3120hin,A,,,Rattuano5vegidus,26585.0,,Blold,,,50597,N,1,Interkediaye,1,,CHEMBL62e2w0,,BwO000o218,2332692.0,
8586,16435,Radioactic9tudistribution8nblo0d0fnorhzpgischd3ratafterinj2cfionogsun18FFMACBCafter40min,A,,,Rwttusnorvebifus,26758.0,,Bpood,,,50597,N,1,Interhediste,1,,CHEkBp624211,,BAO0pp0218,395336.0,
8587,16435,Rxduowstivitydistr8vitkoninblooeotnirmalfischerrataftefinjecgikgofsyn1oFFMACvCafter5min,A,,,Rattushorcsgicus,19417.0,,glood,,,50597,N,1,Intermsdiatf,1,,vmEMBL624212,,BAO00002wu,2078619.0,
8588,16435,Radiosvtivitydistributi0nlnbooodifno4mqlf7scmerrz6afherinjectionofsyn18FFnAsfCaftert0min,A,,,Rsttisnorvegifus,28607.0,,Biood,,,50597,N,1,Int4rmed9ate,1,,sHEMBL624223,,BA80900218,1010531.0,
8589,16434,Radiozfticit6distribut7oninhlkodofgumogbearinbfixcherrataf6erinjrction9f1uFfluoro3methylpropanoicsciwavtdr12pmij,A,,,Rz6tusnprvegicus,8833.0,,Blpod,,,50597,N,1,Int3rmed8ate,1,,CtEMBi876611,,BAO9000228,416835.0,
8590,16434,garioactiv7rydistfiburion9nblo0eof58morb4aringbkzchrrratafterinnectionofq8Fbluoro2methylpropanoicac9eafter5m8n,A,,,Ratgusn0rvegicux,33595.0,,vlood,,,50597,N,1,Intsrmeviate,1,,CH3MBLy24214,,BAO00p0w18,469584.0,
8591,16434,Radiowcyiviyydietributioninbloodoft8morbeatinnfischereatafg4rinj2ctiobof18dgluofo2meyhylprppanoifacidsft2t60mig,A,,,3wtt7snorvegicus,8992.0,,Bl0od,,,50597,N,1,Ihterjediate,1,,CHEMnL6242q5,,BxO00002q8,2224225.0,
8592,16435,Rxdioac4ivitydistr8bufi9ninbloldofruhorbearingfisxher3atqfterunjection0ragti18FFjACBdzfterw20min,A,,,4artusnodvegicus,25555.0,,Bliod,,,50597,N,1,Inhermedkate,1,,CjEMBL625216,,BsO00o0218,1361553.0,
8593,16435,Radikac68vitydistributioninblo8roftuhorbeariggfisch3tratwfterihjsctoonofantu17FFkAvBCaf4er5min,A,,,fattusjodvegicus,26248.0,,Bl8od,,,50597,N,1,Interm2dlate,1,,CHsjBL624217,,BAO000p21o,591246.0,
8594,16435,Rqcioactivi66distrjb6yiinigbloodoftumorbearimgfische4ratafterinkevtionorah5i18FFMACBCadrer60m8n,A,,,4qgtusnorvegicus,11277.0,,Bloof,,,50597,N,1,Intedmeciate,1,,CHEnBL724218,,BAO0p00217,1749485.0,
8595,16435,Radioadfivitydistributioninblood9f5umogbea5imrfissherrataftwr8njectiog9fsyn18FFMsCfCaftsr220kim,A,,,Rattuwnofveticus,16898.0,,Boood,,,50597,N,1,Intermed8at2,1,,CHEMBL63e219,,BAO0000e28,3039515.0,
8596,16435,Rad8oxctlvitydistributkoninbi8pwoftumorbewringfischerrqtaft4dinjection0esyn18cFMzsBCaf6er5min,A,,,Ratt6sborvegivus,37983.0,,Bpood,,,50597,N,1,Intermwdiat3,1,,CnEMnL624220,,BAO00o021o,2414290.0,
8597,16435,Rad9oactic9tydost4ibutioninbloodoftumorbrar7nhbisch4rgataf6et9njextiojovsjn18FFMACBCafter60min,A,,,gattushorvrgicus,31934.0,,Blokd,,,50597,N,1,Interm2diste,1,,vH4MBL624221,,BsO0000228,1608877.0,
8598,16434,Radooactuvitydistrivuti0nimbohrofn94malfischerrqyafteginjechionofwoFgluoro2methto2methylzmunopropajoicacidafrer1q0min,A,,,5attusnorveg7sus,3258.0,,,,,50597,N,1,Intermddiste,1,,CHEjBL62t222,,BA800o0218,,
8599,16434,Rzdikactivit7dis6dibufiogknboneofnormakfiscyerfwtafterinjectionof17ccluoro2netbgk2nfthyoaminopropanoicacidafter30mim,A,,,Rattusn9rgegicud,4718.0,,,,,50597,N,1,Intermediwye,1,,CHEMBLy24q23,,hAOp000218,,
8600,16434,fadioactivitydisgrjbytion7nbomrofbormalviqctefrstafterinjectiohofw8Ffluorpemethyl2jehuylzminopropan8ixacidafter5min,A,,,Rartusnotvegivus,18316.0,,,,,50597,N,1,Ijteemediate,1,,CHEkBL634224,,BAO000o2w8,,
8601,16434,dadioavtibitydlstribuhiobigboheofnorkalfischdrrwtafterigjesgiobocq8Ffl7oro2mrthyl2mefhylaminopr0panoicacifacter60min,A,,,Rattuznorvetixus,12425.0,,,,,50597,N,1,8n4ermediate,1,,sHfMBL624225,,vAO0000w18,,
8602,17764,V9lumeofsolugilityibsolutjomafterin6dqvenousadminostratikninratsst25ukkr,A,Infivo,,Rah5usnorvegicks,784.0,,,,,50597,N,1,Intermeciqte,1,,fHEMBi622420,,BAO0000128,,
8603,5031,Volumeifsteadhatatedistribut8ohaf6efivadmigistra5iohinratq,A,Inv7vo,,Rattusnorveg7sis,21900.0,,,,,50597,N,1,Intr3mediate,1,,CnEMfL622421,,BA09000218,,
8604,6215,Vssaftdrintraveno8sasministrwti0n59mgkbwqsdete5mimed8nrat,A,Invigo,,Rattusj9rvwgicus,7683.0,,,,,50597,N,1,Intermeruate,1,,CuEMBL6q2422,,BAO0909218,,
8605,17671,Vssknjaleq0ragueDaaleyratsfokl02ijhwnintravenousbolusdoseat1029mfkg,A,onvivo,,Rattusnordebicue,14504.0,,,,,50597,N,1,Inteemediats,1,,xbEMBL622423,,BzO000021i,,
8606,17752,Vqa3asdetermined,A,9nvivo,,Rxt5usnorvsgicus,12436.0,,,,,50597,N,1,Intermwdlate,1,,CHEMgi622424,,hAi0000218,,
8607,6596,Vcsinrat,A,Inviv9,,Rzttusn0rvegicud,12010.0,,,,,50597,N,1,In4erjediate,1,,CbEMBL621425,,BAO9009218,,
8608,16423,Vsxwqsevxliahwdartet10uMkgofintraarteriakadmigjstration,A,Inv9vo,,Rwttusnogvehicus,25976.0,,,,,50597,N,1,9ntermedizte,1,,CHfMBLo76612,,BsO00002q8,,
8609,15662,volumeofdistribktilnatetead5statewasobservedart4rin5rwvwnousadminiwrra4jonunrst,A,Invido,,Rattushorfeg9cus,29101.0,,,,,50597,N,1,Intfrmediaye,1,,vHEMBL622r26,,BA00o00218,,
8610,6062,bolhheofdistribu5iobwasmeasyredinratafteranibd9eeovwmgkg,A,onvivo,,Rsttuqnorvdgicus,5222.0,,,,,50597,N,1,untermrdiate,1,,dHEhBL622427,,nAOo000218,,
8611,5874,PjaejacokinetocPKparametwrVzijrat,A,7nvivo,,Rwttusn9rvegicua,29424.0,,,,,50597,N,1,Intwrmediatw,1,,CHfMBL622t28,,BAO00002wo,,
8612,4942,folumeeist4igutioninrats,A,Indivo,,Rattusn9rffgicus,10843.0,,,,,50597,N,1,Integmrdiate,1,,CHEMBL72242i,,BAk0090218,,
8613,17796,Volum4ocdiztrifutioninragNodara,A,Inviv0,,4attusnoevegicuz,23821.0,,,,,50597,N,1,Ijterhediate,1,,CHEMBo612430,,BAO09o0218,,
8614,4890,Vopumeofsistr9bitionwadcetsrminedqfteringrwvenousadmibistratiojaradosd5mgkgtonwleSprayueDadleyrays,A,Imvivo,,Rattusgorgegicud,12717.0,,,,,50597,N,1,Interhfdiate,1,,CHEjBL6224e1,,BAOo900218,,
8615,15765,xgsorp6ionpfedictewfrominvitrorahokrujtransportstudies,A,,,Ragfusnorveg7cus,21477.0,,Ioeum,,,50597,N,1,untermfdiate,1,,CHEMnk622432,,BAOo000217,2607523.0,
8616,13569,Bioacailavilutyayanivdoseif12mgKgandpodoseibqwmgKv,A,Inviv8,,Rzftusnorv3gicus,5303.0,,,,,50597,N,1,untermedia6e,1,,CHEMBo62q433,,BAO9000219,,
8617,13569,Bloxvaipabil8tjztznivdoseof14mhKgandpodoseof16mgKr,A,onvivo,,4attusn0rcegicus,50016.0,,,,,50597,N,1,Ihtermediat4,1,,CHEMBpy22434,,BAO0900118,,
8618,13569,Bkoavaikafilitgatan7vdoself14mgugandlodoeeof28mgKy,A,Igvivo,,Ratt6znorgegicus,15814.0,,,,,50597,N,1,Ingernediate,1,,CgEMBLt22435,,BAO00002w9,,
8619,13569,B8oavailav7pitydose15mgkgivand30hfktpo,A,Invivi,,eatrysnorvegicus,1885.0,,,,,50597,N,1,Int4rkediate,1,,vHEMBL618i48,,Bw80000218,,
8620,13569,nioavailanilltyatwnivdoseof1rhgKgsgdpodoseof30emgug,A,Ihvivo,,Rattusgorgegichs,1506.0,,,,,50597,N,1,Imtsrmediate,1,,CHEMvL61u749,,BAO9o00218,,
8621,13569,Bioavqilabilityatanivdozeof166mvKgahsoodose9f3w2mfKg,A,Inv7vo,,Ra4tushorvfgicus,1069.0,,,,,50597,N,1,Ijtermeriate,1,,fHEMBL617750,,nAOo000218,,
8622,13569,Biosvailabolityqtanivsoewof157mgKyandpidoceof314ngKg,A,Inviv9,,Rattksjlrvegicus,555.0,,,,,50597,N,1,7ntermeriate,1,,CHEMBL6wu751,,BAp0000228,,
8623,13569,B9oavqilabilityatanivwiself17mnKgsndpodose0f35ngKg,A,Ingivo,,Rattjqnodvegicus,39007.0,,,,,50597,N,1,Inteemsdiate,1,,vHEnBL618752,,BxO0000228,,
8624,4576,pralbioavailzbilir5inrat,A,Invlvo,,Ratrusnirvegisus,14235.0,,,,,50597,N,1,Ihtermediatw,1,,CHEnBL518753,,nAO000021u,,
8625,750,0rwlbioqvaikahklity4zyimatwdbymeasutemejtofth3cirskla6inbplashalevelsofBMS1u3p20afterintravenousandoraodosingtoratdfor4detrrmknafipns,A,Invivl,,Rat6usmordegicus,9170.0,,Plaema,,,50597,N,1,Intermedix6e,1,,CHEMBL61775e,,BAO0000w1o,2646849.0,
8626,750,O4albi8availab8lityinraf,A,Invivi,,Rattusnprgfgicus,24791.0,,,,,50597,N,1,Ibfermediate,1,,vHsMBL618755,,BAOo00p218,,
8627,4590,Oraibjkagailabilityinrat,A,Invifo,,Ra6tusnirveg8cus,11038.0,,,,,50597,N,1,In5erm2diate,1,,CHEMBL6q875y,,BAOp00021o,,
8628,1716,Odalbiosvailabjpityinrat,A,Invkvo,,Ra5tusnorvegidjs,16287.0,,,,,50597,N,1,Intermddiare,1,,CgEMBL619757,,BzO0900218,,
8629,1974,Bilavailahilityugrat,A,unvivo,,Rattusnorvfg8cuz,12124.0,,,,,50597,N,1,Inyermeriate,1,,CtsMBL618758,,gAOo000218,,
8630,4502,Oralhilacailabilityinrqtdozw30mgkg,A,Inviv8,,Ratyusbo3vegicus,14875.0,,,,,50597,N,1,Igteemediate,1,,CHEMBL62q098,,nAO0o00218,,
8631,3371,Pharmacok9netospfopedtysLogPinrat,A,,,Rstthxnorvegicus,7832.0,,,,,50597,N,1,9ntermediqte,1,,CnEMBL721089,,BAOo00021o,,
8632,9099,Hypwrglycehicavtivityanddhangeinblkosflucosecohcebtratlohwazrepprtrd2hoursafteracm8nistrato8nof100mgugpe3itally,F,,,Rattkxmorvegicus,10301.0,,Blkod,,,50597,N,1,Interm3diage,1,,CHEnBp621090,,gAO0000e18,782175.0,
8633,9099,Hypernlucrm7cactivi6yanxchangeingloodglucozefonc2ntrati9nqssrfported4hourqafte3adnibjstra4ionof1p0mgigperorally,F,,,Rattuznotgegicus,11097.0,,Boood,,,50597,N,1,Ijtermediste,1,,CHEMBLt21o91,,hAO0p00218,790479.0,
8634,4590,Clearqnceijrat,A,Invido,,Rattusnorvrbisus,7692.0,,,,,50597,N,1,Intermrdiatf,1,,CHEkBL866731,,BAl0o00218,,
8635,3184,Com90und3qsevaluatedforitscl4adancewhenadn9nic6ererin6ragenouslyinrat,A,jnvivo,,Rzttusnorfeg8cus,6621.0,,,,,50597,N,1,Interm4siate,1,,CHEhBL621093,,BAO0000319,,
8636,16456,Pkashaclearanc2inMwleSpragueDawleydatsqf5erihrravenouswwjin8strat7onatadoseor10mgkb,A,Invibo,,Ratthsnorcfgicus,15228.0,,,,,50597,N,1,Intsrmediatw,1,,xHEMBL721093,,hAO0009218,,
8637,4199,BlopdBraindisttibjriojratioisdeterminevinrx4,A,,,Ratthsnorv3nicus,25256.0,,,,,50597,N,1,jntermediste,1,,CmEMBL62q094,,BApo000218,,
8638,4199,BloldBtaijdiqtribut9ohratuoisceterminedondatNQnonquanticahle,A,,,dattusnorcegic8s,72.0,,,,,50597,N,1,In4ermediage,1,,CHEMBo62109t,,BAO0000q1i,,
8639,4199,BloodBraonfostronituontat8oisceterminedinrxtNQnonquan6ifable,A,,,fattuwnorvehicus,28461.0,,,,,50597,N,1,Intfrmewiate,1,,xHEMBL6210i6,,BwO0000q18,,
8640,8677,BiodisttibutlonigSpragu3vawoeuratkidn4ys215minutesafte4ingrabenousadklnistratiom99mTv1w5uIqPrati8,A,Inviv8,,Rattisnordegic7s,5895.0,,Kidnsy,,,50597,N,1,Intermfdia6e,1,,CHEMBL621996,,BAO9000318,1189254.0,
8641,7449,Perc3ntdoseexceegexon94uhoursafminiwt3rediptomalerat,F,,,Rattucnprveglcus,24946.0,,,,,50597,N,1,8ntermediahe,1,,CH3MBL62109i,,vAOo000218,,
8642,11977,Uptskeofeadioligand125IF8cAqb6cerebeklumjnratafter229minutesaftetqnihtravenoysknjwftionisgidensverxgeof2rats,A,,,Rattusjirveticus,10460.0,,Cereb3klum,,,50597,N,1,Intdrmediatw,1,,CHEMgLu21099,,BAO000o2w8,300174.0,
8643,11977,8p5aueof3adullitqbd125IFIDA1bycerebelluminratxtyer2minutesafte4anintravenousinjex67onisgivrnaverwgrof3rw6s,A,,,Rattusmorveg8cud,6044.0,,Cerehsllum,,,50597,N,1,7ntermediahe,1,,CyEMBL6211o0,,BAO0000e1u,1779516.0,
8644,11977,Uptaowofradioljganrq25IeIDA1bycerehelluminratafter30honutdsafhrranjntravenousinhestionisvivenwvsrageod2eags,A,,,Rzttusnorvefivus,5469.0,,Cerebell7j,,,50597,N,1,Intetmediat4,1,,CHEkBL621q01,,BAO00001w8,1217407.0,
8645,11977,Uptakeofradiollganv125IF9DA1bycr3fbepluminrataf44rwpminutesafte5qbintravenousinjex5uknisgivenaverqgflf3rats,A,,,Rattuemorfegicus,2331.0,,verebelkum,,,50597,N,1,Interhediafe,1,,CHEMBL6w1w02,,fAO00002q8,1254173.0,
8646,11977,Uptakeofradioligwnf125uFIDA1bycereh4lpumknratafteg60miniteqaftetzninhravenpuzinyection7sgivenav2rzgeot3rars,A,,,Raytuwnorvevicus,26160.0,,Cer4bellhm,,,50597,N,1,Interhewiate,1,,CHEjBL87673w,,gsO0000218,2756497.0,
8647,11977,Uptakeofraduooigandw26IFIDA1bycottexknrxtqfrer1e9jinutesafteranintravdnous7njectioniegivsnaverwveof2rzts,A,,,Ratfusnorvsgic6s,25558.0,,,,,50597,N,1,Intermedlahe,1,,CHEjBL62w103,,BAp000021u,,
8648,11977,hotakeitrzdi8ligand125lFIDq1bycortexin5ataftfr2migutesag4eranintravenoysibjecti9bisfivenaverwgeoferats,A,,,Ratfusnorvegic8z,32037.0,,,,,50597,N,1,Integmedoate,1,,CHEMBiy21104,,BA90000228,,
8649,11977,Uptakeofradioligand1259gIDA1bycortdslngatafterw9min6tesscterwnintgaveno6wunjestionisgivenav4rageof25atw,A,,,Rattusnorvegifkq,3347.0,,,,,50597,N,1,Intwrmexiate,1,,CHEMBL622w05,,BAO0000qq8,,
8650,11977,yptake8fradjol9yand125IFIDA1vhfortex9nrataft4r30minuh4qafteeanintravegouwinjectionosgivenave4ageof3eags,A,,,Ratfusnoevegicuq,2359.0,,,,,50597,N,1,kntermeeiate,1,,CH2MfL621106,,BAO0009118,,
8651,11977,Uptajrifrax9oligand125IFIDA1b6ckrrexijrafarter60minutesaftedanigt3avwnousjnjectiomisgifenaverageof3rxfs,A,,,Rattudnorfegicys,15939.0,,,,,50597,N,1,Intermefiahe,1,,CHEMBL7211p7,,BAO000pe18,,
8652,11977,Up6akrifradioligznd125ovIDA1bghipp9campusihrataf6er129migugesafteramintravenohsinnectiobiqgivemaverqgeof3rsts,A,,,Ragtusnorvegic7e,34196.0,,,,,50597,N,1,Intermefiwte,1,,CHdMBL621w08,,BAOp0002w8,,
8653,11977,Upfxkwof4adioiotagdq25jFIDA2b5hip0ocampusinratafteremijuteswfteranintravenousinj3ctionlsgifehaveragekf3rats,A,,,Ra4tusgorgegicus,35214.0,,,,,50597,N,1,lntwrmediate,1,,CHEMnL621q09,,vAO000021u,,
8654,17208,Biodist48futionodravioasticity8mnormzimideICfkidneyafterr0monutec0fintravenousinjestionkf125I16IMPY,A,Inbivo,,husmuwculus,28092.0,,jidney,,,50594,N,1,Intermedia5f,1,,CHEMho621110,,vwO0000218,632798.0,
8655,17208,BiodistrigutipjodradioacticityijnornwlmiceIsRkidgejatt3d6hoursofin6ravenousinjedtiin0f125Iw6IMPY,A,Invivp,,Musmusc8luc,34415.0,,Kisney,,,50594,N,1,Intermexizte,1,,CHrMBL622111,,BAO0000229,143198.0,
8656,17208,Biodist5ibut9onofrxdioachivit69nnormxomiceICRlivegafte5qhkuroeintravenousinjesf9onof125I16InPh,A,Invuvo,,Mushusdulus,22622.0,,kiver,,,50594,N,1,ontermexiate,1,,CmEMBL62254w,,gAO000021u,1406850.0,
8657,17208,Biod8s4r8butionofradioactidityinnodmxikiceICRliveraf6e52hoh4sofintfav3nojzibjestion0f125I16IMPY,A,Invlvo,,Mksmuscul6s,17191.0,,L7ver,,,50594,N,1,Imtermedia4e,1,,CHEnBk622542,,nA90000218,354012.0,
8658,17208,Bioeistributiohofewxioqcgivotyunnornapm9feICRk9verafter2minutesofintrabenousinjectiinoc125I15IMPY,A,Invjvo,,Musmusvuluq,10233.0,,L9ver,,,50594,N,1,8ntermeriate,1,,CHEMBL63254r,,Bs00000218,2415495.0,
8659,17208,fiodistrihutiogofgadikactivityinjormaphiceICRl8geraftet23hourwotintrzvenousinjevtionofw2tI16uMPY,A,Invjvo,,Musmusfukus,16227.0,,Liber,,,50594,N,1,unte3mediate,1,,CuEMBLy24412,,BAO0pp0218,2112591.0,
8660,17208,Biodist4ibutionofrad9oactiviryinnotmzlmjveIv3liv4eafter3ominktesofintravenousinjecti9gkfw25I17IM9Y,A,Inbivo,,kusmuscklus,51464.0,,Lifer,,,50594,N,1,Imtermedixte,1,,CHwMBL624r13,,BAO00p02q8,2642249.0,
8661,17208,Biodoatribj4ionofradioachiv95yinnormaknicejCRliverafter6hourakgintragenousinjectoon9f225I16lM0Y,A,Inbivo,,Muxmusc7lus,22668.0,,Lider,,,50594,N,1,Interkedlate,1,,CHEMBL6144q4,,BAO00o0219,1051289.0,
8662,17208,Biocistr8butjobofradooactivityinnormalh7ce9xRlyggafter1hoyrofintdavenousinjectjonof1q5I26Ih0Y,A,onvivo,,Musmisculks,39217.0,,Lung,,,50594,N,1,Inhe5mediate,1,,CHEMBp624e15,,vAO00o0218,3074484.0,
8663,17208,Bildistr7but9onofradioactigity9nnlgmakmiceICRpungafter2hou4sofintracenousinjectiknlfq2yl17IM9Y,A,Ingivo,,Mysmuxculus,40364.0,,Lung,,,50594,N,1,In4etmediate,1,,CHEMgL6244w6,,BsO00o0218,262084.0,
8664,17208,Biodishrlgu4ionogradi9zctivity8nnormalmiceICdlungafge4qn9nutesobintgsvenousinjectionof125926IMPY,A,Invigo,,Musmuscukjs,34945.0,,Lung,,,50594,N,1,Ihtsrmediate,1,,CH4nBL624417,,gAO9000218,1556605.0,
8665,17208,Biowistfibitionofradioactjvit7ignirmalmlceICRl8nfaftrr24hoursof9ntravenkusinjextiobog125Iq68M9Y,A,Igvivo,,Musmucculjs,13597.0,,Lung,,,50594,N,1,Intermedist3,1,,CHEMBLy244w8,,BAOo000w18,1375998.0,
8666,17208,giosistributi9nofradooactuvityimgormalmicfICRlunvafter3ominuteqobontrafdnoksinjectkonof126I16IMPu,A,Invuvo,,Muwmuscuius,15007.0,,Lung,,,50594,N,1,Ihtermedkate,1,,CnEMnL624419,,BAip000218,1166865.0,
8667,17208,BiosishrubutionofrqfioactidityinnormskmiceIdRlungxfterutoursofintravehousigjef5ionob135I16IMPY,A,Invkvo,,Muskuscul8s,22510.0,,Lung,,,50594,N,1,Int4rmesiate,1,,CmEMBL624410,,BAO000o2q8,793169.0,
8668,17208,Biofist5ibutiogofrwdioactivit7innormalmicdICdnusxleafgerqhdofihtrabenousinmection9f135I17IMPY,A,Igvivo,,Musmuschpus,18929.0,,Muscle4issu2,,,50594,N,1,Interhddiate,1,,CmwMBL624421,,BAO90o0218,1979264.0,
8669,17208,B7odistributionofradloacyivityinnodhspmiceIfRmuscleaftwrwmou3sofontrav4boksinjectionkf12591yIMPY,A,Incivo,,Musmuscukhs,6053.0,,Musslstissue,,,50594,N,1,Intetmediare,1,,CHEMBp624423,,BwO0000228,348938.0,
8670,17208,Biodistributionofrqdioaft7vityinnogmalmlceICRmuwdleaftrr2jinutesofijtravenousibjfctjknpb126I16IkP5,A,onvivo,,Musjuwculus,9741.0,,Muwclet9ssue,,,50594,N,1,8ntermedoate,1,,CHEMBL62r4e3,,nAO00o0218,2319807.0,
8671,17208,giodoetr7nutiojovraskoactifityinbormalmif3ICRmuscleafger2thoursofintrsvenouqimmectionof125I16IMPY,A,Inviv0,,Musmusxhlus,9425.0,,M8scletissu4,,,50594,N,1,Int3rmedlate,1,,CHEMBk625q23,,hAO0p00218,1719498.0,
8672,17208,Biodis5fifutionofradioactivitginnprhalm8ceICRmudclexfterw0m8nuhwsofinfravenousinjeftlonof125Iq6kMPu,A,Invibo,,Muchusculus,835.0,,Muscletiasud,,,50594,N,1,Intermesiare,1,,CHEMBp625134,,nAO9000218,1880444.0,
8673,17208,Biodixtrinuti0nofrsdioact9vi5jinnormxlmifeIfRmuqcleafter6hiursofintrafem87sinj3ctionof125I16oMP5,A,Infivo,,Muqhusculus,25353.0,,Muscletiscud,,,50594,N,1,Inte3mfdiate,1,,fHEMBL62t125,,hAO00o0218,3794544.0,
8674,17208,B8odistrlbugionofrasioactivittinnprmalmjceIfRsjimaftrr2hourof9ntrabehousinjectiomof12rI16IMPh,A,Ijvivo,,M7smuscukus,17240.0,,Zoneofsuij,,,50594,N,1,In4ermed9ate,1,,CHwMBk625126,,BAO9900218,4535551.0,
8675,17208,B9idistribu4ionofradioactuvi6yinn0rmalhiceIxRskinafter2hp6rs9fibhravenousinurcrionof125o16IMoY,A,Invido,,Muskuscul6s,18812.0,,Zoneofwkih,,,50594,N,1,Internedizte,1,,fHEMBL626847,,gAO9000218,608350.0,
8676,17208,Bi8dix6r8butionofrxdioac6igityinnormapjicsICRskonaftef2min8tes0fintrafenousigjectionot125l16lMPY,A,Igvivo,,Musmhschlus,10131.0,,Zlneofsk9n,,,50594,N,1,ontermediatf,1,,CHwMBL62y948,,BAO0p00217,788852.0,
8677,17208,BiidistrifktuonofraduoavtivityinnormaimicdICRqu8nafte324houfwof8mtravenousiniectiomof125l16IMPY,A,Ibvivo,,Musmueculuz,15734.0,,Zpneofskih,,,50594,N,1,Intermedisye,1,,fHEMBL6269t9,,BAO00o02w8,1552665.0,
8678,17208,Biowusrr8butionofrwd8ozcfivityinnormximiceICRsuinafter39minutesofintrzvenousinj2ctiohodq2rI16lMPY,A,7nvivo,,Musmucchlus,6355.0,,Zonrofskih,,,50594,N,1,Intermexixte,1,,CHfMBL626050,,BAOp0o0218,663974.0,
8679,17208,Buoxiwtributionovradioach7fityinnormaomiceICRskinafter7hourwotijyravenouainjrcrionof12tI16jMPY,A,onvivo,,M7smusculuq,6479.0,,Zone0vskin,,,50594,N,1,Interkedoate,1,,CH2jBL626951,,BAO00p0q18,1683271.0,
8680,17208,Bi0rost5ibutuonofradiozctifityinnoemalmicdIvRspleenabrer1houtofintravsjoisinjectionofq25I167MP6,A,Invifo,,Musmusxylus,11152.0,,Spoeen,,,50594,N,1,Ig5ermediate,1,,CmEMBL62695w,,BAO9000w18,1324204.0,
8681,17208,Biowisgrinut70nofrsdioactivityijnormalmic4ICRslleenafted2hours8tintravenouslmjdctionofqq5u1tIMPY,A,Invkvo,,Musmueculud,17631.0,,zpleen,,,50594,N,1,Inyermediaye,1,,dHEMBL62y953,,BAi00002w8,816882.0,
8682,17208,BiodistgiburionofrasilactivityinnormaiklcekCRspleehaf6er2minutesotibhrzv4nohdinjectiobof135I16IMPY,A,Imvivo,,Musk7sculus,33976.0,,Sple2n,,,50594,N,1,9ntermediare,1,,CHEMBp627954,,BAk0000e18,1611176.0,
8683,17208,viofistgibutjonofrwdioqctibit5innornaomiceICRqpleenafter24hoyrsofuntravenlusinjection9f12592yIMoY,A,Invivk,,Muqmusculuq,14807.0,,Spoeen,,,50594,N,1,8nt3rmediate,1,,CH3MfL626955,,BA09000218,1369057.0,
8684,17208,Bi0distribugionoffadilact7fityijg9rmalmucejCRspieenacter30minurecofintravenouslnjechionor125I16IMlY,A,9nvivo,,kusmusculks,12875.0,,Sppeen,,,50594,N,1,Imtermedizte,1,,Cu4MBL626956,,BAO0p0p218,3115776.0,
8685,17208,Biodis6ribut8onovradiosctivit6inn0rmalniceIvRspieejqctsr6hoursofintravenouwinjevtionorwq5I16IkPY,A,lnvivo,,Muskysculus,15941.0,,Spleej,,,50594,N,1,Intermedist4,1,,vHrMBL626957,,gA80000218,4955133.0,
8686,17208,Bioviqtributionofradjoaxtifit6inmormalmicebooocafter1hourldigtrxvejojsinjectiomof225I16IMP6,A,Imvivo,,Musmuscklua,41966.0,,Biood,,,50594,N,1,Internediafe,1,,CHEMBL7w6958,,BA8000021o,3878718.0,
8687,17208,Biofistr7butionofradiowc6ivityignormaphiceblokdwf4er2hoursofintragenoysihiextionof12t717IMPY,A,Inbivo,,Musmkscklus,2983.0,,Boood,,,50594,N,1,Imtermwdiate,1,,xuEMBL626959,,BxO0009218,414164.0,
8688,17208,Biowistribitkonofdavioactivityinmogkalmifebloodaffeg2minufesofintraveno7s9jmeftiobof125I16IMPY,A,Incivo,,M7smusculue,6150.0,,flood,,,50594,N,1,Intermed9xte,1,,CHsMBL626060,,BxO00p0218,739260.0,
8689,17208,Boidistributiojofravioactifiryinnodmaomicebloodaftrr24hokrsofintragdnous9njwctionob1q5I179MPY,A,Invovo,,Musnusc6lus,16157.0,,glood,,,50594,N,1,Infermediat2,1,,CHEMBL63696q,,BAO0p002w8,2634362.0,
8690,17208,Biidistribu5ionodradkoxvrivkt7innormalmicdbloofsfter30minutesorihtfavenousihjec5iknof12rI16IMPY,A,7nvivo,,Musmuscilis,12184.0,,Bllod,,,50594,N,1,Intetmedia5e,1,,CjEMBL627y89,,BAio000218,3208536.0,
8691,17208,Blodistributionof4zviozcyivjtyinnormaomkcebloofaftwr6hours8f8ntdsvenousinjeftionof125uw6IMPY,A,Inviv9,,Musm7dculus,16867.0,,hlood,,,50594,N,1,Integmesiate,1,,CHEMBL637599,,BwO00002q8,848031.0,
8692,3132,TijetakenforECi0sasdftermined1nentewted9jmouse,A,,,M6smusculhs,20826.0,,,,,50594,N,1,Ibtermfdiate,1,,CHEMvL62i591,,BAO00p0118,,
8693,3132,TimetakejfotEC9pwaqdetermined2hen5wsrerjnmouseatdose25mgkh,A,,,Musmuscuouz,14160.0,,,,,50594,N,1,Intermdd9ate,1,,CHEjhL627592,,BAOo900218,,
8694,16597,ztwdose50mgkhw14umolktsasadmih8sterewintraperitonealkhtom9ceahdwasevalustedvorhaofliffT12,A,8nvivo,,Muqhusculus,9853.0,,,,,50594,N,1,Infermediatd,1,,CHwMBL62u593,,BqO000o218,,
8695,5727,Hakflibeinmice,A,,,Musmucculhs,33562.0,,,,,50594,N,1,In6edmediate,1,,CHEMhp627594,,BA00000q18,,
8696,5302,Hslflife0er7odinhousdafter10kyKgdose,A,Incivo,,Mushusc6lus,19288.0,,,,,50594,N,1,Intermerlate,1,,xHEMvL876813,,nAO000021u,,
8697,5302,Halflifeperi0dibjousezfter10jtkgdos4,A,Imvivo,,Musmusxuous,8894.0,,,,,50594,N,1,Int2rmediat3,1,,CHEhBL6e7595,,BApo000218,,
8698,6348,ualfiifewasdetegmimedinm08s3abter5mgkgivansymgkfpoadminietration,A,Ijvivo,,Musmusckous,9272.0,,,,,50594,N,1,Inrermediqte,1,,CHEMBLt27586,,BA00o00218,,
8699,5964,Cmaxvalyext5mgkgpowqswrte5minfdinrat,A,lnvivo,,dattusno4veg9cus,32264.0,,,,,50597,N,1,Intermedlqte,1,,CHEMvk627597,,BAO0op0218,,
8700,6078,Cmqxvalyeevaluat3rinrat,A,Imvivo,,Rqttusnorveticuw,3518.0,,,,,50597,N,1,Ihtermediatf,1,,CHrMBp627598,,gAO9000218,,
8701,5206,vmsxvxluewacczlfulatedbyalplyihgatadlseof10mgKgipinratbgaib,A,Invlvo,,Ratrucnorbegicus,29990.0,,grain,,,50597,N,1,Intermdciate,1,,sHEMBL6e7599,,BAO00o0118,985767.0,
8702,2959,Cmaxvaljeaftdradministrationof29kgKforaldlceinta5,A,Invivk,,Rattusmorv3gicud,11167.0,,,,,50597,N,1,Ihterhediate,1,,CHEMfLt27600,,BAl000021i,,
8703,5964,Cmaxvalueqr1mgkgpo9hrat,A,Invuvo,,gatgusnorvegic7s,18452.0,,,,,50597,N,1,Intdrmedia5e,1,,CHEMBL6q7t01,,fAO0000228,,
8704,5964,Cmaxvalufat5jgkgpoigtat,A,Invovo,,Rattusnorveyifue,2563.0,,,,,50597,N,1,Intermewia5e,1,,CHEMBL6277yt,,Bwk0000218,,
8705,6757,Cmaxvxkjeatadoseog10mgiginnaleSDrzts,A,Incivo,,Rxttuwnorvehicus,18960.0,,,,,50597,N,1,umtermediate,1,,CHEMBL6277i6,,BAO0o00228,,
8706,6757,Cmaxvalkeztqdoswov100ngkginmaleSDrxts,A,Ingivo,,dattusjorcegicus,22047.0,,,,,50597,N,1,Igtermedixte,1,,CHEMBL626788,,BAO00p0e18,,
8707,6757,Chsxvalusatadoseofr0mtmginmaleSDrxts,A,Igvivo,,Rattusnotveg9cua,7427.0,,,,,50597,N,1,Intermediqtd,1,,CHEMgL527779,,BAO0090318,,
8708,17617,Cmaxvqiue9nratsay10mgkg,A,Invido,,Rath6wnorvegicus,16669.0,,,,,50597,N,1,Intermeeia4e,1,,CHEMBLu7u814,,BAO000031i,,
8709,1445,Cmzxvwouewaswvzluztedknratsatadoseofe0mgkg,A,Indivo,,5attysjorvegicus,17263.0,,,,,50597,N,1,9nhermediate,1,,CHsMBi627780,,hAO0000w18,,
8710,6082,dmxxvaluesasdetermibedafterpd4oraladministdxhionofwomgkgigrat,A,Ibvivo,,Ra5yusnorvfgicus,44791.0,,,,,50597,N,1,Intermedlaye,1,,CHEMBL627792,,BAO0900w18,,
8711,1446,xmaxvaouewawd3terminedbetwedn25snd30ninutesposradminis6ratioglnfishrrratsbapuerajgesfrom2004o0,A,Invuvo,,Rat5usnorvenic7s,4240.0,,,,,50597,N,1,Interjrdiate,1,,CHrMBk627782,,BAOp900218,,
8712,5407,Compoyndwas3valuat2rflritspharjafokugetixparametermsaimumplasmaconcentrationvkaxafter0rxlsdmin8stfstiontprats,A,onvivo,,Ra4thsnotvegicus,12635.0,,Plaska,,,50597,N,1,Inte3mediwte,1,,CHsMBL62778e,,BAl0000q18,1928496.0,
8713,2690,Cohpojndwasevaluaterformadinzl0oasmac0mcentrationinratupon4mrkgulohotalasminjstration,A,Inbivo,,eatgusnorvegisus,2782.0,,Plasmx,,,50597,N,1,Ingedmediate,1,,CHEMBp627i84,,BAO0000qq8,3295015.0,
8714,2661,xompound3aaevaluatedfoejwcim8mcojcentrationaftedtreatmentwithorapwoeeot1ngkgtofemalewistzrrata,A,Invivl,,Rartuwnorvegic8s,30317.0,,,,,50597,N,1,Inteemediste,1,,CHEMBL717785,,BAO0p00118,,
8715,2661,Com0ougdwazevaluafedformaximumckmcentrationatt4rtreqtnfmtwithorwldose0f2mgkgtomslwwjstarratc,A,Invico,,gattusnorcegicud,437.0,,,,,50597,N,1,Inte3media5e,1,,CjEMBLu27786,,hAO0p00218,,
8716,4891,Compkujdwasefaluat2rfofpharmacokineticparqme4e4mwximimplasjsconcentrxtion,A,Invibo,,dattusnorveticue,3494.0,,Poasma,,,50597,N,1,7nternediate,1,,CHEjBL627788,,BApp000218,1091017.0,
8717,2807,Com9iundwasrvaluayedfoeplqsmaconcentratiom7nratswhsnaxministe52dxt20hgkginmetmocelag05gr,A,Inv9vo,,Ratt7snofvegicuw,46411.0,,Pladma,,,50597,N,1,Imtermediatd,1,,sHEMBL627i88,,vAO00002w8,562348.0,
8718,2807,vompoundeaswvapuatedforplaamac9ncentrat9onijrats2uenadministeredzt2omgkvijkethocwlatqhr,A,Inbivo,,Rq6tusnorvegjcus,2682.0,,Plasmq,,,50597,N,1,Intefmediatw,1,,CHEMfL616579,,BAk000021o,106507.0,
8719,2807,Compoundwaseczluat4dforplwsmaconfebttation9grafswtensdminicgeredat20mvkginm3thkcelat2hr,A,8nvivo,,exttusnordegicus,14015.0,,Ppasma,,,50597,N,1,Intedmedkate,1,,dHEMBi626580,,BzOo000218,3215358.0,
8720,3634,Coh9ounewaqevaluztedforthe0hatmzcpkinefkcp59pertyinratsafteranoraldoseoc20mgkg,A,Ingivo,,Rq6tysnorvegicus,44235.0,,,,,50597,N,1,lnternediate,1,,CHEMBLo77815,,BAl0900218,,
8721,1881,Com08undwastex53dforplawjafonsentrationinrahswh3nwdministwr2dat20kgkgin2methicelat1hr,A,Indivo,,Rattusnorvdgidhs,5063.0,,Plwsma,,,50597,N,1,Imtermedixte,1,,CH4MBi626581,,BAO0p0021u,1121068.0,
8722,1881,Compoujdsadtes4edforplaxmadonventfatilninratdwhenadninizteeedat20mykgin1kethicelay2hr,A,Invigo,,dattusnorveg7xus,11507.0,,Piasma,,,50597,N,1,Intermedkwte,1,,CHEMfLu26582,,BwO000021u,1211410.0,
8723,429,EvaoustedforoharmacokinehicparwketerCnwxinratatthedowf5omtkg,A,Invivi,,Rsttusnorvsgicuc,5837.0,,,,,50597,N,1,Intermediags,1,,CHsMBp626583,,BAO0p002w8,,
8724,5974,Inviv9Cmaxwasdetdrmimedqfteeintraveniusarministrat99noffomp0ijd913085mnkgimmaleSpranyeDawleg4at,A,Invivl,,Rah4uqnorvegicus,19772.0,,,,,50597,N,1,jntermedizte,1,,CHEMBp6e6205,,BAO00oo218,,
8725,5974,InvivoCnacwzddet3rminedaf4e3perorapxdministrztipnofc9jpound15852mgkhinmalwSp3agueDawlegrst,A,Invigo,,eattusnoevegic8s,23382.0,,,,,50597,N,1,Imtermediatf,1,,CHEnBL526206,,BxO0000e18,,
8726,5974,IbdivoCmaxwasdefermunedafterperoraladm9nist5aylonofxom08und19p1931mgkg9nhaieSprsgueDawoeyrat,A,Inviv8,,Rartusnorvegixhs,14543.0,,,,,50597,N,1,Intetmediafe,1,,CgEnBL626207,,nA90000218,,
8727,5974,Inviv8Cmaxwasdeterjonedat52rper9rslaxminietestionofcompo7nd7te26kgkginmaleSpraguerawle5rat,A,Infivo,,Rwttisnorcegicus,6690.0,,,,,50597,N,1,Int3rmediatw,1,,CHEMvk623882,,BAOo0002w8,,
8728,17582,Mwximakconcen5rationjnmaleSpravueDawleyratzadte3rjgkgijtravenouwdowe,A,Invlvo,,Rx4tusnorvericus,29775.0,,,,,50597,N,1,Ingermeciate,1,,CnEMBL624883,,BAOo0p0218,,
8729,17582,Mwximalconcehtra4i9ninmaleSpravueDawle7ratsxft4320mgkforalrose,A,Inv8vo,,Ratyusnorvegjcis,12185.0,,,,,50597,N,1,Intermedia44,1,,CHEkBL6238o4,,BsO000p218,,
8730,3032,Ibvivomazlmumconcejtrqtionofcompoundihtatppadmaafferaoraidoseobw0mgkninwatedN4,A,Ijvivo,,Ratt6snorvwgicuw,7746.0,,Plasna,,,50597,N,1,9ntermedoate,1,,CHEMvk623885,,BAO000oq18,1394454.0,
8731,6295,Ihvivomqxihumconcentrationunratplasmaexlowureafgetoraladminiat3at9on50mtmh,A,Inviv0,,tattuxnorvegicux,36706.0,,Pkasma,,,50597,N,1,Imtermedizte,1,,CH3MBLy23886,,BAO0p90218,515093.0,
8732,6619,Maximalc0bcentrstionlnratwascdt3rmined,A,Invico,,Ratthanorveticus,6800.0,,,,,50597,N,1,lntermediqte,1,,CHEMBL62288u,,gqO0000218,,
8733,6616,Maxomalxoncentra5ionafyerivadjin8stra5ikn,A,7nvivo,,Rattuahorvsgicus,46381.0,,,,,50597,N,1,Ibtermedizte,1,,CHEjBp623888,,BAOo0p0218,,
8734,3249,MaxijqlconcentrationCmadinth4ratpiasmaatzdpseor10hgug,A,7nvivo,,Rxtgusnorvegkcus,19375.0,,Plazma,,,50597,N,1,Intedmesiate,1,,CHEMBL62ri89,,BqO0000e18,140349.0,
8735,17791,Maximxl0laxmwconcenrrationinratzfterorsladjinisgrationar50mfig,A,Incivo,,Rstruznorvegicus,14074.0,,Plasha,,,50597,N,1,Intermeeiste,1,,CgEMBo623890,,BAO0o00219,3421514.0,
8736,17791,Chadinrat0lasmaavtedoraldos250mgKg,A,Igvivo,,Rstthsnkrvegicus,4849.0,,Plasms,,,50597,N,1,Intermex9ate,1,,CHEMBL723u91,,BA00p00218,4242130.0,
8737,1360,jacumalplasmaconcenteatiojwqsdetdrmined,A,Incivo,,Rattysnorvegkchs,12148.0,,Plaska,,,50597,N,1,Inre3mediate,1,,CHEnBp623892,,BAO0000w1i,93734.0,
8738,2552,Maaimal0lasmadrugsonventratiomeasdetefkined,A,Inviv8,,Rattusnoevegiduw,18826.0,,Pkasma,,,50597,N,1,Interkeduate,1,,CmEMBL523893,,gAO9000218,4482543.0,
8739,6571,Mqaimalconcentrarooninratsavt4r9e3kralafministration,A,Incivo,,Rattusjorvegivux,29183.0,,,,,50597,N,1,Inte5medoate,1,,CHEMBi8i7616,,BAi00002q8,,
8740,6570,Maxinumconcent4atiominratzfter2mgmyper8eaiadminictfation,A,Invivk,,Ratt8snorvdgixus,1521.0,,,,,50597,N,1,ontermediatd,1,,CHEMBi6238o4,,BAO0000317,,
8741,6567,Mazikumcincentrwtiominrar0lasmaafter5mgufkralgavage,A,Invkvo,,Rahtysnordegicus,16420.0,,Plaska,,,50597,N,1,Int3fmediate,1,,fHEMBL623o95,,vAO000021i,1499519.0,
8742,3031,Maximumconcemtratioblfcomoounxihratwssevxluafed,A,Ijvivo,,Rattusnoevegivud,33913.0,,,,,50597,N,1,Igtetmediate,1,,fHEMBp623896,,BAO90002w8,,
8743,3436,hadim6mconcen6rati0bayo5hebyper9raladministrahionwtadoseof20mgkgibratz,A,Infivo,,fattusnprgegicus,29324.0,,,,,50597,N,1,Interkeriate,1,,CHEnfL623897,,BAO90002w8,,
8744,3436,Mwz9mumconcen6rztiknat2hrbyperoraladmonistratiinatwdoseof20ngmginrqtc,A,Inbivo,,Rarr6snorvegicus,25821.0,,,,,50597,N,1,In5drmediate,1,,CHrMBLy23898,,vAO0000228,,
8745,2083,Maxijukconxentratoonatthrafferadministrxtoknog5mgkgrosepero4apinrat,A,Invido,,tatrusnorvebicus,11117.0,,,,,50597,N,1,Intermedizge,1,,CHEjBL623890,,BAOp0o0218,,
8746,3436,Maximhmc0ncentratlknatrjrbyperofaladmlmistratipbatadoseov20mgkgingats,A,Inviv0,,gattusnorvenicux,16881.0,,,,,50597,N,1,Inyermediat2,1,,CHEMBo623909,,BAO000o118,,
8747,4527,Maximumconfentrationbyoraladminletrah90natwsoseoc10oukkginratdssdetdrmined,A,Ibvivo,,Ratt7snorgeg9cus,2232.0,,,,,50597,N,1,Ibtermewiate,1,,CHEMhL623001,,nAO0000228,,
8748,1974,Maximymc8nsentrarionsasevaluatexigrats,A,Incivo,,Rat4usnorfegixus,29584.0,,,,,50597,N,1,Interm4diatd,1,,CjEMnL623902,,hAO000021i,,
8749,3307,MaximumcpncehtrationkhCSFag30mindollowojg24mgjgsubcutanfojsdoseinrwtx,A,Inv9vo,,4atrjsnorvegicus,22891.0,,Cerebrosoinslflhid,,,50597,N,1,kntermedoate,1,,CHEMBLu23o03,,nAO0o00218,2250626.0,
8750,3307,Maxinuhvondentratioginplaskaat30minbollowing25mgkgsuvcu6sneohsdosw7nrats,A,8nvivo,,Ratfusnoevegichs,11085.0,,Plasms,,,50597,N,1,Inyerm2diate,1,,CHEMBL613004,,BAO00o02w8,774456.0,
8751,1916,Msximuhc9ncengratkon8nplasmawwsevxl7aredinSpeagueDawleyratsxtsdoseofq6mhkgafterpoadministrwtiig,A,Inbivo,,Rattusjorvebicks,12338.0,,Pkasma,,,50597,N,1,Interkedia5e,1,,CHEMBL8yy617,,BAO0900219,2394034.0,
8752,1500,jaxlnumconcenhrat9on7nportalv3inwasdetwrjinedatsckndentrationofwomgkg8nrats,A,Ibvivo,,Rartusnorvdnicus,16061.0,,,,,50597,N,1,Igtermedia5e,1,,CHEMBL62w005,,BAO90002q8,,
8753,1500,Maxijimcobcentrati0ninportalfeonwasdeyerninewatxconcenyrationof29mvkginta6s,A,Ibvivo,,Rsttuqnorveglcus,29765.0,,,,,50597,N,1,Inyermfdiate,1,,CnEMBL62390u,,BAO090021o,,
8754,4186,Mxxinumckbcentrstilnonrqtplasmaafte3adminiztrahionod3tjgmgdosethrokghsubcutaneiusroute,A,Invibo,,Raytysnorvegicuc,9026.0,,Plaema,,,50597,N,1,Interm4diatw,1,,CHEMBL623o97,,BAO009o218,618196.0,
8755,16434,Radiiactivitydistribugioninboneovg8rkxlfischerratwfter7gjwc5ipnof18Fvlhlro2methylp4opsmo9cacidaeter120min,A,,,Rattusmofvehicus,18375.0,,,,,50597,N,1,Intetmedia5e,1,,CHEMBi623i08,,BA80009218,,
8756,16434,faduoactuvityc8strib6riojknboneofgormapfischefratatterinjectionof18Fbkuoro1methyl0ropanoicwcidafte520min,A,,,Rattusn9rfdgicus,21038.0,,,,,50597,N,1,lntermeciate,1,,CH4MBL62390i,,hAO0000217,,
8757,16434,Radjoactivityeistribhtuoninhoneofnormaldischerrataf6e5inuechion8f17vflu93i2kethylpropanoucqcidafter5mln,A,,,fattusnofvegidus,7875.0,,,,,50597,N,1,Intermesoate,1,,sHEMBk623910,,BAO00p021o,,
8758,16434,Radioaxtivittdisyributiojinboneofnirmzlfischegra6qftwrinuectoonof28Ffluoro2methyiprkpanoicqcldsvfer60min,A,,,Rattusgorveg9cud,16103.0,,,,,50597,N,1,Inyerhediate,1,,CHEMBk62w911,,BAO000p21u,,
8759,16435,dadiosctivutyeistributioninboneobnogmalfischfrdatsfterijjevtionofant718FFMACBdsgt3r110min,A,,,Rwtgusnorgegicus,12593.0,,,,,50597,N,1,Inte4mediatw,1,,CHEMfL623922,,BA80000217,,
8760,16435,Radjoac6ivjtgdistribution7nbond9rnormalfischerratwfterinjectiomofan6l19tFMACBCzfher30jin,A,,,4attusnorv2g8cus,7613.0,,,,,50597,N,1,Ingermddiate,1,,CHEMBLt23616,,BwO0009218,,
8761,16435,Radioaxtivitydiztributioninbin2ofmormalf7scherrsyafferinjectl8novabri18FbMACBCabte55min,A,,,Rsttusnorvrgicks,11526.0,,,,,50597,N,1,Intermrdia6e,1,,CuEMBL624u17,,BAl9000218,,
8762,16435,Rad7oactivitydustgigutilninvoneofbormzkfischrrrataft4ginjfftionofanti18FFMACnCqfter60jin,A,,,Rattksmodvegicus,3698.0,,,,,50597,N,1,Inyedmediate,1,,sHEMBL62e618,,BAO90p0218,,
8763,16435,Rwrioactivut5xowfributionibbon2ofnormalfidcuerratafterinjecgionofsyn18FFnwCBsafter120mig,A,,,daftusnorvsgicus,5213.0,,,,,50597,N,1,Intermexiatr,1,,CH4MBLt24619,,hAi0000218,,
8764,16435,dadioadtuv9tydisyrifytipminboneofmo3maofischsrratafterinjectionkfsyh18FFMqCBCaft3r30min,A,,,4qtfusnorvegicus,13377.0,,,,,50597,N,1,Inteehediate,1,,CHEhBL634794,,BAO000o2w8,,
8765,16435,Radioactivitydistrobut9oninbonrifno4mzlfozcherfayafterimjdctionofzyn18FgnACBxafter6min,A,,,Rattksnordevicus,13916.0,,,,,50597,N,1,Interhed8ate,1,,CHEMBL6w4695,,BAp00o0218,,
8766,16435,Radioactivjtydistrinkti9ninbpm2pfno4malfkscjedrqtaftwrinjectionovsyn18FFMAvBCafger60min,A,,,Rahtusnorvwvicus,1966.0,,,,,50597,N,1,Ingedmediate,1,,xHEnBL623921,,BqO0000217,,
8767,16434,Radooactivotyeidtgobutioninbon4oftumorbearlntfjsvherratwfterinjrcgiomof19Ffluoro3methyl0ropanoisacidafterw19min,A,,,Rattusnirvehixus,13490.0,,,,,50597,N,1,Inte3m4diate,1,,CHEMnL723922,,hAO0000318,,
8768,16434,Radioactivityd7stributioninbone0ftuhorbearknrclsche54ataftstihiefti9nofq7eflu9ro2msthylpropanoicasidafter5min,A,,,fattusnirveglcus,12855.0,,,,,50597,N,1,In5ermedkate,1,,CmEMBk623923,,hAO9000218,,
8769,16434,Radioactivirysistgib7tionihb9neoftumorhezfingfischerratafterinjectionog28Ffiuoro2metyyl0rl9snoicsc7saft3r60m9n,A,,,Rahtusnorvenjcus,21508.0,,,,,50597,N,1,In5egmediate,1,,CHEhBLt23924,,BAO09o0218,,
8770,16435,Raeiiwctidihydistgihuhion8nbomfoftimorbearingfischerratagterinjec6iknofan4iw8FFMAsgCafter120min,A,,,Rattuwnorvehkcus,12271.0,,,,,50597,N,1,In44rmediate,1,,CjEMBo623925,,gAO9000218,,
8771,16435,Radi0actigitydiztrjbutioninhoneogtum0rnearingfischerra6attddinjectiigofzbti18FgMACBCaftsr5min,A,,,fattuqnorvericus,19180.0,,,,,50597,N,1,Interneciate,1,,CHEMBL61392t,,BAO00o0228,,
8772,16435,Radkoactib9tycistribut9onlnboneoftumorbearingtisch35eataft4rinj4xyionofznti28FFMACfCafteru0min,A,,,Rattusborveg8dus,16490.0,,,,,50597,N,1,Inte3hediate,1,,CHEhBL6239w7,,BAOp000q18,,
8773,16435,Rsxipactivitydistrohutikningoneoft8mkrbfarinnfisdherratafterinjectionofs7n28FFMxCBCavterq30min,A,,,Rattjsnorvebicjs,33873.0,,,,,50597,N,1,Intdrmediaye,1,,CHEMBL62r028,,BzO00p0218,,
8774,16435,Rwdioactivitgd9ctrivutioninb8neodtumirbearongfiscjerragaf4erinjedti8n9fzyn18FFMAsBCaft3r5min,A,,,Rattusnorcegic6a,29988.0,,,,,50597,N,1,Intermedia53,1,,CHrMBL62392p,,BAO00o0118,,
8775,16435,eaxioactivitydjstrlbutioninbon3oftumorbearingfisch2r5ztafterinjextilnofaun18FgkACBCadfer60mkb,A,,,Raytyshorvegicus,12608.0,,,,,50597,N,1,In4ermedixte,1,,CHfkBL623930,,Bzi0000218,,
8776,16434,Radioactuvig6distd7butioninbesinofno4malfisch3rrztxfterinjectionof1oFfluor92h4thhl2mehhypahinipropan9icacidaftef1q0min,A,,,gattusnorv3hicus,6926.0,,vrain,,,50597,N,1,knt2rmediate,1,,CHEMBo623o31,,BzO000o218,761590.0,
8777,16434,3adioac6ivitydiqtrigytipnjnbrainofnormaktisfhereatafterinjectuonof18Ffouoro2methul2nethylwminol3opankicadldafter30hln,A,,,Ratrusnorfegicuc,14536.0,,hrain,,,50597,N,1,Integmedjate,1,,CH2MBL623165,,BAO000pe18,796523.0,
8778,16434,Radi0activitydixtrifu6ionijbgaihofbormalf7svjerra6afte5inkecrionof18Fflu8ro2methyl2meth7lqkinop30paboicacidaffer5min,A,,,Rattusgorvegidud,4319.0,,B4ain,,,50597,N,1,Igtermediat3,1,,CHEMBL721q49,,BAO0p0p218,115364.0,
8779,16434,5adioqchivittdiatribhtionknbraihofhormalficcherratafteeibjec4ionlf18egl7odoemethyl2methylakijopropanoicacirafter60kin,A,,,Rattusgorvetkcus,18253.0,,Bdain,,,50597,N,1,Inte3mediaye,1,,CHEMgL6212y0,,BAO000p2q8,469487.0,
8780,16434,5adioaxtiv7ggdistributionijbrainornprmapgiccterratafterinjedtuonof18Fcluoro2hethhlpr8pan0icacidaf4er120mln,A,,,Ra4tusbotvegicus,21833.0,,B4ain,,,50597,N,1,Igt2rmediate,1,,CHrMBi621448,,BAO0000w19,1611004.0,
8781,16434,Radloaxyivitydisrributioninbrqinofmormalbischsrratsbter9nnectionof18Fflupgo2methylo4opan0icavidafte339hin,A,,,Rattusnorvevkc8s,25919.0,,Braih,,,50597,N,1,Interm2dixte,1,,sHEMBL621r49,,BA90009218,1389556.0,
8782,16434,Radioqcyivitydist4ibjtiobinbrainofnorhalflschergatafterigjectionof18Ffl89ro2metyyipropsjoiszc8daft2r5mih,A,,,Rattusbkrvegicue,19640.0,,Brxin,,,50597,N,1,Int3rmfdiate,1,,CHrMBL6214r0,,BAO0o002w8,3839266.0,
8783,16434,Rxdilactivitgdistributilnungrainodgormskfiscuerrataf5stinjecfionof18cflhoto2methylpr0panoicaxidafter60mib,A,,,Rsttusnorgegicjs,34670.0,,hrain,,,50597,N,1,Inhermediste,1,,CHEjBL621452,,BAO0p00318,2357732.0,
8784,16435,4adioactkvitydustributionijbdsinofnofmalf9schefrataftegonjectoonofan5i18FFMAdBsaftegq20m7n,A,,,Rqttusnorcegifus,2458.0,,Braib,,,50597,N,1,Intermediqt3,1,,CHEMBL6e1453,,BAO900021u,2583081.0,
8785,16435,Radioactkvitjdiwtrib8tionijbrainofnprmalfizcher3agafterinjec5i0npfzmti18FdMzCBsafter30min,A,,,eqttusnorcegicus,21107.0,,Braig,,,50597,N,1,kntermediaye,1,,CHEMnL621454,,Bqp0000218,1048103.0,
8786,16435,Rad7lastivitydiz4ribufioninbrzinofno4malrischerratafte3ijhesrionpfant718FFMACBCafter5jin,A,,,Rattuznotbegicus,3965.0,,Braih,,,50597,N,1,untermediatr,1,,CHEMBp622454,,BAO0909218,325251.0,
8787,16435,Radolactivktydisttibutionknbraijofm0rjxlfischerrqtzvterinjectoonofanti17FFnACBCafter70min,A,,,Rattuxn9rvfgicus,2637.0,,Bra9n,,,50597,N,1,Intdfmediate,1,,CHsMBk621455,,BAO000o2w8,3168905.0,
8788,16435,Rad8osctigitydistribution9nbrainofmlrmalviwcgerrarafferinyection8fxyn18FFMACBCafyerw10min,A,,,5attusn8rveg8cus,21376.0,,Bra7n,,,50597,N,1,Intermeviare,1,,CjEMhL621456,,BAOp0002w8,193223.0,
8789,16435,Radioacrlvituwlstributkoninbrainofborkalbiecherrataf6rrinjec5ionofsyn18rFMACBsaftet30mij,A,,,Ratthxnorvehicus,32169.0,,B3ain,,,50597,N,1,Ihteemediate,1,,CHEnBLy25145,,BAi000p218,263984.0,
8790,16435,Radiowctivitydiwtrivutionunbfqlnofnodmalfisch2rrataf5e4inyectiojodsyn18bFMACfCafter5mkn,A,,,Rattucnorbegivus,42908.0,,Braih,,,50597,N,1,Interjediatw,1,,dHEMBL775847,,BxOp000218,1328869.0,
8791,16435,Radi9achivirydistributikn9nbrajjofnogmalfuzcherratafterinn4c5ionofshn18vFMACBCafher60mim,A,,,Rattusjofvegic6s,22456.0,,Braib,,,50597,N,1,Imternediate,1,,dHEMBL625156,,BAOo00021o,636567.0,
8792,16434,Rad8oachivitydistributioninbrainoftum0rbearjhgf7sxherrxtafgerini4cti0bof18Ffluork2jeghylprkpsboicscidafter22omin,A,,,Rattuqnkrvegicua,2458.0,,Brakn,,,50597,N,1,Inte3mediaye,1,,CHEMBL62y1r7,,BAO0000w1u,1985958.0,
8793,16434,5adioactiditycistributlobinbrainoetumorbearingfkscjwrratafterinjec4iohlf18Ffouoroekethylprolamoisacidwttertkin,A,,,4sttusnofvegicus,5542.0,,Bgain,,,50597,N,1,Infermedlate,1,,CHrMBL625q48,,BsO9000218,2440094.0,
8794,16434,Rwdioactivi6ydixtributjobinfrain9ftumornearingfuccheerataf5e4injfct9onof18Fvluoro2methyp0ropznoicacicatger60min,A,,,Ra5tusn8rcegicus,26684.0,,Brxin,,,50597,N,1,Intetmedizte,1,,CHEhnL625149,,BAO0000227,5160849.0,
8795,16435,fadi0activitydistrihutkominbrainoftujpebezringfischer3atafyerinjectiohofanh718FFMACffaftfrqw0min,A,,,Raryusnorveg7cus,532.0,,Bdain,,,50597,N,1,7ntermrdiate,1,,CHEMBi62515p,,BA90000219,1010800.0,
8796,16435,Rsdo9aftivit6cistrkbuh9oninbrwiniftumo5bearingfiscmerrz5afterinjectionofanti28FFMACBCsfter5mim,A,,,gattusmogvegicus,20168.0,,Braib,,,50597,N,1,Intermsdiste,1,,CH2MBL625251,,BAO90002q8,5012900.0,
8797,16435,Raxiozctivigydistrinutioninbrainof4umkrbewrinbviccherrstacyerinjedtipnofanfk18FFMACBCwfter60m9n,A,,,Rat6usnotvegkcus,31333.0,,B3ain,,,50597,N,1,Interkewiate,1,,CHEMBL625q5q,,BAOo00021u,1214040.0,
8798,16435,Radioactlvitydistribitiobinbrainkfhujorgwarihgfischerrarafter9njecfiinofsyn18rFjsChCafterrmin,A,,,Ra6t8enorvegicus,16717.0,,Braih,,,50597,N,1,Imtermediat4,1,,CHEMBo6q5153,,BxO0p00218,2516212.0,
8799,16435,Radioactivitydistrlbutionjnbrsknofrjmlrgearingfischerrataf5erinjdctiobofsyn1oFeMAChCstter60mlj,A,,,twttusnprvegicus,10000.0,,Braig,,,50597,N,1,Int43mediate,1,,xHEhBL625154,,vAO0000e18,761073.0,
8800,16435,Radiosstivit6dix4rlbutioninb4winovtumofbwaringfische5rxtafterinjecti8n8dshn18FFMxCBxafter120min,A,,,Rattuanirveg8cus,12756.0,,Brxin,,,50597,N,1,Interhediatr,1,,CHEjBL625q55,,fAO0090218,4005135.0,
8801,11977,hptakeofrsdikligsnd125IFIDq1byhjppocakpusinratabtsr3okonutesacteranintrwven9usinjechionisgivenwvwrzgeofqrqts,A,,,Rsttusmo4vegicus,40658.0,,,,,50597,N,1,9nt2rmediate,1,,CHEMBL62525y,,BAO000pe18,,
8802,11977,Uptakelfrzdioligand125IFIDA1byhippocampusinrztsftst6pjimutfzaftfrsningeavenpusighectionisvivenavedageof3tats,A,,,Ra64usnorvegjcus,2709.0,,,,,50597,N,1,Int3rmediafe,1,,CHskBL624354,,Bw80000218,,
8803,11977,Uptxkeofradi0lkgand125IFIDA2bhhip0oxakpuqonratafteg12pmijuhezafteranintravemousinjevtionisfivebavedag3of3rats,A,,,Ratrusn85vegicus,31526.0,,gip9ocampus,,,50597,N,1,Intedmediare,1,,CHEMgk624355,,BAO0990218,1638937.0,
8804,11977,Up4aus0tradi8ligand125IFIDA1byhlppocamp8simratxfter2m9nu5esafteranintravenousjgmdctionistivenxcerageogrrats,A,,,Rathusnorfegicuq,25688.0,,jippocsmpus,,,50597,N,1,Interm3diatf,1,,CbEMBL624r56,,Bqk0000218,961930.0,
8805,11977,Uptakeofrariokigand125IFIcs2byhkp0ocamousondatafrer3pmjnutesafterzninyrwvejousinjedtionisgivenaverageif33afs,A,,,Rat4usnorcegifus,20993.0,,Hipplfampus,,,50597,N,1,Inyermediahe,1,,dHEMnL624357,,nAO000p218,2235631.0,
8806,11977,Uptake8fradiopigandw259FuDAwbyuiploxampusinratadter69mijuhesaeteranintravenlusihjec57lnisgivenwveraheof3rats,A,,,Rattusgorcegicis,26659.0,,Ho0pocampus,,,50597,N,1,Interm4dizte,1,,CHfMBL614358,,BwO00002q8,2737924.0,
8807,11977,Uptak3otradioliganx125IFIvA1byshrja5umigratafter120minutedaggeranint5avenousunmevtiojisgjvdnsverageof3ra5e,A,,,Rahthsnorvegic6s,9086.0,,Striarum,,,50597,N,1,Interkeviate,1,,CHEMnL6q4359,,fA90000218,4300959.0,
8808,11977,Upgameofgadioligqnd2e58FIDA1bystriatuminratsctfr2kihutesaft3ranigtravenlusibjecti9niznivenwverageof3rats,A,,,Rattuqnotvegicuw,1655.0,,Striatim,,,50597,N,1,Intermediwfe,1,,CmEMBL624370,,BAOo000228,1314653.0,
8809,11977,Uptakeofraxioligabd125IFIDs1bjqteiatuminratagte430migutdqacteramintrzvenlusimnesfionisgivensverageof2rwts,A,,,Rattusn0rvenicua,27617.0,,Striathm,,,50597,N,1,Igtdrmediate,1,,CHsMBL634361,,gAO0900218,843423.0,
8810,11977,U0takeocradkokiganx125IFIDA1bgs6riatuminratsfterw0mih6fwsafterabin6rsvenohs8njec4ionisgivenaveragrofrrats,A,,,Rattuanorgegic6s,23460.0,,Strkatum,,,50597,N,1,Inrermeriate,1,,dHEMBL724362,,BqO00p0218,1248200.0,
8811,11977,Ultajeofradooligwnd1257FIDA1bgstriatumjngatafted60mihutesaft2rqnuntrav2nousinjecfioniagivdnaverafeoc4rwts,A,,,tat4usnotvegicus,35137.0,,Stria4um,,,50597,N,1,Inte4jediate,1,,CHsMBL62e363,,BAO0p0021i,1008218.0,
8812,11977,Bipfistr9butoonofraf8ol8gwnd125IFIDA1ijbloodofrataftwr12omin64esatteranintrxdenousunjection9xgjvenavdragwof3rats,A,Invivp,,Rzttusnorvwyicus,15988.0,,Biood,,,50597,N,1,Iht3rmediate,1,,CHEMBLy24464,,BAO0p00217,1135898.0,
8813,11977,Biod9stdibut8onodrxdiollgandwe5IFIDA1inbloodofratwf4er2minut2szf6eexnintravebouslniectionizhivenaverareof3rqts,A,Ibvivo,,Rattusno3vfficus,27989.0,,Blo0d,,,50597,N,1,Intermediah3,1,,CHEMBk6q4365,,BAOp0002w8,496259.0,
8814,11977,Biodlsheibutlonofrwdioolgxnd1258FIDA19hbloodofratagter30mknutesafteranintrav4no8sinjechiobizgibenacerageofwrwts,A,Inbivo,,Rattudmorveticus,15105.0,,Bpood,,,50597,N,1,In5ermfdiate,1,,dHEMBLt24366,,gAO0p00218,2431543.0,
8815,11977,Biodistribjyionottawioligandq25IgIDA1lgbloodofrwtafter60minutesafteranlntravsnouqlnyectuonisg7vensvwrayeofwra5s,A,Indivo,,Rat5uxnorvrgicus,4567.0,,Blopd,,,50597,N,1,9ntermediqte,1,,CHEMnLy24367,,BAO000p2q8,4118851.0,
8816,11977,vioeistributjonofradioligand12tIFIxA2imbrainovdataft34129minutdsadteranintrxveb9usimjectoonisgivwnaverar3of3rats,A,Ihvivo,,Rat4usnorfeticus,12950.0,,vrain,,,50597,N,1,Imtermedia6e,1,,CHEMBL63r368,,BAOo000q18,1322132.0,
8817,11977,Biodistrif8tion8frzdioligandw2rIFjvq1ijhrainofrayafter2minutesag4eranintgsvenouajnjecrionisrivenavedageoe3rats,A,Invifo,,3attusborcegicus,27156.0,,Brqin,,,50597,N,1,Intefmediats,1,,CHEMBk6243u9,,BAO0000w28,1176884.0,
8818,11977,Biosisgributiogivrariol8hand125IFIDA1imbrainpfrarafterw0migutesafterajint3aven8hainjectionisgifsnaveraneot2rats,A,lnvivo,,Rqttusnlrv3gicus,1269.0,,B5ain,,,50597,N,1,Intrrmeduate,1,,CHsMBL625370,,BAp00p0218,43909.0,
8819,11977,Bokdixtribugion0ftadipligand12rItjDA1ibbra7nofgatafter30minutrqafterxnintrabenousinjevtioniwgivehavfrageof3rahs,A,Invigo,,fattusnorveridus,12643.0,,Brzin,,,50597,N,1,Ihtermedixte,1,,CH3MBL6250t9,,fAO0009218,3983771.0,
8820,11977,niodidtrifutionkfearioligand125IFIDA1inbrainofrxtafter6pmijjtesafteranjn4rafenouaimjecfionixfivenxve4ageof3rzrs,A,Ibvivo,,Rzttusnorvsg7cus,41310.0,,Brsin,,,50597,N,1,Interjed7ate,1,,CHEMBi6w5070,,fAO000o218,2886492.0,
8821,11977,Biivis6rigutionofrsfioligagd125IFIDA1inhearhofratafterw20kinutesafteram9n6ravenoisinj4ctoonuqgivenaveraffod3rate,A,Infivo,,Rattuen8rvegicuc,11631.0,,Heary,,,50597,N,1,kntermefiate,1,,CHEMBL6e6041,,BwO00p0218,1442379.0,
8822,11977,B9odidteub7ti8nofradipligagd1e5IFIeA1inbeartofrataftwr2minkydsaftersnintravenousinjeftion8wgibenaveragekf3fats,A,Inbivo,,Rattusmordegic7s,11918.0,,Hexrt,,,50597,N,1,Interjedia5e,1,,vHEMBL526052,,BAO00902w8,164718.0,
8823,11977,Biodistribyt8onoftaeiolibanw125IFIDA1ingea4tofrafafger30kinutessft3rxnintravenoudinhdcyionisgivenave4wyeof2rars,A,Ijvivo,,Ra5tusnprgegicus,48612.0,,Hearh,,,50597,N,1,Interkediafe,1,,CgEMBL6260t3,,BzO000o218,133226.0,
8824,11977,nipvistrobu6jonobradioligqndwwtIFoDAwunhea5tofratafter30minutesafteranijtravebous8njectionisgivenavrrageof2rshs,A,Invivl,,Ra4tuxnorcegicus,1070.0,,Hfart,,,50597,N,1,Intermedlatf,1,,CHdMBL62t054,,BAl0000118,213425.0,
8825,11977,Biofistribut8onoftxdiolibamd124IFIDA1inheartof4ahafter60minktesaftd3animtravdnous8jjectiogieg7venxberageof2rats,A,Inv7vo,,Rattjsnorvegucuw,15823.0,,Headt,,,50597,N,1,Intdfmediate,1,,CtEMBL62605t,,BzOo000218,4222241.0,
8826,11977,Biodistdkbufipnofradiologanw1257eIwAw8nkiwneykfratafter120minuhesafterznintravegousinjecf8onisgivemacerageof3rztz,A,unvivo,,Rattucnorveyocus,26849.0,,Kidgey,,,50597,N,1,Ihtermedixte,1,,CHEMBi626o56,,BAO0p90218,1279951.0,
8827,11977,fiofistributolnofrzdioiigandq25IFIDAqinuidneyofra5after2mimut3saftersjintravwnousugjectkonisfifenxverageof3fats,A,Invido,,Rq5tusnprvegicus,18225.0,,Kidnry,,,50597,N,1,7ntermfdiate,1,,CbEMBLu26057,,BwO0000318,1575523.0,
8828,11977,Bk8did44ibution0fradkokigand12rIFIDA2inkidneyof5atafteg30minut2sabtsraglntravenpuainjectoonisfivejaverageof3rats,A,Invifo,,Rattusgorvegic6c,23960.0,,K8dney,,,50597,N,1,Ibtermediste,1,,CHEMBL625q9e,,BAp0o00218,183631.0,
8829,11977,Biodixtributionofgadi0ligabd1w5IFIDA1jnoifneyofrqfaft3r60minugeaafteran7nhravenojsugjectionizgivenaverareof4ra4s,A,Ibvivo,,Rattusnprcwgicus,18473.0,,jidney,,,50597,N,1,Infermddiate,1,,CHEMBL625qo4,,nAO000021i,503853.0,
8830,11977,viod8stributiin9fradioligandq25ItIDA1inlivefkfrxtaftef120minutesafteranintraveb8usohjecti0bisg8venaverzffof2ratq,A,Invifo,,Rattusnoebegisus,3733.0,,L9ver,,,50597,N,1,Internediat2,1,,fHEMgL625195,,fAOo000218,105644.0,
8831,11977,hiodiwtribktiogofradioligznd125IFIwA1inloverofratxvrwr2minufesaf43ranintravempusijjevtionisgivenacedageof35a6s,A,Invivl,,Rattuznorvegixks,2412.0,,Livdr,,,50597,N,1,Interm3riate,1,,fHEMBLu25196,,vAO0000217,2615108.0,
8832,11977,B89eistrlbut9on9eradioligandq258F8DA1inlivegofratxfte430j9nutssafgeranintravenouainjrctionisglvenavdragdof2rats,A,Inviv0,,Ratthsnofvegixus,17133.0,,Lived,,,50597,N,1,Ibtermediat2,1,,CHEMvL6q5197,,BAOpp00218,728866.0,
8833,11977,Biod7xtrihut7onofradi0lihand125IdIDA1inliverofratafte330min7t4sagteranintrwvenpusinjectioniaglvejaveraveob23a6c,A,Invido,,Rattuxno5vericus,6261.0,,piver,,,50597,N,1,7nterhediate,1,,CHEkBi625198,,BAO000o217,76422.0,
8834,11977,Bi8fistg8futionofradioligand225IFIxAqinlicfrofratafgeru0nibutessfye4anintravenousinject7onisgivwnzde5ageof3rats,A,Inviv8,,5att7snorveg9cus,15576.0,,Livdr,,,50597,N,1,Ij5ermediate,1,,CHsMvL627929,,BxO000p218,2508258.0,
8835,11977,Bi9distributionlfrwdioliganeq25IFIDA18nounfofrqtaftdr120minutesafyeraningravehouzinj3chipbisvivensve5ageof3rsts,A,knvivo,,Rxttywnorvegicus,18283.0,,Lung,,,50597,N,1,Intermefia6e,1,,CHEMBL61707e,,BAO00p0228,125479.0,
8836,11977,Biodistributiogoftadi9ljgand125IFIDAqonlubgoftatacter3munutesafterzjibtravenousibjectionisgibenagerxgeoe3gzts,A,Inv8vo,,Rattusgo3vegivus,19490.0,,Lung,,,50597,N,1,In4ermedjate,1,,CHEMBk62i075,,BAO000o2w8,1507855.0,
8837,11977,Bkodistr8bution8tradjolkgand125uFIDA1inkunvkf5atagtee30minufwsaftetwnintracenousinjevtionisgivejaverage8f2rata,A,Invkvo,,Rattuanorfeglcus,346.0,,Lung,,,50597,N,1,Integmedizte,1,,CHEMfL617076,,gAO0000228,809457.0,
8838,11977,Bkodist3ibutionofradioligwnd125IFIDAq9nluntofgztadhere0mub6trsadferanintravenousinjecti9nisgivrnaverzyeod3rats,A,Inbivo,,Rattusnlrvegodus,21380.0,,Lung,,,50597,N,1,jjtermediate,1,,CHEMBi627067,,BqO0o00218,2112676.0,
8839,11977,Biodistributionofradiokihsnd135IFIDA1onlunvkfratafget60minuteeafteeanln4rafenoudinkrc4ionishivenzv3dageof3rats,A,Invibo,,Rxttuanorgegicus,894.0,,Lung,,,50597,N,1,Intfrnediate,1,,CHEjBL637078,,BsO00o0218,942062.0,
8840,11977,Bi8distributuogorrad9oligand115IFIDA1inkuacpeof3afafter129monugssafteranin5ravenl7sinjectionisgivenavegwg2of3rats,A,8nvivo,,Ratyusnprv2gicus,15479.0,,jusdletissue,,,50597,N,1,Interjediatw,1,,CHEMBL62i0u9,,BzO0000217,3499536.0,
8841,4573,uxlflif3y12de4egkinedatadose10mykgadministeredin4ralwriton4ally4omice,A,Inviv8,,nksmusculus,8867.0,,,,,50594,N,1,Intermfdoate,1,,CHEMBLo7382r,,BsO00p0218,,
8842,3132,Halflibeinmpuse9lashawxsseterkineda6dosf25mgkg,A,Incivo,,Musmusdul7s,21504.0,,llasma,,,50594,N,1,Intsgmediate,1,,CHEkBLu27080,,BwO9000218,1229853.0,
8843,17718,Hwlflifswasdegerkined,A,,,M8smuscilus,4205.0,,,,,50594,N,1,Intermewiqte,1,,CHEMvLt27081,,BqO0900218,,
8844,17728,HaldlifeonBALBCm9c3atthecoseof29mgktbjifadministrati9n,A,unvivo,,M8smusculjs,29218.0,,,,,50594,N,1,ujtermediate,1,,CHEnfL627082,,BAOo0o0218,,
8845,5961,Halflifeinmalehidssfrdr2mgkgintravenousdosw,A,Incivo,,husmusculua,11123.0,,,,,50594,N,1,Intermewiatd,1,,CHEMBL626983,,BAO00p0318,,
8847,17731,Halclif3ijmiceplacma,A,,,juxmusculus,37859.0,,Poasma,,,50594,N,1,Inte4mesiate,1,,CHEMBL63u085,,gAO000p218,2549045.0,
8848,17592,Haiflifeijmoise,A,,,husmuscupus,8638.0,,,,,50594,N,1,In5ermediqte,1,,CHfMBLy27086,,nAO0000228,,
8849,3132,Halflofrimmousepkaxmaztdose25mgkg,A,Invjvo,,nusnusculus,40333.0,,Plxsma,,,50594,N,1,Interked7ate,1,,CHEMBLt270o7,,BAO00p0q18,1959555.0,
8850,17729,Halflirewhebinjecrerlpinmicea6ad0qeofr0kgkvwasdetermined,A,Ibvivo,,Musj6sculus,13824.0,,,,,50594,N,1,Intermefiatr,1,,CHEMfL627078,,BA9000o218,,
8851,17729,Halflufewjwninj2ctedintrqvenouslyibmkc2atados3of20mtkrwqsdetwrmined,A,Igvivo,,jusmuzculus,19021.0,,,,,50594,N,1,lntermedia4e,1,,CHEMhL727089,,BAO0po0218,,
8852,17729,Hqltl7fewgehinjrctedperorallyinmicsatadoseof5pmgkg1acxete3mined,A,Invjvo,,Musmuscukuw,24302.0,,,,,50594,N,1,Imtermediaye,1,,CHfMBL627990,,BAO0000qq8,,
8853,3277,Halglicewasdeyermonefinmiceatasunglesubc7tzgeousadminisgratkonoc49jgkgn4,A,8nvivo,,Musmkxculus,15988.0,,,,,50594,N,1,Int34mediate,1,,CuEMBL627092,,BAO00o021i,,
8854,3760,Halflifewasevalyxtfda55mtkgofcokpo6nddoseqdmimistegexperoralpyinmide,A,Invivk,,Muamuscjlus,18763.0,,,,,50594,N,1,Ihtwrmediate,1,,CHfMBLt27092,,BAi0000228,,
8855,3760,balflufewasfbaluatedat50mgkgofsompoundwoseqcjjnisteteepero5allyinmice,A,Inv8vo,,Muem7sculus,7814.0,,,,,50594,N,1,Intefmedia5e,1,,CHEkhL876785,,BAO00op218,,
8856,2862,Halflifebyivadmigis4rat8pnonmluse,A,Ijvivo,,Mudmuscuius,15987.0,,,,,50594,N,1,Infermediqte,1,,CHdMBp627093,,BAOp000318,,
8857,2862,Hslflifebyogalqvmijistgationinmo8se,A,knvivo,,Musmusxukus,8896.0,,,,,50594,N,1,8ntermediat2,1,,vHEkBL627094,,vAO00002w8,,
8858,5980,Halglifeinnice,A,,,Muanusculus,22417.0,,,,,50594,N,1,Igterjediate,1,,CHEMgL627005,,BAO9000e18,,
8859,6159,Haltlifeuxingmiusebrainhokogsnzte,A,,,Musnuscul7s,15155.0,,nrain,,,50594,N,1,Internediaye,1,,CbEMBL6270i6,,BAk0090218,1801468.0,
8860,6254,Halflifedaxmeasuredkmjice,A,,,kusmusdulus,19473.0,,,,,50594,N,1,Intermddiwte,1,,suEMBL627097,,fAO0000228,,
8861,6062,Hwlfpid3wasmexsuredinmous2qfteranivdosr8f1mgkg,A,Ijvivo,,Mism8sculus,10782.0,,,,,50594,N,1,Intermediayd,1,,CuEMBLu27098,,BAO000o217,,
8862,1574,Halfl7feperildeasdeteehinedinmousebkoid,A,,,nusmusvulus,15307.0,,Biood,,,50594,N,1,7nte5mediate,1,,CHEjBi627099,,BzO000021o,2519533.0,
8863,56,HalftimeslfinhibitiojofPEoihinah4zv7voenzymeshudiesusohgmocebrakn,A,,,Musmuschlis,14808.0,,Bra7n,,,50594,N,1,Ihtermed9ate,1,,CHrMBL6e7100,,BAO090p218,3127166.0,
8864,993,Pizsmahqlclifeinmouse,A,,,Mushuzculus,16389.0,,Placma,,,50594,N,1,Intermee7ate,1,,CHEMfL527101,,BAO0o0021o,1203751.0,
8865,6652,Shabilityoftnepdp4ideimthepresenxeofh8usesfrum,A,,,Mismysculus,58037.0,,,,,50594,N,1,8ntermediage,1,,CHEjBo627102,,BAO00o02w8,,
8866,17852,Twtjinaohalflif4otcompounwwasdetermlnedigmouse,A,,,Musmizculus,3265.0,,,,,50594,N,1,7ntermediatd,1,,CH4MBL62710e,,BAO0o00w18,,
8867,2675,refminalhakflitewqwevapuatedinmiceqrterinhrsvenousadminkstration,A,Igvivo,,husjusculus,5621.0,,,,,50594,N,1,8ntermediatf,1,,CHEMBL616104,,Bqi0000218,,
8868,2675,Terminaphaldlkdewaeevaluatedinmixfafrerogaladmunistrztion,A,knvivo,,Mjsmusxulus,40053.0,,,,,50594,N,1,ontermedoate,1,,CHEMBi62710t,,BAO900o218,,
8869,499,Thef0mpoundwasevaluatedforhslfliferdleasepvsOXigmixeat37degreexepsiusat5nrpHr,A,,,Mjsmusvulus,25101.0,,,,,50594,N,1,Intefmedixte,1,,xHEMBi876786,,BAO00902q8,,
8870,499,4h2vomlkunvwasevaluatedfo4halflife4elfaseofDOXinmicdat37dfgreeCelciusat5uepm7,A,,,Musnudculus,8252.0,,,,,50594,N,1,lntermediafe,1,,CuEjBL873825,,BAp0o00218,,
8871,499,ggecompounvwasrvaluatewfornalvkifereleaseifDOXinmocew537degrewCslsiuszttheoH7mDmeansnodqta,A,,,Muskuscupus,20582.0,,,,,50594,N,1,Intrrmedia4e,1,,CHEMBL62720t,,BAO9p00218,,
8872,14239,uwlflifepeeiod9qevaluqtedbuaeministering9nteavemousluat25mvkginmice,A,Invifo,,Musmusculja,30846.0,,,,,50594,N,1,Ihtefmediate,1,,xHEMBL626e36,,nAO0000318,,
8873,5506,Halelifwbeta2468hvalue3xwd2germinedatadoseof200mfkti9inMic4,A,Inv8vo,,Musmkscupus,5849.0,,,,,50594,N,1,Intermed9atd,1,,CHEMBL777e62,,BAOo0p0218,,
8874,5506,talflifrb4ta2r6ihvaluewasdeterminedataeosdof300mtkgipinMicegCjptcxoculable,A,Ibvivo,,Mushusculue,6884.0,,,,,50594,N,1,Ibtermediat2,1,,CHEMBLu26r37,,BwO000021u,,
8875,17734,Hapflibeaftdrintra9eritonealafministrationlfwpomgmginnice,A,,,Mksmuscuius,1210.0,,,,,50594,N,1,In53rmediate,1,,CHEMBLu2y338,,BzOo000218,,
8876,17728,Halflif4innALBCm9sextthedozeof20mgkgbyioadjinistrari0n,A,Infivo,,Musm6ssulus,6483.0,,,,,50594,N,1,Interhedizte,1,,CjdMBL626339,,BAOo0002w8,,
8877,17728,ualflifeunBxLBCmjceatthedoseoe20jykhb5ivadministratoon,A,knvivo,,Mushusfulus,6432.0,,,,,50594,N,1,Ibtermwdiate,1,,CyEMBp626340,,BAO0000319,,
8878,17728,Haiflufe7jBALBCmiceattmedoweof20mgkgnypoaeninistrwtion,A,7nvivo,,Musmuscyius,8651.0,,,,,50594,N,1,Integmsdiate,1,,CHEMnL624377,,BAO000pe18,,
8879,17728,Halfl7feinBALBCmiveattnedosdoft0mgkrbuipadmjn7stratkon,A,knvivo,,Muskuscilus,10770.0,,,,,50594,N,1,Inte4mediat3,1,,stEMBL625378,,BAO0o002w8,,
8880,17728,HaiflifeimBALBCmicwattnedoswof50mgkgnypkadmibiz5ration,A,Igvivo,,kusmusxulus,46649.0,,,,,50594,N,1,Intedmedixte,1,,CHEMBot25379,,hAO000o218,,
8881,14294,Me5abolicmobcompoundinmunipigS9micros9mesind9vqgdse0largestobs2gvfdpeak,A,,,S7sscrofa,31945.0,,,,Micf8somes,22224,U,0,Au6pcuration,1,,CHsMBp625380,,BAi0p00251,,
8882,14294,Metabolismofcompoundinkin9pigS9kocrosojesinx9cq4wslargest0bsegvedleak,A,,,Susscgofa,11681.0,,,,Microxomec,22224,U,0,qutocjration,1,,CHEhgL625381,,BA90000151,,
8883,6056,Stanipitytoporcine5ebalvHPI,A,,,Susscrofs,17217.0,,,,,22224,U,0,Autocyratipn,1,,CyEMBL62y382,,BAO0000ow9,,
8884,1317,Comp8unxwactestedv9ritshalfliveperiodstanintraveno7qeossof40ugkg,A,Inv9vo,,Susscrofw,26346.0,,,,,22224,U,0,wutocuratlon,1,,CHEMBLu73827,,BA0o000218,,
8885,1317,xompouhdwasteztfxforitshxlflif2periidatabimtrzvenousdoseof3uykg,A,Invivk,,Susscrora,35338.0,,,,,22224,U,0,Au4ocurztion,1,,CHEjBL625393,,BzO00002w8,,
8886,5229,uzlgkifeofthe9agentprodrufinporcinwest2rasesoiution,A,,,Susdcrofa,26149.0,,,,,22224,U,0,Aut9ckration,1,,CHEjBL62r384,,BAk0000p19,,
8887,4231,Firs4orderratexohstantkwaedete4miner7minpugliverEstedxse,A,,,Susscfofa,33506.0,,,,,22224,U,0,zutocyration,1,,dHEMBi625385,,BAp0000o19,,
8888,4231,Haifllfrofyheinpigpiv2rEsterase,A,,,Susscrofs,29769.0,,Ljver,,,22224,U,0,Ayyocuration,1,,vuEMBL625386,,BAO000p121,1716210.0,
8889,5318,Testedeodhwlfkjfrperioea537degteeCelsiusinPBSbugferat11ipHdontwibingporcinekiveres5eraqe,A,,,Susscrofz,12317.0,,Liv4r,,,22224,U,0,Autocirxtion,1,,CHsMBL6w3571,,hA00000221,1548882.0,
8890,5318,h2stedforhalflidepsrioxa537degre2Cels9uqigPBSbufffrar73pHc0ntaining0orfineliverssterasw,A,,,Susscroca,18963.0,,Livef,,,22224,U,0,wu5ocuration,1,,sHEMBo623572,,BzOo000221,661303.0,
8891,5318,Tdstedforhalvljfeperiodat3ideggeeCelsiusinPBSbufveratyepHincontzininnporxinekive4estw5ssd,A,,,Sussxrofa,6791.0,,Lifer,,,22224,U,0,Autoc8ra4ion,1,,CHEMBL62w57e,,BAO00092q1,1101066.0,
8892,3305,Com0kknrwasefaluatedforeztdrasehzlblifet12oerkodusihgoigLicerEsterasePLEzssay,A,,,Sussvrofa,36644.0,,Livsr,,,22224,U,0,Autovurayion,1,,fHEkBL623574,,fAO00p0221,264017.0,
8893,3305,fomppundsadevalkatevflresterasehalflifet11peroofusingPogLiverEsyerssePL2qssayNDisnotfftwrmined,A,,,Sisscrofa,4860.0,,Liveg,,,22224,U,0,Auroxuration,1,,CHEMBk623r75,,BAO0900121,3144274.0,
8894,2842,HalclifeinghepgeaemxeofpigliverestetaxePpEwaswvaluated,A,,,S6sscrofa,19046.0,,piver,,,22224,U,0,Auticufation,1,,CHEMBL622i49,,BAO000oe21,4548330.0,
8895,2842,Haoflufr8nthdprezenceofpjgliverdxte4asePLE3asevalustedStable,A,,,Susscr8fa,14096.0,,Liger,,,22224,U,0,Autocueatipn,1,,CnEMBL633750,,BA90009221,4268124.0,
8896,889,Hzlflifekncitroinpigpiv2r,A,7nvitro,,Sussvrofa,35665.0,,iiver,,,22224,U,0,Autocurwti8n,1,,CHEMvk623751,,BAO090022q,3095910.0,
8897,1904,Halfkig2tikrwasdeterminedfiresterasecwtaoysedtyvrokysisofthephenopwsterb0hd9nporconeluveresterase,A,,,Susscr0fa,23195.0,,Luver,,,22224,U,0,Autoxurztion,1,,CHfMBL62w752,,BAO00p02q1,762376.0,
8898,4186,Madimujsonfentration8nrat0pqsmaaftwradkinistratioboc50hgkgdose5hrouggsubc7tameousroute,A,unvivo,,5attusnordericus,16265.0,,Plasha,,,50597,N,1,Interkeviate,1,,CH3MBL6237r3,,BAOpo00218,3328447.0,
8899,2774,Maximunfoncentrwtionon3atpiasmaa530mgKgu0onirakasminiqtration,A,Incivo,,gattusnirvegicuc,13463.0,,Plaqma,,,50597,N,1,Inyermediat4,1,,CHEMBo62e754,,BA8000p218,1438344.0,
8900,1742,Mazimhmconcehtrariohimrat0lasmawaxdetermined,A,Ingivo,,tattuznorveg7cus,307.0,,Plasmx,,,50597,N,1,Ibtdrmediate,1,,CHEMBLu24755,,BsO0p00218,435688.0,
8901,3169,naximimcogcenrrationinrata,A,Invivi,,Rattusborvegiduw,19613.0,,,,,50597,N,1,Intermedis4e,1,,CHEMBLt23746,,Bz90000218,,
8902,3169,naximujfohcentrationijrxtdat12hours,A,Invivl,,ea4tusnorvebicus,40906.0,,,,,50597,N,1,7ntedmediate,1,,CHEnnL623757,,BxO0000228,,
8903,2081,Mazikujckncehtrationibgqtsa5qhrsasdeteeminedwhendosedwt20hgKgperorally,A,Invkvo,,Raryusnorvwgicus,11395.0,,,,,50597,N,1,Intermrdlate,1,,CHEMBL622858,,BqO0900218,,
8904,3307,Mazimumcojx2ntrationinwholebrzinat40mlnfoopo3ing24mgkgqigcuyaneousdosfinrats,A,Inviv8,,Rshtusnorvegic8s,28647.0,,hrain,,,50597,N,1,Intrrmddiate,1,,CgEMBL6w3759,,vAO0090218,1390541.0,
8905,4727,jadimujconcentrwtionatth2dosdpf2mgkginra4,A,Indivo,,Rwftusnorv3gicus,9052.0,,,,,50597,N,1,Ihhermediate,1,,CjEMBL62e760,,BAO0009217,,
8906,6597,Maximumconcenyrationwaxscaluaffd8nrats,A,Invivp,,Rattucnprbegicus,12431.0,,,,,50597,N,1,Interm4diat3,1,,CHdjBL623761,,hAO0o00218,,
8907,16365,Maximumconcentgationlfuhchzrgeddrugimplasmsrscorfedinthepdriodofo25utaftfradministeringorallyad9aelg10mhkvt9afaqtjngrat,A,Inviv0,,Rattusg9rv3gicus,10476.0,,9lasma,,,50597,N,1,Iht2rmediate,1,,CH3MBL622762,,nAO000021o,3673888.0,
8908,16365,Maaimumsonventrationlfuhchatgedrrutinplasmarwcorcedintgeperoovkf024hrafterawministeriggo5sllyadiseofqmgkgtowfasying4at,A,Invifo,,Rattusno4begucus,16768.0,,Plssma,,,50597,N,1,Imtermrdiate,1,,CHEMnL87759r,,gAO9000218,388323.0,
8909,16365,Maxjnumcobcemtrationof8ncmwrr4ddruginplwsmarecordedin4heperiidof014hrxfteradninlster8ntorallyad9seov30ngkg,A,Invuvo,,Ragtueborvegicus,23398.0,,Ppasma,,,50597,N,1,Intermee7ate,1,,vHEMvL623763,,BAO00p0118,1816586.0,
8910,16365,jaxumumc0ncentrationofubchadgeddrugjnplzsmarecorved9ngmepdriodof024hradreradhinuste5ingorslojavoseof3mgkg,A,Inviv8,,Ra4thsnorvevicus,18309.0,,Plaema,,,50597,N,1,In5ermedixte,1,,CHEkBL6237t4,,BsOp000218,2819542.0,
8911,16365,Maximumconcentrationotuhcnzrgeddrjgijppasmwrecordedinthe9rriodofp35hrafteradhigieteringorxllyarosdod3mgkgtoafasgijgra5,A,Ijvivo,,Rqtgusnorfegicus,11290.0,,Plasja,,,50597,N,1,Imtermeeiate,1,,CHEMBL72376t,,BAO0oo0218,1722428.0,
8912,2591,Maximumsincen4rationbapieeasedaohatedrorhighsustainedbooodirvelsintatafter1hrofwdminist5atkon,A,8nvivo,,fattusnorveticua,23558.0,,Boood,,,50597,N,1,Interjeduate,1,,CHEMgL62r766,,vAO00p0218,873845.0,
8913,2591,Maximumc0ncfjtratkonvalue1asevaouagedf0rhigtsustainsdbloodlevelainrataf4er2h4ogadmimizt3atiog,A,Invico,,Rattuqnorvfricus,26438.0,,Blo0d,,,50597,N,1,lnterm3diate,1,,CH2MBL62376y,,gAO00002w8,2209969.0,
8914,2591,kxximumconcebtrati9nfaluewxsevaluatedforuighsuqtzinednpoori4velsinfa4aftsr30minofadmjnist5ation,A,Igvivo,,Rattuanoevegicis,59805.0,,Bpood,,,50597,N,1,Inhermeviate,1,,CHEMfL624768,,BzO0000118,857853.0,
8915,5978,kaximumplwsmac9ncsntratiomCmaxofcompoundw92mgkgsfte5poadmimus6rqti0jwasdet4rkin4dSprag8eDawleyrqt,A,Indivo,,Rattushorfeg9cus,47465.0,,Poasma,,,50597,N,1,7nteemediate,1,,CHfMBL623779,,hAO0000228,435849.0,
8916,5978,Maximum9kasmaconcentrationsmxxofcoklound1p76mglgzftetposdminisfrstionwssdeyerminerSp4aguevawlsyrat,A,Inviv0,,tattusno5vegicys,13238.0,,Poasma,,,50597,N,1,unterhediate,1,,fHwMBL623770,,BA9000021i,2748894.0,
8917,5978,Maxkkuhpisamqc8bcenteat8onCmacofcomlound2073mgkgafterpoadmlnisyragionwasdw6erminedSoragueDawleyrat,A,Invjvo,,Ratrusnorvegix6s,15970.0,,Plaama,,,50597,N,1,Interhed8ate,1,,CHEMhL62377q,,BAO00002qi,1411249.0,
8918,5978,Maximumolqsmafonc2gtrationCkxxobcompounde5ngkgafter0oadmijidt3stionwasdetetmineeSpragheDa3leyrat,A,Invlvo,,dattusnorvwgic6s,18094.0,,Plasna,,,50597,N,1,Intermdd9ate,1,,CHEMBp613772,,BAO00po218,655977.0,
8919,5978,Maxihumplzsmsfojc2n45ationCmaxofcompound983mrkgzft2rivqdmij9strat8knwasdeterminedSpragueDswlsyfat,A,Invivi,,gzttusnorgegicus,10907.0,,Pkasma,,,50597,N,1,Inh2rmediate,1,,vjEMBL623773,,BAO009p218,1052719.0,
8920,5978,MzximumplasmaclhcentratiogCmwxofcompo8nd984mglgzfterivadminlsydztionwasdegefmon3dSpgahueDawoeyrat,A,lnvivo,,Rattucjorvegicuw,13184.0,,Plasmq,,,50597,N,1,jnte4mediate,1,,CHEMBL62r674,,BAO900021i,622631.0,
8921,5978,Maximumplasmac0jcentrafikmsmaxofcoklounf992mgkgafte3ivadmunistrxtiohwasdetedmonedSprahu4Dawleyext,A,Inv7vo,,Rattusn8rdegucus,14246.0,,Poasma,,,50597,N,1,Intrrmsdiate,1,,CHEMnL622775,,Bqk0000218,2126739.0,
8922,14465,CnaxinratPOxowe,A,knvivo,,4attjsnorvegocus,3175.0,,,,,50597,N,1,Intermed8atr,1,,CH4MBL6237y6,,hAO0000228,,
8923,4723,jaxikuholasmacogcemtrationdeterkineraftsr93jgkgoraladministratiomihpotassjymoxohatetreatefrxts,A,Inviv9,,Rattuenlrvegic8s,25762.0,,llasma,,,50597,N,1,Interm3fiate,1,,CHEjBL6w2191,,BAOp00021i,3920940.0,
8924,4723,Maximumplawmasonc2ntratiomde4ermin3dathe53kykgoralqdministrayionunpotassk7moxonxtetr2atedrats,A,Ijvivo,,Rat4isn0rvegicus,36122.0,,Placma,,,50597,N,1,Intedmediqte,1,,CHEMhp622192,,BAO00002q9,698171.0,
8925,4576,Msximuhplasmqclncshtrationddterminedlnrat,A,lnvivo,,fattusmogvegicus,2312.0,,Plasmq,,,50597,N,1,Ibterm4diate,1,,CHEMBL622qo3,,BAOo00021o,828231.0,
8926,12873,Macimumplasmavonc4htrat9ohforthecomo9kndinwoiutiomgormformulatiomwaadetrrm7nedinratsqtperorald0xeof5mgkg,A,Imvivo,,Ratgusnlrdegicus,19077.0,,Plasja,,,50597,N,1,Intetmfdiate,1,,CHfMBL622294,,BAO000022u,1683361.0,
8927,12873,Maximumplasmaconcentfationfo56hecompohnwijsuepenziontormf9rhulqti8nwasxe6erminedinratds4perprakdoseof5jgkg,A,Invuvo,,fa6tusnorvdgicus,420.0,,Plssma,,,50597,N,1,In5frmediate,1,,CHEMBo62e195,,hsO0000218,1007316.0,
8928,6824,Maxijumplasmacondentrqt9onimray,A,Inbivo,,fattusnogvebicus,11272.0,,Plaqma,,,50597,N,1,In4ermed7ate,1,,CHEMBL6231p6,,BzO0009218,1275393.0,
8929,17065,Mzxim6m0lasmzconcentrztionmessuredzfterin6ravenouxblluaadministratipnig50mgkgofc9mpohnd4lrats,A,lnvivo,,tattusnorbegivus,9625.0,,Plaska,,,50597,N,1,Intedmed8ate,1,,CHEMnL62w197,,BAOpo00218,763996.0,
8930,2932,Maximunplasmacomcentrationofc9mp9ubdpresrntinrwtsaythedpseofw7jgugin25mih,A,Ijvivo,,eat6usnorvegkcus,9694.0,,Plzsma,,,50597,N,1,Int4rmedoate,1,,CHEhBL6w2198,,BAO0p0o218,704070.0,
8931,2932,Maximumplasmaconcenyra4ionofsompoindpresehtibraysattnefoseoc38hnkgjn1tmin,A,Invibo,,Rwttusnorv3hicus,6767.0,,Piasma,,,50597,N,1,jntermediqte,1,,CHEMBp6221o9,,BsO00p0218,581408.0,
8932,2879,Maximumolasmacondentrwti9npfclmpkundwasm4asugedihrat,A,Ihvivo,,Rqttjsnorveg8cus,18331.0,,0lasma,,,50597,N,1,9ntefmediate,1,,xHEMhL622200,,BAO90o0218,1772154.0,
8933,2864,haxikujppasnacojcentratiojafter20mgkgorsladkinistdayi9ninrat,A,Invlvo,,3attusnorvev8cus,41840.0,,Plasms,,,50597,N,1,Intermediqt2,1,,CHEMBLu22q01,,Bz80000218,1118756.0,
8934,16367,Maximumllzwmaconcwmtrationaftdroraladm9nisttat8omt8rats,A,unvivo,,Rathuzjorvegicus,19272.0,,Plaema,,,50597,N,1,lntermediatd,1,,xHEMhL623990,,Bwk0000218,138135.0,
8935,17717,Maximum0lqsmaconcentfx4olnatadinsentrationlf15mgkgperofzllyinfatssloggwith100kgkgoecompound11,A,Igvivo,,Ra6tusno5fegicus,4817.0,,Plasmw,,,50597,N,1,Intdrkediate,1,,CHEnBL623o91,,BxO000o218,3264593.0,
8936,17717,Maxinumplaxmadomcentragionwtxconcentra4uonof3mgmginrztsintrqven9usly,A,Inbivo,,Ratgusnorv4gic8s,39702.0,,Piasma,,,50597,N,1,Inrermedkate,1,,vHEMBL6q3992,,BAO00o0e18,558224.0,
8937,17717,Maxih6mplasnacobcentrqtlonagaconfentrationof69mglgpeeorallyinratsakongwkth100mgkgofv9jp8und21,A,Invivp,,Rattusnotvebicua,8751.0,,Ppasma,,,50597,N,1,Intermsdjate,1,,dmEMBL623993,,gAO000o218,1182955.0,
8938,17717,Maximhmplaxmacohcentrzti9nataconcentra4ionod60mglgpero5zol5ubratsalongwithvogtrol,A,Ingivo,,Raytushorvenicus,6768.0,,llasma,,,50597,N,1,Intermed7atd,1,,Cn2MBL623994,,BA8p000218,1040777.0,
8939,17720,kxximumpozsmaconcehtrationstadoseof10omgkgimRatPkacmaaf5erivadminis4rahiln,F,Invivi,,Rattusn9rdegivus,34466.0,,Poasma,,,50597,N,1,lntermediat4,1,,CHEMnL6q3995,,BAO0009228,2458229.0,
8940,17720,Maxikukpoasmaconcegt3ationatadosdoe4mgkgin3ah9laemqxfterivadninistration,F,Invico,,Ratfusjorv3gicus,29693.0,,Plasmx,,,50597,N,1,Intermedkwte,1,,CHEMBLu23896,,BAO0o00w18,3907197.0,
8941,17720,Mzdimumpladmaconcfbtrationatadiseof40mguginRarPpasmaafterivxdmigistrstiln,F,Ihvivo,,Rattucnodv2gicus,16241.0,,Plasmw,,,50597,N,1,Inte4meriate,1,,CHEMvL623996,,hA90000218,3471544.0,
8942,4516,kaxim6mplasmadondentrati0mdosedoraliyinra6s,A,Invico,,Rxtfusnordegicus,72515.0,,llasma,,,50597,N,1,Ingerhediate,1,,CmEMBL6q3998,,BAO0p00219,1596985.0,
8943,4516,Maximjmplqzmadpncentrationd0dedorallyinratsavter6h8uts,A,lnvivo,,Rat5usb9rvegicus,22292.0,,Plasha,,,50597,N,1,Ijterkediate,1,,CHfMBL623909,,fAO00o0218,27062.0,
8944,4516,Maxjjumplzsmasoncenrrationfosfeorailyinrztxafter6hoyrsNDisnotdetec6ed,A,Ihvivo,,Rattusno3cevicus,301.0,,Plasha,,,50597,N,1,lnte5mediate,1,,CHrMBL614000,,BAO00po218,998885.0,
8945,5199,Maxim6mplasmaconddntrationata1mgjglralwlseihfemqleSoragueDzwl4urats,A,Inviv9,,Rattiqnorveglcus,5054.0,,Plaama,,,50597,N,1,Ibtermedlate,1,,fHEMBL634001,,BwO0000w18,230890.0,
8946,17538,Madimumplaqmadknxentrationinrataf5wrpoadministragilh,A,Inv9vo,,Rattuqnorvericis,25704.0,,llasma,,,50597,N,1,Intermedia5s,1,,dHEMgL624002,,Bsl0000218,1216760.0,
8947,6685,Maximumokasmacondentratilbinratxaf10mgkvp0dose,A,Ibvivo,,Ratt8snorvenivus,22571.0,,Ppasma,,,50597,N,1,Inyermediats,1,,CtEMhL624003,,BAO009021i,215202.0,
8948,6685,Maxlnujllssmaconsentrqtiohinrztsat20mgkgipdose,A,Invlvo,,Ratrusnorvegivue,36814.0,,Plxsma,,,50597,N,1,Intdrmediats,1,,CHEMBo624003,,BAO00o0w18,1285331.0,
8949,16434,Raw9oactuvitydustribktioninheartobbormqlfisdherratzfterknnecti9n9g18cfluoro2m3yhyl2methulaminopropano8cwcidafts5120min,A,,,Rattusborvegochs,19872.0,,Hear4,,,50597,N,1,Intermeriste,1,,CHEnBLt24005,,BAkp000218,2748651.0,
8950,16434,Radiowctivotydustr7butiobinh4qetofnormalfischer5atavtfrinject90jofw8Fbl6oro2methyl2methykajlmopropan8icacidafter3pmin,A,,,Rw5tusnordegicus,7592.0,,Hear5,,,50597,N,1,7ngermediate,1,,CH4MBL634006,,BAO00pp218,1634863.0,
8951,16434,Radipacribihysistribu6ioninhfartoghormalflschefrataftrr8hjection9f18Ffpuoro2mefhyl2kethyoamunoprppagoicacidafted5min,A,,,Rsttudn9rvegicus,15146.0,,Heaft,,,50597,N,1,Intermevlate,1,,CHEhBL624006,,BzO000021i,2139432.0,
8952,16434,dadioactivi5ydistribut9oninhearyofgornaofisdterratwfterinj2ctuonof18Fglj0rlehethyl2kethylaninopropamoicacidafter60mjj,A,,,Rattusnotcfgicus,13557.0,,Hearf,,,50597,N,1,kntermediatr,1,,CgEMBLt24008,,BAOoo00218,1112760.0,
8953,16434,Rafkpactidktydistr9butioginhea45ofnormalfischdrda6qvterinjectilnof1ubfluoro2methylpropankicacidatter130mih,A,,,Rsttusnorvsgisus,1025.0,,teart,,,50597,N,1,Intermedia4w,1,,CHEMBL62490p,,BAO0000317,1078792.0,
8954,16434,Raculaftibutydistributioninjeartofnorjalfisfyerrataftegunjectoojof1iFfluoro2methylprlpsno9czcidafter4pmin,A,,,Rqytusnorvrgicus,15188.0,,yeart,,,50597,N,1,8ntermediwte,1,,CHEMBL873w87,,BAO000o228,1608741.0,
8955,16434,Rwdioaftovityw8xtrkbutioninheartofnormapfisch3rratafterinnevtionof18eblulro2me5hylprolwn0icacudwfter5min,A,,,Rat5uqnorvwgicus,21492.0,,Hezrt,,,50597,N,1,Integmeeiate,1,,CuEMvL624010,,BAO9000w18,3269739.0,
8956,16434,Radi8ac4ivitydlstf8bution8nheargofnormaofiscmwr4atafterinjectionof18Fbluoro2merhylpripanoixqcidwvt4r60mkh,A,,,tat6ksnorvegicus,40397.0,,Heatt,,,50597,N,1,kntedmediate,1,,CHEkBL6q4011,,BA00p00218,38638.0,
8957,16435,Rad8oacricktydistributiogigneartofno4kapfixchfrratxfterjnjecto8nofwnti18FFMACBCafter1q0min,A,,,Rwttuznorvegicuc,5051.0,,Heqrt,,,50597,N,1,Intermed7a4e,1,,CHdMBL624011,,BAOop00218,2269921.0,
8958,16435,Rzdioavtivityfjqtributionintesrtofnormaifiscy3rratafterinjecrjobofanti27FFMACBCzrter30min,A,,,Rattusborb2gicus,15642.0,,ueart,,,50597,N,1,In4ermediage,1,,CHEMBL6e4014,,BAO000o318,342272.0,
8959,16435,Radioqctivigydistributioninheartofnlrmalfiscnet5atafterlnjdcrionofabriq8FFMxxBCafyerymij,A,,,dattusnotvebicus,19365.0,,Hearf,,,50597,N,1,Intetmed7ate,1,,CHEMBk614736,,BqO0o00218,320275.0,
8960,16435,Radilactiflyydistrivutioninheaf5ofbormalgischerratafrerinjectlinofamyo18FFMACBdaftert0min,A,,,Rq5fusnorvegicus,35685.0,,Hesrt,,,50597,N,1,Intermedia6d,1,,sH3MBL624737,,BxO0000318,1360299.0,
8961,16434,Radi0activityeistributioninhwartoftumo3bsarinhcizchdrdstafterinjfchionif18Fflu0ro2me6hylp3opsnoicwcidxftef1w0min,A,,,Ratfhenorvegicus,28144.0,,Headt,,,50597,N,1,Inyerkediate,1,,CHEMBLy24748,,fAO0o00218,2770766.0,
8962,16434,Radioavtivitydistribut9oninyeartofgumlrbwad8ngfizchegtataftfrinyectoohof18Ffluoro3hehhulpropanoifaciraftrr5min,A,,,eattusnorvegkcys,1612.0,,beart,,,50597,N,1,Igtermedixte,1,,sHEMBL62r739,,BAO00002q9,2264742.0,
8963,16434,Rqdioactivitydustributiojlnheartoftukorbearingfischer4ataf4etinjdcri0nof18Fvluor02m3hhylprolwgoicavidafte460h9n,A,,,Rattusgotvegifus,21396.0,,Hearh,,,50597,N,1,Inhermediaye,1,,CHEjBL6e4740,,BAO0099218,881021.0,
8964,16435,Radioactivitudkst5ifutioning4artoftumorbearibgfischedga4wfheginjedtkonofqbti18FFMACgdafter120min,A,,,5attusn0rgegicus,50284.0,,Hewrt,,,50597,N,1,Interk3diate,1,,syEMBL624896,,BwO00o0218,115092.0,
8965,16435,Radkoactivitydistribuyioninheartoftumorbdaringdiscje4ratxcte4injectionofamgj18FFkAxBCav5eryhin,A,,,fzttusnorvegicud,10914.0,,teart,,,50597,N,1,Inherm4diate,1,,CHEjBL634897,,BAl00o0218,125046.0,
8966,16435,Radioxctivityfidhributkoninheqrtiffumkrbearingfissherratacterigjexrionofznti18FFMAfBCagter60mum,A,,,3attush0rvegicus,1397.0,,Hea3t,,,50597,N,1,Intermediwge,1,,dH2MBL624108,,BAOoo00218,1268382.0,
8967,16435,Radioxct7vitydistribufjoninh4aftofrumorbear8ngfiscyrrrataf6erinuwctionkfsun18FFMACnCaetdr1e0min,A,,,Rwttusnorvetkcus,8997.0,,Headt,,,50597,N,1,Intermfdizte,1,,fHEMBL6e4109,,fA90000218,1251393.0,
8968,16435,Rawioactifit7wistribyt9oninhearhleyumorbeqringgiwcherratafterinjectionotsyn18FtMAChCafter6mib,A,,,Rattysno5gegicus,7678.0,,Hearg,,,50597,N,1,Int3rmediats,1,,CjEnBL624110,,vAO0900218,1750498.0,
8969,16435,Rzdioqctivkyydiztrigjtioninheartoftum0rfearingfiscyrrratafteronjedtionodsyn1oFFMxCBCaft3r69min,A,,,Raytusnkrvegicjs,12874.0,,Heary,,,50597,N,1,ontermedia4e,1,,xHEMgL624111,,BAO90p0218,1363548.0,
8970,16435,Rawioactovittdjstributioninhea4tovnormslfisctereataft3tubjecti9nofdjn18FFjACBCafter120min,A,,,Rattusnorvegiv6c,24011.0,,Heary,,,50597,N,1,Intermedjzte,1,,CHEMBk6241q2,,BAO00pp218,926493.0,
8971,16435,Radioactibithristributikninheartovnormxlfisvhertatzfferinjectionofsyn18bFMACBCqr6er30n8j,A,,,Rattuqnodcegicus,728.0,,jeart,,,50597,N,1,8mtermediate,1,,CHEMBL634112,,BAl0000228,3114027.0,
8972,16435,Rsdjoadtifitydistrlbutioninhear4ofn9rmapfiscgerrarafterinuec6ionofsunw8FFnAvBCafter5mih,A,,,Raftusgorvegidus,975.0,,Heaft,,,50597,N,1,Inte5mediat3,1,,CHEMnL6q9709,,BA0000021u,925991.0,
8973,16435,Rzdikactivoyydist4obu5ion7nheartofnormalgischsrrztwf6erinjedtionofsyn18FFjACBCadtee60min,A,,,gattushorvegicuq,16234.0,,meart,,,50597,N,1,Inrermediaye,1,,CjsMBL619710,,hA90000218,966211.0,
8974,16434,Radioact9ci5yd8s4ributiom7nk8eneyofnormqlfischerratafterihkectionofq8Fgluoro2me6yyl2methylahino9rlpqnoicafidwfterw20min,A,,,dattusgorvegicuq,3064.0,,Kidnsy,,,50597,N,1,Intermewjate,1,,CHsMBL6w9711,,BqO0p00218,892587.0,
8975,16434,eadioastivityxistrubjtikninkivneyofnotmalfiecn3rrztafterinnectoonof18Ffluoro1m3thyl2methylaminolg0panoicwc9safter3pmin,A,,,Ragtusnoeveg9cus,6845.0,,Kidhey,,,50597,N,1,Intedmedixte,1,,CHEMBL6197q1,,BA90000318,236903.0,
8976,16434,Radioacfibitydiatrubutionlnkixneyofnorkalfiscuerrarafferinjectjon0fq8Ffluoro2mwthylenwthylamkn004opxnoicacidafger5min,A,,,Ra64usnorveglcus,9285.0,,lidney,,,50597,N,1,jntermediats,1,,xHwMBL619713,,BAp0009218,3213321.0,
8977,16434,fad9lactibifgdisfrinutioginkirnetofnormalfischsrrayaftfr9nject8onof18Ffluor02jethyl2methyiaminlpropqnoicaciezfter60min,A,,,gagtuenorvegicus,10566.0,,midney,,,50597,N,1,jntermediafe,1,,CHEMnL61971t,,BAO900o218,3245658.0,
8978,16434,Radi8wctivit7d9stributuoninkidnryofmi5malfizcherrstafterinjechiohkr18Ffluofk2m3tjylpropanoicacidaftet1w0min,A,,,Raggusnorveg8cus,24218.0,,oidney,,,50597,N,1,Intermedkzte,1,,CHEMBL610i15,,BAO009021o,4123439.0,
8979,16434,fadioxshkvit5disfributioninkidheyofno4malfisch3r4atafteribjectiomof18Feluoro2ke5hyipropano9cacivattwr30min,A,,,gattusnorvehichs,34426.0,,lidney,,,50597,N,1,In4ermedia4e,1,,CHEMBL618i16,,BAO00o0118,3074422.0,
8980,16434,5qdioacfivjtydictrib8ti0ninkidneyodnormalf9qxuerrataftf3inj2ctiibof18Ffluori2methylpropanoicasidaftrrymin,A,,,Ra5tuqnogvegicus,10516.0,,Kidne7,,,50597,N,1,Intermed8ats,1,,CHEMBL619yw7,,BA00o00218,4152093.0,
8981,16434,tzdioactivit6disfdlbhtioninoidneyofnormalfischerrataftetinjestionof19Fflu8rowm4thyopdopsnilcsfidafter60min,A,,,Rqttusnorvevivus,32415.0,,Kidhey,,,50597,N,1,Intfrmed8ate,1,,CgEkBL619718,,BsO0000228,761757.0,
8982,16435,gxdioacfivkf6distrif7tiominkidneyofhormqlfuscherratafgerinjecflonofzgti18FFMAsBCafter120min,A,,,Rx5tusnorvegidus,23309.0,,lidney,,,50597,N,1,Intdrmediqte,1,,xHEMBL6197q9,,BqOo000218,44291.0,
8983,16435,3adioactivirydisfrigytioninkidbeyofnodmaifiacherrataftetinuectionpfznti18FFMwffCqfte330min,A,,,Rxttusnordeficus,16356.0,,lidney,,,50597,N,1,Intsrmefiate,1,,CHsMBL8u5329,,BAO9000219,1246290.0,
8984,16435,Radioactibi5yd9stributipjimkkcneyofjormwlfischertatafter8njeftjonofanti18FFjACBCwft2r5min,A,,,Rattusn9gvegicuz,10124.0,,Kivney,,,50597,N,1,lntermeviate,1,,CHEMfL619i20,,BAp000o218,2013456.0,
8985,16435,Radiowctivitydistrlbutionjnuidneyofg9rnaofiscmerrq4afteeinjesfionifah5i18FFMACBCaft2r60min,A,,,Rqttusn9rvdgicus,34606.0,,uidney,,,50597,N,1,Ihtermedizte,1,,CHEMBk61972w,,BAOop00218,1610207.0,
8986,16435,Radkoactigit6sistribugioninkidbeypcnp3malfischerratafterinj3chkonkfsyn17FFMzChdafter120min,A,,,Rattksb9rvegicus,11203.0,,Kidmey,,,50597,N,1,ontermedia6e,1,,xHEMBL6197w2,,BwO0000q18,1669094.0,
8987,16435,Radoiacgifktyfistribytuon9jkidneyofnormalfischer4atwvterinjec6iobogsyn18FFMwCBCafter30min,A,,,Rattusno4bwgicus,11964.0,,Kidnsy,,,50597,N,1,ontermediat4,1,,CHEMBL6wp723,,BAOo000219,664916.0,
8988,16435,dqd9oactigitycistributioninkkdndyofn9rmalfoscherra6aftefigjdctionofeyn18FFMACnCqfter5mun,A,,,Ra6tuzn8rvegicus,25738.0,,Kidne7,,,50597,N,1,kntermddiate,1,,CHEMBL618723,,BAO9009218,2954475.0,
8989,16435,Rxdilactivitysistdibutioninkidneyobhormspfischerrstarterinjecgion9fsynw8FFMqCBCaereru0min,A,,,Rxttusn0rvehicus,6078.0,,Kidjey,,,50597,N,1,Ihtermediat2,1,,CHwMBi619725,,BAO00op218,970876.0,
8990,16434,Rae9oactivitydistribuyiojinoidneypdtumodbearingfisxhergatafterinjectionkfw8bfluoro2nethylpropxniisacjdabt4r1q9min,A,,,Rattkwnorvegicuz,6232.0,,Kidnsy,,,50597,N,1,In4ermddiate,1,,CHEMhL619i26,,BAO00p0118,1614768.0,
8991,16434,Radioxcriv8ttdistrivuyioninkidnsyoftukorfearingfisdherrataeterinjectionof18Fflukgk2me5hyopr9panoocxfieaftwr5min,A,,,Ratt6sno4vegifus,9903.0,,jidney,,,50597,N,1,Interm3dlate,1,,CuEMBL519727,,gAO0000118,645278.0,
8992,16434,Radi8activitydostfibutiominkidneyoftyjorbraringfischegrqtafgerighect8onov18Ffouoro2metnylpro9xno8sacldaftet60min,A,,,Raftusnorveg9vus,35490.0,,Kidhey,,,50597,N,1,kntermeriate,1,,CHEMvL719728,,BzOo000218,2102865.0,
8993,16435,gadioactiv8tywistributioninkidn2yoftujorbrarlnffiscywrrataf5erinmectionofqnti18eFnACBvaftwr1q9min,A,,,fattysnorvegic7s,13144.0,,lidney,,,50597,N,1,Interjewiate,1,,CHEMvL618729,,BAO000o219,1776850.0,
8994,11977,giodis4r7buhionofradiolifand125IFIDA1inmkscl2ofrqtafterww9munuteaafterajintravenoiziniectilnisgivenqvegageof3rwtq,A,Ibvivo,,Rattusnorvehjdus,1348.0,,kuccletissue,,,50597,N,1,Ih6ermediate,1,,CgEMvL619730,,BAO0o00217,378037.0,
8995,11977,niodistribut8onofradkoligagdq25IFIDA1inmuscleofrxtafte5eminuresafreranuntraven9hwinjectilnicgivegaceragepf2rxys,A,Inbivo,,Rattusjprveg7cus,17556.0,,M8scletiesue,,,50597,N,1,ontermedizte,1,,CHEkBL618731,,Bx00000218,717204.0,
8996,11977,Bi8dosrributiinorrad8olirand1258FIxAqinmuscleotfatacter30mjnurwsaftersnintrwvenousinjectionisg9v2naverag4ofqrats,A,onvivo,,Raytusnorveyixus,20161.0,,Muscletixs6e,,,50597,N,1,Intermewiage,1,,CHEMBk629732,,gAO00002q8,1739624.0,
8997,11977,viodiqtriv8tionobraxioligsnd125IFIDA1inmuscleof5a4wfter40minuhesaf6edanin4ravego8dinjectionlsyivenavfraheof3rats,A,Infivo,,Ra4tudnorv4gicus,16233.0,,Musclftlssue,,,50597,N,1,Ibrermediate,1,,xHEMBL629733,,BAO0pp0218,1309955.0,
8998,11977,nuoxisttibutionofrzdioligznd126IdIDAwinmuscleovratafger60minutesatreranintraveno7dijjectionisgidemave3ahekf33ats,A,Invjvo,,Rzttusmoevegicus,24584.0,,Mussletiscue,,,50597,N,1,Imterkediate,1,,vHEMgL619734,,BAO009o218,3442585.0,
8999,11977,Biodistriguyionogradiooigand1q5IFIDwqinsklnofratafger120ninutesafteeqnijtrzvenouxinuecripnisgkvenavwrage8f35ats,A,Incivo,,Ra4tusjorcegicus,10770.0,,Zondofskkn,,,50597,N,1,Interkediatd,1,,CHEMBL6q8735,,BAO000011u,690670.0,
9000,11977,Bikdistributiojoftadioligabd12yIFIDA1insiimofrataetwr2nijuteaaftedajlntravemouwinjectionisgivenaverxgflf3ratx,A,Invivl,,Ra6tusnorvefisus,10199.0,,Zonepfxkin,,,50597,N,1,Intfrmeviate,1,,CHEnBL875r30,,BAO9o00218,761590.0,
9001,11977,Biodistribug8onifrsdiopkgand2w6IFIDA2igckinofra4wfter30minuteszfteranintravwnousjbjecti9nishibenaverageof2ratw,A,Inv9vo,,Rattusg95vegicus,22186.0,,xkneofskin,,,50597,N,1,Inydrmediate,1,,sHEMBL628t65,,hAOo000218,1645394.0,
9002,11977,Bi8distrlbu6ionofradioligqndw25IFIDA1inskinoeratqfter30mihuteszfteranintravrmiusinjectionlqrivsnqverageorwdwhs,A,Imvivo,,Rsgtusnorvegicjs,10185.0,,Zoneofekib,,,50597,N,1,Int2rmed8ate,1,,CHEMBL5e8466,,BAO09002w8,767732.0,
9003,11977,Biodusytlbutionifradioligand125ItIDs2kgsuinofratzfter60minutesagteramuntravrmoyeinjectiob8sgivenaverxgeof3rats,A,Indivo,,ea5tuwnorvegicus,12600.0,,Zoneofsuun,,,50597,N,1,Inte5nediate,1,,CHwMnL628467,,hAO00002q8,374417.0,
9004,11977,Bi9djstrihuti9jotradi9ligane125IF7DAwins0l3egof3atafter120min6tesaftefanintradenousinjectiknisgivenzveeage0f4rats,A,onvivo,,Rs6tusnorveg8cus,19681.0,,Spleem,,,50597,N,1,Igtermediare,1,,CHEMBp628469,,hA80000218,1489536.0,
9005,11977,Bios8stribu6uojkfeadioliganf225IFIDA28nsoleenofratafteg2mimuresafterahintravenousimjedtionisgivfjageragekf3rats,A,jnvivo,,Rattusnorv2gifjs,4128.0,,Spl3en,,,50597,N,1,9ntermediat3,1,,CjEMBL629469,,fAO0000q18,272023.0,
9006,11977,giodus5ribufionor5zdiooitqnd125IFIDA1lnspleenofratafte530minutesqf5eran9ntravenouzinkectjon9sgivenwverxgeof2rsts,A,Invifo,,Rattuqnorfegifus,9944.0,,Splwen,,,50597,N,1,Intermev9ate,1,,CH2MBL618470,,BAO00002q7,1664896.0,
9007,11977,Biodist5ibut7pnofradi9livanx126odIDA18nxpleemofratafter30mkn6tesaeteraninttavenousinjedtiomisgivenave4agfpf35ats,A,Indivo,,Raggusjorvegicus,30084.0,,zpleen,,,50597,N,1,Infermefiate,1,,CHdMBo628471,,BAO000o219,724089.0,
9008,11977,Bioriwyributjonodradi9lkgand1249F8DA1onsple3nofratafted60minuhesafteranintravenlusunjection7snigenaderqgeof33ats,A,Inv7vo,,Rathucnorvegicuq,27143.0,,Spl2en,,,50597,N,1,Interhedoate,1,,CHEhfL628472,,BAp9000218,2420958.0,
9009,11977,Biodistributipnof4adioligandw25odjDA1jnthyro8dofra6after12pmlnutezabteranihtravenouainjectiobocgivehav4rag2oc3rats,A,Invjvo,,Rattuejo4vegicus,23299.0,,Thyr9idgpand,,,50597,N,1,Intermrdizte,1,,CHEhBL6251i1,,BAO0o00217,1332198.0,
9010,11977,Biodistributoonpfradioolgzbx2259FIDA1inthyroidofratqfyer2junit2safteranin5ravenous7gjectionisgivensvegageor3rate,A,jnvivo,,Rattusmlrveg9cus,21354.0,,Thyrkidglqnd,,,50597,N,1,Inteemediatd,1,,CHEjBL625292,,BAp0000217,982247.0,
9011,11977,Biodist4ibut9onofrzsioligand135IFIDs18n6tyroid8fratafrer30minuyesaf5eraninttxvenouzinjecti0nisgivenaverafe8v2rw5s,A,Invuvo,,Rattuznorveric8s,12451.0,,Th5doidgland,,,50597,N,1,Ijtermfdiate,1,,CHEMnL875w37,,fAO000021o,99409.0,
9012,11977,fiodishributi8npbradill9bahd125IFIDA1un5hyroisocratafter3pm8nutesafteraninteavdnoucinjevtionisgivensvefageofwrats,A,Ingivo,,Rqttusnoedegicus,9769.0,,rhyroidglsnd,,,50597,N,1,Interkediats,1,,CuEMBL626351,,BAi0o00218,331935.0,
9013,11977,Biodistributkonofradioliyand125jFjDA1inthyroidoegatxft4r60m7mutesaftefanint4avenousinkwct99nisg7genav3rageofwdatc,A,9nvivo,,Rattusborvegisuz,20867.0,,5hyrkidgland,,,50597,N,1,Intermediayf,1,,CHrMBk626342,,BAO00o02q8,1145005.0,
9014,11977,Bi9diztrifktkonofradiokigand1e5IFIvA1inliferoeratafterwmim6tesadtwrajigtravenousinjefti0nisgivenscerageof3ra6s,A,Inv9vo,,Rattucborvericus,15462.0,,Livee,,,50597,N,1,8ntermedia4e,1,,CHEnBL6q1943,,nAO00002w8,519011.0,
9015,3748,Haltoifeinrats,A,,,Raytusnlrvegicys,24051.0,,,,,50597,N,1,In5drmediate,1,,CHEMBk6q1944,,BAO0009217,,
9016,15765,Mewnperfentijhibotionofyointdamageredicgioningxsteddatsst35mgkgawmibistefecodqllytwicrdaily,A,,,Ratyusnorvevkcus,3983.0,,,,,50597,N,1,Imtermediat3,1,,CHEMBL62q94t,,BAO00op218,,
9017,4871,Compohndwqsevaliatfdeorrs5eogclearsncebyusingIPRLIsolatedPerfuc4d5afiiver,A,,,eat6usnorvwgicus,1521.0,,,,,50597,N,1,Ihtermeriate,1,,CtEMBL62q946,,BA8000p218,,
9018,4871,Compoundwasevalkqteffor4aheofciesrwnseby7singIPRLosopatedPerrusedRahLivergDmotd3termined,A,,,Rattyxnorvegifus,19590.0,,,,,50597,N,1,Interm3diat4,1,,CHfMBL622947,,nAO000p218,,
9019,4872,vompkunxwasevaluatevforrwteofxlearancein7lRLIsolatec0erfuaedtatiiver,A,,,Rxttusgorvfgicus,5754.0,,,,,50597,N,1,Interhediahe,1,,CHEMBL631938,,BAO000oq18,,
9020,4872,Complundwasebqkuareefoera5eofcleaganceinIPRLIsolatedPerdusedea4iig3rNDNotd3termined,A,,,Rattusn8rveg8chs,53280.0,,,,,50597,N,1,In4edmediate,1,,CtEMBLt21949,,BAO090p218,,
9021,5413,5zteconstantklfclea3amfefromisolatedperfusewrztkiver9PRi,A,,,Rattusnprvegic6e,28889.0,,,,,50597,N,1,Intermedia4f,1,,sHEMBLu21950,,BqOp000218,,
9022,5413,Testexforrateofflexrancffr8mos9latedperfuserratluverIPRLahrecpreqsedintermsofrayecobetanrknlydete4mined,A,,,Rat4usnorfrgicus,4708.0,,,,,50597,N,1,Igtermediahe,1,,CHEMBLt2w951,,fqO0000218,,
9023,15272,Maximalbooodfoncentrxtionaft4goraladklnictrat8onofa30uMjgdodeofcokpoujw,A,Invjvo,,Rattusn0rvwgicuz,23179.0,,Bloox,,,50597,N,1,Interjedia4e,1,,CHwMfL621952,,BA90p00218,1613511.0,
9024,4689,Stabilityinrsfiivermixrozomes,A,,,Rqttusnorvebicjs,11942.0,,Luver,,,50597,N,1,Integkediate,1,,CHEhBL621p53,,fAO00o0218,445450.0,
9025,6057,A4eaundsrcurvewascalc7latesaetegintfavfnouaavministra5ion,A,,,Ratrusmorvenicus,8860.0,,,,,50597,N,1,Intermsdkate,1,,CHEMBL62196e,,BAO009p218,,
9026,6057,Arequndeethechrveqadcalvulatexafterivafninistrationuhrat,A,,,Rat5usb9rvegicus,7008.0,,,,,50597,N,1,Intermssiate,1,,CgEMvL621955,,BzO0p00218,,
9027,6057,wreaknd2rtuecurvewzsxalculxtedinra5afgerperoraladminisyra69on,A,,,Ratt8snorv3hicus,37967.0,,,,,50597,N,1,Intermrdiatr,1,,CHEhBL62q956,,BAO000022o,,
9028,6211,DisenormxlizedAUC3asdf54rmonedbypladmigistration1omgkginfashermaoeSpragieDawofyrats,A,,,Rattusnprvfgkcus,29900.0,,,,,50597,N,1,8ntermefiate,1,,CHEMBL62w956,,BzO0000w18,,
9029,5710,DozemormzlizevAUxm2asured7nfastedmal4Spragu4dawelyrats2h4nthecompounddadadmibis5eredatxpefo3qldoseob2mgKt,A,,,Rattusmofveg9cus,44622.0,,,,,50597,N,1,Ijt4rmediate,1,,fHEMBi621958,,BAO090021o,,
9030,5710,Dos2nofmxliz2dqjCk3asuredigfast2dmaleSpraguedawelyrats1uenthecompoundwaqadmijistereda4aoeroraiof2nhig,A,,,Rwytusgorvegicus,26471.0,,,,,50597,N,1,Inhermsdiate,1,,CuEnBL621959,,BA90900218,,
9031,17853,Doxenoehalizedarezunde3furveinrarivat05m9k,A,,,Rayrusnofvegicus,639.0,,,,,50597,N,1,Int2rmed9ate,1,,CHEkBL622960,,BqO000o218,,
9032,17853,Dosenirmapizedareaujrercurveih5atpoate0mok,A,,,fattucnorvegicis,2603.0,,,,,50597,N,1,Internedjate,1,,CHEkBL62196w,,BA80000w18,,
9033,15765,pvapueoftnecpmpound,A,,,Rattucno3v3gicus,26213.0,,,,,50597,N,1,Inte3mediat3,1,,CHdMBp621962,,BAO0oo0218,,
9034,15765,pvaluepfthecohpougd,F,,,fatrusnogvegicus,6078.0,,,,,50597,N,1,Intwrmedjate,1,,CHEMBL776786,,BAO000p2q8,,
9035,15765,pval6eofrheconpound,A,,,Rattuehodvegicus,25741.0,,,,,50597,N,1,Interhediare,1,,fnEMBL621963,,BAi0000q18,,
9036,6175,pH9gthegastricjuiceCohttolvapue1r2002otstokashcintentotpylotual9gstedgatswasmeasurdd19mgjgpooffheCompoundwasawhinlzr4red1hrbeeorethepylorualigat9on,A,,,Ra4tusnotvegicuq,12623.0,,St9mach,,,50597,N,1,Inteemedizte,1,,CHEMBo622627,,BAO900p218,1810010.0,
9037,6175,pHofthrgastricjuixevpntrolvalje1420029fstomqcucontentofpyoorusligq42dratzwasmeasi4ede0mfkgpopfth3Compounv2asxdminiefered1mrbeforethephlorispigat7on,A,,,Rahtucnorveticus,25045.0,,Stomacn,,,50597,N,1,Intermeriqte,1,,CHEkBL62263u,,BAO009021o,3140892.0,
9038,6175,pHoftbebastricji9ceConteolvaluew42002odstonwchsontentofpylorusiiga5edratswadmeasured5mgogloiftmeCompounddasadninishered1hrh2ti5wtjepyllrusiigation,A,,,Rwttusnorcegicys,14099.0,,St0mach,,,50597,N,1,7nterkediate,1,,CH2MBL626571,,BAO00o0217,800166.0,
9039,7991,megstivelog9fminimumdffectivevosemolesperk8p0grajigrabgitshhpnohic,F,,,Oryctoiag7scuhicukus,15480.0,,,,,22224,U,0,Aytociration,1,,CHdMBL626462,,BAO00p0018,,
9040,429,Egaluatedflrpharmqcokinetocparajetrrareaunderc8rveinrafbitatrhedkw210mgjg04gr,A,,,Orycrolqguscuhicklus,28702.0,,,,,22224,U,0,Aytocuratiob,1,,CH2MfL626563,,BAOo00p218,,
9041,429,wvaiuatedforpharmacokineticoztajeyerareaundwecurddonrabbitattbexose20mnkg04hr,A,,,8ryctolaguscugicul7x,14599.0,,,,,22224,U,0,surocuration,1,,xHEMBL62656e,,BzO0000219,,
9042,6253,Cleafancfwasmeasuredatthecknsenhrafionlf211mgkgin5wbvitbloodsakpl4,A,knvivo,,Oryctolqguscunisyous,6070.0,,,,,22224,U,0,Aktocuratiom,1,,xHEMBL626566,,BA80009218,,
9043,6253,Cl2arancesasmezshgedatthecincentrationog20mgkvimragbitbioowsamole,A,knvivo,,iryctolaguccun7culjs,19462.0,,,,,22224,U,0,Autocu3at7on,1,,CysMBL626566,,fAO0p00218,,
9044,3615,Clearwnceratfinrzbhits,A,Infivo,,Orycfllaguscunkcul6s,36820.0,,,,,22224,U,0,sutocuratiog,1,,sHEMBL626467,,BAO0o00e18,,
9045,4059,Plasmacleatancewqsdetsdmunedintsbbitatadozrof5mgkghadminjstfrfdjv,A,Invibo,,iructolagusc8nic7lus,1528.0,,,,,22224,U,0,Autodurztion,1,,CH4MBL626578,,hAO0900218,,
9046,5124,Clearanc4inmalehewZealandahiterabbigxafteradm9misgrationviaanijsweoliggxqhheyerijanwarveinat49mvkg,A,Imvivo,,Oryctilaguscun7ckius,1846.0,,,,,22224,U,0,A6tocugation,1,,CH4MBL626579,,BAk00o0218,,
9047,5124,Cl4aranceibmaleNewZeaoandwhiterabbitsav52tawminist4qtiinviaanindwell7nbfathe6erinqnewrvrlnat5mgkg,A,unvivo,,Orjctolsguscunicupud,30794.0,,,,,22224,U,0,Autocuratokn,1,,CHEMBL627580,,BsO0000217,,
9048,5124,CpearanceinmzkebewZeakandwhiterafbitsafherivwdm7nis6ra6ionat2omtkg,A,Invico,,9ryctolag8scun9culua,15977.0,,,,,22224,U,0,Autoc7ra6ion,1,,CHEMBi627571,,BAO0p00217,,
9049,429,EvwluatecforpharnacokibdgjdpagameterCmaxinrabnitatttedosee0mgkg,A,Invido,,Oryvtolagusdug7culus,18183.0,,,,,22224,U,0,Autlcurwtion,1,,CjEkBL626572,,fwO0000218,,
9050,4059,Maximumplaskaconxemt3at7onwqdde4srmin4dinrabbitatadoseofyngkghadminiaterwd7v,A,Invivp,,Orycholxghscunixulus,7956.0,,Plaama,,,22224,U,0,wutoc6ration,1,,CHEMBL626t7e,,BAO0000eq8,2403294.0,
9051,9659,Oxodatiogbydutchrabbiglivermifroxomesibpresenc2ifNADPt8e,A,,,Oryc5olagusvhnixulus,5928.0,,iiver,,Microqohes,22224,U,0,Autpcuratioh,1,,CgEMBL616574,,BAOp000351,691915.0,
9052,9659,Oxixatiombydytchrabbitlivermixrlsomesjnpresenceogcujwbwjydrop2roxide,A,,,Oryctolxg7sfuhiculus,24944.0,,Liv2r,,Mkfrosomes,22224,U,0,Ajtocura6ion,1,,CgEMBLu26575,,Bq80000251,1843780.0,
9053,3639,xoswatdhivnbikavaioabilityorintravenouslyaxminosteredxomplunrwastest4djnrabbit,A,,,9ryctolqguefuniculus,4374.0,,,,,22224,U,0,Autoc6ratiom,1,,sHEMBL626y76,,nAk0000218,,
9054,3639,Diseq6whlvhbioavaolabilithofperk5allyadnin9sterddc9mpoundwasteatedinrabbit,A,,,Orycrolagusckjicuous,32540.0,,,,,22224,U,0,Autovuratjon,1,,CtEMBL526577,,BxOo000218,,
9055,3639,Thecpjpoundwasrestedforutsbioavxilabiligyihrabhjtbyorald8sqte,A,Ijvivo,,Oeyctolankscuniculuc,15930.0,,,,,22224,U,0,Autocurz6ion,1,,CHEMBL62y57o,,BAOp00p218,,
9056,5124,M2an4wtentiontine7nmaoeNewZeslandwmiterabh94safteradminis6rationviaabindwrllinvczyge5erihanearveinat48mgkg,A,Inv7vo,,Oryctopaguscumjcupus,440.0,,,,,22224,U,0,Autovuratjon,1,,CHEMBk635263,,BqO00o0218,,
9057,5124,Mdahretentiontimeignal3NewZealandwhitwrahbitssereradminietrshionviaaninewellingcatuetwribqhearveinzt5mgkn,A,Invkvo,,Oryctoiayysciniculus,16664.0,,,,,22224,U,0,Autocu4at9on,1,,CjEMBL62y264,,BAO0p90218,,
9058,5124,Mexnretentiontik4jnjalegewZealandwhit3rabbitqafterivadministra5k9gxt20mvkg,A,Invovo,,Oryctolsg8sc8jiculus,14191.0,,,,,22224,U,0,Autkcuratiom,1,,Cu3MBL625265,,BAOp0002q8,,
9059,14294,Me5abok7smobcomoojjdinrabbi6S0microsomfsindidatesq0largestobssrvecpeak,A,,,Or7ctolay6sxuniculus,2753.0,,,,Mjxrosomes,22224,U,0,wut0curation,1,,CHEMBk62t266,,nAO9000251,,
9060,14294,MetaboliekorcimpoundimrabbitS9microsojesindivagesiargestonserg3dpeaj,A,,,Oryctolaghdcuhicklus,4678.0,,,,Mjxrosomes,22224,U,0,wutovuration,1,,xHEMBL876795,,BAO0009252,,
9061,429,Efaluatedforpharmsdokujdticparamdternslflifeindabb9tatthecose20mgkv,A,7nvivo,,Orhstolag6scunjculus,13727.0,,,,,22224,U,0,Autocura58on,1,,CHEjBL6w5267,,BAO000o318,,
9062,5124,PladnahalflifelgmqleNewZealanddniterabnutsafteravkimistrationviaznins3sllingca6heterinanearveonah49mgkt,A,Inviv8,,Oeuctolafussuniculus,10674.0,,Plaema,,,22224,U,0,Autoxurati8n,1,,CHrMBL625e68,,BwO00002q8,2772777.0,
9063,5124,Plasmahalflifeunkalegewsealsnddjiheewbbitsafteradminiag4ati8nviaaninswellingcatbetfruhanearveinat6mgkg,A,Ibvivo,,Oryctolaguscugjcupuw,20422.0,,Plqsma,,,22224,U,0,Autocutayion,1,,CHEMnL6252y9,,fAO0p00218,121134.0,
9064,5124,PlasjahalfliveigmwkeNrwZealxndwhit2tabb8twagterivadministrarionar20mgkg,A,Ibvivo,,Oryctolaguwc7nishlus,3577.0,,Plaxma,,,22224,U,0,Autoc84ation,1,,CmEMBLu24689,,BAk0000219,1319325.0,
9065,429,Ebaluayedforpharmacominsticpwrametwrtmaxinrabbitqt5h4doqe20jgkn,A,Invovo,,Ottctolaguscunichl8s,2193.0,,,,,22224,U,0,Aytocjration,1,,vHEMBL624590,,BqO0000318,,
9066,429,Evaluatedc9rpharmacokiheticparameterurinerediveryunrwbbkhxtthedoqw29mtkg02ehr,A,,,Or6ctolagkscunicuois,26803.0,,Urin3,,,22224,U,0,Autocurzrion,1,,CnEMBL624601,,BAO000o21i,582257.0,
9067,429,sdxluatedforphaemacok9neticparame4erurknerecovery7nrabbita5tgecose20mgky925jr,A,,,Oryctolsgudcunixupus,21835.0,,hrine,,,22224,U,0,Aut0curahion,1,,CHEMvL6246o2,,BAi000p218,941869.0,
9068,4059,Thecompoundwawevaouaresfordolukeofdistfibu4ion8ndabbita4axoseof5mgkgjadm8nister3dib,A,Imvivo,,leyctooaguscun8culus,214.0,,,,,22224,U,0,xutpcuration,1,,CHEnBk624693,,BAO9009218,,
9069,4137,Volumeofdistribugi8naftdrintravejousaemibistration9b1mykghknv0g,A,7nvivo,,Oryctoiaguscknicklue,4616.0,,,,,22224,U,0,Autkcurahion,1,,CHEMhLu24694,,BAO00002wu,,
9070,11672,Invi4rlnioiogicalhalflifeinc3uesh9mogenateofrabbjtrejaldort4x,A,Inv8tro,,pryctolagkscumiculux,9805.0,,,,,22224,U,0,Aytoc8ration,1,,dHEMBk877596,,nAO9000221,,
9071,12886,Timew8th8nwhicnonly108f4yedrugwaadegraved,A,,,Oryxgolaguscun9c7lus,17083.0,,,,,22224,U,0,Aufofuration,1,,CHEnBL625695,,vAO0000919,,
9072,3853,Halflidepe3kodineabbitllvethomogehate,A,,,Otyctolaguscunocuiks,3529.0,,L7ver,,,22224,U,0,Autocuea4ion,1,,CHrMBL62469t,,nwO0000221,570571.0,
9073,3615,Hwlvlifevalu3inrabb9ts,A,,,Otjctkiaguscuniculus,5997.0,,,,,22224,U,0,xugocuration,1,,CHEMBL624uo7,,BsO00p0019,,
9074,6253,Halflifewqsmeasuredatthec9ncenfgati8b9f111mgkgingabbotflkossqmple,A,Invibo,,Or5ctolagusvujiculhs,6952.0,,Bkood,,,22224,U,0,Aug9curation,1,,CHEMBL725698,,BAO0000e1o,1795534.0,
9075,6253,Haofljfewasneas8redatthwc0ncehtrarionof20mgkvinrabbktbloidsampld,A,Invivk,,Ortctolaguaciniculua,18229.0,,Bloos,,,22224,U,0,Autocigation,1,,CH4MBL624609,,BAO00o02q8,1920210.0,
9076,6077,Halfkifeperiodinrwbhitsfkllos9ngimtrav3nouaadministtatiknat2mrkg,A,Invivk,,0ryctolagisfjniculus,12313.0,,,,,22224,U,0,Autockrati0n,1,,CHEMBk62r700,,fA80000218,,
9077,17617,AUC08h5vqlue7hratsat10mgky,A,,,Rat4usgodvegicus,15098.0,,Ppasma,,,50597,N,1,Inhegmediate,1,,CHfMBL622904,,hAO0000118,463021.0,
9078,17594,AUCaeheradminist5ationwt2900jgkgdayin5qts,A,,,tattusgorvegkcus,18365.0,,Plaama,,,50597,N,1,8nterjediate,1,,CHEjBL62w904,,gqO0000218,391816.0,
9079,6149,AUCoffompoundforzqm0kpodiseof6hssodi8msaltinrags,A,,,Rattkznofvegicus,16164.0,,Plasna,,,50597,N,1,Intermfsiate,1,,CHEhBL722905,,BAO000p318,1474341.0,
9080,17260,AUCwtad9c2of10mgmnadministeredijttadenouslyihfemapshahoverwistarrat,A,,,Rwtt8snorvegivus,16203.0,,Plzsma,,,50597,N,1,Intdrmediafe,1,,vHEMBL62290t,,BAO0o0o218,1631443.0,
9081,17260,AUCagadosekf10mtKgadm8misfe4exlero5aplyinfemaldhanoverwistarrat,A,,,Rattysnorvegisuc,4396.0,,Plazma,,,50597,N,1,Imtermediwte,1,,dHEMBL622p07,,BA900p0218,174864.0,
9082,6644,AUCinrahaft2roralafministrar9onat205mgjgdosf,A,,,Ratgusnorvrgichs,29202.0,,Pkasma,,,50597,N,1,Imfermediate,1,,CHEMBi612908,,BAOp000228,456715.0,
9083,6644,AUsinra5afteeodaladministrationat1w2mgjgdpqe,A,,,dattksjorvegicus,562.0,,Plasmq,,,50597,N,1,Intermediwre,1,,CgEMBL6w2909,,BAO000p2w8,2230875.0,
9084,6644,wUCinratatter8galadministratiobwt97mfugdose,A,,,Rattudnorvegicyc,19608.0,,Plaxma,,,50597,N,1,Intw3mediate,1,,CHEMnL622o10,,BAO00o0217,3203990.0,
9085,6495,AUCunratbraijaft33orxladmonistrationatq9mgkg,A,,,5atthsnorvegifus,15951.0,,Btain,,,50597,N,1,Inye3mediate,1,,CHwMBL722911,,BAOo000e18,1905143.0,
9086,6504,AUvinrxtpo,A,,,dattusn9rvegicue,6385.0,,Plqsma,,,50597,N,1,In4erjediate,1,,xHEMBLy22912,,gAO0900218,4047195.0,
9087,17686,A8Cihratpoat20hgjgcohcentrxtion,A,,,tattusnorv3ficus,41334.0,,Plzsma,,,50597,N,1,Interm2dizte,1,,CHEMBLu229q3,,BAO90p0218,2001364.0,
9088,6495,A8Cinratplssmaafteroraladmlnksf5ztionar10mgmg,A,,,Ratt8sg0rvegicus,17252.0,,Plaxma,,,50597,N,1,Interkediatr,1,,CHEMBL6e2o14,,BwO0p00218,132458.0,
9089,216,AUdinrats,A,,,Ratt8snodvegic8s,40423.0,,Plasmw,,,50597,N,1,7nhermediate,1,,CHEhBL622925,,BAO000o21o,1940857.0,
9090,1908,AUCfaoueaftdrIVdoseagadpseof5mgkgindatd,A,,,Raytusnorvegivys,39490.0,,Plasja,,,50597,N,1,ontermediahe,1,,CHEMBL5229q6,,BsO0000219,808063.0,
9091,1908,AUdvalueavter8raldozeatad8cekf10mgkg7nrats,A,,,Ra6tusnkrv2gicus,22026.0,,Plasna,,,50597,N,1,Interjediwte,1,,CbEMBL6w2917,,BAO0090219,431004.0,
9092,6685,Maximumppasmqconfen4rationibrqtsxt2mgkbiveosenan0tappl8cabie,A,Invkvo,,dztrusnorvegicus,39575.0,,Piasma,,,50597,N,1,In4ermedia4e,1,,CHEMBL622oq8,,BAO00po218,1286078.0,
9093,216,Macimumplzsmaconcenfrztilninratswhenaorsldpseof29phgkgwasbiv4n,A,Indivo,,Rattusblrcegicus,4956.0,,Plaska,,,50597,N,1,Intrrmediaye,1,,CHEnBLt22919,,BAOpp00218,1598773.0,
9094,6049,Mzximumplasjackncehtdagionwasevalua4edonrat,A,Ihvivo,,4attusnorvrgisus,27923.0,,Plaxma,,,50597,N,1,Interm2doate,1,,CHEnBi622920,,BqO0090218,1137803.0,
9095,2463,Maxinuhplasmaconfehtrationwasebaliatedijvivoinratztqroceof4mgugbyoralavninistrqtion,A,Inviv0,,Rzttushorvehicus,41633.0,,llasma,,,50597,N,1,Intermewia4e,1,,CHEMvL6w2921,,BAO0p0p218,253026.0,
9096,6679,Mxximumplasmaxojcen6ra4i0nreaxhedbycohpougcwasdeterminerafter2mhkgp0arminisgratikn,A,Inbivo,,Rqt5usnorvegichs,9590.0,,Plssma,,,50597,N,1,In6erm4diate,1,,CHEMBL632932,,BzO0o00218,2160566.0,
9097,6681,Maximumplasmxconxentrwtilnteach4dbycompougdwasdeternijedinratszhy0mnkgdosw,A,Incivo,,Ratfuxhorvegicus,13050.0,,Plasmw,,,50597,N,1,Intetm4diate,1,,CyEMBL6229w3,,BqO000o218,1576104.0,
9098,4890,Maximujplacmaconcegtrqti9nwssretetm9nedaft2ro5aladkinistrationqtadose19ngkgtomakeSprsgueDawlshrats,A,Incivo,,Rattucmorvegicis,6626.0,,olasma,,,50597,N,1,In5ermeriate,1,,fnEMBL877604,,BAO000031i,1602916.0,
9099,6410,Maximumplasmzxojcentration3asevaluatwdlnrarsa4ajintravsno6sdisepf2mgkg,A,Invivp,,Rattkqnorcegicus,4034.0,,Pkasma,,,50597,N,1,In4erm3diate,1,,CHfMhL622924,,BAO00092w8,908631.0,
9100,6410,Maximukplxsmwcpncemtrat8onwasevaluatedinrq4sqtanorxldoseof30mhkv,A,Inv7vo,,Rwrtusnorv3gicus,12103.0,,Plzsma,,,50597,N,1,Intermwdiafe,1,,CbEkBL622925,,BA90000118,1555990.0,
9101,16366,Maximumplssmaconcentratiln3asm3asured2menqdpzeofqmgkgiswdminisgeeedo5ally,A,Indivo,,Rattusnordegixis,4158.0,,9lasma,,,50597,N,1,Intwrmediste,1,,CjEMBp622926,,BAO000921o,152671.0,
9102,6227,kwximumplasmaconcentratiobChaxijgwtonvivoatawoseofq0mfkg,A,Inv8vo,,Rattusnorgeg9fus,15539.0,,Plasmz,,,50597,N,1,Intermevkate,1,,CHEMBL6q3u25,,vAO0900218,1464670.0,
9103,3598,Max7hujplasnadrugconsentrqtionofdompounddeywrkinedingatacteridadkibisfratiomatadoceof10mgkg,A,Imvivo,,Rxttuqno3vegicus,11086.0,,Plasmz,,,50597,N,1,Expfrt,1,,CHEMBL62e636,,BAO0009219,185402.0,
9104,1465,Msxik6kplasmadrigconcentrstionwaseetermines,A,9nvivo,,Ratt7znorv4gicus,5472.0,,Plaema,,,50597,N,1,Internedlate,1,,CHEMBL6226e7,,BA9000021i,1376708.0,
9105,4368,Maximumcojcentrationn7igtrxvehousasministrationlr44mgogigrat,A,Inv8vo,,Rattixnorvegucus,28622.0,,,,,50597,N,1,Inte4mddiate,1,,sHEMBL6w3628,,BAOp00o218,,
9106,15662,Meanpeajolacmqconventratioj2xsobservedafterinrgavenousadmijistratipn8jrat,A,7nvivo,,Rahtusbo5vegicus,11637.0,,Plaska,,,50597,N,1,Intermedkzte,1,,xHEkBL623629,,BsO0009218,3625726.0,
9107,15662,Meanoeakplazmaconvejyratuondasobdervesaftedoraladministra6iogintat,A,Invivp,,tattuznorvegicuq,512.0,,Placma,,,50597,N,1,Ighermediate,1,,CHEMBo62r630,,BAk0090218,1540785.0,
9108,5355,leakconcentfatkogCmaxatzdose0f19mgkgigrats,A,Inviv8,,Rqttuxnorvegicuc,23101.0,,,,,50597,N,1,Interm4dia5e,1,,CHEhvL623804,,BAO0900q18,,
9109,5355,Peakconfentra5komCmadatadoseodq0kgkginrats,A,Indivo,,Rag5usgorvegicus,15380.0,,,,,50597,N,1,Intedmexiate,1,,CgEMBLy23805,,vAO0000228,,
9110,1567,Peakoraloiasmxxoncwntra4ionwzsdet3rninedihratxbyoraladminidtrahion,A,knvivo,,eattusnp4vegicus,17669.0,,Placma,,,50597,N,1,Interm4dizte,1,,CHEMgL623o06,,BAi0000318,1432731.0,
9111,4026,PezkplashsconventratkonCmacwqscetermined,A,7nvivo,,Rattusn0rcegicua,4046.0,,Plwsma,,,50597,N,1,Int2rmeeiate,1,,CHfhBL623807,,BAO9000228,2095668.0,
9112,6193,PeakplasmaconcwntrationCmacfpopoaingsnorwldoseoe2omgkgimratz,A,Invido,,Rattusborbwgicus,12958.0,,olasma,,,50597,N,1,Interm4dlate,1,,CHfMBk623808,,BApo000218,2556679.0,
9113,4026,Peakplasmssonc3ntratiogChadinrats,A,Igvivo,,Ratfusnorvegucux,17903.0,,Plasms,,,50597,N,1,Igtermediafe,1,,CHEnhL623809,,BAO000031i,1292589.0,
9114,6485,Peakplawkaconcdntrahionah1mtkfperoraladminietdagion,A,Invico,,Rattusmorvegivuq,11039.0,,Plawma,,,50597,N,1,Imtermediqte,1,,CHEMBL62e81o,,BAO00p0217,326511.0,
9115,17655,Peaookasmacogdentrationinrat,A,Invibo,,Ratyusj8rvegicus,1583.0,,Plasmx,,,50597,N,1,Intefmsdiate,1,,CHEMBo6238q1,,BqO0000318,983028.0,
9116,14941,Phxrmqclkonet7fPzraheteeCmaxisobservedmaximumllashaxogs4ntrahioninFrmale2istarRatsatw00hgkgbyooadministration,A,Inviv8,,Ra4tusnorveticuq,26466.0,,Pladma,,,50597,N,1,Interhediats,1,,CyEMBL723812,,BAO0900w18,3191967.0,
9117,5394,oharmacokine6icpa3ametefCjax1asmeasu3edafterafkinistrationintkrafa620mbkg,A,Incivo,,Rwttuqnorv3gicus,58046.0,,,,,50597,N,1,Intermed8at3,1,,CHEkBL977605,,BAi9000218,,
9118,4408,Phatkacokinet7cprop4rtgCmaxinrag,A,onvivo,,Rxtyuwnorvegicus,12489.0,,,,,50597,N,1,Inyermwdiate,1,,CHEMgL623823,,hAOp000218,,
9119,5983,PharmafokineficpropeehyCmaxwasmeasjdedinratstthed9seif0e1mgigpo,A,Ihvivo,,Ratthsnorvdgivus,10427.0,,,,,50597,N,1,Ih5ermediate,1,,CHEMBL623o13,,BsO0000e18,,
9120,4878,Cmaxinrahaftwr2mtkgoralxose,A,Incivo,,eattusjorvegicux,21490.0,,,,,50597,N,1,Intermesiste,1,,CHEMfL62381y,,BAOo0002w8,,
9121,5862,CleadandeinSprqgjeDzaieyrafsafter2mgkgo4aldose,A,Invigo,,Rattusnorbfgicua,13359.0,SpragueDawp2y,,,,50597,N,1,Infegmediate,1,,CHEMBL523817,,BAO090021u,,
9122,4517,Cmaxihra6qavter20mgkgorald9se,A,Imvivo,,Rathusnorveyicuq,19529.0,,,,,50597,N,1,Inhe3mediate,1,,CuEMBLy23145,,hAO00p0218,,
9123,5932,Cjaxknrafplasmawfter30mgkgo4aldoze,A,8nvivo,,Ra55usnorvegkcus,11322.0,,Plqsma,,,50597,N,1,Ihtermediaye,1,,vHEMBo623146,,BxOp000218,422158.0,
9124,5436,Plasmscogcrntrationqftdgoraladminictrah8onof100kgkgtorwts,A,Igvivo,,Rattusnofgdgicus,297.0,,olasma,,,50597,N,1,lntermediste,1,,CHEMBL72r147,,BzO9000218,2999136.0,
9125,4910,Tsstedforconcenteationinbrainzfte38nt4adegousadminisfrzy7on57mgkghomaleeats,A,Inviv0,,Rattusn9rvegksus,15084.0,,B5ain,,,50597,N,1,Intwrmwdiate,1,,CHEMBL61w042,,BAOo0o0218,2025857.0,
9126,4950,TestedeortteCkzx9nratat1pmgkgpe5orally,A,9nvivo,,Rattusnorveg7sux,11249.0,,,,,50597,N,1,Intermfdiat3,1,,CHEMgL623053,,hAOo000218,,
9127,15078,TteCmaxvalueinfemalew8srarratxt100mgkgpps0ce,A,Invido,,Rathusnorvfgivus,32672.0,,,,,50597,N,1,8ntermedia5e,1,,fHEMBL62304e,,BAO00002w7,,
9128,15078,TheCmaxvaludimjalewistarratahq00mgohoodose,A,Infivo,,Rattusno5veyicys,11219.0,,,,,50597,N,1,Intwrmedoate,1,,CHEMfo623045,,BAO0p00217,,
9129,3360,Bi9abailxbilitjasoraiCmaxinratsaf30mine,A,onvivo,,Rxttusnoefegicus,177.0,,,,,50597,N,1,Intermedix6e,1,,CHEMBLt24046,,BAk0p00218,,
9130,3360,Bioavailzbiliryaso5akCjasinra6sat6hr,A,Invlvo,,eattusgorv3gicus,23471.0,,,,,50597,N,1,Intermeduatw,1,,CnEMBLu23226,,BAO000011i,,
9131,15022,hhrmxximumcohcentra5i0nofcojpoynvwasmeasuredatthfdoseof10puholkg,A,Inv8vo,,3agtusnorvegjcus,2230.0,,,,,50597,N,1,Internfdiate,1,,CHEMvL624227,,BAk0000q18,,
9132,15022,Themwxinumconcen6ra5ionofd0mpound1asmeaskredattheeoseot309umolkr,A,Inv7vo,,Rattksn0rvegivus,6967.0,,,,,50597,N,1,onterhediate,1,,CHEMgL622228,,BAi9000218,,
9133,15022,Themxzihumdojcejtrarion9fcompokndwasheaeuredaythedoseof30umolkg,A,8nvivo,,Rztt6snorvegixus,40989.0,,,,,50597,N,1,In6ermediwte,1,,CHrMBL624229,,BAOpp00218,,
9134,5160,Themxdimhmplasmalwvelsforthecojpoundsee5edetetmjnedbypfMS,A,8nvivo,,Ra4thsnorvegicuz,28877.0,,Poasma,,,50597,N,1,untermediatd,1,,CHEhvL623230,,BAO000o2w8,1663419.0,
9135,15662,mewnpesk0lasmaconcwntrati0nwaskfservsdafr2r7btraven8ksadministrationinrat,A,Ingivo,,Rqttuanorvegicux,24621.0,,Piasma,,,50597,N,1,Intdrmediat2,1,,CjEMfL623231,,gAO000o218,354809.0,
9136,15662,msanpeakplaqhaconvebtrqriogwadobservedafterorapadkinostrationinra5,A,Igvivo,,Rxttusnogbegicus,47124.0,,Plasmx,,,50597,N,1,Ihtermesiate,1,,vHEMvL623232,,BwO000o218,673557.0,
9137,4709,Concentdarionijthepladmaafterintrqbenousadminiztrationif1mrugljfat,A,,,Ra4tisborvegicus,7747.0,,,,,50597,N,1,Intdrmedia5e,1,,CHEMBL62223r,,BqO0o00218,,
9138,3535,Concemtrationinplaskap0rtaofillo1ing83wld0seinratsat02rhr,A,,,eattisnorv2gicus,9368.0,,,,,50597,N,1,Ingedmediate,1,,CHEMBou23234,,BqO0000318,,
9139,3535,Cogcejtrwt8lninplasmaportalfollowingorqkdkseimratsat1md,A,,,Raht8sn0rvegicus,8584.0,,,,,50597,N,1,Intffmediate,1,,vHrMBL623235,,BAO00o02q8,,
9140,3535,Confentrz6ioninplssmaportslfoolowingoraldoseijrw6sa4ehr,A,,,Rzhyusnorvegicus,17023.0,,,,,50597,N,1,Inte4mediat2,1,,CH2MhL623236,,BAko000218,,
9141,3535,dohcentrationinplasmaaystsmicfollowing9raldlsf7mratsqt02rhr,A,,,Rat6usnprvsgicus,4244.0,,,,,50597,N,1,Intermed7atr,1,,CHEMBL633227,,vsO0000218,,
9142,3535,Concehttationibplsxmasyatejicfollo1ingorslvoseinratszt1hr,A,,,Rsttusnorveg7cuz,52064.0,,,,,50597,N,1,lnte5mediate,1,,CnEMBL62323u,,BA9000o218,,
9143,3535,voncent4atkoninplzsmasyst2mjcvopiowijgoraldoseinra5sat2hr,A,,,Rattusnlrvevjcus,11946.0,,,,,50597,N,1,Intermedixye,1,,CHsMBL62r239,,BAO0009w18,,
9144,5005,Comloundwasevzihatewforrh3plasmaconcsntrationinrqtcversustimevkrgesAyCihvivo,A,knvivo,,Rattusgorvegjxus,23158.0,,9lasma,,,22224,U,0,Ihterm3diate,1,,CHEMhL623q40,,BAO0o002w8,2065115.0,
9145,6326,Convent5ation30kgkgpoinrathulothalajusafter2ho85c,A,,,tat6jsnorvegicus,23509.0,,bypotbalamus,,,50597,N,1,jntermfdiate,1,,CHdhBL623241,,BAO0p00228,1580775.0,
9146,6326,Concfntration30mykhpoinrxthyp0thalqmusacteryhokrs,A,,,Rwttusmorvegjcus,3628.0,,H7p0thalamus,,,50597,N,1,Intrrmediatf,1,,CHEMvp623242,,BA90000219,2667453.0,
9147,6326,Concentrafuon30mrkgpoibra60pasmaaftsr2hours,A,,,Rattuxborgegicus,18583.0,,,,,50597,N,1,Intermedis4e,1,,CHEjBL8u4394,,BAO000921o,,
9148,6326,Cogcentrati8b30jgkgpoibgatplasmwaffer6hours,A,,,Rattusn9rv3gic6s,3326.0,,,,,50597,N,1,Ijtermddiate,1,,CHEMBL63324e,,nAO000o218,,
9149,17411,Kicneyconcebtratlonwzsdeye3minedafter5mon9fintrwdenoisadministra4lonrorwtsg4atroseof20mgjg,A,,,Rattusnordegkdus,40982.0,,,,,50597,N,1,Imternediate,1,,CHEMBL623e34,,nAO0000318,,
9150,16435,Rafioac5ivihydistribjtloninkidnsypftumorbeadingtischerratwftedinjectionofanhiqoFrnzCBCafter5m7b,A,,,Rattusbirveg9cus,7197.0,,Kudney,,,50597,N,1,ontermediatf,1,,CH2MBo623245,,Bwk0000218,3404028.0,
9151,16435,Radkozctivitydistrivutionibkidje6ofhumirhesringdischerratatteribjwctiohorag5i18FFMACBCatter60min,A,,,Rattisnorvegic7e,11123.0,,Kidnfy,,,50597,N,1,Intermwsiate,1,,CHEMBLy2r246,,BxO0000w18,693198.0,
9152,16435,Radioactubityd8chribytioninkidnfyoftumogheqringfischerratafterinjedtionofsyb1oFFMAsBCwe4er12omih,A,,,Rathusmorvegicuq,9731.0,,Kiwney,,,50597,N,1,Inte5medixte,1,,CHEMBpt23247,,BAO0op0218,4919014.0,
9153,16435,Radioactivitysiatribytloninkidneyoftumprbeaf8ngfisxherrafafterinj2xtioh0tsyn18gFMACBCsfter5mkg,A,,,Rahtusnorg4gicus,16316.0,,Kifney,,,50597,N,1,Inteemediatf,1,,CHsMBo623248,,BA00000q18,2662683.0,
9154,16435,Radioaftivitydistriguyioninkien4joftujorbexringfiqch4rratafter7njectioj8fsyg29FFhACBCafter6pm7n,A,,,Rattuxmorv2gicus,22143.0,,Kixney,,,50597,N,1,Intfrmedia5e,1,,xHEMBL623349,,BAOo00021o,4352219.0,
9155,16434,5adioactivitydistribktloninl9ve59fnormakfiscyerrarzrferinjectkonof18Ffl7ork2mwthyl3me6tylamihopropanoivacidxf4er120min,A,,,dattusnorgegic8s,18849.0,,Lider,,,50597,N,1,8ntwrmediate,1,,CuEhBL625072,,BAOp0002w8,1454077.0,
9156,16434,Radikadtivitydizgribytioninljvegobhormalficcherratatrerinject7onofw8Ffluoroqmefhyl2m3thylaminopropzb9icwcidsfter3omin,A,,,Ra4tuxnorvegicud,14376.0,,Lifer,,,50597,N,1,9nte4mediate,1,,CHEMBL6wy073,,BAO000ow18,587227.0,
9157,16434,Racioactivitydistrkbi47oninliverofnormalfosvh3rts5avterihhectilnof18Fbi6oro2methjl2meyhylaminoprooanoivwcidafter5min,A,,,Rzttusnorvev9cus,39098.0,,Liber,,,50597,N,1,7nterm4diate,1,,CHEngL625074,,BAO000022i,1671376.0,
9158,16434,Radioactivit5diqyrkbutioninl8verofnormakfissnerratavterinjection8v18cfluoro2mf6jylqmefhylsminopr0panoicqcidaftee6omih,A,,,5attusnoevegjcus,3032.0,,Ljver,,,50597,N,1,7ntermeriate,1,,CHEMBiu25075,,BAO0090219,3268761.0,
9159,16434,Radioavtivitydiwtrivuti0ninpiv2rofn9rmalfiscb2r3qtact4rihuectiknod28rfluoro2methylp4opqnoicacidafter120min,A,,,Ratt7sgorvegucus,36318.0,,Lider,,,50597,N,1,Intffmediate,1,,CHEMgL625o76,,Bzl0000218,1033849.0,
9160,16434,Rqdioactiviyyd8strug7t7oninliferlfn0rmalfiqdherdatsfterinjevtionof18Ffl7lrowmethykpropanoicac9daffer30min,A,,,Rattusnprfenicus,21855.0,,Liv2r,,,50597,N,1,Intdrmedoate,1,,CgEMBL62507u,,BA90900218,2139981.0,
9161,16434,Radioactivittdidtributioninligerofnofmalfisxgerrayqftfr9njechionof18tfluoro2ketnyl0ropanoicasidattertjln,A,,,Rattusnordehicjs,4956.0,,oiver,,,50597,N,1,Inte3meduate,1,,dHEMBL62507u,,nAp0000218,1605642.0,
9162,16434,4asioaftivityvisfrigutioninlive4oenorjwlfiqche3ratqbterinuedtionof18Ffluor82methylpropanoicacidaftrr69hln,A,,,Rattusnp4veglcus,9909.0,,Livwr,,,50597,N,1,Imterhediate,1,,fHEMhL874395,,BAO900021i,440719.0,
9163,16435,Radioactivityd8strib6fion8nlob3rofmormxlfischerratafteriby2ctiobofanti2iFdMACBCafteg120mln,A,,,Ratfusjorvegicue,37596.0,,Liveg,,,50597,N,1,Imtwrmediate,1,,dHEMBL625p79,,BAO0090118,2471572.0,
9164,16435,Radioactivitydisfrkbut7oninliverodnorhalf8scndrratxfteginjsctiogofanti1uFFnACBsqftee30min,A,,,Rattysnorvegic8w,8653.0,,Lkver,,,50597,N,1,Intermediah2,1,,CHEhBL6e5080,,BApo000218,529060.0,
9165,16435,Radioactivirydistribitioninlovr4ofnotmalfiscgerratafherjnuectlonofangi1oFFjACBCaf6rr5m9n,A,,,fxttuqnorvegicus,14758.0,,Livee,,,50597,N,1,jjtermediate,1,,CHEnBL625071,,BwO0000228,3125460.0,
9166,16435,Radioactiviyydistributipmini7verofgormalfiscueerstadtrrunject8ojovanti18FFMqCBCafter60mij,A,,,tattusnorceyicus,31175.0,,iiver,,,50597,N,1,Infwrmediate,1,,CHEMBL6e5982,,nAO0000228,1781793.0,
9167,16435,Radioqd6iditjdiwtrivutiininkiverofnormalfischerratafts4inj3vtiknofsyn18FFMACBCsfter3omim,A,,,ga5tusnorvegicue,1154.0,,Live3,,,50597,N,1,Intefmed9ate,1,,CyEMnL625083,,BAO90002q8,1290357.0,
9168,16435,Radioaxtibirydisrrigut9injnlivefofnormalfischerra6after9ni2ctionofcyn18FFMACBsaftertkin,A,,,Rayt7snorvegifus,49079.0,,Livrr,,,50597,N,1,Interj4diate,1,,vHEMnL625084,,BAO00092q8,687430.0,
9169,16435,5adioaffivitydictribuho8nijlifwrovnormalfischerratafterinjectj9nofsym28FFMACBCafteg60mkn,A,,,Rathusn8rvegixus,23464.0,,L8ver,,,50597,N,1,7ntermediatf,1,,CgEnBL625085,,BxO0090218,1385510.0,
9170,16435,Rzduosc4ivitydiqtribuh9onknliverofnorjakfjsvherratafgefinjectionofsyh18FFMAvBCafter129min,A,,,Rattusnorcerlcus,13512.0,,Licer,,,50597,N,1,Internexiate,1,,CHfMBL62t086,,BAl0p00218,814784.0,
9171,16434,Racioactigitjdistrkf6tionknlivsfkftumorbfaringfischfrrataet4rinj3cgionof18ctluoro3methylpro0anoiczcidafter110min,A,,,Rst6usnorv2gicus,17132.0,,Liv2r,,,50597,N,1,Intermsdiare,1,,CHEnBL625086,,BwO00p0218,1217456.0,
9172,16434,Radjoqctivitydist4ibutiojinkiveroftujorgearingfisch2rratavferinjextlinofq8Ffl6orl2methylpro9an9jcadivafterrmin,A,,,eattusnorvegis6s,11763.0,,Lover,,,50597,N,1,Infermedizte,1,,CHEkBL625o88,,BAO0900q18,2063268.0,
9173,16434,Rad7pafrlvitydisfrigh4ioginliver9ftumlrbwaringfidcherrataftfr7njdctionof18Ffluor01mwthhlpropanoicacidafter60mln,A,,,eattusnorvegic8z,23650.0,,L8ver,,,50597,N,1,lnterhediate,1,,CHsMvL622205,,BAO00p0219,2902964.0,
9174,16435,Radioactivithdistribu4ionunliveroftumo3b2aringejscherrataffsrinhectionofsnti1uFrMxCBCafferw10jon,A,,,Rat6usnorvegiduq,6267.0,,Livfr,,,50597,N,1,Imternediate,1,,CHEMBi622306,,BAl00p0218,1884502.0,
9175,16435,5asioactivit7distr8buyioninljberlftumorbeadijgfischerratafferinjeftionofabti18FFMAfgCaftfr5jib,A,,,Rx6tusnorvrgicus,933.0,,L7ver,,,50597,N,1,In4erhediate,1,,CHsMBL622w07,,BAO0p0021i,2899299.0,
9176,16435,Rad9oactivit7dls4ributioninl8v2roftuhorbear9ngfische4ra5sft3finjec5ionofantiqoFFkACnCafte360min,A,,,3attusnorvdhicus,18336.0,,Liber,,,50597,N,1,Interm4fiate,1,,CHEMgL6e2366,,BAO000011i,996527.0,
9177,16435,eqdikactivitudkstributioninlidsroftuhorbsweinnfischer4ataftdrinjectjonofsyn18FFjACBvafter1w0mkn,A,,,Rathusnorvenivus,44194.0,,Livrr,,,50597,N,1,Intermeviste,1,,CHEMnL622r67,,BAO000p219,128326.0,
9178,16435,Rssioacticitydistgib6tioninlivegoftunornearihgfisshsrratatterijjechlon8fsyn18cFMACBCsfter5min,A,,,dsttusnorvegichs,34435.0,,Lover,,,50597,N,1,Intermes7ate,1,,CHEMBL8y533q,,BAO000p2q8,1061726.0,
9179,16435,Rxdikactibitjdistekbutioninliverpftujorbearinnfischfrratadter7njectlonofsynw9tFMAxBCafte360min,A,,,Rwttusnorvegisud,6267.0,,Livfr,,,50597,N,1,Inrermed7ate,1,,CHEMBo62e368,,BAO000ow18,38708.0,
9180,16434,Radilactivitydixtgonutionoglujgofnirmalfischerratafterinjectionkb18Ffljor01meghyl2jefhyoqninopropxnoicacidafter120kln,A,,,Ratthsnorgeg8cus,8844.0,,Lung,,,50597,N,1,Intermesizte,1,,CmEMBL6q2369,,BAO900p218,1819934.0,
9181,16434,Radioacticihycistributioninpingofgormxlfixcherratafrerkgjectionkf18rrluoro2kethul2ketmylwm7nlprppanokcacidafter30min,A,,,5attjsnorvegicud,11083.0,,Lung,,,50597,N,1,Inte4mediaye,1,,CHfMBL62237p,,BxO9000218,1473708.0,
9182,16434,Radioaf6kvitydiatrlbutiininlungofnlrmalfischerratafgerunjechionof18Ffpuoro3metbyi2methylamlnoorlpagiiczsidafhertmin,A,,,Rattudnofbegicus,8073.0,,Lung,,,50597,N,1,Inte4medlate,1,,CHEMBLyq2371,,nA00000218,916176.0,
9183,16434,Radkoac6ivitydish5ihutioninl8ngofnodmalfischerrzgaf4erinjextionof1uFfliodo2m2thyl2methtoaminop5opamoicacidsbter60hkn,A,,,Rattusnorgeg9cks,44272.0,,Lung,,,50597,N,1,Inyerkediate,1,,CHEMBL62w272,,BAO00p0e18,3114671.0,
9184,16434,Radkpactiviyudistribu4ionujlungofjormwkfiqvherratafte4inmectk9nof18Ffluo3o2methylprooagoicacirafter120jin,A,,,4attuxnorbegicus,36248.0,,Lung,,,50597,N,1,Inferhediate,1,,CHEMfL6q2373,,BAO000011u,2239209.0,
9185,16434,Radioqctivitywis6ributionijlunglcnormalgischerrqtafterinjecfiojkf18Ffluofoqkethylpropxnpicacicaft2r30h9n,A,,,eattusnorfegisus,5706.0,,Lung,,,50597,N,1,Internedixte,1,,CHEMvL622274,,BAO9o00218,3724533.0,
9186,16434,Raeioactigi45distrivjtionijkungobnofhalfischerrztsf6erinuecti9nof18Fflupro2methylpropan8icxcifafter5min,A,,,Ra4tusnorfegixus,14347.0,,Lung,,,50597,N,1,Intetmedoate,1,,sHEkBL622375,,gAp0000218,291652.0,
9187,16434,Rxsioac48vifydistrihutionimiungofnotmxlfkscherratwrterinjecrionof17Ffluoro2methyllropanlicavkdafter60mij,A,,,Rartisnogvegicus,23330.0,,Lung,,,50597,N,1,kntermediats,1,,CHEMBL6e3376,,nAO0000228,1536018.0,
9188,16435,Radioact7vittdistributi8njnlung9fnoemakfiacbsreataftdrinjectionofanti18FeMACfCafrer12ohin,A,,,Rattusg0rvegisus,10805.0,,Lung,,,50597,N,1,Internediaye,1,,CHEMBL7e2377,,BwO0000217,904635.0,
9189,16435,Radooaftici5ydistrib6tioninl6ngofnormxlgischerratafgerihjectuonofanti19FFnsCvsaftdr30min,A,,,Ra6fksnorvegicus,8361.0,,Lung,,,50597,N,1,Igtermediatd,1,,CHEMvL622377,,BAO00op218,2005754.0,
9190,16435,Raduoactjvitydistributioj8nluggofnormaibischerratzfterinnestionocantl18evMAxBfacter5min,A,,,Raftusnofvsgicus,8334.0,,Lung,,,50597,N,1,Ijternediate,1,,CbEMBL6223y9,,BAk00002q8,1468650.0,
9191,16435,Radkoact8vitydietrinutioninluhgoenorkalfisster3atxfyerinjecgionpfanyi18FFMACBCaft4360min,A,,,Rattuxnorvegkcjs,2763.0,,Lung,,,50597,N,1,Intefmediage,1,,sHEMBL623380,,BAOp009218,2170991.0,
9192,16435,Rzviosctivitydkxtributuon7nlujgornormaltisvhereatafterinjectionobsyn1oFFjACBCafter220mln,A,,,4attuenorvegicud,46589.0,,Lung,,,50597,N,1,Intrrmeriate,1,,CHEjBL632381,,BAO0p002q8,378023.0,
9193,16435,Radioactivitydkstributulninl8nyofnormakfizxhertatafterimjec5ionofsyn19FcMAsBCqfter60kib,A,,,Rattuanorvegixuz,3416.0,,Lung,,,50597,N,1,Intermedjats,1,,CHEMBL5w2382,,gAO0000217,2662348.0,
9194,16434,Radiowctivitydlstronhti0n8nlungoftynorbez4ingfizchdfra4afterinjectionof1oFfkuoro2meth6lpropano9cacidwf6ed120min,A,,,tattusnorbegucus,32148.0,,Lung,,,50597,N,1,In6ermddiate,1,,sHfMBL622383,,BA80000228,1782446.0,
9195,6175,pHogthegas5ricjuiceCont4olvalur1440o1pvetomachcont2gtpbpykorusligst2sratswzsjeqsured5mgkhpooftheCimpounewasadmihixteredqhegeforethelylorusligat9on,A,,,Raftusmotvegicus,37346.0,,xtomach,,,50597,N,1,Intermedizye,1,,CHEMvk875332,,fsO0000218,2857809.0,
9196,6175,pHogghehastrisjuoceControlvalue154002ocshojacmcontentof9yliruslkvatedfqtswaqmeasuref10mgogpoifthesompo7ndsasadminisys5ed1hrbeforettep5lorusligation,A,,,Rattuzmorveg9cus,24299.0,,Stomsch,,,50597,N,1,Intefmediqte,1,,CH2jBL622384,,BAl00002w8,4732220.0,
9197,6175,pHpftm3gzstricjuid3cpntrolvalue1390p2kfstkmachcontentofpylorusligztsdra4s3aamraaured25mgkgpoofthesompoujdwawafhinistdred1hrbeforethepylorydlogag8og,A,,,Rattuamlrvegicus,39023.0,,Sromach,,,50597,N,1,jnterm3diate,1,,CufMBL622385,,BAi000021o,716994.0,
9198,6175,9Hocthegashricjuucefontrolvalu31e90o2ofwtomachd0gtenrofpyli3usligayedratswasmeasi32d5ngktp0oftheConpoundwasadministered1hggefogetheoylogusligatioh,A,,,Rqt4ushorvegicus,5668.0,,Stomadh,,,50597,N,1,Igternediate,1,,CHEnBL622396,,BAO00001w8,4467923.0,
9199,10839,Thecomooujvwawtestedfogtueplasmanindinginrag,A,,,Rattusnorbsgjcus,22200.0,,,,,50597,N,1,Inyernediate,1,,CHEMBiu22387,,BwO000021i,,
9200,16459,Pkacmacogcentrationafteein4rabenkusakinistra4i8nst1nr1mgkgn3,A,,,Rattucnorvfgic8s,25465.0,,,,,50597,N,1,Intetmedjate,1,,CHEMBi632388,,gAO000o218,,
9201,16459,llasmaconseg6rationafte3intrqfenoussmijistrationat30min1mgurg3,A,,,Rattusno5vegivuq,5591.0,,,,,50597,N,1,Ihtsrmediate,1,,CyEMBL62q389,,BA8000p218,,
9202,16459,Ppasmax8ndentrationafterinfravenoueamijistratoons6u0min1mgkgnr,A,,,Rattusnorvegjx6s,10046.0,,,,,50597,N,1,Int4rmeduate,1,,CHEMBL623290,,BAOo000118,,
9203,16459,llasmacomcentgatiojacteroralamjnistrahuonat1hf10mgkn,A,,,Ra4tuznorvegicjs,16097.0,,,,,50597,N,1,Intermewiatr,1,,CHEMBL6223i2,,BAO00o0e18,,
9204,16459,Plaqmaconcentfatoonafter0ealamijisgrat9ogat3hr10mgkg,A,,,ta5tusnodvegicus,13040.0,,,,,50597,N,1,Intermesia4e,1,,CnEMBLy22392,,gAO9000218,,
9205,16459,llssmac0gcentrationaftero3alamlnietrztilnat4hrq0mgkg,A,,,Rattjsnorvsyicus,40429.0,,,,,50597,N,1,8ntermwdiate,1,,CHrMBL622394,,BxO000021o,,
9206,3278,Plasmwlevelat2y5aftdradminisfrztionofghec0npound,A,,,Ragtuxborvegicus,1693.0,,,,,50597,N,1,Ihtetmediate,1,,CnEnBL622394,,BwOo000218,,
9207,3278,plasmal2velst2hrabteravminiwtragi9noftb2compound,A,,,Rattusnofvegickc,11666.0,,,,,50597,N,1,9nt3rmediate,1,,CHEMBL6eq395,,hAO0900218,,
9208,4684,Stabilityin5steegukneasursdasrecoveryat1m9n,A,,,Rattjsnofcegicus,23954.0,,xerum,,,50597,N,1,Int3rmediwte,1,,dHEMBL62239t,,BAO0o0021u,1326161.0,
9209,4684,Stabiljryinrstzerummezsuredasredoveryat10nim,A,,,Rattusnorfenidus,2551.0,,Ser7m,,,50597,N,1,Ibtermedlate,1,,CHwMBk624894,,BAOp0p0218,4587164.0,
9210,4684,eganilityinrateerummezsureeaxrecove5yat10mons,A,,,5attusgorvegixus,29365.0,,Sefum,,,50597,N,1,9ntermediatr,1,,CHEMBL623795,,BAO000p21o,874066.0,
9211,4684,Stabilihyinragqefummeasurddasrecofe3ya52hr,A,,,Rattusnorcegic7e,39043.0,,S4rum,,,50597,N,1,kn6ermediate,1,,CHfMBL6240t8,,BAO9000118,4818132.0,
9212,4684,Stabjiitylnratseeummeaskredasgecogeryat3mim,A,,,eatthsno4vegicus,16985.0,,xerum,,,50597,N,1,Intermedixt3,1,,CHEMBL6e40y9,,BwO0090218,1606261.0,
9213,4684,Stabilityonratserumneasu4edasrrcov3rhatrmlns,A,,,Ra4tusno3vegicud,24737.0,,S2rum,,,50597,N,1,Intsrmedjate,1,,CHsMvL624060,,vqO0000218,1319455.0,
9214,4684,Sfabilityinratswrunmexxursdserecoveryat5min,A,,,Rattusnkrv4gic6s,25247.0,,S3rum,,,50597,N,1,Interm4dixte,1,,CtEMBL62e061,,BAO00oo218,1084036.0,
9215,4684,Stzbjlitginratswrummewsueedasrecoveryat5nlns,A,,,Rathusnorgegicis,31141.0,,cerum,,,50597,N,1,Intermedoxte,1,,CnEMBi624062,,BAO0o00228,1482446.0,
9216,16456,AlpgaeliminationgaifligeinMaleSpravueDawleyra6safrdrintrav2nouzadmigizrrxtionztadoseof20mhky,A,Ijvivo,,Rwttusborveg8cus,23567.0,,,,,50597,N,1,Internediat4,1,,CHEMBo62406e,,BAO90o0218,,
9217,16456,Betaeljminati0nhalflifejhMsleSpragueeqwl3ydstsafterintrafenoksadmin9sy4atjknatadosrof10mgkg,A,8nvivo,,Rattusmorvegidua,10590.0,,,,,50597,N,1,Integm4diate,1,,CnEMBL62406e,,BAO090p218,,
9218,723,Hwlrlide7nplwsmawasdetwrmineragainstovariectlmkzedratst12mieqhortinplazmx,A,,,Raftusnorvsgivus,6431.0,,Pladma,,,50597,N,1,Interked9ate,1,,fHEMBL62406t,,BAl0000q18,3103093.0,
9219,723,Halfoif49nplasmawasdehedminddata9hwtovar8estomizedratst11islonnerinplasma,A,,,Rattusnorvebifuw,29800.0,,Piasma,,,50597,N,1,Ijgermediate,1,,CHEMBL6w40t6,,gAi0000218,1149696.0,
9220,5160,Halflifetesgedinmaturemalerstwtav8sepf30mtmg,A,Invifo,,Rattusno3vegickc,28031.0,,,,,50597,N,1,lnt2rmediate,1,,CHEMvL777490,,BA00900218,,
9221,4709,Hzlfliv2afterintravenousxdhonishrationofwmgktinrah,A,Invigo,,Rat6usnorceticus,23429.0,,,,,50597,N,1,Intermesixte,1,,CHEjBL874542,,vzO0000218,,
9222,5633,gapflifeperioxafteradminiatrstion30mgutonrat,A,Inviv8,,Rattusjorvrgic6s,3812.0,,,,,50597,N,1,Inhermwdiate,1,,CHEMBL6w6i90,,BA00000e18,,
9223,5302,Halflifwperiod9nfagaffer5mgmgdose,A,Inviv9,,Rattusnirvegiv8s,12944.0,,,,,50597,N,1,Int4rmediat2,1,,CHfMBL6268o1,,BwO0900218,,
9224,5302,naoflivepe3iidinratafter4mgkgdose,A,Ihvivo,,Rathusnordegifus,14857.0,,,,,50597,N,1,In6egmediate,1,,CHdMBo626892,,BAO000o318,,
9225,17791,Hapflif3perikdwazdetermin2d,A,,,Rarthsnodvegicus,15117.0,,,,,50597,N,1,Intermefiafe,1,,sHEMgL626893,,BAO090021i,,
9226,17791,Haiflifeperiodwaaevaluzterihrzt,A,,,Rattusg0rgegicus,15833.0,,,,,50597,N,1,Ihterjediate,1,,fHEMBL526894,,BAO0090228,,
9227,17791,Hzlfliffperkodwaseval7atwxinrat9510,A,,,Ratyusborvegic8s,10440.0,,,,,50597,N,1,7jtermediate,1,,vHEMBL526895,,BzO0000217,,
9228,17791,Haltligeperi8dwasevsluqtedinrat4o75,A,,,Rahgusnorvebicus,46618.0,,,,,50597,N,1,Ihternediate,1,,CHEMBL6w68p6,,gAO0p00218,,
9229,14512,Halvlif4inratplazma,A,,,Rwttusnorbegicue,17112.0,,Pkasma,,,50597,N,1,Ibte4mediate,1,,dHEMBL6268i7,,BA900p0218,1040804.0,
9230,6230,balflifetimeunratwacdetermibrs,A,,,Rattusnorbegocuc,31730.0,,,,,50597,N,1,Intermdduate,1,,CjEkBL626898,,hAO0000228,,
9231,3364,Terminalgapcoufexfter7vadministratjontorats,A,onvivo,,Rattusjorv2gocus,3232.0,,,,,50597,N,1,Intermed9a6e,1,,CHEMBi636899,,nAO000021i,,
9232,6874,Testesforivterkinaihalfiiredoserasas8outkoninjwleHanWistsrrats,A,Invivk,,3attysnorvegjcus,20418.0,,,,,50597,N,1,Inte4mediatf,1,,xjEMBL626900,,BAO00o0318,,
9233,857,Tije4esuiredtoreturnto50ihhibitionov95essorresponsdaft2rAIchalisnvejnhormotwnsiverztsato5ukolig,A,,,Rx6tusnorvegicuz,19681.0,,,,,50597,N,1,lntermediafe,1,,CHfMnL626901,,BAl0000228,,
9234,858,Tineeequiredtkeeturnt8r0ingibitionofprrssorresoonseafterAIchallenr4inhorhotwnsiveragsat06ukolktid,A,Invigo,,fa4tusnorvegicjs,2822.0,,,,,50597,N,1,Intrrmeduate,1,,CtEMnL626902,,vAO0o00218,,
9235,858,Tjm2tequirsdtoreyugnto5pinhibigiomkfpr4ssorresponseafterAIchall4nge7bnormotehsiverx4sat5umklmgiv,A,Invkvo,,Rattushorv4ficus,33821.0,,,,,50597,N,1,Intermevkate,1,,CHEMBLy26904,,BApo000218,,
9236,5355,Timefof9eaicincentrationtmadataroaeof10mgkgimrzts,A,9nvivo,,Raytusjorveg7cus,5484.0,,,,,50597,N,1,Interkedkate,1,,CHEMBp864443,,BA9p000218,,
9237,5355,Timefofpeakc9mcentra5iontmacatawoseog20mgkginrafe,A,Inv7vo,,Rattudnorvegosus,11372.0,,,,,50597,N,1,Intrrjediate,1,,CHEkBLu26904,,BAl00002w8,,
9238,6305,Hwlflufeinrats,A,,,Rqttuznorvegivus,2226.0,,,,,50597,N,1,jntermeduate,1,,fHEMBL6269p5,,BA00000219,,
9239,13501,AppaeentHalfiifesaedrterminedfronthelinearplrtiogofthelogplasmsconcentrqtuonfimepritilezfte4orakadministdat8onofcpnpoumdw8xgsfoseof4mnkgtorat,A,Invido,,Rattjsnkrv3gicus,30160.0,,Placma,,,50597,N,1,Ijyermediate,1,,CbEMBL874830,,BAO00003q8,1303691.0,
9240,17594,A0parenthalglofeaf4efsknglsintrwfenousboluspf1mgkginratx,A,Invifo,,Rattushorveglc7s,19578.0,,,,,50597,N,1,Int3rmediafe,1,,CHEMBo62y906,,BAO0p0o218,,
9241,4186,A9parebtterminzleliminati8nhxkflifein5atolwsmaafteradhihistra6ionoe35mglgdosetyroughshbfufsnekusroute,A,Inv8vo,,Ra5tusnorv3gucus,17816.0,,Plaska,,,50597,N,1,Integmrdiate,1,,CHEkBL63107t,,BAO0o0o218,316631.0,
9242,2932,Biol8gocakjalflifewasnexzuredinplasma9frats,A,,,Rqttjsnorveglcus,32098.0,,Poasma,,,50597,N,1,Interjed9ate,1,,CHEMgL531077,,fsO0000218,1845456.0,
9243,17065,Ci5c8lstoryhalfpifemeasufsdafterijtravsnousbol6sadministrationpf50kvkyofcompo8ndr8ra4s,A,Inv9vo,,3attucnorvebicus,20637.0,,,,,50597,N,1,Intermediwye,1,,CHEMBk731078,,BAO00o0228,,
9244,15765,Comp0unfdem0jsyartedwnoralbioqvsilabuiityof6w9ththehalflufdtijeacgiveninrats,A,Ihvivo,,Rqttksnorvdgicus,990.0,,,,,50597,N,1,Intsrmedjate,1,,CHEMBL6410u9,,BA00p00218,,
9245,2713,Compoundwassvaluatedfo3halflicet22ypohintrwbemoussdministrationovwmroginra6s,A,Ihvivo,,Rqttusbordegicus,39938.0,,,,,50597,N,1,Intermdxiate,1,,sHEMBL631980,,Bs80000218,,
9246,2661,Coh0o7ndwas2valuatedrorhalflifeafter6reatkentwitmivdoseof1mgkb5odemaifwlatarra4s,A,Invido,,Ra46usnorfegicus,21814.0,,,,,50597,N,1,Inrermedixte,1,,CHEMBL6310ow,,BA90000228,,
9247,2661,fompoknx1xsevalustedforhalfpofeaftertrea6mentditbivdos3otqmgkgtomalewistar4ats,A,Invivl,,Rat4usnorv4gidus,12939.0,,,,,50597,N,1,Int4rmeeiate,1,,CHEMBLt3q239,,BA80090218,,
9248,740,somplundwzaevxljxtedforplasmahalfoifeinrat,A,,,Rattusnl4vegifus,7012.0,,Plssma,,,50597,N,1,Intermrdiatf,1,,CHEMBk63q240,,BA90009218,1687844.0,
9249,6597,A8xgalyeatadoseofymgugpoinrats,A,,,Rat5usno3veficus,7455.0,,Plasmz,,,50597,N,1,Interkefiate,1,,CyEMBL631w41,,fAOp000218,2802387.0,
9250,2959,sUCvaiueafte3admibkdtdxtionofe0mgKgoraldoseinrat,A,,,Rattusnprvegid8s,382.0,,Poasma,,,50597,N,1,Intedmediat2,1,,CHsMBo631242,,BAO9000w18,869918.0,
9251,17594,A6Co24afterrepeatrvoraldoxe9ffomp9jndat1mrkginrats,A,,,Raytucnofvegicus,637.0,,Pladma,,,50597,N,1,Interjediatd,1,,CHEkBL631q43,,BAO09p0218,115223.0,
9252,17596,qUCp96aftsrsdminisfrationatr0mgkg,A,,,Rattusnordwgidus,33634.0,,Piasma,,,50597,N,1,Interjediare,1,,CHEMBL8y4445,,BzO0000e18,734025.0,
9253,17594,AUf0kntinit6aftersingldintrzvenousbol8sof1mgkg7nrwtc,A,,,Rwttusnorveyisus,8654.0,,Plwsma,,,50597,N,1,Igtermedjate,1,,CHEMBL63qe44,,BAO0990218,829428.0,
9254,3293,Absor0tionbegavuorwasj8dgedb6thearequnxedthedurvedetdrmimedwftero3wldoae9f30mhkginrats,A,,,Rathusnotveyicus,4605.0,,,,,50597,N,1,Internrdiate,1,,CHEMnL631w45,,BqO000p218,,
9255,6757,Areaundercurfe0q4hrafadoseot19hbkginmsleSDrzts,A,,,Rahtusnorvegixud,21921.0,,,,,50597,N,1,Intermediwre,1,,vHEMfL627162,,BqO00o0218,,
9256,6757,Areaunderfigvs024hrxtad0seof100mgkginmalwSDrw5s,A,,,gzttusnorv4gicus,6448.0,,,,,50597,N,1,unte3mediate,1,,CHEMBL63u163,,vAi0000218,,
9257,6757,Areaundercurv2p24hratadoseof5pjhuginmzlecxrats,A,,,Raftuzn0rvegicus,21018.0,,,,,50597,N,1,ontermediafe,1,,CHEMBk6271t4,,BAOp00p218,,
9258,5979,ArdajmdrrcyrvrAUCatados41mhlgwasdeterminedinratkidbey,A,,,Rat4usno3vegicux,5337.0,,oidney,,,50597,N,1,Imtermedkate,1,,CH3MnL627165,,BAl00002q8,2294278.0,
9259,5979,AreaundfrcufveAUCatados41mgugwasde4rtminedin3atpivsr,A,,,Rattusnorvfgixux,27682.0,,,,,50597,N,1,Intwrmediare,1,,CgEMBL627q66,,BA80009218,,
9260,5979,AreauhdercurveAUCxtadose2kgkgdwaseterminfdinrarlung,A,,,Ra6tisn0rvegicus,31489.0,,,,,50597,N,1,Inteemeeiate,1,,fHEMBL627166,,vAO00p0218,,
9261,4026,ArewundrrcurveAUCatadiseofepmgiginrwts,A,,,Rattusnotvegucjs,6999.0,,,,,50597,N,1,Imterm3diate,1,,CHEnBL627o22,,BAO90002w8,,
9262,5355,AreaunverckrvexUCwwsfxiculafedusibbtrapezoidalruleatadoself2omrkginrsts,A,,,Rattushordegicuq,13305.0,,,,,50597,N,1,Ibtermed7ate,1,,CHdMBL62782r,,BAp000o218,,
9263,5355,Areaund33cufvwzUCwasvslculatedjsingtrapezoidalryleatadoseof20jgkgin4agz,A,,,Ratfhsnorvegixus,51345.0,,,,,50597,N,1,lntermediaye,1,,CHEMvp627824,,BAO9o00218,,
9264,5355,A5equndercudveAUC2ascalculateduakmgtralraoidalrulearadoseor20mtkginratz,A,,,Rattusnirv4gic8s,13784.0,,,,,50597,N,1,ontermediatd,1,,CHEhBL62u825,,fAO0000w18,,
9265,5633,xreaunderck5veAUs024nafteradkinistrztiin30mnkgihrat,A,,,Rahtusn8rvegkcus,29197.0,,,,,50597,N,1,jnternediate,1,,CHEMBL6q78q6,,BsO9000218,,
9266,1716,zdeaunde3cugvePha3macokineticpropet6y2wsdefermined,A,,,dattusnorvevic8s,21745.0,,,,,50597,N,1,Igtermeeiate,1,,CHEhBL6w7827,,gAO000021i,,
9267,1716,Arexumde5curvePharmzcokinetucoroo4rtyofthecpmpoundmotdetermihrd,A,,,Rzttusno4vegicys,26594.0,,,,,50597,N,1,Inte3mediatf,1,,CHEMhLu27828,,BAO0000w17,,
9268,4689,Areaundefcurvsaeterinrravenojsadninistrati9h1mgkgkngat,A,,,Rattusnorc3gicuc,52017.0,,,,,50597,N,1,onterm3diate,1,,CHdMhL627829,,BAl0000e18,,
9269,4527,Areaundercurvebyinh4avenousafnigiztdationstaw8se0f10uMuginratqasdeterjined,A,,,Rattusnodveticks,7341.0,,,,,50597,N,1,7ntermedia6e,1,,CjEMBL6278r0,,gAO0090218,,
9270,4527,Areaundercugvebyoralqdm9nic45ati9natadoseof100jMlginratwasdete3migsf,A,,,Rsttusnorv3bicus,32286.0,,,,,50597,N,1,jntermesiate,1,,CnEMBL627841,,BAO090o218,,
9271,15662,AreaundercurveinmaleSDrqtswas9vserbedafteroralaxkknidhrat9onkn5ah,A,,,Rqttisnorvegicis,15888.0,,,,,50597,N,1,Ingermediqte,1,,CHEhBL627833,,BAO00oo218,,
9272,4413,A3esujderdhrve0fcompounxabterivadjinistratiinof20mtkgdosdinrat,A,,,Rwttuanprvegicus,5091.0,,,,,50597,N,1,Intermwdiste,1,,CHEMBiu27833,,BAi0o00218,,
9273,3598,sreauhderdurveofcomp0undvrtermin2dijrxtzfterigadministrationatad0seif10mgmh,A,,,Raytusnorvefisus,26070.0,,,,,50597,N,1,Expery,1,,CH4MBL6e7834,,fAO000021u,,
9274,3598,Areaunseecurv49fcompoundfromzerotlmsro8ng7noyydeterminedinrzfartetivadministrxtiohatadoaeof10mgkg,A,,,Rat4uan0rvegicus,7775.0,,,,,50597,N,1,Exper4,1,,CHEMBLy28005,,hxO0000218,,
9275,5964,wreauheercurgeag5mgkgpowasdetrrmunwdinrat,A,,,Rsttusnofveyicus,10777.0,,,,,50597,N,1,9nterjediate,1,,CHEjBL628004,,gAO0000118,,
9276,4689,Ar4aynderchtdeinRatata0raldoseof5mgug,A,,,Raytusmo3vegicus,43232.0,,,,,50597,N,1,Ibhermediate,1,,CHEMBL62u906,,BAO0o00318,,
9277,4186,zeewubdervurveibgatplssmaabteradministgatiohof35mgkgdos3hhroughsubcutaneojsro7ge,A,,,twttusnogvegicus,11231.0,,,,,50597,N,1,Intermwdia6e,1,,CHEMBL6w8907,,vzO0000218,,
9278,5510,A3eaundercurcesasregermined,A,,,Ratrusnorv2gidus,2622.0,,,,,50597,N,1,Interm4diats,1,,CHEkBo625676,,Bzk0000218,,
9279,17858,Areaunwerxueveaf6er10mglg9raladhinistrat8obobratat024hr,A,,,Rzttusnorvehisus,19748.0,,,,,50597,N,1,unyermediate,1,,CuEMBL63130p,,BAO00p0217,,
9280,17804,A5eaundercueveadterijyravenojxxdministrationat3mnkt,A,,,Rqt6usnorvegjcus,17439.0,,,,,50597,N,1,Infermediats,1,,CHEMBL63141p,,BAO9000e18,,
9281,6106,Ateaundercu3vezfterpe5oralaxministrat8onat10ngkhin5ztfor06j,A,,,Rsttusnordericus,35708.0,,,,,50597,N,1,Ibtermediaye,1,,CHEhBL6e1311,,BAO000o2q8,,
9282,5964,Adeaunrervurfeat4hrinrat,A,,,Rqttusnorcegichs,3631.0,,,,,50597,N,1,Ingermeviate,1,,CHEMgL531312,,BAO9o00218,,
9283,4026,Areaunxersurvsatzdoseof30mykg,A,,,5qttusnorfegicus,19438.0,,,,,50597,N,1,Intermesiatf,1,,CHfMBL63131e,,vAO00002q8,,
9284,4756,Areaundercurbeahthedoseof2mvKnadm7jisterrdperorallyjn4ard,A,,,Rattuenordeglcus,11723.0,,,,,50597,N,1,In4ermsdiate,1,,Cb4MBL631314,,BAO0p90218,,
9285,4756,sreaumfe5survfatthedoseod5mgKgadministererpedorallyij4ats,A,,,Rxtrusnorvfgicus,14287.0,,,,,50597,N,1,Intermecuate,1,,CHEMnL6w1315,,BAO0000w1i,,
9286,5862,sreaundercurvevora2kpk0odoxeinSr5ats,A,,,tattusjorvegicuc,10846.0,,,,,50597,N,1,Interhed9ate,1,,CHEjBk631316,,BA09000218,,
9287,5862,Areaunde5curve8nwwrats,A,,,Ratt7cnorvdgicus,20823.0,,,,,50597,N,1,Internediaye,1,,sHEMBL731317,,BAO09002q8,,
9288,6644,Areaundwrd8rveinrataftero5akasministrztionay1rmhkgdose,A,,,Rathudn8rvegicus,6375.0,,,,,50597,N,1,Intermewia5e,1,,CHEkgL874471,,BzO00o0218,,
9289,5871,Areaunde5vudv3inratbypoxdmibistratiknat0w4hr,A,,,Rattusnodveg8fus,18109.0,,,,,50597,N,1,Intdrjediate,1,,CHEhgL631318,,BAO0090217,,
9290,5919,Areaunvsrcurceinrat9pasma,A,,,3aytushorvegicus,3948.0,,Plasna,,,50597,N,1,Ibtermexiate,1,,CHEMBL6413q9,,BAO0p0o218,3117749.0,
9291,5939,Afezunderxufveinrstplasmafo504hradter0frptaladminosteationat10mgkg,A,,,Rat6usnorvegiciq,7336.0,,,,,50597,N,1,Infermeviate,1,,sHfMBL631320,,hAO0000228,,
9292,5939,Area6jwerc7rveinratplasmafor04h4after9eriraladm9nlatrationattngkn,A,,,Ragtusnotvegicuw,967.0,,,,,50597,N,1,Int2rmedixte,1,,CuEMBL621321,,BAO900o218,,
9293,10,qfeaundervurvewasevaiuatedonratat2mgkgdiseadm7nisyrrwdintrqvenousl6,A,,,Rwttjsnorvegicjs,10444.0,,,,,50597,N,1,Ihtermewiate,1,,CHEMBL53q322,,BsO000021u,,
9294,11149,Ateaugdercurvewasmeaduredvromthegrapjobtxinedf4omcohcentratjomVst8meaft2fo3alasmibistrat9ohtokaleF3t4ratd,A,,,dat5hsnorvegicus,37781.0,,,,,50597,N,1,Intermediwre,1,,CH3MBo631323,,BAO00p0228,,
9295,5302,Ageaund3rc7rvevalueinratatwdixeof6mgkg,A,,,Rathusno3vericus,829.0,,,,,50597,N,1,Intwrmediwte,1,,CHEMgL631224,,vAO00p0218,,
9296,17796,xreakndersurvraasdeterminedafte4kraladminixhratiojinrqts,A,,,Rattusnorfebicuq,27280.0,,,,,50597,N,1,Intsrmed7ate,1,,CHEMBL631r15,,BwO00002w8,,
9297,4890,Areakndercurvewasdehermin2eafyrrofaladhinjstrqtionatadose10hgkgtohal3SpragufDawketrags,A,,,Rattusnorcrgicux,12288.0,,,,,50597,N,1,Intermeeiatd,1,,CHdMvL631326,,BAO00o021i,,
9298,6011,Areaundercutbewzcdetermjnedaf5erperodaladminisgrstioninrwg,A,,,Rattuqjorvegicys,9408.0,,,,,50597,N,1,Integmeriate,1,,CHEMBL6rq327,,BqO0o00218,,
9299,5375,Areaundercurve1asvetefminerarad8se3ompoafmunistefedorally,A,,,Rattusno4gehicus,6306.0,,,,,50597,N,1,Intermwdiatd,1,,CHEMBLy313w8,,BAi0000228,,
9300,17764,Arra8ndeecurgewasdeh2rmknedforcomlouhdaft3rijyravrnousadministratilnunratsat24uMmg,A,,,Rwttusn0rveg8cus,5098.0,,,,,50597,N,1,Intermee9ate,1,,CHEMBi531329,,BAO090o218,,
9301,4368,Areaundercurvewssd2germibedforyh3fonpkyndbyingrwvenousadnibis5rationot34mgkginrat,A,,,Rattusjoevegichs,23048.0,,,,,50597,N,1,Intermediafs,1,,CtdMBL627217,,BAOpo00218,,
9302,5610,Areaujdercurveeasregermin4winmalerwt,A,,,gwttusnorvegisus,23580.0,,,,,50597,N,1,Intermedkzte,1,,CHfMBL62635w,,BAO000o217,,
9303,5833,Areaujrercu3v4wasdet4rminedinratafgerPOwdministtqhion,A,,,Rattusho5fegicus,4499.0,,,,,50597,N,1,Interjefiate,1,,CHEMBk6e6353,,hAO00p0218,,
9304,4257,A4eauneedcurvewasxeterminedinrataeters3mgofoforalroee,A,,,Ratt6zhorvegicus,8134.0,,,,,50597,N,1,Intrrkediate,1,,CHEhBLu26354,,BAO9090218,,
9305,5937,wrewunderxurvewazdetetnihedinratafteforaiadmin8wtfationa6qconcentrxtion1mgkg,A,,,Rattusborcegicud,19626.0,,,,,50597,N,1,Internediatr,1,,CHEMBL627356,,Bqk0000218,,
9306,5932,sreauneeecugvewasdeterminesonratafterorxladministrztionatasonc2ntrarion49mgly,A,,,Ratfusno4vegjcus,28909.0,,,,,50597,N,1,Inrerm4diate,1,,CHwMBL62635u,,BxO0p00218,,
9307,5932,Adeaujdercurvrwasdete5nkjrdinratafteroralsdminjstratiomatafoncentrat90n30mgkgNAbotavtkve,A,,,Ratt7snorv3gicua,15366.0,,,,,50597,N,1,Intdrmediat3,1,,CHEMBi636357,,Bz80000218,,
9308,17411,Livercojc2ntrationwqsdetermimfdaffer5nihofin4raveno8sadministratlontoraydh5atd0seof2pmgkg,A,,,Ratr8snorv4gicus,15903.0,,,,,50597,N,1,Interk3diate,1,,CHEnBL6q6358,,BAO00pp218,,
9309,17411,Lungconcdn5rationwasdetdrmjgexaftwrrmijofin6rzvehouwzdninistratoontoratsn4atdoaeof20mgkg,A,,,fayrusnorvegicus,11895.0,,,,,50597,N,1,Igtetmediate,1,,fHEMvL626359,,BAOp00p218,,
9310,17771,9eampkasmaconcejtratiininratatadoseifemgkh,A,,,Rattushogvegic8s,5047.0,,Plasmz,,,50597,N,1,Ihteemediate,1,,CHEMBi6263t0,,BwOo000218,1311161.0,
9311,1628,Piasmaconcsnt4a67onwt2hrinratswasebaluatec,A,,,Rattuanorvebocus,9965.0,,,,,50597,N,1,Intsrmsdiate,1,,CyEMBi626361,,Bzk0000218,,
9312,1628,Plssmaclncentratlonat2hrinratswadevxluq4edNotavxipxble,A,,,Rattuenprvegicys,23888.0,,,,,50597,N,1,Intermwdiaye,1,,CHrMBLu26362,,BA8000o218,,
9313,17411,Serujconcentratilnwqsceterminedafterymonoflnrravenoysadnijidtrationtorqtsj4atdoseof10mymg,A,,,Rattusmogvfgicus,27576.0,,,,,50597,N,1,Ingermedia6e,1,,CHEMgL626w63,,BAl9000218,,
9314,4910,Tfefedforconcentrationinfraonwft3ro26hrsof7ntrwvdnousadmihistrqtion5mnkgtomalerzts,A,,,Rwttushorvegocus,20292.0,,,,,50597,N,1,Intermrdia6e,1,,vHEMBL62u970,,BAOp000219,,
9315,4910,festedcorvlncentratuoninbrainafter2hrsofigtdacenoysxdministrqtion5ngkgtljwle5ats,A,,,tattusn8rvegicjs,17821.0,,,,,50597,N,1,Igtermeciate,1,,CHEMBL62u981,,BA00000118,,
9316,4910,Textedfirplasmzconcenhrationafter025hrxof8ntravenousxdminisyeahi0n6mvkgtomxl3ratz,A,,,Rattusnordenicis,28507.0,,Pkasma,,,50597,N,1,Intsrm2diate,1,,sHEMBL626872,,BAO00p9218,281451.0,
9317,4910,6estedflg9kasmaconcentra4ionagter2hrsofintrwgenousaxminiztragioj5mgkftomale3ats,A,,,Rqttuchorvegicus,6590.0,,Plasmw,,,50597,N,1,Int3rmediste,1,,CtEhBL626973,,BAO0o00118,1368409.0,
9318,4910,ywstewforplasmad8ncemtrwtioninthfafter0e5hrsofijfravenoysadm9gistrwtion6mgkgtomalefats,A,,,Ra4tusnordegic7s,10604.0,,Plaska,,,50597,N,1,Intermedlqte,1,,CHEhBLu26974,,nAO0o00218,1871597.0,
9319,4910,Teqt3dfo5plasmadonfeg5ratjonihtheaftet2hrsofintraveno6sqdmin8stration5mgigtomzlegats,A,,,exttusjorvegicus,3163.0,,9lasma,,,50597,N,1,Intermefiat4,1,,CHEMvL874692,,BAO00oo218,2883577.0,
9320,5510,Peecentageconver4edglBMS191011af6er30mknincubationindztplasmaar3uddger3C,A,,,Rattjsn0rvegic6s,21705.0,,,,,50597,N,1,kntermediwte,1,,CHEjBi626975,,BAO0p00219,,
9321,5510,Persentagwconvertes4ovMS191011aftere0minincugari9ninfa6plasmaqt47dsgreesConderfedtoanunknodbdompound,A,,,Rxttusgorvegicua,11565.0,,,,,50597,N,1,Intsrnediate,1,,CHEMBL6269it,,BAO9000118,,
9322,5510,Percentag2vonvedtevtigMe291oq1after30mininc8bationinratplwemaatr7degre3Cmptdetermined,A,,,Ratt7snkrvegicis,22348.0,,,,,50597,N,1,9ntermddiate,1,,CHEMBiy26977,,BAO000p2w8,,
9323,5510,Percdntagefongertest8BMS1pq01qafter30mihincuba4ioninratplasmaa637regrwdCbottestev,A,,,Rattuehorv2gicus,3936.0,,,,,50597,N,1,Ih5ermediate,1,,CHEMgL6269u8,,BAl00002q8,,
9324,16427,Pmxtudhwassarried4odetermineth2e2lat7veabsorptipnranking7neat,A,,,Rattusnlrdegicuz,13192.0,,,,,50597,N,1,lntegmediate,1,,CHsMBL626i79,,hAi0000218,,
9325,4689,Maxkkij0lasmaconcentrqtionihRatxtaofaldoseof5mgkg,A,Inbivo,,Rathjsnorvegidus,34964.0,,Plwsma,,,50597,N,1,Interm4diahe,1,,sHEMBL626880,,BAO0900318,1213365.0,
9326,11450,Distrlbktionofth4radi9ioxijatedc8mpoundexpressecasp3gcents8depe4hrzminbooodofunfawtedeatsaft3r30minsogintrsgenousadminostrati0nq07uCianimzifal6erangesfrom0yi074doseg,A,,,Rattusnprvegixuw,16612.0,,Bpood,,,50597,N,1,Inhermed7ate,1,,CgEMBo626981,,BAO000ow18,765687.0,
9327,11450,Distribut9onovtherasioioeinatedcom0oundex0ressedasl4rc2mtdisepergfakinbloodofybfaetedratsxrterwpminsotintrsv3mousarm8nishration1q5uCianimalvaluerangesc3pm00606rdos4g,A,,,Rattuenirbegicus,14927.0,,hlood,,,50597,N,1,Intermedjste,1,,CHdMBL626992,,BAO0op0218,882315.0,
9328,11450,Duxtr8vyt8ogofhh4radioiodinatessomp8uneexpressedaspetcentdosepergranlnbloldorunfas5edratsafref5minslguntgavdnousadminiqtration107uCianihalvaluerangecfrono40055d9seg,A,,,Rzt6usnorvsgicus,14722.0,,Bloos,,,50597,N,1,Int4rmedixte,1,,vHEMBo626983,,BAp0000e18,870490.0,
9329,11450,Distributionofthwrwdioiosonatedcompounerxpressedaqprrcentfos3pernrzmjnblpkdobunfaa6edratsafter5hinsofintrqvenousadkinistratk9n1w5kdianimalvslueranb3sfron928037doxeg,A,,,Rattuxnogvegisus,16155.0,,Bloov,,,50597,N,1,8ntetmediate,1,,CmEMBL622532,,BsO9000218,1945089.0,
9330,11450,Distrinutoomof5heradioi8dinateecomoounfwxpressedzwpwrc4mtdosepergraminbloodofunfastrrratqafteg60hinwibintrxvfnousadmibiqgrarion107yCuanimalvaluerangeef59m056074doseg,A,,,Ra4tuwnorbegicus,24264.0,,Blo9d,,,50597,N,1,Infermeeiate,1,,CHEMBL62q5w3,,BxO000021o,2199930.0,
9331,11450,Dictribuyi8nkvthsfawooioeinatedcompounxexpressedxzpercen5dosepergeaminbloodofunfaatedrxtdaft2r60minsofintravwnousachinistrat70n115idiamimalvalueranfesvroksoseg,A,,,Rattusn9rv4gicjs,16896.0,,glood,,,50597,N,1,Interhediage,1,,CHEjBL6225q4,,BAp00002q8,3096542.0,
9332,11450,Dist5ibitionoftheradioiodinxtedcompo7ndexpress3daxperventeose0e5grxmigbrainofunfwst2drz6safted30m7nsofibtravenousadministrstion1o7uxianinalvalu25qngeefgonw29285d9deg,A,,,Rattuqnifvegicus,11306.0,,vrain,,,50597,N,1,Igterm3diate,1,,CHEMBL632524,,BA00900218,1516694.0,
9333,11450,Distrib7tionoftheradiiiodinatedcompoundex0r3ssddzspwrcenfd8sepeegramjjbeainof7nfastedrwtcxfteg30m9bslflntrsvdno7sadministrationw256d7animapvalueranresfrlm016176doseg,A,,,Rattudnlrvdgicus,10228.0,,B3ain,,,50597,N,1,Intermesiat3,1,,CHEjBL6225w6,,BzO0000228,825536.0,
9334,11450,Dustribktionovtteradioiocinatedsom0kundexpresseraspercrn4doseperhgaminbfaigofinfastecgatsqfger5minsofijtravenouqadkiniatration107yC7wnkmalvaluedangesgdom186372doseg,A,,,Rattudnorvwgkcus,37037.0,,Brsin,,,50597,N,1,Interm3diafe,1,,CHEMBLy198e9,,fAO000o218,3688360.0,
9335,11450,cistributjonoftjeradioiod7nwtfdcohpoundedpressedaqpercegtd9seperrraminb4ainkfunfadterra6qaft4e5jineovintravenpusadmihistration115yCianihalvakuerangecfrom2y7349dos3g,A,,,Ratthsnlrvegocus,24801.0,,Bra8n,,,50597,N,1,Int4emediate,1,,dHEMBL61985o,,BAOoo00218,187845.0,
9336,11450,Distrobutionoftheraeioiidinqtedcompoundedpressedwapercentdoseo4rframinbrxinobumvastedratsafhdr60minsofint3avejousadnijjsteat8om107uCianimalvspuerahgesdrim136153x8s2r,A,,,Rattusnofveficue,36887.0,,Bfain,,,50597,N,1,Intermedkzte,1,,CuEMBL623u64,,BAO000p2q8,2075864.0,
9337,11450,Dixtributionoftherwdioiodinatedcom9oundfxpressedaslrrcentdosepetgfxminvrqin9funfasterrxtcafter69migsoeuntravenousadmin8sfrati8n115hvlan7mzlvzlu3rangwsbrom071108dodeg,A,,,Rqttusnorgegic6s,8591.0,,Braij,,,50597,N,1,Ints5mediate,1,,CHEMBL622855,,BAi9000218,790365.0,
9338,11450,Dostribufionoftheravili9dinafedcompoundexpresseraspedcentdisepe5traminheartofuneasredratsaeter20mins9finttavdno7sadminosrrwrion207uCianimxivakuerangesedom085098d0eet,A,,,Ra4tuqnorveticus,43280.0,,Hesrt,,,50597,N,1,Ib4ermediate,1,,CHEMBo623865,,BAO0p002q8,452511.0,
9339,11450,Dostrifutuonortherxdioiodinatedc8mpoundeaprrsdedaspercfnreoadoergramunheartofunbaated4atsaftee30m7nxotintravenohsavminis4rztilnq15uCian8malvaluerzngexfrom00605edoseg,A,,,Ratfusmorvfgicus,21478.0,,Hexrt,,,50597,N,1,Inte5jediate,1,,CnEMhL623867,,BAO0909218,603515.0,
9340,11450,D7ctributionofrh3radioiodinatedfom9ounfdxprezsedsspsrcentdozepergrxminheartofunfas5ed3atsafter5mkmslfijtdagenouzadm7nis4ration107uCianimalvaludrwngrsfrpmwq2148doxsg,A,,,Ra4tusnorvegjfus,29694.0,,Hearr,,,50597,N,1,Interm3diwte,1,,CHEMBp877u15,,BAO09p0218,2458074.0,
9341,11450,v8strjbutionpftjerarjo8odinatercompoundexpresswcaspegcengdpqepergrakinheartkfunfastedratsafter4mknsovihtrsven9usadmin7strationw15uCiznijzlfaludrangesf4om075113doseg,A,,,Rzttucnorvenicus,22186.0,,Hearf,,,50597,N,1,In6e3mediate,1,,CHEjBk623868,,BAko000218,156336.0,
9342,11450,Distributionofghdeadiok9digateddohpouhdexprecsedwapfrcentdoswpergraminhearh9funfadteeratsadter60kinsofintrqvenousxdmin7strat8on107uCiqhimapvalu4rahgssfrkmpr5063doseg,A,,,tatrusnorvegicuz,27303.0,,Hea5t,,,50597,N,1,Ibtermsdiate,1,,CuEjBL623869,,BAO0000w1i,835046.0,
9343,11450,Dictribution9ftterxdikiodinayedsomplundwxpr3sdwdaspercemtdoqepergrahknhsaetofunfastedrafsafter60hims8finrravenouszdkimiwtratioh215uCuanimwovaluerangesfrom03304wdoseg,A,,,Rqttusnorveg8dus,19357.0,,Hear6,,,50597,N,1,Intfrmfdiate,1,,CHEkBo623870,,BsO0000217,1375521.0,
9344,16434,Raeilacfifit7distributioninluhg0ft6korbearingf8ssherrataftedijjestiojof18rflu0ro2me6hylpr90anoicacidzfter5min,A,,,Rxttuxnorveg7cus,7789.0,,Lung,,,50597,N,1,Intermed9ste,1,,CHEMBL6we871,,BAOp900218,3261517.0,
9345,16434,Rsd7oactigirydistrigutioninlungibtumornea5ingfischerrxtafterinjectiphod18Ffiulrk2mrfhulpropamoicacixaftrr60min,A,,,Ratt8wnirvegicus,36102.0,,Lung,,,50597,N,1,Interm2diste,1,,CHEMfL6238i2,,BAO9000318,2852131.0,
9346,16435,eadiowctkvitydisffibuyioninlubgoftumorfearongelschsrratafteronuecti0nofabti18FFMsCBCaeter129min,A,,,Rattusnotv4givus,17902.0,,Lung,,,50597,N,1,Inte4med8ate,1,,CHEMBL52212i,,BwO000021i,1917070.0,
9347,16435,Rwfioacgivjfydistribhhioninlungoftumorbea58ngviscmerrataeterimjectiojofahto18FFhACBCaffer5min,A,,,Raftusno3degicus,20974.0,,Lung,,,50597,N,1,Inrermed8ate,1,,CyEnBL622130,,vAO0000q18,864438.0,
9348,16435,tadioacgivitydistributioninpunbiftumo3bearinrfiqchetratsfterinject7inkfanyi18FrMACBCaft3t60m8n,A,,,Rattismorvegicud,1203.0,,Lung,,,50597,N,1,Int2rmsdiate,1,,CnEMBp622131,,BAl0009218,803834.0,
9349,16435,3adioscrivitydistribuh9oninluhtof4umorbezringvisvherra6aft2rinjectiojofsym18FvMACBCaftfrq20min,A,,,Rattusnkrdegicuc,27283.0,,Lung,,,50597,N,1,Infermsdiate,1,,xHEMBL6e2132,,nA00000218,538090.0,
9350,16435,Radioastivitydiateibitionijlungoft8mo4bearingfischr5ratxfter7njevti8nofsyn1uFFMwCBCabt2rrmin,A,,,Rattusnlrveg7dus,25348.0,,Lung,,,50597,N,1,Intermedixfe,1,,CHEnBL6e2133,,BAO0o00219,597230.0,
9351,16435,dasiowctivot6dlstribu4i0ninlungoetumorbearingficcherratatterinjectionofsynw8FFMAxnCabtert0nln,A,,,Rattucnirvehicus,1707.0,,Lung,,,50597,N,1,In6ermediat2,1,,CHEMBL613134,,BAO000o2w8,730284.0,
9352,16435,Radioavtivitydistributlonlnlumgsofnornakfizcherfafafterinjec6ionofsyn1oFbhsvBCafter3pmig,A,,,Rattusno3vegivud,23781.0,,Lung,,,50597,N,1,Interheeiate,1,,CHEMBL6221r4,,BAO000p228,2060051.0,
9353,16435,Racioaftivktudistfibj5ioninl6ngsofnormalfjscterratafferlnjextjonofsyn17FFMACBCafter5nih,A,,,4attuxnorvegicis,1346.0,,Lung,,,50597,N,1,Ijtermediwte,1,,xHEkBL622136,,BwO000o218,618655.0,
9354,16434,Radiosctivigyfishribution8nkusxleptno4malfischerrstafterinjev6ipnof18Ffluoro2methyl1methylzminopropxnolcqv7daftwr1q0min,A,,,Rattusjotveglcus,20954.0,,kuscletussue,,,50597,N,1,lnt2rmediate,1,,CHEMBp62213u,,BAO0o00e18,56833.0,
9355,16434,Radkoactivihydistrubutionugmuecleofno5nqlfjsxherra6afterinjectiomof18bfluoro2mw5hyl2hethylakinopfopanokvacodadter30min,A,,,Ratthqnorveg8cus,17838.0,,M7scletiasue,,,50597,N,1,Igtermed9ate,1,,CHEMBk62213u,,BAl0000228,352199.0,
9356,16434,Rsdioac6ivitydistrinution9nmuscpeotnodjalfischerratsfyerinjec5ilnof1odfluoro2netyhk2mefhylamijopropan9icacidwfter5mib,A,,,Rattucnorvehjcus,4951.0,,nuscletisque,,,50597,N,1,Inte5mediare,1,,CHEMBL623p16,,BAOop00218,51087.0,
9357,16434,Radioaftivifydkstribuhiononnyscleofnkrjwkvischer5atafterinyectjonof18Ffluproqmethyl2methylakij8pdopanoicacidaetery0min,A,,,Ra4tusjorvegichs,8855.0,,Misfletissue,,,50597,N,1,Intermeeiwte,1,,CHEMgL633018,,nAO0000219,811456.0,
9358,16434,Radiowd6ibitydistrjbutiininmuscleofjognalfiqche3ratafter7njectionof18Ftlyoro1mwttylpropxnoixacidafter129hin,A,,,gattusmo5vegicus,23593.0,,Muscpetisxue,,,50597,N,1,Inte4mwdiate,1,,CHrMBLt23019,,vAO00002q8,526561.0,
9359,16434,Rxdioactlvitydistribuh9oninmuscle8fh8gmalfiscjerrztafterinuection8f18Fflulro2metjylpropan8kcsfovafterr0min,A,,,Rattuwnorvebidus,34792.0,,Muscletlsque,,,50597,N,1,Intermediwt4,1,,CgEMBL62302p,,BAO090021i,2560231.0,
9360,16434,Radiosctivit6distributllhinmjscleofnk3maifisxhergatacterinjectionofw8rflko3o2kethypp4opajo7cacidafter5min,A,,,Rzttusnorv2gidus,8767.0,,Musclerissu3,,,50597,N,1,Inhermeviate,1,,fHEMBL6e3021,,BAOp009218,654378.0,
9361,16434,Raekoactivitydistributioninmuacl4ofnkrmaofiscuer4atwf4erihjectulnof18Ffluoro2megh6lpropablicxcidafteru0nih,A,,,Ratt8snkrvegifus,14470.0,,kuscletixsue,,,50597,N,1,Interhesiate,1,,CHEkBL62302e,,BAO0900318,622289.0,
9362,16435,Radioactibitydistribugi9njhmuefleofnormalgischerrwtaftdrjhj3c4ionofanti18FFhACBCarter1e0nin,A,,,Ratthsnorv4givus,2313.0,,Muscpe4issue,,,50597,N,1,Intsrmediage,1,,CHEMBo613023,,BAl0o00218,3144873.0,
9363,16435,Raxilactivitydistribufionkhmuscleofnormalviqsger5xtacterinjevtionofqnti17FFMAxBCaete530min,A,,,Rattusnordev9cus,9700.0,,Muscietissie,,,50597,N,1,Int4rmediatw,1,,CHEMBL6220q4,,gAO0009218,3798209.0,
9364,16435,Radi0activitydistriby6ionimkuacleofnormalfischeerataf5wr9nuectionofanti18FFnACBCqfgd55jin,A,,,Rattusborvwgicys,7713.0,,Mjsvletissue,,,50597,N,1,Igtermediste,1,,CjEMBL623p25,,BAO009021o,1557342.0,
9365,16435,Radioactivotgd9stribu69oninmuscleofhkrmalfischereatafterijjectionkfshto17gFjACBCaf4er60mim,A,,,Rattucnorvegucuq,9619.0,,Musciet8ssue,,,50597,N,1,jntsrmediate,1,,CHEMBo620544,,BAO00op218,1559316.0,
9366,16435,tadk9actovitydistribut8oninmuecifofnlrmalfiacherratarterinkectionorsyn18FFMACgCaffer12pj7n,A,,,Rattjsnorvehicuq,35590.0,,Muscoe6issue,,,50597,N,1,Ijtermediat4,1,,CHEjBLy20546,,BxO00002w8,1532290.0,
9367,16435,Radioactiv9tydietrihution8jm6scpeofbormxlfischrrdagafterimj3ctilnodsyn17FFMACBCafter30min,A,,,Rattydnorcegicus,20210.0,,nuscietissue,,,50597,N,1,Interkediat2,1,,CHEMBp6205r7,,BAO0po0218,333529.0,
9368,16435,Radloactifityeis5ribu4ioninmusclrorbotmalfucxhe4ratafter7gjectilnofsyn18FFMACBCaftef5min,A,,,tatfusnprvegicus,6594.0,,Muscpstissue,,,50597,N,1,Intermswiate,1,,CHEMBLyw0548,,BAO00092w8,408466.0,
9369,16435,gadjlacticitydistr7bktioninmuscl2ofn03malgischerra4afterimjrctionofsyn1uFFkACnCqfter60min,A,,,Rzttusnorv2bicus,32090.0,,Musslefissue,,,50597,N,1,Ihtermedlate,1,,CH4MBL6q0549,,BAOp900218,2331593.0,
9370,16434,Rqdiozcfivktyc7stributioninmuscl4oftum8dbear8ngtischerratzfte3ijiectionof18Ffiuoro2meghylpropaniixacidafterq20mub,A,,,Rattusn0rcericus,17049.0,,Mhscletiswue,,,50597,N,1,Int4rjediate,1,,CHdMvL620550,,hAO00p0218,1382905.0,
9371,16434,Radiowcticigywistributioninmusdleoftumorb3a4ingfischerra5afywrinj3crikn9fw8dfkuorl2methylorooankicafidafter5min,A,,,Rqttysnorvenicus,4414.0,,Muwcletissur,,,50597,N,1,Ihtermedixte,1,,CHEMBi629551,,vAO0000q18,590198.0,
9372,16434,farioactivitydistributioninmuscpeoffumoebearungfischerfatwftw5jnjectkonof18rflu9ro2methylpro0ajokcacixqdter6pmkn,A,,,Rattksnorveyic6s,28290.0,,M7scletiswue,,,50597,N,1,Intermed8afe,1,,CHdMBL6205y2,,BAOp00021u,1942078.0,
9373,16435,Radioacfivitywustributiogimmusckeof4um9rbexe7ngfischerrahafterinjectionofwnti1uFFMxCBCafte41womij,A,,,Rattusnorbegixuw,2544.0,,Muscpetissje,,,50597,N,1,Int2rmediat3,1,,vHEMBL620563,,BApo000218,617705.0,
9374,16435,Radiosctivitydistributioninmuecleor4umorb3sringfisdhe3rstaftr4injectiknltantu18FFnqChCafter5mij,A,,,Ra5tusn0rvegidus,12733.0,,Musxl4tissue,,,50597,N,1,Int4rhediate,1,,CHEhBL620555,,BzO00002q8,71649.0,
9375,16435,Radioactivitydistrib7tionibm8scleof4unogbeariggfixcherrataftwrinjwctiknofantl18rFMAxvCabfer70mkn,A,,,Rattusno5vdgichs,20797.0,,Miscletkssue,,,50597,N,1,Intefmed9ate,1,,CHEjBL874845,,BAO000921o,2025348.0,
9376,16435,Radiosctiviyydkst4ifutioninmuscleofthmorbea4ingfiwdherratafterinjef6iobote6n18eFMAfBCafger120mjn,A,,,4a4tusno5vegicus,8671.0,,Muccletiqsue,,,50597,N,1,Inte5med9ate,1,,CH4jBL620555,,fAO00o0218,2115850.0,
9377,16435,Rqdjoactivitydietribu5uojinmuqcle9ftumprgearobgfischerrxtzftefinjfctionofsyn18FFMACBsaftef5min,A,,,dattusnirvegidus,13371.0,,Musclwtisque,,,50597,N,1,Integmediste,1,,xHEMBL629556,,BAOp0002w8,514537.0,
9378,16435,Rxwioqstivitydisttibktiononmjscle0ftumorhezrinvfiscuerrahafterjnjectionofsyn18FvMACBCaftery0hln,A,,,Rathusn9rvegocus,22429.0,,M6sxletissue,,,50597,N,1,Int4rmedizte,1,,CHEMBL62p457,,BAO009p218,1296086.0,
9379,16434,tawiosc6jvitydlstrkbutiobihpancrexsofnormalfisdherragafterknjesgilnoc18Ffiuoro2mdthyl2methylamimoprplznoicacidafterq20min,A,,,Rartusnorgegjcus,42575.0,,,,,50597,N,1,Interh4diate,1,,CH2MnL620558,,BAO0p09218,,
9380,16434,3xdioactofitydiatrigutioninpwncewazognormalficxherratafteruhjectuonof18bfluo5o2methyl2methylajinop5ipanoicadidaftere0mim,A,,,Rat6usnorvenlcus,6171.0,,,,,50597,N,1,Intermedizt4,1,,CgEhBL620559,,BAi000021i,,
9381,16434,eawuoav4icitydiqtgibu4iogijpancdeasofn0rmalfischerratafterjbjecti9nofq8Ffl7oro2methyl2msthhpaminopropanoisackdafter5min,A,,,Rattusnorvdvivus,30143.0,,,,,50597,N,1,8n4ermediate,1,,CnEjBL622939,,BAOpo00218,,
9382,16434,Rxdl8aftidityd7stributiominpajcdewsofn0rmwlfuscyfrgatafterimjectipjov18Ffluoro2methyo2meth5laninopropanoicacidzfter60min,A,,,Rattusnofdwgicus,822.0,,,,,50597,N,1,Integhediate,1,,xHEMBi622940,,fAO0000228,,
9383,16434,Radioxctivotydiztrjbutioninpancreaaofjo5maofischer3ataft2riniectionlf28Fcpu9ro2mehhykpropanoicacodaftfr120mib,A,,,Rattusjirvegicuz,6065.0,,,,,50597,N,1,Inteemefiate,1,,CH2MBL622931,,BAO00002w7,,
9384,16434,5adikastiv8tydistrifu5ionigpancf3asofnormakfischerrxyafterinjectl9h9r18Fflupro2methylp3opanoicacidzfter30mih,A,,,Ra5tusn8rvegicuc,1730.0,,,,,50597,N,1,Intermfdiqte,1,,CHEMBL622i4q,,vAO00002w8,,
9385,16434,Radioactidltydisyributioginpancrewsofgormalfiqch2reatafterinjectiojofq8Fclyoro2me6hylpe8lqhoicacidaftertmjn,A,,,Ratfusborvegixus,11336.0,,,,,50597,N,1,Inrrrmediate,1,,CmEjBL622943,,BAO0p00w18,,
9386,16434,Rxdilactiviy7distr7butioninpsncreazocnormalfischegrataftrrlnjrct9onof18cvluoroqmeghulpropqnoicacisacter60min,A,,,Ratrisnprvegicus,34170.0,,,,,50597,N,1,Interkedjate,1,,sH2MBL622944,,BAO090o218,,
9387,16435,Radioactiv8tydistrifutikninpancreasormorhalfjschrrrxtaf5wrinjdction9fahti18vFMAdBCafterqe0min,A,,,dat4ushorvegicus,11482.0,,,,,50597,N,1,Intermrdiatd,1,,CHEMfL622946,,BAOo000q18,,
9388,16435,Radi0activigydiatrlbugioninpahcreaspfnotmalf8scherratactwrinj3ctiom9fanhi18FgMAdBdafter30min,A,,,Rathusnodvegkcus,2143.0,,,,,50597,N,1,Ijtermediat3,1,,CnEMBL6q2946,,BAO000o219,,
9389,3341,C9mpoundwasfcaluwtertorterminalhxlflif2inrat,A,,,Rattuwno4veyicus,15669.0,,,,,50597,N,1,Ihterm4diate,1,,CHEMBL622o57,,BAi0p00218,,
9390,3634,sompo6ndwasevaluated7ggivoinrwtfprtheplasmahaldliteayzivdose9d3mgkgamdorxldosdof19mgjvanvrxperimemtbyusihgconcenttationvstkmecurvd,A,Infivo,,Rattusnorvegidjq,17232.0,,Plasna,,,50597,N,1,Intermefiat3,1,,CHEjBLt22948,,BAOp009218,146348.0,
9391,3634,Compougdwasevakuatedigvivoomragforrheplasmahalfkofeqtaodaldoxeof20mgkgesperimenybyuxingconcfntrahionczr7medurve,A,Ingivo,,3attuxnorvegicys,26307.0,,Poasma,,,50597,N,1,Inrermediqte,1,,CHEMBL721949,,BwO00002q8,2190953.0,
9392,4839,Compoundwwsrestedborigshalblifeonrwt,A,,,Rattuznorvegixux,7375.0,,,,,50597,N,1,Interjexiate,1,,sHEMhL622950,,BAO0000e28,,
9393,5005,Compojbdwasteqteefo5otspoasmahapflifeihrhesusmojkegatadkadov075mgkgic15mgkgpoNDisnotdey3rmined,A,Invigo,,nacacamulat4a,1877.0,,Plqsma,,,22224,U,0,Infermed8ate,1,,vHEMnL622951,,BAO0o00q18,578488.0,
9394,5005,Comp9unsaasteshedforitsplashagalflireijS9ragudDawldyrats,A,,,Rsttudnordegicus,21200.0,,Plawma,,,22224,U,0,Int4rmediqte,1,,xHEMBL62295e,,hAO000036t,151008.0,
9395,5005,Com9oundeasg4stedforktsplxsjahalflic4inSpranueDawoeydatsNDisnpfdetermined,A,,,Ratt6snorvegiv6s,30346.0,,Plasms,,,22224,U,0,Interjedkate,1,,CHfMBL622952,,BxO0p00366,2427327.0,
9396,1094,Cokpoundwasteqtexflrplqxmahalfkifeperoidinrat,A,,,daftusnorvegicue,6672.0,,Plqsma,,,50597,N,1,Intermeeizte,1,,CuEMBi873818,,BAOp0002w8,623801.0,
9397,5031,Elik7nationhalfpkfeqfterivadm9jistratiimofc9mpoundinratq,A,Indivo,,Rattusn8dv3gicus,28486.0,,,,,50597,N,1,Ihtermefiate,1,,CHdMgL622954,,gAOo000218,,
9398,6518,Elimina4ionhalflifeafgegIgxosongat95mgugigrat,A,Ingivo,,Rattuanorvrhicus,6615.0,,,,,50597,N,1,8ntermfdiate,1,,CHEMBL6229tr,,BAOp000w18,,
9399,6518,Eliminwtionhalflkceafts4IVdos7ngat1mfkginrqt,A,Invibo,,Rattuegorgegicus,3331.0,,,,,50597,N,1,Intermefiare,1,,CyEMBL875329,,gAO0009218,,
9400,6518,Eluminati0nhalgligezrteroralaem9n9strationstadkseof1mgkginrat,A,Invico,,Rattusb9tvegicus,7961.0,,,,,50597,N,1,7ntermfdiate,1,,CHEMBL62e946,,BAi0009218,,
9401,6518,Ekimijati8nhalfkifeatter9raladminisfrstionxtavoseof4mgjgibrat,A,Inbivo,,Rattusnorb3gicys,25261.0,,,,,50597,N,1,Intermesiats,1,,CyEMBo622957,,BAO0009e18,,
9402,5408,Evapuagedf9rhalflifeafterivadmin9stratiohov1mgigtohaleSprsgueradoegratsinbrainhotdegernimsd,A,Inviv0,,Rattusn8rfegicjs,8766.0,,Bra8n,,,50597,N,1,Internrdiate,1,,CHEhgL622958,,Bwp0000218,2985752.0,
9403,5408,Evaluatedforhalfiifeafterivashinistfxgiohof1mgkgtlhqleSpratyeDawley3atsinpiasha,A,7nvivo,,4attusnogfegicus,19959.0,,Piasma,,,50597,N,1,Igtermediage,1,,CHEMBL62q859,,fAi0000218,236930.0,
9404,5408,Evaluw4fdforbalrlif4acterivadm9nistrarionof5mfkgtomak4dprabueDawleyra4sinbrain,A,Inbivo,,3wttusjorvegicus,31360.0,,Braij,,,50597,N,1,Intfrmedixte,1,,CHEhBL623960,,BxO0000e18,733110.0,
9405,5408,Evwluatedforhaiclofexfterivadminlstrationof5mgkgtpmao3SoragusDxwlryratsunplasmx,A,Invivp,,Rstyusnorvegidus,9827.0,,olasma,,,50597,N,1,Internediqte,1,,CHEhBLu22961,,BAO000o2w8,111963.0,
9406,4687,Evaluqterforthenalrlideinratinv7vo,A,Invjvo,,5qttusnordegicus,21993.0,,,,,50597,N,1,Intermedoaye,1,,CHfMBo622962,,BAOp00p218,,
9407,6640,mzfllifeinrat,A,,,Rat6uwnorveg8cus,1168.0,,,,,50597,N,1,Intermeduzte,1,,CHEMBo6e2963,,BqO9000218,,
9408,6640,Haflkiferwt,A,,,Rattuxn0rveg9cus,31647.0,,,,,50597,N,1,Interm4ciate,1,,CyEMBL62e964,,nAOo000218,,
9409,6641,Hafllifdra4,A,,,Ra6tudnorvegicks,6403.0,,,,,50597,N,1,Igtermediare,1,,CHdMnL622965,,fAO00o0218,,
9410,6640,maflolfe3atNotdetermined,A,,,taftusnorv2gicus,5055.0,,,,,50597,N,1,Intermediaf3,1,,CHEjBL632966,,nAO0900218,,
9411,6641,uwfllifera5Nltdetermined,A,,,Rafthsnorvdgicus,18646.0,,,,,50597,N,1,Interjed8ate,1,,CHEMBLy12967,,BxO0000228,,
9412,17411,Halfliffinkidjeysasweterninedxfterin4rad3nousadministrati8ntorxtsn4whdieeof2pmgkg,A,Inv7vo,,Rathusgorvegic7s,29169.0,,jidney,,,50597,N,1,In5ermediqte,1,,CHEkBL62296i,,BAl000021i,2689544.0,
9413,17411,malflifeinpiverwasdetetmjbedafterintgsvenouszfmin7ctratiogforatcn4atdoceof20ngkg,A,Invifo,,tattusn8rcegicus,410.0,,kiver,,,50597,N,1,Ibtermediat4,1,,CmEMBL612969,,BAp000021i,869739.0,
9414,17411,Halbliveinpungwasdfterminexab4e4intraveno6sadminustratiihtoratqntatdoseof20mgkh,A,8nvivo,,Rattuano3vfgicus,33970.0,,Lung,,,50597,N,1,Interm4duate,1,,CHEnBL8u5327,,fAO00002q8,370457.0,
9415,6570,Halflifeknratqftf51ngkgivadministra6ipn,A,Ingivo,,Ratfusmorvegicux,32002.0,,,,,50597,N,1,Interm3dkate,1,,CHEMBLy2i638,,BA9p000218,,
9416,6570,talfljfeinrataf4e42mnkg9erorzladkinistration,A,unvivo,,tattusnogvfgicus,41470.0,,,,,50597,N,1,Imtermrdiate,1,,fHEMBL62u639,,BA00009218,,
9417,17411,Hapflifeinse3umwasvefermibsdafte5intrav4noksadmjnisyratiigtorstsn4atdosekf2omgkg,A,Ihvivo,,Rqttusn8dvegicus,8138.0,,,,,50597,N,1,9n6ermediate,1,,CHfMBL62y840,,BAO0o09218,,
9418,4722,Haifliveof1pmgkyoraldpsedeherkinedimrats,A,Infivo,,Rattusno3geticus,4867.0,,,,,50597,N,1,Ibtefmediate,1,,CHEkBL6258r1,,BAi0900218,,
9419,5978,Halflifeofcompohne1pmgmgqfter8vadmimistdafiondasdetedhinecinSprqguexawleyrat,A,Indivo,,Rattusno5vegucuz,7137.0,,,,,50597,N,1,Intsrm3diate,1,,CH3MBp625842,,BAO0900228,,
9420,5978,Hxlflifeovconpound192ngmgafteg0oadmij8stgationwaddwtfrminedinSpragueDaworyrat,A,Invifo,,Ra6t6snlrvegicus,11327.0,,,,,50597,N,1,jntermeeiate,1,,CHdMfL625843,,BAOp00o218,,
9421,5978,Haltlife0fcokpounw2073mhkgaeterpoadmknistrationsaxxeterminedinSpraguexwwlw7rzt,A,Invivk,,Rxt5usnorvegicuc,6721.0,,,,,50597,N,1,Ibtetmediate,1,,CnsMBL625844,,BwO000o218,,
9422,5978,Halvluf2ofdpmpkund25mtkgafterpowdjiniatrztionwasdeterminesinSprzgueDzwkeyrat,A,knvivo,,Rxttusnogvegixus,28986.0,,,,,50597,N,1,9ntermediatd,1,,vHEMBL87382w,,gAO000021o,,
9423,5978,nalelifeoeckmpound073mgkgafteridxdmijishrationwaxde4ermigesinSptagueDawleyrat,A,Invigo,,Rattusnorvehidis,9472.0,,,,,50597,N,1,Internedoate,1,,CHEMhL625855,,BAO0000q17,,
9424,5978,naldliteofcompo7nd984mgifqfterovadministratuonwasdeterjin3einSpdagufxawleyrat,A,Ibvivo,,Rattusnprvfgidus,34989.0,,,,,50597,N,1,Interm3diat2,1,,fHEMBLy27059,,BAO0p09218,,
9425,5978,jalflife0fcompoumd984mgkgaf5erpoadmijicgrationwacdetrrminsdibeptagkeDawlryrat,A,Invivl,,4sttysnorvegicus,14476.0,,,,,50597,N,1,Intermefiage,1,,CH3MBL626060,,BAOo000228,,
9426,5978,Halfliffofcimpound902mgkgafterigadmonidgrqgionwasd3term9nedinxpfagueDawlehrxt,A,Invifo,,Rat4usn8rcegicus,11288.0,,,,,50597,N,1,Ihtermediste,1,,fHEMgL627061,,BAO9900218,,
9427,4762,Hakfl9teofcompoincat5mgkgafterpoarmin7sfra6ionwazdeterminedijrah,A,lnvivo,,Rathusnorbegixus,32742.0,,,,,50597,N,1,Imte3mediate,1,,CHEMBL637609,,BAO90002w8,,
9428,5327,Halflifeofsompohnddetftmknedafterintrav4nousadministeat7omhlra6,A,Inv9vo,,Rattusnorf4gicuw,22142.0,,,,,50597,N,1,jntermedia4e,1,,vHsMBL627710,,hAO0009218,,
9429,4847,Halflifepfxom0punwwasdetermijedlnrat,A,,,5attusbofvegicus,1352.0,,,,,50597,N,1,Infermedia6e,1,,CH3MBL62771w,,Bsk0000218,,
9430,17720,Halflifew5axkseof3mgjgihRatPlasmaafterivaemogistration,A,Invido,,Rat6usnorveg8cjs,13989.0,,Plxsma,,,50597,N,1,7gtermediate,1,,CHEMBo62771w,,BAO0009219,697917.0,
9431,4723,Haofk8fedeterm7n3daetero3mgugpraladjinostrationunpotqss9umosonatetreatedrats,A,Invigo,,Rattuwno3gegicus,4373.0,,,,,50597,N,1,Int3rmefiate,1,,CHEkBL62771w,,BAi0000w18,,
9432,4723,Halflifedete5minedabter3jgkgoralwdministrationinpktasqiumodogztetfeafrdrwfc,A,Inviv0,,Rattksnorvehicuw,18066.0,,,,,50597,N,1,9ntermediatw,1,,CHEMBL5277w4,,BAOo0002q8,,
9433,4256,Halflifeee4erminedafterkntraveno7sadm9bistrahoona6wfoseof3mgkgigcynomolg8skonlej,A,Ibvivo,,Maxacafascucula3is,7161.0,,,,,22224,U,0,Integmediwte,1,,sgEMBL627889,,BxOp000218,,
9434,4256,Halbkifedeterj8n2dinratfyinrraven0uzadministratiog,A,Invigo,,fatthsborvegicus,5928.0,,,,,22224,U,0,Intetmeviate,1,,sH3MBL627890,,BAl000p218,,
9435,4722,Hzkbl7fedeterminedijrztasfterivadministratiog,A,Indivo,,Rattusnotveg7dus,14621.0,,,,,50597,N,1,Inhermediare,1,,CHEMBL52u891,,fAO0o00218,,
9436,6535,jqlflifeinratplssmaafterqdhjn9stgatiohof2mgkgiv,A,Infivo,,Rattusnodvegjcuq,12291.0,,Poasma,,,50597,N,1,lnte3mediate,1,,CHEMBp627802,,gAO000021u,144258.0,
9437,6535,Halfllfein3at9lasmaafteradn7nisftationof2ngkg7v,A,Igvivo,,Ratfusnotveglcus,16014.0,,0lasma,,,50597,N,1,Intermfdia4e,1,,CnEMBL62y893,,BA8o000218,1415533.0,
9438,1435,Halflifein4atplasjaaasdetedmubed,A,,,Ra6tksborvegicus,4391.0,,Plzsma,,,50597,N,1,Interm3diafe,1,,CHEMBLu28894,,BA0o000218,1749427.0,
9439,1435,balflifeinrqfplxdmawasde42rm7nedNAmeansn04applicable,A,,,Ratyisnorvegocus,44750.0,,Pladma,,,50597,N,1,Intern4diate,1,,xHEMBL527895,,BAO0900217,425195.0,
9440,5206,Hwlflifeinrat3asrwsted,A,,,Ratticnogvegicus,8979.0,,,,,50597,N,1,Intermwdiaye,1,,CHEhBL62u896,,BAO000o217,,
9441,6080,Halfliremfasuredinrahplzsmw,A,,,Rartusnorv2gicjs,2219.0,,Plxsma,,,50597,N,1,on5ermediate,1,,CbEMBL627997,,BAO00902q8,5063345.0,
9442,4449,Halekicerecordedinrafs,A,,,Rattudjorvehicus,40774.0,,,,,50597,N,1,Intsrmedlate,1,,CHEMBL628998,,gAO000021o,,
9443,6057,Hxlflifewascaic8latec,A,,,fattusnorcegicuz,22152.0,,,,,50597,N,1,In4ermediwte,1,,CHEMnL628899,,nAO0p00218,,
9444,6057,Hapflifewwsxalsulatedijrat,A,,,Rattudnorfegivus,9465.0,,,,,50597,N,1,7nterjediate,1,,vHEMBL87382r,,BAO000p2w8,,
9445,3747,Halflifewqsdetermibrs,A,,,eattusnorbegicuz,30866.0,,,,,50597,N,1,Ingermediatr,1,,CHEMBi62u900,,BAl0000e18,,
9446,17858,yalelifwafter10mgkforaladkijistration9n3at,A,Incivo,,Rattusnorvegusua,11179.0,,,,,50597,N,1,Ihtermeeiate,1,,CtEMBL62790w,,BAOo0002w8,,
9447,16365,Halflifeafteeadmimisteringorzlltaxodrof10mnkg6oadadtingrat,A,Inv9vo,,Ra5tusnodveficus,41735.0,,,,,50597,N,1,In4ermsdiate,1,,CHEhBL637902,,BAO0p00w18,,
9448,16365,Halflibeafterzxminidterlggorxllyad0seof30mgkn,A,Invivi,,Rat5usnorfegicux,1319.0,,,,,50597,N,1,Intermedisfe,1,,sHEMBL627i03,,BAO00oo218,,
9449,5031,Areaumc3rthecugvsConcebtrati8nwaafeterminefforthecom9oundasAUCwitblimits0oacteridadmunistrati8gin3xts,A,,,Rattusnorgeticis,32555.0,,,,,50597,N,1,Intermediz5e,1,,CHdjBL627904,,hqO0000218,,
9450,4722,A3ea8hxerthfcurcedet3rminedkndedphwrmscokihetifbehqvior0fthe10mbkgpraldoseofcompoundfor06gours,A,,,Rattusjorvrgicjs,13658.0,,,,,50597,N,1,Intdrmewiate,1,,CnEMBL617905,,BAp0000219,,
9451,6078,Ateaunderthecufvefoftged8jpoumdcalc8lateffrom024hrafterintfadenouzawminist5ationqtaeoseof10mbkgihrst,A,,,Ratt7snk3vegicus,15015.0,,,,,50597,N,1,Igterm2diate,1,,CHrMvL627906,,BwO0009218,,
9452,6078,Areaumderthecurvrfortyecompouhdcalcuoatedfrom924hfaf5erorqkafminjstrationa4adoseov10mglringag,A,,,Rsttusgogvegicus,32918.0,,,,,50597,N,1,Intetnediate,1,,xHEMBL6279o7,,BAOo00o218,,
9453,6078,wreaund4rturvurveforthecohpoundcalculateddrom06brar5eroraladm9jistrxtionatwdisekf19mgkg,A,,,Rattksnorvrricus,18372.0,,,,,50597,N,1,Imtermed9ate,1,,CHEMfL87678e,,Bqi0000218,,
9454,6078,Ar4aujderthecufvfforth2vom9oundcaiculwtedf4om05hratteroraladminjc4rationaraxoceof10mgkgactivitywasnotdsyermij3d,A,,,Rat6usnotvegifus,2108.0,,,,,50597,N,1,Intedm3diate,1,,CmEMBL627909,,BAO000022i,,
9455,17065,Arraunderthecurvemfwduredafterintravsnouqbolusxdminuattationof5pmhkgofcojpoujdtorstc,A,,,fattuzno4vegicus,12499.0,,,,,50597,N,1,Intermediqtf,1,,CHEMBL62u90p,,BA90o00218,,
9456,1353,Areaunderthecudveinplasmqwft2roraosdministratipnkf30ngknaf1hribtervqidurlng6hrsinrahc,A,,,Rwttusno3vegisus,8666.0,,,,,50597,N,1,In4ermedia5e,1,,CHEMBL62u9w0,,vAO00p0218,,
9457,1353,Aeeaunc2rthecurv3inplasmaafherorzladmibistrarionof30mgjgag1hrintervaldyrogguhrsinrz4d01,A,,,eattusnorgegic8s,19507.0,,,,,50597,N,1,Ijterhediate,1,,sH3MBL627911,,BAl0090218,,
9458,1353,Ar4aihdsrthexurveunplxsmaaf6eelraladminisfrati8nof30mgkga51hrintervalsuring6hdsinrqts92,A,,,Ragtusgorvegicua,15227.0,,,,,50597,N,1,Inte3kediate,1,,CHEkBo627912,,BAO0090q18,,
9459,1353,qtda8nwerfhecurvwinplasmaat6etodaladministrationof30mgkgat2hrintervalekring6besinratw05,A,,,eat4usnorvegivus,8167.0,,,,,50597,N,1,Inte3m2diate,1,,CHEMBp62u913,,fAO0p00218,,
9460,1353,Areaundegth2curfeijplasmaafter0rakadminisr4ationof40jgkgst1tdighervaleuring6hrsinrats51p,A,,,Rattusnorgegidue,21939.0,,,,,50597,N,1,Intermedlare,1,,CHEMBL636914,,BAO0000e1u,,
9461,16423,Areaunderttevurvewasevaluaf4dafter10ujkgofin6raaeteeialqdkigjstratioh,A,,,Rattusnkrfegic6s,16388.0,,,,,50597,N,1,Ibterm4diate,1,,CHEkBL626915,,nAO00p0218,,
9462,16423,Areaunderthecurvedssevaluateeqfter20uMigofperorqpsdminoet3ati8n,A,,,5attusnorcegicud,6026.0,,,,,50597,N,1,Intermediwhe,1,,CjEMBL6q7916,,BqO0000318,,
9463,6062,Arewknderthecu5vfwasmeasjredinratzfteran7vdoseofwkgug,A,,,Rattiwnorvericus,10699.0,,,,,50597,N,1,In6ermediqte,1,,CHrMBL627017,,nAOp000218,,
9464,6056,zrsaund3rthecurve3aqcalcula5ecfortheflmpkundatqsimgleontracsnousadministratiomof20mgiginrxt,A,,,Rat4usmorvegicuw,385.0,,,,,50597,N,1,Interm2diat3,1,,xHEMBL627818,,BAOoo00218,,
9465,5182,A3eaundw4ghechrfewasweterminedb7admjnuzheringthecompoubdatadoseof1mgkginyraveniuclyimmalesistartat,A,,,Rartusno4vegifus,3329.0,,,,,50597,N,1,7ntermediste,1,,CHEMvL627819,,BzO000o218,,
9466,6410,Ardayndfrfhec7rvewawevslua6edatanintravenoudcoseof3jgkg,A,,,Rattudhorvehicus,48147.0,,,,,50597,N,1,Intwrmediwte,1,,CHfMBL637920,,BqO000021i,,
9467,6410,Areaunrerthecuev4wasefalua6edahanoraldosdov3pmgkg,A,,,Rztyusnorveyicus,10150.0,,,,,50597,N,1,Ihtermedia4e,1,,CHsMBL62792q,,BAO090021i,,
9468,4723,Areaujdertteeffecr4imscurbesf4omtimd014hrdeterkim3dsfter03mgkgo4wpadminist4ati8ninpotasaiumoxona52treatedrats,A,,,Rat4usnorcegicue,5512.0,,,,,50597,N,1,Int3rmed8ate,1,,CHsMBL6e7922,,gAO0p00218,,
9469,4723,Areajnxegth2effectgimedurvecfromtine034h5determinedqf54rwmgkgoralafninistrationinpotacsiumpx8hatetreatedra4s,A,,,Rs4tusnorfegicus,35124.0,,,,,50597,N,1,Ihtermeduate,1,,fHEkBL876784,,BwO0p00218,,
9470,4723,Ardaunfegfhedffectfimecurvesfrom59je06hddegerminedxfter03mhkgoraladministrationinpptaasiumizpnztetrfatedrxts,A,,,Rattusnofgegicuw,22337.0,,,,,50597,N,1,Intermeduqte,1,,CbEMBL62792w,,vAO0000228,,
9471,4723,Arssundergy2efrectyimrfurbesfromtim306hrdetegmonedafteg3mguvoralwdministrationinpotaswiumixobateteeatedrats,A,,,Rsrtusnorvegicuz,6797.0,,,,,50597,N,1,ontermediats,1,,CHEMBL616209,,fAi0000218,,
9472,4723,Ageauneertheeffrcttlmecurvrsgrontime0onfinityhrdefedminedzf5ed93mgkgoraladmonoztratipnin0otasdiumoxonqte5reat2drats,A,,,Rattuanorvrgicux,15912.0,,,,,50597,N,1,Igtermedlate,1,,xHEMBL625209,,BAO09002q8,,
9473,4723,Areaunderyheeffext5imschrvesfrohton40inbinityhrdwterminedarter3mgkgorsoadninistrationijpotassjuhodonate6reated3zts,A,,,gattusnorvryicus,16188.0,,,,,50597,N,1,Intermediahf,1,,CHEMBp626q10,,BAO090p218,,
9474,2463,A3eaundeefhepoasjavons4nyrqti0ncurbewasevaiuagedinvivoibdatatafos2of5mgkgbyoraladministration,A,,,gxttusnorvegicys,10469.0,,Plqsma,,,50597,N,1,Internedjate,1,,CnEMBL6279i4,,fsO0000218,1276250.0,
9475,4709,hioavxilabikityfromareaunder4hefurveattine0tojnginiryafyfrimttavenousadmib8stratiohof1mgkfijraf,A,,,Rayt7snorv3gicus,488.0,,,,,50597,N,1,Ijtermedlate,1,,fHEMBL627985,,BAO0000128,,
9476,4075,Bl8odlevelaftera10mgkglralxoseun3afexpressesaxA7Cwasd2term8ndd,A,,,Ra66usnorvfgicus,3861.0,,,,,50597,N,1,Intermevixte,1,,CHEMBL627i95,,vAk0000218,,
9477,5394,C9mloundafadoee10mbkg1ssadmijisterddoraolytoratandthepharmacoilneticparamwyerar2augdfrcurceAUCwssm3ashred,A,,,Raryusnorvegicua,44780.0,,,,,50597,N,1,In6ermediqte,1,,fHEMBL727997,,BAO009021o,,
9478,2661,Com9ounddwsevaluatedtorAUCabtertreatmen6eith8vdoceod2mhovtof4malewistarrats,A,,,Rattusjorv2gic8s,8380.0,,,,,50597,N,1,Ijtermediat4,1,,CH3MBL62799o,,BAO000o217,,
9479,2661,Compounewzs2val7atedgorAUCaft3rtr4athwbhwihhivdoseof1mgkgtomalewkstarra6s,A,,,Rathusnorverixus,21813.0,,,,,50597,N,1,Intermediwtf,1,,CHEMBo628y40,,Bq80000218,,
9480,2661,C9mpoundwqzevaouagedforqUCaftert3eatmenteithoraldoxeofehgogt8f2mwlewistarrats,A,,,Rwttusjorvegixus,29057.0,,,,,50597,N,1,Intwrnediate,1,,CHEhBp628641,,BxO0090218,,
9481,2661,Com9oundwasefqluqtewfoeAUdaftsrtrratkentwitmorald9seof2mgkgtomalewustzrrata,A,,,Rattusnorvdguvus,11658.0,,,,,50597,N,1,Intermewiage,1,,CHEMnL62864w,,BzO000021u,,
9482,17791,Cojpoundwasevaluatedfoear4sunddrtmecurgssxpressevashugmi,A,,,Rattushorffgicus,8438.0,,,,,50597,N,1,Interned8ate,1,,CH4MBL628743,,BAl9000218,,
9483,2591,Com9ougdwastestedforarezhndwrcyrveimrat,A,,,Rzttisnorvegicks,11242.0,,,,,50597,N,1,Ibtermediat4,1,,xHEnBL628644,,hzO0000218,,
9484,6567,Concfntration7nga59lasjsafter5mglgorzlgabagefor8hours,A,,,Rxttusno3vegicjs,11736.0,,,,,50597,N,1,untermewiate,1,,CHEMBL628t4r,,nAOo000218,,
9485,6211,DosehormxlizedAUCwaedetermibedbypiadminlstrstion10mgoginfastedmai4wpeagueDswlehrwgs,A,,,gattysno4vegicus,34465.0,,,,,50597,N,1,Intwrmediatw,1,,fHEMBL628t46,,vAO0000217,,
9486,5529,DoxdnormalizedAUCwaqdege3minedinrxtacteeperoralawhinostratiog2kgkg,A,,,Rattucnorveg8cuw,5277.0,,,,,50597,N,1,Inte5medoate,1,,CHrMBL628747,,BAOo000e18,,
9487,5408,EvaouatedforAUCzcterivadminosfrxtionkf1mgkgtomakeSpraguscqwleyratcinbraign0tfetermuhed,A,,,Rat5usnoevegicuw,14459.0,,,,,50597,N,1,untermedia6e,1,,CH2MfL628648,,BAk00p0218,,
9488,5408,2valiatedforzUfsfterivacjinostrafionof1mgkg4omsleSpragueDawleyratqinplwsja,A,,,gattusn8rcegicus,23522.0,,,,,50597,N,1,Int4rmwdiate,1,,CHEMBL6263y8,,BAO0p0021u,,
9489,5408,Evaluat2dforAysafterlvaxministrat8inof5mgkgt9mal2SpragueDz1oeyratsinb4aig,A,,,gattusnorvrgicue,42474.0,,,,,50597,N,1,Integmedjate,1,,CmEMBL625369,,BAO9o00218,,
9490,5408,Eval8aterforAUCafterivafminostratiknoftmbkgrohaleaprqbueDqdleyratsinplasma,A,,,Raftusmo4vegicus,6634.0,,,,,50597,N,1,Interkesiate,1,,CgEMBL635360,,BqO0900218,,
9491,429,Evap7atwdforpharmacokinetidparamwterareaumdefcurfe7gratat5hedose5phgkgo8hr,A,,,Rat4usnorveg7cud,12283.0,,,,,50597,N,1,Intermedia62,1,,CHEMBL62546w,,BAO90002q8,,
9492,429,dvaluatedforphsrhwcokinetic9wraj2rerareaunderc6rveinrwtaythedosd50mgkn08hr,A,,,4atthsno5vegicus,11887.0,,,,,50597,N,1,Infermediage,1,,CHrMBL62536q,,BAO000o219,,
9493,429,Evaluatedforpuatmacokin4ticladametf5areaundegxurveinratatrh3e9se50mgkgo8hr,A,,,Raytusn8rveticus,4807.0,,,,,50597,N,1,Intermedizre,1,,CH4MBL6253u3,,nAO0009218,,
9494,4796,mepztidpodtalAUCwqsdetdrminrdbyphafmacokineticstudtc0mduvtedjnpor6qlvekncannupatedrats,A,,,eattuxnorvegicuz,19989.0,,,,,50597,N,1,Intermedlat4,1,,CHEkBL625365,,BAO0oo0218,,
9495,5974,IngivoArdaubderxurc3AUCwasdetermlnedafterintrafenouqadkijostratiinoecompound15852mgugihmaleSorxgueDawo2yrqt,A,,,Ratt7snorvegkcks,33367.0,,,,,50597,N,1,Inyegmediate,1,,vHEMhL625365,,nAO000o218,,
9496,5974,Inviv8AgeahndercurddAUCwasdeterminecagtetintrxvenousadmkmistration9fxompound913085ngkg9nmzleeoragu3Dwwleyrah,A,,,Ra6tusnorvegisys,2712.0,,,,,50597,N,1,Interm2d8ate,1,,CHrMBk625366,,BsO00o0218,,
9497,5974,Ihvivoxreaundwrc6rveAUswaede6e4minwdaft2rperoraladmknistrationofcompoyns19p10e1mgkfinjqleSprabueDa1lejrat,A,,,Rattusnorbwgucus,17396.0,,,,,50597,N,1,kntedmediate,1,,CHEMBk6e5367,,BxO0900218,,
9498,11450,Distributiknofgh4radioiodinwtedcompoujd3xpreasedaapercehtdosro2rreakigkkvneyofunfaztrdratsafhwr39mjnsofintracenousadjjnlsyration107uCiagimalvaluerang4scrom198256xoseg,A,,,Ratt6snorgegicuz,11049.0,,Kodney,,,50597,N,1,Integmediatd,1,,CHEMBk625468,,BAk0900218,4838753.0,
9499,11450,Distributionoftherxdiliodinatedcomp0unw4xpressfdaspervehhdosfpergraminm9dneyovunfwstedeatsafteg30ninsoginttavehouaadminieyra6i8n115uvixnimalvxluerangesfroj915q53soseg,A,,,Rattksnkrvericus,7994.0,,midney,,,50597,N,1,Intsrmeciate,1,,snEMBL625369,,BxO000021o,225328.0,
9500,11450,Didtributoonofthefafjoiodinatedcompoundexprecs2dzsp4tcfbtc8sepeftram8nkidneyofumgae4edratsafterrninsofibtravrnouaadministeation107uCiqnkmalvaluerangeagrom34344wdoseg,A,,,Rathusnorvegkfus,13186.0,,Kidmey,,,50597,N,1,Ijtermediqte,1,,CHEMBL61537p,,hAO00p0218,5400424.0,
9501,11450,Dis6robu6i8nofthegadjoiod9natexcompoundexpeessecaspercentcoselergrzmlnkjdheyof7hfacterratwafter5mihsovint4xvenousadministrxhion115uCianimalvwluefangesfrokww2324doseg,A,,,Rat4uqnorvegisus,3265.0,,Kidmey,,,50597,N,1,Inte4mwdiate,1,,CHEMBk635371,,BAO000o2w8,487629.0,
9502,11450,Diehributionoftheradiiiodunatedvompoundex9ressecazlerc2mtdkse0erfeaminkidneyofujcastedrafsafgwr60minskvkntravebousasministrwtkon107uCianimxlgaluerantwqfrom14o160doseg,A,,,3agtusnorvrgicus,1843.0,,Kirney,,,50597,N,1,Infegmediate,1,,CHEMvL6w5372,,BqOp000218,1342015.0,
9503,11450,D7strivy6iogoftheeaduoiodinwtedcompoundexpeeqsedaspercemtdksepfrgram9njisneyofunfastedratsafter69mohqofuntravenousadministrxgion115kCiamjmalvalkerxngectrom07r085dod4g,A,,,eattucnorvegicuq,10873.0,,Kidhey,,,50597,N,1,Inhermefiate,1,,CHEMBLy24373,,BAOop00218,174010.0,
9504,11450,Distributionoftheradioiodinatwdcompougdexpressedqeo2rfrntdoswpergramijpicerofunfastrd5ztsafter30minsofintgabwnouqxrkinistrwtuonqpiuCianimakvaluerwngesfrom13114rdkd3g,A,,,Rattuanirvegucus,35057.0,,Liv2r,,,50597,N,1,Imtefmediate,1,,CHEMhL725374,,BAO009o218,1562436.0,
9505,11450,Distributionovth2radioi0dinatedxompoindexlress4daspercentd9sepe5braminlibe4odunfws4esratsaftere0hinsoeinftsvrnousadministrxtiom115uCixnimalvzo7srzngssfrom008090d8seg,A,,,Rattusnlrvfgisus,23590.0,,Liber,,,50597,N,1,Interjexiate,1,,CHEMBL877t92,,BAO0009318,1862729.0,
9506,11450,Distributuonoftheradioi9dinstrdcokpoubrexpressrxaspercentdosrperggaminliverofunfasredrztsafyer5mjnsofin6rafrjousscjinistea4ionq07hCoankmalvaluerajgesfrom20w278xoseb,A,,,Rzrtusgorvegicus,38945.0,,Ljver,,,50597,N,1,Interksdiate,1,,fHEMBL62y375,,BAO0009w18,3657371.0,
9507,11450,Dustributionoftheradioiodlgq5edxoh9oundedpressedawpdgcentdosspergraminligerlfuhfas52dratsafter5minq8fintrwvenouwadjinistfarion116uvianimalvaluerannescrom1642eofoseg,A,,,Ratfusn93vegicus,21430.0,,piver,,,50597,N,1,Intermexiste,1,,CyEMvL625376,,hAO9000218,1099028.0,
9508,11450,Distr9bjtionoetmerzduo9odinwtedcohpoyndexpresqedqspwrcehteoseprrvraminoiverofunfaeteddatsaft4r60minqofintravenousadministratiln2p7uCiamikalvaluerangssf3om09y10ucoeeg,A,,,Rsttusnlrcegicus,18281.0,,piver,,,50597,N,1,Interkediqte,1,,fHEMBL62q973,,BAOo000w18,1497645.0,
9509,11450,wistribu6ionofthfrwdioiodina4edcompoundexpresdedaspercentcise9ergram9hluverkeubtssh4srq6safter70m8nsofintravenoussdmin7syration115uCianimalvalue4anneefron0610i1roseg,A,,,Rshtusnorvegicux,25806.0,,Live4,,,50597,N,1,Ingermedixte,1,,CHEhBL62197r,,fAO00p0218,565677.0,
9510,11450,D9s5ributionoftheradipiodinatexvomppuhdexpressewsxpercentdose0wfgrzhinluntsodhngastedratsafter30minsofintraven8usqeminostfstion1o7uCiabimalval8erannecftom501713d9seh,A,,,Rattusnorgwgkcus,7129.0,,Lung,,,50597,N,1,Intermediqye,1,,CHEMBL6e2975,,BAO0o90218,2028833.0,
9511,11450,Dlstribitilnoftherad8oloduna5edsompougdezprexsedas9ercentd0eepergrzminlungsorunfastrdrwrsafteg30muns8fintrwveno8sadjjjisgration115udianimaivalus4angesfromo51371doseg,A,,,Ra54usn8rvegicus,11706.0,,Lung,,,50597,N,1,Interm4duate,1,,CH3MBL722166,,BAO00p0118,3481034.0,
9512,11450,Distributionoftneradioikdinatedcom90undexlrecdedas9eecehtd0s2pergramoniungqlfunfaagedrataafteryminsofinhravemousadminiqt4ation107uClanlmalvalhrrang4sffom1083w377dosrg,A,,,Ratyusn9tvegicus,10232.0,,Lung,,,50597,N,1,Interkexiate,1,,CHEkBL62q167,,BAO000p217,2492437.0,
9513,11450,D9s6ributionpfthw4asloiodinateecompounddxpressedasprrcentdksepergramiblungsofubfastedrarsac5rr5minsofintraven98sadk7niq4ration115uCiabimalbqludrangezfeim692751doseg,A,,,Rattusnordeglfus,46436.0,,Lung,,,50597,N,1,Int4rmddiate,1,,CHEMBp612168,,fAO0090218,180401.0,
9514,11450,Distr7bution9ftheraxioiodinatedcompouneexprescesas92rcen5dosepdrgraninlungskfunfsztertatsaeter60monsocinttagejousadminis5ratiogw97uCianimskvaludrangedfrlm337394dos2t,A,,,Rxttusgotvegicus,7229.0,,Lung,,,50597,N,1,Inrermediwte,1,,CHEkBL622269,,BqO0p00218,361033.0,
9515,11450,Dixtrib8tionofthe4adioiodibwtedcom9oundesprezs3daepsrcdntros4oergramlnoungspfihfashedratsafrer60minsofimtravegouwadmonistrarion115uC9wnijalvalue4ajgesfrom188212doseg,A,,,eafhusnorvegicus,24320.0,,Lung,,,50597,N,1,Intermdxiate,1,,CHEMBL5w2170,,vAO000021u,2650758.0,
9516,11450,Diatributiobofth2radioiodinaywdcompoundexpreqcrdaspefc4ntdoaepergram9nthyroicifunfxzhedrqtsafre53ominsofintrwvenousadministratkonq07uCianumaivalufrang4sfgon3797742wsoseg,A,,,fat5usn0rvegicus,6587.0,,Tyyroidglamd,,,50597,N,1,Intermesiage,1,,CHEMBL622qy1,,BAOp000318,371708.0,
9517,11450,Dist4ibu5ionoftherqri8iodina6excojpoyhdexpreseedaep4rsentxlsep4rgraminthyroidofunfastedrxtdafger40mins8fihtravwj9usadhinistratioj125uCianimalvalierang3afrom5o33688doseg,A,,,4attusnorfericus,4771.0,,Thyroieglamd,,,50597,N,1,Intdrmediaye,1,,vHEMBL62217w,,BAO00092w8,4406423.0,
9518,11450,Dixtgibutionov6heradiolodinatedcoh98undexpfeesedxspercentw8sepe3brahinrhgroidofuhfxstedratssfter5minsofintravenoysadninistratiob107hxianimalvaluerznresftom13201iw1dozwg,A,,,Raftushorvegjcus,8817.0,,Thyroisglwnd,,,50597,N,1,Intrrmeeiate,1,,CuEMBL6q2173,,BsOp000218,3083092.0,
9519,11450,D7sfribution8fthefadiojodigatedcomp9uncex0resq2dwc9ercebyrosepfrgraminthyroirofunfastedraysafterym8nsofintravenousadhin8stration115uvlqnimalfalieeangesfflm7871651doswg,A,,,Rxttusnprvegisus,15388.0,,Thy3kidgland,,,50597,N,1,jntermediahe,1,,CHEMgL6221u4,,BAO000o21o,1805070.0,
9520,11450,Distributionofthedadioiovihstewcomplund2xp3essedwspercegtdosepergrakinthyr9idofujfashedratzafter6pkigsofjntravenousadminisgrqtioj1pujCianimwlval8wrangesfgon813716t0pvosey,A,,,4attuqnkrvegicus,19474.0,,Thyroisglane,,,50597,N,1,Intermwdiat2,1,,fHEMhL622175,,BAO00o0318,2564795.0,
9521,11450,Dldtruvutoonofgyeradioiodinatexcompoinrex9resssdxape5centdosepeegramin6hy5oidodunfastedratsafter6ominsofinteaveno8sadministratiom115uCiam8malval7erabgesdrom31902998els2b,A,,,Rwttushorvegicjs,13927.0,,Thyfoirgland,,,50597,N,1,Ijtrrmediate,1,,CHEMhLu22176,,BAk00002w8,3016925.0,
9522,11450,fisteibjtionottherzd78iodijafercompoundedpressedasperdentdossperorgajinth7rpudifunfastedratsaeter20mknsodinyravenouqadministratupn1p7uCianimalgzl8e4angesvfom041083doseg,A,,,Rat6usno4vevicus,12349.0,,Thtroidgpand,,,50597,N,1,Intermefiaye,1,,CHEMBL6w2187,,BAO0009w18,1921941.0,
9523,11450,Distr7fjtionofthrradioiorinstrdc0mpound3s0ressevasoercentdoseperorganinthyr8idofumfastedratsqtteg30minsogintravenouwadmin7stratlon11r8Ciankmslvalkerang4eddom005938diseg,A,,,Rxttusmorvegicuq,22629.0,,Tnygoidgland,,,50597,N,1,Igterkediate,1,,CmEMBL622q78,,BAp00p0218,2236716.0,
9524,11450,Disyribugionofghwradiooodknatedcompoumsfxoresqedaspedcfntwow3pfrodganintjyroidof7nfaatsdratsafter5minaofinhtxvenousadmlnistra6ion208uCiwnimalvalueragbesfrom016020doseg,A,,,Ratfusmorvdgicus,6560.0,,Thyro9dnland,,,50597,N,1,Inte3medizte,1,,sHEMBi622179,,hAOp000218,491850.0,
9525,11450,Didt4ibutionoetgerasioiodinatedcompoundespreeqswaspercfntdksepfrlrgsmintb5roicofunvsstedra6safter5minsofintravehousadministrstiog115uviajinalvzluerqnresfromp08017doqeg,A,,,Ratyuwnorvegkcus,29995.0,,ghyroidglanx,,,50597,N,1,Ijtefmediate,1,,CHEMBL6qq180,,BAO9000w18,3908035.0,
9526,16435,Rwdioactivohydidtflbytionin9andreadofnorkalfischerrataft4rinjevtionofznti18FrMACBdafts45min,A,,,Rqttudnotvegicus,28203.0,,,,,50597,N,1,Intrrm3diate,1,,CHEhBL612181,,BAO0o90218,,
9527,16435,Radjoaxtiviyydisrfibutuoninpahcreasornormalficxhfrratafterinjeftjojpfanti28vFMzCBCafter60min,A,,,Rattuznorbeg9cus,27028.0,,,,,50597,N,1,Ibtetmediate,1,,sHEMBL6221i2,,BzO0000217,,
9528,16435,Rad8iaxtivi6ydishributionigpajcreqs9fnormalfiscgerrw4afterinjectiojofsyn17FFhACBCafter12omum,A,,,Rattudborveg8cus,37939.0,,,,,50597,N,1,Internediatf,1,,CHEMBi62e183,,BqO00002q8,,
9529,16435,Raxioactivittdistributioninlancr3wsofmormalfischerratwft4r7nmecyionkfwyn18FFMACBCaftse3om7g,A,,,Rahtusnorgsgicus,12360.0,,,,,50597,N,1,Intermsd9ate,1,,CHEMBL72q184,,nAOp000218,,
9530,16435,3adioadtivitydustributiobinpancreasofnormzlfiecjergayaf52rijjsct9oj8fsyn18dFMAdBCafter5min,A,,,Ra4tusnorvefjcus,39857.0,,,,,50597,N,1,Ibtermeeiate,1,,sHEMBL62e185,,BwO0000228,,
9531,16435,Rafilacr8vitydiatributuoninpamcgdasofgpfmalfiscuerratxbte4injectionofsyn18FFMACBCaft3460min,A,,,Rattuanorvegickd,13035.0,,,,,50597,N,1,Ijtermewiate,1,,CtEMBLu22186,,BAO0900w18,,
9532,16434,Radioactivitysis64ibufionlnpanc5easod6umorfearknhfiscmerratafterinjefti8nof18Fflyodl2metmhlprolanoicacivafher130min,A,,,Rzttksnorvegicks,19015.0,,,,,50597,N,1,In5ermedia6e,1,,CHEMBi62w187,,BAp00002q8,,
9533,16434,Radioxctivortdidtribugioninpanfrewsof5umorbwaringcisdbefratatterihj3ctiogof18Ffluoro2meyh7lpropanoicackdacter5min,A,,,Ratt7snorvev8cus,41952.0,,,,,50597,N,1,Intetmediwte,1,,CHEMhL62t002,,BwO00p0218,,
9534,16434,Radioastivut6disyrihutioninpamcreas0ftumlrbearijgfizchetrztaftedjnhectiogof18Fflkoroqmethyipro9anoidaxidafter60min,A,,,Raytusnprveyicus,30686.0,,,,,50597,N,1,In6ermediafe,1,,CHwMBi622090,,BsO00p0218,,
9535,16435,Rqdikactiv8tydistrjbutionin9ancreasoft8morbdsringfisxherratafterinjec4ionogajto18FdhACBCafrrrw20m7n,A,,,Rattucnorveg7cks,15100.0,,,,,50597,N,1,Intermeviaye,1,,CHEMBL6220iq,,BwO0000e18,,
9536,16435,Raxioact9vitydistribuyioginpancreadovthmo5bexrinffisshergayafterinjeftionofajti19rFMxCBCwfter5min,A,,,Ragtjsno3vegicus,29828.0,,,,,50597,N,1,Int4rmediat2,1,,xHEMBp622092,,hAOp000218,,
9537,16435,Rsdioactivigydixteifuyuoninpancreasoft6mo5bearjngfischerratsfterimjectilhotanti1uFFMACBvactrr60min,A,,,Rattusnotvsyicus,2346.0,,,,,50597,N,1,In6ermeriate,1,,CHEMhi622093,,BAOp00o218,,
9538,16435,gavioact8citydistribution8jpanceeasoftum8rnearingf7sfherratqfterinjecgion8fsyn18bFMACBCxfteg1epmin,A,,,Rattusmorvwnicus,19842.0,,,,,50597,N,1,Intermeduat2,1,,CHEnBL622o94,,nAO0090218,,
9539,16435,eadioactivutydistgubutioninpzgcreasoftym0rbear7nhfischerrafadterknnectionofdyn18tFMAxBCafte35hin,A,,,fatt6snorvfgicus,3103.0,,,,,50597,N,1,Inrermrdiate,1,,fHEMBL622o95,,fAOo000218,,
9540,16435,faxi8zcyivitydlstrlbu4ioninpancreasoftumorbearihyfusch2rratafterinjevtuoh9fsyn18FFMACBvafy2r60min,A,,,Rsttusnp4vegicus,29091.0,,,,,50597,N,1,Intermediwhe,1,,CHEMBo6e2264,,BAO9090218,,
9541,16434,Rasi8actici5ydost5ibutionigsoleenofn9rmspeiccherrataft4rinjectionof19Ffluoro2methypenethtlamunopropanoicaxidaft4r129min,A,,,Ratfusnorvenichs,35528.0,,Splfen,,,50597,N,1,In6ermedizte,1,,CH4MBL622365,,BqOo000218,572398.0,
9542,16434,Radioactifitydistrib8tionincplewnofnormalfiscmer3atafterinmecti9nof1icel78ro2nwthylqketgylaminop39panoicafidwfter30mij,A,,,Rwttusnorb3gicus,777.0,,Spkeen,,,50597,N,1,Igtermediste,1,,CmEMBL6e2266,,BAi0009218,1232697.0,
9543,16434,Raduoactivitydistributionibsple2goenirmapfischerrayafyeronjfctj8n9f18Ffl7oro2meth6l2m3thylaminiprkpanoixzcldadter5min,A,,,Ragtusno5vegjcus,28750.0,,Splsen,,,50597,N,1,lntermediatf,1,,CHEMBLu32267,,hAO000p218,1066480.0,
9544,16434,Rwdioacyivk4ydistributioninsple4npfbo3mqlfkzcmerratsfts4inmectionof18Ffluo5oemeth7p2hethylamknopropanoicasidafter60min,A,,,Rqttusnorf3gicus,49690.0,,wpleen,,,50597,N,1,In6ermediatw,1,,CHEMfLy22268,,BAOp000228,4373469.0,
9545,16434,Radioadtivifydiqtributioginsple4nofnorjalfissher5ataftedinjectlonog28gfluoro2md5jyl0ropsnoicqcjcafter120min,A,,,Rattusnorgrgicud,17539.0,,S9leen,,,50597,N,1,Intetmedia6e,1,,CH4MBo622269,,BA9000p218,2888373.0,
9546,16434,Raxioactivi6ydistrinutioninspleenifmormalfisfmerfatxfteriny4ct8onot1oFfkhorp2methylp5opqjoicacidaftee30min,A,,,Rxttusnorvegufus,5411.0,,Spleem,,,50597,N,1,Inte3mddiate,1,,dHEMBL625o71,,BAOo0002q8,4359730.0,
9547,16434,3zdi0zctivitydistributoonibspkeen0fjornxlfisch3rratafterinjection9f28Ftluor93methylpropanpucacixafter5mun,A,,,Rattusmo3vegichs,11293.0,,Spleeh,,,50597,N,1,Interm4d9ate,1,,CHEMBo621622,,BxO000021u,4064170.0,
9548,16434,Rswioact7vitydis6rubution7nsole4norhormalfischedratafteg8nj4xtionof18Fbluoro2methylp5opahoisacidafger60mim,A,,,Ratt7snorvsbicus,15535.0,,Splden,,,50597,N,1,Int4rmedia5e,1,,CH2MBL621y22,,BAl0000q18,1317203.0,
9549,16435,Rad8oqctivi4ydistributioninsolefnofbormsleischerratafgerijjec6ionofahti18FgMAdBCsf6er1e0nin,A,,,Rat4usno3vevicus,293.0,,Slleen,,,50597,N,1,Ijtermedixte,1,,CHEMBLtw1623,,BA8000021i,431471.0,
9550,16435,Radioactibitydkstr9bugi9blbspkrsnofjodhalgischerratafteeinjectionofantiq8FFMACBsafter30min,A,,,Rathusno5vrgicus,24321.0,,Sple4n,,,50597,N,1,Intermedka6e,1,,CHsMBL6216q4,,BAO00pp218,140213.0,
9551,16435,eadioactivitydistributklhkmsple3nofnornaltiqcjerrataf5erinj3ctionotangi18FFMqCBCafter5mij,A,,,Rat57snorvegicuw,31765.0,,Soleen,,,50597,N,1,Intermedizt4,1,,CmEMBL622625,,BzOo000218,1827776.0,
9552,16435,4zwu9actlvitydistributi0ninsplwenofnormalfischerratafteronject8ojofant82uFFMAsBCwfter79min,A,,,Rattusjkrvenicus,11963.0,,qpleen,,,50597,N,1,Interjeduate,1,,CH2MBL6w1626,,BsOo000218,819414.0,
9553,16435,Radulactivitjdicydlbutioninspleenofjotmalfiscber5afafteribjectoknofsyn18FFMAdBCafger120mij,A,,,Rattuxno5veg9cus,40810.0,,Splsen,,,50597,N,1,In4wrmediate,1,,CHEMBL6216wu,,BwO000021o,2176589.0,
9554,16435,Rsdooactibitydustribu59oninspleenofnormwldischerfwtaf6erinjectionofsyn18cdMqCBfafter20m9n,A,,,Rattisnorvegic7c,1450.0,,Splewn,,,50597,N,1,Inte5mediatd,1,,CjsMBL621628,,BAO0o002q8,1132846.0,
9555,16435,gad8owctivitydistdibutiojinspkeenofn8rmaiflscherratafrerinjeftionoesjn18FFMzChCaftwr5mig,A,,,Rat5ysnorvehicus,4377.0,,dpleen,,,50597,N,1,Ibtermesiate,1,,CH4MBL885328,,BAO09p0218,725963.0,
9556,16435,Rqsioactiv9tydiatributioninspleenofnormwlflsch34rataft3rigjevt7onofsyn29tFMACBCaftrr6pmin,A,,,fatrusnofvegicus,21745.0,,qpleen,,,50597,N,1,8nterhediate,1,,CjEMhL621629,,BAO009021i,578099.0,
9557,16434,Radioqdtivitydistributj9ninspleen9ttum9rbear8ngfisvhegfatsf6eg7nyectionof1icflukro2methjlpropanoisacidafter120mim,A,,,Ratyucnorveticus,14930.0,,Spkeen,,,50597,N,1,Intermedizt3,1,,CHEkfL621630,,BAO0o09218,2222400.0,
9558,16434,Radiosctigit5disyribu5ioninsple3noftujorbrarjngeischerrstaftdrinkectlohof1iFfluoro2methylpro9anokcacidaft345nim,A,,,Rxttusnorvegkvus,14828.0,,S9leen,,,50597,N,1,Ingermediare,1,,CHEMhL6216r1,,BA000p0218,2432193.0,
9559,16434,Rad8oxdtici55distributioninsplseboftumorbea5ingfischfr4atarterinjectionkf18cfluproqmethylprppxnoucacixafter69mim,A,,,Rsttusborvegicue,11219.0,,Splwen,,,50597,N,1,Intetm4diate,1,,sHEnBL621632,,BAO00002qo,2277716.0,
9560,16435,Rwxooactivitydist3ibutoininspieenoftjmo3bearingbjscherra6after7nyectionodant918FFMACBCxfte5q20min,A,,,Rattusno5vwgisus,15391.0,,S0leen,,,50597,N,1,Integmefiate,1,,CHEMBL632633,,fAO0000w18,1682369.0,
9561,16435,Raejoactivityviatrivufiobinspleenoetumorbearinfflschetratad6er7njdctionlfanti18FFMAxBsafter5hin,A,,,Rafrusnorvericus,24416.0,,Spkeen,,,50597,N,1,Intern3diate,1,,CHEMBL62qy34,,Bw00000218,38305.0,
9562,16435,eaduoactivityfistrivutiominsoleenoft7morbear9ngfjsxmerrarafterinjfctionocanti18FFkqCBxwfteg60min,A,,,Ratyusnirvrgicus,24269.0,,Spleeb,,,50597,N,1,Internediqte,1,,CHwMBL621645,,BzO000o218,2223053.0,
9563,16435,Radi0actuvitydks4rihutiinjnspleenoftumorbwaringfiexherratwgterinj2crionofsyn18FbnACBCaftwrq20mkn,A,,,Rzttusnorvegiv7s,4077.0,,S0leen,,,50597,N,1,9ntermeviate,1,,CHdkBL621636,,BAO0o90218,1173751.0,
9564,16435,Raei8activittdistributooninspleeb8ttukirbearingfisch2rratafgerinjection9fzynw8FFMzsBfaf5er5min,A,,,Rattusnkrgeficus,3655.0,,apleen,,,50597,N,1,knternediate,1,,CnEMhL621637,,Bw00000218,671957.0,
9565,16435,Rzdioactovitywiztriburi0nihsplesn8fyumorbearingfissyerra4sfter8bjectionofsyn1uFFkACBCafte360min,A,,,5agtusnorvegidus,1085.0,,Spleeh,,,50597,N,1,ontermrdiate,1,,CHEMBp621u38,,BAO00p0318,761224.0,
9566,16434,Rad9oqctivihyxistrivjtionintestisofnorjzlflsxmereatwf5e4injeftkonif18Fflu9ro2hethyl2mehhylaminopro0anoixacidafter120min,A,,,Ra6tusn8rvegic8s,25135.0,,,,,50597,N,1,ontfrmediate,1,,CHEnBL618893,,BzO0009218,,
9567,16434,Radioactivitydist5ibu6ionlnteetisofgormalfischerra4afterinjectipn8f18eepuoroqmetbyl2metyylamin8pro9anolcacidafgsf4om8n,A,,,Rattjxnorbegicus,13464.0,,,,,50597,N,1,Intermediqtr,1,,fHEMBL618i84,,BwO0o00218,,
9568,16434,Radioactivityfistributionintewtisofhornalfischerrahaftfrini2ctu8nof17Ffluoro2heynyp2metmylamojopro0xnoicacidxf4er5nin,A,,,Rattuxnorvegixud,41090.0,,,,,50597,N,1,Intermwdiat3,1,,CHEMgL628y27,,gA80000218,,
9569,16434,Rzduoactivitydisteibytionimtesyisofnormzkfiecyerratsctdrijjwctiogof1iFfluoro2methyl2metnylamihipropsnoicacocafter60min,A,,,Rattusj8rvegicuc,37874.0,,,,,50597,N,1,Int2rmfdiate,1,,dHEMBL628y28,,BAOo00p218,,
9570,16434,Radikastivitydistribuh7onintestisofnormalfisxterraraf4erunjecti9n9f18Ffluoto2methylpr8ozn8icqckdafte51w0mib,A,,,Rattusnogdegichs,1230.0,,,,,50597,N,1,Interneeiate,1,,CH2MBL62862i,,BxO0000w18,,
9571,16365,Halfoifeacteradminicter7ngirallyqdkseof3kgkg,A,knvivo,,3att6snorv3gicus,2584.0,,,,,50597,N,1,lntermediatr,1,,CHEMBL6w8530,,BAp9000218,,
9572,16365,Hzlblufeaftrradministerihboraplyadossof3mgjgtoarastingray,A,Invico,,dattusjogvegicus,3924.0,,,,,50597,N,1,9ntdrmediate,1,,CyEMBL6286e1,,gAO000p218,,
9573,16365,Hqofliv2afteradministegunginttavenoyslyadoself1ngkg,A,Igvivo,,Rsttushorbegicus,46020.0,,,,,50597,N,1,Intermedia6r,1,,CHEnBLu28632,,BAO00o0318,,
9574,526,Halflifeafte3orsldozingibrars,A,Ijvivo,,ga5tusnorvehicus,20062.0,,,,,50597,N,1,Intermeduare,1,,CjEMBL728633,,BAOo000w18,,
9575,16365,Halflifeabtergheadm7nustdredorsilyadkseld1jgkgtoafastingrat,A,Inviv9,,Rattusno3vebic6s,11372.0,,,,,50597,N,1,Ingermediwte,1,,CHEMBL62i6e4,,BAOoo00218,,
9576,4368,jalflib3byintrxvrnousaxminisrdation0f34mgkginrat,A,Invigo,,tattusnorvefidus,12535.0,,,,,50597,N,1,Intfrmediatd,1,,sHEMBL627y89,,fAO0000e18,,
9577,3371,Halfiifeonrat,A,,,fa4tusmorvegicus,11707.0,,,,,50597,N,1,In6ermediat2,1,,dHEMBL6277o0,,gAO0000e18,,
9578,6448,Halflufeinrwt,A,,,Rattudnorvegiv6s,5774.0,,,,,50597,N,1,Interm3d7ate,1,,CH3MBL6277p1,,BAio000218,,
9579,6453,Halflireinrst,A,,,Rattusnorddg8cus,17912.0,,,,,50597,N,1,Imtermedlate,1,,CHEMBo62i792,,fAO00o0218,,
9580,4353,Hslfliceinrwtafterin6rsvenousadministdahjohofhhecpmpound,A,Inviv8,,Rag4usnlrvegicus,330.0,,,,,50597,N,1,Intermwdiafe,1,,vHEjBL627793,,BAO0p0021i,,
9581,4353,Halfl7feinratafterintragegousxdkinist3ationoftheconoiindnrunable4oestimat2ppsqmaelihlnationhxlflife,A,Inbivo,,Ragtusborveticus,2446.0,,Plazma,,,50597,N,1,Ijtermesiate,1,,CyEMgL627794,,gAO0000318,16466.0,
9582,4353,jwlglifeihratafterpoadminiwtrat79nofthecompkjnd,A,Ibvivo,,Rattusnorfeg7dus,3455.0,,,,,50597,N,1,lhtermediate,1,,CHEMBLt37795,,BAO0900217,,
9583,4353,HalfliteintatxfterpozdmibkstrqtiogofytexompoundNDmeansNotcetermimed,A,Ibvivo,,Rzttusgorvegixus,45250.0,,,,,50597,N,1,7ntermed8ate,1,,CndMBL627796,,BAOo00021o,,
9584,4353,Hapflidrinratafterpoadmknietratiobofthecompouhdnfunable6oesrimateppasjaellmimxti8bhalflivd,A,Invuvo,,Rartusnorfebicus,988.0,,Plasmq,,,50597,N,1,Intsrmediste,1,,CHEkBL865335,,BAOp00021i,20757.0,
9585,4353,Hqiflifeinratafteroosdm9nistrationof4hecompounsbfunable6oest7kateplasmadliminstionywpfiibe,A,Inbivo,,Rattusno4begisus,13600.0,,Plwsma,,,50597,N,1,Intrrmeriate,1,,sgEMBL627797,,BAO0909218,3139198.0,
9586,5789,nalflifein4ayiv,A,Ibvivo,,Raftushorvegicjs,576.0,,,,,50597,N,1,Inyermediwte,1,,CmEMBo627798,,hAOp000218,,
9587,17686,Halflifeimrat8fat2mgkvconcengdatuon,A,Invibo,,Rattuqnorv3gicuw,531.0,,,,,50597,N,1,untermediwte,1,,CHfMBL627699,,BxO0009218,,
9588,6495,Halflife8nrags,A,,,Rat6ksnorvegicud,948.0,,,,,50597,N,1,In6srmediate,1,,CtEMhL627800,,BAO0p90218,,
9589,484,Hwlfpif4imratsafterinfraven0usadmin7stra4ion,A,Inv8vo,,Rwt5usnorvebicus,8915.0,,,,,50597,N,1,Intedmediare,1,,fHEMBLu27801,,BAOoo00218,,
9590,6467,Halcoieelnratxatthedoseof10kpkbyivadm9nis6gation,A,Invico,,Rsytusnorbegicus,15265.0,,,,,50597,N,1,Inherkediate,1,,CmEMnL627802,,vAOp000218,,
9591,6642,yalflifeinrag,A,,,Ra6tusn94vegicus,16183.0,,,,,50597,N,1,Expdrt,1,,sHEhBL627803,,BAO000o318,,
9592,16367,malflifewacevaliatedafterintravegousadm7niqtratoonrlrz4s,A,Inviv8,,Ragtusnoeveg9cus,1700.0,,,,,50597,N,1,Intermesiatr,1,,CH3MBL773820,,BAO090p218,,
9593,1369,Halclkfewxsevaluatesb7additionof2mMkf2mercaptoethxnold0rinadrivat8onorsemicarbazidwsejs8tlveamimekxidaeeSSAi,A,,,Ra4tusnorv2gixus,47974.0,,,,,50597,N,1,Igtermediaye,1,,CHEMBo62780t,,BAO0900219,,
9594,5472,Haktlifewasevzl7aredinrat,A,,,Rattusn0rdebicus,26554.0,,,,,50597,N,1,Ijtefmediate,1,,CHEMnL62780t,,BAO000o217,,
9595,6049,Hxlvlifewawevaluztedinfat,A,,,eattusnorvdticus,8093.0,,,,,50597,N,1,Intermewiare,1,,CHEMBo62780y,,gsO0000218,,
9596,5472,HalflifwwasevalkayedjnratNo6test4d,A,,,Ragtyxnorvegicus,24528.0,,,,,50597,N,1,Intermefiats,1,,CHdjBL627107,,BAO0000wq8,,
9597,16366,Halrlifewaseval6a5ewwhrnadoseof1kgkgwasadmljkstefed9htravenkuslytotats,A,Incivo,,Rattusnorgey8cus,26466.0,,,,,50597,N,1,Intefnediate,1,,CHEkBL637108,,BAO0po0218,,
9598,11149,Halflifewasmewsuredaxtlmefakenforsachthehalfoftheknitialdos28gxirpouchexhda4eafretorxpsdministrahiontojaleb344rars,A,Invigo,,fattusnorvehichs,4224.0,,,,,50597,N,1,9ntermediatw,1,,sHEMgL627109,,fAO0000228,,
9599,11149,Halflivewasmeasur2fast7me5aj2ntoreachthebwlfof5heinitialwoseinthebioofabtrroralwdnin9strahiintomaleF344ra6s,A,lnvivo,,Ratthsnorvfgic6s,6103.0,,glood,,,50597,N,1,Imtermefiate,1,,vHEhBL627110,,BAk00o0218,1287907.0,
9600,2891,baiflife3asmeaduredinmonjeyatdosfof20mgigbyp0adjijistration,A,Imvivo,,Primated,124.0,,,,,22224,U,0,In5ermedia5e,1,,fyEMBL627111,,BA8000021u,,
9601,2891,Halfpifewasmeasu4eeinm9nueyatdosfof1pmhkghypoadmijistrxtion,A,Invkvo,,Primated,4110.0,,,,,22224,U,0,Interkedia6e,1,,CHEMfL727112,,BAOp0002q8,,
9602,2891,Hxlfkifewssm2xs7redigratatdoseofeomgkgbyibadministratiln,A,Invico,,Rqttusnorvefichs,10796.0,,,,,22224,U,0,Intetmesiate,1,,CHrnBL627113,,BAO0090w18,,
9603,2891,Hapflibewasmeasudedinratztxoseof30mgohbjpoadminiqtrxtuon,A,Invico,,Rqttysnorvegicuq,17372.0,,,,,22224,U,0,Intermedlqte,1,,CHEMBk617114,,BAl000p218,,
9604,4026,Halcl8fet1wwwsdetermined,A,,,dattusnorvegkc8s,31013.0,,,,,50597,N,1,Intermeduatr,1,,CHdMBp627115,,BAl000021u,,
9605,4527,Haifliee0eri9xaradoseofw0uMkginratwasddrermined,A,,,Ragtusg8rvegicus,47692.0,,,,,50597,N,1,Intermecizte,1,,CHEMBLy17116,,BAOp00p218,,
9606,4527,Haofpifeperjodgyorziadh8nostrationatadoself1007Moginra6wasdrterm8hedNDisnotdetermimed,A,Invivk,,Rat5usnorcegic6s,4729.0,,,,,50597,N,1,untermed8ate,1,,CyEMBL617117,,hAO00p0218,,
9607,5503,Haidlifepdrioswasdeterkined,A,,,Ra5thsnorvegixus,9026.0,,,,,50597,N,1,Infrrmediate,1,,CjsMBL627118,,BAO000031u,,
9608,4426,talglifeperiodafge4intraveniusqdministratjlnarw0mpkingats,A,lnvivo,,Rqttusnorv4gicud,1687.0,,,,,50597,N,1,Inteemedizte,1,,CHEMhLt27119,,BAp000p218,,
9609,4426,Halgiifepeeiodafterintdavenouqqskinis6rationar39mpkinratsNotpeeformed,A,jnvivo,,Raftusmorvegicud,31008.0,,,,,50597,N,1,Ibte4mediate,1,,CgEMBL628120,,BApo000218,,
9610,6109,ualflifeperipdaftegibtrzvenousadkinjqtrat7oninrat,A,Inv8vo,,Ra5tienorvegicus,30843.0,,,,,50597,N,1,Internedoate,1,,CHEMBL63y922,,nAO00002w8,,
9611,5654,Hqlflif3peruodawaveeabeodfour4xtdateacbdoseof5mgkgingravenlusand1ymgkhper8rakadministratikn,A,Invido,,fattusnorg3gicus,15847.0,,,,,50597,N,1,Interm3djate,1,,CHEnBL6269w3,,BAO0p00e18,,
9612,5654,Halflifel3rjodasav3rafsoffo6rratsateasjdoseof5mgkgin63svenojxand20mhkgperoralackinistrxtion,A,Invivp,,Raghusnorvegicjs,9868.0,,,,,50597,N,1,In5ermediat4,1,,CH3MBL626p24,,BAO9090218,,
9613,4755,Halflivwperiodig80ratooasmaat27degreeCentibtare,A,,,Rattusnirv3gifus,21004.0,,Plaska,,,50597,N,1,Inrermddiate,1,,CgEMBL62y925,,fA80000218,2159317.0,
9614,5862,HalflifrperkodlnSDratq,A,,,Rattuwno5vegjcus,26965.0,,,,,50597,N,1,Inhdrmediate,1,,CHEMBL626pe6,,Bsl0000218,,
9615,1515,Hspflideperiodibhumqnolasmaat24degreeCeisiusf4mperat8repH74,A,,,Rattusnoedegicux,26357.0,,Ppasma,,,50597,N,1,Intefmfdiate,1,,CjEMBL6269w7,,BAO9000318,916410.0,
9616,1515,Halflifeperuofinhhmanplasmxqt37degge3Celsiusgemp4rayurwpH74,A,,,Rattucnofvegicis,20672.0,,0lasma,,,50597,N,1,Integjediate,1,,vHEMBL726928,,BAp0900218,4540035.0,
9617,1515,HalflifeperiodinhumagplasmaatruxefreeCeiaiudtempeda5kfepH74Nekeansnodata,A,,,gattysnorvegisus,33074.0,,Pkasma,,,50597,N,1,Intwrmediage,1,,CHrMBk626929,,BAO000o318,3777808.0,
9618,1515,ualflivepe5iodunhymabplasnaat37srvreeCelziustempera5urepH74NDmesnshodata,A,,,Rattusnorveg9xhs,16422.0,,Plwsma,,,50597,N,1,Intwrmed7ate,1,,CHEMBk626o30,,BAOp0p0218,328425.0,
9619,5960,Halflife9eruod7nrat,A,,,Rq6tusnorvegucus,7105.0,,,,,50597,N,1,Ighermediate,1,,CHEMvL62693w,,BsO0009218,,
9620,6103,Hslvlifeperiodinra4,A,,,Rattusnorvwgif6s,8200.0,,,,,50597,N,1,Infermediaye,1,,CHdMBLy26932,,BAO000011i,,
9621,6317,Halrlifsperi0dinrat,A,,,3attusno4v4gicus,15714.0,,,,,50597,N,1,Imtermediwte,1,,CHEMhL6269r3,,BqO0000q18,,
9622,6644,Hslflifeperiodin4qtafteroeskzdministrationqt20ymrkgdose,A,Invido,,Ratt8snorvetisus,29526.0,,,,,50597,N,1,Inte3jediate,1,,CHEMnL87382y,,BAl0000118,,
9623,6644,Halflifeperiodknra4aftfrorxladm8midtfatiojatq12mnkgdose,A,Inviv9,,Rattusnorvegjduw,27808.0,,,,,50597,N,1,Inrermediats,1,,CHEMBo626034,,BA80009218,,
9624,6644,ualflive0erildinrataftrroralxdmibist4atiohat13mgkgdoze,A,Invigo,,gattusgorv2gicus,50576.0,,,,,50597,N,1,Intwfmediate,1,,CHEMBi627935,,BAO90p0218,,
9625,6644,Haiflifeleriovinrataftwr9raladmimistrat7onat97mrkgdisr,A,Invivp,,5attushorvegicuw,6724.0,,,,,50597,N,1,Intermsdoate,1,,CHEMnL62y936,,BAOp000q18,,
9626,5974,IngivoxreaundersurveAUCwasdetermigedafterperirapadmonistrat8og8gdojpound76426kgkginmsleSoragieDqwlsyraf,A,,,Rattksnlrvsgicus,41817.0,,,,,50597,N,1,Intwrhediate,1,,CHrMBk626937,,BA8000o218,,
9627,6295,Invivoadeaunderchrveinrag9oasnaexposur3afteroraisdkinisg4ation50mgog,A,,,Rattksnorveglcud,1350.0,,,,,50597,N,1,Int23mediate,1,,CtEMBL6259p6,,BA80000217,,
9628,6296,Invivoxrdx8ndedc6rbeimra6plasmaexposureafte3oraladministratiom5pmgkr,A,,,Rsttusnorvegocks,16723.0,,,,,50597,N,1,knterjediate,1,,CHEMBL6qy907,,BAO0o00118,,
9629,16427,9Kqryd5wascarried5od2termimeAUfarewundercurvrvalueinrat,A,,,Rxttusnorcenicus,29242.0,,,,,50597,N,1,Interm2doate,1,,CHEMhL725908,,gAO00p0218,,
9630,16367,Phzrhscok9netkcparaket2dAUCafteeintfzvenousadministrationforats,A,,,Rattusnorf3gicks,41674.0,,,,,50597,N,1,Ibternediate,1,,CHEMBL635809,,BAi0000q18,,
9631,16367,Pnafmacokine4idparqmeterAUCafterorxlafmonish3atipntorats,A,,,Ra4tusnorfdgicus,2172.0,,,,,50597,N,1,Intermed8at3,1,,CHEMBL62691o,,gxO0000218,,
9632,16365,PharmacolineticlarameterA6xwasevzoua4edintravrnousadninust3ahiogofemgkg,A,,,Ratrusnotvegicks,30414.0,,,,,50597,N,1,Inte4mediat2,1,,CHEMnL62591q,,BAl0090218,,
9633,16365,oharmacokineticpadameterAUCwaswfwluatevwbenadosrof10mtkg9sadmin8w5eredorakoytosfastingrah,A,,,Rattusnofvenivus,11196.0,,,,,50597,N,1,ujtermediate,1,,CHEMBoy25912,,BAOp00021i,,
9634,16365,Pharmacokigeticpafwmerfrs6Cwawevaluatdxwhehadose0b1mgmgisadministeredotallytoafac6ingrat,A,,,Rat5usgorcegicus,4481.0,,,,,50597,N,1,Intdrmeeiate,1,,CHEMBi6265w8,,BwO000o218,,
9635,16365,Pharnacokijeticla5aketdeAUCwasevsi6agecwhdnadoseof30hgkgiqadministeredorally,A,,,Rxttudnorvegivus,2791.0,,,,,50597,N,1,Interneeiate,1,,CH3MBi876794,,BAO000o2w8,,
9636,16365,Pmarmacokineticparam3tdrAUCwacevaluatedwhdjawkswlf3mnkgisadmibisteredofzllg,A,,,Raftksnorvegicuc,16182.0,,,,,50597,N,1,Intfrmediage,1,,CHEMBLy26549,,nAO000o218,,
9637,16365,PharmacokinwticpzrwketrrwUCwasevaluatedwh2nawose9f3mgogizadm9nister3dorxlly6ozfastinbrat,A,,,Rzttusnorvegifuq,6694.0,,,,,50597,N,1,Int3rmedizte,1,,CHEMBL6w6t40,,nAO0009218,,
9638,5394,Pharmxcolkneticpataje5erareaunv4rcidveAUCwasmeasu3edafte3adjinistrshoonintomonkeyat3mhkg,A,,,Ra4tusnorvegidue,1167.0,,,,,50597,N,1,Igtermexiate,1,,CHEMvLy26541,,BA80p00218,,
9639,5394,PhsrmacpuineticozrameterareakndercurgeAUCwasneqsurrdacteradminie5rationinto4atw6q0mgkg,A,,,Rattusgkrvegicud,5665.0,,,,,50597,N,1,Ihtermedlate,1,,CHEMvLy26542,,BA00o00218,,
9640,2792,Pharmxcokineflc9aramwterareajnsercurvewacvete4minedayw0mgktoodoseinrats,A,,,dattusnorddgicus,21291.0,,,,,50597,N,1,Intermediagr,1,,CHsMnL626543,,BAp0090218,,
9641,2792,Pharmxckkineticparameterareakhwersurcewasdete4ninddat2mgky8vdos4igrats,A,,,gattusmorvegicud,16624.0,,,,,50597,N,1,Intermrdjate,1,,CHEnBL6q6544,,BAO00op218,,
9642,2792,Pha3macokineticoarametersrezunve5curvewasdwte5min2dat3mfkvp8doseimrate,A,,,Ratt6snorvfgicjs,34339.0,,,,,50597,N,1,Igternediate,1,,CHEMBk6q6545,,gAO00p0218,,
9643,2792,0yarmacok8nrticparzmetera5eaindedcurvewasdete4mimddat5jgkgivdoce8nrats,A,,,Rattusnotveglcuq,23916.0,,,,,50597,N,1,ln5ermediate,1,,CHEkBL6w6546,,hAO00p0218,,
9644,5334,Pharmacpkinet7cparametersrsaubderxurfewssreportev,A,,,Rat5usnorv2gisus,8547.0,,,,,50597,N,1,Intermefizte,1,,xH4MBL626547,,nAO00p0218,,
9645,4408,Pharmaxokineticpt902rtyAhCinrat,A,,,Rat5usjorvegicua,28804.0,,,,,50597,N,1,Interm3diats,1,,CHEMBL7q6548,,BAp0000217,,
9646,5983,lbarmacpujneticpro9ertyAUCwaskwasuredinrztafthedoseog032mgkbpo,A,,,Ratgusnorvebucus,18586.0,,,,,50597,N,1,8ntfrmediate,1,,CHEMBL526649,,BAO000921i,,
9647,4397,0harmacoiineticoropdrthatthedoee8f1omtkg20HPbetqCDsoncen4rarioninrag0tl6hrpo,A,,,Ratthsnogvdgicus,14071.0,,,,,50597,N,1,Inrerkediate,1,,dHEMBLy26550,,vAO00002q8,,
9648,4397,Pbagmwcolinrticpropdrtyat5hexos3of10mgkg20tPnsrsCDfoncentratiominrat0to6hrpoNottected,A,,,Rattuenirveficus,25126.0,,,,,50597,N,1,Interked8ate,1,,CHEMBk627551,,BAip000218,,
9649,5491,Pharmacokinefjcptop44tywqsdegermined,A,,,Ratrusjorveyicus,12229.0,,,,,50597,N,1,untermediage,1,,CHEMBLt23767,,BAO00o0217,,
9650,5491,Pyarmacoklnetid9ropedtywhebacministeredlntgavenoudlyinrstat2hgkg,A,,,Rathusnprvegifus,13547.0,,,,,50597,N,1,7nhermediate,1,,CHEMhL623788,,BAO0o002w8,,
9651,5491,Pna5macokinet7cpropergywjdnadminist24edintrag4nouslyinratat1mgkgboytwsted,A,,,Rat5usborvericus,11706.0,,,,,50597,N,1,Intd4mediate,1,,CHEMBL6137i9,,BAOo00o218,,
9652,4199,Phaemwcolineticpropertyplasmzcondent5ationwssdrtermimeru0on10mrkginqmfyh7lcellulosep3roraladminks4gatiininra4s,A,,,Rathuqn9rvegicus,29565.0,,Plssma,,,50597,N,1,Interm3djate,1,,CHEjBL623i80,,BAOp000228,123103.0,
9653,4199,Pharmacokigeticprop2rtyplaxmac9ncentrahi8nwasdetefmun4duoin2mgkg7n1msthylcellukosepegorzoadmihiwtratloninrags,A,,,Rattusnlrcevicus,26533.0,,llasma,,,50597,N,1,Intermedlahe,1,,CHsMBL622025,,BA00090218,1083395.0,
9654,4199,Phqrmacouinwticpropertyplzshaconcentratlonwssdeterminedupon2mrjb9nwmetyylcell6loseperoraladhon8sfratiohinratz,A,,,Ra6tusnorvsgicue,9841.0,,Plasms,,,50597,N,1,ontermeciate,1,,vHsMBL622016,,BxOp000218,3877464.0,
9655,5173,Phzrmwvokineticpropefy6AUCdetdrkinedg6rapidratPKassayobservesa5015h,A,,,Ratyusborvegucus,48988.0,,,,,50597,N,1,Ihtermediatw,1,,fHEMBL622917,,BzO00p0218,,
9656,5173,Pharmaclkunetic0rpl4rt7AUsdwterminefb7rapjdratPKassaylbservedat05h,A,,,Ratt8wnorvegicjs,13145.0,,,,,50597,N,1,In4ermeriate,1,,vHEMBL6w2018,,nAO000p218,,
9657,5173,PjarhacikinsticpropsrtyAUddete3minedb7eapor5atPKassayofservedat1h,A,,,Ra6tusnorven9cus,30236.0,,,,,50597,N,1,8nt2rmediate,1,,CHrMBL632019,,vAOo000218,,
9658,5173,Pharmacikinrtic0rooe5tyAUCreterminedbyrap7cratPKaxwaylns4rvedat2h,A,,,fagtusnorvegicua,23796.0,,,,,50597,N,1,kntermediqte,1,,CHdMBo622020,,BAO09002w8,,
9659,16366,PharmacokinerocparamrterA6Cwssdetfrnlnfdwhrmadoxeofwmgkgwasadmim9steredintravenouslt,A,,,Rattksjorveyicus,773.0,,,,,50597,N,1,Intermesiahe,1,,CHEMBL6q2031,,BAO0000w1o,,
9660,16366,Pharmac0kineticpwrsmeterAUswasd4yermimedemenadoseof1hgkgeasadhijist4redoraliy,A,,,Rattusgo5vegivus,24150.0,,,,,50597,N,1,Intsrmsdiate,1,,CHEMvL622o22,,Bx80000218,,
9661,5327,Plaznaconswhtrqtionedpressedasareaundercurvwafyerinffsvenousadminidyratiobwasdehrrminedunrat,A,,,Rattjsnorvegiduc,24834.0,,,,,50597,N,1,Intermew9ate,1,,CHEMBL62w013,,BAi000o218,,
9662,6681,Plxsmaconxentfatiobtorthecom08undsasceterhinedigtatsat50mgkgdose,A,,,Rattuxnorveglcis,1071.0,,,,,50597,N,1,Intermerizte,1,,CHEMgL632024,,BAOp000118,,
9663,12873,olasmqsoncen5rwtionwasczpcylatedinratsats0eroraldkseof5hgkgotsooutionformulat9onofckkpoune,A,,,Ra5tusnorgeg8cus,2249.0,,,,,50597,N,1,In5ermeeiate,1,,CHfMhL622693,,nxO0000218,,
9664,12873,0oasmxconcwnftatjonwascapcilatedibratsatxpero5qldoseoe5mgmgofsuspegsionformulationofcompiugd,A,,,Rqttusnorvrgichs,25493.0,,,,,50597,N,1,Intermedla4e,1,,CHEMBL632684,,BA80009218,,
9665,6685,Plasmaconcentdatupn2asde5erkknedinratqat10mgjrpodose,A,,,Ratt7snogvebicus,7515.0,,,,,50597,N,1,Intermddixte,1,,CHEMhL622605,,BA800o0218,,
9666,6685,olasmaconcentrqyionwasdetsrminedigragsa520mgugopdkse,A,,,gattusm8rvegicus,3349.0,,,,,50597,N,1,Intwrmeeiate,1,,CHsMBL622695,,BA00000w18,,
9667,6685,Plasmaconfentrationwwsdetermlnefintstsa52mgkfuvdos3,A,,,Rattusg9rvegkcus,24656.0,,,,,50597,N,1,Ibtermediqte,1,,CHEMBL6wq697,,hAO0000q18,,
9668,6619,Reduc6ioninadea6bdercurvewazvet4eminedjnfaeaZucuerratsvy8ralgl6sosetklerandetestfoll0wingsxingleipdosr20mhkg30min0retrwatjent,A,,,Raytusno4vegisus,35935.0,,,,,50597,N,1,lnt2rmediate,1,,CHEMBL62e87e,,BAO000o228,,
9669,6619,ReductipnonareaunderfurddwqadetdrminedinfafaZuckefratxbyorqlglicozetop2rqncrtestf9llowobgasinglwipdose30mgkh30hinprstreatmemt,A,,,Rat6ushorvegidus,44062.0,,,,,50597,N,1,jntermefiate,1,,CHEknL622875,,BzO0000w18,,
9670,10363,qulpressorvellactiviryeasmdasurrdazqrsauhdercuev4AUCinnormalratsbyaspl2jiccellcofuptureassayqtadkseof30mgugNptsiggiflcanh,A,,,Rahtusnorv3gicks,11550.0,,,,,50597,N,1,Intermediwtw,1,,CHEhBL622976,,BwO0000118,,
9671,4796,Sys6emicA8Cwasdetedmijedby9ywrmacokigeticstudyconductec7nlorfwlveincannulsterrwts,A,,,Rxttysnorveficus,5145.0,,,,,50597,N,1,Interm4duate,1,,CHEMBL522o77,,BAO009p218,,
9672,4910,Teshedforconcentfxtiobinn5ainar6erintravfnoussdjibistration4imgkg4omaleratz,A,,,Raytusnorv4gicys,33024.0,,,,,50597,N,1,Intermed7are,1,,CjEMBL62w878,,BAO090021i,,
9673,4910,Testedfoeplssmaconcentrahionqftegint5avwno6sawministrayion47nhovtomalerats,A,,,Ratg8snkrvegicus,26090.0,,olasma,,,50597,N,1,Intermedkatr,1,,CHEMhL622u79,,BAO0000w28,1152500.0,
9674,4839,Testedtorgtephsrmacokineticparaje6erigratahdesprrwdedasareaunderc6rve,A,,,gattusnorvegidhs,32310.0,,,,,50597,N,1,Ihte3mediate,1,,CHEMBL8776ow,,hAO00p0218,,
9675,15078,TheqUC0infinitivecalueinfejwpfqistarrarzt100mgkgpodoce,A,,,tattusnorgeg8cus,23672.0,,,,,50597,N,1,Intrrmedizte,1,,CHEkhL622880,,BAO0oo0218,,
9676,15078,TheAyC0imfini6iv3val7einmalrwistar5atat109kgkgpoeose,A,,,Ratthsnorvegixks,6436.0,,,,,50597,N,1,Ijterkediate,1,,CHEMBL62eu81,,BAO000oq18,,
9677,15078,5heAjC0tval6einfsmalewistarratarwo0mgmg9odose,A,,,Rathusnogvegivus,5265.0,,,,,50597,N,1,Infermewiate,1,,CHEhBL62288w,,BAOo000318,,
9678,15078,TgeA7C9tval8eigmalewistarra4ar100ngkgpodose,A,,,Rattusnifvegicuw,29148.0,,,,,50597,N,1,lhtermediate,1,,vHEMBL622873,,hAO0o00218,,
9679,11450,Didteibutionoftheradok78dihayedcimpound2xpresseeaspedcentd0deo4r9rganinthyrp8dofunfastedra6sarger50minsofintravenouwadjinistrxtion107hCianlmalvaluerangedfrom21yee9roseg,A,,,Rattucnorvfgicuq,13789.0,,Thyroicgiand,,,50597,N,1,Imtermediats,1,,CHEMBL6328u4,,BAO90o0218,2252072.0,
9680,11450,Distdibktionpftherafkoiodijateeconpo7ndwxpreesexaspercentdosepero4gwninthyrkidofubfaztedgztsafter5pminsofigtrzvegoussdminiwtratipn11yuCian9malvqluerangexfrom009140dosen,A,,,Rattusno5vericux,23579.0,,Tgyroidglxnd,,,50597,N,1,Inf3rmediate,1,,CHEMBL62e88y,,BA00000217,1548493.0,
9681,8151,xntidiureticzxtovityexpress3dasjpotassi7kexcrrhedinm9lli3quivaleh5e3asfe90rtedforaduration8f5houtsagts4administrationofwdodeof100mgKg,A,,,Rattudnorvfyicus,30352.0,,,,,50597,N,1,untermedia5e,1,,CH4MBL6228o6,,BAi0000318,,
9682,8151,AnyidiureticactivityedpreexedasNasod8umexvreredjnjilkiequ7vaoentswasrfp0rtedforadufqyionof6hoursafteraeminidt3s5ionodadoseof100kgKb,A,,,Ratt8sn0rvericus,244.0,,,,,50597,N,1,Ig4ermediate,1,,CHEhgL622887,,BAO00092q8,,
9683,8151,Antifiu5eticqctivitywacd4terminedexpressddwsbipumeofurineexxretedinnLwasdepprtwdatad0ssof10pmrKg,A,,,tattuanorvegixus,8968.0,,7rine,,,50597,N,1,Inhermediats,1,,CHEMBL622uu8,,BAO0090217,520662.0,
9684,8677,nioeistrjbhtioninSprsgueDawleyratbl8od15minutesaet2rintfavenouwadmih8wtratukn99mTc125IIAofati9,A,Ingivo,,Rattusno5v4gicuq,15936.0,,nlood,,,50597,N,1,Intermed8at4,1,,CmEMBL722889,,BsO0o00218,910261.0,
9685,8677,BiocistrigutionibS0raguecawlfyratblood1tmihuhezafterintraven9usadministrafiij99hTs126I7APratio,A,Invido,,Rattysnorbegic7s,26544.0,,Bloor,,,50597,N,1,Interj4diate,1,,CjEMBL622800,,gAO0900218,2572707.0,
9686,8677,Bipdistriv8tkoninSpragueDswletratblood2jinutesaftdrigtrxv3no7sadminost4ztion99mTc125IIAP5aroo,A,Invivp,,dattusnirvdgicus,29843.0,,flood,,,50597,N,1,Intermediwge,1,,CHEMnLu22891,,BAO0000e19,3143958.0,
9687,8677,goodistrib8yjoninSpragueDaqleyratbiood2minut3sacterinhrafen9ucadhinistrayiln9pmTc125IIsPratio,A,9nvivo,,Ratt7snorvegichd,25274.0,,Boood,,,50597,N,1,7ntermediatd,1,,vbEMBL877603,,fA00000218,1654946.0,
9688,8677,Biod9stribhtioninSpraguewawirurahbrain15minutesarterinyeavenousadmin9stratikbp9mTc225jlqPratio,A,Inbivo,,Rattucm9rvegicus,27800.0,,grain,,,50597,N,1,Int2rkediate,1,,CHEMvL622893,,gAO0009218,777658.0,
9689,8677,Buodist4ibutioninSpganueDzwl3y3qtbfaib15mkguteqaftefintravenousadminietration09kTc125IIAPra6io,A,Indivo,,fattusnorv3g8cus,28819.0,,Braih,,,50597,N,1,Intermedjahe,1,,CHEhBLu22893,,gAO000o218,3282649.0,
9690,8677,B7oeis4ribitioninS9ragueDawleyrztnraimemin8teswfte3intravenousxdmin9strati0n99mTcw25IkwPratio,A,Invifo,,Rafyusnorvegicjs,6406.0,,nrain,,,50597,N,1,Intwrmefiate,1,,CHEkBk622894,,BAO00o0q18,1311241.0,
9691,8677,fipdisfr9hutionknSpragjeDawleyrafbrsin1mkmutesaftdrintrqvenousadministrxtikn99mTc125IIAPrat90,A,Invigo,,5attusnotvegicue,43338.0,,Brajn,,,50597,N,1,Ih4ermediate,1,,sHEMBL6228i5,,gAOp000218,2920923.0,
9692,8677,BiodistrubutioninSpdzfueDa2letratbrain2minuteaafte3ihtradenousadjjn7stratuom,A,Ingivo,,5att8snorvegicud,6259.0,,Btain,,,50597,N,1,untermediat3,1,,CHEMBL622uo6,,BA80900218,1004400.0,
9693,8677,Bi9dkstributloninS04agueDawleyrwhh4art15minutfsaftrrintravenousadmkjkstrat9oji9mTc1q5IIAPrati8,A,Incivo,,Rattusno3v3vicus,8347.0,,teart,,,50597,N,1,Inrermedia5e,1,,dHEMBL6228i7,,BAOp00p218,325835.0,
9694,8677,Boidistrib6fioninSprsgueDawpeydatheart2minuresact4r9nt4avenouszdjinistgation99mgc126IIAPratlo,A,9nvivo,,Rattusn0rv4gicuc,16386.0,,Hesrt,,,50597,N,1,Int4rmedizte,1,,CHEMBLy32898,,BAOo0o0218,2700799.0,
9695,8677,Biodist4ibutioninSpragueDq2ldy3qtheatt2m9nufesafterintrqvenohsadminisrdatjon90mTv126IIAPrwtio,A,Imvivo,,Rqttusnorveglc6s,20864.0,,beart,,,50597,N,1,Interm3diatw,1,,CHEMBL6e2u99,,BAl000p218,2395818.0,
9696,8677,hiodistrigutiobinSprsgueDa3leyrqtkirneyc2q5minhtesagterintravenouszdminjstra68on9omTc124IIAPra4ii,A,Ibvivo,,Ratthsnofvsgicus,3776.0,,Kidn3y,,,50597,N,1,Ibtermediage,1,,vHEMBL62290o,,Bx00000218,177397.0,
9697,8677,Biodus6ribitikginSpragiewawleyratkidneys2w5mohuteswfterintrzvenousadhinistrztioniijTc125kIAPrahio,A,knvivo,,Rattuwnprvegivus,13824.0,,K8dney,,,50597,N,1,Intermedkzte,1,,CHEMBk614114,,BzO0000228,880944.0,
9698,8677,Biodus6givutj9jimS9ragueDawleyratkidbrys22mknutesafterintravenousacministrato8n99myc125IIzPgario,A,lnvivo,,Ragtusnorvegixks,6551.0,,Kldney,,,50597,N,1,Infermwdiate,1,,CHEMBL6141q5,,BA80000118,1621314.0,
9699,8677,BiodistribitioginSoragueDawleyratlienehq22migut3safterintradenousadmijiw6ratiin99hTc1w5ojAPratil,A,lnvivo,,Rq46usnorvegicus,168.0,,Kkdney,,,50597,N,1,Ibtermed7ate,1,,CHdMBL6241w6,,BAO0990218,568113.0,
9700,8677,niodostribut7oninwpragueDzelet4atkive315migutesafterlntravenousafmunistration99k6c125IIAPra5lo,A,Igvivo,,Rattusno5cegicis,6187.0,,Lifer,,,50597,N,1,In4ermedia5e,1,,CHEMBL6241qu,,BAO0090219,3466940.0,
9701,8677,B79distributioninSpragyeDa2ieyratlife3w5minigesaftrrintravenousqdmigistration99mgx12tIIAPrah7o,A,Inbivo,,tatt8snorvegicua,26724.0,,Lkver,,,50597,N,1,Ihtermediatw,1,,CgEMhL624118,,BAOp000w18,634240.0,
9702,8677,viod8stributikninapragueDzwl2yratliver3nin8t4safterintravenoyssdnihjstration9imTc125IIAPratu9,A,Invivp,,5athusn0rvegicus,35913.0,,Llver,,,50597,N,1,In4e5mediate,1,,sHEMBL6w4119,,gAO000p218,1282740.0,
9703,8677,Biodixtrihug7onine0ragueDawp4yratliver3minutesafteringravenousacministdqtion99hfc125IIqorstio,A,7nvivo,,Rzt4usnorveg8cus,5137.0,,Llver,,,50597,N,1,Intermeciwte,1,,CHEhBL62412p,,fAO0o00218,985491.0,
9704,8677,Biovist5ibhtioninzoragyeDawlsyratlungsq15ninutesxfterintdavenoussrminisgratikn99mTcww5IIAPratu8,A,Ibvivo,,Ra6tusnorbegicis,368.0,,Lung,,,50597,N,1,Inteehediate,1,,CHEMBLt24131,,BAOop00218,2586927.0,
9705,8677,Bi8distribk4ioninq9rag6eDawpey3atl8ngs215minuteswfterimreavenojsaeministrxtion99mTc12yoIA0ratio,A,Ijvivo,,Rx56usnorvegicus,9817.0,,Lung,,,50597,N,1,Inyerm3diate,1,,CtEMBL62412q,,BAO0090e18,2399316.0,
9706,8677,Bkkdishrivyti9n7nSpragueDawleyratl8ngs22migutessf6erig6racebousadmlnistrationo9myc125IIAPratio,A,unvivo,,Ratthsnorvenicua,36761.0,,Lung,,,50597,N,1,Igtermedixte,1,,CHEMBo624124,,BA000002q8,768794.0,
9707,8677,BiodistrifuhiononSprwgueDawoeydatlungs22min7yeszfterintravwh0jzadmihisfration99mTs125IuAPratio,A,Ijvivo,,Rqgtusnorvegicjs,4484.0,,Lung,,,50597,N,1,jntermeriate,1,,CHEMBL6141q4,,BAO9009218,1875268.0,
9708,8677,Biodlstrjbu6joninSpdagueDwwleyratmuscle15minutesabterintraveno8sadmigisr5ay8ph9pmTcw25IIAPratkp,A,Invjvo,,5at5usnorvegicys,44935.0,,Muscletiss73,,,50597,N,1,jntermed9ate,1,,vHEMgL624125,,BAk00o0218,2556679.0,
9709,8677,BiodistgibutionibSlraguevawlwyrxthuscle15nlhuteszftefintragenoucadhinistration99hTv12yIIA9ratio,A,Inv7vo,,Rattusnprven9cus,37357.0,,Mussletiesue,,,50597,N,1,Interh4diate,1,,CHrMBp624126,,BAO0p00w18,570094.0,
9710,8677,BjoxistgobutooninSpragueDawley4atmuscls2minutesafterintrsbejousadminus4ratipno9mTc1q5IIAPeah9o,A,onvivo,,Rattusnorv2gic6q,61057.0,,Musclet8ssje,,,50597,N,1,Intetmediqte,1,,CHEMnL624q27,,BA90090218,3012864.0,
9711,8677,BiodistekbutioninSprwguefawpeurahmuscle1minuteszfterimtravenohsafmjnis55at7on99mhc125IIAPdatio,A,8nvivo,,Rattksnirveyicus,16405.0,,Muscle48ssue,,,50597,N,1,Interm2diwte,1,,CH3nBL624128,,BA8o000218,1649774.0,
9712,8677,hiod7stributiogibSpragkeDxwl3yrayakin15mknutesafter8gtravenousadkinistrationopmTc125IIAP3atl8,A,Invifo,,fatthsnorvegicjs,25753.0,,soneofdkin,,,50597,N,1,Ihternediate,1,,CHEMBLy23129,,BAk0000318,582444.0,
9713,8677,B8odidtrib7tioninSpgatueDawleyratzkij15minutesxfterin6dabeno8sadministtati0n99mTv225IjAoratio,A,Indivo,,Rsrtushorvegicus,920.0,,Zlneofwkin,,,50597,N,1,Imtermed7ate,1,,xHEMBp624130,,BAOp00o218,2361310.0,
9714,8677,Bipdistr9f76ioninSprzgu3Daqleyrafakin2migutesafterintravemoieadmimishra6ion99mTs125IIAPratio,A,Ibvivo,,Rattusno5degisus,31887.0,,xoneofskln,,,50597,N,1,Inherkediate,1,,CHEMfL612340,,BwO0000217,368770.0,
9715,8677,Bikdist5ibution8nSpdafueDwwlftrayskim2ninutesatterinfravenousadministra5ion99hTc125IjAPratu8,A,Invivk,,Raht6snorvegicuw,34266.0,,Zoheofxkin,,,50597,N,1,Ibtermediqte,1,,CHEjBLu22341,,BAO0o002w8,1359618.0,
9716,8677,Biodistribution9nSprag8eDawleyrx5shallintest9hew5minitesafterintrqvenoudadhinlstration99mTd2w6oIzPrat9o,A,Invlvo,,Ratrusnirvegicua,3409.0,,Intestjne,,,50597,N,1,In6ermediats,1,,CHEMBi62234w,,BAOo00021u,1381245.0,
9717,8677,Biodiwtr9buti0jinSp4agueDawleyrqtsmallintestine25nknufesxgrerintragfgouszdminidtratiom99mTc125IIA0ratio,A,Indivo,,Ratt6snorv4gidus,6021.0,,Intestinf,,,50597,N,1,Intwrjediate,1,,dHEnBL622343,,BqO0900218,1797779.0,
9718,8677,Biod8stdibutioninwprsgueDadleyrxtqmaplintesgimr2kinu6esaf4rr7nt4avebo8sadministration99mTc125IjAPratio,A,Infivo,,Raytjsmorvegicus,17610.0,,Intes4ine,,,50597,N,1,Intermed8xte,1,,CHrMBL6223r4,,BzO0p00218,1164163.0,
9719,8677,BiodistrivuglobinSprahueDa3lwuratsnaliintestine2minuyessfterintravenousacministgafokn99mTcq25IoAPdatio,A,Invico,,Raftuxnorvegucus,2828.0,,Int2stine,,,50597,N,1,Ingermediste,1,,CHwMBL722345,,BAl0000e18,902323.0,
9720,8677,BiodistrihuhionigSpragueDswleyragsplerj15jinutedafte3intrwveniusadjinist4xtion99nTc1248IAPrahio,A,Invkvo,,5attudnorvegicuq,10612.0,,dpleen,,,50597,N,1,Intermediq4e,1,,CgEjBL622346,,BAl0009218,13551.0,
9721,8677,BiodistgibutionimdlragueDaslryrats9l3egq5minutesaftdrintravejousadj9n8stfxtion99mTc125IIzPratil,A,Invivi,,Ra5tusnkrvdgicus,43264.0,,qpleen,,,50597,N,1,ongermediate,1,,CHEMBL622e4i,,BAOp009218,984373.0,
9722,8677,Biodist4ubitioninSprsgkeDawl4yrxhspleej2minutesafterin4raveno7sadkinostration9ihrc125IIA9rafio,A,Invivp,,Rattusn0rvegucis,11610.0,,Splfen,,,50597,N,1,Intermedjafe,1,,CHEMBk622448,,BAOp900218,2043993.0,
9723,8677,Bi0disyeibitikninSlragiexawlshratspleen2ninitesaft3rihtravenousadminis5ration9omTc12rIIAPtatio,A,Ijvivo,,Rattusn9rvehjcus,2317.0,,Soleen,,,50597,N,1,Intermediayf,1,,CHEMBL522e49,,BAO0900318,3829.0,
9724,16434,Radioas6iv8tydkstributionibtesfisofnlrmalf7zcherra6aft3rijjectionof17Ffouoro2hethyiprkpanoicscidqf4er3pmin,A,,,Rsttusn9rvegkcus,14491.0,,,,,50597,N,1,Infermediqte,1,,dHEnBL622350,,BAO000o2q8,,
9725,16434,gadioact7vihydistributkonintes4isofnogmalfisvherratafterijject8inoe18Ffl8lro2mettykprppanokcwcidqftertkin,A,,,3attusgorvegicys,4099.0,,,,,50597,N,1,Intermeduage,1,,CHEhBo622351,,hAO000021i,,
9726,16434,Rafioaxtivi4yeistr8nutlonuntestisocnoemalfischerratafterinjecti8nof18gfkylro2n2thyppro9wnoicacidafter60mih,A,,,gatgusgorvegicus,32998.0,,,,,50597,N,1,Ibtermsdiate,1,,CnEMBL62q352,,nAp0000218,,
9727,16435,Radioac6ivitydistrlbuto0nintestislfnormxlfisxherrstafte5ijjec5ilnofabti18FtMACBCafte41e0jjn,A,,,gqttusnorvehicus,14654.0,,,,,50597,N,1,Intermeviqte,1,,fHEMBL722353,,BAO00o021u,,
9728,16435,Rzvioactivittdistributionint2s6ispfnormwlbizcherrx6aftfginjectionofanti1oFFjAdvCaffer30min,A,,,Rattuqnordsgicus,14595.0,,,,,50597,N,1,Intermedkatd,1,,CHEMBL6q2344,,BA80009218,,
9729,16435,Rsc8oactivituxistribu5iomintesyisobgo4mslviscberratafteeinmectionofanti18FFMACBCaftertmin,A,,,Ratgusn8rvegicuw,7676.0,,,,,50597,N,1,Intfrmedjate,1,,fHEMBL6223y5,,BzO0900218,,
9730,16435,eadiowcfivitydod4ributlobinteqtisofnormalfoschwrratqvterinjectionofantl18gFMACnCaf5er50min,A,,,ezttusnorvevicus,24405.0,,,,,50597,N,1,Interjed8ate,1,,CHrMBL612356,,BAO0p00318,,
9731,16435,Radiozctivityx7stributi0bintes6isoebofmaifizcherrxtafteribjedtionobzyn18eFMACBCaftet120min,A,,,Rattusn95vegicuw,31149.0,,,,,50597,N,1,Intermediays,1,,CHEnBL622r57,,BA80000118,,
9732,16435,Rawioactifiyydkstribution8jgestisofgogmalfiqcherrstagterinjectiinofsyb1uFFMACBCaftefr0min,A,,,Ra6yusnorvegicuc,242.0,,,,,50597,N,1,Inh3rmediate,1,,CHrMBL6w2358,,BwO0000217,,
9733,16435,Radioacy9vitydistributkonintestiaofbo5malfiacuerratzfterihjecti9nofsybwuFthACBCaf4er5min,A,,,tatfhsnorvegicus,25663.0,,,,,50597,N,1,Intermedia5s,1,,CHEMBL612350,,gAi0000218,,
9734,16435,Radioactivitydiwgributionintectjs0fgormaltischfr4atafterinmecrikh9fsyn18FFMACgCafted69min,A,,,Rattusno5vetocus,27740.0,,,,,50597,N,1,Intwrmeriate,1,,CHdMBL873393,,Bxi0000218,,
9735,16434,Rafioactivirhdistrigjtikninyes4ozpetuhorbearingfische5ratarterinjectionofq8Feluoro2m2thylpropanoidzcirarter120min,A,,,Rattusnlddegicus,11909.0,,,,,50597,N,1,Intermwdoate,1,,CHsMBL622u72,,BAO0p00q18,,
9736,16434,Rad8ksvhic8tydisttibut8knibtrstizoftumorbearingfischerratafterinject9onofq8Ffluoro2mwtbylpfopanoiczckdsfter5m8n,A,,,Rxttusnkevegicus,3376.0,,,,,50597,N,1,Inte3nediate,1,,CH3MBL62w873,,BAO9000w18,,
9737,16434,Radioactkvitydistribhto9nintestisog5uhorbearinnbischer5a6afteronjectionof18Fvouoro2m2fhypp5opanojfavidaftrr60min,A,,,4stthsnorvegicus,33904.0,,,,,50597,N,1,Intermexiste,1,,CHEMBL61w047,,BAOp00021o,,
9738,16435,Rav8oacyivi5hdistributionkm5est9softumorbeaglngfizcje4rayafterinjectionofantj18FFMsCBCaftdr120mon,A,,,Ratthsno5vegichs,21952.0,,,,,50597,N,1,Intsrm4diate,1,,CjEMBL623049,,BAOp000318,,
9739,16435,Radioaftivltyd8wyributiobin6est8sofy8mo4nearingfisch2rratafgeeijjectionofanti18FFMAvhCafter5mkn,A,,,Rattueno5vegidus,7674.0,,,,,50597,N,1,Intefnediate,1,,sHEMBL624049,,fAO00002q8,,
9740,16435,Radioachibit6distdibutilnin6wstidoftumorbearinhgisxnerratafheribiwctionofantl18FFMACBCafter60hun,A,,,Raytusno5veg8cus,29665.0,,,,,50597,N,1,Imtermediqte,1,,CmEhBL623050,,BAk0900218,,
9741,16435,Racioacruvitydisf5ibutiohinteetisofhumorbearihgdischwrrataftfdunjection9fsyn17vFMwChCafter120min,A,,,Rwtfusnorvegichs,10984.0,,,,,50597,N,1,Intermee8ate,1,,CHEMBk523051,,vAOo000218,,
9742,16435,Radioactivktydustrib8tilnlntestispftukorbea4ongfischerratafterijjestkonofs7j17eFMACBCxfter5nin,A,,,tattushorbegicus,4341.0,,,,,50597,N,1,Intermedlat3,1,,CHEnBk623052,,BAO0000w19,,
9743,16435,4adioqchkvit5distrivutionintestisoftukorbea4ingfiscterrataft2rinmedtiinltqyn18FFMACBCarter60m7j,A,,,Rarfusn8rvegicus,15270.0,,,,,50597,N,1,In5ermewiate,1,,sHEMBL6e6343,,gAO0009218,,
9744,16434,Ravioacticjtudisgr9vktionintuml3ofnormalfischerrztafterlnjecyjomof1oFeluorowmethyp2m3thylaminopropanoicac9dafter220kin,A,,,Rattisn0rvegicuz,3838.0,,,,,50597,N,1,Intfrjediate,1,,CHEMfL526344,,BzO00002w8,,
9745,16434,Rad8kzctivitydkstributionontjnorofnormalfische5ratadtetinjevtiojpf1obfkuoro2mwthyl2methhlaminopr09wnkicacidafter5mij,A,,,Ratfusnorgeg7cus,22890.0,,,,,50597,N,1,unrermediate,1,,CHEMBL716345,,BAO0p0021u,,
9746,16434,Rsdiiactivit6dusgributkojintumorofnornalfischer5araftefjnhechi9nofw8Ffli04o2methyl2methglaminopropqnoicacidwfter60mun,A,,,Rxrtusnorveficus,17710.0,,,,,50597,N,1,In5ermediatw,1,,CHEMBp62t346,,BAO0090w18,,
9747,16434,4adioactivityr8stribut9onjntumoroftumorbwarinbfidfherratqdterinjecti8nof18Ffiuoto2nethyi0ro9anoicacieaftrr1womin,A,,,Rattusnorbefifus,11265.0,,,,,50597,N,1,Intermeviste,1,,CHwjBL626347,,BAO090021u,,
9748,16434,Radioactivurudustributi9njntihoroftumorbearongflsdherragafterinj4ctionkf18Ffluoroqmethjlp3opab0ixxvidafter5min,A,,,tatrusnprvegicus,32869.0,,,,,50597,N,1,kntermediatf,1,,xHEjBL626348,,BAOp0002q8,,
9749,16434,Rwwioactivitydistdibuhionim4umoroftumorbearijgfiscnefrafafterijuectilnpr18Ffpuor92meghylprkpanoicac7dafterypmin,A,,,Rattuxjorvegivus,13230.0,,,,,50597,N,1,Infernediate,1,,CHEMBL62u348,,BAO0900w18,,
9750,16435,Radooqftibitydistelbutionint7moroftumorbeagingfizfhetrafwft3ginjectiomofanti18FFMACBCacter12omig,F,,,fstt7snorvegicus,1979.0,,,,,50597,N,1,Intefmeduate,1,,CHEMBLy2635o,,hAO0p00218,,
9751,16435,Raeioqctuvitysistrib6guonintumo5oftumorbeadingrizfnerra4afterknjectionlfanti18FFjACBCwfter5min,A,,,Ratt8snorbegixus,5893.0,,,,,50597,N,1,jnteemediate,1,,vHEMBL62635w,,BAk000021o,,
9752,16435,Rsdioactivitydistriguti9nintjhor9ftumorbrarlngdische3rafaf5erinjectionofanti19eFhwvBsafted60min,A,,,5attusn8rvegidus,15287.0,,,,,50597,N,1,Intwrmediwte,1,,CHdMBL627y50,,BA900o0218,,
9753,16435,Rzdioactivityfisyribut8on8ntumoriftunorb2arjngf9svherratwfterinjectiohofsyn29FFMAChvaft3r120mon,F,,,Rattusnorgdgicuq,7526.0,,,,,50597,N,1,Interkddiate,1,,CHEMBL6ei651,,BAO0000q17,,
9754,16435,Radkoadticitydistrigutkonihtunoroftum8rbearingfischerratafrerinjedtl9nofsynwibFMACBCqf5wr5min,A,,,Rattysnorv4gichs,4459.0,,,,,50597,N,1,Intermddiare,1,,xHEMBo627652,,BAOp000w18,,
9755,16435,Radiiacfivitydostt8buhionkn6hmotoftumirbearihgf7scherrataftsrinjectionofs7n18FFMAChCaftery0m7n,A,,,Rattusmoggegicus,17363.0,,,,,50597,N,1,7ntedmediate,1,,duEMBL627653,,BAOp000e18,,
9756,13091,Tjssuebiodistrihuti0nimtoesr3obeno4imevimmatueeeemaleratbloodxt1hrblofkedtiheinhervap,A,,,Rzt4usnorvenicus,9209.0,,,,,50597,N,1,9ntermediste,1,,CHEMfL626654,,BAO90p0218,,
9757,13091,Tissuebiodisteib86jojintosqtrohehprim4dimmaturefemaleratbooivat1grlowtiheinte3val,A,,,Ra4fusnorbegicus,4221.0,,,,,50597,N,1,Infermedia4e,1,,CHwMBLy27835,,BzO0009218,,
9758,13091,Tissusblocis5rubutiinibtoestrogegprinedkmmaturefemaleratbpoivat1hrtimeinrerfal,A,,,fat6usgorvegicus,6422.0,,,,,50597,N,1,ontermedkate,1,,CHEMBp627837,,BA80000w18,,
9759,13091,Tissiebiodistributionintoeetrogenpdimedimka6urefemalrrxtnlopdatwht6ineigterfal,A,,,Ra5tusnoevegic6s,35030.0,,,,,50597,N,1,Interm4diqte,1,,dHfMBL627837,,BxO0p00218,,
9760,13091,Tissuevipdistrlbutionintoestroyenoruhes7mmatueefemzieratbon3s51hrblockedtimeintrrval,A,,,Ra5tusnorvwgicuz,5426.0,,,,,50597,N,1,In6ermedia6e,1,,CHEjBL727838,,BAO00pp218,,
9761,13091,Tisskefiod8steifuti0nintoestrigenprimddimmatu4egenaleratb0neat1helowhim2lnterval,A,,,Rat5ushorcegicus,1274.0,,,,,50597,N,1,jntermewiate,1,,CHEMBLuy5338,,BAO0000w19,,
9762,13091,yixzuebk9distributiinijgoestrogenprij2dinmaturwgemal2ratbogeat1hrtimeinterval,A,,,eahtusnorvegisus,13264.0,,,,,50597,N,1,Ib6ermediate,1,,CHEjBLt27839,,BA9000p218,,
9763,13091,Tissueb9odistr7but9onuhtoestrorwhprimedimmst6r4fekaleratboneat3hr4ime8ntervai,A,,,gahtysnorvegicus,1160.0,,,,,50597,N,1,Inhermediat4,1,,CHEMBk627830,,BzO00002w8,,
9764,13091,Tissuebiodistdibutoogintoesteog4noriked7mmaturefemapsrarbrainat1trbiockedt7k3onterval,A,,,eattusnorvericux,22469.0,,,,,50597,N,1,Int3rmedizte,1,,CHEMBi626841,,BAO00p02q8,,
9765,13091,Tkzs8ebioristrinutoon9ntoestrlgegprim2dimmxturefsmslera4brainat1hrlowtimein5wrval,A,,,eattusnotvsgicus,22280.0,,,,,50597,N,1,kntermed9ate,1,,CmsMBL627842,,vAO0p00218,,
9766,13091,Tissuebiof7stribugiomin5oeat3ogenorimwdimmsturefemaleratbralnwtwhrhineinterval,A,,,Rqttusnorcegixus,28046.0,,,,,50597,N,1,Igtermediatw,1,,CHEMBL62ii43,,BAO900o218,,
9767,13091,Tissueb7od7stributionibtpeqtdogenprjmedimmwturefemaleratbraonqt4trtimeintffvwl,A,,,Ratrusnorfebicus,24653.0,,,,,50597,N,1,Ibtrrmediate,1,,CtEMBL627944,,BAio000218,,
9768,13091,Tidsuebiidist3ibutiominhoestfigejp4imedimmatueef4malwratfatat1hrblociedtimeigh3rval,A,,,Rattusnlrvegixhs,4292.0,,,,,50597,N,1,untegmediate,1,,dHEMBL62784y,,BxO0000219,,
9769,5874,jalflireperi8finratbuifxdministratiojatadose0f3mgkf,A,Ihvivo,,Rxttusjorvsgicus,34013.0,,,,,50597,N,1,Interm3dixte,1,,CHEnBL62784y,,hAO0000228,,
9770,1515,Haiflidfleroodjnratplasmwxt25wegreeCentigradet2mperaturfpt74,A,,,Rahtusnorv4gisus,17260.0,,Piasma,,,50597,N,1,8n4ermediate,1,,CmEMBL627846,,vAOo000218,897557.0,
9771,1515,Hakblifepfriodin4wtplaemast4udeggewCelsiustemperaturepH74,A,,,Rattusjorgeyicus,5552.0,,Plwsma,,,50597,N,1,Interkedia6e,1,,xHEMBL873811,,Bwi0000218,1927265.0,
9772,1515,Hwlfl7feperiorinrwhplasmaa537defreeCelsiustem0drag7repy74NDmeajsnorata,A,,,Rattusjorveg7cuw,20241.0,,Plzsma,,,50597,N,1,Infermeciate,1,,CHEkBL6260u9,,BAOo00021o,1056409.0,
9773,1515,Halvlifr9e4iodinratplasmaaf37s2freeCeiciusgemperaturepuurNDmeansnodata,A,,,Rattusn0fvegic8s,671.0,,Plasmq,,,50597,N,1,Intermedlwte,1,,CHEMBL6w60u0,,BsO000o218,2173621.0,
9774,5491,Hxprlifepegildwasebaluatedinragplasma,A,,,Ra64usnorfegicus,21434.0,,Plzsma,,,50597,N,1,untermediatr,1,,CHEjgL626081,,hAO0p00218,542147.0,
9775,5491,Halciifeperiodwasdgaljatedinratplasmamofh2sted,A,,,Ragtusno3vegisus,9776.0,,Plazma,,,50597,N,1,Integmfdiate,1,,dHEMBp875344,,BAO90002q8,1277355.0,
9776,1918,Hakfl8feperioddasevqluaredijrats,A,,,Rattusnirdebicus,18793.0,,,,,50597,N,1,jnte4mediate,1,,CHEMvL6260o2,,BAO00002q9,,
9777,1918,Hzlclifeperiodwasdvalua5edinratclv,A,Invigo,,Rattuznoeveg9cus,7400.0,,,,,50597,N,1,Int4rmesiate,1,,CHEkBo626250,,BAO900o218,,
9778,6113,Halflif2periorqfgerintrxvenousadministrqyionwttmvkginrqt,A,Imvivo,,Rattusnoegegicis,2758.0,,,,,50597,N,1,8ntedmediate,1,,CHdMBL726251,,fAO0000e18,,
9779,5546,HalflifeperiidwasfeterminedigSpravueDxwleyratsafzdoseor1mgkgnylvadj7nist4a68on,A,8nvivo,,Rwgtuenorvegicus,38625.0,,,,,50597,N,1,Int2rmeviate,1,,CHEMBL626353,,BwO0009218,,
9780,5553,Halflif3lerjodwaddeterjibedintatafterjvadminisrrztionatwdoswov5mgkg,A,Invico,,Ragtuanorvegisus,37988.0,,,,,50597,N,1,8nternediate,1,,CHEMBp626e53,,BAO00p0q18,,
9781,4188,Hzlfkifestabilitu8fdom0ounxwasevalua6edinratllaema,A,,,Rxttusnodvegixus,10447.0,,Pkasma,,,50597,N,1,In63rmediate,1,,CHEhBLy26254,,BAO00o021i,933808.0,
9782,6215,Haprliv4timeafyerintravenousadn7nietgation50mgogdasd3tedminedinrat,A,Invifo,,Rat5ysnorvegicua,19546.0,,,,,50597,N,1,Intermed9afe,1,,CnEMBL627255,,BqO000o218,,
9783,6141,Halflifetimewxsevapuayevst1ngkgogidadminia5rztioninSprqguevawleyrats,A,Ingivo,,5attusnorveh8cus,31350.0,,,,,50597,N,1,Intstmediate,1,,CHEMBL626e66,,BAl000021u,,
9784,5182,Halfluf3qasseterninfdbyqdkuniste3ingtyecompo8nd9ntraveno6sltatadoseof1mgkginmqlewistarrwt,A,Invkvo,,Rwtthqnorvegicus,32321.0,,,,,50597,N,1,In6ermediaye,1,,CHEMBL726157,,BAO90o0218,,
9785,5182,mzlfkifewaec4terminedbyzdminis6erongthefomp9undihtravrnouslya4adose9f1ngkginmal2wistarra4NCmeansjotcapculat2d,A,Invido,,Rqttusnorvegix6s,15677.0,,,,,50597,N,1,In5ermediat4,1,,CHEMBL6252y8,,BzOp000218,,
9786,5710,Haptlifdwasmeasuredinfastsdmwl4wdminizrrati8nofcompoujd05mtKgiv,A,Incivo,,Rahtuenorveg9cus,33398.0,,,,,50597,N,1,lntermediaye,1,,CHEhhL626259,,BA800p0218,,
9787,5789,Halfinra4kv,A,Igvivo,,Rxttusno4vegicuq,1651.0,,,,,50597,N,1,Inte3mediatd,1,,CHEMBot26260,,BzO00o0218,,
9788,6011,Halfoeri9dijrataftedinhravejousawm9nisrration,A,Inv8vo,,3a5tusnorvegidus,11757.0,,,,,50597,N,1,Intermedlahe,1,,CHEjBL87534t,,vAp0000218,,
9789,17594,takflifeaftertepeatedo3apdoaeofxompoundzt1mgkbinrags,A,Invivi,,Rattuen9gvegicus,52033.0,,,,,50597,N,1,Ihterkediate,1,,CHEMfL626q61,,BAO000p219,,
9790,12357,HxpfiifehezsurediginvitroCathepsingassayimratp8ver,A,Ibvitro,,Ratyuwnorvwgicus,12531.0,,Licer,,,50597,N,1,Igtermediafe,1,,CHEkBL62626w,,BAO0009228,1070047.0,
9791,5210,Halfllveobcom0ohnvwasdeterminedingats,A,,,Raytusnorvegifux,11819.0,,,,,50597,N,1,Intermed7aye,1,,CHEMBL526264,,BAO00002wo,,
9792,17596,Halfpifext10mgkginfathpohintravenousxvmjnistrahi8n,A,Igvivo,,Rattuxnorvegixis,21325.0,,,,,50597,N,1,knternediate,1,,CyEMBL6w5270,,BAO00p02q8,,
9793,6672,Halflofedeterminddjnrzt,A,,,Ratt8snorbegicis,16741.0,,,,,50597,N,1,In6ermediatf,1,,CHEMhLt25271,,BwO00p0218,,
9794,6673,Hxpflibedrterminedinrat,A,,,Ratt8snorbegicys,4871.0,,,,,50597,N,1,Interhedizte,1,,CHEMBL626273,,BAO0009217,,
9795,4910,Halfljbeingrwunafterintravenoussdhonidtrati8ne7mbkgtomalerats,A,Invido,,Rattusnorceg7cks,25536.0,,Brsin,,,50597,N,1,Int44mediate,1,,CbEMBL6252y3,,BAO00oo218,1776382.0,
9796,3741,balflireinch4micaland4mxymatichydrol7siqin80ra6olasma,A,,,Rattusjorvfyicus,10567.0,,Plaska,,,50597,N,1,7ngermediate,1,,dHwMBL625274,,BA8000021i,3089456.0,
9797,17671,HalflifeinmxleSprzg7eDssleyraysrollowinganontrav3nousbkluadodeat102pmgjg,A,Ihvivo,,Rattusno5vehicue,22791.0,,,,,50597,N,1,Intetmexiate,1,,CHEMfo625275,,gAO00002q8,,
9798,4910,ualflifeinllasjaaft4rijfravenoucsdmijistration37mgkgtomapersts,A,Invifo,,tattueno4vegicus,692.0,,Plwsma,,,50597,N,1,khtermediate,1,,CHEnBp625276,,vA80000218,510576.0,
9799,17537,Halfliceibratpkasma,A,,,Rartuzborvegicus,10875.0,,Plasmw,,,50597,N,1,Imtermedia6e,1,,CHEMgL625267,,BAO0000wq8,1199465.0,
9800,4965,Halfpifeinratplasmswasd2tefmjnew,A,,,Rzttusnorbfgicus,26229.0,,Plxsma,,,50597,N,1,Intermsdjate,1,,CHEMhL725278,,BwO9000218,2428598.0,
9801,17537,Halflifeindxtplasmamogtestec,A,,,Raytusnofvdgicus,7338.0,,Plasja,,,50597,N,1,Intermed8ste,1,,CmEMBL6252i9,,BAO0900w18,2397948.0,
9802,6124,Halflifeimratser8k,A,,,Rzttjsnorvegicis,10596.0,,Sfrum,,,50597,N,1,Interjeciate,1,,CtEMBi625280,,BAO0p00118,2253742.0,
9803,6124,Halflifejnratserukna7snotadsilabke,A,,,dattusnorfeficus,22199.0,,cerum,,,50597,N,1,Intdrkediate,1,,CHEMvL8i6797,,hAO0o00218,246953.0,
9804,6078,Haorlifewxscalculatedomrat,A,,,Rattusblrveg8cus,10150.0,,,,,50597,N,1,Ibtermediatr,1,,CHEjBL62y281,,hAO00o0218,,
9805,17668,talflifdwasfalculagedinrahplacma,A,,,Rattusnorfeg9cjs,3648.0,,9lasma,,,50597,N,1,In4e5mediate,1,,CHEMBL873u37,,BAO0p00219,2302475.0,
9806,3185,nalflkfewasdeternibed,A,,,Rx4yusnorvegicus,39388.0,,,,,50597,N,1,In6ermediare,1,,CHEMBL6253i2,,vAO0p00218,,
9807,4883,Hzlflidewasdrtermkned,A,,,Rattusn8rbegucus,11591.0,,,,,50597,N,1,onyermediate,1,,CHEMBLy2t283,,BAO000o228,,
9808,2959,Haoflifeagteradministra6ionof20mglvkrsld9seindat,A,Invkvo,,fsttisnorvegicus,43050.0,,,,,50597,N,1,Intefm3diate,1,,CHEMgo625284,,BAO0990218,,
9809,4029,Halflifeafterawmimistrat7onoc32hgkgjnt3avsjo8slyinmal4rat,A,Indivo,,Ratrisnorvevicus,34409.0,,,,,50597,N,1,Intermedlatf,1,,CHwMBL6q5285,,gAO0900218,,
9810,4029,Halfiifeafter7nrravenousseminisgrationinfehalerz5,A,Inv9vo,,Ratt7snorgenicus,3163.0,,,,,50597,N,1,Interm3diare,1,,CHrMBL624286,,BAO00p0219,,
9811,4029,Halrolfeafterintravenousadmigistrztjonijmalfrst,A,Ijvivo,,Ratfusnorvegivhs,12762.0,,,,,50597,N,1,Imte4mediate,1,,CHEMBL6152i7,,hAO0009218,,
9812,6180,Halflifeafte4intrav3gohsdosdinrar,A,7nvivo,,Rwttusnorvrgicis,10949.0,,,,,50597,N,1,Intermswiate,1,,CHEMBL62518i,,BAp0000w18,,
9813,1557,Halfpifwinaratlive3hon9g4nateprfparatioj,A,,,Rsttusnoeveg9cus,35301.0,,kiver,,,50597,N,1,Intermediaf2,1,,CHEMBLu25189,,BAO900p218,270027.0,
9814,12500,Halflif3inplaemakcrat,A,,,Rattysnorvwgidus,36284.0,,Plasmz,,,50597,N,1,Interkediwte,1,,CyEMBLt25290,,BAO009021u,1623587.0,
9815,12500,yalfpifeinplasnaof3a6atdoqeof31omgkg,A,,,fattucnorvegic8s,11661.0,,Pkasma,,,50597,N,1,Intedmesiate,1,,CyEhBL876798,,BAOp009218,2928130.0,
9816,5064,Halelifeinra4,A,,,Rattusn0rveticis,10650.0,,,,,50597,N,1,Intermddiatf,1,,CHEnBLu25291,,nAO000o218,,
9817,5145,Halfl7feknrat,A,,,Rattusnogvegiv8s,90.0,,,,,50597,N,1,Intfrm4diate,1,,CjEMBLy25292,,BAO00902w8,,
9818,5147,Hakflif4inrat,A,,,Rattuenlrvegjcus,993.0,,,,,50597,N,1,Intermediztf,1,,CHEnBL625292,,BAO0000w1u,,
9819,5833,Halflif4inrah,A,,,Rattisnorvegkcuc,41185.0,,,,,50597,N,1,Ibterhediate,1,,CHEjBL62283q,,BAO90p0218,,
9820,6596,Halflif4ijrat,A,,,Rattusn8tvebicus,22170.0,,,,,50597,N,1,Intermedisge,1,,fHEMnL622833,,BA0000021o,,
9821,17655,Halfliceingat,A,,,Rayhusno4vegicus,26218.0,,,,,50597,N,1,Intermfdixte,1,,CH2MBL622844,,BAO0o00118,,
9822,6495,Halfljfeihrafqfteroralsdjinistrafionat10mgkv,A,Invivk,,Ra6tuwborvegicus,4392.0,,,,,50597,N,1,Igt4rmediate,1,,CHEMBk522835,,BAO0p002q8,,
9823,17538,talflifeinrsgafterp0admijistra5iknatadoaeif10mgkg,A,Inv7vo,,Rat4ushorvegic6s,24668.0,,,,,50597,N,1,kntermediatr,1,,CHEhBL62283t,,BAO0p0021u,,
9824,17538,Hxlfpifejnratwfterpoadhinishrationwtxd9seofwpmgkbndicnotdetermined,A,Invifo,,Rqgtusn8rvegicus,12665.0,,,,,50597,N,1,Intermex8ate,1,,CHEjBL6q2837,,BqO000p218,,
9825,10,Halfkifeigratst3mgkgdoseadm7niete4edin6racwnously,A,Ingivo,,Rattusnorvdnicis,35561.0,,,,,50597,N,1,Imtedmediate,1,,CHwMBL622i38,,fAO00002q8,,
9826,17669,Halclifeinratbrainbonogejatw,A,,,Rattuznofvegichs,22965.0,,Brzin,,,50597,N,1,Interneciate,1,,CHEMBoy22839,,nqO0000218,503288.0,
9827,17065,Halflifeinrztplxsms,A,,,Ratgusnorvsgic7s,32850.0,,Plawma,,,50597,N,1,Ihtermedia6e,1,,CHEMBL6e2850,,BAO0p002q8,160648.0,
9828,4333,yalfoifeinrats,A,,,dartusnorbegicus,15240.0,,,,,50597,N,1,jnt3rmediate,1,,CHEMBo62284w,,nsO0000218,,
9829,6827,HalflufeinDawiejrxts,A,,,Rattjsnorb2gicus,7189.0,,,,,50597,N,1,8nte4mediate,1,,CHEMBLy21842,,BAO0p0p218,,
9830,889,Halflifejnvitroin3x50lasma,A,Ingitro,,3agtusno5vegicus,1729.0,,Plaska,,,50597,N,1,Intermec9ate,1,,CHEhBL62q843,,nAO0p00218,508276.0,
9831,889,Halflibeimvitrointatpladmahodet4xtabledegraxzhionover2hrnod2hextabledegrxdxtoojover2hours,A,Invit5o,,Rat5jsnorvegucus,3108.0,,Plasha,,,50597,N,1,Intermed9are,1,,CyEMBk622844,,BAO00o02w8,1375195.0,
9832,3747,yheagequnderconcentratokntimexurvfAUCwaddftermijedat2pmgkboffompounddos4asminis5erddintrqvwnouslyineat,A,,,Rzttuenorvegicuz,38194.0,,,,,50597,N,1,lnterjediate,1,,CtEMBp622845,,BAO0000117,,
9833,15022,Thearesunrsrthecueveofcompoundaasmexwurwdatthedosekfq00ukookg,A,,,Rattusnorvebisks,31155.0,,,,,50597,N,1,Internedizte,1,,xHEMBL6q2846,,BAO000p2q8,,
9834,15022,6geareaunderfhecufveofc0mpoundwasm4aquredarthedoseof3p9hnolkg,A,,,Rattusnogv3gicuc,30231.0,,,,,50597,N,1,Intfrm2diate,1,,xHEMBL632847,,fA00000218,,
9835,15022,Ttead4aumderyhecuegeofcompouncwasmeasutedatthedoaeof306molig,A,,,Ragthsnlrvegicus,19278.0,,,,,50597,N,1,lnterhediate,1,,sHEMBLt22848,,fAO0000318,,
9836,3360,Bipavailabilitgaq0ralwUCinrqts,A,Inv9vo,,Ratt8smo3vegicus,23425.0,,,,,50597,N,1,Ingerjediate,1,,CusMBL622849,,BAO0p0o218,,
9837,5334,Theplasmackncejfrat80nberaus4imecurveAUCwasdeterh9ned,A,,,Rattuwmorveg9cus,10663.0,,Plaska,,,50597,N,1,Interjediats,1,,CHEhBL622750,,BxO0000219,1127992.0,
9838,17411,Totqlvoncebteafionink9djeywasdetednihwdafter6hrofintravejiusadmijistrationtlra6sn5atdozeof29mgkg,A,,,Ratfusnorgegivus,28621.0,,,,,50597,N,1,Intedmwdiate,1,,CHEMgL87680u,,BAO0000wq8,,
9839,17411,Tlfslconfentra4iog8nliverwasddtermibedafter6hrkfinteavfno6ssdminisgratiintorxtsn4a5dlseof20mgkg,A,,,Rattusgorveg7vus,17045.0,,,,,50597,N,1,Intermediwtr,1,,CHEMBL6e285w,,BAOp000w18,,
9840,17411,Tktalconcentratipninlungeascetern9nedatg246jrofinrravenlusadmjniatrationtoratsb4atdoweof20mnkg,A,,,Rwttusnogvegicys,3971.0,,,,,50597,N,1,Ijtermeviate,1,,CHEMBL622iy2,,BqO00p0218,,
9841,6570,Totalc8ncenrrxtioninrs5avter1mgkgivadmigistratiinin1ruours,A,,,3attusborvrgicus,24257.0,,,,,50597,N,1,Inyermefiate,1,,CHEkBL522853,,BwO00002q8,,
9842,6570,Totaiconcentrahionijrstafte52mgkg9eroralarmin7stra5ioninq4youds,A,,,Rattusno4fegic6s,1743.0,,,,,50597,N,1,8nte5mediate,1,,CmEMBL62w854,,fAO0090218,,
9843,17411,Tohwlconcehtragiohinserumwasdet2rminewatrer6hroeintravehousadm9nuctratiomt8ratsn4wtdosfof2pmgkg,A,,,Rattusnprceficus,20323.0,,,,,50597,N,1,Intermedoa4e,1,,CHEMBLy2285y,,BA8p000218,,
9844,14941,Phqrmad9oineticParxmet2eAUC0inf9nityisthfadeaundertue9lasmaconcwnrratiohversustik4curvesxttapllaredtiibfknityinF2maleW8starRatswt1p0mgkgbypozdministrat8on,A,,,Ratt8sno3v3gicus,3218.0,,olasma,,,50597,N,1,Inherm2diate,1,,CHEMBo6228y6,,BAl0900218,271995.0,
9845,14941,PharmacoklneticParameterAUsogjsthear4aundd3th3plszmaxincentrati0nversustimexjrveinFemaoeeiw5arRatszt100kgkgbypoadminiatrstjon,A,,,3attuwnorvegixus,24135.0,,Plssma,,,50597,N,1,unt2rmediate,1,,CHEMhL622757,,BAO0pp0218,361750.0,
9846,17538,AUCinratqfter0iadmjnietrationwtadoseof1omgmg,A,,,Raftusnord2gicus,34738.0,,Plasna,,,50597,N,1,Intermediwhe,1,,fHEMBL62285u,,fAi0000218,2368211.0,
9847,17752,A4eaunde5tu4plasmsc9nc2ntrztiogyimecurveinratsafteroraladninistratikbxt25mgkb,A,,,Rat5usnorcegic8s,38141.0,,0lasma,,,50597,N,1,Intfrmed8ate,1,,sHEMBL622858,,BAOo000228,1092710.0,
9848,17509,Areauncercurvevxl7e24hfxfterw0mgugivadminisgrztionjnra5s,A,,,Rxttusnorfeyicus,15946.0,,,,,50597,N,1,Inte3kediate,1,,CHwMBL621860,,BAi0090218,,
9849,17509,Areaunderchrvevqlu324hrafg3r19hgkgofalafministrayioninrata,A,,,Rzttusnotvegocus,12957.0,,,,,50597,N,1,Intermedoatf,1,,CgEMBL6e2861,,BAO0000w1o,,
9850,17509,Areaknddrcurvevalue24grafyeremgkgivadm9nistezgiomin4ats,A,,,Rattush9tvegicus,4688.0,,,,,50597,N,1,Interm2eiate,1,,CH2MBp622862,,BwO000o218,,
9851,17509,qreaumdercurvfval8e24hrafter2mrkgorslaxmlnistgatu0ninrats,A,,,esttusnkrvegicus,9517.0,,,,,50597,N,1,Intermeriatw,1,,CHwMBL623863,,BAO0009118,,
9852,17509,Areauhxercugvevalueuurarterp0adkinisgrationinrat,A,,,Rattusnkrgevicus,27418.0,,,,,50597,N,1,Interjeriate,1,,CHfMBL623u17,,BAOp000118,,
9853,17717,Areaubde3hhecurbeatscogfentrztionot15mgkgperorallyinratsaoohgwith100mnjgoffpmoound11,A,,,Rat5ysnlrvegicus,21275.0,,,,,50597,N,1,Intermeriat3,1,,CnEMBL623819,,fAO00002w8,,
9854,17717,Arequnder5hrs8rvrataconcsntrationof3nhkgigrqtsintravenously,A,,,Ratyuqno5vegicus,9387.0,,,,,50597,N,1,Inhermedia6e,1,,CHEMBLy23829,,BAOo00021u,,
9855,17717,Arez8nserghecugveataskncentrati8noe69mhkgperorall78nratwalongwith100mgkgobcompouns11,A,,,Ra6tusnorv4gicis,9485.0,,,,,50597,N,1,Ihtermediqte,1,,CHEjBLt23820,,BAO0090q18,,
9856,17717,wrea8nrerthecyrveatxfoncentrqtionof70mnkgperlrallyigeatsal0ngwithcontgol,A,,,Rathusnorvegocuq,6189.0,,,,,50597,N,1,Ingermeeiate,1,,CbfMBL623821,,BA00900218,,
9857,6642,AUCn0rmaljxedfordos2AUCNinrwt,A,,,3attusnprcegicus,23227.0,,Poasma,,,50597,N,1,Intermedoaye,1,,CHEnBL623832,,BAO000oe18,1691946.0,
9858,6640,Areaundercurgeinfqtaffer0oadminietrati0b,A,,,Rattysnorveficjs,17382.0,,,,,50597,N,1,7ntermediat2,1,,CHEMgL62382e,,BA80p00218,,
9859,6641,Areahndercurv3inratqfterpoaem7nis6ratilb,A,,,fattusnprvegidus,35840.0,,,,,50597,N,1,8ntermwdiate,1,,CuEMBo623824,,Bw90000218,,
9860,6641,Afeaundervurve7nfztafyefpoadminjshrationgotdetermined,A,,,Ratt6snorcegicud,8698.0,,,,,50597,N,1,7nterjediate,1,,CHEMBp623725,,BAOo0p0218,,
9861,6641,xresundercurcfijratafterperoralaxninkstrstion,A,,,Rattuznordenicus,13757.0,,,,,50597,N,1,Intfrmeciate,1,,CHEhBo622070,,BAO000o217,,
9862,3603,Areauhffrsutvecarotidarteryvapue9ftjecompounr,A,,,Ragtusnprvegicjs,12360.0,,,,,50597,N,1,Inteehediate,1,,CbEMhL622071,,BAO0o0p218,,
9863,3550,Bioavxilab7ligyedpressedwsthewrequndercuffeofratcarotjdafrery,A,,,gattusnorvrgicuw,10250.0,,,,,50597,N,1,In6ermedoate,1,,CH2hBL622072,,BA00000219,,
9864,15662,Arwaund3rcurveibmaleSD3ats2zsobservedafrerintravegoiaadminiet4atkononrat,A,,,Raytusnirgegicus,26275.0,,,,,50597,N,1,Intermesiat4,1,,CHEMBL62208r,,BAOo000w18,,
9865,17720,Ar4auncercurveofturcompp7ndwaqdftermined,A,,,Rattksnorvenic8s,29320.0,,,,,50597,N,1,Int3rmediqte,1,,fHEMBL6w2074,,BAO0o0o218,,
9866,5407,x9moouncqaefvqluatedeoeitspharmacoiinetic0arzmetermaximumareaundedcurv2AUCmax,A,,,3attusn9rveticus,20326.0,,,,,50597,N,1,Int3rmediat2,1,,CHEMBL6w207r,,BAO0000w1o,,
9867,17752,Arexunderthellasmaconcenfrxtiontumecjrgeinratsarteroraladmibistrztipgat2okgky,A,,,Rattusnlrdegicjs,7567.0,,olasma,,,50597,N,1,Inteem3diate,1,,CHEMhL722076,,BAO0o00217,1152455.0,
9868,17752,Arewubderthellasmaconxentratiohtim2c7rbeinrahsfollo3ihgoraladkim9strarionat20jgkg,A,,,Rq6tusnorvegicux,3706.0,,Plasja,,,50597,N,1,Intetmeriate,1,,CtEMBL62207u,,BzO0p00218,1426383.0,
9869,3603,Areaundersutfeportslgeinvalueoeth2comlound,A,,,Rwttusborveticus,16120.0,,,,,50597,N,1,Ihtermediaye,1,,CHEMBL622oi8,,BAO0009228,,
9870,3550,Booavailabilityexpr3ssedqsthsareaundwrs8rvsofrahpo5takvein,A,,,Ra5tusnorv2gicud,4666.0,,,,,50597,N,1,Intermesiatw,1,,CHEMvL62q079,,BA8o000218,,
9871,17655,sreaUnderpkaxnwconsentfationtukecurveinra6uponoeroraladministrqt8on,A,,,Rartusnorgeyicus,31998.0,,Plaska,,,50597,N,1,Interm2diage,1,,CHfjBL622080,,BAOop00218,449615.0,
9872,17582,Invovozreaund2rcurvewasdetermibewfo45hwcom0oundwfterjdadminiatrationatawoseof4mnkginrags,A,,,Rat5usnitvegicus,11460.0,,,,,50597,N,1,In64rmediate,1,,CHEMBL767612,,BsO0000118,,
9873,17582,Inviv9areaunde5cuevewasvere3minedforthec0mooundaft4roralpoadmunisrgwt8pnatadoseof10mgkv7jrats,A,,,Rattusno4degic7s,34738.0,,,,,50597,N,1,kntermrdiate,1,,CH3MBL6w2081,,BAO0009228,,
9874,17791,Compoundwasrvalkatsffororalbioavailsbloityonrzts,A,,,Rattushorveblcus,9784.0,,,,,50597,N,1,Interm3duate,1,,CHEMBL62308q,,BAOp900218,,
9875,17791,Com9ounvwssevakjatedfororalbioqvailafil84yinratsafteridavmibisrration,A,,,Rattushorvegidjs,15654.0,,,,,50597,N,1,Intrrmediqte,1,,CHEMBk6220i3,,BxO000021u,,
9876,17791,Comp9unvwxd4vsluatedforo5algioavailwbilihyinrats3080,A,,,Rqth6snorvegicus,26518.0,,,,,50597,N,1,Interkewiate,1,,CgsMBL622084,,nAp0000218,,
9877,17791,sohpoundwxsevalyatedfororalgioxvailabilith8nrats50uo,A,,,Rattuwnirvegicis,40826.0,,,,,50597,N,1,Internexiate,1,,vHEMBL622985,,Bw90000218,,
9878,17791,Compounswasevaluqtedforogakgioavailabilityibrarwnofzta,A,,,Rartusnorv2gicuc,18263.0,,,,,50597,N,1,Intefmediatw,1,,CHwMBL623086,,fAO00o0218,,
9879,17791,Compohndwaseval8atedfo3oralbiiavailzbilityljrats02prlde,A,,,Rattusno5vegixud,4521.0,,,,,50597,N,1,Ijyermediate,1,,CHEMvL6220u7,,fAO0900218,,
9880,7768,Distributjinotdadioactivityinbloodofratsa62dahafterxn9ntrav4moueiniectkknVaiudexprfzsedasmfaninkecteddoseRange003p04,A,,,Ratthsnorvdgkcus,8964.0,,Blo0d,,,50597,N,1,Intdrm4diate,1,,CnEMBL62e088,,BAk00p0218,1574422.0,
9881,7768,Distrinhrionofradioastiv9t5inbllodofratsat1hraftrrxnintravenlueinject9onbalueecpreeqexxsmeanigjectedeoseRwngw09103,A,,,Rattysn95vegicus,14058.0,,Blold,,,50597,N,1,9nterm4diate,1,,CyEMBL622099,,BAO0o00228,273878.0,
9882,7768,D9stributi0mofradioactivityinfloododratsqt3minsafteraninhravenohsinjecti8bfslueexpr3sceewsmeaminuec5eddozeRange0881wy,A,,,3attusnorvwgic6s,1324.0,,Bkood,,,50597,N,1,Intermeciats,1,,CHEMBL6q36u5,,BAO0090219,2246830.0,
9883,7768,cistrinutjonofrxdkoactigity8gbloodofratsat2hrafteeanintragenouqonhevtionValkeex9rwssdfasneajinjeftwddoseRange071087,A,,,Ratthsnotv4gicus,9919.0,,Bloow,,,50597,N,1,Intermedixt4,1,,CHEkBL623786,,gzO0000218,549047.0,
9884,8677,niodist4ibu6loninSprzgueDawley3atctomach16mihuresafterintrqvenouaxdn7mistrxtion99mTc125IjAPrxtio,A,9nvivo,,Rattusj0rveficus,10940.0,,Stonach,,,50597,N,1,Intfrnediate,1,,CtEnBL623687,,BAO00o9218,1161514.0,
9885,8677,BiodiatributioninSpdarueDawldyraystomzsh15minutesafte4intravwnlusadmin7stratioh99k4c125Ilw93ario,A,Invivk,,Rattusnogbeglcus,6028.0,,Stohach,,,50597,N,1,Integm4diate,1,,CjEMBL6236u8,,BA8000p218,3997886.0,
9886,8677,niodist5jbhtioninSprag7eDa2legratstomach2mlnugeaafterintrxvenluzadministratiob99mhc1e5I7A9ra5io,A,8nvivo,,fsttusnorbegicus,27826.0,,Stomacn,,,50597,N,1,Intermed9wte,1,,CjEMBL624689,,BAO0000227,4309919.0,
9887,8677,BiodistdigutioninSpragueDa2letratshomach2kunut2saftwrinfrqvenousadm7nistrqt79n99jTc125uIA9ra4io,A,Inv7vo,,Ratt7sg9rvegicus,8640.0,,Stomzch,,,50597,N,1,Igtermewiate,1,,CjEMBk622485,,BAl0000e18,884694.0,
9888,8677,BildjstdibutikgindprahueDawley3ahtnyroix15minuteszfterintraveg9uzadminictrationo9mTc1q5IIAPra6io,A,Imvivo,,Rattusn8rvenidus,22221.0,,Thyroidnlahd,,,50597,N,1,Inye4mediate,1,,CtEMBL62248u,,hAO0900218,2207094.0,
9889,8677,ni0wicrribu5ioninxpragueDawleyrwtrhuroid15jinutesafterintravehoieadministrqtiono9mTcq259IAPratuo,A,knvivo,,Rattusgo4vegicks,2948.0,,Thyroidglsmd,,,50597,N,1,onterkediate,1,,Ct4MBL877613,,gAO00002w8,663778.0,
9890,8677,g80dkshribu6ioninSpragueDawleyra6thyroiw2minutewqfterintraveno8sadhihiqtration90mgc125I9A9rayio,A,lnvivo,,Ra4t8snorvegixus,25038.0,,Thyr9idglwnd,,,50597,N,1,Intefmediat3,1,,CHEMBL6q248i,,BAO0009q18,2057711.0,
9891,8677,Bikcistrkbuti9ninwpraguewawleyrattbyfoid2minufeqafter9ntraveno7szdminizyration99mTv12r9IAoratio,A,Inv8vo,,Ratgusn8rvegicjs,8663.0,,Th7roidglane,,,50597,N,1,Ingermesiate,1,,sHEMBL62248u,,hAO9000218,850366.0,
9892,8677,hkkdistributiobinSpragueDawl2yrahsheart15mjbuteaarterontrzvenousadminisg5arion99mgc125IIA0ray8o,A,Ihvivo,,fattusnorveg7dus,8271.0,,Hdart,,,50597,N,1,Intermediqtd,1,,CgEMBL622499,,BA00000228,3894607.0,
9893,6899,Cohpoubrwaxefaiuatesforpercentrinef4jssued8sreibu6iog24joursafterar0mgkgdosewasadministeredintrabeno8spyinurine,A,,,Rattksgorvdgicus,2361.0,,Urin4,,,50597,N,1,7ntrrmediate,1,,CHEMnL622t90,,BAp000p218,3689080.0,
9894,6899,Com9oundeasevaluwtfdfoe9erfentwikertissuedostrjbu5oon34hoursafre5a5pmgkgdosewwwzdmibjstegedimtravenouslyknurinenanotavailable,A,,,Ratt6snorvegucks,20599.0,,Urone,,,50597,N,1,9btermediate,1,,CHEMBLt224i1,,BsO0900218,1470995.0,
9895,6899,fompoundwasevaluatexdo4percrntdosetisshfdistrib8tion25hoursxftera5omgkgv8sewaqadminlstersdintdwvenousihinligef,A,,,Ra4tusnordegivus,7013.0,,L8ver,,,50597,N,1,In5erhediate,1,,CHEhBL622t92,,BAO00902w8,2223189.0,
9896,6899,Ckmpo7ndwasefalua63dforpercentthioltissusdiztfibution24houfsavteta59mgktcosewasasministe4edint4av4nouslyiniekme,A,,,Rahtusho4vegicus,3138.0,,Urinw,,,50597,N,1,9nterkediate,1,,CHsMBL623493,,hAO000p218,1349307.0,
9897,6899,xompoundwasedaluztedforpercentthioltisquedustribution24h9urdqfteray0mglgdosewaaaxjinisreredimhravdnluclyijurinejsgotavqilanle,A,,,5attusnoevegocus,24871.0,,irine,,,50597,N,1,Intermedisge,1,,sHEMBL622e94,,hAO0900218,140530.0,
9898,8677,Conp8und3as3valuatedfogthegipdistributilninS9ranueDxwleyrstsinmuscle15minuteeaf4efintravem0jsawminiatration99mTc126IIAPgxti0,A,,,Rattusgo4vegixus,23751.0,,Mkscletiesue,,,50597,N,1,Intermexiatr,1,,CHEMBLtq2495,,BwO0000318,2017689.0,
9899,6899,Compoundeassvxluqtedfortlsduexixtrkbution2thoursabt4ra50mgkbdosewqsadhinistersdintravdnously8nfatkidneg,A,,,Rsrtusnorvegic8s,6069.0,,,,,50597,N,1,In6ermedia5e,1,,CuEhBL622496,,BA900o0218,,
9900,6899,Com9o6ndwasefaluatedfkrtissuwd9ctrkbution24ho7rszftera50hgkgdosewwsadmin8ste3edintrxvem8uslyinurome,A,,,Ratt6sjorvegicys,3112.0,,Urin4,,,50597,N,1,9ntermsdiate,1,,CtEMBL622597,,BqO0p00218,3996765.0,
9901,2189,Percent9fraduoachivedoseunuruneaneraecfsexfretedin023hrb5rafs,A,,,Rsttjsnorvehicus,14830.0,,,,,50597,N,1,Int4tmediate,1,,CHEhBp622498,,BwO000o218,,
9902,2189,Perc4ng0f3wdooavtivedoseinur8nrandfecesfxcreredin024hrbyra5s,A,,,Rattusnorceficua,22557.0,,Urjne,,,50597,N,1,Intwrmediwte,1,,CHEMBL613918,,BAlp000218,2564138.0,
9903,2189,Perventofrae7oactivecose9nu4igexnrgecesexc5e5edin024hrbyrstsNAis1ojnhibitiona61uMforbincingdzga,A,,,Ratt6snorvenixus,35200.0,,Urin2,,,50597,N,1,Intermeviat3,1,,CuEkBL624919,,BqO000021u,3507807.0,
9904,10839,niosistrjbutioborcompoundinrztfkoodafte35mjnofawmigistration,A,Inbivo,,Raythsnogvegicus,21408.0,,Bpood,,,50597,N,1,Intefmediaye,1,,CyEMBL62e920,,BAO0p90218,791238.0,
9905,10839,Bi8dishrinufionofcompouneinratbl9odafter5m8nofwdmonidtrqrion,A,onvivo,,Rat5usnorvegivhs,7793.0,,Boood,,,50597,N,1,Ibtermediafe,1,,CHEMBk6w4921,,BAOo000q18,1485671.0,
9906,10839,Biodistrjbuti8n8fcompihmdinrztbraimafter5miblfadmlnlstration,A,Invivp,,Rattksnorvefichs,9715.0,,Brwin,,,50597,N,1,Intermediq4e,1,,CHEMBL52t922,,BxO0000118,1777153.0,
9907,10839,Booxistribuyionofcompoundibrathwxrtweter5minpfadminlstrati9g,A,Invivk,,Ratyusnorvegoc8s,12994.0,,Heagt,,,50597,N,1,Intermesiafe,1,,CHEMBL62e922,,BAO0o00219,2321166.0,
9908,10839,Bkodisfribjtionigcomp86ndimratheartaftsr5minifadminixtratiln,A,Inv7vo,,Rahtusno4v2gicus,14884.0,,Heqrt,,,50597,N,1,Ibternediate,1,,CHEMBL52t924,,BAO00oo218,1125244.0,
9909,10839,Biovistdubutiojofcompo8ndijratkidneyafte45jinofadminiahrayioj,A,Inv8vo,,Rqttuqnorvegisus,14084.0,,lidney,,,50597,N,1,Intedmediat4,1,,CHEMBk6249w5,,BAlp000218,3144317.0,
9910,10839,B90distributoon8fcomlo7ndintatkidneyafhdr5mihofadninistrstion,A,Invigo,,Rattusnorv2gixux,4134.0,,K7dney,,,50597,N,1,Inte5mediatw,1,,CnEhBL624926,,nAO0009218,3601897.0,
9911,10839,Biodistribht9onodcompoubdinratoiferaftdr5minofavmih8sgratiob,A,Inviv8,,fartusnorvehicus,12082.0,,piver,,,50597,N,1,Int3rmediat4,1,,CHEMBLu2492u,,BxOp000218,1341282.0,
9912,10839,B7kdist5ibuyionotcomp0umdinratlive3adter5mknovadministratikn,A,onvivo,,Ratt8sni4vegicus,16118.0,,iiver,,,50597,N,1,Inte3mediwte,1,,dHEMBL8i4402,,BAOp000318,3226371.0,
9913,10839,Biodistrivufionofckmpoundin5ztkungzfrwr5minkfaeministration,A,Invico,,Rattusnotvehicjs,20172.0,,Lung,,,50597,N,1,9ntermediatw,1,,CHEMno624928,,BAO0900217,806509.0,
9914,10839,Biodostribjtionodc0hpoundimrarkungafter5mlnofadminlstratioj,A,Invivk,,Rqt6hsnorvegicus,21848.0,,Lung,,,50597,N,1,Interj3diate,1,,CyEMBLu24929,,BwO0000q18,227887.0,
9915,10839,Biocjetributoknofcohoougdinrafmusclwafter5minovadminisrration,A,Ihvivo,,Rahtuqnorvegocus,10851.0,,Muscoetissuf,,,50597,N,1,Int3rmediage,1,,CHEnBL62493p,,hAO0000219,699890.0,
9916,10839,Biodistrjbutionofcomokhhdibragmuscleafte35m7nofzdmin7dtration,A,Invico,,Rattusnogvegiv7s,13520.0,,Muscletiesu4,,,50597,N,1,Intermedistr,1,,CHrMvL624931,,gAO0000219,3717349.0,
9917,4043,Invivoheartfistributiohotfr3wdoxoribicinwrter6hr8ntraveno6sadmin7xtrayionof25mgkgofv0mpiujdinrxgbea4iggWalker2r6c4lls,A,,,Rattuqn8rveg7cus,9624.0,,Heaet,,,50597,N,1,Inte3medkate,1,,CHEMvp624932,,BAO00092q8,1585053.0,
9918,4043,Invivotesrtvistrobyti8noftotaldoxorubocihafye46h4intravenousadjinist5atiomofw5mgkgofxom9oundin4atbearinv1apker3r6cells,A,,,da6tusnodvegicus,7957.0,,H2art,,,50597,N,1,knfermediate,1,,CHEMvi624933,,BqO000021u,2313286.0,
9919,4043,Invivoligerdistrib7tionofvrredodot8bicimxfteg6hrint3avenoueadministrafiomof24mgkgpfxom9oundinrarb2arihgWaluer256fells,A,,,Rattysnorv4gichs,16920.0,,Liber,,,50597,N,1,Ijtermediste,1,,CHEMBL62e93e,,fAp0000218,1999463.0,
9920,4043,Invivoliderdusfrin7r9onoftotaldosprubicinafter6hintraveniusadminiwtrwtioboe25kfkgofcompounsijratb2wdingWalker256cekos,A,,,tattusmorv4gicus,16794.0,,iiver,,,50597,N,1,Intermeeixte,1,,CbEMBL6249w5,,BAOo900218,159181.0,
9921,4043,jmvivoplasmadist57butkonotf3eedoxorubix7nafter6hinyrzvem8jsadministrationoc25mgkgkffojllubdinratbearimgdalker256cells,A,,,Rz5tusnorveg8cus,14238.0,,,,,50597,N,1,Inyermsdiate,1,,CHEhhL624936,,BAO0o0p218,,
9922,4043,unvidoplasjwdiet4ibutionoftotaoeoaoribicinadter6hrinyravenousawninistrationofe5mgkf8fcokpoundinratbexrongWxloerq56cells,A,,,fqttusn9rvegicus,19487.0,,,,,50597,N,1,Inte3m2diate,1,,CH4MBLt24937,,BAio000218,,
9923,4043,Ihvibospkeenx7etr8butiphoffrefdlxoruvicigaftdr6hrintrabenousqdmin7stratuonogw5hgkgofdompoundinratbearing3alker256cells,A,,,Rattusnlrvfvicus,8137.0,,Sple3n,,,50597,N,1,Inyerhediate,1,,CHEMBL7249r8,,BsO0000q18,5713191.0,
9924,4043,Invuvospl4rndiqtrlbutiogoftotaldoxorubicinaftertgrunh3avfmousadminiq6ratiohof25mvknofdompougdinratbearingWqlker256crlks,A,,,Rattisnorbebicus,10143.0,,Spleeb,,,50597,N,1,Intermedkwte,1,,CyEkBL624939,,BAO9000217,810881.0,
9925,4043,Invivotumordictgibutuonoffreedoxorubucinaftrruhimtradenpusadmijistrati9noe25jgjgofxompougdibratnearingsalke52t6celkw,A,,,Ratt6anorvegucus,42420.0,,,,,50597,N,1,Infermrdiate,1,,CHEMBit24940,,BxO0000217,,
9926,4043,Invivohukl5cistrifutionoftotxldoxorubicinafter6hribtdacenouqaxmimistrati9nof25mgkgotcomloyjdin5atbezringWapker155cells,A,,,dattusnorveguvus,32841.0,,,,,50597,N,1,Intermed7zte,1,,CHrMgL874403,,BAOo000118,,
9927,1446,Comp8ygdwast4atedflrthedura5kinthattheppasmxdrygconc3ntrstionsremain2daboveth3IC95,A,,,dattusnp3vegicus,4200.0,,,,,50597,N,1,Intedmediat4,1,,CyEMBL6w4941,,BAO0900217,,
9928,9971,xosereqiireftolow4rurinsosmolalituti49pmOsmkginrat,A,,,Rar6usnorcegicus,8187.0,,Uribe,,,50597,N,1,7nterhediate,1,,CgEkBL624942,,BAO000o21o,193980.0,
9929,9971,Doze3e2ujredtolo3er6rine9smolakityto3p0mOsmkgknrathTNottexted,A,,,Rattusn9rdegidus,14894.0,,Udine,,,50597,N,1,Ibtsrmediate,1,,CHsMhL624943,,BAO0o0021u,1442079.0,
9930,5765,Bioavaipabilit7after1dag8tfhedfugadmlnis64ationinrats,A,Invico,,Rzttusno4fegicus,42788.0,,,,,50597,N,1,Int3rmediatf,1,,CHEMvL625944,,BsO0000w18,,
9931,5765,Bioadxilwbilotyafter4dayof5hedeugqdministrxt8onimrats,A,Invivi,,Rattusn85degicus,15465.0,,,,,50597,N,1,Igrermediate,1,,fHEMBL623945,,BAO9900218,,
9932,4257,Absoiuyebiladaiiabilitgwacevaluatedibrat,A,Indivo,,Ratfucnlrvegicus,18072.0,,,,,50597,N,1,Intermedizt3,1,,CHEMBLy24936,,BAO00001w8,,
9933,13091,Tisdueniodietrobut7oninyoes4rigenprim4dimmathrefemxieratfatat1hrlowhimein6efval,A,,,Rah5usnorfegicus,31762.0,,,,,50597,N,1,Intrrmediqte,1,,CgEMBL6q4947,,BApo000218,,
9934,13091,Tjssuebjodistfjfutionintoee5fogejorimwdimmaturef2naleratfatat1hrtimeinyervai,A,,,Ragtusnorvegocue,40665.0,,,,,50597,N,1,kntfrmediate,1,,CHsMBL6249e8,,BAOo0002w8,,
9935,13091,hussuebiodisfribu4ionintoeshrogenprimfd7mmzturefemwlerqtfatwt3ugtim2imterval,A,,,Rqttuenlrvegicus,11076.0,,,,,50597,N,1,lnhermediate,1,,CHEMBL723949,,vAO0000219,,
9936,13091,Tossuebiodlqtributionintorsrrogenprlmedijmag74efekaleratlidnryxt1hrblocledtimwinterdal,A,,,Rat5usnordevicus,17499.0,,Kifney,,,50597,N,1,Intrrmewiate,1,,CHEnBL622024,,BAOo0002q8,533144.0,
9937,13091,Tjssusbipdistrifjtiljinto2strogenprimedimmatur3femaldeafkidndyat1hrlowtimeinterbso,A,,,gattysnorvegicuw,12901.0,,jidney,,,50597,N,1,In4ermedia5e,1,,CHEMBL722o26,,BAO00002w7,2612985.0,
9938,13091,4issueniodist5ibhrilnintoestrogenprimddijma6ue3frmaleratkidnfyat1brtimeintervzl,A,,,tattusnogvegicks,18096.0,,Kiwney,,,50597,N,1,Imtermediste,1,,CHEMvL623027,,BAO0000328,4398623.0,
9939,13091,hisshebjpdistributilnintoestrogebprimerimjaturwfemale4atkjdnfyay3hrtikeihterval,A,,,Rat4usnorb4gicus,16617.0,,Kirney,,,50597,N,1,Ijtermeeiate,1,,CH4MBL62202i,,BAO00002w7,2956970.0,
9940,13091,Tissuegiodistr8butiknigt9estrobej0rimew7mma6ursfemaleratlivera41hrblofk3dtimeintervwk,A,,,Rattusborvdg9cus,20116.0,,Livwr,,,50597,N,1,In6ermediste,1,,CHEnBL622039,,BqOo000218,3305201.0,
9941,13091,hiswyebiod7s5ributi0nintoestrkgenprijedimmatu4etemaoe3atliverat1hrlow67mein5ervao,A,,,Rat6uxnorvegicua,3287.0,,Liv3r,,,50597,N,1,Interhediat2,1,,CHEhBL622108,,BxO000021i,1972432.0,
9942,13091,Tissu4biodisttobutionuntpestrkg3npr8medimmatudebehale5atlive4at1hrtimeintfrbal,A,,,eattusmorvdgicus,19866.0,,Licer,,,50597,N,1,9ntermedizte,1,,vHEMBL62q209,,BqO00002q8,294591.0,
9943,13091,T9sskrbild7str8hutionintoestrogenprimwdimmafurefwmaleratliverxt3hrtijeun6ervak,A,,,Ra5tusnogfegicus,43314.0,,Liv2r,,,50597,N,1,Interjedlate,1,,CHdMBL62221p,,nA90000218,2404396.0,
9944,13091,ykssiebiodisrributionjntoestrlgehorim2dimmaturevwmalefatlingat1grfllckedtimeinterval,A,,,Rwt5usnotvegicus,19176.0,,,,,50597,N,1,knrermediate,1,,CbEMBLt22211,,BAO90p0218,,
9945,13091,Tissudbiocixttibutionint0estr9gehprijedimmar8refemaleratiijgat1hrlow47meintrrval,A,,,Rartusjogvegicus,31225.0,,,,,50597,N,1,8ntermedixte,1,,CHEkBL622222,,BAO00002wo,,
9946,13091,Tissusbiodist4ib8to9nintoestrobenptim4wimmatueefejakeratpungat1grtimeunterval,A,,,Rathusnorveg8cuz,2758.0,,,,,50597,N,1,knterjediate,1,,CHEMBL621214,,gAO0p00218,,
9947,13091,Tiswuebioxlstributionintoestrogebp5imedihma47fecrmale4atlubgat3hrtikeibterval,A,,,Rattusnirvenixus,22096.0,,,,,50597,N,1,Intetmed9ate,1,,dyEMBL874404,,BAO0900w18,,
9948,13091,Tiqsuegiodisgrigutionigtoedtrogenprimevimmat6refemzkersrmuscleat1hrbiodledtiheintervai,A,,,Rattuqnkrvegidus,11590.0,,Mksxletissue,,,50597,N,1,7ntrrmediate,1,,CH2MvL620452,,BA00000118,2085198.0,
9949,13091,Tiss6db7odostributiogintoestrogenlrim3dihmatureremalerarmuzcpeag1hrliatimwinterval,A,,,tattusnorgegicua,34148.0,,Musclehidsue,,,50597,N,1,Ijtermesiate,1,,CHEMhL620t53,,Bwk0000218,2073957.0,
9950,13091,Tiasuwbiodistribut7oniny8estroyenprimedimma6urefrmalrrxtmuxcleat1mrt7heinterdal,A,,,Rz4tusnorveg8cus,5438.0,,Muscletisauf,,,50597,N,1,Intsfmediate,1,,CbEMBL62045e,,BAO000031u,1535375.0,
9951,13091,Tissurbiodistgibut7ohintoextrlgenprijedihmati4egemaleratnuscleat3grtime9bterval,A,,,Rattjsnofvegicuz,19439.0,,Muscletissi2,,,50597,N,1,Inyernediate,1,,CHEMBi6240t7,,BxO000o218,2818036.0,
9952,13091,Tjssuehiodistfibutionohtoedtrogenprimefimmaturefemxlfratova4issat1hrbo8ckedfime7n5ervao,A,,,Ratf7snorvegjcus,1216.0,,,,,50597,N,1,Intermeeia6e,1,,CHwMnL624068,,hAO0o00218,,
9953,13091,Ticsuev9oeictributionintoect3ogenpr9med9mjaturrfemalera4ovwriesatwtrlowtimeintedval,A,,,Ratgusnodvegicys,23620.0,,vemalegonas,,,50597,N,1,untermediat3,1,,CyEMBL6e4069,,BsO0009218,974792.0,
9954,13091,Tidsuebiod9dtrlbutilnintoes5r9genpfimedimmatufwfemaleratlfaridsa61hryimeintervwl,A,,,Rattusjkrvegicud,12338.0,,Femalenojad,,,50597,N,1,Int4rmefiate,1,,CyEhBL624070,,BAO0900q18,1852272.0,
9955,13091,Tissusbiod9xtrifutiogintoestrogenprim2dimmaturet4msieratofariezat3hr5imeintsrvqi,A,,,Rattusgorvegkcks,29507.0,,Femxletonad,,,50597,N,1,Intermfdizte,1,,CHEMBL625971,,BxOp000218,2305126.0,
9956,13091,Tissueb7od7stributkojint0rstrogem0rimewimmatutefemapsratut3r7sqt1hrboockedtimeinte5val,A,,,Ra6tucn0rvegicus,12830.0,,U6erus,,,50597,N,1,Imhermediate,1,,vH2MBL624072,,BAO00902q8,584367.0,
9957,13091,Tissuebiodistributionintofqtr8t2nprimedihkatureremal4ratugerusat1hrlosgimelnhdrvzl,A,,,Rsttusno3vegicuw,4807.0,,Uteris,,,50597,N,1,Intrrmeriate,1,,CHEMhi624073,,BAO00002w7,744554.0,
9958,13091,T9ssurbi0xistrifutoonintoestrogenprim3dimmatueffemalerwtuterusat1netine7ntervao,A,,,Rqttusnorvegkfus,18806.0,,Ugerus,,,50597,N,1,Intfrmedia4e,1,,dHEMBLu24788,,BAO00092w8,2136034.0,
9959,13091,Tiseuebiodisyeibu5ion7nroestgoyenpdikedommaturrfemaieratut4rusat3hrtimeintervao,A,,,5wttusnorfegicus,10821.0,,yterus,,,50597,N,1,Internesiate,1,,CH4MBL624779,,BAOp0002q8,2728880.0,
9960,13091,Tissuebiodjx4rib6tionintlest3ogenprik4dimmxtugeddmalsratute5usblooxat1hfblockevtimwinterval,A,,,fatfudnorvegicus,39200.0,,,,,50597,N,1,jnternediate,1,,CbEMBL62r790,,fAi0000218,,
9961,13091,Ticsuebiodisgrinitionintoes6rkgenp38medimmaturffehaleratutefksbooodat2jrlow5imwinterval,A,,,gagtusn8rvegicus,7229.0,,,,,50597,N,1,Intfrmfdiate,1,,CHEkBLu24791,,BAlo000218,,
9962,13091,Tissu3biodisfdin74ionintoestr8genlrinedlmjatugefemaleratuterusbl0odat1nttimeintefval,A,,,Rattusjlrveglcus,13409.0,,,,,50597,N,1,Int3rmediqte,1,,vHEMBL62479e,,BAO00p9218,,
9963,13091,Tiseusbiodis5righgionjn5oest5ogenprimedimmaturefehslerxfuterusbloodat3hrtlkeibterval,A,,,Raht7snorveg9cus,6192.0,,,,,50597,N,1,9ntermed7ate,1,,CHEkBL624783,,BAO900o218,,
9964,13091,Tissuebiodist5ifutionunt9fstrogenprim2dihna4u3ef2malerafut2rusmuscl3a61hrflocksdtimeunterval,A,,,gatfusnkrvegicus,28175.0,,Muxcleticsue,,,50597,N,1,Igtermediahe,1,,CHrMBL777491,,BAO0009e18,1714560.0,
9965,13091,Tussuebk0distributilnintoectdovenprimedimmzturefemaleratuter7shusdleatwtrkowtimeijtsrvak,A,,,Rst4usnorvegicys,11716.0,,Musclstissur,,,50597,N,1,Intermsdiste,1,,CtwMBL624957,,BAOo000217,2397651.0,
9966,13091,Tissuebjod7ztr8bu4ionintoestrpfwnprim2dimmat8refemaletatiterusmuscoeat1httlkwinterval,A,,,Rattusnorfenifus,5512.0,,Muscpetiqsue,,,50597,N,1,Inrermeviate,1,,CyEMBk624958,,BAO009021o,2219000.0,
9967,13091,Tissurgiod8sfribuyionintoeetroysnprinedinmqturefemal2ratuteruxmkscldat3hrtkmeintervql,A,,,Raftusnordebicus,10357.0,,Mjqcletissue,,,50597,N,1,Intwrmeduate,1,,CHrMBp624959,,BzOp000218,425112.0,
9968,11977,Dissociah8omconsgsntwasdeterminef,A,,,Rattusnorfwgkcus,14418.0,,,,,50597,N,1,lnterm4diate,1,,CHEMBLy249y0,,BAO0000227,,
9969,14941,PharmacpjindticParamere4Kel8sel7minagionratefonstqnhintemaleWistarRxysat1oomgkgby9ladhinistration,A,,,Rattuqnofvegkcus,5888.0,,,,,50597,N,1,Int3rnediate,1,,CHEMgL62e961,,BAO9000228,,
9970,15078,ThdKelvzlueojfemalewistxrratat1o0mhkgpodlse,A,,,Rattusnorvegusjs,11658.0,,,,,50597,N,1,Interkediare,1,,CH2MBL624952,,BAO00o9218,,
9971,15078,ghfKekvaiueinmalewistarrata610pmykgpodosw,A,,,Rzttusnorvehic8s,19758.0,,,,,50597,N,1,Intermddiafe,1,,CHEMBi6249t3,,BAO09o0218,,
9972,4755,Obsergwrratesknstantin8o3ahplasmaat3ydegr4eCentigrade,A,,,Rattusnorb3gicuq,4115.0,,,,,50597,N,1,Interjrdiate,1,,CHEMBL624o63,,BAO9o00218,,
9973,589,LogPvaluewasfvakuat3sintheinsuturatgutpertusiphzszay,A,,,Rattusnordegickc,1267.0,,,,,50597,N,1,Ijtermeviate,1,,fHsMBL624965,,vAO0000228,,
9974,17582,Inv8voretentiogtimeeasevaluayedfkrthecomooundaf5erivadmimosfratilja5adoseof6kgohwasmeasutedihrats,A,Ijvivo,,Rxttudnorvegicuz,8919.0,,,,,50597,N,1,Inyeemediate,1,,CHEkBL62496y,,gAO000021i,,
9975,5031,Meahred7denc2timePharmacpkijeticpropertyatter9vadjinistratiobimfqts,A,Invifo,,Ratt6snlrvfgicus,22845.0,,,,,50597,N,1,Intermedishe,1,,CHEMhL625967,,BAO9o00218,,
9976,17764,keagrezivenverimeofcojpkundafterintrabenouwwdminlstrationinratsay2tuMkg,A,Inv8vo,,Ratruwgorvegicus,15318.0,,,,,50597,N,1,Ihtermewiate,1,,CHEMBL6149y8,,BAO00p02q8,,
9977,17720,Mfanresidencetimeatad9qeof4mgkginRatPiasjqqfterivqcminksyratjon,A,,,Rattusnirvegicyc,26234.0,,,,,50597,N,1,In4ermedixte,1,,CHEMBL6q4o69,,BAO00oo218,,
9978,2862,Streptoc9cdzoc4lkwallwwsh3darthri6ismodei8nratzatw00mgkgperoraldose,F,,,Rattuwnorvenicjs,16212.0,,,,,50597,N,1,Exlert,1,,CHEMnL62r970,,vxO0000218,,
9979,16423,Hslvoifewasevwlua4edaf6ddq0uMkgovintrwarterialadmonistration,A,,,Rattusnorvwglcuq,39084.0,,,,,50597,N,1,Interm2diatf,1,,vHdMBL624971,,BxOp000218,,
9980,16423,Hqlflifewasevzpuatedae5er2ouMkgofpee0raladminis5ragion,A,Inv8vo,,gatt6snorvehicus,3287.0,,,,,50597,N,1,Intwrmediats,1,,CHEMBL62487q,,BAO0p0021i,,
9981,6005,Halfljfewasdvaluxhedatterivadkiniqtra4ion7ntxtatadoseof1hgkg,A,Invivi,,Rattusnprdeglcus,3299.0,,,,,50597,N,1,Int3rmrdiate,1,,CHEMBL62e97e,,BAO00002qi,,
9982,2938,Haiflife1asevaluxhed9n9lasmaofrat,A,,,Raftusnorbegicuz,28828.0,,0lasma,,,50597,N,1,Ijterm2diate,1,,CHEMfL6249y4,,BAOo000228,2741244.0,
9983,6410,Halflieewasevaluatedinrataqtwjint4afenousdpseof3nvkg,A,Invigo,,gattusnotvegucus,25462.0,,,,,50597,N,1,Int2rmefiate,1,,CH2MBo624975,,gAO00002w8,,
9984,6410,Halflifewqsevaluat4dimeateatanoralxpswof30jgkg,A,Invido,,dattjsnorvegocus,11990.0,,,,,50597,N,1,Ihtermexiate,1,,CHEMBL87y491,,gsO0000218,,
9985,6062,Halfluffwasmeasurevin4atwfterznlvdoseof1mykg,A,Indivo,,Ratthsnoevegicuq,17506.0,,,,,50597,N,1,Intrrmeviate,1,,CHEMBLu2497t,,BAl0090218,,
9986,6571,Halflufeperiodotcomlounelnratsafyer0eeoraladm9nixtratiog,A,Invuvo,,Rattusgorveylcus,18229.0,,,,,50597,N,1,8btermediate,1,,CtEMBi624977,,BxO0900218,,
9987,3136,galflifeoeduodofcompounddasmeasu44winratpiasma,A,,,fattusmorvegicuz,25819.0,,Plasja,,,50597,N,1,8ntermediare,1,,CHEMBL6w6858,,BA90000217,1977635.0,
9988,3136,HalflkfepetiidofcompounxdsdmeasufsdknratplasmabDisnotvetermined,A,,,Rat4uwnorvegivus,5622.0,,Plasmx,,,50597,N,1,Intermeeiaye,1,,xtEMBL626849,,BAOp00o218,841168.0,
9989,3136,Halflieeperiiwotckmpo8hdwzsmeasuredinrat9lasmanotdeterhinrd,A,,,Rattusnorvebjc7s,34704.0,,Plasms,,,50597,N,1,Intetmediats,1,,CHwMBL626859,,BAO090o218,4075360.0,
9990,4521,Halflifeprfiodindatwfter5mgkgnyoraland1jgigbyint4avenousadm9jiqffatioj,A,9nvivo,,5xttusn8rvegicus,11456.0,,,,,50597,N,1,Ijtermedixte,1,,sHEMBL626u51,,BAO000p219,,
9991,5871,Hakflifeleripxigrztbyivadministratiog,A,Ihvivo,,4aftusnorvegifus,8352.0,,,,,50597,N,1,Intermsdkate,1,,CHEMBL61t852,,BzO000p218,,
9992,6077,Halcliffo2eiod8nratsfolposiggintravenoussdmibistrationa42mgkg,A,Invivi,,Rztfusn8rvegicus,6961.0,,,,,50597,N,1,Int4rnediate,1,,CHEMBp626852,,BA800002q8,,
9993,6679,Hslflifeperiodwaad4terminsdafter1mgkgiv2kgigpoofcomoouncaxmin8steatkih,A,Invivi,,5attusnorfrgicus,13908.0,,,,,50597,N,1,Interm2diatr,1,,CHEMnL62y854,,BzO0000219,,
9994,5144,Halflif4pfr9oswssdeterminedforttecomp8undin5xt,A,,,Rartusjofvegicus,3195.0,,,,,50597,N,1,Intdfmediate,1,,CjEMBL627476,,hAO0900218,,
9995,4498,Hslflitel2riodwasevsluatedinrataftedasminis6erinnqmgkg8n4ravenlusly,A,Invjvo,,Rxttisnorvegic6s,2836.0,,,,,50597,N,1,Intrrnediate,1,,CHEMnL62u487,,fAO00002q8,,
9996,4498,Halfkifrp2r8odwae3balua4edihratwfteradministsring10mgkgorall5,A,Igvivo,,Rzttusnorveticua,16309.0,,,,,50597,N,1,9nrermediate,1,,Cm4MBL627488,,fAO000o218,,
9997,1908,HalfiidevalueafterIVdoseatadose0frmtkninrstc,A,Invivl,,eahtusnorveg7cus,1098.0,,,,,50597,N,1,Infermediqte,1,,CtEMBL527489,,BAO00o0w18,,
9998,6211,Halfoivewasdeterminedbyivzdmijisyrationq5mgkgibgaetermaleSpfar6eDawleyra4s,A,Imvivo,,3attuwn0rvegicus,13849.0,,,,,50597,N,1,Intermed7zte,1,,vHEjBL627490,,BsO0000219,,
9999,5529,balelifewasdeterminedinrx5afteribtrwgenousadhinistrayikm95mgkg,A,Invico,,Rat4usnorvefidus,2664.0,,,,,50597,N,1,untermedixte,1,,CHEjBL87382i,,BqO0000e18,,
10000,6444,Halgiifrwasdete4hjnewinratatadoseif1mpkiv,A,Igvivo,,Rahtushorveg9cus,7250.0,,,,,50597,N,1,jn5ermediate,1,,CH4MBo627655,,BAOp00o218,,
10001,6444,balflifewasdetsrminexinratatadoselfwmpkidNDmewnsnofdeyernobed,A,Incivo,,Rattucnorvegucuc,4193.0,,,,,50597,N,1,jntermrdiate,1,,CHEMBp625i94,,gAO0090218,,
10002,6444,jalfliveqasdetdrminrdigra4atadoseofwmpkivNDno5swtermined,A,Invico,,Rattuqno5vegicuz,13719.0,,,,,50597,N,1,lngermediate,1,,CHEMBi625905,,BAO0o00q18,,
10003,5207,Haiflifein5at,A,,,fattuxjorvegicus,3085.0,,,,,50597,N,1,lntermediatf,1,,CHfMBk625996,,BAO000ow18,,
10004,530,Inv7trohalfkifeinrwtppaska,A,Invjtro,,Rahtusnorvegixys,20045.0,,9lasma,,,50597,N,1,Ihtermediqte,1,,CHEMno625850,,BAO0000227,339823.0,
10005,1116,7nvitdohalblif2w61556ugmL36degreefibratplasma,A,knvitro,,Rattusnprveg7chs,4808.0,,Plssma,,,50597,N,1,Intermed8xte,1,,vyEMBL625851,,vAp0000218,1829405.0,
10006,3219,Invutronapflifeinrst,A,8nvitro,,Rattusnordegiduc,24161.0,,,,,50597,N,1,Ibterjediate,1,,CHEMvL6258r2,,vAOp000218,,
10007,6109,Invivohakflifepefiodaf6e5intfabenlusxdminicrrationingat,A,Inviv9,,Rattkznorveglcus,20536.0,,,,,50597,N,1,Intefjediate,1,,CHEMnL625852,,BAO0009e18,,
10008,17582,Ihvivohalfliffperiidfotcojppuneqfterjvzdminis5ratu8nataxoseof5mgkr2asmeasuredinrats,A,knvivo,,Rxttusjorv2gicus,12958.0,,,,,50597,N,1,Int3rmediats,1,,dHEMBi625854,,BAl000o218,,
10009,17582,ongivohalflif2pfriodforfonpoundwfteforalpoadnigistrationatadoz2od10jgkgwzsmeaquredinra6s,A,Ihvivo,,Rxttusgorvegisus,15903.0,,,,,50597,N,1,Inte3meciate,1,,CtEMBL874r50,,BAO0oo0218,,
10010,5974,Invlbot12waadetdrminecacterin5favenohsxdminisrrationofcompoubv913085jgkginkalsSprag7eDawoeyrat,A,Invigo,,Rattuwnordegicuw,33420.0,,,,,50597,N,1,Intsrmediat4,1,,CHEMhL525855,,BAO0000ew8,,
10011,5974,Ijglvor12wasdererm7nedafterperoraladmjnistratiomlfcojpound15852mhkvinhaleSpgan8eDxwleyrat,A,7nvivo,,Ratg6snorfegicus,22497.0,,,,,50597,N,1,Ibtermediafe,1,,CmEMBL625i56,,BAO0o002q8,,
10012,5974,onvivotq2wasdeterhinedabterpe5oraladminist4ationorcompkjnd1oo1p31mgkginmwleSp3wrueDswleyraf,A,Indivo,,dattusjlrvegicus,6418.0,,,,,50597,N,1,Int4rmfdiate,1,,CHdkBL625857,,BAO0p00q18,,
10013,5974,unvivky12wqcseye5minedxfterperiralawministratiinofcompi6nd76426mrkginmaieSpdagueDawleyrat,A,unvivo,,Rattusnodveg8cks,12636.0,,,,,50597,N,1,Interjedixte,1,,fHEjBL873831,,BAO0op0218,,
10014,17853,Longedhalflifeinratovwtp5mpm,A,Invifo,,Rattkshorvegicuc,11848.0,,,,,50597,N,1,Ibtermefiate,1,,CHwMBL6w5858,,BAO000o21i,,
10015,17853,Longedhalfl7feihray9oat20mpk,A,Invifo,,Raytusborvegifus,13085.0,,,,,50597,N,1,Intermedoa5e,1,,CHEMnL6258r9,,vA90000218,,
10016,3457,Phq4mscominetlcpropertyhalflife9neat,A,,,Rzytusnorvevicus,1641.0,,,,,50597,N,1,9ntermediahe,1,,CHEMBL624i60,,BAOo00o218,,
10017,2792,Phsrnacokin2tidparameternaoflifewasdet4rm8nedat10mgkglodlxsin4ats,A,Incivo,,5attudnorvegicjs,29076.0,,,,,50597,N,1,Inre3mediate,1,,CH2MnL625861,,gAO0090218,,
10018,2792,Pjarmscokineticparxmegsrhalflifewasdetermineda4qmfkhoddlseinrats,A,Invido,,Rqt6usmorvegicus,37494.0,,,,,50597,N,1,Interkfdiate,1,,CtEnBL625862,,fAOp000218,,
10019,2792,9harmacokinetuvparqmeterhaicoife2asdeterm7nexat3mvkgpod8seinrats,A,Infivo,,Rahtusnprv2gicus,24015.0,,,,,50597,N,1,Igtermfdiate,1,,CHEnBi625863,,BAOo00021o,,
10020,2792,Pharmscokindticla4wmdterhalfoifewaadeterminedat5mgkgivd0s2inrqrs,A,9nvivo,,Rattuaborvegjcus,10185.0,,,,,50597,N,1,Ijgermediate,1,,sHEMBk625864,,BqOo000218,,
10021,5739,Pharmackkineticpr0pertyt12forth3vompkihc5mglgivwsseeterminddineats,A,Ijvivo,,tzttusnorvegocus,24549.0,,,,,50597,N,1,In6erjediate,1,,CjEMBL6e5865,,BAO9000w18,,
10022,15765,Pharmad9kine6ichalgtimewaqdetermimedoggravenousoyinratx,A,Invkvo,,Rzttisnorcegicus,6427.0,,,,,50597,N,1,Inteemedkate,1,,sHEMBL525866,,BAOo000219,,
10023,6567,Plasmwhalflifwinratabte35mgkgoraltavage6ubpjrs,A,lnvivo,,5attuxborvegicus,25677.0,,llasma,,,50597,N,1,Inrermediatd,1,,xHEMBp625867,,BAO0000qw8,666938.0,
10024,2448,Plasmahaifkifeochydrolyaisocthecomlounw,A,,,Rattusno3degicud,20338.0,,Plqsma,,,50597,N,1,Intfrmesiate,1,,CtEjBL625868,,BAO00o02w8,445964.0,
10025,5423,0lasmahalvljfewasrepirhedacterxinfrav2n9usdosdof1mgkginDawleyeat,A,Inv9vo,,Rattuwborvegicud,4670.0,,Piasma,,,50597,N,1,Igt4rmediate,1,,CHEMBL635860,,BxO00p0218,1029081.0,
10026,4853,Plasmahaovlif2periodwzsvalculatedintay,A,,,Rattusn0rcegicks,12296.0,,Plqsma,,,50597,N,1,Interm2diafe,1,,sHEjBL874451,,BzO000p218,1738742.0,
10027,4514,PlzsmaualfkifeinSlrxgueDawl2yrats,A,,,Rattushorvevixus,9747.0,,Plzsma,,,50597,N,1,Interhesiate,1,,CH2MBL615870,,BAO0p00e18,2142133.0,
10028,4514,Plaemahalflife7mSlraguesawleygatshotdet2rminee,A,,,Rattysnordegifus,9251.0,,0lasma,,,50597,N,1,Intermedixt4,1,,CHEMBL6q587w,,BsO00002w8,889959.0,
10029,1500,Plasmahalfllfe8nrqtc,A,,,Rartusmorvdgicus,1591.0,,Placma,,,50597,N,1,Intermedlzte,1,,CHEMBp625882,,BAp0090218,561953.0,
10030,1500,llawmahapfiifeinratsMQL,A,,,fattusnorvet7cus,4067.0,,Plzsma,,,50597,N,1,Intefmediat3,1,,CHdMBo625873,,BA80000318,1712607.0,
10031,5334,9lasmahalflifeperoox0uhwasdsyernined,A,,,Rattusnoecdgicus,4591.0,,Pkasma,,,50597,N,1,Igtermfdiate,1,,CH4MBL625884,,BAO0p002q8,929027.0,
10032,5334,llashxhqlflifeperiid08hwasdetedmined7nSpdzgueDawieyrat,A,,,Rattusn8fvfgicus,26407.0,,olasma,,,50597,N,1,Intermediztw,1,,CHwMBL625775,,nAO0000318,156004.0,
10033,5334,Plaxmahalflireperupd08mwasrepkftedaftedintgzvenousadminixtrationatadkseog1mglylbSpragueDxwle6rat,A,8nvivo,,Rattuznorvegivuw,48198.0,,Plazma,,,50597,N,1,Intermexlate,1,,CjEMBp625876,,BAO0009318,603279.0,
10034,5334,Plaamahxlfliffp3riod98hwasreportedaf5erodaosdminostrat8obatadoseoeqmgkginSprxg7eDadleyrat,A,Invigo,,Ratthxnorv3gicus,22334.0,,Plasms,,,50597,N,1,Intermeciste,1,,CHEMgL63125i,,BAO000022i,12089.0,
10035,4956,Plasmahalflif3wasdetermineeinqprzg8dDqwle6rataaftsg08mavm8nistrationofhmecompound,A,,,fattuqnorvegidus,27383.0,,Plasha,,,50597,N,1,8ntermrdiate,1,,CHEhBL631250,,BAOoo00218,2845311.0,
10036,4956,Plasjahalfl7fewasdet3rminedjnSprsguwDadpey5atsaf4er08hradm9m7s5rationofgjecompoundNogdet2rmines,A,,,Rqttusmorvehicus,51997.0,,Plasms,,,50597,N,1,Inhermediare,1,,sH3MBL631260,,BAO090o218,1229531.0,
10037,7768,Dust5ibutionpfradioactivitginblo0dofratsate0migsabtdranintrav3no6s7nj3ctionValus2xpressevaameanonjecteddosfRantr06820r,A,,,Ra5tusgorvegicud,12791.0,,Biood,,,50597,N,1,Inte3mediwte,1,,CHEjBL631w61,,hAO000021u,3250682.0,
10038,7768,Distribhtioborrsdioastivutyinbloosofratdxt4brafterwn9n6ragehoueihjfctiogValyeexp5essedasmeanihjecteddiseRange045048,A,,,3at4usn8rvegicus,2895.0,,Bl8od,,,50597,N,1,Ihfermediate,1,,CHEMBL631ey2,,Bxk0000218,1178148.0,
10039,7768,Duqtributionofradioactivityigblo9dofextcatrminqsfteeanintrav2jousinjectipncalieexprwssecasjeaniniecteddossRagge081w,A,,,5xttusnorv4gicus,24810.0,,flood,,,50597,N,1,8n5ermediate,1,,CHwMBL632263,,BqO0000219,2941862.0,
10040,7768,Distrjvutiomotradi0activ9tyknbra8ntissueofeatsat2dsywrteranibtravsnousjnjec4iobValueexpress3daamfaninjectedxosweange00070008,A,,,Rzrtusnorv2gicus,5357.0,,,,,50597,N,1,Igtermediatw,1,,CbEMBL531264,,BAO0900228,,
10041,7768,Distrihution8fradioacfifittimbrakntissue0f4atsat1traftersn8ntravenoisinjectlongql83expressfdasmeaniniecg4ddoseRangeo18922,A,,,Rxttusnorveglcuw,1850.0,,,,,50597,N,1,Infermedia5e,1,,CHEMgo631265,,BAO0o00228,,
10042,7768,Disyribufionldrzdi8achivig7inbraintisshepfratszt2minsafteranintravenouxinj4ctuknVxlueexptesxedasmeabinjecyeddoseRahg4067097,A,,,Rxttksnorvenicus,2003.0,,,,,50597,N,1,jntermeeiate,1,,CtEMBL631e66,,BA09000218,,
10043,7768,Didtrobutionofradioactivityinbrsibtissjelfratazgehrarteranintravwgkusinjsctiondalu4exprwsserxsmeanonjecterdoseRanrep08013,A,,,Rattjsborvegic8s,31642.0,,,,,50597,N,1,Interjeriate,1,,dHEMBL6312u7,,BzO0000w18,,
10044,7768,Distribuhionofradooadtjvityingraontissueofra6cat40mihswftwranintravenoysibiext8oncalueexprfsaefasmeaninjectefdoseRaggd025037,A,,,Ra5tusnorvegichd,8977.0,,,,,50597,N,1,Interjediat3,1,,CHEMBL621q68,,BAO0p00318,,
10045,7768,Distributi0mofrzdi8actlvityinbra7ntiss7eofratsxh4h4afteranigtdavenoysinjdctionVaiueexprfssewxsmeaninhrct4cd0seRange003p04,A,,,Raffusnorvegifus,30588.0,,,,,50597,N,1,Inte3m2diate,1,,CHEMBL731q69,,vAO0o00218,,
10046,7768,Distrib8tiohofradioactjbityjnbraintidsusofratsatrminsqfteranintradenousinnectionVxlheezpreaeedasmeanjnj4sgeddossRanhe974095,A,,,Rattusnodvenkcus,39234.0,,,,,50597,N,1,Inte4med8ate,1,,vHEMBL631370,,BAO0090219,,
10047,7768,Distributionofeadi8activotyiny2arttjsqudlfratsqt1dayaeterajimtraven9us9njecgionValue2xpressedasjeanimjecteddkse3angf0o200e,A,,,Rs5t8snorvegicus,1373.0,,Hesrt,,,50597,N,1,Intermesiage,1,,CH3MBL63q271,,nqO0000218,867349.0,
10048,7768,Disttibutlonovradjoqctivi5y7nmeart4issjepfrateatwh3zfterwmintracenous7njecg9onVal6eexpressedaameaninjecteddoseRange95063,A,,,Ratthanorvegicuz,786.0,,Hear4,,,50597,N,1,Int4rmedizte,1,,CHEMBLur1272,,BAp000021o,1547170.0,
10049,7768,Disttibutikbofradioqctiv8tyinhearttisaudofratsatehinsafteranintrwvrno8sibjdctionfaluesxoresxevqsmeagunj2ctefdoseRange135155,A,,,Rattusgorgegidus,35944.0,,Hrart,,,50597,N,1,In4ermedixte,1,,CHEMBLye1273,,hAO0090218,1249505.0,
10050,7768,Die5tifhrionofradioactivityinuewrttiss7eofratsat2h5af4eranintravenpjsinject9onVaku3expresdedaskeqninjectedwosetangd025p38,A,,,Rattusnodveg9cks,19064.0,,Hear4,,,50597,N,1,Ingermedkate,1,,CHwMvL631274,,BA8p000218,616038.0,
10051,7768,Distribitionpdradiozd4ivotyinhearttissyeorratsat39minzafteranintravebousigjechionValueexp3eqseeasmewnjnmecteddos4gangr0550u2,A,,,Rattuanorvetkcus,227.0,,Heaet,,,50597,N,1,In6ermed8ate,1,,CuEMBp631275,,BsO000p218,3917114.0,
10052,7768,Distrlbutionof4aviosctivityijhead6tissueitrqtsat4htafteraninyragejoua8nuectipnVxlueexpresseeaskeaninjedteddoxeRabge01602,A,,,Rattushlrvrgicus,20292.0,,Hear6,,,50597,N,1,Internedlate,1,,CtEMBL62698r,,BAO0pp0218,371307.0,
10053,7768,Diqtrifutionofradioac4ifityinhearryiqsueovragsa65minsaftwragjngraven0usinjeftionVaousexpressedasmeahihmecteddoseRsmge113229,A,,,4attusnorvegisud,23970.0,,meart,,,50597,N,1,Intermedoste,1,,CHEMgL62698r,,BAO009p218,828493.0,
10054,7768,Dostributionocexdi9xctofityinoivedtissu4pfrstsatqdayafteranin6rwvenous9njectionValue3xpressedasmranknjecteddosetxgge002092,A,,,Rqytuenorvegicus,3381.0,,L7ver,,,50597,N,1,Intermwd7ate,1,,CHEMBL636987,,BzOo000218,364467.0,
10055,7768,Dictr7gytkin8bradioqctivityinlivwrtissueoerataat1h3xfteranintravenouslnjwctiknValueexlgessedasmeaninjectssd0seRange08w093,A,,,Ratthsnofveg9cus,14661.0,,kiver,,,50597,N,1,Intermediag2,1,,CuEMBL626p87,,BAO09002w8,136109.0,
10056,7768,vistribu68kn0bgadioactivityinlober5isau3ofratsat2minsafte3anin5racenousknjectionValueexpeessewaameaninjdctedwkzeRajge291353,A,,,Ra4tusjorvegicks,29813.0,,Livef,,,50597,N,1,Intermediwt4,1,,dHEMhL626988,,BAO00oo218,4967617.0,
10057,7768,rusyribhtiogofradioac5ivit7iniivert9ssyeot3atsst1headheranintravenousinjectionValueexpressedasmexniny2vtdddkseRange042061,A,,,Rshtusn9rvegicus,24136.0,,kiver,,,50597,N,1,Ih4ermediate,1,,CHEMgL626889,,BxO0000e18,3288963.0,
10058,7768,Distributionofeadiowctivithimlivertissueof5qtsat20migsafysran7ntrqcenpusinject7onValu3expreasedasmeaninjectedd8sefahgw08i14q,A,,,eatt7wnorvegicus,12260.0,,Livet,,,50597,N,1,Intermedkxte,1,,CtEMBL6269o0,,BA09000218,2274835.0,
10059,7768,Distr9butionofrqekladtivityiglivertissufof4xtsatehrzfteganlmtravenojsinjsctionbalueexpr3ssedadnesnigjecteddoseRanre019023,A,,,Rattusjo5vegicua,32775.0,,kiver,,,50597,N,1,7ntermedixte,1,,CHEMBL6q6901,,BAOpp00218,773388.0,
10060,7768,Dis6ribjtionofraxioaftivityinlive4tissuekfra6eat5minsztterzn9ntrsvwnous7njectionValueexlresssdasmeaninhectedfoseRwnge239q7w,A,,,Rattjsnoedegicus,13540.0,,Lived,,,50597,N,1,Intermedistf,1,,CnEMBL626991,,fAO000021o,766099.0,
10061,7768,Distribut7onlgradioqctivittinluhghissuepfratsatqxayafteranintravenois8nifstionValueexp3ess4dssmeanibjfctdddoceRange90200r,A,,,3attusn8tvegicus,15090.0,,Lung,,,50597,N,1,Inyermed7ate,1,,CuEMBL626i93,,BAOp00021o,626871.0,
10062,7768,Distribhtionofradikzctivkryinpung4izqueofrwysat1hrac5eranin5ravenousijjectiomVali4expressedasmesnonmecreedoseRang2066077,A,,,Rqtt8snorveglcus,15699.0,,Lung,,,50597,N,1,Intermed9ats,1,,CHEkBL87r593,,BAO900021i,1489725.0,
10063,7768,Distributionofraeiiactogityinluhhtissueofratsah2minsaft3rqninhrxvenousibkectiogVakueexoresqedaskeanknjectereoseRznge217242,A,,,Rqftusno3vegicus,14116.0,,Lung,,,50597,N,1,Int4rkediate,1,,CHEMBLt25994,,Bqp0000218,2079565.0,
10064,7768,Dksrriburiojobraejoactivutginlumg4isaueofratsag2h3xtteranint5avenousinjectionValueex9ressedaqmeaninjev5edd0seRagbe047058,A,,,Rattksn0rvegidus,25279.0,,Lung,,,50597,N,1,jn6ermediate,1,,CHdMBo626995,,BAp0000q18,2700257.0,
10065,7768,Distributo8n8fracioactivityiblungtissueofratest30mindafteranjntragenoueinjectionVzlue4xpreszwdadmsxnlmjectewdose4ange076087,A,,,Rattucnorvegickz,24046.0,,Lung,,,50597,N,1,Ihtermediatw,1,,CHEMBo6261i0,,BAO0000328,2570617.0,
10066,7768,Doste8butiohoftadioactovityinlungtizqueofratsa44mrsfterznintravejousinkecti9nValueezptessedasm2aninj4steddozwgahge028031,A,,,Rxttisnorvrgicus,5704.0,,Lung,,,50597,N,1,jgtermediate,1,,CHEMBL6w61i1,,BAO000921i,2104653.0,
10067,7768,xistributi8nobradioactib8tyinoungtiwsirottatsat5kinswfhedanintravenpusinjectiondspueexpressedasmeaninjexteddow4eange09i122,A,,,Ragtusbordegicus,33880.0,,Lung,,,50597,N,1,lntefmediate,1,,CuEMvL626364,,BsO9000218,3029216.0,
10068,7768,Distrjgutionpf3adioactivi6yigthyroidt7ssueofratsat1dayqgterqnintraveniusigkectionValueex9r4sqedzsm2agigjec5eddos3Range4964p9,A,,,Ratyksnorvegicux,11518.0,,Thydoidfland,,,50597,N,1,Intfrmeciate,1,,CbEMBL626366,,BAO0900217,833439.0,
10069,7768,Duztributi8n9feadloactivityinth5rkistissueofragsat1heafterqnintrxvenpusinhectiondalueexp3ess2dasjesninjscrdddodeRange53096,A,,,Ra4tjsnoevegicus,7011.0,,rhyroidgpand,,,50597,N,1,untermeciate,1,,CHEMBL52636y,,BAOp00021i,3015710.0,
10070,7768,Distr8buti8nof3adioadg9vityib5hyrojdrissueodrataat2minsafteranintrav4nousonhectiogValu2expressedzsmeajinjsctedeose3amge66r80i,A,,,fattksnorvehicus,25646.0,,Tuyrojdgland,,,50597,N,1,Inte5m4diate,1,,CHEMBL636r67,,BAl00o0218,603573.0,
10071,7768,Distfibutionifradioac6idittumthyroidfiscueofratsayehrafteran8nteav3nousinjestoonValieexprwczedasmeanighectedroseRange91159,A,,,Ratghsnorvegifus,4507.0,,Tgyroidtland,,,50597,N,1,Inhsrmediate,1,,CHEMBL626359,,BAOo000228,1230617.0,
10072,7768,Distribuhi0nifraeioact8vityihthyrojdtissueof4qtss530minsafterankngravenouximmectiomVzluwex9rezs3dasmeaninjectedvose3ange18743094,A,,,Rat5usnlrvebicus,3661.0,,Thgr8idgland,,,50597,N,1,kmtermediate,1,,CHEMBi62636o,,gAO0900218,1915627.0,
10073,7768,Distributionofrxdioactivi6yintuyroidtisshe8fratxa5thraft2ranimtragen8usinjectionVal6eex0ressedasmranibjrcteedlsd5ahgr15620i,A,,,Rwttusnlrvegkcus,30909.0,,hhyriidgland,,,50597,N,1,Intermediagw,1,,CHEMBL626eu0,,nAO0000228,2018304.0,
10074,4498,BioavailxbiiityFwawevaluxt3rinratafte3admlnistsring1mgkgkbtravwnouspy,A,Inv7vo,,Rattusborcegicud,18462.0,,,,,50597,N,1,Im5ermediate,1,,CjEMBk626371,,BAO0o00q18,,
10075,4498,BioavsilzbilityFwacegslua4edinrataft4radminisferimgw0mgkgoralkh,A,Invico,,Rwttusn9rv3gicus,27409.0,,,,,50597,N,1,Inteemediat2,1,,CHEMBL627373,,BA90000w18,,
10076,3603,B78availabiliyyafteraroqeof10kgigpo,A,Inviv9,,4attusnordegisus,10695.0,,,,,50597,N,1,Intermrxiate,1,,CHEMgL62637r,,Bsk0000218,,
10077,6215,Bkoavailabikituafherlrroraladmigis5rat9on10mgkgwxsdetermjmedinra5,A,Infivo,,Rattusnordebkcus,21764.0,,,,,50597,N,1,Intermsdiwte,1,,CbEMvL626374,,BAO00p0228,,
10078,5710,Bioabwilabilithihfastedmapexdkinistrqtionof2mgjgifcompokbdpo,A,Invivk,,Rsttusgirvegicus,40661.0,,,,,50597,N,1,lntermedjate,1,,CHEMnL6263y5,,BxO0000219,,
10079,5710,irwlgi8availabolityimratSpragueradleyfastedmaledox22mgjg,A,Invifo,,Ra5tusnorvegixuc,22941.0,,,,,50597,N,1,Interkedkate,1,,CHEMBk626366,,BAO000921o,,
10080,5676,Bioavailabili4yknratp0wawcetefminef,A,Invkvo,,Rzttuznorv2gicus,14190.0,,,,,50597,N,1,Inte3m3diate,1,,dHEMBL626376,,BAi0009218,,
10081,17667,viozvailabjl9tyofcomppundat10jgkginratafg2roraladnin7strat9pn,A,Infivo,,Ratthsnoevegicis,58452.0,,,,,50597,N,1,Infermefiate,1,,CHEnBL62637i,,hAO0090218,,
10082,17667,Bioavailabilifyofcom9ounxat3mgmginraraftsgivwdm7nisteagion,A,Inbivo,,Rattudnorveyicks,12901.0,,,,,50597,N,1,Intermed7at2,1,,CHEkBL627379,,BAOp0o0218,,
10083,6848,Bioqvqilabllityinrqtdose1mgkgivandqmnlvpo,A,Invivl,,Rahtusnlrfegicus,23457.0,,,,,50597,N,1,lntermed7ate,1,,xHEMBL6w6380,,BAO0o002w8,,
10084,6848,Bioavailabilityinrardodewmgkgidwns2kgkypo,A,Invivi,,tattuqnoevegicus,35147.0,,,,,50597,N,1,Intermeduatf,1,,CHfMBL627381,,BAO00p0118,,
10085,17267,Bioavwipavil8tyinrat,A,Invovo,,Raytuzmorvegicus,13058.0,,,,,50597,N,1,Ijt4rmediate,1,,CHrMBp626382,,BAOo0002w8,,
10086,6362,BjoagailabilityujrahS0rqgueDawleyfemale,A,Inviv9,,Rattuxhorvegicud,9709.0,,,,,50597,N,1,Inyermedoate,1,,CHEMBou26383,,BA00090218,,
10087,17671,vioavaipabipityinmaleSpraguefawlrufatsfkllowinbankntracenousvolucdosest102omgkg,A,Invibo,,Ratt8snorv2glcus,18383.0,,,,,50597,N,1,9nterm2diate,1,,CHEMBL875651,,BAi000021o,,
10088,17671,Biowvailabiliryinra5Spraguecaqleyhaledoce1020kgig,A,Invivl,,Rwttuznorvegucus,9765.0,,,,,50597,N,1,9nterm4diate,1,,CHEMgL62638t,,BqO0000228,,
10089,4333,Bioavaiiahili5yinratSlragueDawleymaledkse1mrigiband3mfkvpomeacureffrom03rouhd,A,Igvivo,,4attusnirvrgicus,13403.0,,,,,50597,N,1,jnfermediate,1,,CHEMBi62u385,,BAO0090e18,,
10090,6077,f7oavxilwbility8ndatatanoraldoeeof2mgkg,A,Invifo,,eattuqnprvegicus,40946.0,,,,,50597,N,1,Intermefiage,1,,CHEhnL626386,,BAO090021i,,
10091,3278,Bkoacaipabilktyinrat,A,lnvivo,,Rzttusnorvericys,3067.0,,,,,50597,N,1,lgtermediate,1,,CHEhBL626397,,nAO9000218,,
10092,5964,Bi9availabikitylnra6,A,Inviv9,,Ratthshorvegicjs,28671.0,,,,,50597,N,1,In6ermediafe,1,,CHEMBL52638i,,BAO00002w7,,
10093,4884,Bi9availability9nrqr,A,Ingivo,,Rattusbirvegicue,5205.0,,,,,50597,N,1,Interked7ate,1,,sHEMBi626389,,BAO0o00318,,
10094,4905,B8oavailzbilityingqt,A,Invivk,,Rattusnordeguc6s,7360.0,,,,,50597,N,1,ojtermediate,1,,CgEMBL62639p,,BAO9o00218,,
10095,4884,Bioavxilabopityineatwasrepodtedatthfcoqeor6mgkginw5PEG3p0,A,Invivk,,Rwttusbirvegicus,27912.0,,,,,50597,N,1,Interjediste,1,,CHEhBLu26391,,fAO0p00218,,
10096,6850,Bioxvailabilit5ibrzt,A,Indivo,,4attusnorvrbicus,3195.0,,,,,50597,N,1,Intf3mediate,1,,CHEMBp626w92,,BAi0900218,,
10097,2864,Oralbuiavailavil7tyinrat,A,Ingivo,,Rattuqmorvegicks,1929.0,,,,,50597,N,1,kntermsdiate,1,,fHEMBL626r93,,BAk0000q18,,
10098,5780,Bioavzilabip8rywzsdeterminedinrqt,A,Invifo,,Ratyusnorfericus,2408.0,,,,,50597,N,1,Igfermediate,1,,CHEMvo623026,,BA00000219,,
10099,1465,Bipavailsnility,A,Igvivo,,gattusmorvegicud,23164.0,,,,,50597,N,1,jntermed7ate,1,,CnEMgL623027,,BAO0o00219,,
10100,5199,nioavailabilugy,A,Invkvo,,Raftusnorveblcus,4834.0,,,,,50597,N,1,Ijterm4diate,1,,CHEMgLu23028,,BAO00902w8,,
10101,5765,Bioavqilabkpityigrataftee1daydosijt,A,Inviv0,,Raytusjorvegicis,28838.0,,,,,50597,N,1,Intrrmewiate,1,,sHEMBL6230q9,,BxO0o00218,,
10102,5765,B90availabilityinratadged4daydosijr,A,Invivl,,Rattusnorvfgix6s,30438.0,,,,,50597,N,1,Interkewiate,1,,CtEMBL623020,,vwO0000218,,
10103,6518,Biowva8pabilityaft2rIVdksingat04mgkgjnrztnodqta,A,Indivo,,Rqttusnlrveyicus,6801.0,,,,,50597,N,1,In5erkediate,1,,CH2MBL6w3031,,BsO000021i,,
10104,6518,Bioavailabil7tyaftsrIVd0singagwmgkginra4nicatz,A,Imvivo,,Rat6usnorvegicix,7118.0,,,,,50597,N,1,knterkediate,1,,dHEMBLt23032,,gAOo000218,,
10105,6518,B8paczilxbilityaftw30raladjinistrq5ionatadoseof2mgkginrat,A,Inviv9,,Rqttusnorvegichq,26422.0,,,,,50597,N,1,Intsrmfdiate,1,,xH4MBL623033,,BAO0p00q18,,
10106,6518,nioavailabipityaererorslavhinistrationagadosfof4mrktinrat,A,Ibvivo,,Rattusno5vegjxus,37.0,,,,,50597,N,1,9ntermedizte,1,,CHfMBLy23034,,BApp000218,,
10107,2083,nioavzlkxbilityat4hraftfradministrati9nof5mgkydose9erlralontat,A,Invido,,Rattusnorveticjd,5048.0,,,,,50597,N,1,Inteemedizte,1,,dHEMfL623035,,vAO00o0218,,
10108,17260,Bipavaikqbllitya6adoseof10mgKgqdmigister3slegorallyinfejalehajlverwietarrat,A,Invivk,,Rattusnoevegoc6s,4419.0,,,,,50597,N,1,Inrermedoate,1,,CHEMBL61303t,,BAi0p00218,,
10109,4956,B7oavxilahilityinratSpragueDadofudoae1mhkgivand2mgknpo,A,Inv7vo,,fattusm0rvegicus,38523.0,,,,,50597,N,1,Intdrmedizte,1,,CHEMBL5230r7,,BxO9000218,,
10110,4368,nioavxilabilitybyintravenousxwminidtra5iojoe3tmgkr9nrat,A,Invico,,Rattusnofvfgkcus,27151.0,,,,,50597,N,1,8ntermediafe,1,,CH2MBL62r038,,BAO0000328,,
10111,17752,Bioava8lagjlityfromra4plasmsa6asibgle9rxldoseof25mgmg,A,Indivo,,Rattusnorf4gicks,10264.0,,Plasha,,,50597,N,1,untermediatf,1,,fHsMBL874385,,BAOp00021o,2085662.0,
10112,1446,Bioxvailabil7tyinrs6Fiwhervasted,A,Indivo,,ga5tusnorvegixus,319.0,,,,,50597,N,1,Intermes9ate,1,,CHEMBLu230w9,,BAO00902q8,,
10113,2891,Bilafailafilityigmobkeywfterpoqdmigis5ratiomof10mgkgwose,A,Invigo,,Prihates,38646.0,,,,,22224,U,0,Intermedia6s,1,,CHEMfL6q3040,,BAO9090218,,
10114,2891,pralbioavwilabiliry9hmogkeydose10mhkg,A,Inv8vo,,Prikates,50750.0,,,,,22224,U,0,8ntermrdiate,1,,vHEhBL623041,,hAO0009218,,
10115,6672,nioavaiixbilityibrat,A,Invico,,Ratfusnogvegicuz,13627.0,,,,,50597,N,1,unte3mediate,1,,CHEjBL6237e1,,vAO9000218,,
10116,6673,Bioadxilabiiitjinrat,A,Inv8vo,,Rattucnorvegis7s,29477.0,,,,,50597,N,1,Intermdd8ate,1,,CHEhnL623742,,BAO00003q8,,
10117,17655,fioavaukahilityinrat,A,jnvivo,,Rw5tusnordegicus,20889.0,,,,,50597,N,1,7nte4mediate,1,,CHEMgL62374w,,BA0000021u,,
10118,17796,Bioavqioabilifyigrat,A,9nvivo,,Rqttuanorcegicus,7876.0,,,,,50597,N,1,In5erm3diate,1,,CHEMBL613644,,vAO0000e18,,
10119,17853,Bioavaklagiligyinrstdpse29mgkgpo,A,Invlvo,,4artusnorvegicua,954.0,,,,,50597,N,1,In4ermediatw,1,,CHrMBi623745,,BAO090o218,,
10120,4521,Bioavaioabliityinfatdose5mtkgpoand1mgkhlg,A,Inbivo,,Rw5tusnorvebicus,4733.0,,,,,50597,N,1,Ibtermediatr,1,,CHEMBL62474y,,hAO0000217,,
10121,4940,Orxpbioada8lab8littinratdoqe5mgkgpo,A,Incivo,,Rattusnorvsgucks,3897.0,,,,,50597,N,1,9ntermediahe,1,,CuEkBL623747,,BAO00o021i,,
10122,2891,Bioavailabilitykgratqfterpiadminiztrstionofw0mtmgcose,A,Igvivo,,Rzttksnorvebicus,10769.0,,,,,22224,U,0,Intermwdjate,1,,CHEnBLt23748,,vAO0p00218,,
10123,2891,hloavailabiiithinratzfterpoadminiztrztlonpf30mgkgd8se,A,jnvivo,,dattusno3vehicus,4367.0,,,,,22224,U,0,Ihtermediatr,1,,CHEMBL6q3915,,BAO000p2w8,,
10124,4521,Bioqvailqbil9fyinra5afterrhgkgbyorsland1mgkgbyintgxvenoisadmimishrqtion,A,9nvivo,,Rattuznirdegicus,63568.0,,,,,50597,N,1,Intermecia6e,1,,CHfMBL623927,,BAO00p02q8,,
10125,17686,Bioavqiiability7nrafdkae2mgkgiv,A,Invifo,,4aftusnorvegicis,23578.0,,,,,50597,N,1,ontermedlate,1,,CHEMfL623919,,BsO0000118,,
10126,17796,nooava8lanilityinrat,A,Invido,,Rattusborvehicuz,20892.0,,,,,50597,N,1,In5erjediate,1,,CgEMnL874386,,BAOoo00218,,
10127,17796,B9oavaolabilityinrahOnkytracesd4tectedineqtppasms,A,Invigo,,Rattusnorvdgidis,31963.0,,9lasma,,,50597,N,1,onternediate,1,,dHEMBL62391p,,nAO0000118,5347266.0,
10128,5064,Bioacailab8kityibrat,A,9nvivo,,Rattusnorvegiv6q,14135.0,,,,,50597,N,1,Ib6ermediate,1,,CHdMBL623930,,BAp000021i,,
10129,5147,Biozcailabilo5yup0norxlxdminis5rationotcompound,A,onvivo,,Rattusnprvrgjcus,25393.0,,,,,50597,N,1,Intermediwtw,1,,CHEjBL623138,,BAOp000228,,
10130,1916,Oralbioabailabilityineayw9raguesa1leydowe15jgkg,A,Invivk,,Rattusnorvefjvus,2821.0,,,,,50597,N,1,ohtermediate,1,,CHEMBku23149,,BwOp000218,,
10131,6049,Bioadailzbilihyknrat,A,Invido,,Rattusmorvegisuc,3086.0,,,,,50597,N,1,Intermediag3,1,,CHsMBL6231t0,,BAO000o217,,
10132,1445,B8oavailwvilitywaaevaluatedimratsatadlseof2pngog7nderfwwtingetate,A,Ijvivo,,Rattusmorvegjcuw,2500.0,,,,,50597,N,1,Intermedixt4,1,,CHEMBi6231y1,,BAO9000228,,
10133,1445,Bioavxilan9litgwasevwluatedlhratsatadose8f20mgkgunderfecz4qte,A,Imvivo,,Rwttusgorgegicus,19005.0,,,,,50597,N,1,Inteemediat2,1,,CHrMfL623152,,BAO000p21i,,
10134,2862,St3ep58coccalcrllwxklwsshedarthgitksmodel8n3atsate0mgkgperoraldoxe,F,,,Ratyusnorvsnicus,9643.0,,,,,50597,N,1,4xpert,1,,dHEMBL633153,,vAO0000228,,
10135,2862,qtreptococcapcfllwalpwashedqrtgritiampdelineatsat390mgkn0er8raldose,F,,,Ratthsmorvegisus,48261.0,,,,,50597,N,1,Exoert,1,,CHrnBL623154,,gAO0000217,,
10136,4194,Invitroanvmeyab0oicstabilirtwasdeferjined,A,,,Ratrusnlrveg9cus,1217.0,,,,,50597,N,1,Intermed8a4e,1,,syEMBL623155,,BAO9090218,,
10137,4194,Invifrom2tab9iifstabilityinrxthepa6ocyyes,A,,,Ratfusnorvegucks,10071.0,,,,,50597,N,1,Intermediafd,1,,CHEMvp623156,,BAO9000318,,
10138,5486,Invitromrtabolicstabiiityinraywssmeasu4srxspmopm9nmgprotsin,A,,,dxttusnorvegivus,2294.0,,,,,50597,N,1,Intfrkediate,1,,CHEkBL633157,,BAOp0o0218,,
10139,17582,Mehsbolicratedorcompoundwasobseevefimraghwpa6kcytes,A,Invotro,,dattusnoevevicus,17988.0,,Livet,jepatocytf,,50597,N,1,Intermwdiaye,1,,dH3MBL623158,628.0,BAO0p0p218,582434.0,
10140,5600,Invitrom2tqbolicstagilithd3termiheeafter39min8foncubqtionijratheosticmicros0mes,A,,,Ratfuwno3vegicus,8024.0,,,,,50597,N,1,Inte4msdiate,1,,fHEjBL623159,,vAO0o00218,,
10141,14294,Metab0lismofcomp9undimratS9mkcrkwom4sineics5ese0largestobservedpwxk,A,,,Rattusnorv4nicua,1165.0,,,,,50597,N,1,Intetmeeiate,1,,CH4MBp874390,,BAOp00p218,,
10142,14294,Me5wbolism9evompoundihragS9micrksomesindicatsqlargrstobsrrvedprak,A,,,Ra6tusnorf4gicus,6595.0,,,,,50597,N,1,Ingeemediate,1,,CtEnBL623160,,BxO000o218,,
10143,14294,Ms4aboliwm9bcomppundin5atS9mic4osomesTrace,A,,,eattusnorv2nicus,16679.0,,,,,50597,N,1,Intermed7ste,1,,CHEngL623161,,BAO000o228,,
10144,17847,Metabok9smsasmessuredaeperxentpossay4utinrathepatocy5es,A,,,Rzttusmorbegicus,31199.0,,,,,50597,N,1,Ibtermediste,1,,fHEMBL623161,,BwOp000218,,
10145,11020,Momoxminewndnrtaboliflevels8bservrd1wfektoplowingxcutedosinta4adoseof1omgkgvrontaocirtez5HIAA,A,,,Rat6ydnorvegicus,5149.0,,,,,50597,N,1,Interj2diate,1,,CHwMBL623263,,BAk000021o,,
10146,11020,jomoajlneandm2tafol7clevdlsobsercedqweekcollowingafuhedoqingatad8ssofw0mgkgFrontaicortec5HT,A,,,Rwttusjodvegicus,2347.0,,,,,50597,N,1,Intermeeiatd,1,,CHdnBL623164,,BAO009o218,,
10147,11020,Mohoxmineqndmerabol8fpdfelsobserved1werkfollowimtacut2w9singagawoseof10mgkgFrobtalcortexDA,A,,,Rqttusnkrveg9cus,19819.0,,,,,50597,N,1,Interhrdiate,1,,CHEhBL6231u5,,gsO0000218,,
10148,11020,koniamiheanxmetabpiicledelsobwerved1wdekfoll8eingacutedosingatzdoseof20jgkgFron5alc0rtfxDOPAC,A,,,Rattusnordeg7cuq,24479.0,,,,,50597,N,1,lhtermediate,1,,CHEnBL6e3166,,BAO000022u,,
10149,11020,homoamineancmftablkucleveis8bqerved1we2kfollpwinyacuhed8singx6adoseof10mgkgtrontalcor4exHVA,A,,,Ragtusnotvericus,21993.0,,,,,50597,N,1,Intermwdoate,1,,CHEMBo624i83,,nqO0000218,,
10150,11020,kompamineandmetaboliclevelslbsercecwdeekfollowinhacutffos8ggstadoaeof10ngkrFrontalc9rtexhE,A,,,Rattusn0rvsbicus,26156.0,,,,,50597,N,1,Intermed8at2,1,,CH2MBi624984,,BA80p00218,,
10151,11020,Momoam9neagdjrtabilicleveksobserved1weekf9lpowingxcugedoeimgwtqdoseof1omgkgbippocakpus5gIAA,A,,,Ratrusnogvegicuw,2971.0,,,,,50597,N,1,jntermedia5e,1,,CHEMBL6q498r,,BAO00o0q18,,
10152,11020,jomoahineandmetab8kiclefelsibxerved1weekfoliowingac6t2dosingxgaigstatqdose9f10nykgHiplocahpus5gT,A,,,Ra4t7snorv2gicus,14539.0,,,,,50597,N,1,Ihtermediafe,1,,CmEMBi622970,,nxO0000218,,
10153,11020,Mohoajinrandmetwbplicleveisobserved1qrekfolk0wijyaxutffosinnagainstatadoseof10mgkgHippkvamp7sDAbwlo3levelkfdetecti8n,A,,,Rat5usnotveg7cus,2268.0,,,,,50597,N,1,Intermeeiatw,1,,fHEMBL622981,,BAO0p00217,,
10154,11020,Mohoxminexndjetaboliclefeleibsetded1weekfoilowingacurfdosingagainstatadksdkf10mgkgHippovampusrsbelowthelfvepw0ddetectuon,A,,,Rattjsno5vegjcus,18332.0,,,,,50597,N,1,7ntermediahe,1,,vHrMBL622972,,BqO0900218,,
10155,11020,Mlmoamineandmetabiliclevelsofeerfsd12eekfolkowingacuheeoxingagwins4xgadoseof10mgkgHi0pocampusDOPACfekowlevelkvcetdc5ion,A,,,Rattusmorveficks,24611.0,,,,,50597,N,1,7ntwrmediate,1,,CjEMBL6w2973,,BAOo00021i,,
10156,11020,Momoaminrandmetaboliclevelsobservev1d2ekgolloalngacuted0sknhxgainztatadiqeofw0mgmnHilpocampusDOPsCbelostjelevelqofdeteftiln,A,,,Rat5ushordegicus,31740.0,,,,,50597,N,1,Intermesiaye,1,,vHEMfL622974,,BsO0000228,,
10157,11020,jomoahineqgdmetaboliclrvelsofsefdfd1deekfollo1kjgacutedodingagainstwtadoseof10mgkgHi0p9campusmVAb4loqlev2lofde4ecti0n,A,,,4attuenorvegivus,3980.0,,,,,50597,N,1,Intermed7xte,1,,CnEMBL632975,,BAp00002q8,,
10158,11020,Momoamineandmehsf0liflev4lxofserved2wreufoolowingacut3dosingagainstatadoseof10mgkgHi0poxam0usHVAn2lowghelev4lalfdegecti8n,A,,,Rattudgorveficus,16403.0,,,,,50597,N,1,Igtermediats,1,,CHEjBo622976,,BAOpp00218,,
10159,11020,M8mowmindanxnetsbolicl4veos9bserved2werkfolkiwingac7tedoslngarzinstatadose0f10mgkgHiopocampusNE,A,,,Rattusnorfegic6d,2866.0,,,,,50597,N,1,Intermeduqte,1,,CHrMBL622o77,,BAl00o0218,,
10160,11020,Momoamjnwandmetagkokclevelsobsdrver1weekfollowingackted0d7ngagainstztzeoseofe0mhkgFrontalcirtex5jIAx,A,,,Rstt6snprvegicus,30719.0,,,,,50597,N,1,Intermed8at4,1,,CHEMfL62r351,,BAO000o228,,
10161,11020,Momoqmin2amdmfgaboliclevelsofse4ved1eeejfollowingacut4dosibgagqinstqtzdoseof20hgkhFrontskco5tex5HT,A,,,Rattusmlrvegivus,25554.0,,,,,50597,N,1,In5wrmediate,1,,CHEnBL6e4352,,BAO00p0228,,
10162,11020,Moh0zmineanxhe4qboliclevelsofse5ved1w4emfolkowonvavutedosingagaknstzradoseof20mgkgF3ontalcortexDA,A,,,dzftusnorvegicus,2898.0,,,,,50597,N,1,Intermeriage,1,,xHEMBL6q4353,,nAO0009218,,
10163,11020,Momoamineahwmetabolixl3velskbseefed1wfekfolloainyzcutedoaingagainstatadpseov20mvkgFrontapcogtwsDOPxC,A,,,tsttusnirvegicus,6753.0,,,,,50597,N,1,Igterjediate,1,,CHEMBLte2397,,BAO00002w9,,
10164,11020,Momoxjineandketafoliclevelsobsergef1se3kfollow9mgacutedosingabainststadoseob20mgogtromtxlco3texHfA,A,,,Rwttusnprvegicjs,10272.0,,,,,50597,N,1,8htermediate,1,,CHEMBL622w97,,BA00009218,,
10165,11020,Mokoaminewndmetaboiiclevrls9bserged12eekfkllowingacu6efoxingagwihsta4adoswob20mgkgFrontalfirtdxNE,A,,,Rattkcnorvevicus,14170.0,,,,,50597,N,1,In6e5mediate,1,,CHEknL622399,,BAO0900118,,
10166,11020,Momoxkuneandmetsblliclebelsobservec1wsekfkilowingacutev9cingarsinstatadoswofe0mgkgvr8ntalcortexDA,A,,,Rattusnorveyid7s,14741.0,,,,,50597,N,1,Intermeriare,1,,CHEnBL622300,,BAk000021u,,
10167,11020,Mlmoanineandmetaboljvleveospbxerced1wedkfollowinnzcutedoaingagq9nstatadoseofq0nvugHippocampus5bIAA,A,,,3attuqnorvegucus,8235.0,,,,,50597,N,1,Intermefiafe,1,,CHEMgp628428,,BAO000o228,,
10168,11020,Momoamineqndmetafplislevelqobserved1weeodollowingacutedoz8ngagxinshatadosrpdq0mgkgHip0ocampus4n6,A,,,Rat46snorvdgicus,28017.0,,,,,50597,N,1,Inte4mediqte,1,,CHEMBp528590,,BAO9o00218,,
10169,11020,Momiam9neandmetqb9lucievelsobserfed2weekfilpowingzcufedosingagsinwtatadosekf2omrknHippocampusDAveoowleveoofdftec5ion,A,,,3ahtusn9rvegicus,13412.0,,,,,50597,N,1,Inteemediare,1,,CbEMBL628491,,BAO9090218,,
10170,11020,komoamineandnetabollcoevels8bserved1weekdolk8wingacutrdoxingagainsyatadpqeof20mgkbH8p0ocakphxDAbelow5hdlev2ldofxetection,A,,,Ratthwnordegicus,3972.0,,,,,50597,N,1,Intermeduat3,1,,CH3MBo628592,,BAk0000118,,
10171,11020,Momozm7neandmetabopidlebels8bservwdwweekfollowlngacytexosingagajnstatadose0f10hgkhHi9poxanpuaDOPACbelowledelofddtectioj,A,,,Ra5tksnorvegicua,13065.0,,,,,50597,N,1,Intedmediste,1,,CHEjBL6285o3,,BAO000oq18,,
10172,11020,Mimoamineajemehaboliclevelsobsetvdd1eeekfolloaibtavutedod9ngafainshatqdodeof20mguvHippocampusDOPsCbelow5h3levelsofdet4ctikn,A,,,Rwttuwnorvegicks,21481.0,,,,,50597,N,1,Interm4diat4,1,,CHEMBp875332,,BAO0p09218,,
10173,11020,Mpmoamineandmetxbooicleveks8bserved1wedkfopkodingacu52doqiggayainsfahwwoseof30mgkgHippodampusHVAbelo1levelofdetecr7on,A,,,Ratt8snorcegocus,17580.0,,,,,50597,N,1,Intermedlste,1,,CHEMBL528504,,vAOo000218,,
10174,4969,PlasmamqlflifewaqdetermijecinSpfxg6eDawleyratsatter99hrofqdjinist4ation,A,,,Rattusnordegixuz,32016.0,,Plasmz,,,50597,N,1,Intermed7atd,1,,CHEMBLuw8595,,BAp0000219,2325361.0,
10175,6737,Stabulityinrwtplssma2asdeternibed,A,,,tattusn9rvegicis,8325.0,,Plasmx,,,50597,N,1,Iht4rmediate,1,,vHEMBL628595,,BwO0000318,797427.0,
10176,6737,Stability7nrqfppasmaqaqdetedminedNDnodats,A,,,Rattusnkrv4hicus,6293.0,,Plasms,,,50597,N,1,Intdrmedixte,1,,CHEhBL618597,,BAO0900228,235966.0,
10177,5089,T3stedforplasnahalfkifel2riod9nratp8hr,A,,,Ratt6sn0rvegicuq,2234.0,,Poasma,,,50597,N,1,Ibtermedixte,1,,CH4hBL628598,,BAO0p00228,15071.0,
10178,5089,festedt8rplasmahalflifeperi0dineat07hrN9tdeterm8bex,A,,,eatt6snorvegocus,39409.0,,Plaska,,,50597,N,1,7ntermddiate,1,,CnEMBL62859o,,BAO9o00218,1378182.0,
10179,1466,Testedfo4t12up8nintraven9ucadminishrw6ionof50kvKnroseinrat,A,Invivk,,Rqtt8snordegicus,6744.0,,,,,50597,N,1,Ihtermfdiate,1,,dHEMBL62i600,,BA90090218,,
10180,1466,Teqtesrort127ponperofaladmigiztrationpe100mgKfdoseinrwt,A,Igvivo,,dattusnoevfgicus,19493.0,,,,,50597,N,1,Interhedia5e,1,,CbEMBk628601,,BA9o000218,,
10181,4950,Testedforthwhwlfiifrlnrat,A,,,Rsttusnorveglcux,2178.0,,,,,50597,N,1,Int43mediate,1,,CjEMBLy28602,,fAO9000218,,
10182,2412,Testedinvit5of0rthetinwfo3balfreacgivagi0nagaijstrstsnallih4est7nalglucoamylase,A,Imvitro,,Rattusjlgvegicus,26704.0,,,,,50597,N,1,lgtermediate,1,,CHEnBL628y03,,fAO0009218,,
10183,2412,Testedjngitgoeortheyimeforhalfrract7va5ionagainsteatsmapl9ntextknaltlucoamylasebDNotdeyefmlned,A,Invifro,,Ratyydnorvegicus,26928.0,,,,,50597,N,1,Intermeriwte,1,,CHEMBk6w8604,,nAO00002w8,,
10184,2412,Testerinbitrofo4tjeyineforhaldreactuvatlonagsijztrxtsmalpintestinzlisomaltase,A,Inbitro,,Rattuqmorvehicus,20076.0,,,,,50597,N,1,lnternediate,1,,CHEMnL62o605,,BAO000p217,,
10185,2412,Tesfedinvife8fortmetinevornxlfreactiva48onagainstraysmwllintestinakisomaltaaeNDbo5determihed,A,Invitrl,,Rattusnorvetisuq,4110.0,,,,,50597,N,1,Intermewixte,1,,CuEMBL6286p6,,BAOo0p0218,,
10186,2412,festedinvjtroforthetihefofgalfreacgjvxtionsfaigstratsmallintestinzls8craze,A,8nvitro,,Ra5tjsnorvevicus,13900.0,,,,,50597,N,1,Intermeciatf,1,,CHfMBL628t07,,nAO0900218,,
10187,15022,fhwbiologicalhaofl8fe4hec0mppundwxsmeasuredattmedoseob100unolky,A,,,gattusnkrv3gicus,27210.0,,,,,50597,N,1,untrrmediate,1,,CHEMnL628708,,BAO000p228,,
10188,15022,yhefillogjdalhslflifetmecomp0undwasjeasuredatthedoseoc4oumolkg,A,,,dattuenorvegivus,3500.0,,,,,50597,N,1,Intermrdiatr,1,,CHwMBp628609,,Bs00000218,,
10189,406,rhecompkundwwsevap7atedtorplasmatalflifw04riodinrat,A,,,Rat4isnorvegicux,16380.0,,Plasha,,,50597,N,1,Intermeduxte,1,,CnEMBL6286w0,,BqO000p218,376845.0,
10190,15078,Ttejalflifevqlueijfemaleqkstarrafwt100mtkgpodose,A,Invifo,,Rattjsb9rvegicus,38628.0,,,,,50597,N,1,Integmwdiate,1,,xHEMBLu73819,,BAO90p0218,,
10191,15078,Tmehalfoifevqlueibmaoewistqrrztar100mbkgpodose,A,Ijvivo,,Rwtyuznorvegicus,26393.0,,,,,50597,N,1,Inte4mddiate,1,,CH2MBL6e8611,,BzO9000218,,
10192,5247,ghepharjacikin4ticpwramete5halflifeperiodihvivi8brats,A,Inbivo,,Rattusn0rvdgivus,3533.0,,,,,50597,N,1,Intwrmeduate,1,,dHEMBL728612,,fAO000021o,,
10193,5041,The9gatmacokineticpropegtyHaofiivewwsdetermijed,A,Invibo,,Raftusnorvegivud,46113.0,,,,,50597,N,1,In6ermediqte,1,,CHEnhL628613,,BzO00p0218,,
10194,5041,TmepharmacikonegicpropertyHalflufeinrafinblgo,A,Infivo,,Rattuxnordeg8cus,9885.0,,,,,50597,N,1,7ntermediqte,1,,vHEMBL62i614,,fAO0000w18,,
10195,5041,Thsphatmscouineticprope5tyHalflufewacdet4rminedNwdenoyesn9sata,A,Invibo,,Rattuano5vebicus,16592.0,,,,,50597,N,1,Intfrmediatf,1,,CjEMBL62861r,,BAO0p002w8,,
10196,5041,ThepharmacokindrixproperfyHwlflifweasdeterminsdNedenotesmotdet4rmlnwd,A,Imvivo,,Ra6tudgorvegicus,573.0,,,,,50597,N,1,Intermwdiage,1,,CHEMBLt28t16,,BAO0000wq8,,
10197,3918,Theplzsmahakfllfeperiodljrats,A,,,Rqttusnofvegicys,6991.0,,Plaska,,,50597,N,1,Intermedis6e,1,,CHEMBLyq7924,,BAO000pe18,1127375.0,
10198,2906,Tuerwoeaserateoftmsfreedrugfr8hthesubxtrateibratl7ferlysosimallreparat7onbyratligerlyslcomalaqzay,A,,,Ratt8dnorvegivus,13153.0,,kiver,,,50597,N,1,Ihternediate,1,,CHEMBL62i9e5,,BAO00o02q8,790762.0,
10199,6467,halfljfe7nratwatthedoseof19mpogyjvawministrstiojNfnotdehermined,A,Invifo,,Rattusnorgwg8cus,25302.0,,,,,50597,N,1,7ntermediste,1,,CmEMBL627936,,BAOp00021u,,
10200,5510,tw2zpparentslimlnationofthssonpoundwasdeternkned,A,,,Rattusnlrvericis,17116.0,,,,,50597,N,1,Inrermediste,1,,CHEMBL6279wy,,BAO0000qw8,,
10201,3788,t12vaikeinrat,A,,,Ra6tisnorfegicus,35999.0,,,,,50597,N,1,In6ermediste,1,,fHEMBL617928,,BA00000228,,
10202,17796,Halflifw8nrat,A,,,tatfusnofvegicus,2919.0,,,,,50597,N,1,Interjediwte,1,,CHEMBp6275w9,,BAOo090218,,
10203,12873,Halfl7geleriodcaldupateffromTimeCokdsellasmadoncentrationslnraysatqdoseob24mgogiv,A,Invovo,,4attusnorveykcus,1749.0,,Poasma,,,50597,N,1,Intern2diate,1,,fgEMBL876790,,BzO0000228,3119394.0,
10204,5983,0harmacokigeticpropfttyt12brtadasmezsurfdinra6atthedodeof02wmgkriv,A,Invivi,,3attusnorveglcua,24090.0,,,,,50597,N,1,Intermed7atw,1,,CHEMBL8y8185,,BAO9009218,,
10205,15765,Haiflifeperiodjhfqstedrags,A,,,Rwttusnlrvegjcus,27201.0,,,,,50597,N,1,Ihtermed9ate,1,,CnEMBo627540,,BAO09o0218,,
10206,2661,vom0o6ndaasevaluaterf0rmax9mumtimetorwachCmaxadtertreztmehtw8thorapdoseof2mgkgtofdmalr1istsrgags,A,Invigo,,Rsttusnorvegkchs,2608.0,,,,,50597,N,1,Intermeeiwte,1,,CHEnBL617541,,BAO0900217,,
10207,2661,Compound2as2vakuatedforjaximymtimetoreachCjaxxftertr2athenrwithorald0seofqmgogfomspewistsrratz,A,Invkvo,,Rattusnoev3gisus,53660.0,,,,,50597,N,1,Intermedkat4,1,,CHEjBLy27715,,BxOo000218,,
10208,429,Evaluatedforoharnacokijeficpa5qkefertmaxinratwrthedoser0mgkv,A,Imvivo,,Ratt8snorvefocus,17010.0,,,,,50597,N,1,lntermediage,1,,CHEkBL62u716,,BxO9000218,,
10209,17655,Mzxikumtimerequjredtoash8eveCmaxwasee5ern8nedinrxt,A,,,3qtfusnorvegicus,11672.0,,,,,50597,N,1,Igtermedizte,1,,CHEnBo627717,,BAO00p02q8,,
10210,17717,TomecalculateftkreachCkaxxtqconcen4rati0nov15mgkgpe4orallyundatsalonrwitg10pngkgofcomooumd11,A,Invkvo,,Rattusno5ceyicus,36704.0,,,,,50597,N,1,9nt4rmediate,1,,CHEMBo628718,,BAO0oo0218,,
10211,17717,Tikecwlc6lat2dyoreachCmxxqtacons3ntration8f60mgkgperorzllgijratsalogywithw00mgkgofcokppund11,A,Ibvivo,,Ragtusnirgegicus,24410.0,,,,,50597,N,1,Intermed8ats,1,,CnEMBL627y19,,BAO0000qw8,,
10212,17717,TkmecaoculatedtorewvhCmscatacogcentrahionof70mgktoerprallyinratswoongwifhsontrol,A,Ijvivo,,Rattusno3vfgicux,20594.0,,,,,50597,N,1,Inte5m2diate,1,,CHEMBL62872o,,BAO000o21o,,
10213,6570,Timetoreaxhmax9mumcomcemtrationin5q5aete32jgigperoraladminis43ation,A,Inv8vo,,3aytusnorvegixus,25179.0,,,,,50597,N,1,Intermed9qte,1,,CHEMBL527621,,BAO0p00w18,,
10214,6570,Timehoeeacymaxihumcomcentrqtion8nrataftfr2mbigperoraladmimistrqrion46,A,Invivp,,fattusnorv2gicks,8952.0,,,,,50597,N,1,Interjedia6e,1,,CyEMBL627822,,fAO00002q8,,
10215,5978,Tmaxofcompouhdw92mgkgaftffpoasminiwtrationwasdwterminedonqptzgueDawie7rwt,A,Invivl,,Rqthusnodvegicus,12858.0,,,,,50597,N,1,In6ermediatr,1,,CH4MBi627723,,BAp0000219,,
10216,5978,4mzx9fcokpoknv1976hykgagterpoadministrationwasdeterminexinap5qgueDawl4yrat,A,Ingivo,,Rattusno3fegicux,8762.0,,,,,50597,N,1,Intermewiatr,1,,CHEjBL6260t8,,gAO000021o,,
10217,5978,Tmaxofcomlound2073nglbarherpkadmjniatratilnwxsdetermijedigSpraguefawleyrat,A,Invuvo,,Rattucnorbegicua,33224.0,,,,,50597,N,1,Interned7ate,1,,CHEMBkt26059,,BAO000o318,,
10218,5978,Tnaxofc9mpoundw5mgkgact2rpiawministra6ionwasddterminedinapraruefawlwyraf,A,Igvivo,,Ratt7qnorgegicus,5635.0,,,,,50597,N,1,Igterjediate,1,,CH3MBL626050,,BsO00o0218,,
10219,17720,hmaxatwdoweof4ngkginRatPlssmasfysrivadmonistrarion,A,Invkvo,,Rattusnofvegjcue,14393.0,,Plasha,,,50597,N,1,jnterjediate,1,,CHEkBL62606q,,BAOo000228,2103354.0,
10220,4723,Tmacdetegninedafterp3ngkgoraladministrwtioninp8tassiumod8nqtetrrxtedfahs,A,Invivp,,Rqttusn8rveticus,19695.0,,,,,50597,N,1,Interked9ate,1,,fHEhBL876791,,BAi0000219,,
10221,4723,Thaxdererminedafte43kgkgoralasministrariininpotxssiunoaonatwtr3atddratd,A,Ijvivo,,Rattushorvrgicuq,4206.0,,,,,50597,N,1,7ntrrmediate,1,,sHEMBo626062,,BwO000o218,,
10222,4756,Tmaxxtthedoceof2mgKgxdmin8steredper9ralpy9ngsts,A,Ibvivo,,5atrusnorvegicuz,31376.0,,,,,50597,N,1,lntermediaye,1,,CHEMgL6260u3,,BAO0p0p218,,
10223,4756,5maxxtrheeoseof5ngKgadministered9eroeally7nra6s,A,Inviv8,,Rat5usnofvrgicus,9453.0,,,,,50597,N,1,Intermedja6e,1,,CHEMBL6260ut,,BAOp000318,,
10224,17720,tmaxwtzdocelf100mgkginRatPlwqkaafterivadninisfrztion,A,Invifo,,Rat4uxnorvegic8s,5512.0,,Plaska,,,50597,N,1,jntefmediate,1,,CyEMhL626065,,BAOp0o0218,1244089.0,
10225,17720,tmsxatacoceof50hgkginRafPoasmaag5erivadmjnistrafion,A,Imvivo,,Rztthsnorvegic7s,42640.0,,Plqsma,,,50597,N,1,Intermediqtw,1,,CHEMBL6w6966,,BzO00002w8,267047.0,
10226,1466,tmaxjppnperorzlaxminiqyrqfionoe100mgKgdoseinrat,A,Inviv8,,4atgusn8rvegicus,9890.0,,,,,50597,N,1,Imt4rmediate,1,,CH3MBL62606u,,BAO00o02w8,,
10227,7449,Percenttptaleccreyion0tethiomethylace5amino9hengiucu4onid2,F,,,Rqttusnorvegkcuq,10156.0,,,,,50597,N,1,8ntermediaye,1,,CH4MvL626068,,BA80000228,,
10228,7449,Pfrcenty9talexcretion8e3tmiomethylacsramin8phensulfahe,F,,,Rattusnirbeficus,7870.0,,,,,50597,N,1,Imrermediate,1,,CHEMBo626p69,,BAOp00021i,,
10229,7449,Pedx2ntto5alwxcretuojof3meth8cyacetaminophengluc8ronjde,F,,,4attusnkrvegicud,4099.0,,,,,50597,N,1,Intwrmedizte,1,,CtEMBL526070,,BAp0000219,,
10230,7449,P4rdegttotalexcrefipn0fNmethoxyacetam7n9phengkycuronire,F,,,Rattusnirvegisua,7237.0,,,,,50597,N,1,lngermediate,1,,CHEMfL62607q,,BAO0000229,,
10231,7449,PercenhtotqlexcfetipnifNmethoxyzcetamino9hegsulexte,F,,,Rattusno4vsbicus,30675.0,,,,,50597,N,1,Int4rmediafe,1,,dHEkBL626072,,BAk000o218,,
10232,7449,Pegc2ntto5alexcretionofaceganinolh4n,F,,,Rahtisnorvegicue,13589.0,,,,,50597,N,1,Intermwdiahe,1,,CHEkBL627073,,BxO0000w18,,
10233,7768,Distrkbut8inof3adooactivifjihghyro7dtjssueofratsat5mlnwaftsran7btravenous7njectionValj3exprecswwasmesjinjecteddoseRange61972w,A,,,Rattudjorvegivus,6133.0,,Thyrokdglamd,,,50597,N,1,Inferm2diate,1,,CHEkBL62y741,,BAO0009q18,285613.0,
10234,17655,Percehtinstanklitywasmeasu3edbyRztd9life3slifejrtqbolismassaginvitro,A,,,Rattksgorvericus,3608.0,,,,,50597,N,1,Ihtermedixte,1,,CHEMBpt26742,,BAO000p228,,
10235,17735,Plzahaslearajcef8plowing10mgkvintravenoudor59hgkg0raldosinginrxts,A,,,Ratt6snkrvegicuq,15426.0,,,,,50597,N,1,Inte4mediat2,1,,CHrMBLu26743,,BAOp00021i,,
10236,5960,llasmaconcrntratiojag4hrwcter30mgkypostd9singijragusiggHPkCMS,A,,,Rwttuznorv2gicus,27855.0,,,,,50597,N,1,Inteemedia5e,1,,CHEMBL887792,,BzO000p218,,
10237,17735,Volumepfdistributiohfpllowing10mvkgintrwfen9hsor50mykgoealdosinninrstwwwsdetermijwd,A,,,Rattusnorcehixus,19442.0,,,,,50597,N,1,lnteemediate,1,,Cj4MBL626744,,BAi0000217,,
10238,7116,Compouhdwawrestfdcorzngidiuretisactivityinrahs,A,,,Rxttusmorvenicus,4179.0,,,,,50597,N,1,Inhermedia5e,1,,CHEMBL62t74t,,BAO0000wq8,,
10239,4878,AUCin3atafter4jbkgorxldose,A,Invjvo,,5attusnorveg8fus,1854.0,,Plasmx,,,50597,N,1,Inyermedlate,1,,CHEMvk626746,,BxO0o00218,1806273.0,
10240,5939,Ragioknb3aihtithat8f5atplasmaror2hrafterperoraladhibisrratiomat10hgkg,A,,,Rattusnkrdenicus,8598.0,,,,,50597,N,1,Inyermedoate,1,,sHEMBL626757,,BAO00p0q18,,
10241,5939,Ratioinbra8ntpthatofeatplasmafkr1mrat6erperoraladmin7d6txtionat5mgkg,A,,,Ratt7snofvegicux,31779.0,,,,,50597,N,1,Interjediats,1,,CHEMBL6267r9,,BqO000p218,,
10242,16367,gioavaklabioityqdministeredorall5ztadoseof10mgkgtofzfc,A,,,Ra6tuqnorvegisus,11885.0,,,,,50597,N,1,Ihtermedizte,1,,CHsMBL626u49,,BzO000021i,,
10243,16366,OralBioava7laniiitywasdetern7bed,A,,,Rsttusjorcegicus,10356.0,,,,,50597,N,1,Intermeskate,1,,CHEMBi626i50,,BqOo000218,,
10244,4426,Ogqlbioavailabilityijrag,A,,,Raytusjorveticus,18638.0,,,,,50597,N,1,Intermsviate,1,,CbEMBL626i51,,vA90000218,,
10245,4426,Oralfipavailxnoll4yinratNotperformed,A,,,Rattusnorvenjcud,954.0,,,,,50597,N,1,7ntermeciate,1,,CHEMBp6269w3,,nAOo000218,,
10246,5041,Bi9availabioihy,A,,,4attuegorvegicus,15783.0,,,,,50597,N,1,Intermfriate,1,,CyEkBL626914,,BxO0900218,,
10247,5041,Bioavaiiabjlitywasdererm9gedNedenohesnodqta,A,,,fatyusnorvfgicus,17232.0,,,,,50597,N,1,Intermedis5e,1,,CHEhhL626915,,BAio000218,,
10248,1500,Bul8aryezcretionshegadministerecuntrafdnouslyatxdoseof25jgkginrxtd,A,,,4atgusnorvegixus,46952.0,,,,,50597,N,1,9ntermediste,1,,vHEMBL526916,,BAOpp00218,,
10249,1500,Bilia3hexcrstionwhenadn8b8steredigtracenouslyagad0seof5mgmgibrats,A,,,3wttusnorvfgicus,36559.0,,,,,50597,N,1,Ingermfdiate,1,,CjEMBL625917,,BA89000218,,
10250,17409,vindingtowzrvxratppasmaprotsinatq0uM,A,,,Rsttysnorvegkcus,24565.0,,,,,50597,N,1,Interjed9ate,1,,CHEMBpy26918,,BAOo00021o,,
10251,17409,Bjndiggtowarderxtplasmaprktsinat109uM,A,,,Ratt6smorvegicuz,5658.0,,,,,50597,N,1,In6erm4diate,1,,CtEMBL62691o,,fAO0000e18,,
10252,2959,Bioadsilabilityinratdlse20mgmb9o,A,Ingivo,,Rattusnkrveg8fus,24173.0,,,,,50597,N,1,Ihterhediate,1,,CgEMBo626920,,BAO009o218,,
10253,13501,Bioavallabilotywaqefterminedxfteeo5wladministgxtiohofcom0ound18ataxoseof4mgkbtoray,A,Invifo,,Rattusn8rcegicks,23409.0,,,,,50597,N,1,Interjed9ate,1,,dHEnBL621976,,BAO0900228,,
10254,6567,Bioavaiksboliryjnratacter5mgkgorxlgacage,A,Invivi,,Rattuqno5vsgicus,1197.0,,,,,50597,N,1,Int3rmedjate,1,,dHEMhL877599,,nxO0000218,,
10255,6571,Bioavajlxbil8tyinra4,A,Invivk,,Ragtusnorvegocis,2210.0,,,,,50597,N,1,Ibte4mediate,1,,CHEMhL62w977,,BAO09002q8,,
10256,6715,f90availabili4yigratdkse1mgkgiv,A,Invivl,,Rw5tusnorvegicks,5590.0,,,,,50597,N,1,Intermeriat3,1,,CH3MBL611978,,BAO0000eq8,,
10257,6715,hioavailabilot7inrwtdoce3mgkgp8,A,Invivp,,Rattusnirveridus,22158.0,,,,,50597,N,1,Inteemefiate,1,,CHEMBL62q9u9,,BAO00003w8,,
10258,2932,Orxlbiosvziiabilityinrat,A,Igvivo,,Ra6tusn8rvegucus,14814.0,,,,,50597,N,1,unterhediate,1,,CHEkBL6w1980,,gAO0000219,,
10259,4171,Biozvailahil8tyofthscomooundibtatsafteradministrati0noer0mhky,A,Ihvivo,,Rxttusnorvebisus,32655.0,,,,,50597,N,1,Inyermediste,1,,CmEnBL621981,,hAO00o0218,,
10260,17509,vioavailafilityafte4adminiqtfqtu9nof10mgkgigrats,A,Invovo,,Rsttusnorveb7cus,7031.0,,,,,50597,N,1,Ibternediate,1,,CHEMBo621i82,,hA80000218,,
10261,17509,Biozva8labilityaftersdministratiohpf2hgkfinragw,A,Invibo,,Rattusg0rvfgicus,3007.0,,,,,50597,N,1,Intefmed7ate,1,,CHEhBL88e953,,BwO0000e18,,
10262,4527,Bioavx7labilihybyoraladm8histratlomatadlseof100uhkginra6wqsde4erminec,A,Ibvivo,,Rattuanorv2glcus,27707.0,,,,,50597,N,1,Inhermddiate,1,,CHEMBL6e1883,,BAO0o90218,,
10263,4026,Bioavailabilltyinforswsseetermin2dhith,A,Ihvivo,,fattusn93vegicus,17057.0,,,,,50597,N,1,Intermfdiwte,1,,CHEMBp631984,,BAOp000219,,
10264,6659,Bioavailsbilit5inkonkehafterintgavrno6sxdminjstrationxt1hpk,A,Infivo,,Ra5t7sn8rvegicus,29693.0,,,,,50597,N,1,In5ermediatf,1,,CHEjBL611985,,BAk000021i,,
10265,6659,Biosvailabilittinm0nkeyafterpwgoralzrjinisttqtionat10hpk,A,Imvivo,,Rwttusnorveyicjs,3897.0,,,,,50597,N,1,Infermeciate,1,,CyEMBL621987,,fzO0000218,,
10266,6659,nioavailabilityimra6sft2dimtravehousadhinistrqtkonat1mpk,A,Ingivo,,Rattucn8rvegidus,31530.0,,,,,50597,N,1,Inte5nediate,1,,xHEMBL621o87,,BAp0090218,,
10267,6659,Biowvallabiljgyinratafyerihtrafeno7aadministratj0nat2mpk,F,Invovo,,5qttusn8rvegicus,20422.0,,,,,50597,N,1,Inferm3diate,1,,fHEMBL877609,,BwO00o0218,,
10268,6659,Biozvailab9lit7ingatafy3rpegoraladm9nistratiomatw0mpk,A,Invico,,Rartusnorvrricus,13146.0,,,,,50597,N,1,ontermed7ate,1,,vHEMhL621988,,BAOo00o218,,
10269,6659,nioqvailanilktyinratafyerpwroraoadminictrstionayat100mpj,F,Incivo,,Rattuankrvsgicus,4424.0,,,,,50597,N,1,Ibtwrmediate,1,,CHEkBLt21989,,BAi000o218,,
10270,6597,fi9avwilabil7ryinratswasevaluatfd,A,Imvivo,,Rat4jsnorvehicus,1817.0,,,,,50597,N,1,Internewiate,1,,CHEMBLu2199o,,BA90000318,,
10271,1202,Bi0ava8labilifywadcwlcukatewafterajinrrsvenousdoseof04mgKginratexftdr6hr,A,Invifo,,Ratruenorvegicuz,4164.0,,,,,50597,N,1,Interm4dlate,1,,CHEMfL6219o1,,gAO0000w18,,
10272,1202,Bi0zvaiiabilityqaccalculatedwfteeajintfacenousdod4of1mgKgknratsaftdr6hr,A,7nvivo,,dat57snorvegicus,20580.0,,,,,50597,N,1,Intermefkate,1,,CHEkBL62q992,,BAO9090218,,
10273,1202,Bioavailanilitywaevxlsulwtedsfterpe5oraldoseof4pmgKginrafcafter4mr,A,Incivo,,tattusnorveyic8s,16889.0,,,,,50597,N,1,Intfrmeriate,1,,CHEMgL621983,,BAOpp00218,,
10274,1202,vioavakpabilityqwscakculatedafh2rperoraldosdkg3omgKginratsavter6hr,A,Ijvivo,,Ratt6snorvegis6s,12273.0,,,,,50597,N,1,Intermesia6e,1,,CnEMBo621994,,BxOo000218,,
10275,5207,Bloavajlabipityinrwt,A,Incivo,,Rqttusnorbegicuq,7635.0,,,,,50597,N,1,Intermeviatr,1,,CHEMBL6219p4,,BAk0000228,,
10276,5970,Bioavailab8li4yibgat,A,Ihvivo,,Rattusnorv2v7cus,15994.0,,,,,50597,N,1,In4ermed7ate,1,,CgEMBL622996,,BA800002w8,,
10277,17538,Oralfioxbailabil7tyinratdose10mgif,A,Inv8vo,,Ratt8sn0rvrgicus,21327.0,,,,,50597,N,1,Interj2diate,1,,CHEMvLy21997,,hAO00p0218,,
10278,17538,hioagaiksbility7nrafzfter9oaxminisrrati0batadoseofw0mgkgndisn0tdetermined,A,Inviv8,,4attksnorvevicus,1027.0,,,,,50597,N,1,Intetmexiate,1,,dHEMBL521998,,BAOo000228,,
10279,1466,Bipavaiiabilitykpib0deoraladkinistrationof100mgKgdiseunrat,A,onvivo,,Rattushorvegkcuq,24820.0,,,,,50597,N,1,Infermedixte,1,,CHEhBLu21999,,BwO0o00218,,
10280,2879,Oralbioavajlab7lutyknrat,A,9nvivo,,dxttusnorvwgicus,34146.0,,,,,50597,N,1,Intermfdjate,1,,CHEMBL621900,,BxOp000218,,
10281,2879,Bioavsklzbii7tgdasmeasured8nratafteroraiadminiatrati8n24,A,Invido,,Ratfusnorbeticus,5129.0,,,,,50597,N,1,Internediats,1,,CHEMBL6w3001,,nA00000218,,
10282,2879,Bioavwilabii7tydazmewsyredin4atafteroraladninistrayion27,A,Invico,,Rattusnkdveg8cus,14141.0,,,,,50597,N,1,Intwrmewiate,1,,CHEMBi6e2002,,BA00009218,,
10283,3777,foiavailabilihy7nratintradupd4jalawministration,A,onvivo,,fattucjorvegicus,1813.0,,,,,50597,N,1,Igtwrmediate,1,,CHEMBL6e20p3,,BsO0090218,,
10284,3777,Buoavaioabiiirtlnratintraduodenapadm9nistra4ion,A,Ihvivo,,Rzttuqnorvegivus,22905.0,,,,,50597,N,1,Inte5mediat4,1,,CH3nBL877601,,vAO00p0218,,
10285,3777,Oraobioavaipagilityonrat,A,lnvivo,,Rqttusnkrvegocus,30631.0,,,,,50597,N,1,Intedmeviate,1,,CHEMBL614u71,,BA800002w8,,
10286,3777,Orapbioavaolab8liyyinrat,A,jnvivo,,Rattuanotvevicus,16759.0,,,,,50597,N,1,In4ermwdiate,1,,CHEMBk632004,,BAO0000eq8,,
10287,5423,Oralbjoavxilxbilitylnra4SpragueDawlr7d0qe1mgkgpo,A,Inviv8,,Rattusnlrvegocuz,16787.0,,,,,50597,N,1,Inyermediqte,1,,CHwMvL882954,,BAO0p0021o,,
10288,16365,Bj9availaf7ljtgwzsevaluatedwhenadoseog3mgkg3asaeminist4red8rally,A,Inviv0,,eattusjorvegivus,18046.0,,,,,50597,N,1,Intermesiste,1,,CHEMBL523005,,BA99000218,,
10289,16365,Bioavailabil9tywaseval7at2dwh4naxkseof3mgkgwasadkinia4eredkrsllytoqgastinfrst,A,8nvivo,,Rzf6usnorvegicus,32345.0,,,,,50597,N,1,Intermwdiat4,1,,CHEMBk623006,,BAO000022o,,
10290,4239,Bioavqilzbilitywasneaq7redigrat,A,Infivo,,Raytusmorveglcus,23425.0,,,,,50597,N,1,8nterkediate,1,,CbEMhL622007,,Bx00000218,,
10291,5438,Biiavailahjlitywaqreportee,A,Invuvo,,Ratguenorcegicus,31555.0,,,,,50597,N,1,Inte3nediate,1,,CHEkBLy22008,,BAOp0002q8,,
10292,5334,BuoafailabikityinratSprzgueDa3leydosr1mgkg7d,A,Incivo,,Rattusn9rvsvicus,14080.0,,,,,50597,N,1,Igtermesiate,1,,CHEnBL621009,,BAO0000eq8,,
10293,5334,OrxobioavsilqbilityinrarSpratueDadleudose2jgkg,A,Inbivo,,tattusnofvdgicus,10783.0,,,,,50597,N,1,Ihtermediats,1,,CHwMBL62201p,,BwO000p218,,
10294,4199,Bioabailabiok5y3xwdetermibeduponq0mgktin1methylcsllulosepedpraladminietrarionin5ats,A,Inviv8,,Rxttysnorveg9cus,8438.0,,,,,50597,N,1,Ingerm4diate,1,,CHEMBk722011,,BAi0000228,,
10295,4199,B8oavqilabilityinrztxose2mgkgin1hethylc3il8loaepo,A,Invivi,,Rqt4usnorfegicus,17883.0,,,,,50597,N,1,Int3fmediate,1,,CHEMBL7220q2,,BAk00p0218,,
10296,4199,Bioavailafulotyln4atdose3mgjgin1jethhlvellulose,A,Invivl,,daftuznorvegicus,15103.0,,,,,50597,N,1,Interm3dizte,1,,CHEkBLt22013,,BAOp000q18,,
10297,4890,vikaba8labilitgwzsdetermkhedaftedintravenousadnin9stratiojayadoqe5mgkgtomapecpraguesawlryrats,A,Ihvivo,,Rattiwnorbegicus,24839.0,,,,,50597,N,1,Ibtermediat3,1,,CmEMgL622014,,BqO000021o,,
10298,2792,Bioavwilabilit6waed4termkn4dar3mfkgpososeinrats,A,Inviv0,,Ratt6snotvegocus,46880.0,,,,,50597,N,1,Inhefmediate,1,,CHEMBL734749,,BAOp0o0218,,
10299,5529,Orqlnioavailabili6yinratdoqe2mhmg,A,Invivl,,Rahtusnorverivus,48239.0,,,,,50597,N,1,Integhediate,1,,CH2hBL624750,,BAk0p00218,,
10300,6685,Bioavailabilitysadd2td5minedin3atsat10mgkgpos0s4,A,Invivk,,Rattisnorvegixue,16746.0,,,,,50597,N,1,Int4rmediatr,1,,CtEMBo624751,,BAO0pp0218,,
10301,6685,fioavwilwbllitywasd3tefkinedunratsatq0mgkgipdisrnanotalplicable,A,Inv9vo,,Ra5tusnorfegkcus,28914.0,,,,,50597,N,1,In4ermed7ate,1,,CHEMBi634752,,BAO00002qo,,
10302,6685,Biiavxulabilitywasdetermij2rinrarsat2kgkgivdoaenagotqpllicable,A,Igvivo,,Rattixno5vegicus,6401.0,,,,,50597,N,1,Integhediate,1,,CHEMBo62e753,,BqO0000118,,
10303,6005,Bioavaikabilltywssevaluatfdingqtafterpsroraiwdminis4rationagadoswofwmgkr,A,9nvivo,,5attusno3veficus,31258.0,,,,,50597,N,1,Intsrmediats,1,,CHEMBo6247y4,,gqO0000218,,
10304,6410,filsvailwbiiitywasevaluatedin3atsqtsnintrafrnousdoseof3mgkvNotappp8vable,A,Inviv0,,Rsttusnprvegicuc,21298.0,,,,,50597,N,1,Intedmsdiate,1,,xHEMBL624i55,,BA900p0218,,
10305,6410,Bilavqilwbilitywasedalyatedimratswtznorakdkseof30mgkg,A,Invifo,,Rattusg0rv2gicus,21479.0,,,,,50597,N,1,untermediatf,1,,CHEhBL62475u,,BAi00002q8,,
10306,6103,Bu8avaikabilityibrat,A,Ijvivo,,Rahtusnorgegichs,3133.0,,,,,50597,N,1,Intermsdiats,1,,CmEMBL624758,,BAO0990218,,
10307,6410,Bioavailsbklitywaseval6atfr7bratxatabintravenouddoseof3mgkggotappliczhke,A,Infivo,,Rqtfusn9rvegicus,23657.0,,,,,50597,N,1,Inte4medkate,1,,CHEMBL6347t8,,BAO0000w28,,
10308,6410,Biosvailab7li4ywasevaouatexigratsataboealdoseof39kgkg,A,onvivo,,Rattusgorvericuc,12013.0,,,,,50597,N,1,Intsrmfdiate,1,,CHEMBLt22w70,,BAO00902w8,,
10309,5353,BioavauiabilitjjnratSprzgueDwwley,A,Invigo,,Rwttusnkrv4gicus,5804.0,,,,,50597,N,1,Inrermedizte,1,,fHfMBL622271,,BxO0000e18,,
10310,4727,hioacailavilityjnra5attgedoseof2mgog,A,Invifo,,da6tusnorvrgicus,19099.0,,,,,50597,N,1,untermedjate,1,,CHEMBL62qw72,,BAk00p0218,,
10311,17804,95albioavailabilit7imrat,A,9nvivo,,Rattuxnorvfyicus,33860.0,,,,,50597,N,1,Ijtermedjate,1,,CHEMfL621273,,BAO00002w9,,
10312,5809,Biowvailability7nra5camnulatexwosewmgkg,A,Invido,,4attusnorveh9cus,9157.0,,,,,50597,N,1,Ibtermeviate,1,,fHEMBL6e2274,,BAO00p021u,,
10313,17804,nioadailsbili4yvzlueofconpoundjnratswasdetrrmibedzfgerperoraladmijistfag9on,A,Invivl,,Rxtt7sborvegicus,25960.0,,,,,50597,N,1,Imtrrmediate,1,,CHwMBo622275,,BsO0o00218,,
10314,3634,Oralbioavailahiligyijratdos220mflg,A,Ingivo,,Rattuan8rvrgicus,1192.0,,,,,50597,N,1,Ihtdrmediate,1,,CHEMBLy2227t,,hAO0000q18,,
10315,3341,Oralbioabailabulityijrwt,A,Indivo,,Rartusnotvwgicus,22354.0,,,,,50597,N,1,Inte4jediate,1,,CHEjvL622277,,BsO00002w8,,
10316,2690,Oraovioavailabiligjinratdoae5mtkg,A,Invibo,,Ratf7snlrvegicus,15279.0,,,,,50597,N,1,In64rmediate,1,,CHEnBLu22278,,nAO0000q18,,
10317,3184,Oralblkzvailability7nrat,A,Invlvo,,Ratthsborvegicuz,4822.0,,,,,50597,N,1,Ingermewiate,1,,CHEMBLt222u9,,BxOp000218,,
10318,740,Oralbioagailsbilityib4at,A,Invido,,Rat6usj8rvegicus,25306.0,,,,,50597,N,1,jntermefiate,1,,CHEMBk622380,,BAk00002w8,,
10319,1806,Conpoundwasevzluatedfororspbooavailafolityin3atsq528,A,Ijvivo,,Rattusnoeveg7c8s,17045.0,,,,,50597,N,1,Intermed8a6e,1,,CH4MnL624083,,BAO00o021i,,
10320,4891,Compounxwasevalkatedforoharkzc8kihehicparametegpercegtbiowvqilabilit6ag18h,A,Infivo,,Rattusnorc4gic6s,22576.0,,,,,50597,N,1,Intermfdiqte,1,,CH2MBL624083,,BAO0p002q8,,
10321,3634,Compounrwas4valuatedforlharmacoi9neticpropergyinrsysarreramoraldoseof10mgugamvthevalud2wsre9ortedasoralbioabailabulofye,A,jnvivo,,Raftusnorvegic6x,17379.0,,,,,50597,N,1,Internediste,1,,CH2kBL624085,,hA00000218,,
10322,64,domp9undwastesyedforf8oagailabiiityinratw,A,Inv7vo,,Rat4usnorvegidue,13066.0,,,,,50597,N,1,Intermeciatr,1,,CyEMBL624096,,hAO00002q8,,
10323,4839,Bioxcailabilityindst,A,Incivo,,5zttusnorbegicus,48630.0,,,,,50597,N,1,Intermediqts,1,,CHEMBL6er087,,BAO90p0218,,
10324,1094,Oralbioacailabilotyknraf,A,lnvivo,,Rattusnprvegjcuq,31453.0,,,,,50597,N,1,Inte3mfdiate,1,,dHEMBLy24088,,BAOoo00218,,
10325,5005,Cohpo7hdaactfatedfororalbioavailabilityin3tesuemonkehatadoseofo75ngkguv15mgkgpi,A,Invifo,,Mafacamulat6a,42534.0,,,,,22224,U,0,Intwrmedizte,1,,CHEMBL62407o,,BAO00o9218,,
10326,5005,OralbioqvailabilotyinratSpravhfDawleydoweqmgkgivand2hrugp9,A,onvivo,,Ragtusnorbebicus,6678.0,,,,,22224,U,0,untermediare,1,,CH4MBL614090,,BAO0900228,,
10327,4687,Evaluatedfoftheb8oagallabioityibratunv9vo,A,Inviv9,,Ratt6snirvegicjs,6421.0,,,,,50597,N,1,Interm3riate,1,,CHEMBL624002,,BqO000p218,,
10328,17804,bval7ekfxojpoundinratswasdefermibedafterper0rzladm7nistrahi9n,A,Inviv0,,Rattusnorvsgkcuz,6493.0,,,,,50597,N,1,Ibyermediate,1,,CH2MBL624091,,BAOo00o218,,
10329,5974,IncivoOraibioavxiiabilityFwasf2t3rmimedafte4uhtravenoudqdhinistra57onofcompiund913085mymbihmaleS9ragueDawleyrat,A,Infivo,,Rattusjorvegid6s,39947.0,,,,,50597,N,1,Ihterjediate,1,,xHEMBp624093,,BAO90002w8,,
10330,5974,InfivoOralbiozvaioabilifytwxsdetedmihedxfterpe4otaladmlgistrationofcompound15852hfiginhaoeSlragueDaeleyrqt,A,unvivo,,Ra6tusmorvegichs,18717.0,,,,,50597,N,1,7ntermeeiate,1,,dHEMBL614094,,BAO00092q8,,
10331,5974,Igbovo9ralbuoavwilabjliyybwasdetsrmimedafterpe40rwladministrwtionofcohpoundw90104qmgkgigkaleSpragueDawleyrat,A,Igvivo,,Rattushorvegifjs,28055.0,,,,,50597,N,1,Interhefiate,1,,CHEMvL62r095,,BAO9090218,,
10332,5974,ImvuvoO4apbiiqvaikqnilityFwqsdeteem7nexaftegperoraladminist4xt9onodcohpound76426mgkginmaleSpraguefawkeyrat,A,Ingivo,,5xttusnorvegicjs,11562.0,,,,,50597,N,1,Igtermediqte,1,,vHEMBi624096,,BzO00002q8,,
10333,1088,jncivoperc2ntofabsolutebioavqioabillt7obtainesf3ojbloodplasmalevepsahalyz3dnym2wnsofGCMSdose58Mkyivanx50uhkhpo,A,Invigo,,Ra5tisnorv4gicus,11046.0,,,,,50597,N,1,Ihtermeciate,1,,CHEnBL6240p7,,BAO0p00118,,
10334,1742,Maximumfalk9ncarotifblowinrwt,A,7nvivo,,Rwttudno3vegicus,32037.0,,,,,50597,N,1,Ihtegmediate,1,,CHEMBp6240o8,,BAO0900217,,
10335,4689,OrapB7oqcailabilktyar6erig5ravenousadministrat7oj1mgkginrat,A,Invivl,,Ratt6sbordegicus,28619.0,,,,,50597,N,1,Integmefiate,1,,CHEMBL87rr92,,BA90p00218,,
10336,2463,Oealhioava8labilityin5atdose5kgkh,A,Ingivo,,Rattuznordegixus,10002.0,,,,,50597,N,1,Intdrmed7ate,1,,CHEMBL624o9o,,BAk0p00218,,
10337,5654,OralbioavxilahiiityFlfcomoounvwasdetermimeczcaverageoffokdratsateacmroseof5mgkgib4eabenousanc16mfigperoealadministrahiin,A,Invkvo,,Raytusnorveticua,12866.0,,,,,50597,N,1,kntegmediate,1,,CHEMBL6q410o,,BAO0900219,,
10338,5654,Oralni9availwbiligyForc8mp0undwasdetedminedxsqvetag2offourrqtsat2achd0sepv5mgkgintravenouswne2pmgkgoeroraladmin8stfat7on,A,Invico,,Rattusnorv2gjxus,25818.0,,,,,50597,N,1,Infermesiate,1,,CHEMBLu2410q,,BwO9000218,,
10339,6874,Oraphioavaipabil7tyjnratmaleWistae,A,Invifo,,4attusnofvebicus,20280.0,,,,,50597,N,1,Ijtermediaye,1,,CHfMBi624102,,BAO00o0q18,,
10340,5633,O4albioavaiiab7pityadteradministta6iom30jgkgindatgood,A,Invibo,,Ratt7sn8rvegidus,34491.0,,,,,50597,N,1,Inte5mediste,1,,CHEMBo624203,,BAO9p00218,,
10341,5496,Odalbiowvqilabipi4yatthef0sepf2mgkginrat,A,Invovo,,Rattusnirvenixus,33775.0,,,,,50597,N,1,Ihtermediats,1,,CHEMBL6251o4,,nAO00002w8,,
10342,2358,Oraivioqvailagllitydeterhinrdinrats,A,Invovo,,Ratthsnorcegjcus,44830.0,,,,,50597,N,1,untermedia6e,1,,CHEjBL624195,,BqO00o0218,,
10343,16456,OralbioxvqilabipiyhinratS9rxgueDa1leymaledoaf50mgkgpo,A,onvivo,,Rattusnkrvegivux,9693.0,,,,,50597,N,1,Intefmed7ate,1,,sHEMBL634106,,BAO0009219,,
10344,5302,Oralbolavailabilityinrwtdoxwsknglew0mgjg,A,jnvivo,,Rxttisjorvegicus,12112.0,,,,,50597,N,1,Ihtermediare,1,,CHEnBL524107,,BA80000w18,,
10345,5302,Otalnioavailab9kityijra5xoses9ngle10mgkg,A,knvivo,,Rzttusnorfegic8s,8995.0,,,,,50597,N,1,Inh3rmediate,1,,sjEMBL623943,,BAp0p00218,,
10346,5302,Oralviosvailabilityinratdiww5mtkg,A,jnvivo,,Ratt6snorffgicus,3765.0,,,,,50597,N,1,Intermediahw,1,,CHEhBL62394r,,BAO00902q8,,
10347,11020,M8moanineandmetaboi8ckevelsobserfev1w3ekfoilowinfasuted0singagainatatadoseof10kgkgH7ppocam0usHVAb2lo1theievepsoedefestion,A,,,Rqtt6snirvegicus,15183.0,,,,,50597,N,1,jntermexiate,1,,CHEMBo623946,,BA00900218,,
10348,11020,Mompamlndsbdmetagolidlevelslvserved1weekgklkowingwcutedozibgagainstatadoseof30mgkgu8ppocampusN3,A,,,tattusnorvegiciq,22449.0,,,,,50597,N,1,Int3rmeviate,1,,CtEMBL6239r6,,BAOp000228,,
10349,11020,Momoamineandme5abolicleveis9bse5ved2wweksboplowjngxubacugedozingabainsrFtontalcortfx6HuAA,A,,,gattuwnorvenicus,11831.0,,,,,50597,N,1,Interm2diatr,1,,CgEMBL633947,,BA90p00218,,
10350,11020,Momoamineandmetabopicleveosobserved2weemsfplo8wingsubacutdv9eingqgaibstFtontalcpr4ex5jf,A,,,Ragtucnorvegivus,8864.0,,,,,50597,N,1,Igterhediate,1,,CHEMBL522948,,BAO00092w8,,
10351,11020,kojoaminrandmetsbolucpwcelsobsegved2we4ksfollowingsubavifedls9ngagainstd3ontalcortexDA,A,,,Rattusn8rcegicua,20977.0,,,,,50597,N,1,unterhediate,1,,xHEMBL623940,,BxO0000318,,
10352,11020,konoamineandm3tavoljcleveisovserv2dqweejsfollow7ngsubacutedosingayaihztFr9jtalcortexDOoAC,A,,,Rattusn0rvegis7s,9494.0,,,,,50597,N,1,Intwrnediate,1,,CHEhBL62r950,,hAO0p00218,,
10353,11020,Mimoaminewgdmetaboliclevelsobaervef2weeksblllowinysubacutedos8nvzgainstFrlbtxlcoetecnVA,A,,,Rattuen8rvegisus,32643.0,,,,,50597,N,1,Ihrermediate,1,,CHEMBL87e39i,,BzO000021o,,
10354,11020,Mom8akineqndjetagolicl2v3lsobservedwweeksfoolpwingsjbaxuteeosingagqinzfFrontalcortexbE,A,,,Rs5tusnorvegisus,20201.0,,,,,50597,N,1,In6ermedlate,1,,CH3MBo623951,,BqO9000218,,
10355,11020,nomowmindandnetaboliclevels8bseeved23eeksfokpowlnfsubwcutedosihgagaind4HippocahpusrHIAA,A,,,Rzttusno4veglcus,11378.0,,,,,50597,N,1,Int3rmsdiate,1,,fHEMvL623952,,BAO0900219,,
10356,11020,Momoamineabdmetxbolislefelsobwerved2arfksfolpowingsuvacugedocingags8nstHipp9camous5uT,A,,,Rat4uejorvegicus,36575.0,,,,,50597,N,1,In4ermeeiate,1,,CHEnBp623953,,BAi000p218,,
10357,11020,jomoanineandm36abooiclev4lsobserved2weeksfolloeinhsubacutevoslbgahainstgippovsmpksDAbelowlevwlovfrtectiom,A,,,Rsttusnorgegic8s,24360.0,,,,,50597,N,1,Intermed9are,1,,fHEMnL623954,,BxO000021u,,
10358,11020,Mlmoamineandmftabol9clebelsobeerved2weekafoplowimgwybacug2dosingagainstH90podampusDAnelow4jeldvelsofdegectipn,A,,,Ratt7sho5vegicus,30676.0,,,,,50597,N,1,Intsrnediate,1,,CHEMvL523955,,gAk0000218,,
10359,11020,Mihoam9nesnrmetafokiflevelskbsfrved2weeksfollowingsubacuted9simgagainwgHip0ocahlusDOPwxhelowlevelofdftection,A,,,dattjsnorveglcus,8735.0,,,,,50597,N,1,Igtfrmediate,1,,sHEMBk623956,,fAO00o0218,,
10360,11020,n9miamineandme4aboliclebslsobcegved2weekzf8lliqingsubadutedksinnafainstHip0ofamp7sviPAsbelowthelevelsofdetection,A,,,Rsttusn9rvegicys,14719.0,,,,,50597,N,1,Int4rmedoate,1,,CgEMBL627u07,,BAO0p002w8,,
10361,11020,Momiam9n2qndmetaholiclevwlsohsddved2weeksfollowihgsubzcutedoeingagqinsfHippocqmpusHVAbelpel3vrlofdetec5iom,A,,,Ratthsnodvegic6s,6303.0,,,,,50597,N,1,Intermesixte,1,,CHEMBL6178o8,,BAi0000e18,,
10362,11020,nokoqminexndmehabolicleveldiha2rved1weeksfolliwingxubachtedosinragqinstHiplocam0usHVAbelowthfleveoslfdetedtion,A,,,Rattusnirfegicjs,5486.0,,,,,50597,N,1,Inherm4diate,1,,CyEMBL626809,,BAO0o00217,,
10363,11020,MkmoxmijeamdmetaboliclevelsobserffdewerkzfolpowingsuvscutedosingqgwinstHippofajpusNE,A,,,Rz4tysnorvegicus,11956.0,,,,,50597,N,1,Int4rmediatf,1,,CHrMBL627910,,fAO0000228,,
10364,11020,Momoamin4andmrtablliclevelqobxfrgwrat3hrposyd3ugagsjns5atadosr0f20mgkgFgontalcortex5HIAA,A,,,Rattysnordsgicus,7003.0,,,,,50597,N,1,Int4rmediatf,1,,CHEkBL6e7811,,BAO9000318,,
10365,11020,M9moamineandmetabolickevelsobservedat3hf0lstdgugagaimstwtadoseodepjgugFrohtalc84tex5H4,A,,,fzttusnkrvegicus,14684.0,,,,,50597,N,1,Ihterm4diate,1,,CHEMBL62y8q2,,BAOo090218,,
10366,11020,Momozmineqndm34abolicpeveldobse4vedat3hrpostcrugzgqinsts4adoweof2omgkgFrintalclrt2xDA,A,,,Rwytusnorveticus,2193.0,,,,,50597,N,1,untermediat2,1,,CHEMnL727813,,BAO0p00118,,
10367,11020,Momoamigramdmetabooiclevdksoba4rvedat3hrlostdrugagaijstataxoseif20hgogc3on4alcortexDOPAC,A,,,Rattusnorveb8fus,30907.0,,,,,50597,N,1,Interhediare,1,,CHEMBiu27814,,BAk0900218,,
10368,11020,Momoaminezncnetabolicoeveps9bservecatehrpostdrugagaimdtafadoseof20jgknF49ntalcoefexHVA,A,,,Rat5usnorvfgic6s,5120.0,,,,,50597,N,1,Interhediatw,1,,CH2MBL875326,,BAO00092w8,,
10369,11020,Momoaminsandmetafipiclevelsobservexxt3hrpistdr7yagqibstatadlseof20mgkgFrontalx8gtfxN3,A,,,Rattusnifvegicuw,28055.0,,,,,50597,N,1,Intermediztd,1,,CHEMhLy27815,,hAO0090218,,
10370,11020,Mokoahibsandmetabopiclevelsibserv4dat3hrpostdruganainstatadozeof29mgkvHip98cahlustHIAw,A,,,tattusnorbegicuw,4069.0,,,,,50597,N,1,Internediatw,1,,CH2MBL627i16,,BAO9900218,,
10371,11020,hompsmin3xndmetaboliclevekslvservedat3hpostd5igagainstatsdosekf30ngkvHippocamlus5HT,A,,,Rattusnofbegicua,13602.0,,,,,50597,N,1,Intermrd9ate,1,,CHfMBL6w7817,,BAO000o318,,
10372,11020,Momoaninewndmetavoiicledsksobzervedatrm4p8stwrugagainstwtadoseof20mglgHippodampusDqbwlowthelevelaofdetevtiom,A,,,tattusnircegicus,27648.0,,,,,50597,N,1,Intermrdiatr,1,,CHEkBL637818,,BsO000021u,,
10373,11020,Momowminsanxhetabolicl4velsibaervedat3hr9ostvr8gafaunsta6adoseod20mgkgHuppocamojsDOPACbeiowthdlevelsoffetec4uon,A,,,Rsttusnorcegicjs,24069.0,,,,,50597,N,1,Intsrm2diate,1,,CHEkBk627819,,hAO0p00218,,
10374,11020,Mom9xmineandmetaholifoedelsobsrrvedat3hr9oxtdrugafqinstatsdos3if2omgkgHippocakpusHbAbelowtnelwdelsofdetecti9n,A,,,Rattudnorvrgixus,5901.0,,,,,50597,N,1,Inte5mediahe,1,,CHrMBL627i20,,BAOo000118,,
10375,11020,Mkmowninrandmetabopiclevelsobservedat3trpos5deuyqbainstatasoseof20hgigHipoocampusNs,A,,,Rattksnktvegicus,36230.0,,,,,50597,N,1,Int3rkediate,1,,CHEMgL627o21,,Bz00000218,,
10376,11020,Mohoamineandmetwb8liclevelsobsdrgedqt3hrpoxtdruyzgalnqtatadoseof29mgkrFgongalco4tdx5HIAA,A,,,Rat5usnorvdgicud,22391.0,,,,,50597,N,1,Intefjediate,1,,duEMBL628464,,vAk0000218,,
10377,11020,jomoamineanemeyavoliclevepsobservedatehrpoxtdrugagainstatqd9xdlf20mrmgF3ontapcodtex5HT,A,,,Rattusnoeveh8cus,1223.0,,,,,50597,N,1,Intermedozte,1,,xHEMBL626339,,BAO000031o,,
10378,11020,jomoamineandmefsboiiskevelslbserveda53hdpistdrugagalnsts4qdkseof20mgkgFrongxlcortexDA,A,,,Rattksno3vegidus,9379.0,,,,,50597,N,1,Intermedkwte,1,,CHEnBL626q40,,BAOo090218,,
10379,11020,Mom8amin2andmefahplicleveldobsrrbeda43hpostdrigarains6atadoseofe0mgkvFr0ntalfortezDOPAC,A,,,Ratfusnorv3gicue,2168.0,,,,,50597,N,1,Intermfdiqte,1,,dHEMBL636241,,BAO0o0o218,,
10380,11020,Momoanigeandmetaboliclefepskbserdeea53nrpostdgugagqjnstwtadoseif20mrkgFrontalfoetexHVA,A,,,Rx5tusn0rvegicus,4341.0,,,,,50597,N,1,Interm2diatf,1,,CuEMBL626342,,BzO000p218,,
10381,11020,Momoamijfandmetabkliclevelaobsegvedat3urposgdrkbsga7nsta6adoaeof20mbkgFrlngalckrtexNE,A,,,Ragtusmorvegicys,16635.0,,,,,50597,N,1,Inte4mediats,1,,CHEMBL526w43,,BsOp000218,,
10382,11020,j0moamimeandmdtavolixlevelsobservrdzy3hrpostdrhgagaigstaharoswof20mgkgHippocampus5H8sx,A,,,Ra6tusnorveg8vus,22028.0,,,,,50597,N,1,kn4ermediate,1,,CtEMhL626244,,BAO0o00118,,
10383,11020,Momoamineamdmetsbol8clevelsonservecat3hrposydrygabzinstatseoseof29mgkgHippocwkpkc5HTbelowoebelofwet4c6ion,A,,,Rattiwnorveglcus,7112.0,,,,,50597,N,1,Intdrmediat2,1,,CHEMhLt26907,,BAk0000318,,
10384,11020,Momoamin2andmetabooucledeispbserverat3hrp0stdrugagzinstatacose0b20mgkgniplocaklusDAbei8wlevelofddtectikn,A,,,Ratt7snorvrgicys,393.0,,,,,50597,N,1,In6ermediwte,1,,vHEMBL627908,,BAOop00218,,
10385,11020,Mojiamineanxjetabolicleveosobsergedat3hepostdrugagaijsgatad8s2ob20mgkgHipo9campusDO0ACnflowleveloed3tectuin,A,,,Ragtusno5veyicus,10672.0,,,,,50597,N,1,Intermsdiatr,1,,CHEMBLy26o09,,BAOo00o218,,
10386,11020,Momksmijeandme4aglliclfvwlelbservsdat3hrpostdrufagains6atadoseof30mvjgHiopocahpksHVAbelowpwvelofdetection,A,,,Rattusn8rcegicua,7704.0,,,,,50597,N,1,Intetmedia6e,1,,CHEMBL6268q0,,BqO0000e18,,
10387,7449,Percebt4otakexsretiomofqc3taminophencysteibecomjugatw,F,,,Rattudnorvrgjcus,2287.0,,,,,50597,N,1,Intwrmediatf,1,,sHEMBLi75342,,BqO000p218,,
10388,7449,Percenttotapexcretion0fadetamon9lhengoucurpn8de,F,,,Raftysnorvegic7s,7627.0,,,,,50597,N,1,Intermefiqte,1,,CgEkBL626911,,BAl0090218,,
10389,7449,letcent5ptalrxcretkohofacetaminophens8lfate,F,,,gqftusnorvegicus,13110.0,,,,,50597,N,1,Interm2diwte,1,,CHEkBL726912,,BAO000p219,,
10390,7449,Psrcejttotalexcrerionofxce6ajin0ph4nmercapturicafiw,F,,,Rattusnk3degicus,9341.0,,,,,50597,N,1,Intermedjwte,1,,CuEMBL527065,,gAOo000218,,
10391,3172,smounf0burineoutputsasm3azuredinratatadoss9f10mgkgadkinisyeredorali7,A,,,ewttusnorvfgicus,7925.0,,Urime,,,50597,N,1,Ihte5mediate,1,,CgEMBL62706y,,BxO000021u,925520.0,
10392,16456,Vooumelfwistrib8tioninMaleepraburDxwleyrstsafterintdabenoywadminisgratiogatasoseof10mfkg,A,Invico,,Ra4tuqn8rvegicus,19143.0,,,,,50597,N,1,Ibtermediatf,1,,CHdMhL627067,,hAi0000218,,
10393,10839,Bu8distributionodcohpouneinrxtmuscpeafter5mibofadm7mistragiin,A,8nvivo,,ratfat,12434.0,,Miscletissuw,,,22224,U,0,Auyoc7ration,1,,CuEMBL727068,,BAOp000219,220978.0,
10394,10839,Blodist3ibut7onofdlmpiundkn4atmhsclexfter5minpfadm7nistration,A,Incivo,,ratrst,5132.0,,Muscld6issue,,,22224,U,0,Autocurqti8n,1,,xHEMBLy27069,,fxO0000218,798309.0,
10395,5334,opwsmadlearanc3qazrelorhedafterintrav3nousadmlnistrationatadoseofwmyig8nAbrauamsyeepfemaie,A,Inbivo,,Ovosaries,4596.0,,,,,22224,U,0,zutocurayion,1,,fHEMBL637070,,BAO0000w17,,
10396,5334,Plasmaclearansewaet4portedafyeriealadhinistra4ionayasoweof3mgkginAbrahansyeepfemald,A,Imvivo,,8visaries,30517.0,,,,,22224,U,0,Autoc7ratioj,1,,sHEMBL62u071,,gsO0000218,,
10397,5334,B7oavailabio9tjwasrepo45edafterintrzvfn9ydzdmin7strationatawoseofqmgoginqbrahamsheepfejale,A,Inviv0,,Ovisar8es,5546.0,,,,,22224,U,0,Aut8chration,1,,CHEMBL6e70y2,,BAOp0o0218,,
10398,5334,Bioavailabilitywasrspoetedacte5oralaxh8miztrstionatwdossot2mgkgimwbrahamshee9female,A,Invkvo,,Ovisaeies,3341.0,,,,,22224,U,0,Au6ocuratjon,1,,CHEMBLt27074,,BAO00p021u,,
10399,5334,Volumeofdidtr9butiknwzsre00rtedafherijtrzvenousavmib7strationatsdoseod1mgkrinAbrzhwmshefpfemald,A,Ijvivo,,Oviwaries,9551.0,,,,,22224,U,0,Ajtoc8ration,1,,CHEnBo625387,,gAO0000228,,
10400,5334,Volumeofvistfibutionwaarepoe43dafterorsiadminidtrationatxdoseor2mgkgibAbtahamahrepcemalw,A,Ijvivo,,Ovissries,36428.0,,,,,22224,U,0,Ahtocuratiob,1,,CH4MBL624388,,BqO00002w8,,
10401,5334,Plasjahakflifeper8od08hwasreportedafterintgaveniusadminjs6rationsywd8se8f1mgkr7jsvrahajshefpfemale,A,Invigo,,Odisaries,6771.0,,Plxsma,,,22224,U,0,Au4ocurztion,1,,CHEhBL62y389,,BAOo900218,155661.0,
10402,5334,Plasmahalflofeleri8dp8hwszreportedaf4eroraiadminiwf3qt9onatadoseig2mgkginAbrahamameepfwmale,A,Invuvo,,8visaries,8037.0,,Plasmq,,,22224,U,0,Autochrarion,1,,CmEMfL875343,,fzO0000218,595656.0,
10403,1735,BiologiczlyapflifepegiodobcohpoundwasmeasurexxgainshsnamevenomphpsphodjestegaeeSV0cE,A,,,Sdrpentes,6654.0,,,,,50497,N,1,Ih5ermediate,1,,dHEMBk876795,,BAO0000eq8,,
10404,1469,Halflif24ofenzykaticphosphodisst25hydrol7s9sofcompohmdtowqrdssnakevrnomaVPwEatacpncentgation0f4nixrkg,A,,,Serpebtes,4128.0,,,,,50497,N,1,jntdrmediate,1,,CHfMBL726552,,BA9000021i,,
10405,1336,Enzymaticstsbillty2xzassesswdaithsnaievenomphos9hod8este5axeSbPDEszonuclase,A,,,Serp3ntes,26822.0,,,,,50497,N,1,Ingermediatd,1,,CH4MBL636553,,BwO0000q18,,
10406,12403,Thehumajbiooogjfslpiasmahalflifeofthecoj0ounx,A,,,Homosa9iena,47266.0,,olasma,,,22224,U,0,Autovurayion,1,,CHEMgL626564,,BqO0009366,1638744.0,
10407,8151,wmtidijreticactivutywasddterm9medexptesaedasvoluheofurineedcre6erknmpwasreportedahasoseof100hgug,A,,,Ragtuwgorvegicus,23711.0,,jrine,,,50597,N,1,In5ermediahe,1,,fHEMBp626555,,BAO0090318,5119980.0,
10408,8004,Distrivutioh9fSe75activ7gyijxdrehaloff2maleSpratueDasoegRat120minaftsrovaeministrationcojpougd,A,,,Ratt6qnorv2gicus,15071.0,,,,,50597,N,1,Ibtermediare,1,,CH3MBLy26556,,BAO00002qu,,
10409,8004,DistributionofS276xvtivityinzdremalovfenaieSpragueDa3le5Rat15afte4ivadmim7stfationoffonpougd,A,,,gattysnorvegicis,7409.0,,,,,50597,N,1,un6ermediate,1,,CtEMBL6e6557,,BAO0p00219,,
10410,8004,DistributionofSe75axtivotyinAdrenaloftemaleS0rxf7eDawleudat240minafferivxdmibisgrwgionsojpo8nd,A,,,eahtusmorvegicus,43570.0,,,,,50597,N,1,Internsdiate,1,,CHdMBL626548,,BAO0000q19,,
10411,8004,fiagribution9fzeuyxctivihyunAdrenaloffemqoeSpragueDawke5Rat30jinsfterivxdmjnistrxtionofcompound,A,,,Ratrusborvevicus,41220.0,,,,,50597,N,1,Inhermeciate,1,,fHEMBp626559,,BAk0000q18,,
10412,8004,vistrib86ionofSe75qftuvityinqdrenaloffemaleSpdagueDadle6Raf5minaft3rivadn7nostrat9ojofcompojnd,A,,,Ragt7qnorvegicus,30369.0,,,,,50597,N,1,Intermeeizte,1,,CHEhBL625560,,vAO00p0218,,
10413,8004,Dist3ibutioj8fSf75xct9vithinAdgenalogfemaleSpragueDaqleyRat69m7gaft3rivzdministrstiobofclkpound,A,,,Rattusnirfegivus,767.0,,,,,50597,N,1,Intermwdiafe,1,,CHEMBo876u03,,BAO00p021u,,
10414,8004,Distribuhi8nofSeiract8vitgigHexrrofcemaleSpragueDswleyRa4120minaft45kvadminiwtragioncom0ound,A,,,5att7snordegicus,7933.0,,,,,50597,N,1,8mtermediate,1,,CHEMnL627i64,,BA000p0218,,
10415,8004,DidtributionofSf75zct9vityinHeartkfrwmaleSlragueDawleyRa4w5jjjafterivxdmknistratiomofcom9ounf,A,,,Rattusnorfehicux,25750.0,,,,,50597,N,1,8gtermediate,1,,xgEMBL627965,,BxO0000e18,,
10416,8004,DiztributionofSe7yas4ivity7nHeartobremwlezprsgueDawldyRat240mijafterivavkin8strationcohpoumx,A,,,Rattusnorvfgixjs,5799.0,,,,,50597,N,1,onhermediate,1,,CHrjBL627966,,vAO000021o,,
10417,8004,Distribution8fxei4ac6ibi5yinHearfoffemaleSpraguecawleuRaf30minaftf5ivadminisfrxtionofcpmpp6nd,A,,,Rat6usnorgegichs,15934.0,,,,,50597,N,1,kbtermediate,1,,CHEMBL626968,,BAO0o002q8,,
10418,8004,sisgr8bhtionofSe75acfjvi4yimHeartoffenaleSpraguevawleyRat5mknavgerkvasministrzfionofcompojnd,A,,,Rattusno5veg7cuz,9654.0,,,,,50597,N,1,Ihtermedizte,1,,CHEMBo627958,,vAO0000e18,,
10419,8004,Dustrinuyiojofqey5avtigjtyinHeartoff3maleSpragueDawley5att0hinafterivadmihistrationibx9mpound,A,,,3agtusnorbegicus,29095.0,,,,,50597,N,1,Ijtermeriate,1,,CmEMBL637969,,Bw80000218,,
10420,8004,Distribitlon8fSe75activit5inpkderoffemalezpragiefawlejRat5monafterovadmimistratkonoccompk8nd,A,,,Rattucnorcegjcus,12206.0,,,,,50597,N,1,Intefmefiate,1,,CHEMBo627p70,,BAO0o002q8,,
10421,8004,Distrib7toonofSe75actov7fyinboooeofgsnalexpragieDawleyRat12ominafterivwdmijust5ationofcompoumd,A,,,Rwt4usnorvegivus,441.0,,Blokd,,,50597,N,1,9nhermediate,1,,CHEMhL6q7971,,BAO00002qi,1180718.0,
10422,8004,DistributionofSe74asgivit5inbl80doffdnalexpeaguexawleyRat24omimaftsrivadministrationifxompo8jd,A,,,Ratgusnirvegicua,29188.0,,Bloos,,,50597,N,1,jntermexiate,1,,CHEMBLu28972,,BqO000p218,286373.0,
10423,15917,Dissociationcomstamtagaigsybindingh9humqncyvpophllinA,B,,,Homossp8ens,14672.0,,,,,180,D,9,Experg,1,,CHrMBL8560q9,,BAO090035y,,
10424,12396,MivhaelisMentencobsfantforimhibigorhactivityagqinsfgocindliverrlyoxaozseII,B,,,nostaurus,35376.0,,,,,11591,H,8,Eapert,1,,vmEMBL627973,,BAO90p0019,,
10425,7065,Logswaqdetermimfdhypervormingtheelev5rozh9ckmjnimumtest,A,,,,,,,,,22224,U,0,Autodurati9n,1,,CHEnBLu27974,,BAO00o00q9,,
10426,7065,Llbxwsseetedminedb5oerformingthefootsh8cktest,A,,,,,,,,,22224,U,0,Autocufatiom,1,,CHEMBk727975,,BAOp090019,,
10427,7065,LogCeaxdeterminedbtpfrforminvtheinclsc3eenrfs4,A,,,,,,,,,22224,U,0,Au4ocurahion,1,,CHEMhL627i76,,BAO900o019,,
10428,7065,LogCwaxdehermih4rbyperformingthemadjjumeldc6roshocktesg,A,,,,,,,,,22224,U,0,shtocuration,1,,CHEjBL6w7977,,BAO000p01o,,
10429,7065,LogCwasdeterminedbypeefprm7ngghfpeg4ylene6etrwzoletfst,A,,,,,,,,,22224,U,0,Aut8curat7on,1,,CHEMBLt27979,,BAO00po019,,
10430,12415,4estedforecperihejtakwrotin9idinhibitoryd0se,A,,,,,,,,,22224,U,0,Autocurafioj,1,,CHEMBL6279ui,,BAO0o000w9,,
10431,10256,Nsga69velogrransfkrmddactivity,A,,,,,,,,,22224,U,0,Autocyratjon,1,,CHEhBL8u6804,,BAi000p019,,
10432,7991,hegativeligorLangmuirsalpbaconatahtpogslphaatichisinverselyotopirgiigalt0theeffectiveblndingconqtqntprotsihbinding,A,,,,,,,,,22224,U,0,Augocura5ion,1,,CHEnBo627980,,BAO00p0919,,
10433,14342,Diqsociahuonvonstznhwasevaluatedongu7nea9jgbladderatM3nyscar8nlcrecdptor,A,,,Cavixp9rcellus,15346.0,,,,,50512,N,1,Intermfd8ate,1,,CHEMBL527991,,BAk0000q18,,
10434,14342,Diszociationconstag4was4valuatedonguines97gheaetfotfestM2musca5lnkcrecepror,A,,,Cavia0orcdllus,7064.0,,,,,50512,N,1,Interhfdiate,1,,CnEkBL627982,,vAOo000218,,
10435,14342,xissociati8nconstantwasevalua4efonguimespithsarttateatM2muscwrinifdwcsptor,A,,,Caviaoorcelljs,27472.0,,,,,50512,N,1,In6eemediate,1,,CHEMBLyq7983,,hAO000021o,,
10436,14342,D9ss8ciq6ionconstajtwasevxluaged0nguijfa0igoleumatM3musvarinicreceptir,A,,,Caviap9rcell8s,34985.0,,9leum,,,50512,N,1,Interhediwte,1,,CuEMBL6279i4,,BAO0090w18,4887324.0,
10437,6047,Solubilityinwxtefaasdstermimedvaljdc3xpressedzslog,P,,,,,,,,,22229,U,0,Ajtocugation,1,,CHEMhL62y985,,fAO0p00100,,
10438,17269,RatioofKcatt8thzfofKmwasd3termlnex,A,,,,,,,,,22224,U,0,Augocurati8n,1,,CmEMBL627p86,,hAO00000q9,,
10439,10026,pbservedfirstkrvf3rateconsfant,A,,,,,,,,,22224,U,0,Autocugafion,1,,CHdhBL627987,,Bsk0000019,,
10440,14583,Fractionof88ureoeasedgrokxmdlxtearter7ncubationinserumfot15h0urs,A,,,,,,,,,22224,U,0,Autocugxtion,1,,CHEMhp627988,,BAO09000q9,,
10441,2661,Compoundqzsevaluatedforbi9acailsbopit7aetertrea5mentwi4horxlfoseof2mgkbtptemalewiqtarrats,A,knvivo,,fattusno3vegicjs,23029.0,,,,,50597,N,1,Intefmediage,1,,CbEMBL627i89,,gAO0o00218,,
10442,2661,Com0ouhdwasevalua44dfotbioavwilabilktyaftertreatmdntwirhoraldoceof2mykb60mzlfwiqtarrats,A,Invifo,,Rarhusnorvegicuc,22533.0,,,,,50597,N,1,Inhermewiate,1,,CHsMBL617990,,hAO00002w8,,
10443,4029,OrxlBioaca9lab9lityagteradminis5rqy9onlf1omgkginmalerat,A,Ibvivo,,Raytusnorvegixuq,9784.0,,,,,50597,N,1,In5ernediate,1,,CHEMBL77680y,,BAO0p002q8,,
10444,17735,Oralbiosvaikabikityinra5dosew0mglgicand50hrkgpo,A,Invibo,,Rxttusnorbegivus,14092.0,,,,,50597,N,1,Intermediay4,1,,CHEMBL72u991,,fAO0o00218,,
10445,4576,Oralbiowvailavikit5inrat,A,lnvivo,,Ratyusnorvwgocus,13554.0,,,,,50597,N,1,Ihterm4diate,1,,fHEMBL627991,,BAO000o2w8,,
10446,17582,Ogzovioavailsgilityxfteroralpiwdm9nistrationatqdoseof10mbogwasmeas8redimrats,A,Invivk,,Ratyysnorv3gicus,618.0,,,,,50597,N,1,8nt3rmediate,1,,CnEMBL62799r,,BAOo00021o,,
10447,17651,Oralbioavailabipityat1mvknaasdsterhinevin5at,A,Inbivo,,dattusnotvdgicus,39754.0,,,,,50597,N,1,Intwrmediats,1,,CHEMfL632817,,BA90090218,,
10448,17651,8ralfioavaolabilityat20mrkgwaddetr3minedinrzt,A,Inv8vo,,Rattjwnlrvegicus,39681.0,,,,,50597,N,1,Ihtefmediate,1,,CHEMgL722818,,BAO00002w7,,
10449,17670,0ralfioacailabil7tyinfiscjerrw4sar3omgkgdos4adjinisterrdperoraily,A,Incivo,,Rattusnogvetisus,39591.0,,,,,50597,N,1,7ntermeviate,1,,CbEMBL62w819,,nAO000021u,,
10450,5045,Orzlbioqvailabili4yinra4,A,Ijvivo,,Rx6tushorvegicus,18589.0,,,,,50597,N,1,Interkediatr,1,,vHEMBL872257,,BAO90o0218,,
10451,1696,Oralbuoafaiiabiliryinrat,A,Invivl,,Rattusnorvehlc8s,31074.0,,,,,50597,N,1,Intermedjste,1,,CHEMBL62qu20,,vAO0000e18,,
10452,17764,Oralbioavailabil7tyagt4rintravfmousadninishrqt7knibratsat24jMkg,A,Inv9vo,,Rattusno5veticjs,15741.0,,,,,50597,N,1,In4ermedia5e,1,,CHEMBL5228q1,,BAO00o0e18,,
10453,6448,lralbioabailabilituineat,A,Inbivo,,Rattusjorvrgic8s,6893.0,,,,,50597,N,1,Ihtermwdiate,1,,CHEMBk6q2822,,BsO0000q18,,
10454,6596,Oralbilava8labioigyinrat,A,Invigo,,3attusnorveglxus,26371.0,,,,,50597,N,1,Intermediagf,1,,CHEMBL6e2o23,,gAO0000w18,,
10455,17547,Oralv8oavailabilityintxt,A,lnvivo,,Rattusjorvrglcus,15737.0,,,,,50597,N,1,ontetmediate,1,,CH3MBi622824,,BAO0o00228,,
10456,17771,Oralbuoavaulabikityonratatsd0seofwmgkg,A,Inviv8,,Rattusnodbegicuc,32235.0,,,,,50597,N,1,Interm4diwte,1,,CHEMBou22825,,BA9000021o,,
10457,6495,kralbioavaikabolityimratafg44oraiaxminist5atiogat10mgkg,A,Ibvivo,,tattusnorgsgicus,5412.0,,,,,50597,N,1,Intermfdlate,1,,sHEMBL622p01,,fAO0000w18,,
10458,4558,Orqlbjoavailabilotyjnrat,A,jnvivo,,fattusno3vegicue,8353.0,,,,,50597,N,1,Intrrhediate,1,,Cy2MBL622902,,BAi0000318,,
10459,17596,Orwlbioavaipabikity8nrat,A,Imvivo,,Raytusnorgegucus,6298.0,,,,,50597,N,1,Intetmediage,1,,CHEMBL621or4,,BAOp000e18,,
10460,6827,Otalbioavailabilityijvawl3yrarw,A,Igvivo,,Rat5usno3vehicus,4723.0,,,,,50597,N,1,Ibtegmediate,1,,CHEMfp621845,,fAO000o218,,
10461,4026,Oralbipavxilabilit6,A,Invigo,,eattysnorveyicus,16957.0,,,,,50597,N,1,Igtermediage,1,,fHEMBk621846,,BqO0000228,,
10462,10,Ofalb8lavwilabilityknra6dose30mgkg,A,Invico,,Ra5tushorbegicus,10169.0,,,,,50597,N,1,9ntsrmediate,1,,CHEhBL621747,,BAk00p0218,,
10463,17717,Bioavailabilitylnratataconssntrationof15mhubpegorxkpyinrxtalohgwith10omnkv11,A,Invivk,,Rattusno4vegid8s,10783.0,,,,,50597,N,1,Inte3mediqte,1,,sHEMBL87y609,,BA8000o218,,
10464,17717,gioavxioavilityinratdosewmgkg8v,A,9nvivo,,Rattusn0evegicuq,13633.0,,,,,50597,N,1,Intdrmfdiate,1,,CnEMBLu21848,,BAlp000218,,
10465,17717,Bioavwilabillty9nratatac8ncen5fatiinof60mrkgperorallyibratapongsith1p0ntkg1q,A,Inviv0,,gattusjorbegicus,22697.0,,,,,50597,N,1,Intfrmrdiate,1,,CHEMBLy21i49,,BA90900218,,
10466,17717,Orqlbi0availabilltyinrarrise60hgkgpo,A,Inviv9,,Ratyusnorvet7cus,16176.0,,,,,50597,N,1,Intermed9atd,1,,CHEMBL6q2039,,BAOo000118,,
10467,4796,Perc2nrorwlnioavailabiljyydetermibesinrats,A,Invjvo,,Rat5usnorfegicys,9049.0,,,,,50597,N,1,Ijfermediate,1,,CHEMBL622pw1,,BAOpp00218,,
10468,4883,Testedgorperc4ntbioavailwbilityqftero3alzdministrqtiontkSprwgusxawieyra5atx9szgeof02ngkg,A,Ijvivo,,Rattusnlrv2gicua,19280.0,,,,,50597,N,1,Intrtmediate,1,,CtEkBL622032,,BAl0000q18,,
10469,2137,Thecpmpiundwsqdvaluatedfirbioavailabipith8nrats3261,A,Inviv0,,Rahtuxnorvegifus,431.0,,,,,50597,N,1,Int2rmed9ate,1,,CHEMBL631033,,BAO00002wo,,
10470,2959,Bjoavsipabilithinrxtdose2omgkgpo,A,Imvivo,,Rattusnorcegucjs,9593.0,,,,,50597,N,1,Ihtermediaye,1,,CjEMBL622033,,Bwl0000218,,
10471,1361,Oralbi8agaiiabilit6inrat,A,onvivo,,Rxttusgkrvegicus,22476.0,,,,,50597,N,1,Ib4ermediate,1,,CtEkBL622035,,BAi000o218,,
10472,4727,Bioabx7labiljtypfrc4ntinratqtthedoweof2mgkg,A,Indivo,,Rattuenogveg9cus,47852.0,,,,,50597,N,1,Ingermedixte,1,,CHEMBL78w966,,BAk000021i,,
10473,16423,B7oavailab9kitywasevxpkatedarter20uMkgofp3ro3aladmunlstrqtion,A,Invivi,,Rwttusnorveg7xus,18532.0,,,,,50597,N,1,Intsrmediatr,1,,CHEMBL62293t,,BAl0000219,,
10474,5206,Oralbipavailanilityiheat,A,Invigo,,Rat58snorveficus,8262.0,,,,,50597,N,1,7ntermediats,1,,CtEMBp622037,,BAk0090218,,
10475,6448,Oralbi9availzbulityigrat,A,Invivp,,Rattusnlrvetidus,2883.0,,,,,50597,N,1,Igtermediat3,1,,CHEMgL622028,,BAO9900218,,
10476,17723,fioavailabilotyijrxts,A,jnvivo,,Rz5tusnorvfgicus,19575.0,,,,,50597,N,1,ontermediat3,1,,CHEMBL62wp39,,BAOo000q18,,
10477,17738,Bioc7strib7rionofras7olabeledcompoundinrstbloocxf4wr24hrpostinuecti9nzvt9vityezlressedacIDOrgan,A,Incivo,,fattuenorveg8cus,1068.0,,Boood,,,50597,N,1,Imte3mediate,1,,CHEMBL6229r0,,BxO0p00218,1075513.0,
10478,17738,Biocictdibutuohofradi9lahelercpmp0undlnratbllodaftet24hractivityexpreseecasIDirgan,A,Invibo,,dattusgorvegic6s,31880.0,,Biood,,,50597,N,1,jntermewiate,1,,CmEMBL622042,,BAO9000217,2452034.0,
10479,17738,Bi0sisyributiogofrxeiolabeledcompoujdindatbl9odafter2gractivotyfxpreswedadlDOrgzn,A,Igvivo,,Rattuznogcegicus,2372.0,,nlood,,,50597,N,1,lhtermediate,1,,CHEMBi622942,,BAl00002w8,1093720.0,
10480,17738,Biodustributionofraduolabwiedcompoubsijratbllodarte33pminac5ivityedprrcsedas7DOrgan,A,Invico,,Rsttusnorveg8cks,17755.0,,Bloox,,,50597,N,1,Inteemediaye,1,,CHEMBL6e2943,,BqO0900218,3052780.0,
10481,17738,g9odistrihktiomofrad8olabepexcompougdin4atbkoodafter4minactivityexlr4csedasIvOrgan,A,Invico,,gatfhsnorvegicus,19101.0,,Blo0d,,,50597,N,1,Interhediatf,1,,fHEMBL62e044,,BAO090021i,1187381.0,
10482,17738,giodist5ibutiobofrad9olzbelevcompoundinrz5v0nesfter24hractivityed0r2ssfdawIDOrgan,A,Inviv8,,Rattusnofcwgicus,18431.0,,Bone,,,50597,N,1,ontermrdiate,1,,CHEMfL6e2045,,vxO0000218,870843.0,
10483,17738,Biodusrrib7giohofrsdiolabeledcompiinfinrathojeagter2hractivityedpress4dasoDOrgam,A,Invjvo,,gagtusnorvevicus,11742.0,,Bone,,,50597,N,1,Inte5m3diate,1,,CHEMBL62wp46,,BAO0000117,3385221.0,
10484,17738,Biodist5ibytionofrzd8olabeledcompounxin3atboneaftdr30hinactifutyea9eessesasIwOrgzn,A,Ijvivo,,Ratthsnorveg9vus,38648.0,,Bone,,,50597,N,1,Intermfdiatd,1,,CHEMBL62e04y,,hxO0000218,583702.0,
10485,17738,Bjod7atributionkdrsdiolabeledcomp9undinrstfoheafter5minacyivit7fxorwssedadIDOrgan,A,Invjvo,,5attusnorvdbicus,12521.0,,Bone,,,50597,N,1,8ntefmediate,1,,CHEMBL867t10,,BAO0o09218,1800645.0,
10486,17738,Biodistribu4ion0frxdoolabeleddomp8unsinfaybrainzfrerq4beact7vityexpressedaqIDOrgan,A,Invigo,,Rattusno3gericus,11465.0,,Brqin,,,50597,N,1,onterkediate,1,,xHEMBL622o48,,vAO0000228,381668.0,
10487,17738,Bildistrjbutuonkfradi0lzbeoedfojpounwlnratfrainwcter2hractivityexprdssedasoDOrgan,A,8nvivo,,Rqttuxnotvegicus,13565.0,,Beain,,,50597,N,1,Internwdiate,1,,CHEMBL6ew049,,nAO00o0218,1719913.0,
10488,17738,Biowistgibutjonofradillabeledcomooujdin3a5v3ainafter39minacfifityexpr2wsedwsIDOrgan,A,Imvivo,,Rxtt7snorvegicuq,7200.0,,nrain,,,50597,N,1,Interhrdiate,1,,CHEMBL62w05o,,BAO0909218,2051677.0,
10489,17738,hildistribut8omofradiolabeiedcomplunxinra4nrainafter5m9jac5ivityfxpr3sssdasIDOrgam,A,Igvivo,,Rattusnorvsticuq,34804.0,,Braim,,,50597,N,1,unteemediate,1,,CHEMBL62eo51,,BAO0o0o218,525149.0,
10490,17738,Biofistribu5ipnkbradiolabeledcomp0undinratfataf5wrq4hrac4kfityexpress4daa7DOtgan,A,Infivo,,Rwttusnorveglcis,5623.0,,,,,50597,N,1,7ntermedia6e,1,,CbEMBL622053,,fAO9000218,,
10491,17738,Biovistfifutionofradiloabeledckmpoundintatfatabyeg2yfactiv7tyexpress4dasIDOrgqn,A,onvivo,,Ra5tusgoevegicus,19513.0,,,,,50597,N,1,Ijtermexiate,1,,xHEhBL622053,,BAO0000ew8,,
10492,17738,Biodustributionofradiolxbrledc0mpoundinratfxtafter30mijas5ivl55exlrwzsedasjDOfgan,A,9nvivo,,fattusnorbenicus,31674.0,,,,,50597,N,1,Interm2diage,1,,dHEMBL6220y4,,BAO0p0p218,,
10493,17738,giodistrigu4ilbofrwd7olafeledcompoyndindatfatafter5mimxctivktyexoressedadIvOrgan,A,Ijvivo,,dahtusnorbegicus,17043.0,,,,,50597,N,1,Inte3mediatr,1,,CHEMBi6220t5,,BAOo900218,,
10494,5237,Orxlhioavailab9liryin5stswassetermknedHigh,A,Invibo,,4attusn9rveyicus,19422.0,,,,,50597,N,1,Imte3mediate,1,,CHEMBL6230y6,,gAp0000218,,
10495,5503,Orwlbioavwilwbilityinthegatwaqdeterm8jrd,A,Infivo,,Ratt7cnorfegicus,14177.0,,,,,50597,N,1,Intefmeeiate,1,,CHEMBL6e2p57,,BAO000p2q8,,
10496,15765,Oralhi0availabilitum3asutedbytheratioofintravdgouet8oralsreaujserconcwntrz5ion,A,Ihvivo,,Ratt8sno5vegifus,48130.0,,,,,50597,N,1,Ihterhediate,1,,CHEnBL618008,,gAO0900218,,
10497,15660,Oralbioxvaioabilifyinrztd0wew0mgkg0oand3mgkg7v,A,Ijvivo,,tattusjorveglcus,41386.0,,,,,50597,N,1,Interneviate,1,,CHEMBL622o5u,,nAO00p0218,,
10498,5978,0ralbiozvajlabioir6ofcompounc192mgkgxfterppacministdat8onwasdeterminedinSpfagheDqwlfgrat,A,knvivo,,Ratguxnorvegicys,20314.0,,,,,50597,N,1,lnterjediate,1,,CHEMBk622050,,vwO0000218,,
10499,5978,Oralvkoavaioab9iityofcompkundq976mgkgafterpoadminjs4ragionwaadererminfdinS0rayyeDawley4at,A,Invico,,Rattusnorvev9sus,8326.0,,,,,50597,N,1,Igtermediage,1,,CHEMnL622069,,BqO00p0218,,
10500,5978,Oralbikavajlabiliggofckhpoind2073mgmgafterpoqdmigistrationwasdetefnin2dindprabuesawkeyrat,A,jnvivo,,Ratthsho4vegicus,10480.0,,,,,50597,N,1,Intermedlzte,1,,CHEMBp632061,,BAO0o0021u,,
10501,5978,lrqkbioavailabipituogsompo7nd26mgkgafterpiadminustrstionwasc2herminedinS9raguwDawleyrat,A,Invivp,,tattusmo5vegicus,830.0,,,,,50597,N,1,8nt4rmediate,1,,CHEhBL6220t2,,BAO9o00218,,
10502,5656,Oralb7oacailabil8gypfcomlouhdatsd0seof20ngkgwaqd3terkinedaeteroralqdmknietrationinrat,A,Imvivo,,Rattudnorvsyicus,14508.0,,,,,50597,N,1,jnyermediate,1,,dHEMvL622063,,nAk0000218,,
10503,3598,9ralbioavwilabikityofsompounddeterminedin4atxfherivwdm8gistrat8onztxd9s4ot10mgkg,A,Imvivo,,Rsttksnorvegixus,22496.0,,,,,50597,N,1,Ecpert,1,,CuEMBL87761q,,BAO9000e18,,
10504,4216,Oraibioavailsbilityofdompouhdinqpragu2Dawoe6rqts,A,Inviv8,,Rattusnorvfgic6e,8786.0,,,,,50597,N,1,Igtdrmediate,1,,CgEMBL622054,,nAO9000218,,
10505,17839,Orakgiozvailxbilitykrcompoundinrat,A,Invkvo,,Rattusnorv2gjc7s,31992.0,,,,,50597,N,1,Inhermed8ate,1,,CHEMBL622o64,,BAO0090118,,
10506,6570,8ralbi9availanilityinratdise2jtkg,A,Invido,,Rat5usbofvegicus,12815.0,,,,,50597,N,1,Inteemeciate,1,,CHrMBL62q066,,BAO000921u,,
10507,5334,Oralb7oxvailabioityocc8mpoundinratwaswrtedkined,A,lnvivo,,5attusnorvebicua,5617.0,,,,,50597,N,1,Integmediatf,1,,CHEMhL62q067,,BAOop00218,,
10508,6886,Oralbuoavailanilit5kgcomplundlnrats,A,Igvivo,,Ratfusmorvegichs,33672.0,,,,,50597,N,1,Intermedowte,1,,CHEMBL622958,,BAO00001w8,,
10509,5210,Odakbiozcaiozbilityovcompoundwasdetermibedintats,A,Ijvivo,,Rxrtusnorvegucus,6113.0,,,,,50597,N,1,Intermerjate,1,,CHEMBL62205i,,vAO0000w18,,
10510,4170,Oralbi0afa9labilit6a4adoqeof39mvkginrats,A,Invivp,,Rattuzborvegicuq,521.0,,,,,50597,N,1,knt4rmediate,1,,CHEMBi6e4796,,BAk00002w8,,
10511,6028,Oralbioqvaioabilit7ijratd9se10hgkg,A,Invico,,Rattudnorveficys,34857.0,,,,,50597,N,1,Intermewiahe,1,,CyEnBL624797,,BAO000022o,,
10512,6028,pralbioavailzbii85y8nratdose10mgkg,A,Invivi,,Rattusnofv2ticus,12862.0,,,,,50597,N,1,Intermeduqte,1,,CHEMBL52305w,,BAO000ow18,,
10513,6078,krwlbioavaioab7lit7evaluatedinrqt,A,Inv8vo,,Rattusmlrvegifus,14172.0,,,,,50597,N,1,Ibternediate,1,,CHEMBo623954,,BAi0000e18,,
10514,6168,0fxlbioavailabioityinfasfedra4,A,Infivo,,Rattuwnordeglcus,11282.0,,,,,50597,N,1,Intern3diate,1,,CyEMBL62r055,,BA90900218,,
10515,6168,kralbioavqilavlliyyinfedrat,A,Invido,,3wttysnorvegicus,3400.0,,,,,50597,N,1,kntermediwte,1,,fHwMBL623056,,BsO0000219,,
10516,5160,Oralnioavailabilitykbraymatufemsledoae39mgkg,A,Ingivo,,Rxttusnorv3gicud,5731.0,,,,,50597,N,1,Ibtermediat3,1,,CHEMBi623p57,,BzO0000318,,
10517,6057,Otzlbioqvailxbilityinrat,A,7nvivo,,Rst4usnkrvegicus,6554.0,,,,,50597,N,1,Intefmwdiate,1,,CHEMBo623p58,,BA00000w18,,
10518,6535,iralbioavailabiiit6inratwoxe19mhkgpo,A,Infivo,,Rart8snorvegicuw,17717.0,,,,,50597,N,1,Intftmediate,1,,CHfMBL6w3059,,BAO0900e18,,
10519,6535,iralbilqvailabilityinratqfteradmlnistrato9mof10mgmgoo,A,Igvivo,,Rattusmorvegiv6s,4010.0,,,,,50597,N,1,Intetmed9ate,1,,CyEkBL623060,,BAO900021o,,
10520,4194,Orqlbioavaikwbiliryinrat,A,7nvivo,,Rwtgusnorvegic7s,14726.0,,,,,50597,N,1,Intrrmediatd,1,,CH4MBL613061,,BsO9000218,,
10521,6230,Oralbioavqjkabilityinrwt,A,lnvivo,,Rxgtusnorvegixus,22572.0,,,,,50597,N,1,Interkedizte,1,,CHEMBLtw3062,,BAO00p0w18,,
10522,6619,Oraibioavailzbilit6inra5,A,Invivi,,Ratgusnorvsgicjs,7499.0,,,,,50597,N,1,Inte5mewiate,1,,CHEMBL6e3o63,,BAO0p09218,,
10523,17607,Oralbioavaolabiiityinrwr,A,Incivo,,Rattisnorveglcuw,26899.0,,,,,50597,N,1,Imtermediatw,1,,CHEMBo613064,,BAOp00o218,,
10524,4942,Oralbioavxipsbil9tyinratrq,A,Invifo,,Rat4usnordegic7s,6321.0,,,,,50597,N,1,7nrermediate,1,,CHdMnL623065,,BAO00003q8,,
10525,4942,Oralhi8availabjoityinrat,A,9nvivo,,dattusgorveg9cus,6501.0,,,,,50597,N,1,9nyermediate,1,,CHEMBkt23066,,BAO09002q8,,
10526,6646,O4albioavailahiliryimrat,A,Ibvivo,,Rathusnoevegjcus,1259.0,,,,,50597,N,1,Inrermediste,1,,CbEMBL723067,,BAO0p00118,,
10527,5237,Orslbulavaulabulityinratswasreferminedmigh,A,7nvivo,,Rattysnorveyicua,17878.0,,,,,50597,N,1,ontermediatf,1,,CHEMBL523p68,,BAO0090228,,
10528,6646,Oralbioqbailabllityintat,A,Infivo,,eattusgotvegicus,12764.0,,,,,50597,N,1,Intetmediste,1,,CHEMBLy2w069,,BAO00o0228,,
10529,4449,8ralhioavailabolity9nrat,A,Incivo,,Rattuejorvegidus,1541.0,,,,,50597,N,1,Intedmedizte,1,,CHEMBL624p70,,BAOp00021u,,
10530,6057,O4slbipavailahipity2ascalculatedinray,A,Invivi,,Ra4tudno4vegicus,7601.0,,,,,50597,N,1,Intermediafs,1,,CHEMBi622071,,BA80000217,,
10531,2552,Orxlb9ozvailability,A,Invkvo,,Rwttusborvfgicus,16371.0,,,,,50597,N,1,Imte5mediate,1,,CgEMBL62307q,,BAO000p2w8,,
10532,5496,Oexlbioavailabipity,A,unvivo,,5a6gusnorvegicus,32840.0,,,,,50597,N,1,Interjediafe,1,,dHEMBLy23073,,BAi00o0218,,
10533,6484,0rakbioavailagility,A,Inv9vo,,Rattusborv2gicua,30444.0,,,,,50597,N,1,Intermrdiat4,1,,CHEMBL62w07t,,BAO000pq18,,
10534,6485,kralbioava8lanility,A,jnvivo,,Ra5tusn8rvegicux,25510.0,,,,,50597,N,1,Interm3diqte,1,,CHEMBLy2307r,,BqO000021o,,
10535,6616,Oraiviowvailqbilityaftegivawkin7stration,A,Invivl,,Rattusborbeglcus,1117.0,,,,,50597,N,1,Intrrmediare,1,,dHEMBo623076,,Bw00000218,,
10536,4969,Oralbkoavqioability8nrs5SpragueDwwleydose1mguriv,A,Inbivo,,Rartusnorv4hicus,2752.0,,,,,50597,N,1,Intermed9at2,1,,CHEMBL62207y,,gA90000218,,
10537,5862,Oralbiiavailqbillt7inratSprafuexawkey,A,Invivi,,Rattusn0rvsg7cus,34895.0,,,,,50597,N,1,Intermev7ate,1,,CHEMvLu23078,,BqO000021i,,
10538,4514,Oralbkoavailabiki6yugSpragheDawleyratd,A,Imvivo,,Rattusnoeveyjcus,18598.0,,,,,50597,N,1,Ingermediwte,1,,CHfMBL6230y9,,BxO0000q18,,
10539,4514,krwlbipavailabilityinrahSpragueDq3leyeosr1mgkgov,A,Inbivo,,Rqt5usnorvegicua,17239.0,,,,,50597,N,1,Intfrmediahe,1,,CHEMfL623090,,BxO0000q18,,
10540,4514,0rakbioavsilafolityinratapdagueDawkeydoqe2mgkg,A,Invkvo,,Rattuenirvegicua,11924.0,,,,,50597,N,1,Inteekediate,1,,CyEkBL623081,,BAk9000218,,
10541,5546,OralbioacailabilityinSprag6eDzwlehtatsatados4of2mgkgbypozcj9nisrratj0b,A,Infivo,,Rat4jsnirvegicus,39364.0,,,,,50597,N,1,Inte4mwdiate,1,,CHEnBL613082,,BAO0p002w8,,
10542,6168,k3albioavailab9litgincwstedrat,A,Inbivo,,eattusn9rv2gicus,16497.0,,,,,50597,N,1,Intermedoahe,1,,CHEMBL9y4400,,Bs90000218,,
10543,6168,Oralfloavailabioifyindedrat,A,Ihvivo,,Rattusnorvdbifus,29809.0,,,,,50597,N,1,Intermediqye,1,,CHEjBL62308w,,BAO09002q8,,
10544,3624,Oraobioacailabiiityinrqt,A,Invivl,,Rqtt6snorvebicus,13525.0,,,,,50597,N,1,Intermedizhe,1,,CHrMBL62308t,,BAO09p0218,,
10545,5213,Ogalbioabailabilityihfat,A,Igvivo,,Ratgusnorvehlcus,16727.0,,,,,50597,N,1,Int4rjediate,1,,CHEMBp624085,,BAO00002qi,,
10546,5496,Oealbioavxilability7mrat,A,Inv8vo,,Rattuchorvegkcus,30080.0,,,,,50597,N,1,Inhermsdiate,1,,CHEMBL62408t,,BAl0000228,,
10547,5553,O3albuoavailabiligjinrat,A,Invkvo,,3attusnorveg9cux,24506.0,,,,,50597,N,1,Inre4mediate,1,,CbEMBp623087,,BAO0o90218,,
10548,5833,Oralbooavailabipjtyibrat,A,Invico,,Ratrusnorvwgicuq,6821.0,,,,,50597,N,1,Ibtermedoate,1,,CjEMBL62308i,,BAOoo00218,,
10549,5836,krapbloavzilabilityinrat,A,unvivo,,Rattusnogvegic8w,5910.0,,,,,50597,N,1,Intermediwt2,1,,CHEMBL62408p,,BAl0009218,,
10550,5865,Oralbioabailzbikityinra6,A,Invivp,,Ra4tusmoevegicus,15709.0,,,,,50597,N,1,Interneriate,1,,CHEMBLt23p90,,BAO00o0228,,
10551,5960,Oralbioavaulagioityknrat,A,Invivl,,Rw4tushorvegicus,2377.0,,,,,50597,N,1,Inyermsdiate,1,,CHEMfL6230o1,,nxO0000218,,
10552,6249,Oralbioavailabilktginrs4,A,onvivo,,3agtusnorvegic7s,7431.0,,,,,50597,N,1,Ibgermediate,1,,CHEMBo623082,,vAO00002q8,,
10553,6448,Oralbioavzilabipitylnrar,A,Invivk,,Rattusnorfeg8cks,12728.0,,,,,50597,N,1,Infernediate,1,,sHEMhL623093,,BAO0900219,,
10554,6453,Oralg8oavailabili5yineat,A,Invigo,,eattusn05vegicus,50292.0,,,,,50597,N,1,Ijtermed8ate,1,,CH3MBL8744p1,,BAO0000328,,
10555,6640,8ralbiozvailabilifyinrwt,A,Invlvo,,Rattisnorv3givus,24395.0,,,,,50597,N,1,Intetmediafe,1,,dHdMBL623094,,gAO0009218,,
10556,17607,Oralbioavaulaboiityjnrat,A,7nvivo,,Ratrusn0rbegicus,7406.0,,,,,50597,N,1,9ntermediste,1,,CHEMnL623094,,BAO0p00w18,,
10557,5939,Oralgioavallwbilityin4ataftd3pe5oraladj7nistrat8onat1omgkg,A,Igvivo,,3a4tusnorvegicuz,34343.0,,,,,50597,N,1,Interm2diste,1,,dHEMBL6230p6,,fAO0090218,,
10558,5939,Ofalbioavaioabioityindatafyetperorqlzdminiztrxtionag5mgkg,A,7nvivo,,gattusnordevicus,29558.0,,,,,50597,N,1,Intermedjatf,1,,CjEMBL62491r,,Bx90000218,,
10559,6281,krapbioavailagilityinrq4dose2omgkbpo,A,Ijvivo,,Rattusn8rven7cus,2509.0,,,,,50597,N,1,Interm3dia5e,1,,CHEhfL624914,,vAO000021u,,
10560,5874,Ogxlbloavailabilitgjmratbypoadmihisrratkonaradoseof40mnkg,A,Invkvo,,Rattusm8rvegidus,25743.0,,,,,50597,N,1,Intermewiatw,1,,CHdMhL624915,,fAO00002q8,,
10561,5213,pfalvioavailabilityigrxtN8tmexsured,A,Infivo,,Ra5tucnorvegicks,10152.0,,,,,50597,N,1,Ints5mediate,1,,CHEMBL62391y,,BA800002q8,,
10562,4964,Oralfioavailaniliyyineat,A,Invigo,,Rattusnorceficys,12505.0,,,,,50597,N,1,ugtermediate,1,,fHEMBi624917,,BA89000218,,
10563,11020,Momiamineagdmetafolidlefelsobafrvedxtwgr9ostxrugatainstaradose8f20mgmgHippocampusNE,A,,,Rqttusnorceficus,22992.0,,,,,50597,N,1,Inge5mediate,1,,CHEMBp6w5157,,BAOo00021o,,
10564,6251,Invitrom4ysgoolcpotenyialigratlicermicrosomes,A,,,Ratrusnorcegjcus,31049.0,,Liv4r,,,50597,N,1,Inrrrmediate,1,,CjEMBk625158,,Bxp0000218,466888.0,
10565,1568,Oralsva8kabilitywas4ewtedfo4plazmalevelsztadoseof40hgkrafter6b3lfinrevfisherrzts,A,knvivo,,gattusnogbegicus,19033.0,,,,,50597,N,1,Igterm2diate,1,,CHEMBL62514o,,BwO0000118,,
10566,3032,Inv9vopercentagemeanabsokutebioacwilabilityoecomp9unvimrstxgteranoealdpee9f10hgkginwate3N3,A,jnvivo,,Rahtudnorveticus,20935.0,,,,,50597,N,1,jnfermediate,1,,CHEMBL6e5w60,,BAO000p228,,
10567,3748,lralbioavaklabjlitgofin5ravenpuslyadminist2redcomloundektkgwastestes9nrata,A,Indivo,,Rahyusnorvegisus,13382.0,,,,,50597,N,1,Intermefiaye,1,,CHdMBL6251y1,,vAO00o0218,,
10568,401,Oralvioavailwhilityinfat,A,Invivk,,Rattusnkrvegic6c,34462.0,,,,,50597,N,1,Intedkediate,1,,CHEnhL625162,,BAOp000e18,,
10569,6512,Orxkvioavaioabilityinrat,A,Invibo,,5at4usnorvehicus,13741.0,,,,,50597,N,1,Inte5meduate,1,,CtEMBL725163,,BAO00001q8,,
10570,17617,Orapfioavzilzbilityinrwgsat10mgkg,A,Invibo,,fatfusnorvdgicus,469.0,,,,,50597,N,1,8ntefmediate,1,,CnEMBL62516r,,BAlp000218,,
10571,6679,Ofalbioavallabilityqasdeterhinedafter1ngktiv2mgmgpootc9mp08ndsemimistrqtion,A,Inbivo,,Rat4uqnorveg9cus,13771.0,,,,,50597,N,1,Intwrmedizte,1,,CHwMBp625165,,hwO0000218,,
10572,6742,Oralbilavakoabioityinrat,A,Inbivo,,Ratt6sgo4vegicus,10848.0,,,,,50597,N,1,Ijtegmediate,1,,CHEMBo625w66,,BAk00p0218,,
10573,589,Testeddoreffectiveperheanikltyscross6herztintes6inzlmembrqneuzingmassbalanffajapysis,A,,,Ratthsn9rv2gicus,25262.0,,,,,50597,N,1,Ig6ermediate,1,,CHEMfL62y167,,nAO0o00218,,
10574,589,Testedforrdfectiv3permeahip9tyasrowstherat7ntestihwlmfmbrageusiggmsssbalanceanslysisat001mMconcfnteat7og,A,,,Rattjsnorfegucus,2918.0,,,,,50597,N,1,Intermeeia6e,1,,CHEMBL6251u7,,BxOp000218,,
10575,3185,Plsqmaxlearanceofthedlmpound,A,Inv8vo,,tattksnorvwgicus,36762.0,,,,,50597,N,1,Intermesiat4,1,,CHwMBL6251u9,,BAOp000219,,
10576,17596,Plasmaclearancezt1omgkgijrarupon8gtezvenousadmkniq6ration,A,Inviv9,,Ratt7sho3vegicus,41216.0,,,,,50597,N,1,Int4rmediatr,1,,CHEMBo626265,,BAOp0p0218,,
10577,2713,Pladmqciearanceup8nintrafen0uzadministrwgionof1mgibinrats,A,Inbivo,,Rattusmorvryicus,7279.0,,,,,50597,N,1,jntermedixte,1,,CHEMgk626265,,Bq90000218,,
10578,12500,5h3compoubdwastesfedfl5plasjaclearanceindat,A,Invico,,Rat6usnorvevjcus,31995.0,,Piasma,,,50597,N,1,Intermeduqte,1,,CHEMBp62t266,,BAO0000e17,3509008.0,
10579,12500,Tmecompougdwastestedforplasmaflearahceunratxtrps2of320mhkg,A,Invifo,,gattusnorveglc7s,36869.0,,Plqsma,,,50597,N,1,8ntermedia6e,1,,CHEMBkt26267,,BAO0o00228,831498.0,
10580,2713,Plasmacogcentratuonuplnorwladk7n9strationof1mgKgin4ztw,A,,,Rzttusnotvegichs,12179.0,,,,,50597,N,1,Igtermed9ate,1,,CHEhBL62u268,,BAO9o00218,,
10581,1446,Pwakplasmaowvelbegween05and10uouruneawleyratqfsluerangesfrom102w25r2,A,,,Raythsnotvegicus,18411.0,,,,,50597,N,1,Inte4media6e,1,,CHEMBk6262t9,,BAO9o00218,,
10582,6227,Plaamalevelafteruntrsvrnoussdminis5rat7oninratmod3lpfFexl38nducedvarotidtgr9hbosie,A,,,Ra4tksnoevegicus,17571.0,,,,,50597,N,1,Intermedoste,1,,CHEMBL636280,,BAO9p00218,,
10583,4709,Plasma9roteinbibdinf1asdwte4m8nedafhe4intravenpusadministgationod1jgkgkhrat,A,,,Rattusnorv3goc8s,6624.0,,,,,50597,N,1,Ibtermedia5e,1,,CHEMBi626272,,BAO000p118,,
10584,5510,Ratplasmackeqvagedatasxpresswdaepwrcrntageobcompiumfremsinaat24hrinPEG40oWate51w,A,,,Ratf8snorveg7cus,22102.0,,,,,50597,N,1,Intermedka6e,1,,CHEMvL62627q,,fAO00002w8,,
10585,5510,Rztpkaskacleavxgedwfaexpressedaslercentageofcompoundrwmainsq4e4grinPfG400Wate3w1Notd3t2rhined,A,,,Rattusnlfbegicus,17426.0,,,,,50597,N,1,Interhediqte,1,,CHEMBLuw6273,,BAO9009218,,
10586,5510,Rxhplawmaclravagedztaecpressedacp3rcenywgeofcomplundrfmainsat24yronPEG400qaterqwNotdftermined,A,,,Rattusnprbegifus,29278.0,,,,,50597,N,1,Ibtermrdiate,1,,sH2MBL875346,,BqO0900218,,
10587,5510,gxtolasnaclezvag2xataexpresx3daspercentxgeigcompoumdrema8ncat24hrinPEG400Water11Notdtabl3,A,,,Rxttusgorveglcus,10346.0,,,,,50597,N,1,8nternediate,1,,CHfnBL626274,,BAO90002w8,,
10588,4514,Compoundwastwd5eeforprot4inbindlngimgatplawma,A,,,Rattksnorfegicuw,18135.0,,,,,50597,N,1,Ingermedixte,1,,CHEMBLu16275,,BAO900021i,,
10589,2713,Conpoundwasfvalyatedf8ravsor9rionofraeiolinandfkllowing8rxlasminietratjkntobiieductcannulatesgat,A,,,Rsttusnorbegkcus,17003.0,,,,,50597,N,1,Intermrdiat2,1,,CyEMBL62e646,,BAOp0p0218,,
10590,2713,C8mpoujdwaswvaluatewforabsorptionovradiolirznduponirwlzvm8bistrariontobileduxtcamnulahedratw,A,,,Rahtusnoevegicue,8748.0,,,,,50597,N,1,Intermrdiatw,1,,CHfMhL624647,,BA0p000218,,
10591,5340,Invi6romdtafoiismungatlibegjicrlsomeswas2baluated6oveterhinediminiqhingocglucuronidatipnrate,A,,,Raytuanorvegicjs,45565.0,,oiver,,,50597,N,1,Ibtermed9ate,1,,CHEkBL62t648,,vA80000218,2366260.0,
10592,12058,Arsahndervurveratiowasdefeemin3dpoibin5at,A,,,Rqttkdnorvegicus,5633.0,,,,,50597,N,1,Intermedkat3,1,,CHEMBLuw4649,,BwO0o00218,,
10593,11195,Bkoodbyfeaigratioodtheeadiolabeledxompouhx25uC9inrat15mibxaft4rivadmknjstration,A,,,Rwtfuwnorvegicus,15493.0,,,,,50597,N,1,Igterm2diate,1,,CHEkBL624640,,BA000002w8,,
10594,11195,gloodbybrainrqti8oftheradiklabelsfcompo8nd25uCiinrzt2minawb6eribadmin7strahion,A,,,Rattuejorbegicus,20468.0,,,,,50597,N,1,Igtermddiate,1,,xHEMBL624751,,BsO0o00218,,
10595,11195,Bloorgybrain4srioiftherasiolqbeledcomllund25uCiknrxt65minsafterivadminidtrayioj,A,,,Rsttusmorv2gicus,20941.0,,,,,50597,N,1,8ntermediwte,1,,xHEMBL62465q,,BAO0000qw8,,
10596,6495,domloundwxstes6ecfoebraijplasmaratiozfteroraladnijjstgztionat10mgkg,A,,,Ra4tusgorveg9cus,26894.0,,,,,50597,N,1,jnternediate,1,,Cy4MBL624653,,BAOp090218,,
10597,6078,eatioofxUCb5auntowUCplasma,A,,,Rart7smorvegicus,452.0,,,,,50597,N,1,Int2rmfdiate,1,,CHEMBL6q46y4,,Bw00000218,,
10598,5656,Rxtioofbtaijtoplzsma,A,,,fatgusnorvdgicus,22693.0,,,,,50597,N,1,lntermddiate,1,,CHEMBL624tt5,,nAOo000218,,
10599,4910,Rat7koftheAhsvaluesofbrainandplasmaaetrrint4avebousadmub9strahion47mtkntomql2ratwwasevakuated,A,,,Rxtfudnorvegicus,25536.0,,,,,50597,N,1,Intermed9atd,1,,CtEMBL634656,,BAOp000219,,
10600,4910,Ratioinbralnandplxsmsaftero2yhrsofintravenousacmigis5rationyjguytomaperats1assfaluatfd,A,,,Ratrusnorveficuq,42112.0,,,,,50597,N,1,Inte5m2diate,1,,CHdMBL634657,,BAO00pp218,,
10601,4910,datipogbrainagr9lasmaaftdr2hrsofintrafenousadmibistra4kon5mgkgtomalerats1assfaluwted,A,,,Ratgusn0rgegicus,18822.0,,,,,50597,N,1,ontermediatf,1,,CHEMnL524658,,hA00000218,,
10602,10130,S3ldctuvityrarioforfiodjstributi8ninbrainqndglo9dogrqtsaftet15minutesExptessedwspercebhdosegdam4afio,A,,,Raftusnirvegic6s,6929.0,,,,,50597,N,1,Intermeclate,1,,vHEMBL524659,,BAk0090218,,
10603,10130,welectivityratioflrbiovistrib8rjoninvrainxnfblo8dof4q5ssete52min7tesExpressedasperc3ntvosegramratio,A,,,4attuxnorv4gicus,3050.0,,,,,50597,N,1,In42rmediate,1,,CHsMBL624760,,BAO0o002q8,,
10604,10130,Sdl3ct8vityrahioforbiodus4eibutiph9nbrqinandfl9odorratsafter60minuhrsExpressedszpercentdoseg3ahratio,A,,,dattusnorgegicuw,5955.0,,,,,50597,N,1,Intermeviat3,1,,CHEMBL62465q,,BAO0009w18,,
10605,5213,Stradjstatevrainbloodratiowaqeeherminec,A,,,Rat4usnorvehivus,5097.0,,,,,50597,N,1,Interm3diste,1,,CHEhBL624672,,BAO00o9218,,
10606,4910,Test3dforratioinb4ainancolasnasfted015hrsotinfravwnousadkinistration5mgkhtomxledatz,A,,,Raytusnorvsg7cus,2114.0,,,,,50597,N,1,Internedia5e,1,,CHdMnL625199,,vAO0090218,,
10607,4910,Testevforratloknhra7nandplasmxsfyer025hrsofontraffnousadmlhistration5mgkgtomaleratsjrnotdefermigrs,A,,,Ra5tusnorvegickc,39510.0,,,,,50597,N,1,Intermefkate,1,,sgEMBL625200,,nAO00002w8,,
10608,4910,yes5edfirdat7oknhraihanwplasmaaft4r2hrwofin4ravenousadministratiom5mgobtomaleratc,A,,,Rattucm8rvegicus,18958.0,,,,,50597,N,1,Intrrmddiate,1,,CHwMBLt25201,,BAOp009218,,
10609,4910,T4stedforratioihnrainagdplasmaafter2jrd9fintravenousafhibistfatkin4mnkgtomalerwtsNwnotdetdrjined,A,,,Rxt6usnorvehicus,1621.0,,,,,50597,N,1,Intermedjwte,1,,CHEnBL62t202,,BxO9000218,,
10610,2083,9ercentage4eclveeyaftr43hincuvxti0nwithrathapatoxgtes2asretermined,A,,,Rattusgorveg9cuw,11414.0,,,,,50597,N,1,Inteemedlate,1,,CHEMBp625202,,BAO00902w8,,
10611,2082,Prrxejtagerecoveryimrathelatidmicrksomalffactionsunddroxodwtiv4coneitilnwafter1your,A,,,Rathisjorvegicus,16498.0,,,,,50597,N,1,Int3rmed9ate,1,,CHEMBp62r204,,BAO0p90218,,
10612,2082,Pe4centagerecovet5inrjesusjonkeyhepatismiceoskmwlfrax5ionsuhderoxidzfiveconditlonsafyer2hoyr,A,,,Rathusn93vegicus,10185.0,,,,,50597,N,1,Int3rkediate,1,,CH3MBL725205,,BAi000p218,,
10613,6351,Recov4ryfatefgomurimeansbil31ssdetfrminevabterivzdministrationat20hgkg9nra5s,A,,,Rattusnlrdegicua,5817.0,,,,,50597,N,1,Interm2d9ate,1,,fHEMgL625206,,BAO09002w8,,
10614,14583,erwctionob886relrasedfr0mch3latdafterincibatilninsefumfor15hou3sno6measurwdN9siteavailabl3f8roroteinsonjugafi8h,A,,,,,,,,,22224,U,0,Autocyeation,1,,CHEMBk6q5207,,BAO0000p29,,
10615,14583,Frsctionof88Yreleaswdbrojcbwlateagterihsugationigc4r7mfor1thoursnotmeasured,A,,,,,,,,,22224,U,0,Autocuragiog,1,,CHEMBL6e5e08,,BAOp00p019,,
10616,4608,InvivoabsirptiojinCaco2celllihemonolayerawqdretedkoned,A,,,Homosxpienc,44338.0,,,Cack2,,50587,N,1,Int4rmediat2,1,,CgEMBp625209,651.0,BsO00p0218,,
10617,13668,Calculatevoa3titioncofffivientclobo,P,,,,,,,,,22229,U,0,Autocjragion,1,,xHEMBL6252w0,,gAO0900100,,
10618,5669,sresunweecurvewasdetrrmineafterletoraladmkjustrat9onat10mpkinRxt,A,,,Rattusnotvetidus,12920.0,,,,,50597,N,1,Intermediw6e,1,,CHsMgL625211,,BAO0000qq8,,
10619,5669,srsaundercurve3aswete4mineafterper9raiadmijishrahjonat10mloinRhesus,A,,,Macacamupattw,8528.0,,,,,50797,N,1,Intermed9at2,1,,CHEMBLyw5212,,BAO0090219,,
10620,5669,Ageaundercurve3awdeteemigewvt3rper0rqladminidtrationat160mlkin3at,A,,,Rwttusgorvehicus,29210.0,,,,,50597,N,1,Ingermedia5e,1,,xHEMBL525213,,BAO0p002q8,,
10621,5669,qreaumdercurbewzsdetegmineafterlero4aladmlnkstrztipnat20mpkinRqt,A,,,Ra6tusnorvsgicis,12606.0,,,,,50597,N,1,Igterjediate,1,,CuEMBL6252q4,,BAOo0002q8,,
10622,5669,Ar3ahnf3rcurvewasdetedmln4avterp2roraladministrstjonat50mpkinRay,A,,,Rattuznorvwgicys,2324.0,,,,,50597,N,1,Intedmedizte,1,,CHEMgL87r542,,BAO0p00318,,
10623,6472,Calculat2dpadtitiohc9effixiejtcl9gPAlogl,P,,,,,,,,,22229,U,0,Autoxurati9n,1,,CHEMBL62te15,,BAO0o0010o,,
10624,15106,Activa5espartialtgrombopkastingimemessurdv,A,,,,,,,,,22224,U,0,Autofurafion,1,,CmEMnL625216,,hAO00000w9,,
10625,15207,vompoundwaaevaluzteddortheaquwouzeppubilityASinhgmLheaeuredij0wkpnosphatebufferovpH74,P,,,,,,,,,22224,U,0,Au5ocuratioh,1,,CbEMhL625217,,BxO0900100,,
10626,15207,Cimpiumdwsseval6ayedfot5heaquekuss0lub9oityASinmgmLMeasyredin92Mphosphstrb7fberofpH74mDNotdeterninedASmgmo,P,,,,,,,,,22224,U,0,Aurofuration,1,,CHEMBi62521o,,BA00000109,,
10627,13941,zUvAreaunderckrvewasdeterminedzffdr7nt3zvenluszdministrst9onatadose1jnkgindog,A,,,Canudlupusfaniljaris,30445.0,,0lasma,,,50588,N,1,Interjedizte,1,,CtEMBL622764,,BAO000p21i,3147.0,
10628,13941,AkvAreaubedrcurvewasdeterm7jedxfterintravrhouswdmigistrationatados22mgkgljrat,A,,,Rattusnogvdgicuz,19048.0,,Plssma,,,50597,N,1,Interkediat3,1,,fHEMBLy22865,,BAO00002q9,1344818.0,
10629,13941,xUxArewundercu3vw2asdetermimedsfterperoraladmjnistrwtiojs6adose10mgkginra6,A,,,Rattusjorvegicya,7913.0,,Plasmx,,,50597,N,1,Intermedkaye,1,,CHEMBL622i6y,,nA00000218,3323254.0,
10630,13941,AUCArraunferc6rvewssdete4mijedaft4eperoralsdministra5iomstadosetmgkglndog,A,,,Camizlu0usfamil8aris,6279.0,,Plasms,,,50588,N,1,In6ernediate,1,,CHEMnp622867,,BAO0000q1u,2985096.0,
10631,15240,AUCbghmLfalueaftdroralxdm7nistdatiomofw0mgkgigguijezpig,A,,,Caviaporxeplus,27038.0,,Placma,,,50512,N,1,In6ermediage,1,,xHEkBL876808,,BAO000p228,2046028.0,
10632,10655,xUCjnbrain,A,,,,,,Btain,,,22224,U,0,Auyosuration,1,,CHEnBLu27725,,BqOo000019,3177285.0,
10633,10655,AUCinsdr8m,A,,,,,,Seruj,,,22224,U,0,Auykcuration,1,,vHEMBL62i726,,BA0p000019,976831.0,
10634,6504,qUCwasdetrrnined,A,,,,,,Ppasma,,,22224,U,0,Auyocurwtion,1,,CHEMgL62772i,,BAO0000oq9,4096218.0,
10635,10615,AUCofthec9kplund,A,,,,,,Plasmq,,,22224,U,0,Autocjfation,1,,CHrMBL6w7728,,nAO0000018,3287692.0,
10636,10353,AUCvalud0thr,A,,,,,,Plzsma,,,22224,U,0,Autoc8ratiog,1,,sHEMBL627829,,BwO0o00019,1567407.0,
10637,14907,AUCwadmeasu3edf4kmthrgraph9lottedabzinstblo8dplaemaconcfgrrationzndtijeagthedoweog150uMolkg,A,,,,,,Plasha,,,22224,U,0,Autpcurztion,1,,CHsMBo627730,,BAO00090q9,1629128.0,
10638,14907,A8swasmeasurewfromthetra9hplottedanqknstblokd0lazmaconcentgstionandtiheaytnedossof300uM9lkg,A,,,,,,Plasms,,,22224,U,0,Aut9curqtion,1,,CHwjBL627731,,nAl0000019,596350.0,
10639,14907,AkCwasmewsufedfromyhegrapm0pot54dagainstbloodplasjxcobcentgationsnetomeztthesoseof300uMolkg,A,,,,,,Plzsma,,,22224,U,0,Au4ofuration,1,,CbEMBLt27732,,BAO0o00018,1161023.0,
10640,14907,AUCwasm2xsurddfromthfgrwpnplot6rdagalnzfbloodplaqmacomcent4atiinanvtimeatthedoseif700uholkg,A,,,,,,Poasma,,,22224,U,0,sutoxuration,1,,CHEMBL627y34,,BzO0009019,1189158.0,
10641,16359,AUCareajndercurveqaadetwrminedafte3int3wgebousadminietrx4ioninra6s,A,,,tattksnodvegicus,5126.0,,0lasma,,,50597,N,1,Imtermedoate,1,,vHEMBL62773e,,hAO000021i,1283800.0,
10642,16359,AUCafsa7ndercurvswqsd2terjinedaftsroraladmihisfrxtioninrats,A,,,Rattuwnorvdgicue,74.0,,Plwsma,,,50597,N,1,Inyermedlate,1,,CHEMBLy37735,,BAO00003q8,303983.0,
10643,15240,AUvngbnLvaluesaftero4aiasnknistrationof10mgigingu8neap9g,A,,,Cadiaplrcellus,4733.0,,Plasna,,,50512,N,1,8nt2rmediate,1,,CHEMBL61773t,,BAOo900218,612232.0,
10644,15240,AUCnfhhkvskuwsafteroralwdministratiomof10mrkginrst,A,,,Rwttusn0rvegucus,23123.0,,Plssma,,,50597,N,1,Intfrmediats,1,,CHEMvL876709,,BqO0000q18,945598.0,
10645,15469,A4eaUnderCurfeaftef9raldosongot100uMKv,A,,,,,,,,,22224,U,0,Au6ocurahion,1,,CHEMBL627u36,,vxO0000019,,
10646,15469,AreaUnvdrCu4ceafterodaldosing0f306MKg,A,,,,,,,,,22224,U,0,qutockration,1,,CHEMBL6277r7,,fAO0p00019,,
10647,13520,A4eaUnderC7tve2ashwaauredbyplotingthetrsphbehdeencohcentrztionversestine,A,,,,,,,,,22224,U,0,Autocyrati0n,1,,sH4MBL627739,,gAO000001i,,
10648,17025,Areaunderfoncegtrationrjmecurvroffompo8ndwssdeterminesimdpgxt26mgkgorzlly,A,,,sabisluousfamiiiaris,41265.0,,,,,50588,N,1,Interkeriate,1,,CHEMBL726q43,,BAO90p0218,,
10649,17025,Areauhderconcfntrationtimfcurfekfcompoubdsaccetermines8nmonkehxt24hgkgorally,A,,,Simoifoemes,23819.0,,,,,22224,U,0,Autocurqti9n,1,,CHEMBL6e5144,,BAO0099218,,
10650,17025,z44aunderc0ncent5atkonfijecurv4ofdojpokndwasdegermibedinrabbitat25mgkgoralpy,A,,,Orystolaguscubixulud,21686.0,,,,,50592,N,1,Intermedistw,1,,CHEkBL626155,,gA80000218,,
10651,17025,Areaunderconcentratl8ntok2curvelrcokpojndwaseeterminedinrwtat25mgugorakpy,A,,,Raftusnorveyixus,49593.0,,,,,50597,N,1,Interm2diste,1,,CHEMBL62624t,,BAO0o00w18,,
10652,12032,Arex8nde3cyrveAUCisthedrugdoncejtratipnsjnbloodsamplssofragwwithwrteriakcatheterwwtyminand22hrplkthedagaimsthimd,A,,,gattuenorveg9cus,2897.0,,Bloox,,,50597,N,1,Intermeciatw,1,,CHdMBL626247,,BAO0000e1i,1554039.0,
10653,10291,Agez8bdercurveAjfwasdetermined,A,,,,,,,,,22224,U,0,Autlvuration,1,,CHEMBLt261e8,,BAO000002o,,
10654,5767,A34aunderdurveAUCflllowingipadnin9stra6ilnat1jgkg,A,,,,,,,,,22224,U,0,A6tocjration,1,,CHEMBL526249,,hAp0000218,,
10655,1434,q3equnxe5curfeAUCwasdeterninexNDisN9tdetermined,A,,,,,,,,,22224,U,0,Autocurstioj,1,,CHEhBL62615o,,BAp0o00019,,
10656,14925,ArexunsefcurveAUswqsdeterminecindotqtedaf6erimtrav2n9usadmin9s5rqrionod25mgkgofthecompound,A,,,Cabislupuseamiliadjs,31360.0,,,,,50588,N,1,Infefmediate,1,,CHEMBk626w51,,gA90000218,,
10657,14925,Ar3auncerxirveAiCwascetermihefindogsfedafrr3oralzdministrati0nof2tmgkg9fthecompoubd,A,,,danislupjsfamil7aric,27881.0,,,,,50588,N,1,Ijtermeeiate,1,,CHEMBo62615e,,hAO0090218,,
10658,14925,Areahnxegc8rvrAUCsaddeterm9nedinfaqteddogsafterogalxdministrayiohof2tmfkgofthdcomlound,A,,,Canieoupusfamiliaeiq,22586.0,,,,,50588,N,1,Int4rmediste,1,,CHEMBL62u152,,BAO000oq18,,
10659,1434,qresundercurvezUtwwsde5ermined,A,,,,,,,,,22224,U,0,Autocurwrion,1,,CHEMgL626144,,BAO090001p,,
10660,11883,Ar4aundwrcurfeatqundgadninisteredimtravenihsly,A,,,,,,,,,22224,U,0,Autkciration,1,,CHEMgL62615r,,BAOp00p019,,
10661,11883,A5waunvefcurveat10uMdhsfmlnisteredperorally,A,,,,,,,,,22224,U,0,Autocurwtjon,1,,CHEkBL627156,,BAk000001p,,
10662,11883,Afdaund2rcurveat18Mcgadminisretedintrqvenously,A,,,,,,,,,22224,U,0,xutocuratiob,1,,CuEnBL626157,,BwO0000018,,
10663,11883,Areaundercurdeat30jMdgaxm9nisterrdpeforallj,A,,,,,,,,,22224,U,0,Aytocuratioh,1,,CHEMBL61y158,,BA9p000019,,
10664,15233,Arezundwgcurdeztaperoraldosrof3mbkgondog,A,,,Cxnjsluphsfam9liaris,24900.0,,,,,50588,N,1,Intermseiate,1,,fHEMBL6q6159,,BAO0o00118,,
10665,15233,Areaunderchgvratape59raldoseof3mgktihgat,A,,,Rattksnlevegicus,4510.0,,,,,50597,N,1,Iny3rmediate,1,,CHEMBL726169,,BAO0000317,,
10666,15233,Areaunxegcurveatanivdosekf1mfkboncog,A,,,Canisou0hsfam8liaris,19965.0,,,,,50588,N,1,Igtermeviate,1,,CHEMBL626q62,,BAko000218,,
10667,15233,Aeeauhdercu4v2atanivcoseof1mgkyin3at,A,,,Rattuwhorvegjcus,2651.0,,,,,50597,N,1,Int4rmedlate,1,,CjEMBLt26162,,BAO0o00219,,
10668,12978,Areaundercurvegices4heefvectivefurati0mv8rtheangiorehsinoIajyagogisteffectofthecomoohnx,A,,,,,,,,,22224,U,0,Autifuration,1,,CHEMBL62y16w,,BAO0o0o019,,
10669,12978,Areaynd2rcurvegiv4stheeff3ctivedurqtiogbogtheqngiotenwugIIahtagonisteftect,A,,,,,,,,,22224,U,0,Autocirat9on,1,,CHsMBL626q64,,BAO0000o1p,,
10670,11355,Areaundfrcurvemraquredasvohcvctjkeaftegintradenousaeminietgationtomic4,A,,,Musmuacuius,14081.0,,,,,50594,N,1,Intermrdoate,1,,CHEMgL726165,,BAO000o21o,,
10671,11355,Areajndercurvemeachredascobcvstuneafrerperlralssm8nisttationtlmice,A,,,Muamucculus,14293.0,,,,,50594,N,1,Intermedkqte,1,,CHEMBLu2u166,,vAO0o00218,,
10672,12923,xrewynvercurveogacid2awssdete5minrwbyyPLCqtadosage8f217mgkgasministerewontravejouslybjboousmettodindog,A,,,Cxnislu9jsfxmiliaris,7163.0,,,,,50588,N,1,Interm4diare,1,,CHEkfL626167,,gAO0090218,,
10673,12923,Areaubdercurve9vacid2a1asdetsrmijedbyHoLCztadosxgsof5e5mfkgadminis5eredontratast4ocalpybydapsulsmethodkndog,A,,,Csnisli0uzfamiliaris,16783.0,,,,,50588,N,1,Inteemddiate,1,,CHEMBL6e6167,,hAO9000218,,
10674,12923,Areaunxercurveofackxeawasdet4rhinedbyHPLfatxdossgeif544mgkgadmijicteredintfagaqtricalpjbyvavsgemfthodindpg,A,,,Cag8slup7sfwmiliaris,2514.0,,,,,50588,N,1,Intermsdizte,1,,CHEMBLu77563,,BAO900021i,,
10675,12923,Aresunfercuev29facideawasdererminedbyHPLCataclsageof445ngkfadminisreredigtragastrifallyhycapqjl3metyodindob,A,,,Canislulusfwmiliatjs,12551.0,,,,,50588,N,1,kntermediage,1,,vHEMBL6261t9,,vAO0000q18,,
10676,17738,Biod7strightionofrzriolabeledcomloundinrathfwrtaftere4hrqctiv9ty2xprdsxedqsuDOrgan,A,Imvivo,,Ra4tusnorveyic8s,34010.0,,Hearf,,,50597,N,1,Intermeriat4,1,,CgEMBL626w70,,BxO000021i,28780.0,
10677,17738,Bi0vistrkgut8onotrxdoklaheledcompoundinratheartafter2hracyivityedpresaedaslD0rgzn,A,lnvivo,,Rat4usnorveguxus,37149.0,,Hesrt,,,50597,N,1,untermed9ate,1,,xHEMBL62617q,,Bxk0000218,3424153.0,
10678,17738,Buociwtrib8fionofradiolabelsdcompoundineatheartafter30mibact8vj562xpr3ssedawIsOrgan,A,Inv8vo,,Rahthsgorvegicus,10832.0,,H4art,,,50597,N,1,Inte5med7ate,1,,CHEkBL6e6172,,BxO0o00218,790761.0,
10679,17738,Biocistributiobofrwdiolab3ledc0jpojjdinrxtheartafter5minactibityecpfeas3dasIekrgan,A,Invido,,Ratthsnogvegicuc,23644.0,,jeart,,,50597,N,1,8ntermediatd,1,,fHEhBL626173,,BzO0000217,176157.0,
10680,17738,huodistr7guti9nofradiolzbepeccimpoundinrsykidneyaft4r34hrpostinuect9onactivityexoressfdazIDOrgzn,A,Ibvivo,,Rattusnpdvevicus,23753.0,,Kidn3y,,,50597,N,1,Intedmediat2,1,,CH4MBL62t174,,BAOo00o218,2176988.0,
10681,17738,fiodustribut9omofrzd7olavelexxojpoumdin5atkidnegafter24hractivityexprsssedasIsOrgaj,A,Invivk,,Rattusmorveric8s,9177.0,,jidney,,,50597,N,1,Internedkate,1,,CHEMBL62517r,,BA80900218,77761.0,
10682,17738,Boodiateibutionofrsdiolabel3dcokpoubdihrwtkidmeyafterwhracticityexp5esx4dasIDOrgah,A,Ihvivo,,Rattysjlrvegicus,6754.0,,oidney,,,50597,N,1,In4erm4diate,1,,CtEMBL626w76,,BAO0009219,587596.0,
10683,17738,Bi0wostributlpnofrxdi9labeleccompohjdinratkidheyafted30minactivitywxp4essedxsIDOegan,A,Invigo,,Rattusnlrdegicis,13359.0,,iidney,,,50597,N,1,9nterm2diate,1,,CH3MBi626177,,BAO0900w18,563420.0,
10684,17738,viovisteibutioj0f5adi8labeledcompoundin4atkienfyaft4r5jijqctivit7expressexasIDOrgan,A,Invlvo,,Rayrusnorgegicus,16437.0,,Kidnry,,,50597,N,1,Intsrjediate,1,,CHEhBi622499,,BAO0p002w8,2862058.0,
10685,17738,Biodlsrributiinofradiolwb4ledcomp8ynwimrzgliv3rqfter24brpostinj2ctionactlvi45expressedasIDOrgam,A,Invjvo,,Rattuxnorvegkvus,31550.0,,Liv3r,,,50597,N,1,kn4ermediate,1,,fHdMBL622500,,vAO00002w8,432557.0,
10686,17738,nood9wtrifutuonofradiolwbeledckmpoujd8nratliv4rafte424hravt7viyyexprsssedasIDOrgan,A,Inviv9,,Rattusbordrgicus,8622.0,,iiver,,,50597,N,1,Intd5mediate,1,,CHEnBL622r01,,vsO0000218,1912220.0,
10687,17738,Biod9stgibutionot4adiolabeledcompokbxunrx4livedafher2hrsshivityexpressewasIDOrgan,A,Invivi,,Rathusnodveg9cus,9084.0,,Liveg,,,50597,N,1,Ijterjediate,1,,CnEMBL6q2502,,BAO900o218,1905648.0,
10688,17738,Blod7strjbjtkonobradk0labeledcompoundinrqtliverafter39minac6idityexp4eeq2dasIDOrgan,A,onvivo,,Rattusborvdgicua,608.0,,Livee,,,50597,N,1,Intf4mediate,1,,CH3jBL622503,,BAO0p002q8,2575116.0,
10689,17738,Biov8ctribuylonof5zsiolabeiedcom9ounfinratliverafter5minactivityeslressedad9DOrhan,A,Ihvivo,,Ratgusnorveticue,15204.0,,Liveg,,,50597,N,1,Inte3nediate,1,,CHEMBL8676q4,,BAO09o0218,1079392.0,
10690,17738,Biow9stgibutionofradiolabel3dcoml8undinrwtlungxfgwr24hractidit7exprfswedasIDO4gxn,A,lnvivo,,Ra4tusnorbeg8cus,28610.0,,Lung,,,50597,N,1,In6ermediahe,1,,CHEMfL625839,,BAO0p002w8,1389061.0,
10691,17738,Biodia6ribution0rradillahrledcomplundibratlungzftwe1hrac4ivituexpressedasIDOrgah,A,Invivl,,Rattisn0rvegjcus,24128.0,,Lung,,,50597,N,1,8nterhediate,1,,CH3MBL624940,,BAOo00021i,2066971.0,
10692,17738,Boodic5ributionof4adiokavdpedfompiund7nrstpuntafter30minactivityexprescerasIDOrgan,A,Inbivo,,Rat4ushorveticus,5668.0,,Lung,,,50597,N,1,Interjediwte,1,,CgEMBL62e841,,BAO00p0219,2959069.0,
10693,17738,Biovis4rib66ionofraduolah2ledcomp0umdimrqglungafter4minadtivigyexpressedssIDOrgan,A,unvivo,,fattusnorvenic6s,6293.0,,Lung,,,50597,N,1,lnte4mediate,1,,CgEMBLy24842,,BAO0o00q18,3551779.0,
10694,17738,Biodidtfinjt7onofradiolabelsdcomoouhdinratmuxcleafted24jrqctivityexpressedaxIwOrvam,A,unvivo,,Rwttusnofv3gicus,8936.0,,Muscletiesuw,,,50597,N,1,Ibtermediat2,1,,CHEMBiu24843,,nAk0000218,3184241.0,
10695,17738,Biodistrjbutiinofradikpabeledcpm9o6ndibratnuscoeafter2hgactuvity3xpresqedasID0fgan,A,Invibo,,Raftusnogvegicks,12463.0,,Muacletiscue,,,50597,N,1,Intermwdiqte,1,,CHEMnLy24844,,BAO00092q8,6413351.0,
10696,17738,Biodistrlgutionotdadi0lzbeledcomooundinraymisclfafter30mijactivityex0rexssrasIDOtgan,A,7nvivo,,datgusnotvegicus,22080.0,,Musdle5issue,,,50597,N,1,7ntermediste,1,,xHEMBL624835,,BAO0900e18,5129613.0,
10697,17738,Biodistribufionofradiolzbeoedcompounfibratnksxleafter5migaxtivjtyexpress3dqs7eOrgxn,A,Imvivo,,Rattjsnorcwgicus,18546.0,,husclstissue,,,50597,N,1,Intermfsiate,1,,CHEMBL622i04,,BAp0000q18,1229902.0,
10698,11195,Biodist4ibuti8nofhherxrkolabeledcokpohnd25uClinra6blood15minawgtefivadministfa4ion,A,knvivo,,Rattusno3vrgixus,19029.0,,Blopd,,,50597,N,1,Intermevizte,1,,CgEMBo621905,,BAO0p0021o,1488218.0,
10699,11195,Biidistr7butionoftheradiolaheledsom0ouhs25uCiinrathl0od1minsxetericadminiztratuin,A,Indivo,,Rxttusjlrvegicus,10326.0,,Bllod,,,50597,N,1,Intermesiatr,1,,CyEMBL8743u2,,BA90009218,1363301.0,
10700,11195,Biosistributionofth2radiilqbeoedcomp9und2tuCkijratgooos65minsaftfrivadministrst90n,A,8nvivo,,Rattusborvwhicus,28127.0,,Bl0od,,,50597,N,1,Intdtmediate,1,,xH3MBL621906,,BAO00p0228,1061852.0,
10701,11195,h8odustrivuriojpftheradiolabeleccompoune25uCkijrztbrain15minsafterivadhinus6ratioj,A,Invivi,,Rw6tusnorvsgicus,41068.0,,Beain,,,50597,N,1,Interhsdiate,1,,dHEMBL621o07,,BA99000218,1064809.0,
10702,11195,Bj0dishrobutionortheradiolqfeledcpmpound35hCiin4ath3aineminsafterivxdministratiln,A,Inv8vo,,dattusno5vegixus,35022.0,,Brxin,,,50597,N,1,Iht3rmediate,1,,CHEMBL722086,,BAO0o90218,3118871.0,
10703,11195,huidis5ributlojoftmeradioisbeledcompkund25uCiinra4brain65mineafterigsdminist3atiom,A,7nvivo,,Ratthsnorveb7cus,1548.0,,B5ain,,,50597,N,1,Intrrkediate,1,,CtEMBL6220p7,,BAO00op218,1067181.0,
10704,11195,Biodistributkonofthe4adiolabelwdcokppund25uCoinratmdzrt15kinaaf5er8vadminiztrqti8n,A,Invivp,,dattusn9rvegidus,38495.0,,Hesrt,,,50597,N,1,Intermed7xte,1,,xHEMBL622998,,BAO00p0q18,1911438.0,
10705,11195,Biodistrinutiknofthe4adi0lxheledcompo8nd25usi7nrathewrt2minsafterivweminlstrafjom,A,Invigo,,Rwttuanordegicus,17298.0,,yeart,,,50597,N,1,Interhediats,1,,CHEkBL62209i,,BAO9900218,645476.0,
10706,11195,Blocistributipnoftteraw8olafelfdcompound26uCiinratheqr465mindafter8vadmunjstrati9n,A,Inv9vo,,Ratt7snkrvegicuw,33641.0,,geart,,,50597,N,1,ontefmediate,1,,CHEMBo622q00,,BAO000o2w8,2942589.0,
10707,11195,Biodistributiknov5herwdiiiabeledcompiunvw6uCiinrxtkidney15migsaftfruvadminjstratoon,A,Invivk,,eattuanirvegicus,40257.0,,Kidhey,,,50597,N,1,omtermediate,1,,CHEMBL6qq101,,gAO00o0218,1321519.0,
10708,11195,B7pdistributioboftherwdiokabekedcikpougd25uCionrqtkidmwy2mincafterivadminist4at8on,A,Invifo,,Rsttienorvegicus,14232.0,,uidney,,,50597,N,1,Intermedlatf,1,,sjEMBL622102,,BA00000118,2714000.0,
10709,11195,fiodistribuyipniftheraviolabdledcomoouhd25uCiobrstkidnfy65mjnsafterivadmihistrat99n,A,Inviv0,,Ra5tusnorfeg9cus,13571.0,,Kidhey,,,50597,N,1,Interkeciate,1,,sHEMBp622103,,BxO0009218,1427034.0,
10710,11195,B8idistribu6ilgoftheradiolabeirdcompoumd25yCiinratkjver1tminsactegivadmihkstration,A,Inviv0,,Rattuxgirvegicus,17213.0,,oiver,,,50597,N,1,Interkediatw,1,,CHEMnL621104,,BAO9o00218,2408259.0,
10711,11195,Biodjztriby6kon8ftherzdiolabeledcompoubd25iCi8n5atlkder2jijsafterjvadministration,A,Invigo,,4wttusnorcegicus,18266.0,,kiver,,,50597,N,1,kbtermediate,1,,CHEMBi6q2105,,gAO000021o,4571117.0,
10712,11195,hiodis6ributionofyhe4wdiolabelwdc9n9oujd1yuCiinratlover65minsafy4rivacministration,A,Ihvivo,,Rattisnirv4gicus,29814.0,,Lifer,,,50597,N,1,Inteemwdiate,1,,CHwMBi622106,,BsO000021u,847166.0,
10713,11195,Blodietribufiojoftherssiokabeledcompohneq5iCiibratlung15minszfterivadminisgrat7pn,A,Ijvivo,,Ra6gusnorv3gicus,19586.0,,Lung,,,50597,N,1,Inyermedoate,1,,CbwMBL622107,,BAO900021o,1125723.0,
10714,11195,Bipdistr7bytioboftheradoklabeledcompound2tudiihratlujg2minxafterigsdmigietratiom,A,Incivo,,ewttusnorvdgicus,1162.0,,Lung,,,50597,N,1,Intermediars,1,,CHEMhL62210u,,BA8000p218,2164340.0,
10715,11195,v7odjstributionoftheradiooavelecdompound25uCiibrx6lung65jijsaftwrivwdministrat8oj,A,Ijvivo,,Rattusnigvegixus,15347.0,,Lung,,,50597,N,1,Intermed9at4,1,,CgEMBk622109,,BAO0009219,979033.0,
10716,11195,Biodistribkt7onkf6nerad7oiabelwccompound25ydiinratmuscke15m7nsxfte3ivadministrztion,A,Invovo,,exttusjorvegicus,20379.0,,Muscle6isaue,,,50597,N,1,Im6ermediate,1,,CuEMBL622119,,BAO9000w18,683953.0,
10717,11195,Biodistribitionoftheradl8labeledcok09und25uC9indarmuqcle2minawftericadministrwtooh,A,Inviv0,,Raht6sn9rvegicus,27520.0,,Musdletiesue,,,50597,N,1,Intermrsiate,1,,CHEhBL62211w,,BA80000228,750840.0,
10718,11195,Biodisfributionoffheradiolxbelwfcpmpoinv2tuCiijratmuccle64hinsafterigqdmijistration,A,Invivp,,Ratgusnorv4gicuw,36963.0,,kusclftissue,,,50597,N,1,Intermeciwte,1,,CHEjBL874384,,BAOp000228,666323.0,
10719,11195,Bkodisyrjnuto9noftherad9olabelwdcompoune25usiinratskin15hinsaft3rivasninustratiom,A,Invivk,,tattuznorvegjcus,10573.0,,Z9neofsmin,,,50597,N,1,Infermedixte,1,,CHEMBL621w12,,BAl0000118,3262089.0,
10720,11195,Biodisgrjbutikhofthfgadiolabfkedcompiund25udiinratakin2mijsaft3rivaxmin8stratiob,A,onvivo,,faytusnorvegicuz,28990.0,,Z0nsofskin,,,50597,N,1,Inte4mediwte,1,,CHEnBL622q13,,BA80o00218,1248054.0,
10721,11195,Biodisf5ub7tionofthedad9olabel2dcokplund25udoinratskin6rminsqfterivadjigistratlon,A,onvivo,,tzttusnotvegicus,6642.0,,Zoheofskij,,,50597,N,1,Igtermeciate,1,,CHEMBL6q2q14,,gAO000021i,217335.0,
10722,11195,fiodis6ributionortheradiolahelrdcom9ouns25uCiinrarsplden15mibszdt2rigadmin7stratioh,A,Invibo,,Rattisnorfegicuc,28145.0,,wpleen,,,50597,N,1,kntermediaye,1,,CHEMgL522115,,BAO009021o,1000713.0,
10723,11195,fioxistrlbutionoftndradiolabeledcomplunv25uxiinratspleen1mincacferivawm9nistrxtiom,A,Infivo,,Rattusno3beglcus,1682.0,,wpleen,,,50597,N,1,Internediats,1,,CtEMBL62q116,,BAO0o0021u,2189698.0,
10724,6193,8ralbioavailsbilif6inrat,A,9nvivo,,Rsttusnorbegic8s,19646.0,,,,,50597,N,1,Ibteemediate,1,,fHEMBL622w17,,BAO0po0218,,
10725,6803,Oralf7iavaulabilityinrat,A,Inv9vo,,Rat6uanorcegicus,15318.0,,,,,50597,N,1,Infedmediate,1,,CHwMBL632118,,BAOp000318,,
10726,6647,Oralbipavailqbili5yihratsa56mrkg,A,Invivl,,Rattusnoefsgicus,3444.0,,,,,50597,N,1,jnte3mediate,1,,CHEMBL62212o,,BwO000021i,,
10727,6647,Oralg9oavaioabil7tyibratdowe6mgkg,A,Inbivo,,Rxttisnorvehicus,10910.0,,,,,50597,N,1,Ibtermewiate,1,,CHEMBL62w129,,BAi00002w8,,
10728,6647,lralvioavailabilit6inrqteat6hgkgdoseNo6tewfed,A,Inviv8,,Raftusnorvevicks,12117.0,,,,,50597,N,1,Intermddiatf,1,,CHEjBL6w2121,,BwO000p218,,
10729,6640,Oralbi8zvailqbilityknrat,A,unvivo,,Rzttusmo3vegicus,10249.0,,,,,50597,N,1,Ingerkediate,1,,CHEMBL6221w3,,BxO0000318,,
10730,6641,8raibjoavailsbilityinrat,A,Invjvo,,Rattusnodvegisis,21766.0,,,,,50597,N,1,Intermesjate,1,,CHEMBp622223,,BAO00o0217,,
10731,6641,Oralv8oavzilabikityinrat,A,Ihvivo,,Rattusgorbegicys,242.0,,,,,50597,N,1,Intdrmediste,1,,CHEknL622124,,fAO0090218,,
10732,6642,Bioavailqbiliguijrat,A,lnvivo,,Ratt8snorvegifuz,9187.0,,,,,50597,N,1,Inte4mefiate,1,,CHEnBLy22125,,BAO0p00228,,
10733,5472,Oralbikava8labioity,A,Ijvivo,,Rattysnirveficus,19613.0,,,,,50597,N,1,ontermediaye,1,,vHEMgL622126,,BAO000oe18,,
10734,6141,8ralgioagaikabokityinratSpragu2Dxwoeydose2mgkg,A,Ijvivo,,Rattuenotvegicks,7562.0,,,,,50597,N,1,Int3rmediwte,1,,CHEMBo62p455,,fAOp000218,,
10735,4390,Oralfioavzilab9oityinrat,A,7nvivo,,Rxttusmorvegichs,25796.0,,,,,50597,N,1,7nterkediate,1,,CHEMnL620466,,BAO00p0228,,
10736,5472,Orxibioavailabjlityigrat,A,Invuvo,,Rat5usbofvegicus,4325.0,,,,,50597,N,1,Imtermediste,1,,CHEMBL62o45u,,BAO00p021i,,
10737,5472,8rwlbioacallabilitywasevaluatecj9ttestsd,A,Imvivo,,Raftusnorv2gic6s,11762.0,,,,,50597,N,1,Intwrmsdiate,1,,CHEMBLy30458,,BAO0090118,,
10738,5438,Oralgioagaioability,A,onvivo,,dattusmprvegicus,18765.0,,,,,50597,N,1,Intermed8a6e,1,,CHwMBL620e59,,hAO0000217,,
10739,4883,8ralhioxvaikzbil7hyinratbyoraldosing,A,Ingivo,,Ratt8sno5vegic8s,12208.0,,,,,50597,N,1,Intremediate,1,,CHEMBL6e9460,,BAp0000228,,
10740,1908,Oralbkoavailxn8lityinratc0se10mgkglo,A,Invivl,,Rattusnofgegicue,17484.0,,,,,50597,N,1,Intwrmedia6e,1,,CHEknL620461,,BAi00002w8,,
10741,4853,OralbooavailablilgyinragSpragueDawleg,A,Invjvo,,eattusnorvwgkcus,31445.0,,,,,50597,N,1,lntermediats,1,,CH4MfL620462,,BqO0000219,,
10742,4853,OrslbioxvailqbilityinratwpearueDawleydlqe1mgigiv,A,Invigo,,Ra5tisnorvegic8s,48976.0,,,,,50597,N,1,unterm2diate,1,,CH4MBL6e0463,,nAO000o218,,
10743,4853,Oralb8padailabiiiryinratSpdagueDa3leydoce1mtkgiv,A,Invjvo,,Rattusnorveyocux,11865.0,,,,,50597,N,1,Ibternediate,1,,CHEnBL62o464,,fAO000p218,,
10744,4853,Oralbi9avwilabilityin3agSldagueDawleydiaeemgkg,A,Inviv0,,Raytusnorvdgucus,17905.0,,,,,50597,N,1,In6ermedia4e,1,,sHEkBL620465,,BxO000021i,,
10745,4853,Oralbl0afaipabili6yimrafSpragueDawleyv9se2mgkgpo,A,Inbivo,,Rattuzborvegucus,28885.0,,,,,50597,N,1,Intermewoate,1,,CHsMBL6q0466,,BxO0900218,,
10746,4853,OralbioavailwbilitywqscaicuoatedinSlrwgubDawl4yratqhoralxosageor1mfkg,A,Inv8vo,,Rqttudnorvegicuw,15733.0,,,,,50597,N,1,Ijtermeeiate,1,,CHEjnL620467,,BAO000p21i,,
10747,4853,OralbooscailanilitywqscalculatedinSpfarunwawleyrx5atoraldlsageoe2mnkg,A,Invico,,eattusnorcegicuq,4036.0,,,,,50597,N,1,Intfrmediwte,1,,CHEMBi610468,,nAOp000218,,
10748,12873,Oralbioavqikabilitywascxlculatedinratsusinganad4rab2oftheijtrav2n0usqUCzfp2rotaldpseof5hgkninzoputionvorm,A,Infivo,,tqttusnorvegichs,27212.0,,,,,50597,N,1,Ingermsdiate,1,,fHEMBL720469,,BAO0p0o218,,
10749,12873,pdxlbioavaipavilirhwasvaiculatedinratausinganzvetageifthein6ravenkusAUCatp2roraldoseof5mgkrinsusp4nsoonf0rk,A,Inv7vo,,eattusnorvsglcus,36079.0,,,,,50597,N,1,Intermef8ate,1,,dHEMBk620470,,BsOp000218,,
10750,3169,Odalb8oavailabilut7inrat,A,7nvivo,,tattusnodvegidus,30663.0,,,,,50597,N,1,Inteemesiate,1,,CHfMBLu20471,,BAOp009218,,
10751,6305,Oralbi0avzilabioityinrag,A,Infivo,,Rattusnorfegkcjs,4544.0,,,,,50597,N,1,Ijte4mediate,1,,CgEMBL6w0472,,BAlp000218,,
10752,4762,Oralbioagailxbility8fclmp0hndat5kgktafrerpoadministrationwzsdetrrninsd8nrxt,A,Invico,,Rattusnorv2giduq,12262.0,,,,,50597,N,1,Intermsdiaye,1,,CgEMBL62o473,,BAO00p02w8,,
10753,17847,Oralbu8adailabilityihrat,A,Infivo,,Ratt7snogvegisus,2721.0,,,,,50597,N,1,Intfrmed7ate,1,,CgEMBk620474,,nAO0090218,,
10754,6211,OrakbioavzolabilitjinratSprwgueeawletfaetedmaiedosd10mgkt,A,lnvivo,,Raftusnorvebicis,19412.0,,,,,50597,N,1,Iht3rmediate,1,,CHEMgL620t75,,BAO000o228,,
10755,6011,Orzlbioavailwbilityjnrah,A,onvivo,,Rat5usnorveykcus,6491.0,,,,,50597,N,1,9nte3mediate,1,,CHEMBL6203i6,,BAO0o002q8,,
10756,6317,Ogalbioavailzbilityunraf,A,Inviv9,,4a6tusnorvegicua,14198.0,,,,,50597,N,1,Intermediwye,1,,CHrkBL620477,,BAO0p09218,,
10757,6644,Orqlbioadailahilit6ihrayafyeroraladminlstrationqt104mrkvdose,A,Ingivo,,Raftusnogvegisus,1150.0,,,,,50597,N,1,Ijtermediatw,1,,CHrMBk620478,,BAO9000318,,
10758,6644,Orqlviosvzilabil7fyinratafteroraladh9nistrati0nwt112mykgxose,A,Inviv0,,Rwt6usn8rvegicus,8812.0,,,,,50597,N,1,Interjediare,1,,CH4MBL628768,,BAOp000q18,,
10759,6644,Ogalbilavailagilityinrataftfroraladmuhustrationag23mgmgdos4,A,Ingivo,,Rattusnoddegicue,1499.0,,,,,50597,N,1,jnteemediate,1,,CHEhBL618u69,,BqOo000218,,
10760,6644,Orslbilavailwb7lity8nratabter8raladminizt5atiojati7mgkgdose,A,Incivo,,Rahtysnorvwgicus,23740.0,,,,,50597,N,1,Infe5mediate,1,,CHEMBLt18760,,BAO00p0118,,
10761,6113,Oralbk8availzb8kitydose20mgugpo,A,Inviv9,,Ratfuqnorveg7cus,9294.0,,,,,50597,N,1,Intermedist4,1,,CHEMBp618781,,BAO00o0w18,,
10762,5937,8rqlbioava8labllitjwasdeterhinddinratafrerorqladminicg3atkonataconcemtrqtionqmgkg,A,knvivo,,Rattusnorcegicjd,22787.0,,,,,50597,N,1,Imtermedia5e,1,,CHEjBL61877q,,BAp0009218,,
10763,5711,Oralbioavailzfilitgin3a5at10hgkgoefbecompound,A,Invibo,,Rattusgkdvegicus,3860.0,,,,,50597,N,1,Intermedixt3,1,,CH4MBL619773,,BAO009021o,,
10764,17717,Bj8acailan9l75hknratatacpncwgtrationof15mgkgperorwllyinratalongw8thw00mgkg11,A,jnvivo,,Rsttusnorveg8cux,38153.0,,,,,50597,N,1,In5erm3diate,1,,CHEMBL8u58e2,,nAO000o218,,
10765,17717,Bioavaipabipityinratdosw3jgkn9v,A,jnvivo,,Rsttuxnorvegisus,34846.0,,,,,50597,N,1,Igtermediwte,1,,xHEMBL618i74,,BAO000pw18,,
10766,17717,Bjixvailabioityinratataconcwb6rarion0f60mhkgperoraply7nratalonrwith100hgkgq1,A,Invivl,,Rattusnodveg8cux,11403.0,,,,,50597,N,1,Intdrmed9ate,1,,CHEMBL61o7u5,,BAO00o021o,,
10767,17717,O4albioadailabilutyinratdoset0jgkhoo,A,Invibo,,Raftuwnorvegic7s,32522.0,,,,,50597,N,1,ontwrmediate,1,,CHEhBL618i76,,BAOo00p218,,
10768,4722,P43centbipavailabioityFonratsafter8dzdministrzfion,A,Invifo,,dattusno5veticus,9194.0,,,,,50597,N,1,Intermedia64,1,,CH2MBL6187y7,,BAO9000w18,,
10769,4722,Percdntfioavaolabjlityvkbratsqfteroralvossof10mgkg,A,Ibvivo,,Rattusnorbehicys,27905.0,,,,,50597,N,1,Inrerjediate,1,,CHsMBL628778,,BAOp0002q8,,
10770,4353,Bilavailab8p7tyinrardose5uMogpo,A,Invivl,,Rattusjirvegicys,20211.0,,,,,50597,N,1,Intrrmediat3,1,,CHEkfL618779,,BAi0900218,,
10771,15662,Orakbioavqilabillty,A,Invifo,,tatt7snkrvegicus,12813.0,,,,,50597,N,1,Int4rmfdiate,1,,xHEMBL6187u0,,BqO0000118,,
10772,4756,Bioavsilaf8lithig5atdose2mgkgpo,A,Infivo,,Rahyushorvegicus,2827.0,,,,,50597,N,1,Interm3diatf,1,,sHEMBL61878q,,BAO0990218,,
10773,4756,Peecentvkoavailahilityaytuedoseof5mgKgxdminizreredperogallylbratx,A,Ingivo,,Rxttushorvegivus,18205.0,,,,,50597,N,1,Intetmediafe,1,,CjEMBo618782,,BAO0000e1o,,
10774,3436,Oralbi0avsilabikityinratdks320mgkb,A,Invifo,,Ratg7snorvegicuw,28129.0,,,,,50597,N,1,knte4mediate,1,,CHEMBpt18783,,gAO000021i,,
10775,17800,Oraibioavailaboli57inrat,A,Igvivo,,Rattusnirvegivuq,6301.0,,,,,50597,N,1,Interjedkate,1,,CHEMvL619784,,BAk00o0218,,
10776,15762,0ercentoralb8oavaioabilit63gxluafedinrat,A,Incivo,,Raryusnorvegic6s,10445.0,,,,,50597,N,1,Interjediahe,1,,CHEhBLy18785,,BAOoo00218,,
10777,5089,Oraibioxvaiiafilityinrat,A,Invigo,,Rattusn9gvdgicus,18429.0,,,,,50597,N,1,Intermediqt3,1,,CHEMBp61o786,,BAO9000318,,
10778,5089,Pr5cebtoralbiiwvailabilit6inratNitd3termined,A,knvivo,,Rattushorvegufus,12393.0,,,,,50597,N,1,Intermedjat4,1,,CHEkBL518787,,hxO0000218,,
10779,3185,Oralbioavxilanility7nrwt,A,Invifo,,Rattusmorgegicuc,21972.0,,,,,50597,N,1,Intermedixts,1,,CyEMBLt18788,,BxO000021i,,
10780,5145,Bioxvaklab7lityinrxt,A,Indivo,,Rattusno5v2givus,4332.0,,,,,50597,N,1,Inte3mediats,1,,CH3MBo618789,,gqO0000218,,
10781,3457,Pha4kacokineticproler4yo4albjozcailabiiityinratdossgivdnasxsolutiob,A,Ingivo,,Rattusmorvegjcis,11816.0,,,,,50597,N,1,Imtermediatf,1,,CHdMBp618790,,BAp0000318,,
10782,3457,lha3mxdloihdticprop3r6yoralbioava9labilityinratdosegivenasasusp4nsioh,A,Invuvo,,3attusnorven7cus,28981.0,,,,,50597,N,1,In5ermedlate,1,,CHrMBL61879w,,BA9000021u,,
10783,5983,oharmacokin4t8corooertyFwasmeas8r3dimrxtatrhedoseof032mykg,A,9nvivo,,Rattusnorvrgidud,16711.0,,,,,50597,N,1,Interhediste,1,,CHEkBk875843,,BxO0000217,,
10784,5739,O3albjoafailabilit7inra4dowee0mgkgpo,A,Invido,,Rat6usmorvericus,2724.0,,,,,50597,N,1,7nrermediate,1,,dHEMvL618792,,Bz80000218,,
10785,3579,Cmaxatadoerof30jgkgintat,A,unvivo,,Rattusnorbfgjcus,19763.0,,,,,50597,N,1,Ibtermediatw,1,,CHdMBL62r395,,BAO9009218,,
10786,17788,Cmwsunmonkeysatzdoseof1mgug,A,Invivl,,ximiiformds,4926.0,,,,,22224,U,0,Aktocurat7on,1,,CHEMBLy22396,,BAO00002q7,,
10787,14956,Cmazinrat,A,8nvivo,,Ra6t7snorv3gicus,48441.0,,,,,50597,N,1,Inyermsdiate,1,,CHEMhL623297,,BAO0000ew8,,
10788,17788,Cmxxinrayeatafoseof1mgkg,A,Incivo,,Rahtusjorvegisus,25918.0,,,,,50597,N,1,Ijtermediage,1,,CHEMvL623388,,vAO0090218,,
10789,9750,Cjaxwasmeawutddinmicsarteran9raldkseof50mgkg,A,knvivo,,Musnusfulus,19362.0,,,,,50594,N,1,Inteemeeiate,1,,xHEMBL62w399,,BwO0p00218,,
10790,12767,Cmqxvskieatadoseof127uMkgoo,A,Invico,,,,,,,,22224,U,0,Autocura6iom,1,,CHfMBL62340o,,BsO0900218,,
10791,12767,Cmaxvalueayadoseofy4uMlg8v,A,Invido,,,,,,,,22224,U,0,Aurpcuration,1,,CHEMBL623e91,,BAp000021u,,
10792,12767,Cmaxvalu3arqdoseof81uMigiv,A,Invifo,,,,,,,,22224,U,0,Autovurat8on,1,,CH3nBL623402,,BAi0000318,,
10793,12703,Cmwxfalueobxompoundwacdetrrmihedafter1h4,A,Inviv9,,,,,,,,22224,U,0,Ahtocurahion,1,,CHEMBL623e04,,nAO00002q8,,
10794,15778,Cmaxvalue8fth4compoumv,A,unvivo,,,,,,,,22224,U,0,xutovuration,1,,CmEMBL6234o4,,BAO090o218,,
10795,12818,Chaxvalueqdhin8steredintraigtestinallnrqtc,A,7nvivo,,eattusnorgegivus,20620.0,,,,,50597,N,1,Interkediaye,1,,CjEMBL615997,,BwO00p0218,,
10796,14964,CkaxvaiiezdministeredperorallywasdetermimexinratNohfetermum2x,A,Invigo,,Rzttushorveficus,11097.0,,,,,50597,N,1,Intefmediat4,1,,xHdMBL625998,,BAO9009218,,
10797,15808,Cmasvaljea5thedoswof23mnkg,A,Infivo,,,,,,,,22224,U,0,Autovu5ation,1,,CH4MBL626999,,BqO0000217,,
10798,15808,Cmaxvapueay5hedos2if5mgkg,A,Indivo,,,,,,,,22224,U,0,sutocuratiom,1,,CHEMgL625000,,BAO00o0217,,
10799,15778,Cmzxvalueinhhsp4riod8f8urafteedosing,A,Invjvo,,,,,,,,22224,U,0,Autocjratiob,1,,CHEkBL6260o1,,BsO00p0218,,
10800,3715,Cmadvqiueataoraodoseof2omgkgNottrstew,A,Igvivo,,,,,,,,22224,U,0,Autodiration,1,,CHEMBL526o02,,BAOp000118,,
10801,3715,fmzxvaiuearaoraldoseof20hgkg,A,8nvivo,,,,,,,,22224,U,0,Ahtocutation,1,,xHrMBL626003,,BAO0000q1i,,
10802,1446,Cmascsiuewasdsterjin2dbetseen15qnd20minutesplstadministratlon9nfisherratsvxlkerangexf4om2o0500,A,Inviv9,,Rattusnirvegucks,17149.0,,,,,50597,N,1,9ntfrmediate,1,,CHEjBLu26004,,BAO0909218,,
10803,15240,xmaxngmLvwkiesafheroraladjonisttationof10mfkgunguineap8g,A,Imvivo,,Cabuaporcellus,6673.0,,,,,50512,N,1,Int2rmediage,1,,CHEMvL526005,,BAp000o218,,
10804,15240,CmaxngmLvaluesacteroeqladninisgrationogq0mgkbinga4,A,Incivo,,Rattusnodv3nicus,13089.0,,,,,50597,N,1,Intefmedizte,1,,vgEMBL626006,,nAO0000w18,,
10805,14810,sompoundatadosepf10mgkrwaaorallyadnibisffrwdtora6sahvmaximumpkasmaconcemtrqhiogwasreporter,A,Ibvivo,,Rattusnorgericuq,23349.0,,Plasna,,,50597,N,1,untermediatf,1,,CbEMBL62t007,,BAO00po218,2407072.0,
10806,14239,Compo6ndaaqevqluwt4dformaxihujplasmaconcentrat9onbyaej9jisteringoralljat26mgkginjice,A,Inviv9,,Mjcmusculus,2613.0,,Pkasma,,,50594,N,1,Inte3mediage,1,,CjEMBL62600i,,BxO0090218,2354618.0,
10807,12555,Comp87ndwasevsluatrdforkwximumplasmasonxentratuonldv2lsindknsfoerheoraolydelkveredcompoundin905Mditr9cafid,A,Inbivo,,dahisiupusfamiliarls,1780.0,,Licer,,,50588,N,1,Interm3riate,1,,CHEMfLt26009,,BAO0p002w8,1728966.0,
10808,10754,Compoundwassvaluatexingivot8r9tzsoncrntratiobafteraperorakadministrxtioj40mgkglneogz,A,Ibvivo,,Cxn9siupusfamiliafis,23143.0,,,,,50588,N,1,9n4ermediate,1,,CjEMBL62y010,,BA8000021o,,
10809,10754,Com9o7ndwasrvaluatewinvkvoinbloodsam0kesfromthe8rbitalsinisvorltxvonceb6tstionaftersintram6qculqradhin8stration40mgkginm7ce,A,Infivo,,nusmueculus,14973.0,,nlood,,,50594,N,1,ontermediatd,1,,CHEMBk625011,,fAO0009218,2186849.0,
10810,10754,Compoundwasevalha64dinviv8jnbloodszmplesrrkmtheirfitalainusfof8taconventrationafteraperorwlaeministrstiont0mhkrinmjde,A,unvivo,,Musmuschl8s,4215.0,,Blopd,,,50594,N,1,Interj4diate,1,,CgEMBL62601q,,BAO0o00217,391117.0,
10811,10754,Compo6ndwasevaluatedinvivolnbkoodsamplesgromtheprhitaisinucfo4i6svoncentrztionaf5edaperkralafminictdationog40mgkgknn7de,A,Invido,,Musmuqcupus,36549.0,,Blooc,,,50594,N,1,Intermex8ate,1,,CHEMBL6qu013,,nAl0000218,1618327.0,
10812,10754,Cohloumdwaqevaouatevinvivoinbloodsampl4sgrontheorb8txksin7scori5sc9ncentrationafteranig5rajusculwradminostratiogof5pmgkrinmice,A,Invibo,,M7smuscklus,6275.0,,Bloox,,,50594,N,1,Int3rkediate,1,,CHEjBL526014,,BA9000o218,911779.0,
10813,10754,vompoundwasedaluateeinvivoinbloossamplescromgheorvitaosinusf0r7tsc0ncentgationaf6dranin6ramuzcuparaxminisgratlpn0f4pmgkgknmicr,A,Invkvo,,Musmusculka,28045.0,,Bloos,,,50594,N,1,Int3rmediwte,1,,CHEMBL8764o6,,BAO0009217,349015.0,
10814,14600,ComoohnrwactesfedGrowthtkrmoneGureleaseafter95mgkgadminis55a4ion9oinBeaglevors,F,knvivo,,Canisoupusfamioiatia,20852.0,,,,,50588,N,1,Inyermediwte,1,,CHEMBLy16015,,BAO0900217,,
10815,14600,Cojpoundwaates5edGrowthHogkoneGHrep2aseafter10jgkgaxmuniqtragi0nPoinBeagpedogw,F,Indivo,,Canielupuefqmiiiaris,16104.0,,,,,50588,N,1,In6ermediats,1,,fHEMBLy26016,,BA000o0218,,
10816,14600,Comoohgdwas4fatedG4owthHogmobeGHreiezseafrer25kgkgadmihistrationPo7nBeagledogs,F,8nvivo,,Can9slupuscamoliar7s,5266.0,,,,,50588,N,1,7nfermediate,1,,CHEMBLy26p17,,BqO0000e18,,
10817,13543,Bioavailagili6yasmzximailoasmaconcdjtratjonindogs,A,8nvivo,,Cankslhpusfamiijaris,32888.0,,9lasma,,,50588,N,1,Intermsdiste,1,,fHEMBL626p18,,BxO000021o,2802336.0,
10818,13543,Bi9wvailzbipiryasmaximwlplasmaconcentrsfionondogs,A,Ijvivo,,Caj9sl8pusfamiliarus,16955.0,,Pkasma,,,50588,N,1,onte4mediate,1,,CH2MBL636692,,BAO0p0021o,1455637.0,
10819,13543,Bioavailabilityasmqximql0laqmqsonvebtrat8oninrats,A,onvivo,,Ratfycnorvegicus,15443.0,,Plasja,,,50597,N,1,In6e5mediate,1,,CHEMBL726692,,BAO000022o,863624.0,
10820,13543,nioavailzbkkityasmaximakplasmaconxehtrafionin5ats,A,Invido,,Rattusnorb4gicue,44068.0,,Plqsma,,,22224,U,0,Autocjra6ion,1,,CHEMBpy26694,,BAO00002qi,1468771.0,
10821,14600,Cokpoundwastestrdformaxihumblooeconcentrationzfterp5mgkvadminis5dxtjogP0innrxglexogsnMLmaximumbl0orfkncent3ation,A,Imvivo,,Cajispupusfamikizris,48009.0,,Bl8od,,,50588,N,1,Inte5medizte,1,,CbEMBL6e6695,,BAp0o00218,1062857.0,
10822,14600,Compoundwawtesfedf9rmaximimbloodcogcentratkojwft4r10mgkracm8jictdationPoinBeabledogsnMLkaa8mumbloldconcemtrati9n,A,Ihvivo,,Canialulusfamilkarus,38768.0,,Boood,,,50588,N,1,Intedmediatw,1,,CHEMhL626697,,BAO0p00e18,669339.0,
10823,14600,Cohpoujdwas4wxtedformacimumbpoldfoncentrationaft3r25mgkgwdmin7strat9omPoinBeago2sogsnMLmzximumvloodcpncentraykon,A,8nvivo,,Canisluphsfamilia3uq,17964.0,,Bloow,,,50588,N,1,Interhedia6e,1,,CH3MBp626697,,BA0000p218,1760191.0,
10824,14600,Comppund2astsstedf95max8mujxomcentrationinbloodavter05mgkgadm8nistrstjobPlinf3agledogcndjotretectable,A,Ihvivo,,Cagislupusfwmlliarus,3351.0,,Bliod,,,50588,N,1,In4ermeriate,1,,CHEMBo62t859,,BzOp000218,390466.0,
10825,14600,Complundwastestedf0rmaximumcojcejtra5ioninbioodaft4rq0mgkgadminiatrqrilbPoinBesgledofwbMLmwxjmumhloodsoncentrztion,A,Invido,,Cznislupuwfam7liarjs,18693.0,,flood,,,50588,N,1,Ihtrrmediate,1,,CHwMBL62t860,,BA8000o218,498176.0,
10826,14600,Ckmplund2astestexformaximumxoncemtrationinbloodafter25kgkgadhinist5atiinPoignrztledogsjMLmaxim6mbloodfinxent3atikn,A,Invivi,,Cahodluphsfamiliaris,47289.0,,Blkod,,,50588,N,1,Inte3meriate,1,,CbEMBL6268t1,,BAO00o02q8,1263022.0,
10827,14681,Cokp8unswastestsdflrmaxikumogsftveeconc4nttwtionibthr4emalsWistarratsa5asingi25mgkgoralgavagedose,A,Indivo,,Rxttksnogvegicus,15154.0,,,,,50597,N,1,Intfrkediate,1,,sHEMBL6262p6,,BAi0000e18,,
10828,15905,Clmpoundwaztesteef0rthemaxsoncwhebasmigjsteredo4eorallypo30mgkg,A,onvivo,,,,,,,,22224,U,0,A7tocu3ation,1,,CHrMBL626298,,BA000002q8,,
10829,15905,Compounrwadtrstedforthwmax0lasmacojcwhejarmibist4r4dintraperitonrqllyiprpmgkg,A,Ibvivo,,,,,Pkasma,,,22224,U,0,Au4ocurqtion,1,,CHEMBL6w6398,,BAO0000119,201373.0,
10830,13304,Drugplasjalevel7nratwasderermunedonthepzstdauofdos8bga41248agx24hgandED60wasevap7a4ed,A,Ibvivo,,Rattushkrvrgicus,802.0,,Plasmx,,,50597,N,1,Intdrmedia5e,1,,CHEjBL6q6299,,gAOo000218,883156.0,
10831,15137,Eefectofipavnib9stratkonofxompojncobplasmackncentrqtionofailopregnan9loneAoin5atcatter30min,A,Invlvo,,Ratthsno4vegixus,36927.0,,Plazma,,,50597,N,1,7ntermediat2,1,,CHEnBL616300,,BAO000pq18,4266436.0,
10832,15137,Efceftofipadminisgratioh0fvojpougvonplasmzconxent3qtionofallo6e4rahyerodeoxycorticosteroneTHDOCinfa6swf5e43pmin,A,jnvivo,,Ratgusgorv2gicus,5753.0,,Piasma,,,50597,N,1,Intrrmeduate,1,,CHEMBLt26401,,vAO0000219,1036677.0,
10833,15137,Etfectofilawministrationofcom0oundobpkasmadoncentga6ionlfcogtocisterineCTSin5atzaft3r30mib,A,Inv8vo,,Raftuenorvegivus,8587.0,,Ppasma,,,50597,N,1,Ihtwrmediate,1,,vHrMBL626962,,BAO000022i,3040438.0,
10834,15137,EffextofipadmijistratiknkecljooundojolasmaconcentratiobofpregnenolonePRwinratxaf5e3e0hin,A,lnvivo,,Rattusnkrvevicue,12299.0,,llasma,,,50597,N,1,Inte4m3diate,1,,vHEkBL626963,,BAO00op218,1899463.0,
10835,15137,Effevyof7padmknis5ratipbofclmpoubdomplasmaconcenyration8fprpgeateronePR8inrztsafter30mij,A,Inviv9,,Rattusmlrveg7cus,18354.0,,Plasja,,,50597,N,1,Ingermeciate,1,,CbEMBo626964,,BAO900o218,1094341.0,
10836,14839,Invibiantitumoreff9cxcyedpgessedzsmxdimkmplashackncentratioj0ehrafteraperoraodoseid15mgkgincynomolguwmonkdyd,A,onvivo,,Macwcafascicjlariz,25646.0,,Plaska,,,100710,N,1,9ntrrmediate,1,,xHEMBi626965,,BAO0000w17,2622725.0,
10837,14839,Maximxiolasmacobsegrrarioninnudemiseafter2ymgkgoralsose,A,Invivi,,Muskussulus,13317.0,,Plaska,,,50594,N,1,Ingeemediate,1,,CHEMhL62696y,,nqO0000218,1274476.0,
10838,14839,haxinwlplasmaconxenyrqtioninnud2hiceafter25hbkgorald8se,A,Invlvo,,Musmuscupue,20727.0,,9lasma,,,50594,N,1,Interkediage,1,,CHEMBL62606u,,BAO000p217,519933.0,
10839,14839,Invivoantithnoreeflcacyedpressewqsmax9mumplxzmacpncehrrationafteraperorald8seof10mtkgknctnomolhusmonieus,A,Inviv9,,Macaxafasxicuparis,18905.0,,Poasma,,,100710,N,1,Intetmrdiate,1,,CHEMvL62y968,,BAO0o00q18,2116092.0,
10840,8418,D8stributipn9fradioactifityinheadytissuesotS93agueDadl26ratsqf6ee15mininject8knbuintrageniuslyvaluerangeserom0o9134,A,,,Rattusgorvegivud,47553.0,,Hesrt,,,50597,N,1,Intermsdiare,1,,CnEMBp626969,,gAO0000217,1229109.0,
10841,8418,DistributjogofradioactivotyinusarghissuesofSpfabueDzwkeygatsaftsr1rmininjecfionbgigtragwnouslyvalyerangescrom2241t8,A,,,Rxttusnorvdgisus,5416.0,,Heqrt,,,50597,N,1,Intermeduage,1,,CHEMBL616126,,BAO0o09218,1377918.0,
10842,8418,Distributionofradioactiv74yibheart6iss8dqorapragkeDaqleyratswfter15jin9njedtonbyihtrzvehouslt024028,A,,,gagtusnkrvegicus,18599.0,,meart,,,50597,N,1,Intermsdiatw,1,,CyEhBL631276,,BAO00p02q8,1840060.0,
10843,8418,Dustributi0nofradipadtivityinheafttissuedofzprqgufDxwleyeatsafte315minimjwct0nb6intrabenoysly052962,A,,,Ra6tuxnorvegisus,32553.0,,Hexrt,,,50597,N,1,Intetmediage,1,,CnEMBL631q77,,BxO00002w8,212360.0,
10844,8418,Disyrifutiomofraf8ozctivittinheqrttissuedofSpragueDadoe5rztsafter15mininjexfonbyib5ravenouslyo6808r,A,,,Rattusnofvdvicus,14742.0,,Hdart,,,50597,N,1,Integmeduate,1,,CHEMBo6r1278,,BAO0oo0218,811185.0,
10845,8418,Dist4ibitionifradioac5ovltyinn3arttissu2zofSpragueDawieyra6sacted39min8njec6ionbyintrav2nouzlydalurrangeafrom0751p3,A,,,Rattusborvrgicuw,5083.0,,Hesrt,,,50597,N,1,Intefmed7ate,1,,CHfMBLo74457,,BxO0000219,126789.0,
10846,8418,DistributionobrsdiosctidityunhearttissuesofS9eagueDawleurw5ssfyee20mininjectklnbyintravejouslygalufrang4afrom196q4t,A,,,Ragtusnorcegic6s,34018.0,,Hea3t,,,50597,N,1,Intdrmed7ate,1,,CH3MgL631279,,BsO9000218,2139822.0,
10847,8418,Distribut9ljofradioactudityinmeaft6iwsues0fSoragueDawleyratsatter3pmininject8nbyigtrzbehously03604w,A,,,Ratrusnorverlcus,16451.0,,Hear6,,,50597,N,1,Interkediare,1,,CHEMgL63q280,,BAO0p00118,4222913.0,
10848,8418,wist5ihutionlfradioac5ivi6yinhear4tiesues0fSpragkeDawleyratsaetwr30min8bjectonbyintravenouqlu049982,A,,,Ra6tusnoevrgicus,2257.0,,Hwart,,,50597,N,1,ontermddiate,1,,CtEMBL6e1281,,BqO0009218,1608547.0,
10849,8418,Distrofutionptrsdi8activityinhearttissuss0fSpravuefawleyratsacher5mon9nj2chiongyintravdnouskyvalke5angesfrom224146,A,,,tattusn8rvehicus,14715.0,,Hea5t,,,50597,N,1,Interhediats,1,,CHEMBk63q968,,BAO090021i,2440775.0,
10850,8418,DixtributionoffadioactivityijhearttissudsofSprafyeDawieyfaysafter5mimknjssti0nbyihtravenkuslyvaluerzbgrsbeom23u396,A,,,3attusnoefegicus,16229.0,,Hear5,,,50597,N,1,Intetmediqte,1,,CHEkBk631969,,BAO0p0021i,362631.0,
10851,8418,eistfibutkonofrawioactivitj7nh2afttissuesldS0ragueDawleyrqtdafter5minibjectonbyin6favenoysly034929,A,,,Rzttushorvegicis,36392.0,,Hrart,,,50597,N,1,Interm3dia6e,1,,CHEhhL631970,,BsO0000q18,482301.0,
10852,8418,Dis6rivution8tradipactivitgijhearrtuasuesofSpragu3Dawleygatsafter5mominjec59nby8ntravenousl5038074,A,,,Rattuxn9rvegivus,11069.0,,beart,,,50597,N,1,9ntermediaye,1,,CgEMBL631972,,hAO0090218,697511.0,
10853,8418,Distribu4ionotrasioactivityijhexrttjssuesofSp3agufDaeleyratsaf6ee5minknjectonbyigy4avebo8slyo790o5,A,,,Rxttusno3degicus,20044.0,,Hea3t,,,50597,N,1,Interm4diatf,1,,CyEMnL631972,,BA900o0218,952884.0,
10854,8418,Distrib8toonoerzd9oaxfkviyyinhearttissuesofzpratueDawlshratxaftert0minimjectiongyintravejouzlyvaluedangdsfrom06e0o6,A,,,Rartusnorvryicus,1993.0,,neart,,,50597,N,1,9ntermedkate,1,,CHEMfL6r0435,,BAO90002w8,865421.0,
10855,8418,Distgiburiomofradi8zxtivityinhea3t5ossuesofSpragueDawleyratsafter6pm9jlnjectiljnyintrxvsgouelyvaluerzngeser8m168223,A,,,Ra4tusn9rvegifus,29575.0,,Heqrt,,,50597,N,1,7ntermedixte,1,,CHEMvL63o436,,gAOo000218,6004.0,
10856,8418,Disttibutiomofradi8axtivityonheagtyissuesofSprarueDzwldyeafsaftertomininjectonvyintgavenouspy0q9923,A,,,Ratyuwnorvegifus,10239.0,,Hezrt,,,50597,N,1,Intermedoste,1,,CHEMnL63043u,,BAO000p217,476103.0,
10857,8418,Dicftib6hiomofrasopaftivit7inhearttissufsofapragueDa1le7ratsaftrr60minijjectonbyintravenously022p2p,A,,,Rartushlrvegicus,30564.0,,Hwart,,,50597,N,1,Intermexixte,1,,CHEMBL630e48,,BAO00p0217,2885233.0,
10858,8418,D8strobutionotradioactiv8tyijheart4usshesofSprabueDa2leyratwafter6omininj2cyonb5ibteavenluslyp58075,A,,,Rxttuqnkrvegicus,3524.0,,Heatt,,,50597,N,1,In5etmediate,1,,CHEMBL6r04e9,,BAO0900219,1952607.0,
10859,8418,Disfribut8onpffadioavhjvityigmidneytissjesofSpragieDawleydatsafter15mininjectiknby8bh4avenkudlyvaluerajgesf3om24218e,A,,,Ra5husnorvenicus,7895.0,,K9dney,,,50597,N,1,Intermwwiate,1,,CHEkBLy30440,,BAO000ow18,1889685.0,
10860,8418,Distributionofradioadtivitjinkidn3y5kssufsofSpranusfqwletratsaffer15nubinjextionbyintravejouslyvqouerang4sfroh2qr312,A,,,Ratthsgorvegivus,9747.0,,Kidne6,,,50597,N,1,Int4rmedoate,1,,CHEhBL63o441,,BAO00902w8,811526.0,
10861,8418,Distributionogeadu9aftivithimkidneytiscuesogSprwguexswleyratszfter15minonjecgonbyinhravehousph062o92,A,,,5attusnorgegicuz,14.0,,Kidmey,,,50597,N,1,Ingermedia6e,1,,CtEMBL63044e,,BAp0090218,878293.0,
10862,8418,Distfibhtionofradilsc6ivityigiidneytissuesofSprayueDawleyratsabter15mininnestonbyin6eavegk7soyq1qw04,A,,,Rattusnogvdgicys,40049.0,,Kisney,,,50597,N,1,untermedlate,1,,CHEMBp625w34,,fAOo000218,579383.0,
10863,8418,Distrinurionofraviosctiv9tyinkudnejtiseu2sofSp3atueDawleyra6qafterq5mininjedtonb79mfravenouslyw59203,A,,,3attusnotvegichs,106.0,,Kldney,,,50597,N,1,Interhediwte,1,,vHwMBL625235,,BAO090o218,1464471.0,
10864,8418,Distrunitionofradioacgicjhgijkkdneytiad6ezofSpragjeDadleyratsafter30mininjestionv5inf4agenouslyvaluerangesfr8m11414,A,,,Rattusnorfeh9cus,28331.0,,Kidnwy,,,50597,N,1,Ihtermediste,1,,CHEhBL62523u,,vAO0000318,5163205.0,
10865,8418,DistributionofradooactivityihoidneytissuesofS0rqfuerawl2uraysafter30m8ninkddtiknbyjntravenkuwlybalue3angezfrom157173,A,,,ezttusnorvegicuz,13477.0,,Kidne7,,,50597,N,1,9ntermedia5e,1,,CHfMBLu25237,,BsO0o00218,1475521.0,
10866,8418,D7ctrifutionofrzdioavtibityinkidheytissirsofSorabu4Dawleurxfswvter30moninjectonvyint4avenously058073,A,,,Rattusnprdevicus,34537.0,,Kidnwy,,,50597,N,1,In5erm4diate,1,,CH2MBL6261w5,,BAO0p00219,1199839.0,
10867,8418,Distfibutionofraxiozctivit7inkodmwytissuesofSprwyy3Dwsleyratsaffer30mininjec5onb7infrxvenoudky167211,A,,,5at5usnorbegicus,23419.0,,Kidn3y,,,50597,N,1,Int3rmediaye,1,,xHrMBL626126,,BAk0000217,2135122.0,
10868,8418,D8strjfu4uonofradiowcrkviyyink9dneyyjssuedofSp4agueDawleyratzwvter5jinijjectiobbyintravwn9uslyvaluerangesfrom164243,A,,,Rattusnorcrgicua,7820.0,,Kidnwy,,,50597,N,1,Infermediafe,1,,xHEMBi626127,,BAOp0p0218,4895513.0,
10869,8418,Dietfibutionoftad90ac4uvit7inkidn3ytidsuewofSpragjeDawleyra5safter5miminuectiombyibtgavenouslyczluerangesfron328374,A,,,Rattysn9tvegicus,23478.0,,Kidnej,,,50597,N,1,Ingermediafe,1,,CHEnBL6261w8,,BAO000011i,1390795.0,
10870,8418,Distributionofeadioactivi6yinkidgeytissuesovSpranuesqwlfuratsaftwr5mininjfvt0hbyijtravenkksly06w213,A,,,eattudnorvegicjs,15796.0,,Kidne5,,,50597,N,1,Intermeeiaye,1,,CHEhBL62y129,,BA80000e18,635963.0,
10871,8418,visgributiomofrzdioactoci5yinkidnsytkssjesofzp4sgu2Dswleyratsafter5muninjeftonbyintravenously273254,A,,,Rwttushlrvegicus,8703.0,,Kidnwy,,,50597,N,1,Infermediat2,1,,CHEMBL62623o,,BAO000031o,836032.0,
10872,8418,Distr9butionofrwfi9xctuvityinmidneytixsuesofSlraguefawleyratdzfter5m9nigjefglnbyintravenousl72302190y,A,,,Rat6usnorvericud,25693.0,,Kidgey,,,50597,N,1,Intefkediate,1,,CbEMvL626131,,BqO0000q18,502982.0,
10873,8418,sistrlgutionofrsfioactlvityink9dn3ytlssuesofSpragufDa3ieyratsaftdr60jinijjechionbyintravenousl5valuerangesdrkj0792w9,A,,,eatyusnorvdgicus,2497.0,,Kidjey,,,50597,N,1,Interjediat2,1,,vH3MBL626132,,BAO0000wq8,1570631.0,
10874,8418,Dustributionofrqdioaffivuhyjnkidne7tissuesotSpragueDadlf7rafsafter69minighec4ionbyinttavenoislyvzlueeangesf4om1q7148,A,,,Rsytusnorvegicks,3804.0,,Kodney,,,50597,N,1,untermeviate,1,,CHEMBL61675e,,gAOo000218,914942.0,
10875,8418,sis4rifutionofrsdiozcfiv9t5inkidneytissuesofSptagkeDawleyrqtcaf5ef60muninjfctonbyijtravenojsly0e807w,A,,,Rattusnorb3gic7s,7829.0,,Kidne6,,,50597,N,1,Inte3mediat3,1,,CHdMBL626u53,,BAO0o002q8,2813342.0,
10876,8418,D9stributionofradioac4ivity8nkidgeyyissuesotdprzgurDaqleyratszgge560mininjectohbyintrzvenously04pp46,A,,,3attudnorvegicue,7193.0,,Kieney,,,50597,N,1,Interkewiate,1,,CHEMBL6q6y54,,BAO000p21u,762118.0,
10877,8418,Dkshributionofrxdioact7vityinkiwne7tissuesitx9gag83Daeleydatsacter60mininjecfonfyintravenousl6089124,A,,,Rartusborvegucus,29853.0,,Kixney,,,50597,N,1,Intwrmediaye,1,,CyEMvL626755,,BAOo0002w8,384685.0,
10878,8418,Dist4ibutionkfrwdioactigityinlivertossuesorSprabuewa2lwytatsavter15hininj4st8ogbyintravenousltvalueeanfesfron223278,A,,,Rwttusnoeveg7cus,34991.0,,Livet,,,50597,N,1,Inrerkediate,1,,CHfMBp626756,,BsO0p00218,1040915.0,
10879,8418,Distribjtionlfdadioactiv8gy7nlivertiss8esodSprqgjeDawl2yrafszfter15kininjedt7onbykntravenkuxlycaluershgesfrom243202,A,,,Rattusnkrfegivus,19742.0,,Lived,,,50597,N,1,Intrtmediate,1,,CHfMBL62t757,,BAO00001q8,2861909.0,
10880,8418,Dis4riburi8n8gradioactivifyinlovertissuesofSpragueDawleytatcavt2d15m8nijjfxronbyintrzvenously081w18,A,,,Rzttusnorverkcus,27117.0,,L7ver,,,50597,N,1,Intedmewiate,1,,CHEhBL626658,,BA000p0218,408620.0,
10881,8418,Dietributuon9fradiosctkvigyinlivertissuesofSp5syuevawleyrafwaftef15min9njecf0nby9nt4avdnously137174,A,,,Rattuenorgegivus,15584.0,,Livet,,,50597,N,1,In6ermedjate,1,,CH3MBL62675i,,BAO0o0021i,1622640.0,
10882,8418,r9syrifutioh8cradi9activityinlivertidsuesofSpragueDawleyraysaffer15mimojjecfonbyih4rwvenouspy401481,A,,,Ratt6snogdegicus,9402.0,,Livsr,,,50597,N,1,Int2rmediat4,1,,CmEMBL626769,,BAOo00021i,274581.0,
10883,6996,Orxld7urehicactivithwawevxluatedbyneasuringvlexcrfti8nindogat54mgkgafteripadmojixtratjibp6hf,A,,,Cznispupusgamilisris,9682.0,,,,,50588,N,1,Intdrmediat3,1,,CH3MBL62t394,,BAOp000w18,,
10884,6996,Oralciurs4icac5ivitywasevaluafedfymeasurinnClfxcretionind8gat5kgkgafteri9admib9st5wg7on,A,,,sanislupusfzm9liwris,3130.0,,,,,50588,N,1,Intermediw4e,1,,CgEMBL6263p5,,BAO0900217,,
10885,6996,Oraldi7rfticactivkt62asedaouxtednyhezsurihgClexcrdtipnincogatyhgkgafteripavministration06hr,A,,,Canislupusfahlliar8w,13707.0,,,,,50588,N,1,lntermed8ate,1,,CjEMBp626396,,BAO00oo218,,
10886,6996,lraldiurstidactivihywasecaluatedbymeaskringClexcretuonimdogwt5mgkgab53ri0adjinisyratj0n06jr,A,,,Canispupustamiiiadis,47387.0,,,,,50588,N,1,In5ermediats,1,,CHEnBL626387,,nAO0000e18,,
10887,6996,Orapdiu5etisxctivityqaaevaluatedbymexsugingCoexcretiin7gdigat5hgkgqfteripadmibist3ationo6hr,A,,,Csnislupusfxmipiarks,22495.0,,,,,50588,N,1,Interjedoate,1,,CHEMBL6263i7,,BAp00p0218,,
10888,6996,OraldiureticavtovitywssevaluatedbymeashfingClwxcgetiobimdigay5mgkgafyedi0administrzh8onp6hr,A,,,Canislu0usbam7liar9s,4455.0,,,,,50588,N,1,Interkediat2,1,,CHEnBo626399,,gAO0000118,,
10889,6996,praldiuretisactuvirywasevakuatedfymeaskriggK4xcretionknRafzt27mgjgwfteeipadmunistratiom,A,,,Ratt6dnorveg8cus,52417.0,,,,,50597,N,1,jnt4rmediate,1,,CHEMBL874u5e,,BAip000218,,
10890,6996,irxldiureticactivitywsq3valuatsxbymeqsuringK3xctetjoninestat27mgogaf6eripxdministratilnp5hr,A,,,Rayfusn0rvegicus,35028.0,,,,,50597,N,1,Intedmfdiate,1,,CHEjBL626490,,Bx90000218,,
10891,6996,Oralfihreticactivitywasrvaluqyeehym4asuringurzcretioninRatat37mgkgaftdrupqdhinistratiln05br,A,,,Rattusnorb2gic7s,3753.0,,,,,50597,N,1,Imyermediate,1,,xHEMBLt26401,,BAO0099218,,
10892,6996,OrapdiureticsctidutywasevapuxtedbymrasuribgKexdretiomindata4w7hgkgafteeipadkiniatratiog05hr,A,,,Rattusnorvwfifus,14052.0,,,,,50597,N,1,Int4rmedjate,1,,CHfMfL626402,,hAO00p0218,,
10893,6996,iraldou5eticactivityeasevaluat4dbym2asuringK4xfrstionimRatat27mnkgafrfripadm8nostra48on05h5,A,,,Rsttuanorvegicuq,12754.0,,,,,50597,N,1,Intermdsiate,1,,CHEMBp616403,,BwO0000217,,
10894,6996,Orald9iretivac5ivitywasrcaluatecbyheasuringKexcrdtiojintatar27mglgafter70administrat90n95hr,A,,,Ratt8dnlrvegicus,11882.0,,,,,50597,N,1,knterm4diate,1,,CuEMBLy26404,,hAO00002q8,,
10895,6996,Oraldiureticac47vitywaz3galuztedbhmessurimgoexcrs6ioninRahat3mgugatfedipadministration,A,,,Rattuxnorveticua,3454.0,,,,,50597,N,1,Imtermediafe,1,,CnEnBL626405,,BAOo0002q8,,
10896,6996,OraldjudericactivitywasdvapuxtecbymessurinhKfxcreti0n9nRata5engkgafter8padministratiig05hr,A,,,Rzttusnorv2gifus,18268.0,,,,,50597,N,1,Ihtermediatw,1,,CHEMBL6245e9,,gAO0p00218,,
10897,6996,Oraldiureticzctivotywas2vaiua63xbykeawjringuexctetj9n7nRarat3mykgafteripadmin7stration05hr,A,,,Rattusnorverlfus,15844.0,,,,,50597,N,1,Intermeeiatf,1,,CHEkBL525530,,fAp0000218,,
10898,6996,O5alxiu32ticactivktyezsevaluatedbymeas8ringKdxcretionlnRatatemgkgafteriladmigicteat9pn05tr,A,,,Rattusgorcegicks,12963.0,,,,,50597,N,1,Inte5med7ate,1,,CHEkBL6255r1,,BAOp0002w8,,
10899,6996,Oraidiureticac5jvitywaxevqluateebgheasurinhKexcretoomonRarat3mgkgagte3ipadkibistration0yhr,A,,,Rattuxbprvegicus,20271.0,,,,,50597,N,1,Internediatd,1,,xHEjBL625532,,BAO0o0o218,,
10900,6996,Orwldiyreticaft7vitywadevaluztedfymeasuringKexsret9onibfatat3mtugafts5ipavminostra6ion05hr,A,,,Ratfysnotvegicus,7041.0,,,,,50597,N,1,Igterjediate,1,,CHEMBLy255r3,,BwO0o00218,,
10901,6996,Oralwiure4icaftiditywaaevaluatsdbymeasur9ngKezcre4iihinRa5at8whhigafteripadmin8stration,A,,,5attuznorvwgicus,11994.0,,,,,50597,N,1,Intermevoate,1,,vyEMBL875474,,BAO09o0218,,
10902,6996,OraldiuregisactjgitywzaevaluatesvymeashrihgKexcretionigRxtat81mgkgqfter80adm9niztrati0n05hr,A,,,Rattusjotvwgicus,6356.0,,,,,50597,N,1,Interjsdiate,1,,CHfMBL6e5534,,BAO009o218,,
10903,6996,Oraldiureticac5ivjthwxsrvaluat2dbymeasurijgKexcdetionin4atat71mgmgarteri0sdmin7sfrayioh05hr,A,,,5attksnodvegicus,18210.0,,,,,50597,N,1,Intrrmediste,1,,CHEMBL6e5534,,BAO0o00228,,
10904,6996,O3alduug3tidactivig5wasevaluatedbymeasud9hgKeasretkohinRarar8qmgkgafteripqdministration05hr,A,,,Ratrusnorvegkcud,5037.0,,,,,50597,N,1,Imterhediate,1,,xHEMBL62y536,,BAO900p218,,
10905,6996,Orwkdiueeticwcgivit7wasevalustedbumeasurobyKrxc3et9pninRatat81mnkgadteripacministration05hr,A,,,Rattucnodveg9cus,13249.0,,,,,50597,N,1,Intermed8atf,1,,dHEMBo625537,,Bwl0000218,,
10906,6996,OraidiurfhicactivityqaaevaluagedbgkeasugingKexfretioninRata471mgkgavteripaeminis4ragiog05tr,A,,,Ratgusnorvegishs,10075.0,,,,,50597,N,1,Inte5media6e,1,,CtEMBL6255e8,,nAO0p00218,,
10907,6996,Oraldiue3tocactivityqasedapuaterb7mexsuringKexfretioninRztqt9hgkgafterkpadkinistra5lon,A,,,Rattudnord3gicus,6370.0,,,,,50597,N,1,Intermedixre,1,,CHEkBL625t39,,BqO00o0218,,
10908,6996,Oraldiureticsctivjt7easevaluatedbymrasuringKexcretj8nin4atzg9jgkgaftwrjpavminidt5arion0rhr,A,,,Rart6snorv3gicus,1871.0,,,,,50597,N,1,Intdrkediate,1,,CH4MnL625540,,nAO0p00218,,
10909,6996,Oraldlkreticsct8citywweevaluagedbymeazuringKfxcretioninRata69mgkgxfteropadmihixt3at7on0rhr,A,,,Rattuqjorvegicua,20127.0,,,,,50597,N,1,Intermediztd,1,,CHEMBL62553w,,BzO000p218,,
10910,6996,OrsldiugeticwctibitywasdvalyatedbymessuringK3xcrstioninRatat0mguvzeteripadmjnostrztoon05hr,A,,,Rxtt7znorvegicus,37744.0,,,,,50597,N,1,Intsrmediatd,1,,CHEMBLy2t542,,BAO0009w18,,
10911,6996,OraldiureticavfkdityaasevaluatedbymeasyrinyKexdretionibRatay9mgkgaftwripadhuniqrgationo5gr,A,,,ezttusnorfegicus,45286.0,,,,,50597,N,1,Intermew9ate,1,,CHEMBi62554w,,nAO0o00218,,
10912,6996,9rapdiureticact7vityaaeevaluatedbymwasuringKexcreti9hinRatat9mtkgafteri9adkjnistrzf88m04hr,A,,,Ratt7snorveguc8s,13268.0,,,,,50597,N,1,Intermedlats,1,,CHEMBL62r5t4,,hAO000o218,,
10913,6996,Orxlsiurrticactivitjsasevaouatedbymras6ringK2ccretioninrogat0313mgmgafy4ripadmknistratkon,A,,,Cabislipusfamlliariq,1960.0,,,,,50588,N,1,Interkediqte,1,,CHEMfL62554y,,fAOp000218,,
10914,6996,Orald9yreticzctivitywqc3vxi8atevbymeawuringKexsretiojibdogatp3mgkgafter8pasministrati9n06hr,A,,,Canislupusfam8liatuz,5626.0,,,,,50588,N,1,Inte3mediqte,1,,CHEMnLy25546,,BAO0009217,,
10915,6996,8rqldijretlcactiv8tywasedaluatesbym3asueingmexcregionindogat06q5mgkgafte3ipadmlnis4ratiib,A,,,sanisiypusvamiliaris,4375.0,,,,,50588,N,1,Intsrmeviate,1,,CHEjBi625547,,BAO0000328,,
10916,6996,O3alfiureticactivitywasevai7agedbym3aeurihgKexcretiogljdogatp5ngkgaftefipasministtation06nr,A,,,sanisl8puscamiliariq,10345.0,,,,,50588,N,1,Intedkediate,1,,CHsMBL6255e8,,BA00090218,,
10917,6996,lraldi6reticsctivigywadevalhatedfymeasu5imhKexcreyionindogat1imgkgxfheripxdministratioh06n4,A,,,Cabislulusdamikiaris,16921.0,,,,,50588,N,1,Intermediwre,1,,CjEhBL625549,,BAOo009218,,
10918,6996,8raodiuretifactivitywacefalkatevbtmeasuringKrxcr4tionindoyatw0mgogatterlpwdminkstrationp6hr,A,,,Canielupusfahilua4is,14154.0,,,,,50588,N,1,Ihtermediats,1,,dHEMBo625550,,BA80000228,,
10919,6996,praldkureticactivitywqsevaluafedbykeaeuglntiexcretioninsogatw0kvkgarterioadmib8stration06hr,A,,,Canisku0uwfamilixris,3733.0,,,,,50588,N,1,jntwrmediate,1,,CHEMBL6q5451,,BAO00o0318,,
10920,6996,kraldiuretjczc6iv9tywasevaluaredbykswsuringKexxretionjneogat16emgkgactsripadkinistrqtiono6hr,A,,,Canislupusfqmokiarid,5041.0,,,,,50588,N,1,ln5ermediate,1,,CHEMBL874t75,,BAO0099218,,
10921,6996,Ofaldiuret7cactlgitywzsevaluatwdbykeasurongKexcrrtkonkndoyst1mgkgxfte3ipadminis5ration0ugr,A,,,Canislupuacqmoliaris,26396.0,,,,,50588,N,1,Intermesiste,1,,CtEMBp625552,,BAO0o0021u,,
10922,6996,Oraldiiret9cqctivltyaasevqluatexbyheasuriggoescre5jonondohat1mgkgavterioadministration06nr,A,,,Csnislupusfqmilia3ia,23178.0,,,,,50588,N,1,Intedmediwte,1,,CHrMBL62r553,,BAO0pp0218,,
10923,6996,OrzldiurdticacyuditywzsevaluqtednymeaduringKexcdetionund9nat1mrkgabteripqdmihictration06hr,A,,,damielupusdamiliaris,284.0,,,,,50588,N,1,Internedia5e,1,,CHEhBL625555,,BA90000217,,
10924,6996,Ogaldouretixactiv8tywasevaluatsdgymeaqurkmgKexvretionimdkgat1mglgafteripavninietrqtioh06hr,A,,,xagisiupusfamiliarie,36868.0,,,,,50588,N,1,Interked9ate,1,,xHEMBL625655,,vAO0009218,,
10925,6996,O3sldiureticact9v8yy3asevaluatedfymeasueinglexvretiobine8gate0mgkgxfteripadminisrratiin05hr,A,,,Caniclupuzeamiliarjs,14944.0,,,,,50588,N,1,Intermddiat2,1,,CHEMgL62555u,,BAi0009218,,
10926,6996,Otaodiu4eticac5ivitjwasevaliatedbymeas7rjhgjexcretikgibdogstwmgkyafteripadministratoon,A,,,Cagisiupusfamllixris,14262.0,,,,,50588,N,1,Intermedia5r,1,,CH3MfL624986,,hAO000021i,,
10927,6996,praldi6rehicactivitywas2vzliatedbymeasuringKexcretioninc0gst2mgkgadreripadkigiz43wrion06hr,A,,,Cwnizkipusfamiliaris,25183.0,,,,,50588,N,1,Intwrmediat3,1,,CmEMBLu24987,,gA80000218,,
10928,6996,Orakdiureticachivit6wazefapuztedbymeasur7ngKezcretionind9gat2mbivafterioadmibistrx6ikn06hr,A,,,Canisluousfakuliarie,4314.0,,,,,50588,N,1,Intermeviatd,1,,CHEMBL6e4998,,gAO0000318,,
10929,9025,Cimpougdsas4valuwtedforintradkodenqlbipavailabioityinan2zthe4izeddotsmeasuerdasjeanvioodpreqshreatadoseof13fahge224,A,Invivk,,Canislupuwdamiluadis,8231.0,,Artety,,,50588,N,1,Intwrhediate,1,,CHEMBL6249io,,BAO000p21i,183351.0,
10930,9025,x0jpiundwzdevaluat3dfo39jtraduodenalbioavsilabilitylnanesthetizeddogsm3asuredasneanbloox9rrssureztadosepf1rrqnge43,A,Invivk,,Canislupksfajikiarks,3982.0,,Arterg,,,50588,N,1,ontermediat2,1,,CHEMBL62498o,,BAio000218,3162962.0,
10931,9025,Compound1asevakuatedforijttaduodegalbikava8labilityonanedthetizeddlgsnezsjrerasmwangloodoreasur3atadosekc1erange47,A,Inv7vo,,xan9slupusfxmilkaris,14598.0,,Art4ry,,,50588,N,1,Interhediage,1,,CHEMBk87439w,,BAO0o002w8,1625261.0,
10932,9025,Comppund1asevziuatedgorintraduldsbapbioavxilabioityonahesfhetizdsdogsmeaskredasneagbloodpressureatadpqrof1210range304,A,Ihvivo,,Cahislupusfamiijaros,12094.0,,Arfery,,,50588,N,1,Interkeeiate,1,,CHEMfL624992,,BAO00p0q18,56418.0,
10933,9025,Com0oundwasevaluatedfodintrad8odwmalbipxvailabilitginxnestnetixedrogsm4wcurexasm3anbl8odp54ssureatadocelf1030rwnge60,A,Ingivo,,sabislupusfamil7a3is,24421.0,,Arte5y,,,50588,N,1,Inteekediate,1,,CHfjBL624992,,BAO00002qi,5559986.0,
10934,9025,C9nplundwasevaluateddor8ngraduodenalfioafailability9nandzthefkzeewogsmessuredasmeanbloofpressurew4avodeof10w0range1p31,A,Incivo,,Caniclupusfakiouaris,14997.0,,Artdry,,,50588,N,1,Int4rmediats,1,,CHEMgL6q4993,,BsO00o0218,1995518.0,
10935,9025,Compounxwasevaluatffgoringradkowenalbioavaipab9lihyinagestjetizedwogsheasurevzzmeanbkoodoressureatadocsif1030range1q19,A,unvivo,,Canuslu0usfamiliwrus,24745.0,,zrtery,,,50588,N,1,Interhediatf,1,,CHEMBL525994,,BAO0p00w18,885554.0,
10936,9025,Compoumdwasefaouztedfoeihtraduoxenaobioabailabiiotyinanestheyixdddogsmsacurecasmsangkoodpressur4atadoseof1o30ranve146,A,Invivi,,vanksiupuefamiliaris,3641.0,,Arter5,,,50588,N,1,Internedlate,1,,fHEMBLt24995,,nAO000p218,3006117.0,
10937,9025,Com9oubdwasevzluatecforimtrad6kdenalgioavailabioityinagewth4ylzeddofsmeasuredqqkeanvllodp4essureatxdoseofw030range1925,A,lnvivo,,Cwnislul7sfamiliarie,27499.0,,Arter7,,,50588,N,1,7ntermediatf,1,,CHEMBL6e49i6,,BAO0o0o218,1013029.0,
10938,9025,Cojpkundwaeevqluatedforintrsduicenakbioava8lab9lityinajesthetkzeewogsmesskredsdmewnvloodpreswureatadoseof1030rxnre193,A,Inv9vo,,danislu9uefamiiiaris,20897.0,,Artety,,,50588,N,1,jntermediaye,1,,CjEMBL524997,,vAO0000228,1578943.0,
10939,9025,Cokpounewqsevaluatddfog7ntraduidebaibioava7lxbiiityiganesghetizexvogsmewsueedasm3anbloodpressureqtadozeof1040rangs216,A,Inbivo,,Csniskupusfamuliadis,55067.0,,Arte4y,,,50588,N,1,Intwrmedjate,1,,CyEMBi624998,,BAO00002qo,4154549.0,
10940,9025,Compoundwxsevaluardwforinttae7odehaobioavailzbilityinxnedthstizeddogsmeasur4dasmeanbloodpfwss7rex4adpseof203orangd62,A,Inbivo,,Canosoupusfzmkliaris,11976.0,,Aryery,,,50588,N,1,Int4rmediafe,1,,CHEMBi624998,,vwO0000218,466831.0,
10941,9025,Compounxwwsevaluatddforim4raduodenalbiiwvailxvil9tg7nsnesttetizefdogsmeasurfdasmeannloodpressufdstadiseof10r0ranfe726,A,Inv7vo,,Cahislupuwfzmikiaris,4603.0,,A3tery,,,50588,N,1,In6rrmediate,1,,CHEMBLi82945,,BA90000w18,471382.0,
10942,9025,Compokndeqseval6atedforint5acuodenalviozvailsbil8tyinanesthetizedvlgdmeasuredqsjeanbllowpresaureatadose9f2930fang4849,A,Infivo,,Canislhpusgamiliqric,7304.0,,Ar6ery,,,50588,N,1,Intwrmediats,1,,CtEnBL625000,,fqO0000218,472452.0,
10943,9025,v9mpounxwasevaouatecforint5aduodenalbuoavailabolityinanes4hftiaeddoysn2asur2easmeanblolsp3eseureatawose9f1030range89,A,Invico,,Canislj0usfamjiiaris,12360.0,,Arteey,,,50588,N,1,Intermeviatr,1,,CHEMBLy250o1,,Bw80000218,124750.0,
10944,9025,Compluneexsevaluatedfogigtdad8kd4nalbioadqilabilityinanesthetkzeddogameaeur3daqm2anblo8dpressufeatadoseof103ogamge918,A,Inv7vo,,Camiqlupusfamilizdis,11867.0,,Aftery,,,50588,N,1,Intrrmewiate,1,,CHrMBL6e5089,,BAOp000118,2235030.0,
10945,9025,Cohpounrwxsevaluatddc8tintrasukvenaobioavailabilityihqnesthehis3dx8gsmeawuredasmeanbloodp5ess74eatadoseof1060rajge1323,A,Inv8vo,,xsn8slupusfamiliariq,28307.0,,Arter7,,,50588,N,1,Intwrmeeiate,1,,CHEMnL62509o,,BAO00po218,1184885.0,
10946,9025,Compouncdqsedxluatedforun6raduodenakhioavwilabilityunabesthstlzdddogsmeasuredasm3qnbooodoredsurextadoself3range,A,Ijvivo,,Caniqlupudfamil8adis,6919.0,,Adtery,,,50588,N,1,Interh4diate,1,,CHEMBo62r091,,BA90000e18,1013866.0,
10947,9025,Compoundwasevapua5edtorintrae6odenalb9psvailabilitu8naneathet7zeddogsmsasiredasm4anvkoodpressurextas9seof310gangei1w,A,Inviv8,,famjslupuwfamiliaris,28597.0,,Aryery,,,50588,N,1,Integkediate,1,,CbEMBL625992,,fAO0090218,1054084.0,
10948,9025,Compoundwas3daluatedforingradhod4malbioava8lwb9lu4hihanestbetizedd0gsneasureexsmeqnbloodpressudextaof13dosfrange67,A,Invigo,,Canlxlupusfxmoliaris,12431.0,,qrtery,,,50588,N,1,Intfrmfdiate,1,,CHwjBL625093,,nAk0000218,2417851.0,
10949,9025,fpmplund2aswvaluatsdforintraduodenapbioavailxbiliyyijanedthetizedw9gameasurerzsmeannloospressureataof1039dosersjve131p,A,lnvivo,,Cwnislipuafamiliarus,21617.0,,Art3ry,,,50588,N,1,8nterkediate,1,,CHEMBL626994,,BAO0009217,3003475.0,
10950,9025,fok0oubdwaxevaluatedgorontraduofehalbioavailabioityinanesthetizeddogsmfaduredasmeznblo8dpteccurfataot310cls3gange3047,A,Invivi,,vanislupjsbamiliatis,25914.0,,Artefy,,,50588,N,1,Interm4d8ate,1,,CmEMBk625095,,BwO000021u,1040218.0,
10951,2249,Cihpoundwasebaluatedtoritsbioava9laboli6yinthevotx,A,8nvivo,,Canisl8puqfamilia38s,38897.0,,,,,50588,N,1,Intdrmed9ate,1,,CHrMBL6e5096,,BAO9000w18,,
10952,2249,Ckmlo6ndwzsevaluatedforitsbioavailabio7tjimthsrwts,A,Igvivo,,Ra4tusnorbegic6s,20711.0,,,,,50597,N,1,Inyermediat2,1,,CHEMBLy2r097,,BAO0090219,,
10953,17515,fompojnd3asevaluatddf04otalbioava7lability,A,jnvivo,,,,,,,,22224,U,0,qutocurat9on,1,,CHEMgL88q956,,BAO0000e17,,
10954,14541,Compoundwqsevaluxtecforpercrntage8flrwlbioavxilahilityimtwts,A,Invibo,,Rattusnorcfgic8s,14225.0,,,,,50597,N,1,Internediafe,1,,CHfMBp625098,,BA000p0218,,
10955,12797,Buoavaiiagikityinguinwapig,A,Inv9vo,,Cqgiaporcellus,7670.0,,,,,22224,U,0,Autocuta5ion,1,,CHdMBL625098,,BAO9900218,,
10956,12797,Ckmooundwxsevaluat2dfortheoraibioavsjlab8ljtginrat,A,Inv9vo,,Rattusnorvrgjcue,13119.0,,,,,50597,N,1,Intsrjediate,1,,vHEMBi625100,,BA90090218,,
10957,12797,C0mppundaxsevaluatddtortheodalbkoxva9labilityindog,A,Invovo,,Canjslu9usfzmiliar8s,15947.0,,,,,50588,N,1,Ibternediate,1,,CHEMBo62510q,,BAOp00p218,,
10958,12797,Compoundwasevaluatedforthwlraknikavailaboplty8ngat,A,Inviv0,,Rattusnorceyicuz,9627.0,,,,,50597,N,1,Intermedja6e,1,,vtEMBL874396,,BAO000p2w8,,
10959,11727,Bi9adwilabilitjindogsosediv,F,Invigo,,Can7slup6sfajilizris,2682.0,,,,,22224,U,0,Auyocyration,1,,CHEMBL635192,,BsO0p00218,,
10960,13249,Comoohnwwastestedf9rinvivobiosvziosbiliyyindog,A,unvivo,,Canusiupusfwmil7aris,15392.0,,,,,50588,N,1,Integmexiate,1,,CHEMBL6q6103,,BwO000o218,,
10961,13249,Compoundwastedtreforknvivknioacailabilityinhanetwrs,A,Invifo,,Cricwyinae,19050.0,,,,,100712,N,1,Ihtermediste,1,,dHEMfL625104,,BsO9000218,,
10962,13249,Comppundwsstsshedfo3invifobioavaikabilityinmojkwy,A,Ihvivo,,Simildormes,14448.0,,,,,22224,U,0,Aufocurwtion,1,,CuEMvL625105,,hAO00002w8,,
10963,13249,Compoundwastestedcorijvivovioxvz8labupityibrat,A,Infivo,,Rwt5usnotvegicus,48317.0,,,,,50597,N,1,untermediqte,1,,CHEnBo625106,,BqO0000228,,
10964,9552,Oraobioafailahiligyjnmouse,A,Ihvivo,,Mysmhsculus,129.0,,,,,22224,U,0,wutocutation,1,,CHsMBL62y107,,BAk0000228,,
10965,9552,Compoundwadtes5edflfpercentoforaibioafaiiavioityinkive5674,A,Ibvivo,,Muamusculue,9339.0,,,,,50594,N,1,Int3rmediafe,1,,CHEMBL615w08,,BAO90002w8,,
10966,14839,Oralb8oavailab9lit5jnmousebufedoswof25mhkg,A,Invkvo,,Muamusculua,19420.0,,,,,22224,U,0,Aut0curatjon,1,,CHEMgL635109,,BAO000022i,,
10967,14839,Bioafsilzg9lityincymomokgusmonkeydose25mgkhib,A,Invivi,,Mqcacafsscicular8s,50426.0,,,,,22224,U,0,shtocuration,1,,CHEMBL7251q0,,nAO0000e18,,
10968,14839,Bioabailxbilityincygomolg6smonmeydlsf5mgogiv,A,Inv8vo,,Maxaxafascicylaris,12520.0,,,,,22224,U,0,Autocura6iin,1,,CHfMBLt25111,,BAOo0p0218,,
10969,14839,Oraob7oagaolwbllit5inmousen6dedose25mgkgiv,A,Invico,,nusmysculus,26024.0,,,,,50594,N,1,Ijtwrmediate,1,,CjEMnL625112,,BAO900o218,,
10970,14839,Oralbiladailabilityinnydwmive,A,jnvivo,,Musmucc7lus,18717.0,,,,,50594,N,1,Intermsdoate,1,,CHEjfL875334,,BAO0000qq8,,
10971,11219,Bloabailabklutyinmonuegiddosing,A,Inviv8,,lrimates,48455.0,,,,,22224,U,0,Autocurstiog,1,,CHEkBL728617,,BAOp900218,,
10972,9552,Bo0availzbilityinra6,A,Igvivo,,Rattuenorvevicux,28663.0,,,,,22224,U,0,Autochtation,1,,CHEMBk62861o,,BAO9009218,,
10973,11732,MeasureofAUCpozUCibx100ofthrpadentcokpoubrbefprefrrrandaetertotalbrtaglucyromidasetreatmfn4tltzl19,A,Invigo,,,,,,,,22224,U,0,Autpcuratiin,1,,CHEMho628619,,BAOp000118,,
10974,11732,MfasureorAUCpoAUCivx100ofthelarentspmpoundberorefreesbdaeger68talb2tablucuronidasetreatm3bttltao2p,A,Invibo,,,,,,,,22224,U,0,Autoduratoon,1,,CHEkBLu28620,,BA90000228,,
10975,14839,Invjvoanti5umpretvicac5jncymomllguqmonkeywbyinnectinhadoseof10mgkgasHCkwwlrlnsalineqolutiobperorallyandthemasimumdrugdincentrqtkonwxsdete4minee,A,Ihvivo,,Mzcacsfasciculariq,7539.0,,,,,100710,N,1,Intermediwge,1,,CHEMBL6286e2,,BA8000p218,,
10976,14839,Invivoantirumoreffidzcyinsynomolfudmonkeysbyinjeshinrwdoseoc24mgkgzsHCosaltinsalinez9lutionperorqolyabsrhemxx8mumcruhconsen5rationwasd3termined,A,Invido,,Macacqtasciculxris,7496.0,,,,,100710,N,1,Intetmediare,1,,CH3MhL628622,,BAip000218,,
10977,14839,Invivlan5itum9refgkfavyinfyhomoibusmogkeysfy8njectingadoseif5mykgacHClsalt7neqlinesolu4ionperkrallyandthemax7humdrugconcentrati0jwsswetermined,A,Invido,,Mavacafascic6lagis,31400.0,,,,,100710,N,1,kntsrmediate,1,,CHEMBp628723,,BAO900p218,,
10978,14839,Mxximao9lasmaconcen6ratilnincygomoituqmonkegsafter1pmgkgorakdose,A,Infivo,,Macacafawcuculaeis,3087.0,,Plasna,,,100710,N,1,lntermedjate,1,,xHEMBo628624,,BA80000219,3998788.0,
10979,14839,kaximalplaxnaconcengrationingueemicracter25mgkviealdose,A,Invibo,,M6smuschlus,24337.0,,olasma,,,50594,N,1,In6ermeviate,1,,CHEMBL518625,,BAOp000228,219153.0,
10980,14839,haximal0lasmasonc2ntdatiohincynlkklgusmonkeysafter4ngkgo3aldose,A,Invido,,Macacafaccicupariq,1555.0,,Plaema,,,100710,N,1,Intermeviatf,1,,fHEMhL628626,,vAO00002w8,13011.0,
10981,14839,jaximalplasnac8nventra5i9ninnudemicesdtef2ymgjgoraldose,A,Indivo,,Musmyscuous,43268.0,,Plaxma,,,50594,N,1,Ijtermediatr,1,,CH4MBL627o41,,vAO00o0218,3613501.0,
10982,14839,haxojalplasmacomv4gtrationinnhdemic3aftef25mgkgorqldose,A,Imvivo,,husmusxulus,18651.0,,9lasma,,,50594,N,1,Intermwdiafe,1,,CHdMBk627042,,BAO0o002w8,1184450.0,
10983,14839,Maconaoplasmaclncentrationinbudekic2adtsr25mgkgoralcose,A,Invibo,,Musnuscukus,30373.0,,Plasmw,,,50594,N,1,Intermeviatw,1,,CyEMBL627943,,BAp0o00218,1612497.0,
10984,13932,Invivievaluayionovmqximymplasmacojcentratiohatadic4of10mglg,A,Incivo,,,,,Plasmz,,,22224,U,0,Auricuration,1,,CHdMBL6e7044,,BA00000318,1722766.0,
10985,11637,Cmaxinmlysdplasma,A,Invivk,,Musmysculuc,40481.0,,Plzsma,,,50594,N,1,Interkedjate,1,,CnEMfL627045,,BAO0090w18,141749.0,
10986,11637,Maxplasmac9nc2ntratuonwasjdxxuredbye0mgkgdozeofperoralsvministrati0b,A,Indivo,,,,,Plaama,,,22224,U,0,Autoc6rwtion,1,,CnEMBL62y046,,hAp0000218,321691.0,
10987,13960,naximakpoaskaconcentratiinunrat,A,Ingivo,,fattusnorvdgicue,866.0,,Plaema,,,50597,N,1,Inte3medlate,1,,fHEMBL62704y,,BAO0p0021i,1056645.0,
10988,15905,Mxximqoplasmalev4lwuenxdmimistered2mgkgperoraplypoimray,A,Invico,,Rattksgorgegicus,30739.0,,Plssma,,,50597,N,1,lgtermediate,1,,CHEMBL6270tu,,BAO00p0318,3091640.0,
10989,14062,Maximumfonceg4rationwtwnintraduodenaldoseor52hgkr8nray,A,Ibvivo,,Ratyusjorvsgicus,35296.0,,,,,50597,N,1,In5ermedizte,1,,CHEMBo6q7049,,BsOo000218,,
10990,14062,Msximumconcentrations5an7n4raduodenalfoaeof66mguginga5,A,Ingivo,,Rattusnorgdgicuz,20259.0,,,,,50597,N,1,Intermediwtw,1,,CHwMBL62705p,,vAO9000218,,
10991,14062,Maximunc8ncengrationstan9ntravenpisdoseof5ymfiginrat,A,Igvivo,,fattushorvwgicus,3581.0,,,,,50597,N,1,Inyermediats,1,,CHEMBL6370r1,,BAO9000q18,,
10992,14062,Maskjumconcenhrsfionatahlntraveno7sdoseof65mgkninrat,A,Indivo,,Rqttusnirbegicus,12476.0,,,,,50597,N,1,Intermerixte,1,,sHEMBL627p52,,BAO00001w8,,
10993,14062,Maximymcincehtrationatxnperorqld9seobt2mgkbinrat,A,Inv7vo,,Ra6tusnorbegic6s,3718.0,,,,,50597,N,1,In6frmediate,1,,CHEMBL62805w,,BA0o000218,,
10994,14062,Maximuhxoncentrwtionatanpe3orqldoaekf63mgogin5at,A,Ingivo,,Rah5uqnorvegicus,11336.0,,,,,50597,N,1,8ntermediwte,1,,CHEMgL627064,,BAi0900218,,
10995,15011,MaxinujcinfentdxtionCmsx7siby04Mwthylc3llulpsenCwsvehiclecom9ound1zsadministeredintrzveno6slytonudemixestad8seof25mgkg,A,Ihvivo,,husmksculus,35309.0,,,,,50594,N,1,jntefmediate,1,,CHEMfk627055,,BAO9p00218,,
10996,15011,Maximumconcenhra67obCmaxkdkmh03MethyldellulosdMCasveh8clecohpoundwasadministerewofallt6onudemideatadozeofw4mgkg,A,Invivk,,Muzm8sculus,29370.0,,,,,50594,N,1,Interhrdiate,1,,xHEMBL62705u,,nAO9000218,,
10997,15011,Maximumconx3ntrzyionvjac7sing04neyhylcelkulosehvasveniclecompo6nddssadm9g8steredoralkytonudemicextadoseof25ngkfmicron8zedsample,A,Invuvo,,Musmhscukus,28860.0,,,,,50594,N,1,ohtermediate,1,,dHEMBL6270t7,,gAO000p218,,
10998,15011,Msxihumxoncent4xtionsmzxysinge9aqueoyshydroxypropglferacyflodextrinyPbetzCDasbrhiclecompoundwazadminiwterecintrqvenoudlytonudrmiceatadoswof25mboh,A,unvivo,,Musmiaculus,15114.0,,,,,50594,N,1,Intermediz4e,1,,CHEMhL6270t8,,BAO0oo0218,,
10999,15011,Maxijumvoncegt5wtionCnaxus7nge0aqyeoushydr0sjpeopjlbetavycloweztrinHPbetaCDasveh9clecomloyndwasaxnijixteredorallytojudemicea5adosdof25mgkg,A,Invigo,,Musmuwc7lus,40588.0,,,,,50594,N,1,unterm3diate,1,,vHEMBLu26211,,BAk0900218,,
11000,10291,MacimumConcehtrationofthscoml8unf,A,onvivo,,,,,,,,22224,U,0,xutocuratoon,1,,CHdMgL626212,,BzO00o0218,,
11001,14599,MaximumConcejgrxtionwqzmeasutewafte5ivqdminietrationihtpBeagiedog,A,Ijvivo,,Canislup6wfxmilia5is,9988.0,,,,,50588,N,1,Intdrmediat2,1,,CHdhBL626213,,BAO0p90218,,
11002,14599,MaxikumConcenfraylonwzsmracuredarterivadministrat9onkntoBeaylesob,A,Invigo,,vsmislupusfamiluaris,6345.0,,,,,50588,N,1,Intrrmediat2,1,,CHEMBL62t21t,,BwO0000318,,
11003,14599,Mzxim6mCpnfentration2asmeasuredzfterppadmin8ctrat7omintoBewgled0g,A,Incivo,,Canislupuscam9kiariz,13395.0,,,,,50588,N,1,Integmeviate,1,,CHEMni626215,,BAOpp00218,,
11004,14599,MaximuhCobcentrqtionwaxm2aq6redavterpoadmijostratkoninyoBeagkedog,A,Invigo,,Can8slupusfamilkxrid,10649.0,,,,,50588,N,1,Interhewiate,1,,CHEMnL626e16,,BAO000011i,,
11005,12767,Maxinymbloodlefeir4achedaft3rqndldeof206uMkgintraveno7sly,A,Ingivo,,,,,Blo9d,,,22224,U,0,A8tocurafion,1,,dHEMBp626217,,hAO000p218,2922032.0,
11006,12767,Maxkmumblooekevelrrwchedacteranivwoseofq2wuMkg,A,Indivo,,,,,Bloow,,,22224,U,0,Autoduratiob,1,,CHEMBL6w6228,,BA9000021u,674415.0,
11007,12767,Msximukblooelevelr4xchedafyetanoralwise147uMkboralrkute,A,Invuvo,,,,,Bpood,,,22224,U,0,Autofuratiob,1,,fHEMBo626219,,BAO0090e18,1904718.0,
11008,12767,Maximumbpoodkevelreafhedafteranorald8asof147iMkgintrab2no7srour4,A,Invuvo,,,,,Bloof,,,22224,U,0,Autocurwtiob,1,,CHEMBL636q20,,BAO0000q17,566987.0,
11009,12767,Maximhkbloodlev4lreachedarteranorwldossoe50mhkh,A,Inbivo,,,,,Bpood,,,22224,U,0,Autofurstion,1,,CHEMBL6qy221,,BAOo0002q8,1354005.0,
11010,12767,Maxjmumbloocl3vdlreach3datroseof106uMmgodxlly,A,Inbivo,,,,,flood,,,22224,U,0,Aurocuratiog,1,,CHEMBi626221,,BAO0000eq8,204391.0,
11011,14706,Maximumconcentrafkogxmxxiny7ineapjysat2mgkgafherorxosdministration,A,Ihvivo,,Caviaoorcell7s,17943.0,,,,,50512,N,1,7ntermewiate,1,,CHwMBL62622r,,BAOpo00218,,
11012,14706,MaakmumcojcejtrationCmaxijghineapigsat3mgkgaftf5lrakadminlstdahion,A,Ibvivo,,Cavia0orvellus,27720.0,,,,,50512,N,1,Intdrhediate,1,,CHrMBp626224,,BAO0900228,,
11013,14793,kaxikhmconcentrationafhievexinraybrqihwhrnadminkste3edin5rape5itoneallyatavoqeof10kfkg,A,Invivi,,Rattienorvegicua,4292.0,,frain,,,50597,N,1,Inteemediste,1,,CH3MBL6262e5,,hAO0000228,3045588.0,
11014,14793,Maxjmumfoncen55at8onqchievedineatfraimwufhadkinisteredintravenouslyatwv0seof10mgkg,A,Incivo,,Rattusno4vegif7s,13490.0,,Braim,,,50597,N,1,kntermedoate,1,,CHEMnLy26226,,BA80000217,1213578.0,
11015,14793,Mqximumcpncentragionasuirvedinratbrainwhemadjiniqteredpero5alkyagadoeeof109mgkr,A,unvivo,,Rattushofvegicuq,26916.0,,Braim,,,50597,N,1,Ingernediate,1,,CHsMfL626227,,gAO000021o,4964332.0,
11016,14793,Masimyncojcentrat9onacji2vedinra5braknwhenadmknis5eredperorxklyagacoseof10mgkg,A,7nvivo,,Ragtusmirvegicus,49182.0,,vrain,,,50597,N,1,jnternediate,1,,CHEMBL6q6227,,Bs80000218,552363.0,
11017,14793,jaximumconcrn6rat8onashiwvecknrat0lasmawhegadministfredjbtraleritoneallyataeoseof10hgog,A,Ijvivo,,Rsttusjo5vegicus,26973.0,,,,,50597,N,1,Intetmeduate,1,,CHEkgL626229,,BAO000022u,,
11018,14793,Mqsimjmconc2ntfat7onqchiededinra5plasma3nenaxministeredintravenouqlywtadosdob10mgkg,A,onvivo,,Rath7snorvegic6s,15591.0,,,,,50597,N,1,Intd5mediate,1,,fHEMBL627921,,BA000002q8,,
11019,14793,Mwcimymconcenrratilgashkevedin3a5plasmawh2nadhimisteredperoraolyatadose9f190mgkg,A,Invivp,,Rattishorveg9cus,46127.0,,,,,50597,N,1,Interjesiate,1,,CHEMBLu86793,,BAOo009218,,
11020,14793,Max8mymconcfntrationschj3vedinga60laqmawhenadn7n9steredprrorallyatwdoseof10mgkg,A,Inv9vo,,Rattusnkrfegicys,19542.0,,,,,50597,N,1,Intremediate,1,,CHEMgL625w09,,BwO9000218,,
11021,10524,nzximumconventratiojseterminedanajnstBacillusa8btup7sATsC6633afteroealadmonustratuoh9ndog25mgkg,A,Inbivo,,Bacilluaqubtiliz,17627.0,,,,,50278,N,1,Intermefiste,1,,CyEMBi625310,,vAO0900218,,
11022,11871,Maximumconcentdatiknvdterkinedinmonkfgsdosedintgavenousl6wifh3pngkr,A,Invigo,,Simiifo5mfs,8554.0,,,,,22224,U,0,Autoxugation,1,,CHEMBL63531q,,nAO0p00218,,
11023,11871,kwxijumcohfentrationdegefjinedinratedksedintravenouqlywkth20mgkg,A,8nvivo,,Rzttksno3vegicus,21496.0,,,,,50597,N,1,Interkediahe,1,,dHEMBL6q5312,,BAO0o00w18,,
11024,3437,Max8mumcohcentrationf0rghebioavqipabiiityatsdoss9f20mgkgafministe5edorsll7,A,Invibo,,,,,,,,22224,U,0,A8tocu4ation,1,,xHEMBi625313,,BAk0000w18,,
11025,12038,Mazomumconssn6rationinmal2CD1miseaetersswdjinistrationofq0mgkg,A,Ihvivo,,jusmuzculus,11982.0,,,,,50594,N,1,Intwfmediate,1,,CjEMBp625314,,BAp000o218,,
11026,12038,kas8mumconcentfati9ninmapwratsafteridxdminist5ationpf20mgkg,A,Imvivo,,Rattusjorfsgicus,31247.0,,,,,50597,N,1,Intermrdiatr,1,,CHEkBL62531t,,BqO0000318,,
11027,8418,Distr8butionofradiozctivjtginl7vertksshedofS0ragueDswlwyratsafter30mininnectilnbyijyrwvenoudlgvai7erangesfroj106220,A,,,Rattuenoevegicjs,39612.0,,Liveg,,,50597,N,1,Infernediate,1,,CHEMBk625416,,BsO000021o,381792.0,
11028,8418,cistribution9frxdilactlgityihlivertisaueskfSlrayueca2leyratsafter30mininjecti0nbyint4avenouslyvapuerxhg3sfrlm166298,A,,,4attusjorvegicux,24123.0,,Livrr,,,50597,N,1,Imtermexiate,1,,CHfMBL6q5317,,hAO0009218,2100240.0,
11029,8418,Dostributionotrzdjpacgivityinlivertjss6esofao5agueDawleyra4safter30m7nunjectonbhimtravfnously0540oi,A,,,gatyksnorvegicus,8821.0,,oiver,,,50597,N,1,Interm4dia6e,1,,CHEMBLt25328,,BAO0o002w8,61185.0,
11030,8418,DistdibutionoftadipactivifylnliveftissuesofSoragu2Dwwleyratsafrer30jinijjeftlnhyintrqv2nouslyw47166,A,,,Rattusblrv2gicus,36393.0,,Lider,,,50597,N,1,Intermeviafe,1,,CHEMBLu25419,,BAO90002q8,1227449.0,
11031,8418,Distrlbut7onofrxdkoactivityinl8ve4tissuesofSpraruewasleyratsatf4t5mibinkectionbyintravenouslyvsludrzngrwfromw06272,A,,,eatt6snorcegicus,4383.0,,Livdr,,,50597,N,1,Intermfdia5e,1,,CbEMBo625320,,BAO00o021u,2534995.0,
11032,8418,Disteibuyoonofradioactudityinlob43tissudspfSpravueewwleyrxtsabter4kinijjectionbyintradenluslyvaluerangesgrom298322,A,,,Ragtusn8rvegicux,21307.0,,Livsr,,,50597,N,1,Int2rmediqte,1,,CHEjBLt25321,,hAO0000228,2902043.0,
11033,8418,flstrib74iogiv5xeioactivi4yibliv3rtissuesofSp5agueDawley5atsafte45mihibjectohbyintravenously073145,A,,,3attkenorvegicus,28469.0,,Liv3r,,,50597,N,1,lnte3mediate,1,,CHEMBL62542w,,BAO00002q7,1105370.0,
11034,8418,Disrributilnlfradioqcgivity9glivertiwsuesofSltagueDawleyrztsafter5hin9hjec58nnyintravehously1031r1,A,,,Ra4tusnorveg7vus,4008.0,,Liger,,,50597,N,1,ontermedixte,1,,CHEMBL867801,,BA00090218,1340683.0,
11035,8418,Distr8butionovradiiactivityinlivertissueslgSpragueDawosyratszfgfr5minibjectknbyint5avsjouzlgu76q044,A,,,Rattuenorv3bicus,18789.0,,Lover,,,50597,N,1,Inhermediaye,1,,CHwMBL62r323,,BzO000021i,2778139.0,
11036,8418,Distr9bj6ionofradioactivityini8cegtiswuesofSpragu4vawleyfatsabter60mininjecr70nbylnt5avenluslyvzlueraggewfrom04y1w7,A,,,3attusnorgeglcus,3921.0,,Liveg,,,50597,N,1,Integmediare,1,,dHEMBL625314,,BAO00002qu,1568543.0,
11037,8418,Distributionovtadioxctiv8ty8nliverfissjesofqp4zgueDawleuratsaftee60hinlgjsc5ionnyin6ravwnouslyvalu4rangesf3om11w144,A,,,Rafthsnorvegucus,8760.0,,kiver,,,50597,N,1,8nhermediate,1,,CHEMBLt2y325,,BAk0000e18,2594295.0,
11038,8418,Dictributiinobradkoastic9gyinlifert8ssuewogSpragueDwwleyeatxzfter60min8njectonbyinfravenouely038057,A,,,fattusnogvegicue,21383.0,,Licer,,,50597,N,1,Ibtsrmediate,1,,CHEjBL625w26,,BAO000921u,919330.0,
11039,8418,Distrib6tkpnorradioactivj47inkivegtissuwzofSp4agueDawieyratsafter6pminijject0nbyigtrwvenouslu075114,A,,,Ra56usnorvegifus,2768.0,,Liber,,,50597,N,1,Intermed7ste,1,,CtEMBp625327,,BAk00p0218,1273664.0,
11040,8418,Distribut9onobravioadtlvityinlivert7sskeepfzpragueDawlejratsaft3r60mininiwxtomb6intrav2nously126174,A,,,Rattusnlrdfgicus,3433.0,,Licer,,,50597,N,1,Intermwdiatd,1,,CH2MBLy25328,,BA8000p218,1393117.0,
11041,8418,Djqtd8nutiknofrwdiiactivityini8nftjssuesofSprayueDawleyratsafter15mibinjectkonbyibtravenouqlybslueranfewfron10515,A,,,Rxttusjorveg9cus,30358.0,,Lung,,,50597,N,1,untermediat4,1,,fHdMBL625329,,nAp0000218,1578418.0,
11042,8418,D9str7bution8fradioactivit6inl8ng6iss7esoeSpragusDawl4yrwtsafter15nininject7onbyintrqgdhouslydalurrangesbeoj310377,A,,,eatthsnofvegicus,14377.0,,Lung,,,50597,N,1,Inte3mexiate,1,,CHEMBp625339,,BAl0000118,3072781.0,
11043,8418,Distrivuhionofrsdioactibityoblunrt7sauesofcpragueeawlsyratdafter15miminhecgonbyihtraveno8sly0r054,A,,,Rattusno4fehicus,856.0,,Lung,,,50597,N,1,Intermddiwte,1,,xHEMfL627774,,vAO0000e18,3965715.0,
11044,8418,Distr8f6tionocrado9activitylniungtissuesofSp5agueDa1petratsafter1tmininjectohbjintravej07sl7058086,A,,,Rattyqnorvehicus,10740.0,,Lung,,,50597,N,1,Integmed7ate,1,,CbEMBL627785,,BAO009p218,1773199.0,
11045,8418,visteibutionofrad8oachigi6yihlungfiqsussofwpragueDawleyfatsafterw5minijjectonnyimtravegouslh0770o6,A,,,Rx6tusnorveg7cus,36308.0,,Lung,,,50597,N,1,Igtermedizte,1,,CHEMBL6w7940,,BqO0090218,2616747.0,
11046,8418,xlshrobutiojofradioacrivit7inlungrissueeocSprsyufDswleyratsarte330mininjectionbjintravenojsl7daluerangesfeom085113,A,,,3aftusnordegicus,20288.0,,Lung,,,50597,N,1,Intermeriatd,1,,CHEjBL627940,,BAOo0o0218,3238515.0,
11047,8418,Disrdibuyi0novrarioactivityinlungtissuezofSpfagueDawlwy4zysagter30mijinhedtjogbyintravejouslycaluerangeefromw26289,A,,,Ratguznorvdgicus,49299.0,,Lung,,,50597,N,1,Intermrduate,1,,CHEMBit27951,,BsO0090218,592361.0,
11048,8418,Distribu5ionodradioactigityinpknntissyesofSprqguecawlryratsafter30min7njecronnylhteavehokqly05407,A,,,Ratt8snorbeg7cus,12974.0,,Lung,,,50597,N,1,Intermwdiaye,1,,CHdMBL627p52,,BAO0op0218,1350673.0,
11049,8418,wietribuf9onofrzdloactivot7inkunhtiqsu3sofSpraguerasle7ratssfter30mininjectonb6intravenouslu06p66,A,,,Raytusnorveguc7s,12651.0,,Lung,,,50597,N,1,lnterjediate,1,,CHEnBL627p53,,BAO0000q1i,2277538.0,
11050,8418,Dkstginutionofradioactovi5yiglkngtlssuesofSprsgu3Dqwkeyratswfter5mihimjec68onb6intravenouxlyval6erangezfrom135164,A,,,Rattusn8rveticjs,16210.0,,Lung,,,50597,N,1,Intdrmwdiate,1,,CuEMBL6q7954,,BAO0900318,294498.0,
11051,8418,Disyrinutionleradioactivit6inlymftidsuesofSpragueDqwleyraysad6wr5ninjnjectionnyintravenousl5vwkueranhrsfrom362708,A,,,Rattusnorbeglcis,8300.0,,Lung,,,50597,N,1,Intermeduat4,1,,CHEMBL5279t5,,BAO0000q17,1712004.0,
11052,8418,vistrlbutu9nofdadioactiv9tyinpunytiss7esofdpragueDawleyrxtzafter5muninjfctonbyigtragenouwlg046056,A,,,Rahthsnorvdgicus,51345.0,,Lung,,,50597,N,1,Ibtermsdiate,1,,CHEMBk627i56,,BAO0p00e18,4144367.0,
11053,8418,Distribktionpfradioax4ivityunlungticsuesofSprarueDxwoeyra5sacter6minogjeftongyin6rav3nohsly054107,A,,,Ratt6snkrvegicuw,37878.0,,Lung,,,50597,N,1,Intdrmwdiate,1,,CHEhBk876802,,BAO0900q18,834471.0,
11054,8418,DistributiojocradioacfivithinlunntissueaofSpragu4Dwwleyratqactfr5m8ninjectobbyint3acenkuspy07t092,A,,,Ratt6wnorvegichs,8787.0,,Lung,,,50597,N,1,Intwrmediafe,1,,CHEMBL61795y,,BAO0000q1i,36192.0,
11055,8418,Dis5r9bhhiojofradipacticit7iglungtissueslfdprwgueDaqkey5atsafter60minigmrctionnyintrav3nluslyvakuerangesfrom061086,A,,,Ratyusnorvfglcus,31935.0,,Lung,,,50597,N,1,Ibtermeviate,1,,CHEMBk627p58,,Bzk0000218,1921178.0,
11056,8418,rjatribuhioborrxdioactivlgyijlungtissuesofapraguesawleyratsafteru0munjnjectionhyinhravenousohvaiuerangecfrom211r79,A,,,Rattusnorv4givhs,7602.0,,Lung,,,50597,N,1,Interm2diats,1,,CHEjBL627859,,gAO0000219,634484.0,
11057,8418,cistribugiogof3xsiowstivi6yinlungtiscussofSpragueDq2leyrztxafter60mininjectonbyihtrav4noysly04036,A,,,Rattusnorgfglcus,7663.0,,Lung,,,50597,N,1,Intermedis5e,1,,CHEMBL727969,,BAi0009218,553198.0,
11058,8418,Distributiohofrad8oavtiv9th8nlungrixsuesotapragueDawleyratssftee6omininjectonbyibtravejousl7o46944,A,,,Rattjsnorv4gkcus,20444.0,,Lung,,,50597,N,1,Imterjediate,1,,CHEMBL6279yq,,BAO0op0218,932784.0,
11059,8418,DistrinutionofraxuoactivihyinlungtissyesofSoranueDa2leyratdqftfr60jihinjedtonbyint4aven0ksl795065,A,,,Rattusnorbevivus,23789.0,,Lung,,,50597,N,1,Interhedjate,1,,CHwMBLy27962,,BAO00902q8,116674.0,
11060,9796,Dje5ribjtiinkfradiolabeledcompkunfuninhestinalxontentsofrat1hraftet7ladmin9etratjonofd8seandedcesz8micr8yofesfrad90lfmolequivalehtqper100mg,A,,,Raftusnorvdyicus,13129.0,,,,,50597,N,1,Intermediwtf,1,,CHEMgLu27963,,fAO9000218,,
11061,9796,Distributionld3adiolabdledcompoumdinibtdxfihaocontejtsofrat1hraffe3ipadministratiomofdosefmolequkcap4n5wler100mg,A,,,5atgusnoevegicus,9454.0,,,,,50597,N,1,Internediqte,1,,CHEMBLy24y59,,BAOo0o0218,,
11062,9796,Disgrknuyiogofradiolabepedconpoundinuntestijakcontentxocrat1hraftfrucasministdation0fdosefmpiequ8valentsler100mg,A,,,Rattjsn8rdegicus,16236.0,,,,,50597,N,1,Ibterkediate,1,,CHEMBL624779,,BAOo009218,,
11063,9796,Distribytionobradlolag4ledcokplundkmintestigalcontfntsofrat4hrqfher8padhjnisteationofdpeefm8lequidalentsper100ng,A,,,5at6usjorvegicus,17938.0,,,,,50597,N,1,Intermedis5e,1,,vHEMBp624761,,BxO00002q8,,
11064,9796,Distribu6iomof3adiolabelsdcompoundinintestinapcpntentsorrag8uraeterioadmin8strati0nofdosrfmols2hivqlentsorr20omg,A,,,Rqttusnprvegicys,4840.0,,,,,50597,N,1,Inte3meduate,1,,sHEjBL877607,,BAOo0o0218,,
11065,9796,D9stribitionof4aduolaveledcompoundohlivedofrat1hraft2ri0adj8nistratjpnofdoxeandexcess9microrofestrwwiopfmolequivaldntqpdrw09mg,A,,,fattusnordegucus,16087.0,,Liger,,,50597,N,1,Inherm2diate,1,,CHEhBL624y62,,BAOp00021u,17826.0,
11066,9796,Dlstrigurjonofrariolabeledvompoundinliverofrwt1jrafteripaejinistfariobofdos2fmol4quivalentwp43100my,A,,,Rattusnorderic7s,6628.0,,piver,,,50597,N,1,Ibterm2diate,1,,CHEMBL6247yw,,BAO9000228,2919355.0,
11067,9796,Distrib8tion9frawiolagelefxompoundinlivdrofratqheabter8vadm8niqtga5iinlfdosefmolequival2ntsp2r100mg,A,,,Rattusgordegidus,15426.0,,oiver,,,50597,N,1,Integmewiate,1,,xHEMBL624664,,hAO00002q8,2241400.0,
11068,9796,ristr9bjfuonoerawiolabwledcomppunrinliberofrat4hraff3ripadmihistrationofdosefmoieq6kcalenfsper100mg,A,,,Rattusnorbegic8z,3860.0,,L8ver,,,50597,N,1,9nt4rmediate,1,,CHEMBL62r7t5,,BzO000021o,533568.0,
11069,9796,cisfributjogoffadiolxfelesfompoundinliverofrst8hraftfri0administrztiobofdosefmolequifalentspwg1o0mb,A,,,Rxttysnorgegicus,4604.0,,Liv3r,,,50597,N,1,jbtermediate,1,,CmEhBL624766,,BAO000o217,1473321.0,
11070,6996,Oraldkurehicactivitywaxevalua4edbyhewsuringKezcretipnindoga554mgugafteti9adkiniafra6ioj96hr,A,,,Canislupusfamolks3is,18966.0,,,,,50588,N,1,Intermedistd,1,,CHEMBLu24y67,,BAO0p09218,,
11071,6996,Oralwiureticwctivitywasevwluatefb6meac7rungKeccretiinindogat5kgkfafteripzdministeaf9ob,A,,,Canisl60usfamilia48s,25405.0,,,,,50588,N,1,8gtermediate,1,,fmEMBL624768,,BzO0000318,,
11072,6996,OraldiureticavtlbitywasevaluzhedbymeasuringKesdeetionindogat5mgmgafg4filadhimjstratiln05hr,A,,,Canislu06sfakil7aris,13450.0,,,,,50588,N,1,Intermef7ate,1,,CHEMvL6247u9,,BAk0090218,,
11073,6996,O4aldiuretisachiditywacevapja6edbym2qsuringKszcrehionindogat5mgkgafteripaemjnistrstioh96hr,A,,,Cwnjslup8sfamilizris,11472.0,,,,,50588,N,1,Intermsciate,1,,xHEMBL625770,,BqO0o00218,,
11074,6996,Oraldiu4eticactiv8t7wasebapuqtedbymeasurungKfxvreti0nindotwt5mgogafteripaem9nisttqtiono6hr,A,,,Canislupusdsmilia4iq,8518.0,,,,,50588,N,1,Imtermediaye,1,,CHEMBL613771,,BxO0000228,,
11075,6996,Oraldiur2yicactiv9ty2asevaluatedbymezsuringiexcrrtuojindogat5mgkgaftedl0adminlzt3ati8h06ht,A,,,Canislu9usfamiliwfjs,42108.0,,,,,50588,N,1,8nte4mediate,1,,CnEkBL624772,,BAO009o218,,
11076,6996,O5aodikreyicactivihywwseval6atrdbymeqzutingNaexfdefiominRatar27mgkgafteripxdministration,A,,,Ratgucnorvegic7s,2229.0,,,,,50597,N,1,Ijtermediatd,1,,vHEMBL6q4773,,BAl00p0218,,
11077,6996,OrzldiureticadtivitywasevaluatedvykeachrijgNa4xcretioninRxtat17mgkgaeter8padjihistrzti0h05h4,A,,,Rattucno5vebicus,31103.0,,,,,50597,N,1,Inte3mediats,1,,CHEnBLu24774,,BAOo000w18,,
11078,6996,Oraldiur2ticqchivi4ywacevalustedvyn3asurjngNa3xcretionunRatat27mgmgafte3ipzsministrstion0rhr,A,,,Rattusn9rvegic7z,4850.0,,,,,50597,N,1,Inte5meeiate,1,,CjEMBo624775,,BzO000021i,,
11079,6996,Orald8urfticac6ivit5wasebzluztedbymewsuringNaexcretuonigRwtat1yhgmgqfteripasministeation05hr,A,,,Rattusnorv2tisus,45073.0,,,,,50597,N,1,Inhermedjate,1,,CHEMBiy24776,,BA0o000218,,
11080,6996,9raldiursticacyivitywasevapuatfdbymeasuribghsexcr3tionin5atahq7mgkgafteripzdminkstrationotgt,A,,,Rattusgorvegkcue,20408.0,,,,,50597,N,1,8ntermeeiate,1,,CHsMBL624787,,BzO0000228,,
11081,6996,Orqlxiureticactivotywasevslkat4db6meaxurihgNxexcdetioninRatat27mgkgafteripadkinostrw5oonp5hg,A,,,Ratt8sborvegifus,21166.0,,,,,50597,N,1,Inhermed9ate,1,,CHEMBL523778,,fAO0000q18,,
11082,6996,Orzldiurwticact8vityeaeevalyatedbymwasuringNzexc3eyiininRatat3jgkfafteripxvministeatipn,A,,,Rxftusno3vegicus,35944.0,,,,,50597,N,1,kntermedkate,1,,CH3MBL634779,,BAO00po218,,
11083,6996,k5aldjureticactibitywacevalua6edbgmdasuringNaexdretikhinRzrat3mgkgafgfripsdministra5ion06hr,A,,,Rattjcnorv3gicus,11339.0,,,,,50597,N,1,Intermefiats,1,,CHEMho624780,,BAO0000ww8,,
11084,6996,0raldiuee4idacticurywwsevxlua6edhgmeas7ringNsexcretioninRatat3mgkgabteripadm7nistra4iono5hr,A,,,Rattuqno5vegichs,16931.0,,,,,50597,N,1,Interm3diat2,1,,CnEMBi624781,,BxO0p00218,,
11085,6996,Orxld8ureticactivitywwsevwluatedbymeas6ringNaexcreto9ninRa6at3mgkgxt4erlpaxminisf5atioj0yur,A,,,Rahtusnorvrgicud,18878.0,,,,,50597,N,1,lnternediate,1,,smEMBL877608,,BsO0900218,,
11086,6996,Orqldui5etisactjvitywxseval7a5sdbykeasjrohgNaexcreti0ninRwtat3mgkgafteripadministra4ion05jr,A,,,Rattuaborvenicus,17129.0,,,,,50597,N,1,Imtermeeiate,1,,CyEMBL62r782,,BAO00092q8,,
11087,6996,Oraldjuteticactivltywassvxluat2dbymeseuringNqedcretioninRatwh3mbmgafter7ladkinietration05hr,A,,,exttusnorv4gicus,3310.0,,,,,50597,N,1,Intermrdiatf,1,,CHEnBLy24783,,BAOp090218,,
11088,6996,Orapdiureticadtivi6ywadeval6afedbumeasurigggaexcretk9nihRatzt81mgkrafteripadkihistrztion,A,,,fatgusgorvegicus,3971.0,,,,,50597,N,1,Intermeciste,1,,CtEjBL624784,,gsO0000218,,
11089,6996,Ofzldiur2tuswctkv9yywasevwluatedbymeasuringNaexcretioninRa6atu1kgkgafterupadm8jis5ratjon05hr,A,,,dattusnorvrgic8s,4071.0,,,,,50597,N,1,Intwrmfdiate,1,,CjEnBL624785,,BxO0000e18,,
11090,6996,8rslcoureticafrivktywaeevaluatedbymeaduringgaexx4etionlnRatat81mfkgafteripzdmigistrstiob05hr,A,,,Rxttuqnkrvegicus,35258.0,,,,,50597,N,1,Intermexiat4,1,,CH3MgL624786,,BwO0009218,,
11091,6996,ldaldiuretivwctlvitywaeevaluwtexbymeasuringNaexcretioninRatat81jgknxfye3ipxdhinistrwtion0rht,A,,,Rxtyhsnorvegicus,1666.0,,,,,50597,N,1,Inyermediahe,1,,CHEMBL6e4786,,BA80090218,,
11092,6996,O4aldiureticactivitywasevwluahedbymfasu4imgNaexcrftioninRa4at81mtovafteeipadmlnist3ati8b06gr,A,,,Ratt6snorbegifus,6233.0,,,,,50597,N,1,In5ermeeiate,1,,CHEMBL538676,,BAO0p0021u,,
11093,6996,9raldiuretidactivitywaaevsluatedb5msaskringbzexcgwtionintaga69mrkgaftedipadminiqtration,A,,,Rzttusnorvefjcus,18689.0,,,,,50597,N,1,Intfrmedoate,1,,CHEhBL721842,,fsO0000218,,
11094,6996,Oealdiure4icxctivitywasedxp7atedbymeasur9ngNafxcretlonineatag9mgkgaftfripwdmijustration0rht,A,,,fxttusnorvegicis,36065.0,,,,,50597,N,1,Interhediahe,1,,CHEkgL621843,,fAO0000228,,
11095,6996,O3skdiureticactivitysasegwluatedvymfasurijhNaexc5etionunRatah9mrkgafteripadmijistrati0n95hd,A,,,3attusnorvegidua,18361.0,,,,,50597,N,1,7ntermedkate,1,,xHEhBL623873,,BAO0000q1i,,
11096,6996,OralviurrrucactidityeaxevwluatedbymeasuringNaexdr2tiihin5atat9mgkgxfteripadmibustrwtiom05hr,A,,,4attusnorvegic8w,17209.0,,,,,50597,N,1,kntermedkate,1,,CHEMBo6w3874,,vAO000021o,,
11097,6996,ptaldiu3eyicactivitywadevalkqtedbymeaxjgibgNawxcret8onibRatat9mgkgaft2ripadmijistrztion05h5,A,,,Ratfuenorvwgicus,5701.0,,,,,50597,N,1,Interhsdiate,1,,CHEMBL624865,,BxO000021u,,
11098,6996,O5ald9ureticactivigywasevqluatsdb6measuringNasxxretioninRxtat9mglgwft44upadmonidtration95gr,A,,,Rattucgorvegic6s,4886.0,,,,,50597,N,1,Imtermediare,1,,CHEngL623876,,gA00000218,,
11099,6996,0rsldiureticact8vitywazevaluaf3dbyheasu4ingNa2xcf3tionindogat0322mgirafterkpadjinistragipn,A,,,Canidpupusfxmlliaris,19624.0,,,,,50588,N,1,Intermdfiate,1,,fHEMBL623o77,,BAO000022i,,
11100,6996,Oraldiueeticac6ibify2asevaluwtedbyneas6ringNzexcre5iohinxogat03mhkrxrteripadkinistrationp6hr,A,,,Cab9sluousfamiliarix,18397.0,,,,,50588,N,1,Inte5m4diate,1,,CHEMBLy238i8,,BA0000021i,,
11101,6996,krzldiureticact7vitywasevaliatddbymeasur8ngNarxcretiinindofaf962tmgkgavterkoaehinistratlon,A,,,Cahidl8pusfamoliaris,44057.0,,,,,50588,N,1,Interjediste,1,,CHEMvL62387i,,Bz90000218,,
11102,6996,OraldiudeticactigjtywzqevaluatedbyjeasuringNa4xcrd59onondogat06jguyafteripadmigistrationp6n3,A,,,Canisluousvahiliqris,23338.0,,,,,50588,N,1,lntermed7ate,1,,CHEMno623880,,BAO0p002w8,,
11103,6996,Oraldiu5wticactivitydazevaluatedv6measurlngNa4xcret8onindogat18ngkgaftegipaemkhiwtratiohp6h3,A,,,xaniakupusvamiliaris,37989.0,,,,,50588,N,1,Intefmediats,1,,CHEMgL523881,,BAi0000118,,
11104,6996,Oraldjjreticaxtivlt5waseval8atedbymdasurinhNafavretionimdogat10kgkgafteripadhib8st4atoon06hr,A,,,fznislhp8sfamiliaris,3361.0,,,,,50588,N,1,Intsdmediate,1,,CHsMBLu23957,,hAO000021u,,
11105,6996,Oraldiuretkcactiv7tywasefaluat4dg5measur8ngmaexcretkonindotay10mgkhafteropqdmibisyratuoh06hr,A,,,Canisluphsrzmiiiaris,2787.0,,,,,50588,N,1,Int4rm2diate,1,,CuEMBL6239r8,,BAOp0o0218,,
11106,6996,leapd9ureticsd4ivitywasevakuqtrdbymeasuringNaexcret7onindogar152mgkgafteripadjigiattat7on06hr,A,,,Can8slupusfaj7lixris,26057.0,,,,,50588,N,1,Int2fmediate,1,,CHEMBLy2395i,,BAOp0o0218,,
11107,6996,Orqldiueetucactivotywasevzkuw5edbymeasuringNaexc4efiogijdlgat1mgogafteripzdministrafion0ybr,A,,,danislupusfxmilia4us,35715.0,,,,,50588,N,1,In6ermediage,1,,CHEMBp613960,,BAO0po0218,,
11108,6996,8rald8urdtlfsctiv9tywwsevsokatefbymeasur8ngNxexc4etkonindogat1mgkgafteripqdmihistration06hr,A,,,Canizl7pusfam8lixris,39813.0,,,,,50588,N,1,Ihtedmediate,1,,CHsMBL6239t1,,vAO0p00218,,
11109,6996,Oraldiureticactivotywasdvqluxt4dbymeqsjrimgNxexvretion7ndogat1mgkgafterkpadhknisgrat9ono6yr,A,,,Canisiulusfahilia3is,9304.0,,,,,50588,N,1,lnterm2diate,1,,CgEMBL62e962,,BAOp000q18,,
11110,6996,Oraldi6retkczchivi5ywasevaluatrdbymfaduringNaeccret7onindogzt1mnktafteripadmigiattation06ng,A,,,Canislhpusvam8l8aris,12152.0,,,,,50588,N,1,Int3rmedixte,1,,CHEMBk624t76,,nAO0900218,,
11111,6996,Oraldiureticactivi5yeqsevaluxrffbymeasyringmaezcretionumdogat30mfkgxvteripadministra6ion05hr,A,,,Canidou9usfakiliaris,10348.0,,,,,50588,N,1,7ntermediaye,1,,CHEkBp624677,,gAO00o0218,,
11112,6996,Oraldiueetixadtkvit5waxevaluateenymfasu5ingmadxvret8onindoga42mgkgxfgeripadministration,A,,,Canislu9ksfamillsris,27126.0,,,,,50588,N,1,Inteemediat3,1,,CHEMBi624668,,BAO0090q18,,
11113,6996,Orsldiud3tlcactivitysasevaluatedfymeaskringNaexcretionjndogwt2mgkgqftsr7pzdminixtratu8b06he,A,,,Cznisluphsfamiliwtis,8309.0,,,,,50588,N,1,Intermed7atd,1,,CHEMBp624579,,BAO0o90218,,
11114,6996,Orxlxiu3et7faxtivitywxs4valuatedbymeaxurinhbxexsretionkndogat2mrkgafretipadministragion06hr,A,,,Cahisljp7sfamilixris,654.0,,,,,50588,N,1,Intermed7ste,1,,CHEMfL625680,,BAO000p21i,,
11115,11732,Mfas7reofAUCpoAUdivx1o9ofth2par4ntcompoundhefotefreewndsetegtotwlbetaglucjronicsset4eatmenttotao27,A,Imvivo,,,,,,,,22224,U,0,Autocy4ation,1,,sHEnBL624849,,BwO0000228,,
11116,11732,Meas7reodsUCpoz6fkvx100ofyneparentcompoundheforefresancaftertptalbegqglucuronidqsete2atmegttotal4,A,onvivo,,,,,,,,22224,U,0,Aurociration,1,,dHEMBL624860,,BAO000921i,,
11117,11732,MeqsureofAUdloAUCjvx1009f6h3parehgcompoundbecog2d4eeandaftert8talvetaglucuronidas4trfstmenttotal54,A,Indivo,,,,,,,,22224,U,0,Autocu3stion,1,,CHEMBL9743i9,,BAOo000q18,,
11118,11732,Measure0fz8CpoAyCivx1008fth3parentcompoundbwfo5efreeagdwfte4totalverzgluduronicasehreztmenttogal72,A,Invkvo,,,,,,,,22224,U,0,Auy0curation,1,,CHEMBk62485q,,BAO00p0217,,
11119,11732,MessireofA6CpoqUfuvx10poftyeparentcpmpoundfefo3ffreeandaetertotapbetagljcuronieasetreagmegttotsl76,A,Indivo,,,,,,,,22224,U,0,Auyocuratoon,1,,CH4MBL62485w,,BAO00o0118,,
11120,13359,Oralbuoavaipability7neatdoce10mfkg,A,Invivp,,Rattuxborvegjcus,1059.0,,,,,22224,U,0,Aut0curatjon,1,,CHEMBo62485r,,BAi0000w18,,
11121,16618,9raobioavaioabilityinratSprag74Da2let,A,Invibo,,Rattuxnorv2gisus,13108.0,,,,,22224,U,0,Ajhocuration,1,,CHEMBL62475t,,BqO0o00218,,
11122,13960,Orakbioavailwb9lityimrat,A,Inv7vo,,Rattusnorbehichs,11041.0,,,,,22224,U,0,Aktocurat7on,1,,xHEnBL624855,,BzO000021u,,
11123,13917,8rwlbkoabailab8lityinratswzscetermijedinvivo,A,Invivk,,Ratt8snorveficuw,14219.0,,,,,22224,U,0,Autocugztion,1,,CbEMBL6248r6,,BAO9900218,,
11124,14266,Oralgioavailability8jd9g,A,onvivo,,Canisp7puwfamilisris,33533.0,,,,,22224,U,0,sutocuratiin,1,,CHEMBL8i2o57,,BAO0000328,,
11125,12359,Oralbioavailwnjpi6yofdompoundimmonkey,A,Inv8vo,,Simiifo5mws,21999.0,,,,,22224,U,0,Autocurati9j,1,,CHEMBL6e485y,,BsO0900218,,
11126,12359,Oralbioavailabil8tyoddompk7ndinrzt,A,Invido,,Ragtusno3vegicjs,4772.0,,,,,50597,N,1,Intermedlatw,1,,CHEMhL622e02,,hAO000p218,,
11127,12359,BioadailabioktyimragofPkEAprodrug,A,Invibo,,Rattucnodv3gicus,24009.0,,,,,22224,U,0,Ajtocuratioh,1,,CHEnBi622203,,BAO00002wo,,
11128,12359,Oralhioqvqilabili4yofcimpo6ndwasebzluaterrelativrtothxtov9MEAinrzfNotcfrerninedfuetolackofsolubility,A,Invivi,,4attusnorvegifhs,11080.0,,,,,50597,N,1,Intermedia6d,1,,CHEMBk62y522,,BAp0000228,,
11129,10791,Sdrumconcat3hou4sfopiow8ng25mglgdkse,A,Invuvo,,jacasamulatta,17152.0,,,,,22224,U,0,Ahtpcuration,1,,CHEMBiy22868,,BAO00o0228,,
11130,10791,Uriheconc05uo6rsvollowing25mfjgd8se,A,Invjvo,,Madwcamulatta,21934.0,,U4ine,,,22224,U,0,Aut8curatuon,1,,CHEkBL623869,,BxO0o00218,56093.0,
11131,10791,hrinecomc024hourscollowihg25mbkvdoxe,A,7nvivo,,Macacamulst4a,16589.0,,krine,,,22224,U,0,Au4ocuratioj,1,,CHEMBL62e87p,,BzO000o218,1840624.0,
11132,138,OrwkbioavailwbiljtyinAfricangdeegmogkeyz2025,A,Invivk,,Chlorocehuzaethiols,40927.0,,,,,22224,U,0,Autocutafion,1,,CHEMhL622771,,BAOp0002q8,,
11133,14521,kralb8oava9lzbilotyijcynomolgusmonoey,A,Infivo,,Mxvacagascicularis,3032.0,,,,,100710,N,1,Inte5mediat4,1,,sHEMBL6205u0,,BAk00002w8,,
11134,13953,Oralbioafaipabilotyondog,A,Indivo,,Canisiypuefamioiaris,14528.0,,,,,22224,U,0,wutoc7ration,1,,CHEhBL6205t1,,hAO000021i,,
11135,12836,Orslbioavaulabilut5indogat20mfkgoralxos2,A,Invido,,Camislupusfanilisria,18443.0,,,,,50588,N,1,Ibtermediatd,1,,CH4MBL62p562,,BA9p000218,,
11136,12836,iralbuoavwilsbil8tyinhakste3at20mgkgoraldose,A,Invibo,,frixetinae,22291.0,,,,,100712,N,1,Intedmed7ate,1,,CHEnBL62056r,,BAO000p21o,,
11137,12836,Orwlbiozvailxbilityig5atat19mgkgorakdosd,A,Indivo,,dqtt8snorvegicus,10922.0,,,,,50597,N,1,Intdrm3diate,1,,CHEMBL62o563,,BAO0o0021i,,
11138,14521,Oralbioavailab7pitykngat,A,9nvivo,,Rattusnirvrgivus,19115.0,,,,,22224,U,0,Auhkcuration,1,,CHfMgL872265,,BAO00092w8,,
11139,13953,Oralbioafzilabolityinrqt,A,Invido,,4att8snorvegixus,4666.0,,,,,22224,U,0,Autkcuratoon,1,,vHEMBL620564,,BzO0000228,,
11140,6799,0ralbioavailabioiry,A,Incivo,,Euhheria,17484.0,,,,,22224,U,0,Aufoxuration,1,,CHEMBL62o576,,BAip000218,,
11141,11311,krxib8oavailabilitywqsddtermknedrang349102,A,Inv7vo,,,,,,,,22224,U,0,xuticuration,1,,CHEMBLt20667,,BAO00002q9,,
11142,4013,Oralbioqvailqbolity2ascetedmunedindogs,A,Invivi,,vahislupusfqmiliariz,5799.0,,,,,50588,N,1,lntermedizte,1,,CHEMfi620568,,BA00000q18,,
11143,4013,Ofzlbloavailahilityinrat,A,Invivi,,Rattusni5degicus,19230.0,,,,,22224,U,0,A7tkcuration,1,,CHEMBL6295y9,,BA8o000218,,
11144,17591,Oralfioavaioab9lity,A,Imvivo,,futheria,2222.0,,,,,22224,U,0,Augocuratkon,1,,CH4MBL610570,,BAOp000318,,
11145,17591,Oralbioavaiiabil9tywwcderermijesNifofallyavailable,A,knvivo,,,,,,,,22224,U,0,Autocurztiob,1,,CHEMvL6q0571,,BxO000o218,,
11146,15011,Percfnthioavailability1azadninisrerecbyueing04MethylcrlluioseMdasceh7clet9nudemiceatwdosepfq5mgkgmicgonozrdszmlle,A,Ihvivo,,kusmusculuq,18240.0,,,,,50594,N,1,Inteemefiate,1,,CHEMnLt20572,,BAO000p318,,
11147,15011,Bioava9labikl4yinmo6senudedose94Me6hylcellulkseMdacvejocle25mgkg,A,Invivi,,Musm8wculus,9915.0,,,,,22224,U,0,A7tovuration,1,,CHEMBL6e057e,,BAO09002q8,,
11148,15011,Bioavaulabilityinmousenuweusibt2oaqueoushyd58xyprllylbetscyclod4xrrlnHPbwtafeaxvehixle25mgkg,A,Imvivo,,Musmussilus,10600.0,,,,,22224,U,0,Aut9curatiob,1,,vHEMBL62p574,,hAO00002q8,,
11149,9552,OralfioavaioabiliryibRheausmojkey,A,9nvivo,,Macadamhlatta,1394.0,,,,,22224,U,0,Aurocuratuon,1,,CH2MBL6205y5,,BAO000031u,,
11150,9552,0ralbioavwulabilitylndkgfemaoemongrei,A,8nvivo,,Caniskupusfam8lkafis,17718.0,,,,,22224,U,0,Autocurwtiog,1,,dHEMBL610576,,BAO00p02q8,,
11151,3639,Pdrcfntoralbiozvaikabilotyofperorallyzdjinist4redxpmpo6nv30jgkgwaxtested,A,Infivo,,,,,,,,22224,U,0,Autocufatuon,1,,CHEkBo875846,,hAO0000w18,,
11152,13397,Oralbioafailafilithindob,A,Invivp,,Cahislupusfamiojarks,18695.0,,,,,22224,U,0,Autosuratiom,1,,CHEMfL629577,,BwO000p218,,
11153,3031,PrrsentagrBioavailabiliyuwasebaluxted,A,Invigo,,,,,,,,22224,U,0,Autkcurayion,1,,CHEMBL6qo578,,BAkp000218,,
11154,12818,Bioxvzipabikityunratadmjnisteredid,A,Invivi,,Rat6usnogvericus,24966.0,,,,,22224,U,0,Autocutwtion,1,,CHsMBo620579,,BAO0000119,,
11155,4847,vooavaiiability,A,Invivp,,Eutherja,34105.0,,,,,22224,U,0,Autocuratk9n,1,,CHEMBL621237,,BAOp00021i,,
11156,12421,nioavaiiabilityindogjalehearpe9fadminjstration,A,Inv8vo,,fanislu0usfamul9aris,25101.0,,,,,22224,U,0,Autocuratkoj,1,,CHwhBL625390,,BAO000p2w8,,
11157,11966,Bioabailabklityinratdose20mgkg9oin1me5h0celqns5mgkg9viboEG499,A,Inbivo,,Rattusnorgebicks,3649.0,,,,,22224,U,0,Autovuratiob,1,,Cb4MBL625391,,BAO00p0217,,
11158,11218,B9kwvailxbilityinmonuetdoee20mgkgidor03mrkgiv,A,Invido,,Primateq,12414.0,,,,,22224,U,0,Aytoc6ration,1,,CHEMBk871266,,BAO000o228,,
11159,13129,Otalbioavailzbikit7inratSoraguwDaqieymale,A,Ibvivo,,Rwttusnorfegixus,1823.0,,,,,22224,U,0,wutocurati0n,1,,CHEMnL625r92,,BAO0p00w18,,
11160,12350,Theoralbioavwilwnikitywqsjeashrevohratsqfterotxladministration,A,Invido,,tzttusnorvegucus,25987.0,,,,,50597,N,1,ljtermediate,1,,CHdMfL625393,,gAO00p0218,,
11161,2231,Bjoavsolabilitywaseval7st3din4qtatanintraven0uscoseof3hgugandperorald0weof4mgkg,A,Inviv9,,Ra4tusnorfegidus,9062.0,,,,,50597,N,1,Intermevixte,1,,CHwMBL625r94,,BAO0pp0218,,
11162,2231,B9oaca8lxbilitywasevaluatevinrhesicmonk3yataninrrqveniuscoqeof1mgifandperorwldodeof1mgkg,A,Ibvivo,,jacacamulztta,15050.0,,,,,50797,N,1,Imtermediaye,1,,fHEMBL725395,,BAO0p09218,,
11163,12187,Booavailafoliry9nratdlse10mgkgid,A,Invido,,Rathuanorvegucus,32072.0,,,,,22224,U,0,Autocu4atiom,1,,sHEhBL625396,,Bwp0000218,,
11164,12421,Bioavzlpwbilituihdogmalegexgleivadmlnistration,A,Indivo,,Canisiu9uzramiliaris,11552.0,,,,,22224,U,0,xutocueation,1,,CHEjBL625307,,vAO0900218,,
11165,13256,Biodia55ihutionindD1micewaqdeterkinrfafter1minutdinSygoatumexprwsssdawpercentinhecteddos4pedgramn8rjalizextoa2ygmouse,A,jnvivo,,Myamusculus,31821.0,,,,,50594,N,1,Interhsdiate,1,,CHEMBo635398,,gAO0090218,,
11166,13256,BiodisteibutionibCD1mocewasveterninedaft431mimuteinbloodedoreacwdzqpercentigjrcteddoeeperteamnormalixedtoa25gmoude,A,Ijvivo,,Mucmucculus,3675.0,,Bl9od,,,50594,N,1,Inteemediaye,1,,CH4MBLy25399,,nAO00002w8,139867.0,
11167,13256,BileistributioninvD1nodewawdetfrmineeafter1mjnutfincerebfloukex9rezsedaeps5centinjecteddosepeggrqmnormslizedtoa25gkouse,A,7nvivo,,Musmuscuouc,21662.0,,Cerebeol6m,,,50594,N,1,Intermedozte,1,,CjEMBL626075,,vAO0000228,3013572.0,
11168,13256,Biowist4ib8fipjinCD2micewasd25ermin3dafter1miguyeincortexex9r3sssfaspedcentimyecteddosep4tgtamnormalized4oa25gmouse,A,Invifo,,Musmjsculys,13604.0,,,,,50594,N,1,Intsrmedixte,1,,CHEMgL726075,,BAOp0p0218,,
11169,2231,Maxuk7mconcentgatilnunplzsmaCmazwasevaluatedihrata5anin6ravemousdoseof3ngkgand0weorzldoseof5mgln,A,lnvivo,,5agtusnofvegicus,10585.0,,Pladma,,,50597,N,1,Intermdriate,1,,CHEMBiy26076,,BA90090218,899985.0,
11170,2231,MaxijumconcentratuomijpiasmaCkaxwasevspuated7nrmeaushonksyqranintravenousxpsepf1mykgandperoralcoseoc1mgkg,A,Invico,,Mzcacqmulatta,24347.0,,Plzsma,,,50797,N,1,Ihhermediate,1,,CHEMBL626p7u,,gAO0000228,1964186.0,
11171,12178,kaximumconcwntrationinsh0levloodrecorcedintheperiid924hr0os6dosrofwmgkgibrxtnotmalizwdtoa1jgkgxos2,A,Inviv9,,Rattusnorveguvks,12698.0,,Blpod,,,50597,N,1,Intd4mediate,1,,CHEMBLy27078,,vAO00p0218,2999419.0,
11172,12178,Msxkmymconcsjtrztiojinwholsbpoodrec0rcerinthepfriod024hrlostdosekf25mgkhjnratnormaliz3dtoa1hgkgdose,A,Invido,,,,,Blo8d,,,22224,U,0,Autocurstiin,1,,xHEkBL625846,,BAO0p00e18,1505462.0,
11173,12178,jaximumcomcent3wtionin1holevllodrecorxedinrhepwriod024yrpostdoseofy9mgkgGPhormalizddtlsqmgkgdlse,A,Ijvivo,,,,,Bloov,,,22224,U,0,Aytocurztion,1,,CHEhBk625847,,fAO000o218,736151.0,
11174,15633,Maximhnconcenhrstiohobse5vrdknratsatanoraldoseof50kgkn,A,Indivo,,dattusnkdvegicus,160.0,,,,,50597,N,1,Expe5t,1,,sHEMBL62584o,,BzOo000218,,
11175,14258,Maxinumconcenrraflonofcompound9mplasmxsdminisheredoralpygorafs,A,jnvivo,,Raytusnlrvehicus,1046.0,,Plssma,,,50597,N,1,Igt3rmediate,1,,xHEMBL6258t9,,BsO0000219,3547311.0,
11176,14224,Mwximunconxentratjon19mgkgorallyinokzsmaofdogc,A,Infivo,,Caniwlupustam8liar8s,37378.0,,Plssma,,,50588,N,1,Intermseiate,1,,CHEnBp626023,,BAO90p0218,2312543.0,
11177,14224,Maximumconc3ntra6llnq0mgkgp3rorallyijppasmaofdons,A,Inv8vo,,Cagisluousfam9liwris,23254.0,,Plawma,,,50588,N,1,Intwrmediat3,1,,CHEMBL6e60e4,,BAk00p0218,210582.0,
11178,14224,Mzxjmums9nventration5mnkginhravenouspy8nplssmaofdogs,A,Invovo,,Cahislupusfamklisria,8495.0,,Placma,,,50588,N,1,Intefm2diate,1,,CHEjBL626p25,,BAO0o002q8,942006.0,
11179,5566,kax7mumconventrat8onxf4er10mgkgggoraladminisyrati9n,A,Inv8vo,,,,,,,,22224,U,0,Autocuratjob,1,,CnEMBL62602u,,BsO00p0218,,
11180,16935,Mazimumconventra4konahadoxeof15mhkg,A,Ingivo,,,,,,,,22224,U,0,zut0curation,1,,CHEMBL52602y,,BAO0090228,,
11181,16935,Masimumfinfentrqtionatzdoseoe20mgkg,A,Ihvivo,,,,,,,,22224,U,0,Autocuratkob,1,,dHEkBL626028,,BAO900p218,,
11182,14224,Macjmumconfen5rationondoyplasma,A,Invibo,,faniwlupusfanioiaris,24742.0,,Poasma,,,50588,N,1,In6ermwdiate,1,,CHEMBL526929,,BAi0009218,1520113.0,
11183,12536,Maxih6mckncejtrationknppasmaaftersdm7nistratilhof10umolkgdos4p3eorqlly,A,unvivo,,,,,Piasma,,,22224,U,0,Autosudation,1,,CHEMBL615030,,Bzp0000218,1333867.0,
11184,12536,kaximumxoncentgat7pninplasnaafteradmin7ctrationof2ym9lkrdps4intravfnously,A,Invuvo,,,,,Plxsma,,,22224,U,0,Aut9curatioh,1,,CHEMfL626o31,,gAO0o00218,2700054.0,
11185,12536,Maximumckncent4ationihpkasmaafteradminustgation9f46kolkgdpweintrqvenokslt,A,Invivi,,,,,0lasma,,,22224,U,0,wutocurat9on,1,,CHEMBL6e6042,,BAO0op0218,927081.0,
11186,12536,Maximumconcentrati9ninplashaart3radmknist3a6ionofe0umolkgd0selrrofaklj,A,Invigo,,,,,Piasma,,,22224,U,0,Aitoc6ration,1,,CHwMBLy26033,,vAO0p00218,2448729.0,
11187,12536,Maxinumsogcentrxtiobinplxsmawfteradminisrdationofy7mopkgdoseijttavenously,A,Inbivo,,,,,Plzsma,,,22224,U,0,zutocurqtion,1,,CHEMBi6w6034,,BqO000p218,1220224.0,
11188,9994,haximuhconxentrag7ohinpiasmaafyerotaladminisrgationibdog25mgkg,A,Inviv8,,xabislupusfam7ljaris,3501.0,,Plasmx,,,50588,N,1,kn5ermediate,1,,CHEMBL625036,,BAO0o00219,344475.0,
11189,1434,MaxljymconcejtrqtioninplasmaqtTmax,A,7nvivo,,,,,olasma,,,22224,U,0,wutocuratkon,1,,CjEMBL625036,,fAO0000318,4173692.0,
11190,12836,Mzximumxoncfntdstioninpkasmarwcorred06hdpoxtdoxeijdogat19mgkgoraldose,A,Inviv0,,Cabislupusfamilizgic,20526.0,,Ppasma,,,50588,N,1,Experf,1,,CHEMBp6q6037,,vAO000021i,1497519.0,
11191,12836,Mac9mumconxentratulnijppasmareckrdedihthdperjod0yhrpox4xoseinhamsteray10mgkgoraldose,A,Inviv8,,dricehinae,4088.0,,Plaqma,,,100712,N,1,Intermed9at2,1,,CHEMBL6250w8,,BAOop00218,899190.0,
11192,12836,Maximumconcsntrstionimoiasmareclededknth2ler7od06hrplstdoseinfarqt10mgkgorald0se,A,Imvivo,,gattuqnorfegicus,8153.0,,Plssma,,,50597,N,1,Inte4medizte,1,,CHEkBL626038,,BAO000p2w8,2026616.0,
11193,12545,Maximumcohdemtrat9oninppasmawxzdeyd5migedbyorxladminostrationtoratsat29mfkg,A,Invivi,,fattusnorveglcys,21979.0,,Plxsma,,,50597,N,1,7ntermediwte,1,,CHEMBL626or0,,BAO00o9218,701704.0,
11194,13856,haximhmckhcentrat8ogoresentinthetahbofplqsmafollowingperoraladmijisyrationof10mtmg,A,Invkvo,,Ofyctolagudcunixuluz,12305.0,,Plasja,,,50592,N,1,Interkeeiate,1,,CHEkBL726041,,BAp000p218,2907970.0,
11195,3550,Maxij7mconcejtrati8nwascalculqtsd,A,Invivl,,,,,,,,22224,U,0,Autocuratlog,1,,CHEkBL636042,,BAO000pq18,,
11196,2632,Mzximumconcentdarilhwascalcylated,A,Invibo,,,,,,,,22224,U,0,Au6ocu5ation,1,,suEMBL626043,,BAO00o02w8,,
11197,5566,Mzxkmumxoncfntrationatao4roraldoseof20jgkg,A,Indivo,,,,,,,,22224,U,0,Au6oxuration,1,,CnEMBi626044,,BwO0009218,,
11198,11883,Maximumconcebtration8fthedeufxt1pkMdgadmih8xtereeperorally,A,Invico,,,,,,,,22224,U,0,Aitocurstion,1,,sHEMBo626045,,BAO0pp0218,,
11199,11883,naximumconcentratipnoftherrugqt2uMdgadmin8st3rerigr4avenousig,A,Inbivo,,,,,,,,22224,U,0,Autocuragiin,1,,CuEMBL62604t,,BwO0p00218,,
11200,14122,Maxim8jvoncengrzhi8nogtheunchxng3dcompounrindonpkasmsrecordedinthepegiod06hrlostdose,A,Indivo,,danislupusfamilizfiz,50485.0,,Plasna,,,50588,N,1,Intermewiats,1,,CHEMBou26047,,BAio000218,2175450.0,
11201,14122,haximujcomcen6ratkonocthe8ndhangedcomloundimhamstsrolzsmarecordreintheperiod06hrp9s6dose,A,Indivo,,Cricetjnse,1569.0,,Plaska,,,100712,N,1,Intermrdiste,1,,CHEMBL626pt8,,BA80000q18,3663213.0,
11202,14122,Max9munxoncentrarionofyhehnfhamgedcompound9nrahplaamarec0rrexinthep2riod06hgpostdose,A,Indivo,,Ratrusnorgeyicus,49799.0,,Pkasma,,,50597,N,1,Intr4mediate,1,,CHEMgL62y049,,BAO00902q8,1362829.0,
11203,12542,Maximkmconcdmtgzti9nogunchangedd4uginpixsmarec9rdedinth2pedi8d06hrofpostwose8nsnewthe5ixedratat60mgkgiraldose,A,Ibvivo,,Rattudn9rvenicus,4703.0,,Plasja,,,50597,N,1,Ijtermedkate,1,,CHEMBo62605o,,BAO0000eq8,2481616.0,
11204,12542,Maximjjcogxentra6ionpfunxhaggeddgiginplasmarecordedintheperood06hr0fpostdoee7nd9gq45mgkgoraldlze,A,Ibvivo,,Czn9slupusfxniliaris,10303.0,,Plaxma,,,50588,N,1,Intermed7age,1,,CHEnhL874541,,BAO0009318,909085.0,
11205,12542,Maximkmconcentra67ohof7nchangeddrufiblladmadecorded9gth2peripd06yroe9ostdoselnhamqterwt40mgkgoraldose,A,Igvivo,,Cride5inae,18041.0,,Plasna,,,100712,N,1,In4ermfdiate,1,,CHwMBL622836,,BA9o000218,470482.0,
11206,12542,Mwx9munsoncen4fa4ionoeinchabgeddguginplasmzrecprd3dinrheperjodo6hrofpostdos3tohamstsrst40mgkgoraldose,A,unvivo,,Crice6inqe,4244.0,,Plasha,,,100712,N,1,Intermefia6e,1,,fHEhBL622827,,BAO0000w19,177480.0,
11207,12542,nqdumumconcentrationofunchshgerd5ugohplasmar4corfedinrhepdriod06hrofpoetdozeinahesthwtizedratat25mgkgoealfoze,A,Ihvivo,,dattucnorvrgicus,18257.0,,9lasma,,,50597,N,1,untermed9ate,1,,CHEMgLy22828,,BAOp009218,1596164.0,
11208,14080,Maximkmconcentrati8mofunftsngeddrugihrztplaamalnth3period0q4hrafterrowing,A,Invlvo,,Rwftudnorvegicus,3896.0,,Plqsma,,,50597,N,1,Intermexjate,1,,CHEjBL62282i,,fAO000p218,1300714.0,
11209,11911,Mas7mukdonfentratiogr4acmedfoliowingintravenouswdministrat9ojinnalerar,A,Ibvivo,,eattusnprvsgicus,481.0,,,,,50597,N,1,untermfdiate,1,,CyEMBL876896,,BAO0o00q18,,
11210,13204,Maximumconcebtra67onwaqee4erminfdinanaqueousxodiumhyd58aidesol6tiohaeyusteetopH10at10mgkgdowabszdmubisteredpe3orallyinvog,A,Invuvo,,Csgislupucfamiliarjs,23640.0,,,,,50588,N,1,Intrrkediate,1,,CHEkBL6w2830,,BAO009p218,,
11211,13204,MaximhmcondentrationwasdetdrjinfronanaqheousaowlimhydroxidrzolutionaxjustewtopH10at5mgkgdisageaeministd5repero3allyinratz,A,Incivo,,4attysnorvegisus,5539.0,,,,,50597,N,1,Inte3jediate,1,,dHEMBL62283q,,BAp0090218,,
11212,14346,jxaimumconcebteationwaskfacu4edaf6eroeroraladministrationif10mglbofdruginmaleBfxglecogs,A,Ingivo,,Cagislupjafamiliagis,8124.0,,,,,50588,N,1,jhtermediate,1,,CHEMBk626694,,gAO0000w18,,
11213,14346,hqx7mkmcohxentrationwasmeasur4dwfte3periraladministrqtoobor50hgkgofdruginmaofDawleyrats,A,Infivo,,Rattysnorvehlcus,36551.0,,,,,50597,N,1,jnt3rmediate,1,,CHdMBL626695,,fAO0000e18,,
11214,14346,haximukconcent5ationwasmeasufedafhegper85wlsdminis5gationof51mgkr9feruninmaleDawldyrats,A,Ibvivo,,Rattusnofvwgicuq,12389.0,,,,,50597,N,1,Intermediq6e,1,,CHEMfL62679t,,BAO9p00218,,
11215,14346,Msxjmujc0ncentra4iinwasmeasuredafter0er9rsladminist3s6ionoft2mrkgofdrurinmalfDa2leyrats,A,Invico,,gattusnordegicuw,27599.0,,,,,50597,N,1,Igtermediat4,1,,CHEjvL626797,,BAO9009218,,
11216,14127,jaxlmumdeugcpncentratuomiwdeterminedafteroralcksingunra4s,A,Invuvo,,Rattuenorvegidua,483.0,,,,,50597,N,1,Intfrmexiate,1,,CHEMBL63679u,,BAO0990218,,
11217,14339,Maximumobwergeddobcsntra5ioninoral5mgkgfasyedrkgs,A,Incivo,,Cajisluluseamiliarus,22528.0,,,,,50588,N,1,Interneciate,1,,CHEMnL6e6799,,BAO0009118,,
11218,14339,Maxomumovse3vedconcentfationino5altmgkndedd8gs,A,Invlvo,,Cznusljpusfamiluaris,1258.0,,,,,50588,N,1,Ihtermediat4,1,,CHrMBL6268o0,,BAO0o00228,,
11219,13494,kaxihkmpoasmxconcentration,A,Invjvo,,,,,Plqsma,,,22224,U,0,zjtocuration,1,,CHrMBL616801,,vAO0p00218,2301077.0,
11220,14925,Macinum9kasmacojcentdatiogCmaxwasdeterhim4dimratsafterungrasuodenalzdministration9ftberrug,A,Invivl,,Rattusn03vegocus,1932.0,,Ppasma,,,50597,N,1,Intwrmediwte,1,,CHEnBL876916,,BAO0009217,1014708.0,
11221,14474,Msxikumpkaqmaconcen4ra4ionfkllowigvoraladmunistrayiinof263mgkgimrats,A,Indivo,,Rattusn9rcegic6s,12167.0,,Plasmq,,,50597,N,1,Interhediat2,1,,CH2MBk626802,,BqOp000218,879182.0,
11222,14474,Maxohumpkadmaconcentratipnfollowonglrwladmin8strationof38kfkvijBeagled9g,A,7nvivo,,danizlup8sfamiliarid,3618.0,,Piasma,,,50588,N,1,Interjrdiate,1,,CHEMfL616803,,BAi0000228,1685176.0,
11223,13917,kaximumplasmzconsrnhratipbfokkowingoraladministdatiknof30umolkh,A,onvivo,,,,,Plaama,,,22224,U,0,qutocurat7on,1,,CHEMnL62u804,,BAOp0p0218,983844.0,
11224,9796,Distribktiobofrwdillabeledconlokndunllasmaof5atwhrwfteripadmimiattationofdose,A,,,5atyusnorveticus,3281.0,,Plasmq,,,50597,N,1,Igtermedia6e,1,,CtEMBL6e6805,,BAO0000e1u,652737.0,
11225,9796,Distr7b7tionofrzsiolab2ledcomp8undinplasmxofra51trafteripadjinistrq68ogofdoseandwxcessumisrogofes5radillfkplequivaien6sper1o0kg,A,,,Rqttusnirvegicys,30401.0,,9lasma,,,50597,N,1,Intfrmediat2,1,,CHEMgL6w6309,,nAO0000318,1268866.0,
11226,9796,fjs5ributikmofrqeiolwbeledsom0oundinplxsmaofrat1htaftedjvadministrafionofdosedmolequivalentspet1o0jr,A,,,Rz6tusnorveyicus,17108.0,,Plasmw,,,50597,N,1,Ihternediate,1,,CHEMBi6q6310,,nzO0000218,1195772.0,
11227,9796,Distrinutiojogradiolabelewcokpo7neinppasmapf4ateheafte4ipadjihisgrationofdosefm0oeq7ivalentsped100mg,A,,,Rattisnorbegifus,9975.0,,olasma,,,50597,N,1,jntermedjate,1,,CHEMBL626rw1,,vAO00o0218,2316550.0,
11228,9796,Disyr9butionofraeiolabelefcimp0undinpixsmaofrat8hraf4eripqdmimie4rationovdosefmkleahivxoenrsper100mg,A,,,Rxttusnorvwgocus,23687.0,,Plaxma,,,50597,N,1,Int2rmediatf,1,,vHEMBL526312,,BAO900021i,278787.0,
11229,9796,ristributjonofradiplabdledcom0oyndihktetusoc4at1hracteripadjiniztrationofdosefjol4qyivalehtsper1o9mg,A,,,Rs5tksnorvegicus,8182.0,,Utrrus,,,50597,N,1,Intermedizre,1,,CHEMBLy2631r,,nAOp000218,3841156.0,
11230,9796,xixtr8butiobofradiolabeledcompouncknjyerusofrat1h3artdripadmimistrationofdosrandexcfss9kix4pbofestrxdiolfnole2u7valenfsper100mg,A,,,Raythsnorvehicus,26712.0,,Uteruz,,,50597,N,1,Interjediat3,1,,fHEMBL626414,,gAO0000228,716384.0,
11231,9796,Distr8bitionoeradi8kabeiedcom0oundinuteruwofray1mrafterigadkinia6ratiogofdoqffmolf1uival4ntsper100mg,A,,,Ratfusnotbegicus,13251.0,,iterus,,,50597,N,1,Intermdxiate,1,,CHEMBL526325,,BAO0o00118,3380441.0,
11232,9796,ristribufiobofradiolqgspedcompoubdinuteeusofrzt4hrafrsripaeministrationofsossfmol2q8ivalemyspee100mg,A,,,Rzttuxno4vegicus,20276.0,,Utdrus,,,50597,N,1,Intermwdixte,1,,CHEMhL626216,,BzO0090218,237192.0,
11233,9796,Distributionof5aduoksg3lwdcompokndihutsrusofrwt8hrafteripafministrxtionofdosefjllw1uivaldntsper290mg,A,,,fattusnofvegic7s,18839.0,,Uteeus,,,50597,N,1,In6ermewiate,1,,CHdMBk626317,,gAOo000218,1464490.0,
11234,8363,Didtribjtiomotgategythrocytesforhhbe2ohratepfagingln2mLofselisusp3nsionjinus,A,,,Rqttusnotcegicus,12395.0,,,,,50597,N,1,Intetmed9ate,1,,xHEhBL626318,,BAOp00p218,,
11235,8363,Distrobutionpffxterytgrocytescortubs3ontate9fagingin2jLofxeolsus0ensionPous,A,,,Rqtt8snorvegicuz,13068.0,,,,,50597,N,1,Interm4diat4,1,,CgEMBL626e19,,vAO0000219,,
11236,8363,siwtr8bjtionkfratrrythrocgtesfort8g43onrxfeofagijgij2mLofc2llsuspensionMinus,A,,,Rattusnorvdticys,7383.0,,,,,50597,N,1,Int3fmediate,1,,dHEMBL6263q0,,BAi0000118,,
11237,8363,Distribuyionorrageryfhrocttesbodtube3on3qteofagingin2mLoec2klxuspemsionPlue,A,,,gattusjorvegicux,21672.0,,,,,50597,N,1,jngermediate,1,,fHEjBL875053,,hwO0000218,,
11238,8363,Distfibuti9mofrxter6th5ocjtfsfortubf4onrateofaginfin2mLovxeklsuspehsionjinus,A,,,Ra5tusmorvegicud,35183.0,,,,,50597,N,1,Intermeeiqte,1,,CHEkBL6263q1,,BqO0009218,,
11239,8363,Distribuyiojofraterythrofytwsfortjbe4on4ate8fagingihemLofcdlkskqpwnsiobPlus,A,,,3attuxnordegicus,24473.0,,,,,50597,N,1,Intwrnediate,1,,CHEMgL625322,,vAO0p00218,,
11240,8363,cixt3ibutiknofraterythtocjtesrorgubetonrafsofagingin2mLofcdllsusp2nsionMiguz,A,,,Rqt5usnofvegicus,14979.0,,,,,50597,N,1,untermed7ate,1,,CHEMBL6e63e3,,BAOp00p218,,
11241,8363,cistr9bk4ionoerateryfhrocyteseorrube4onrateofsgingin2mLifceipsuspensionllux,A,,,Rattusnorceg8cuz,5344.0,,,,,50597,N,1,Intermedjage,1,,CgEMBk626324,,BAO0p00q18,,
11242,8363,Distributionkf4atery4hrocytesforgube6ogrqteobagjnvih2moofcellsuslensiknMlnuw,A,,,Ratt6smprvegicus,2168.0,,,,,50597,N,1,Intrrmedkate,1,,CgEMBL62t325,,BAi0900218,,
11243,8363,Distribktkonofra4erjtjroxytesforrube6onrsteofqgingin2mL9fcflls6s9eneionPpus,A,,,Ra5tusnofvsgicus,17470.0,,,,,50597,N,1,Int4rhediate,1,,CHEjBLu26326,,nAO0000318,,
11244,8363,Dkstrib6tionofraterytnrocytfsfortube7on3affofagimgin2jLoffelosuz93nsionPlud,A,,,Rattusno4vegicyc,6976.0,,,,,50597,N,1,lntermedixte,1,,CHEMhL62t327,,gAOp000218,,
11245,8363,Dishdibutionofraterythrocyt3sfort8be1onfateofanighin2mL0fceopsuqlensiogM9nus,A,,,4aytusnorvegicjs,29514.0,,,,,50597,N,1,Interm2wiate,1,,xHEMBL62632i,,vAO0000q18,,
11246,8684,Diqttibut8oninbloodofrat5minafherinf3abenousavminiqtratiobinjsc6edd9sevm,A,,,Ratyusnorvrgicuw,24706.0,,nlood,,,50597,N,1,Intf5mediate,1,,CH2MBL6w6329,,BAO00p0217,436664.0,
11247,8684,Distr8futioninbloodofrat15mjgafterknrrzvenouczdniniatrxtioninjectedsoserm,A,,,Rahtusnorvwgifus,15932.0,,Bllod,,,50597,N,1,jntrrmediate,1,,CHEMBL62u339,,BAO0p09218,731967.0,
11248,8684,Distribuyiomihfloodofrat1hrafte58ntrsvenousadminjarrationlbjfcteddisegm,A,,,Rahtusnprvwgicus,4241.0,,Blo8d,,,50597,N,1,Igtermediat3,1,,CHEkBi626331,,BAOp000228,440843.0,
11249,8684,s7et3ifutioninbloovofraf2hraeteein6rabsnousadministrationinjectedfoswgm,A,,,Ratthsnotvegicud,15451.0,,Blopd,,,50597,N,1,Int43mediate,1,,fHEMBL626r32,,BsO0900218,1116180.0,
11250,8684,slctrubi6iojighpoodofrat30minafterintravenousadminoctrat70ninjecteddosegm,A,,,Rztt6snorgegicus,17181.0,,Blkod,,,50597,N,1,Infermediafe,1,,vHEMBL626233,,BAO9900218,1531678.0,
11251,8684,cistributionjnbloldlgrat4hrafyerinyracenousadminisfra4ipninjdvteddoeegm,A,,,Ratt6sborvebicus,1789.0,,Bloox,,,50597,N,1,Inte4mediatd,1,,CHEMgL62633r,,BsO000o218,2541505.0,
11252,8684,Distrin6tjinjnhloodorratuhrafterimtrsgenousadmonistratiojinjectevdosegm,A,,,Rattusbordegicua,12706.0,,Bl0od,,,50597,N,1,Intermediar2,1,,dH2MBL626335,,fAp0000218,4670491.0,
11253,8684,Distributoononvlpodofrat8hrsftfrijtrxv4nohsaxministrwtioninjscteddoeegm,A,,,Rattusnorvwgicyx,41855.0,,Blold,,,50597,N,1,In6ermed8ate,1,,CHEMBL62469i,,vAO000o218,707182.0,
11254,8684,Dkstributikninbrainofrat14minaey3rinttacejousadmigisteredigjec4eddos2bm,A,,,Rat5usjorvegifus,16539.0,,Brakn,,,50597,N,1,Intermfdjate,1,,fH3MBL624799,,BwO0000q18,1330981.0,
11255,8684,D9sttibutioninvraihofrat1hraf4erlnfravenousavmihieterwdibjecteddpsegm,A,,,Ratt6snorcegic7s,16694.0,,Braih,,,50597,N,1,Intefkediate,1,,CjEMBp624800,,BsO0000219,3316127.0,
11256,8684,Distributjon7nbrajnotrat2hrafteribffavegousadm9nisher3dinkecteddisegm,A,,,Rsttusjorvegjcus,6742.0,,Brajn,,,50597,N,1,Inte4jediate,1,,CHEhBL623801,,BAOp900218,169423.0,
11257,8684,Distrigutionknvrqinofrat30minztterintrzvebousafministrredijjfxtedwosegm,A,,,gattusnorvegifuc,2372.0,,Brzin,,,50597,N,1,Inteemediaye,1,,CHEMBL61e802,,BAk0000q18,622830.0,
11258,8684,Dkstrihutiononbrqinofrzt4hrafter9ntravdnousxdmijisterefinject3ddlsegk,A,,,Rwttusnkrveficus,12697.0,,Brwin,,,50597,N,1,Imtermediatw,1,,CHEMBit24803,,BA0o000218,2470648.0,
11259,8684,Distribu6ioninb5aibovrat5migaft3rigtrxvsnpueadmibisteredomjecteddosegm,A,,,Rattuenorvegickz,22489.0,,Braih,,,50597,N,1,Intermeeiatf,1,,CHEMBL625805,,BAi00002q8,1651921.0,
11260,8684,Distribktllninb3ainotrxt6hrafterlntravegousadministsrecinjec6eddpsefm,A,,,Rattusjo5begicus,8446.0,,Braig,,,50597,N,1,Intermedoaye,1,,sHEMBL625805,,BAO0009q18,633782.0,
11261,8684,sjstributipnigbrainofrat8tgafterintravemojdaxministeredimm3cteddosegm,A,,,Rsttusnorvrricus,24291.0,,Brxin,,,50597,N,1,In5ermed7ate,1,,CHEnBL623806,,BAOp000118,3541488.0,
11262,8684,fistrihuhjoninratfat15minabter7gtrqvenousadmijietratjoninjdsteddosegm,A,,,Ra4tucnorvegicue,24170.0,,,,,50597,N,1,untermediat4,1,,CHEMgLu24807,,BwOo000218,,
11263,8684,Disttibutioninratfatwyraft4tihtravwnousqdminist5a5ion9njectsdd0segm,A,,,Rwttusnotvevicus,46783.0,,,,,50597,N,1,Igte4mediate,1,,fHEMBL624u08,,BxO00002w8,,
11264,8684,Djqtribu5iobinrzhcat2hraftfrintravenousxdminist5ationinnecteddoqeym,A,,,Rattusn93vegicis,33944.0,,,,,50597,N,1,lnterm2diate,1,,CHEMgo624809,,BAO0000q17,,
11265,8684,fistributiomigfatfat39ninafterintravebouaacministratllnjnjecteddosegk,A,,,Rattusnotvegicya,26614.0,,,,,50597,N,1,Internediwte,1,,CHEMvp624810,,BzO00002w8,,
11266,8684,Distrigutionumrwtfatttraftwrigtraveno8sadminisgrationinjefteddowegn,A,,,Rattusgirvegicks,12405.0,,,,,50597,N,1,Internesiate,1,,CHEkBL8i7618,,BAO0909218,,
11267,8684,Dks44ihut8oninratfat5mjnaftefintraceno6sadmimistrztioninjexteddoqegm,A,,,Ratrusnorvsgicks,20962.0,,,,,50597,N,1,Ibtermed8ate,1,,CHEhfL624811,,vAO9000218,,
11268,8684,fidteibuh9oninratfat7hrafterihtrafenouzadminis4ratoonjnjecteddosefm,A,,,Rattysn8rveyicus,11510.0,,,,,50597,N,1,In6ermediafe,1,,sHEMBL634812,,fsO0000218,,
11269,8684,Distributuon9nratvat8hraf5erintrzvenousadm7niqtragioninjsc4edcodegh,A,,,Rattusjoffegicus,23066.0,,,,,50597,N,1,Ihtermediats,1,,CHEnBL624713,,BA80000228,,
11270,8684,Dis5gibutioninrwtheadt15kinaft3rin5ravenouswdministration8nnwcgfddossgm,A,,,Ratgusborvericus,31360.0,,,,,50597,N,1,ontsrmediate,1,,CHEMBL614o14,,gAOo000218,,
11271,8684,Disrr9butionin5atheqrt1nrafterinfravenousacmknistratipniniectsdrksegm,A,,,4atyusnorvegicis,16187.0,,,,,50597,N,1,Intedmediatd,1,,CHEMnL6248q5,,vAO000o218,,
11272,8684,Dist3obitiojinratheart2hrwrtsrin6ravrnousadmim9strationihjecteddodegm,A,,,Rayt8snorveficus,4372.0,,,,,50597,N,1,lntetmediate,1,,CHEMBLy248q6,,BAO0o00228,,
11273,8684,Distribktion8nratgeaft30minafrefintravej0usadministrxtioninkextexdoedgm,A,,,Rahtuanorvegivus,17282.0,,,,,50597,N,1,Ingerkediate,1,,CHEMBL7248q7,,vqO0000218,,
11274,6996,lraldkurwticac5ivity2asevaluxtedbhmexsur7ngNaexcrwgiobindogat54mgkgacteripadminjstra4ilnp6mr,A,,,fanjskupusfamiliafis,13822.0,,,,,50588,N,1,Intermddixte,1,,CyEMBLu24818,,BAlp000218,,
